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Abstract 
Individuals respond differently to medication as a result of their genetic inheritance. 
These differences can result in the under- or over-dosing of medication, which may affect the 
efficacy or in the case of aminoglycosides (kanamycin) and polypeptides (capreomycin), 
result in toxicity. In South Africa, administration of the standardised Drug Resistant -
Tuberculosis (DR-TB) medication regimen is simplified across four weight bands. These 
bands accommodate the formulations available in the country while complying with 
international requirements for minimum, maximum and average dose per kilogram. There is a 
dearth of information on the ideal concentration, pharmacokinetics, and pharmacodynamics 
of kanamycin (KM) and capreomycin (CM) in patients with DR-TB and relationship of this 
on hearing levels. Thus, this study aimed to establish the feasibility of investigating the 
pharmacokinetics and pharmacodynamics of kanamycin and capreomycin in patients with 
DR-TB and the relationship between hearing levels. 
This feasibility study employed a prospective, cross-sectional, exploratory, 
descriptive and case series research design. A total of 22 participants (mean age 33.78 years, 
±7.3) participated in this multi-site study at Helen Joseph (HJH) and South Rand Hospitals 
(SRH). The majority of the paryicpants were females (68%, n=15). Participants underwent 
audiological (otoscopy, tympanometry, ultra high frequency DPOAEs, ultra high frequency 
pure tone audiometry) and pharmacological assessments at baseline and every two weeks for 
the first three months of treatment. Creatinine clearance was measured, and the overall 
outcome of treatment was evaluated in relation to the pharmacokinetics.  
Results revealed high-frequency hearing loss with both kanamycin and capreomycin, 
specifically in the ultra-high frequencies (9kHz to 16kHz). Clinically significant ultra-high 
frequency loss noted was with pure tone audiometry from week four after the initiation of 
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treatment, and from week six in the high frequencies (6kHz to 8kHz). Pharmacokinetic 
measurements showed erratic levels of kanamycin and capreomycin, with considerable 
differences among individuals, specifically with the peak readings. Mean peak levels for 
kanamycin were within the target range yet were subtherapeutic for the capreomycin 
participants. Kanamycin also correlated to more reduced kidney function when compared to 
capreomycin. Participants’ culture converted within the first two months from baseline, 
however, long-term culture results are unknown. Trough levels were also below 10 μg/ml and 
not within a toxic range, despite the hearing loss detected. 
This research identified many challenges with regard to establishing the feasibility of 
investigating the pharmacokinetics and pharmacodynamics of kanamycin and capreomycin in 
patients with DR-TB and the relationship between hearing levels. Participant enrolment was 
poor, with high attrition. This study also highlighted the need for a standardised ototoxicity 
monitoring protocol designed for this population which led to the development of ‘Ototcalc’: 
an ototoxicity calculator in the form of a mobile application designed to assist healthcare 
professionals in the classification of significant ototoxicity as well as with management 
recommendations. With the considerations identified in this study to further enhance the 
feasibility, the pharmacokinetics and pharmacodynamics of kanamycin and capreomycin are 
recommended for further exploration in relation to toxicity and efficacy with a larger sample, 
combined with the use of ‘Otocalc’. 
Keywords: Drug Resistant-Tuberculosis, Ototoxicity, Pharmacokinetics, 
Pharmacodynamics, Kanamycin, Capreomycin, Otocalc
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Definition of Terms 
Absorption: Absorption of a drug refers to the transfer of the drug from the site of 
administration to the bloodstream via one of several procedures (Clark, Finkel, Rey et al., 
2012; Atkinson, Huang, Lertora et al., 2012). The drug absorption from the site of 
administration allows the entry of the therapeutic agent into the plasma.  
Aminoglycoside: Aminoglycosides are a well-known and successful class of antibiotics 
(Huth, Ricci & Cheng, 2011). 
Cochleotoxicity: Cochleotoxicity is the toxic damage to the cochlea; initially occurring to the 
outer hair cells at the basal end of the cochlea. Here the high frequencies are transduced, and 
thus cochleotoxicity initially affects the ability to hear high-frequency sounds. With 
prolonged exposure to the ototoxic drug, impairment proceeds to the apical end of the 
cochlea which is responsible for the processing of low-frequency sounds (Peterson & Rogers, 
2015). 
Disability-Adjusted Life Years (DALY): The DALY is primarily a measure of disease 
burden as it weights the disability to the loss of functioning and it takes the age, the origin of 
disability as well as the quality of life weights into account (Sassi, 2006). 
Distribution: Distribution is the method by which a drug reversibly leaves the bloodstream 
and enters the interstitium and intracellular fluids (Clark et al., 2012). Four main factors are 
under consideration, namely; blood flow, capillary porousness, the degree of affixing of the 
drug to the plasma and tissue proteins and the volume of distribution (Clark et al., 2012).  
Excretion/Elimination: Excretion or elimination refers to the way the drug leaves the body. 
Elimination of drugs from the body requires the drugs to be satisfactorily polar for effective 
elimination. As the drug enters a system, elimination begins via one or more of the three main 
routes of elimination namely; hepatic metabolism, elimination in bile and elimination in 
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urine. Excretion of the drug takes place via a number of methods; the most important process 
is through the kidney and urine (Clark et al., 2012).  
Metabolism: Metabolism refers to the process where the drug may be bio-transformed by 
metabolism of the liver or other tissues. The drug and its metabolites are subsequently 
eliminated from the body in urine, bile or faeces (Clark et al., 2012).  
Multidrug-Resistant TB (MDR-TB): MDR-TB is TB resistant to two first-line drugs: 
isoniazid and rifampicin (WHO, 2015). 
Mycobacterium Tuberculosis Complex (MTC): There are five closely-related 
mycobacterium species, also known as the MTC, which can cause TB in humans or other 
living things (Addo et al., 2007). The MTC comprises of Mycobacterium, Mycobacterium 
africanum, Mycobacterium microti, Mycobacterium canetti and Mycobacterium tuberculosis 
(Addo et al., 2007). 
Ototoxicity: Ototoxicity is defined as a toxic reaction to medication causing damage to the 
inner ear which often results in hearing and/or balance difficulties (Frymark et al., 2010).  
Pharmacodynamics: Pharmacodynamics describe what a drug does to the body and the 
stimulus of drug concentrations on the degree of the response (Clark et al., 2012).  
Pharmacokinetics: Pharmacokinetics refer to what the body does to the drug. It includes 
aspects such as absorption, distribution, metabolism, and elimination (Clark et al., 2012).  
Quality-Adjusted Life Years (QALY): The QALY calculation is based on a multi-attribute 
theory where utility independence between life years, health status, constant proportional 
trade-off and risk neutrality on life years are considered, QALYs are used in many cost 
analysis situations (Sassi, 2006). 
Rifampicin Resistant TB (RR-TB): RR-TB includes any resistance to rifampicin, whether 
mono-resistance, multidrug resistance, polydrug resistance or extensive drug resistance 
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(WHO, 2015). Phenotypic or genotypic means, with or without resistance to other anti-TB 
drugs detect RR-TB. 
Therapeutic Drug Monitoring (TDM): TDM is the clinical practice of measuring particular 
drugs at chosen periods to maintain a persistent concentration in a patient's bloodstream. 
TDM optimises individual dosage regimens (Kang & Lee, 2009).  
Tuberculosis (TB): Tuberculosis is a contagious, potentially lethal airborne disease 
(National Department of Health – Republic of South Africa, 2011) caused by mycobacteria; a 
bacterium of a group of acid-fast bacteria are highly pathogenic organisms (Hatta et al., 
2010). The lungs (pulmonary TB) are usually affected, but other sites within the body (extra-
pulmonary TB) can however also be affected (WHO, 2015). 
Vestibulotoxicity: Vestibulotoxicity is the ability of a substance to destroy or damage the 
structures and function of the labyrinthine hair cells and their connections through the eighth 
cranial nerve to the central nervous system (Selimoglu, Kalkandelen & Erdogan, 2003). 
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Chapter 1: Background and rationale 
This chapter introduces the background and rationale for this study. It then details the 
outline of the thesis with all the chapters and outlines the contents within these chapters. 
1.1. Background  
Drug-resistant tuberculosis (DR-TB) is becoming increasingly common in South 
Africa. In 2015 the incidence of new tuberculosis (TB) patients was 10.4 million cases 
worldwide, with South Africa being one of the six top countries which together account for 
60% of the new cases. It is hypothesised that the increase is due to resistance to at least 
isoniazid and/or rifampicin; two bactericidal drugs used as part of first-line treatment in the 
fight against TB. As per the 2014 South African National Department of Health (NDoH) 
guidelines, the treatment for DR-TB involves the use of aminoglycosides and other 
polypeptides to preserve the life of individuals diagnosed with DR-TB.  
Aminoglycosides and some polypeptides are known to be toxic to individuals 
(Bardien, et al., 2009). Aminoglycosides, such as kanamycin, are inhibitors of prokaryotic 
protein synthesis at commonly accepted therapeutic concentrations. However, it may also 
affect the protein synthesis of cells at larger concentrations, leading to toxicity, such as 
ototoxicity, vestibulotoxicity and/or nephrotoxicity (Touw, Westerman & Sprij, 2009). The 
toxicity profile of capreomycin, an antimicrobial cyclic peptide particularised by 
Streptomyces Capreolus, is similar to that of aminoglycosides (Peterson & Rogers, 2015). 
The use of capreomycin in treating TB is an alternative to kanamycin and amikacin in the 
treatment of DR-TB (Duggal & Sarkar, 2007). The prevalence of cochlear damage due to 
aminoglycosides ranges from 7 to 90% (Petersen & Rogers, 2015). This variability could be 
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due to a potential of underreporting, as well as the lack of distinct parameters for examining 
ototoxicity (Edson & Terrell, 1991; Petersen & Rogers, 2015).  
Nevertheless, in South Africa, the administration of the standardised regimen of DR-
TB is simplified and implemented across four weight bands. These broad dosage ranges are 
employed to adjust the formulations available in South Africa while conforming to the 
international criteria regarding the minimum, maximum and average dose per kilogram 
(NDoH, 2011). However, individual patients have their own optimal target concentration 
based on the susceptibility of the microorganism, co-administered anti-bacterials, immune 
status and co-administration of other nephrotoxic or ototoxic drugs (Touw et al., 2009). These 
individual differences can result in an under- or over-concentration of the medication, which 
may then affect efficacy, or result in toxicity of treatment (Touw et al., 2009). Patients taking 
kanamycin or capreomycin for DR-TB should not be exposed to any greater risk of toxicity 
than is justified by the need for the drug, nor obtain any less of the drug that is minimally 
needed for its effect. Therefore, it is evident that knowledge of the antimicrobial 
pharmacodynamic properties of medication provides a more rational basis for determination 
of optimal dosing regimens (Levison & Levison, 2009). 
1.2. Rationale for the Study 
It is evident that ototoxicity is prevalent in the DR-TB population, specifically in 
South Africa. Kanamycin and capreomycin are ototoxic and cause irreversible hearing loss 
which affects the quality of life, as well as social, emotional and occupational well-being. 
Monitoring and management of ototoxicity is a concern (Khoza-Shangase & Stirk, 2016) and 
currently no comprehensive protocols for monitoring ototoxicity in this population exist, with 
various different methods in use in South Africa. There is some evidence for the support of 
therapeutic drug monitoring (TDM) to reduce ototoxicity, however, more research is 
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required. Also, interdisciplinary communication with monitoring and management, is rare. 
The existing ototoxicity grading systems do not seem relevant as they were not developed for 
this population and frequencies higher than 12.5 kHz, as well as interpretation of audiological 
results seems to differ between individuals. This difference makes management of the DR-
TB difficult for physicians as there are various opinions of a significant change in hearing 
and thus physicians do not have a combined decision of what is ‘significant enough’ to 
motivate for change in the drug regimen of these patients. Lastly, the use of different 
monitoring protocols and classification of hearing loss also makes it difficult to infer the 
incidence and prevalence of ototoxicity.  
Furthermore, there is a dearth of information on the pharmacokinetics of kanamycin 
and capreomycin when used to treat patients with DR-TB, a unique and vulnerable 
population in South Africa. This dissertation postulates that the pharmacokinetics and 
pharmacodynamics could relate to the levels of ototoxicity of kanamycin and capreomycin in 
patients with DR-TB. In order to recognise the association between drug levels and 
ototoxicity, exploration of this is required. Understanding the pharmatherapeutics 
(pharmacokinetics and pharmacodynamics) of kanamycin and capreomycin in patients with 
DR-TB could thus assist health care professionals in prescribing and administering the 
correct dosages. This understanding would include dosage forms and frequency of dosages in 
order to possibly reduce ototoxic effects and the impact thereof on hearing levels of patients 
(Touw et al., 2009). This could lead to the further investigation of a contributory relationship 
of high trough levels of kanamycin and capreomycin to ototoxicity. Subsequently, the 
possibility of the individualisation of dosages can be explored to reduce this toxicity, 
specifically ototoxicity. This is especially relevant in patients with DR-TB as post-treatment, 
many patients are left with disabling hearing loss (Ramma & Ibekwe, 2012; Feldman et al., 
2007; Harris et al., 2012). This disability affects their ability to obtain jobs (Hogan, 
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O’Loughlin, Davis & Kendig, 2009), their social and emotional well-being and ultimately 
their quality of life (Monzani et al., 2008; Hogan, Reynolds & Byrne, 2013). By reducing 
ototoxicity, quality of life for these patients will be improved. This will increase social-, 
emotional- and occupational well-being and decrease the burden of morbidity associated with 
TB on the society (Monzani et al., 2008; Hogan et al., 2013).  
Thus, this research aimed to establish the feasibility of addressing the paucity of 
information in this field; by determining the pharmacokinetics of kanamycin and 
capreomycin in patients with DR-TB as well as the relationship between the 
pharmacokinetics and pharmacodynamics of kanamycin and capreomycin with hearing 
levels. 
1.3. Research Questions 
• What is the feasibility of investigating the pharmacokinetics and pharmacodynamics of 
kanamycin and capreomycin in patients with DR-TB and the relationship with hearing 
levels? 
• What are the changes in hearing levels in patients treated with kanamycin and 
capreomycin for DR-TB? 
• What are the kanamycin and capreomycin pharmacokinetics in patients treated for DR-
TB? 
• What is the relationship between kanamycin and capreomycin pharmacokinetics and 
hearing levels? 
1.4. Chapter Outlines 
This thesis comprises nine chapters. Chapter 1 provides a basic orientation to and 
motivation for the study as well as an outline of the chapters in the study.  
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In chapters 2, 3 and 4 the conceptual framework for the study is provided. Chapter 2 
commences with a description of TB and its pathogenesis and then introduces DR-TB with 
risk factors, the burden of disease as well as the diagnosis and treatment of TB and DR-TB. 
Chapter 3 introduces the pharmacology of kanamycin and capreomycin, with explanations 
regarding pharmacokinetics and pharmacodynamics, design and optimisation of a dosage 
regimen and lastly the pharmacokinetics of kanamycin and capreomycin. Ototoxicity is 
introduced in Chapter 4. In this chapter, the theories of ototoxicity are discussed, specifically 
relating to aminoglycosides such as kanamycin and capreomycin. Furthermore, the incidence 
of ototoxicity is mentioned, as well as ototoxicity specifically in the DR-TB population. 
Subsequently, ototoxicity monitoring is discussed in detail, as well as the impact that this 
hearing loss can have on a patient’s quality of life. 
The methodology of this study is particularised in Chapter 5 and includes a 
description of the aims and research design. This chapter contains the study design, study 
site, study population and the participant sample. It further elaborates on the data collection 
process; the personnel involved as well as the procedures and equipment involved with the 
audiological and pharmacological measures. It then continues to discuss the ethical 
considerations, data management, analysis procedures as well as the reliability and validity 
concepts.  
Chapter 6 provides an overview of the results obtained. Data are organised and 
analysed so that considerations and conclusions can be drawn regarding the aims of this 
study. 
In Chapter 7 the findings are discussed in relation to existing literature whilst 
Chapter 8 brings forth an outcome of the study in the form of the development of an 
ototoxicity monitoring protocol and mobile application. Chapter 9 finally concludes the 
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thesis with the summary of the findings, strengths, and limitations of the study followed by 
the implications and recommendations for future research. 
The references are then presented followed by the appendices. The appendices 
supply essential information for the understanding of the data collection and analysis 
procedures, and thus the replication of the study. 
1.5. Summary  
This chapter provided the rationale for the study by describing the background 
information that led to its development, as well as a description of the purpose of the study 
and research questions. The chapter concluded with an outline of the different chapters by 
which the aims of the study are described and realised. 
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Chapter 2: Tuberculosis  
The chapter begins with the description of TB and its pathogenesis. DR-TB is 
subsequently introduced, and pertinent risk factors for TB and DR-TB are discussed. 
Examinations of the burden of disease follows; regarding incidence, prevalence, mortality, 
and Disability-Adjusted Life Years (DALYs). The diagnosis of both TB and DR-TB are 
reviewed in detail followed by the treatment possibilities of TB and DR-TB. Treatment is 
discussed for both drug susceptible and resistant TB, with the influences of HIV on treatment, 
the treatment in South Africa, with specific reference to the decentralisation. Lastly, 
adherence to treatment is discussed. 
2.1. Tuberculosis 
Mycobacteria, a bacterium of a group of acid-fast bacteria, are highly pathogenic 
organisms that cause leprosy and TB (Hatta et al., 2010). Tuberculosis (TB) is a contagious, 
potentially lethal airborne disease (NDoH, 2011). There are five closely-related 
mycobacterium species, also known as the Mycobacterium tuberculosis complex (MTC), that 
can cause TB in humans or other living organisms (Addo, Owusu-Darko, Yeboah-Manu et 
al., 2007). The study postulated that the progenitor of this complex arose from a soil 
bacterium and that the human bacillus may have been derived from the bovine form 
following the domestication of cattle by humans (Cole et al., 1998). The MTC comprises of 
Mycobacterium bovis (M. bovis), Mycobacterium africanum (M. africanum), Mycobacterium 
microti (M. microti), Mycobacterium canetti (M. canetti) and Mycobacterium tuberculosis 
(M. tuberculosis) (Addo et al., 2007). M.tuberculosis, or TB, is a gram-positive bacterium 
that contains an additional layer beyond the peptidoglycan that is exceptionally rich in 
unusual lipids, glycolipids, and polysaccharides.  
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TB can affect any part of the body. The lungs (pulmonary TB) are typically affected, 
but other sites within the body (extra-pulmonary TB) can however also be affected (WHO, 
2015). Pulmonary TB is the most common form (Sharma & Mohan, 2004) and is also the 
most infectious. Extra-pulmonary TB is a consequence of the spread of mycobacteria to other 
organs, most frequently the pleura, lymph nodes, spine, joints, genito-urinary tract, nervous 
system or abdomen (NDoH, 2014). Not all organs are vulnerable to the TB bacteria. Specific 
organs and tissues are notably resistant to the multiplication of these bacilli. For example, the 
bone marrow, liver, and spleen are almost always sowed with mycobacteria, but the 
unrestrained duplication of the bacteria in these sites rarely occurs. 
The multiplication of these mycobacteria in specific organs, specifically in the lungs 
(pulmonary TB) results from the spreading of droplet nuclei, as discussed in the pathogenesis 
below. 
2.2. Pathogenesis  
The pathogenesis and transmission of TB are implicated with a droplet nucleus 
mechanism (Riley, 1974; NDoH, 2014). 
There is some controversy regarding the factors that clarify the prospect of 
transmission of TB. According to the Centre for Disease Control (CDC, n.d), four factors 
determine the probability for the transmission of M. tuberculosis, namely: (i) susceptibility of 
the exposed individual, (ii) infectiousness of the person with TB (which is directly related to 
the number of tubercle bacilli he/she expels), (iii) environmental factors that affect the 
concentration of M. tuberculosis organisms, and (iv) the proximity, frequency and duration of 
exposure (CDC, n.d). 
However, according to the NDoH (2014), three factors establish the probability of 
transmission of M. tuberculosis namely: (i) the amount of TB organism expelled; (ii) the 
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concentration of TB organisms as well as (iii) the period exposed to contaminated air. The 
NDoH does not include the environmental factors as per the CDC classification.  
The CDC (n.d) discusses that smaller enclosed spaces place an increased risk for 
transmission, while inadequate confined or general aeration results in deficient reduction or 
removal of infectious droplet nuclei. The recirculation of air containing infectious droplet 
nuclei as well as positive air pressure also stands as a risk for infection (CDC, n.d). Although, 
later in the NDoH guidelines (2014) it mentions that the concentration of these bacilli in the 
air, which is affected by the volume of space and the aeration, also affects the likelihood of 
infection (NDoH, 2014). Transmission is highest in dark and poorly ventilated spaces, while 
direct sunlight kills TB bacteria quickly (NDoH, 2014). 
Thus, TB has a complex life cycle, which includes two types of infection, namely 
primary and post-primary TB (Hunter, 2011).  
2.2.1. Primary Infection  
Primary infection occurs on first exposure to the TB bacilli from respiratory 
secretions from a patient with an infection of the respiratory tract (NDoH, 2014). This 
infection contaminates surrounding surfaces and becomes suspended in the air after 
coughing, sneezing, spitting and other respiratory acts. These small suspended respiratory 
droplets evaporate in the air and become tiny droplet nuclei (Riley, 1974). Droplet nuclei are 
small particles, one to five micrometres (μm) in diameter, containing one to five highly 
infectious bacilli. These droplets are minute and able to reach the alveolar spaces within the 
lungs (NDoH, 2014). An infectious dose of TB is only one to two bacilli, yet an infected 
individual can produce 3000 droplet nuclei and sneeze up to a million droplet nuclei which 
contain bacilli. The most infectious cases are those with smear-positive pulmonary TB (TB 
with more than 3000 bacilli), yet smear-negative pulmonary TB (TB with fewer bacilli) cases 
are less infectious (NDoH, 2014).  
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After inhalation of the tubercle bacillus in the droplet nuclei, these nuclei transmit 
down the trachea-bronchial tree and accumulate in a respiratory bronchiole or alveolus 
(Smith, 2003), normally in the lower part of the upper lobe or upper part of the lower lobe 
(NDoH, 2014). Here the alveolar macrophages ingest the droplet nuclei that produces a 
nonspecific response to the bacillus. Other macrophages and monocytes are enticed to the 
area and create an immune response. This inflammatory area is known as the Ghon focus. 
Bacilli and antigens drain from the Ghon focus via the lymphatics to the hilar lymph nodes, 
and together these form the primary (Ghon) complex. The inflammatory response generates 
the typical picture of caseous necrosis. Within the lymph node, the T-lymphocytes mount a 
specific immune response and activated macrophages inhibit the growth of the phagocytosed 
bacilli. This primary focus contains 1 000 – 10 000 bacilli that gradually lose their viability 
and multiply increasingly slowly. The tubercle bacillus grows slowly, splitting around every 
25 to 32 hours within the macrophage (Hunter, 2011; NDoH, 2014).  
In addition to the macrophages, dendritic cells play a crucial function in the initial 
stages of infection since they are better antigen presenters than macrophages and ostensibly 
play a central role in stimulating T-cells with specific M. tuberculosis antigens. As dendritic 
cells are nomadic, unlike discerned macrophages, they also may play an essential role in the 
dissemination of M. tuberculosis (Smith, 2003). Fibrous scar tissue replaces the inflammatory 
area in the primary focus, sometimes with calcification, in which the macrophages 
comprising bacilli are isolated and die (Hunter, 2011; NDoH, 2014). 
Extra-pulmonary TB can occur in organs that favour the growth of the TB bacilli such 
as in the kidneys, bones, and brain (NDoH, 2014). Although it is postulated that M. 
tuberculosis bacilli are unable to increase within this caseous tissue due to its acidic pH, the 
low availability of oxygen, and the presence of toxic fatty acids, some organisms may remain 
dormant but alive for decades (WHO, 2015). Thus, extra-pulmonary TB is, therefore, 
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bacteriologically confirmed or a clinically diagnosed case of TB involving organs other than 
the lungs, for example, pleura, lymph nodes, abdomen, genitourinary tract, skin, joints, bones 
and meninges (WHO, 2015). 
Nevertheless, TB is not always transmitted and does not always become infectious. In 
persons with an effective cell-mediated immunity, the infection may arrest permanently at 
this point (Smith, 2003). The strength of the host cellular immune response governs whether 
an infection halts here or progresses to the next stages. This enclosed infection is referred to 
as latent or persistent TB and can endure during a person's life in an asymptomatic and non-
transmissible state. Individuals with dormant TB infection are not infectious, as they do not 
have repeating bacteria and cannot spread the organism (NDoH, 2014). Also, in some cases, 
when TB is transmitted, the cellular immunity develops, and macrophages kill the infectious 
bacilli. Although the bacilli are killed it often results in the formation of the caseous centre in 
the granuloma, surrounded by a cellular zone of fibroblasts, lymphocytes, and blood-derived 
monocytes (Smith, 2003).  
2.2.2. Post Primary TB or Secondary TB 
Post-primary TB / Secondary TB may occur either by reactivation of latent bacilli or 
by re-infection (NDoH, 2014).  
Reactivation occurs when dormant bacilli, persevering in tissues for months or years 
after primary infection, start to reproduce. This may be a reaction to a prompt such as waning 
of the immune system by HIV infection for example (NDoH, 2014). Wong and Jacobs (2016) 
discuss that post pulmonary TB cases and almost all transmission of the disease is due to 
post-primary TB. It differs from primary TB in the genes that modulate susceptibility, clinical 
presentation, complications and age distribution of hosts. Post-primary TB is typically 
restricted to the upper lobes of the lungs and does not involve lymph nodes or other organs 
(Hunter, 2011). Post-primary TB develops mostly in immune-competent adults who gained 
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immunity earlier in their life from their first M. tuberculosis exposure and primary TB (Wong 
& Jacobs, 2016).  
In contrast, re-infection occurs when an infectious person exposes a person who 
previously had a primary infection. Following primary infection, rapid progression to intra-
thoracic disease is more common in children than in adults. Chest X-rays may show intra-
thoracic lymphadenopathy and lung infiltrates (NDoH, 2014). Sputum smears are regularly 
positive, and there is commonly no intrathoracic lymphadenopathy (NDoH, 2014). 
2.3. Further classification of TB 
TB is further described and classified as outlined by the Global TB Report (WHO, 
2015) and other sources (Pontali, Matteelli & Migliori, 2013; NDoH, 2011). 
• Bacteriologically confirmed case of TB -A patient from whom a biological specimen 
is positive by smear microscopy, culture or WHO-approved rapid-diagnostic-test (such 
as Xpert MTB/RIF) (WHO, 2015). 
• Clinically diagnosed case of TB -An individual who does not match the criteria for 
bacteriologically substantiated TB but has been diagnosed with active TB by a 
clinician or other medical expert who has decided to give the patient a full course of 
TB treatment. This definition includes cases diagnosed based on X-ray abnormalities 
or suggestive histology and extra-pulmonary cases without laboratory validation 
(WHO, 2015). 
• New case of TB -A patient who has never received treatment for TB or has taken anti-
TB drugs for less than one month (WHO, 2015). 
• Retreatment case of TB -A patient who was treated for one month or more with anti-
TB drugs in the past. Retreatment cases of TB could be a relapse, treatment again after 
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the failure of previous treatment, treatment after the loss to follow up and other 
unknown reasons (WHO, 2015). 
• Drug-Resistant Tuberculosis (DR-TB) - Strains of TB that are resistant to anti-TB 
antibiotics (Pontali et al., 2013; WHO, 2015). DR-TB may vary from single drug (DR-
TB) to multiple drug resistance (MDR-TB) (Pontali et al., 2013). The Global 
Tuberculosis Report describes DR-TB according to RR-TB, MDR-TB and Extremely 
Drug-Resistant TB (XDR-TB) (WHO, 2015). DR-TB can also be described according 
to Rifampicin Resistant TB (RR-TB) which is TB resistant to rifampicin, detected 
using phenotypic or genotypic methods, with or without resistance to other anti-TB 
drugs. It includes any resistance to rifampicin, whether mono-resistance, multidrug 
resistance, polydrug resistance or extensive drug resistance (WHO, 2015). Further, 
Multidrug-Resistant TB (MDR-TB) is TB that is resistant to two first-line drugs: 
isoniazid and rifampicin. For many patients diagnosed with MDR-TB, the WHO 
advocates treatment for 20 months with a regimen that incorporates second-line anti-
TB drugs (WHO, 2015).  
• Extremely Drug-Resistant (XDR-TB) is resistant to rifampicin, isoniazid and two of 
the most critical classes of second-line anti-TB drugs, namely a fluoroquinolone (such 
as oxifloxacin) and an injectable drug (namely amikacin, kanamycin or capreomycin) 
(WHO, 2015). XDR-TB is a particularly dangerous form of DR-TB (NDoH, 2011). 
DR-TB, whether RR-TB, MDR-TB or XDR-TB, can be further classified according to 
the TB treatment history with regard to resistance in new patients, resistance in 
previously treated patients or resistance levels in re-treatment (NDoH, 2011). The 
treatment of DR-TB involves second line drugs which are less potent and more toxic 
than those used for drug-susceptible TB (Pontali et al., 2013).  
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2.4. Associated Risk Factors 
There are several risk factors associated with TB, involving exogenous and 
endogenous factors. Exogenous factors play the main role in emphasising the advancement 
from exposure to infection (Narasimhan, Wood, MacIntyre & Mathai, 2013), while 
endogenous factors are aspects related to the individual (Narasimhan et al., 2013). 
2.4.1. Exogenous factors 
According to NDoH (2014), MDR-TB is a human-made problem, which is a 
consequence of human error, which can include either management of drug supply, patient 
management; including prescription miscalculations and/or patient adherence (NDoH, 2014). 
This assumption involves the social risk factors as discussed by Zhao, Li, Zhang, Wang and 
Liu (2012) but does not include other influences such as long-term illness, age, and poverty 
(Zhao et al., 2012). Conversely, Günther (2014) postulates that MDR-TB strains are being 
actively transmitted from person to person with accumulative regularity, and not always a 
direct consequence of human error.  
Risk factors can further include the aspects related to the TB itself (exogenous) and 
the person (endogenous) (Narasimhan et al., 2013). The exogenous features mainly include 
the bacillary load in the sputum and the proximity of an individual to an infectious TB case 
(Narasimhan et al., 2013). Correspondingly, endogenous aspects guide in the evolution from 
infection to active TB disease and are often host related.  
Regarding exogenous influences, the risk factor of the bacillary load refers to the 
concentration of the bacilli in the sputum from the TB case. Thus, a higher concentration of 
bacilli in the sputum results in a more infectious sputum sample. A high concentration of 
bacilli (smear positive) in the sputum is more likely to be transmitted than a smear-negative 
sample with a lower concentration (Narasimhan et al., 2013). Close interactions of infectious 
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TB cases (including household contacts and caregivers/healthcare workers) are at a higher 
risk of becoming infected with TB and the expansion of primary active tuberculosis 
(Narasimhan et al., 2013).  
2.4.2. Endogenous factors 
Endogenous factors include a more extensive variety of aspects which involve the 
effects from the individuals. These effects can include immunosuppression such as human 
immunodeficiency virus (HIV), malnutrition and a young age, as well as, evolving variables 
such as diabetes, indoor air pollution, excessive alcohol use, use of immunosuppressive 
drugs, and excessive tobacco smoke (Narasimhan et al., 2013). Socioeconomic and 
behavioural factors, as well as specific groups such as health care workers, are a factor in the 
susceptibility of TB infection (Narasimhan et al., 2013).  
Malnutrition, (both micro- and macro-deficiency), is another endogenous factor 
shown to increase the risk of TB because of a weakened immune response. TB disease can 
itself lead to malnourishment because of declining appetite and changes in metabolic 
processes. Although there is a link between malnutrition and risk of TB, the specific levels 
that place one at risk still need identification (Narasimhan et al., 2013). 
Furthermore, the presence of diabetes (Type 1 and Type 2 diabetes) also indicates an 
increased risk for the development of the active TB disease. It is approximated that currently 
70% of people with diabetes live in low- and middle-income countries, and the rates are 
progressively increasing in areas where TB is endemic, including India and sub-Saharan 
Africa. Diabetes is an endogenous risk factor as it directly prejudices the innate and adaptive 
immune responses, thereby accelerating the proliferation of TB (Narasimhan et al., 2013). 
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2.4.3. Additional factors 
Other factors that place one at risk of contracting TB include low socioeconomic and 
behavioural factors, alcohol abuse and indoor air pollution (Narasimhan et al., 2013). People 
with a low socioeconomic status are at risk for malnutrition, indoor air pollution, alcohol 
abuse. They are more likely to live in overcrowded and less ventilated spaces as well as are 
more likely to become infected with HIV. In South Africa, many dwellings are overcrowded, 
and unhygienic due to poor economic conditions, which increases this risk of infection 
(Narasimhan et al., 2013). 
Some working environments may also put some at risk for indoor air pollution. In 
developing countries, more than 80% of solid fuels for cooking is used. Firewood or biomass 
smoke has been recognised previously as a non-aligned risk factor for TB disease. Excessive 
alcohol consumption places one at an increased risk of alterations in the immune system, 
specifically in modifying the signalling molecules responsible for cytokine production. The 
association between tobacco smoke and TB has also been reviewed and shown that smokers 
have more chance of contracting TB than non-smokers. Also, health workers are at increased 
risk of exposure to TB (Narasimhan et al., 2013). Lastly, issues with health care systems may 
increase the risk for transmission of TB. Delays in the diagnosis and treatment initiation place 
an infected individual at risk of transmitting the disease (Narasimhan et al., 2013). 
Apart from the multifactorial process influencing the outcome of the disease, 
involving both environmental or host-related factors, in conjunction with the actual pathogen, 
genetic structures may also be affecting this disease progression (Mboowa, 2014). Studies 
from Canada and Australia have shown that indigenous people or Aborigines are at a higher 
risk of developing TB than the non-aborigines (Wang, 2000). A study conducted in Canada 
showed that several aborigines had a gene deletion that may have predisposed them to 
developing active TB disease (Greenwood et al., 2000). Additionally, Human Leukocyte 
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Antigen (HLA) alleles are found to be associated with susceptibility and resistance to 
infectious diseases including TB. A study from various populations throughout the world 
showed countries further from Africa have lower HLA diversity, indicating possibly African 
genetic susceptibility to TB (Mboowa, 2014). Furthermore, a susceptibility locus of 
rs4331426 on chromosome 18q11.2 for TB in the African population has been identified 
(Mboowa, 2014). 
XDR and MDR-TB have the same root cause: negligent case-management and poorly 
operational public-health services. The magnitude of this public health problem is instigated 
by incorrect prescription of drug regimens, poor drug quality, erratic drug supply, non-
adherence by patients, and inadequate infection control (Van Rie & Enarson, 2006). The 
deteriorating health care system, in conjunction with the other exogenous and endogenous 
factors, is specially problematic, as in South Africa, decentralisation of treatment occurs, 
where patients are treated with an outpatient regimen. These guidelines do not consider the 
poor living conditions, as many South Africans reside in homes with little or no ventilation as 
well as factors such as malnutrition, overall health aspects, and alcohol abuse to name a few. 
2.5. Burden of Disease 
Burden of disease describes the total and cumulative effects of a defined disease with 
respect to disabilities in a population. These outcomes include health and social aspects as 
well as costs to society (Kirch, 2008). Burden of disease is measured generally in terms of 
incidence, prevalence, and mortality (WHO, 2014). It is also often measured with DALYs 
(Institute for Health Metrics and Evaluation, 2010).  
The overall burden of TB has been declining at an annual average of 2.2% (between 
2010 and 2011) yet the number of patients with DR-TB in increasing (Heychendorf, Olaru, 
Ruhwald & Lang, 2014). The poor treatment outcomes also indicate the extent of the burden 
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of disease. A systematic review was conducted with the aim to synthesise available evidence 
on treatment outcomes from community-based multi-drug resistant (MDR-TB) and 
extensively drug-resistant tuberculosis (XDR-TB) treatment programs. Unfortunately, no data 
mentioned South Africa. Of this population, 65% of patients had a successful outcome, 15% 
defaulted, 13% died, and 6% failed treatment for a total of 35% with unsuccessful treatment 
outcome (Weiss, Chen, Cook & Johnston, 2014). In the research reported in the NDoH 
guidelines (2011), 71% of patients started DR-TB treatment in 2010. It does not mention 
success rates of this though. However, in the meta-analysis above, 65% with a successful 
outcome is not enough. Unfortunately, this study was not able to obtain data regarding the 
overall outcome of treatment, but it does highlight the considerable burden of TB and DR-
TB. 
2.5.1. Incidence and Prevalence  
In 2015, the global incidence of new TB cases was 10.4 million, of which 5.9 million 
were men and, 3.5 million were women, and one million were children. The top six countries 
that accounted for 60% of the new cases were India, Indonesia, China, Nigeria, Pakistan and 
South Africa. The rate of decline in TB incidence was only 1.5% from 2014 to 2015 
worldwide (WHO, 2016b). In 2015, there were an estimated 480 000 new cases MDR-TB 
cases worldwide and 100 000 RR-TB cases who were eligible for treatment, yet only 12 000 
enrolled (20%). In the 2016 WHO TB Report, globally, the MDR-TB treatment success was 
only 52% (WHO, 2016b).  
In 2012, 14 161 cases of MDR-TB were documented in South Africa (Conradie et al., 
2014). Günther (2014) writes that in 2012 in SA, 1.8% of new cases and 6.7% of retreatment 
patients had MDR-TB within an overall estimated TB incidence of 1,000 per 100,000 people. 
However, the precise global trends of DR- TB incidence and prevalence are currently ill-
defined because of inadequate investigation and recognition methods (Günther, 2014). In this 
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article by Günther in 2014, XDR-TB had been detected in 92 countries and with an average 
of 9.6% of MDR-TB cases having XDR-TB cases. He further states that there have been 
publications on totally drug-resistant TB (TDR-TB), where such patients are resistant to all 
second-line anti-TB medication tested. However, TDR-TB is not yet officially recognised 
nomenclature. 
South Africa has the third highest absolute number of reported incident cases as well 
as the fifth highest number of estimated prevalent (undiagnosed active TB) cases. After 
adjusting for population size, South Africa has the highest incidence and prevalence of TB 
among high burden TB countries (Churchyard et al., 2014). Although the prevalence of TB 
may be decreasing, the prevalence of DR-TB is increasing.  
Earlier, a review by the South African National Tuberculosis Association (SANTA) 
found that with an approximate population of 41.4 million and an estimated 130,000 TB 
cases in 1995, South Africa had one of the maximum annual TB incidences (311 per 100,000 
populations) in the world. The TB incidence did, however, vary radically by both 
geographical region and population group (SANTA, 2013). Gauteng was not ranked as a 
province with a higher incidence of TB, as were the Eastern Cape, Kwa-Zulu Natal and the 
Western Cape (Kanabus, 2017). Onyenekwu, Zemlin and Erasmus (2014) further reported 
that that the incidence of TB in the Western Cape is higher than the national incidence rate of 
823/100 000 population, at 935/100 000 population (Onyenekwu et al., 2014). 
From these 10.4 million cases, 1.2 million were HIV positive. HIV, a prominent risk 
factor increases the probability to acquire active TB than those with healthy immunity. The 
NDoH (2011) describes the combination of HIV and TB as a lethal combination, each 
speeding the progression of the other disease. Worldwide, the proportion of TB cases living 
with HIV was highest in the African Region (WHO, 2016b). South Africa also has one of the 
world’s most significant TB epidemics driven by HIV. It also has the most substantial 
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number of HIV-associated TB cases and the second-largest number of diagnosed multidrug-
resistant TB cases (after India) (Churchyard et al., 2014). TB is a prominent cause of death 
among individuals who are HIV infected (NDoH, 2011). Fifty to 60% of HIV positive people 
infected with TB will go on to develop active disease. 
 The yearly risk of TB in an HIV positive individual is 10% contrasted to a lifetime 
risk of 10% in a healthy individual (NDoH, 2014). Globally, according to the TB report 
(WHO 2016b), in 2015, 55% of TB patients had a documented HIV test result. In the African 
Region, 81% of TB patients had a recorded HIV test result. The relative number of known 
HIV-positive TB patients on antiretroviral therapy (ART) was 78% globally. Also, according 
to this report published in 2016, globally, 15% of TB patients with an HIV test result were 
HIV-positive (WHO, 2016b).  
2.5.2. Mortality 
In 1993, the WHO declared TB a global public health emergency (WHO, 2014a). 
Since 1990, TB mortality has fallen 47%, with most of that improvement taking place since 
2000. Between 2000 and 2014, an estimated 43 million lives were estimated to have been 
saved through correct diagnosis and treatment (WHO, 2015a). 
An estimated 1.4 million TB deaths transpired in 2015, and an additional 0.4 million 
deaths resulting from TB disease among persons living with HIV occurred. Although the 
number of TB deaths fell by 22% between 2000 and 2015, TB remained one of the top 10 
causes of death worldwide in 2015 (WHO, 2016b). 
2.5.3. Disability Adjusted Life Years (DALYs) 
The global burden of disease study, conducted in 2010, was a collective project of 
approximately 500 researchers in 50 countries led by the Institute for Health Metrics and 
Evaluation (IHME) at the University of Washington (IHME, 2010). Global Burden of 
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE 
RELATIONSHIP BETWEEN HEARING LEVELS: A FEASIBILITY STUDY 
21 
Disease serves as a global public to advise evidence-based policymaking and health systems 
design. Amongst others, the IHME evaluated Disability Adjusted Life Years (DALYs) 
(IHME, 2010). DALYs quantify both premature mortality and disability within a population. 
In South Africa, the top three causes of DALYs in 2010 were HIV, diarrheal diseases, and 
interpersonal violence. TB ranked fifth after lower respiratory infection (IHME, 2010). In a 
population of 54 490 000 in South Africa, the fifth ranking on the DALY list demonstrates 
the immense problem of TB and the number of people it affects; in many aspects of their 
lives.  
2.6. Diagnosis of Tuberculosis 
Prompt and accurate diagnosis of all forms of TB followed by provision of treatment 
in line with international benchmarks prevents death and limits ill-health among individuals 
who develop the disease. It also prevents further spread of infection to others (WHO, 2016b). 
Diagnosis of TB and DR-TB requires a comprehensive assessment that includes a 
comprehensive medical history, physical examination, bacteriological investigations and 
other adjunctive clinical tests to confirm the diagnosis (NDoH, 2014).  
2.6.1. Medical History  
A comprehensive medical history is vital to understand the patient’s history of TB 
exposure, infection or disease (CDC, 2016). In addition to general medical history, the 
clinician should probe areas relating to previous TB infections and current symptoms of TB. 
Should symptoms be present, the clinician would continue with further enquiries regarding 
the specificities of the symptoms, as well as if the patient has had contact with a person with 
infectious TB disease. Equally important is obtaining information on whether the person was 
diagnosed in the past with latent TB infection or TB disease. Clinicians may be required to 
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contact other districts or treatment sites regarding previous infection, treatment regimen and 
known outcome (CDC, n.d). Demographic factors should also be obtained such as country of 
origin, age, ethnicity, occupation, or racial group as these may increase the patient’s risk of 
exposure to TB infection. Clinicians should further determine if the patient has underlying 
medical conditions, specifically HIV or diabetes (CDC, n.d; Tattevin et al., 1999). 
2.6.2. Physical Examinations 
The physical examination is an essential part of the evaluation of any patient (CDC, 
n.d; NDoH, 2014; Herchline & Amorosa, 2016). Although the physical examination cannot 
confirm or rule out TB disease, it does provide valuable information about the patient’s 
overall condition, inform the method of diagnosis, and reveal other factors that may affect TB 
disease treatment, if diagnosed (CDC, n.d; NDoH, 2014; Herchline & Amorosa, 2016). 
Specific aspects of identifying patients with possible pulmonary TB would include 
raised body temperature, increased pulse, and abnormal signs when listening to the chest. 
Other symptoms of TB and DR-TB can include dyspnoea, haemoptysis and systematic 
symptoms (fever, chills, night sweats, tiredness, anorexia, weight loss). When listening to the 
chest, one would listen for crackles in the lung apices to be more pronounced on deep 
breathing; localised wheezing in local obstructions or pressure; dullness where there is 
effusion and in chronic disease there may be extensive fibrosis with the trachea pulled to one 
side (NDoH, 2014). There may also be manifestations unrelated to the site of involvement, 
including haematological abnormalities, hyponatraemia, and psychological disorders. Extra-
pulmonary DR-TB, however, is more difficult to diagnose because it often involves very 
inaccessible sites (NDoH, 2011). The doctors’ medical history and examination would try to 
identify the above symptoms. (CDC, n.d; NDoH, 2014; Herchline & Amorosa, 2016). 
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2.6.3. Bacteriological Investigations 
Definitive diagnosis can only be attained based on bacteriological investigations. 
According to the WHO (2014a), among pulmonary TB cases, 58% were bacteriologically 
confirmed (as opposed to clinically diagnosed) in 2013. The remaining 42% of patients who 
were not bacteriologically confirmed could result in a false diagnosis with individual’s 
enrolment on TB treatment when not necessary. Furthermore, a low rate of laboratory 
confirmation reflects an under-diagnosis of true TB cases and contributes in part to the 
continuing global gap between notified and estimated incident TB cases (5.7 and 9.0 million 
in 2013, respectively). Also, detection of TB without investigating for drug resistance can 
lead to ineffective treatment, further development and spread of drug-resistant strains and 
additional suffering and costs for patients. 
All forms of bacteriological TB diagnoses occur by using a variety of bacteriological 
investigation methods (NDoH, 2014). The diagnostic tests available to confirm 
bacteriological TB include: (i) Smear Microscopy, (ii) Culture Methods, and (iii) Molecular 
Methods [Polymerase chain reaction (PCR) based assays: Line probe assay and Xpert 
MTB/RIF].  
Microscopy and culture are still the basis of TB diagnostics. Sputum smear 
microscopy is the most common method for diagnosing TB worldwide (Desikan, 2013; 
NDoH, 2014). Sputum smear microscopy entails the examination and observation of the 
bacilli in sputum samples under a microscope (Desikan, 2013; NDoH, 2014), using either one 
of two staining methods, namely the Ziehl-Neelsen staining method (NDoH, 2014, Truffot-
Pernot & Cambau, 1994) or fluorescent auramine staining method (NDoH, 2014). The 
staining procedure depends on the ability of mycobacteria to retain these dyes when treated 
with acid and alcohol solutions (NDoH, 2014). 
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The use of sputum smear microscopy is controversial. Sputum smear microscopy is 
fast, inexpensive and requires minimal bio-safety standards (Desikan, 2013; Steingart et al., 
2006; WHO, 2014b). However, it is not a sensitive test, particularly in children and people 
living with HIV as it provides no information on the viability and drug susceptibility of the 
bacilli. The viability and drug susceptibility were observed in a study published in 
Stellenbosch, South Africa, where the objective was to assess the use of a sputum register to 
evaluate the TB diagnostic process and the initiation of TB treatment. TB patients were 
classified as patients with two positive smears. Over the entire diagnostic process, up to 5% 
of TB cases were missed (Botha et al., 2008). The sensitivity is grossly compromised when 
the bacterial load is less than 10,000 organisms/ml per sputum sample. It also cannot 
distinguish between MTC and non-TB mycobacteria (Desikan, 2013; WHO, 2014b).  
Culture methods, in comparison, are more sensitive than smear microscopy as they 
detect a higher proportion of cases among patients with symptoms (David, Katalinić-
Janković, Fattorini & Cirillo, 2016; Desikan, 2013). It allows for the detection of very low 
numbers of bacilli (approximately 10 bacilli/ml of sputum compared with at least 5000 
bacilli/ml of sputum for microscopy) (David et al., 2016). The use of culture tests increases 
the number of TB cases found by 30–50% (David et al., 2016). Culture tests diagnose 
extrapulmonary TB, distinguish TB from non-TB mycobacteria and detect treatment failures. 
Culture testing is also critical for monitoring patients’ response to treatment for DR-TB. 
Molecular methods have been the recent breakthroughs in TB diagnostics in the past 
decade, to diagnose TB and DR-TB (WHO, 2014b). In 2010, the WHO endorsed 
Xpert®MTB/Rif (Cephaid, Sunnyvale, USA), a PCR-based diagnostic tool (Günther, 2014). 
Molecular biology is now becoming more critical in the diagnosis of mycobacteria. It 
supports culture either by serving as a rapid direct test on specimens or by enabling a rapid 
and unequivocal species differentiation from culture material. Nucleic-acid-based methods 
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have primarily displaced the classical methods (Hillemann, Miychell, Drobniewski, 2016). In 
countries with more developed laboratory capacity, cases of TB are also diagnosed via 
culture methods (the current reference standard) (WHO, 2014b). Molecular genetic tests offer 
considerable time advantages in the identification of mycobacteria, enabling a more rapid 
initiation of resistance tests and specific treatment. Molecular methods are useful tools for the 
detection and differentiation of mycobacteria from cultures and can have a high specificity 
and sensitivity. It should be stated, however, that they cannot/should not replace the currently 
endorsed standard methods of detecting mycobacteria and determining drug-susceptibility 
patterns. Instead, their use should support the diagnostic work-up. Confirmation of the test 
results should always be through the use of the standard methods (Hilleman et al., 2016). 
In South Africa, there are two PCR technologies available which provide different 
information that is helpful in the management of TB and DR-TB. They include the 
Xpert®MTB/Rif test using the Gene Xpert (GXP) instrument, which is useful for rapidly 
diagnosing TB as well as it allows rapid screening for Rifampicin resistance. Results can be 
available within two hours in the laboratory but only become available within 48 hours in 
health facilities (NDoH, 2014). In clinical evaluation studies, its sensitivity approaches 100% 
in smear-positive pulmonary TB patients and 57–83% in patients with smear-negative 
pulmonary TB (Pontali et al., 2013). 
As per the South African guidelines when diagnosing DR-TB rapid testing using 
Xpert®MTB/RIF, confirmatory drug susceptibility testing for patients with RR-TB, rapid 
tracing and linkage to treatment and rapid tracing and evaluation of contacts is suggested 
(NDoH, 2014). Gene Xpert is the method most commonly used in South Africa. 
Line probe assay is the second molecular test that can be performed on all respiratory 
specimens and other specimens where the detection of rifampicin resistance in MTB is the 
primary purpose of the investigation (Hilleman et al., 2016). This is useful for drug resistance 
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confirmation and detects resistance to both Rifampicin and Isoniazid. Line probe assays is 
specific for MTB complex and can differentiate MTB from other mycobacteria. Line probe 
assays can only be performed on smear positive or culture positive sputum specimen (NDoH, 
2014). 
Where molecular tests, such as the GeneXpert are available, culture may still be 
required for HIV positive patients where TB is suspected yet have a negative GeneXpert test 
(NDoH, 2014) and RR-TB cases, where testing for another drug resistance is necessary 
(NDoH, 2014).  
There are a few other bacteriological tests that can be used in conjunction with the 
methods mentioned above but should not be used in isolation as a diagnostic test. These tests 
include: (i) Interferon gamma Release Assays (blood tests that detect MTB infection but 
cannot distinguish latent TB from active TB), (ii) blood culture (may be used to detect MTB 
and other species of mycobacteria in HIV-infected patients; especially those with low CD4 
count), (iii) TB LAM (detects lipoarabinomannan antigens in urine - further studies are 
however required to determine the role of this test), (iv) histological examination (can be 
conducted on a tissue specimen, but this is not considered to be bacteriological confirmation 
of disease) and (v) the Tuberculin skin test (limited value in clinical work as the test shows 
hypersensitivity to proteins of the TB bacillus, as a result, either of infection with M. 
tuberculosis or induced by Bacille Calmette-Guérin vaccination) (NDoH, 2014). 
2.6.4. Other adjunctive tests  
Adjunctive tests can include chest X-rays, ultrasound, computerised tomography (CAT) 
and Magnetic Resonance Imaging (MRI), the erythrocyte sedimentation rate (ESR) test and 
Adenosine DeAminase (ADA) detection. 
Chest X-rays, despite that they can result in the over-diagnosis of TB, can also miss the 
diagnosis of TB, as many other diseases mimic TB on an X-ray. Chest X-rays are necessary 
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for patients who cannot produce sputum or who have negative Xpert results and are HIV 
positive, and where extra-pulmonary TB (such as pleural effusions and pericardial TB) is 
suspected (NDoH, 2014; van Cleeff, Kiviha-Ndugga, Meme, Odhiambo & Klatser, 2005). 
Additionally, ultrasound are used as a supplementary test in the diagnosis of extrapulmonary 
TB (NDoH, 2014). Computerized Tomography and Magnetic Resonance Imaging are 
extremely expensive, but they can prove useful for imaging TB lesions which may not be 
visible on a standard X-ray (NDoH, 2014). While Erythrocyte Sedimentation Rate (ESR) test 
is not a confirmatory test for TB, but is a complimentary test, as a number of other infections 
and diseases also result in elevated ESR (NDoH, 2014; Al-Marri & Kirkpatrick, 2000) Lastly, 
ADA is an enzyme found in most cells, but it becomes elevated in TB effusions (>30μl) 
(NDoH, 2014).  
Despite all the above measures to diagnose TB, traditionally TB services have relied 
on passive, self-presentation of persons with TB symptoms to the health facilities (NDoH, 
2014). However, due to the increase of DR-TB, it is crucial to increase the awareness of TB 
and DR-TB to ensure the early identification of TB, via the appropriate and available testing 
methods, which can assist in the prevention or reduction of the transmission of TB (NDoH, 
2014). 
2.7. Treatment of Tuberculosis 
As a result of the variety of risk factors that expose people to the higher possibility of 
contracting TB, treatment of the infected individual is thus not only essential for the patient, 
but also for the individuals in his/her environment. If the infection goes untreated, each 
person with active TB disease will infect on average between ten and fifteen people every  
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year, as the disease is airborne (WHO, 2012). All types of drug-susceptible TB 
(pulmonary and extra-pulmonary) are treated in the same way (NDoH, 2014). However, DR-
TB requires treatment with different drugs and a different regimen.  
2.7.1. History  
The South African National TB Association, established in 1947, describes the history 
of TB in South Africa. The knowledge of the history of TB in South Africa is relatively 
limited, due to the lack of data during the apartheid era.  
The significant changes to TB control started in 1994 when South Africa recruited 
expert external help for the first time with a visit by Dr Karel Styblo, ex-director of scientific 
activities at IUATLD, to perform a rapid appraisal of the TB situation. Dr Styblo found that 
the national guiding principle (established in 1979) was not instigated, there was a lack of 
focus on infectious cases (smear positive), and the information system was insufficient 
(SANTA, 2013). 
In 1995, a revised National TB Control Program (NTCP) was established based on the 
WHO’s Directly Observed Short Course. The programs aim was the application to gradually 
replace the non-standardized of short -course chemotherapy in use throughout the country for 
several years (SANTA, 2013). In 1996, South Africa requested the assistance of the WHO to 
evaluate the epidemiology and control activities of TB in order to produce a recommendation 
to improve TB control and treatment in South Africa (SANTA, 2013). 
In 2012, the South African government produced a National Strategic Plan (NSP) for 
tacking HIV, Sexually Transmitted Disease and TB. The plan aimed to control the spread of 
TB with the ambitious aim of zero new TB infections and deaths by 2032, and a halving of 
the 2012 rates by 2016 (Knight et al., 2015).  
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2.7.2. Drug-Susceptible Tuberculosis 
Effective TB drug treatments were first developed in the 1940s. In South Africa, the 
recommended treatment for new cases of drug-susceptible TB complies with international 
guidelines (NDOH, 2014). The standard six-month treatment regimen of four first-line drugs 
consists of an intensive phase lasting two months and a continuation phase lasting four 
months (NDoH, 2014). The TB drugs used are Isoniazid, Rifampicin, Pyrazinamide and 
Ethambutol/Streptomycin. Standardised regimens use a combination of medicines, and fixed-
dose combination tablets are also available for adults and children in some cases. Pyridoxine 
(Vitamin B6), as an adjunctive treatment, is implemented for all adults and corticosteroids is 
recommended in extra-pulmonary TB cases (NDoH, 2014).  
The drugs can also result in side effects as in Table 2.1. 
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Table 2.1 
Side Effects Associated with TB medication 
Drug Side Effects 
Rifampicin Anorexia, nausea and abdominal pains 
Orange/red coloured urine 
Skin rash 
Jaundice 
Vomiting  
Confusion 
Generalised purpura 
Isoniazid Burning sensation in the feet 
Skin rash 
Jaundice 
Vomiting  
Confusion 
Pyrazinamide Jaundice 
Vomiting  
Confusion 
Streptomycin Skin rash 
Deafness  
Dizziness 
Ethambutol Visual impairments 
(NDoH, 2014) 
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Globally, in 2013 the treatment success rate was 86% among all new TB cases 
(WHO, 2015). In 2012, the treatment success rate TB patients in relation to HIV was 
persistently worse for HIV-positive TB patients (74%) than HIV-negative TB patients 
(88%).The difference was smaller in the African region (75% and 83%, respectively). 
Conversely, there were substantial differences in the Western Pacific and Eastern 
Mediterranean Regions, where the treatment success rates among HIV-positive TB patients 
were only 55% and 53% respectively, compared with 94% and 82% among HIV-negative 
patients (WHO, 2014a).  
2.7.3. Drug-Resistant Tuberculosis – Internationally 
The 2016 WHO guidelines for the treatment for DR-TB are a revision of the 2011 
guidelines. In an article by Pontali et al. (2013), a study in MDR-TB patients showed that the 
use of amikacin, kanamycin, capreomycin, moxifloxacin, ethionamide/prothionamide, and 
cycloserine were all correlated with considerably higher probabilities of treatment success 
(Pontali et al., 2013). These 2011 guidelines were amended slightly in 2016 specifically with 
regard to the classes of drugs, duration of treatment and the role of surgery. 
Ahuja et al. (2012) conducted a patient meta-analysis to assess the impact on 
outcomes of the type, number, and duration of drugs used to treat MDR-TB. This analysis 
was based on the retrospective analysis of 9153 patient records from individuals with 
resistance to at least isoniazid and rifampicin, from 32 observational reviews investigating the 
effect of type, number of drugs and cycle of treatment on the outcome (Ahuja et al., 2012). 
From this examination, the general treatment success in this group was 54%. The study 
showed that the probability of treatment success is uppermost using at least four in-vitro 
susceptible drugs in the intensive phase of treatment and at least three susceptible drugs 
during the continuation phase for patients who had not received second-line drugs 
beforehand. The study also emphasised the importance of later-generation fluoroquinolones 
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for effective treatment and the possible benefit of ethionamide and prothionamide in DR-TB. 
The most significant chance for positive treatment outcomes was with an intensive phase 
(including an injectable in the) for seven to eight and a half months, and a total treatment 
duration of 25–27 months. This study underlines the massive challenges of DR-TB treatment. 
These guidelines DR-TB for management are based on retrospective, observational data, 
where just half of the patients successfully completed treatment (Ahuja et al., 2012).  
2.7.3.1. Drugs. 
Treatment for DR-TB (both RR-TB and MDR-TB) involves the inclusion of four 
categories or groups (A to D) of drugs. In patients with DR-TB, a regimen with at least five 
effective TB drugs during the intensive phase is recommended, including pyrazinamide and 
four core second-line TB medications - one chosen from group A, one from group B, and at 
least two from group C2 (Table 2.2). If this regimen cannot be given for some reason, an 
agent from group D2 and other agents from D3 may be added to bring the total to five 
effective TB regimens.  
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Table 2.2 
WHO recommended medication for the treatment of RR-TB and MDR-TB (WHO, 2016b)1 
Category of Medication Name of Medication 
Abbreviation of 
Medication 
A. Fluoroquinolones2 Levofloxacin 
Moxifloxacin 
Gatifloxacin 
Lfx 
Mfx 
Gfx 
B. Second-line injectable agents Amikacin 
Capreomycin 
Kanamycin 
(Streptomycin)3 
Am 
Cm 
Km 
(S) 
C. Other core second-line 
agents2 
Ethionamide/Prothionamide 
Cycloserine/ Terizidone 
Linezolid 
Clofazimine 
Am 
Cm 
Km 
(S) 
D. Add-on agents  
(not part of the core MDR-
TB regimen 
D1 Pyrazinamide 
Ethambutol 
High-dose isoniazid 
Z 
E 
Hh 
D2 Bedaquiline 
Delamanid 
Bdq 
Dlm 
D3 p-aminosalicylic acid 
Imipenem-cilastatin4 
Meropenem4 
Amoxicillin-clavulanate4 
(Thioacetazone)5 
PAS 
Ipm 
Mpm 
Amx-Clv 
(T) 
Note. 1The intention of this regrouping is to guide the design of conventional regimens; for shorter regimens 
lasting 9-12 months the composition is usually standardised (See Section A);  
2Medicines in Groups A and C are shown by decreasing order of usual preference for use (subject to other 
considerations);  
3In some cases, streptomycin may substitute other injectable agents. Resistance to streptomycin alone does not 
qualify for the definition of XDR-TB; 
4Carbapenems and clavulanate are meant to be used together; clavulanate is only available in formulations 
combined with amoxicillin 
 5HIV-status must be tested and confirmed to be negative before thioacetazone is started. 
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Class B consists of the aminoglycosides, which are bactericidal aminoglycosidic 
aminocyclitols. They are used for the treatment of TB but also used for advanced bacterial 
infections (Schacht, 1993). Aminoglycosides investigated explicitly in the current study, 
kanamycin, as well as polypeptides, specifically capreomycin, have been shown to be toxic; 
both ototoxic and nephrotoxic (Njuguna, 2013). Nephrotoxicity results from acute tubular 
necrosis as these drugs appear to concentrate in the renal tubular cell (Alamadi & Rutka, n.d). 
Ototoxicity, a significant public health concern is occurring in the DR-TB population, 
specifically in South Africa (Njuguna, 2013).  
In the industrialised world, aminoglycosides are limited generally to treat severe 
infections, due to their toxicity. In the developing world, such as South Africa, 
aminoglycosides are used more frequently because of their low-cost potent antibacterial 
activities, outrivalling more expensive antibiotics with less severe side effects (Huth et al., 
2011). Despite their toxicity, they are still in the WHO (2016b) guidelines for the treatment 
of DR-TB. 
The WHO does not recommend alternate and more recent drugs such as bedaquiline 
and delamanid for routine use in MDR-TB treatment. However, they remain as options in 
cases where acceptable schedules are impossible to design with medications from the other 
groups (WHO, 2014b). In South Africa, they are referred to as third-line-drugs and are 
currently only available at designated sites and are only available to patients with specific 
criteria (NDoH, 2015).  
Further, for the HIV positive population, along with the complicated DR-TB 
medication regimen, the inclusion of antiretroviral therapy (ARV) is a necessary factor in the 
HIV infected patients’ treatment. ARV is advocated for all patients with HIV and DR-TB 
needing second-line anti-tuberculosis drugs, irrespective of CD4 count, promptly (within the 
first eight weeks) following initiation of TB treatment (WHO, 2011). 
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2.7.3.2. Duration. 
Currently, in the treatment of patients with DR-TB, the WHO suggests an intensive 
phase of eight months for most patients, and modifications to the duration may ensue 
according to the patient’s response to therapy (conditional recommendation, very low-quality 
indication) with a total treatment duration of 20 months (WHO, 2014b).  
According to the WHO, where a shorter duration is based on a qualified 
recommendation with very low-quality evidence, the updated guidelines in 2016 include a 
shorter duration. They include patients with RR-TB or MDR-TB who have not previously 
received treatment with second-line drugs and in whom resistance to fluoroquinolones and 
second-line injectable agents has been excluded or is considered implausible. For these 
patients, a shorter MDR-TB regimen of nine to 12 months may be utilised instead of a 
conventional regimen (WHO, 2016b). 
The optimal duration for treatment of patients with DR-TB, however, differs between 
individuals as it depends on a variety of factors, such as the extent of the disease, the immune 
status of the patient, and the virulence and the drug resistance of the causative strain of M. 
tuberculosis. Personalization of the duration of treatment for DR-TB would be highly 
beneficial. Until recently there has been little interest in the identification of biosignatures 
that could eventually lead to individual recommendations for the duration of anti-TB therapy 
(Heychendorf et al., 2014).  
2.7.3.3. Surgery. 
In patients with RR-TB and MDR-TB, elective partial lung resection (lobectomy or 
wedge resection) may transpire alongside a recommended MDR-TB regimen (WHO, 2016b). 
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2.7.4. Drug-Resistant Tuberculosis: South Africa 
2.7.4.1. Regimen. 
In South Africa, all patients newly diagnosed with DR-TB (MDR-TB and RR-TB) 
receive a standardised treatment regimen, unless otherwise indicated. Four weight bands 
guide the administration of the medication: <33kg, 33-50kg, 50-70kg and > 70kg. The dose 
of the injectable is provided respectively at: 15-20 mg/kg, 500-750 mg/kg, 1000 mg/kg and 
1000/kg mg respectively (NDoH, 2011). This regimen complies with the international 
standards specified by the WHO (2011) and since 2014 includes delamanid and bedaquiline. 
Depending on prior use and tolerability, different drugs are utilised. However, mostly, 
treatment involves a standardised regimen which consists of at least six months intensive 
phase treatment with five drugs: moxifloxacin, ethionamide, terizidone, pyrazinamide and an 
injectable (kanamycin/amikacin) taken at least six times per week during the injectable phase. 
A continuation phase treatment ensues with four drugs; moxifloxacin, ethionamide, 
terizidone and pyrazinamide taken at least six times per week for 18 to 24 months beyond 
culture conversion (NDoH, 2011; NDoH, 2015). Isoniazid may be included in the DR-TB 
regime depending on the patient’s resistance profile. Wolff and Nguyen (2012) discussed 
how the limitation of the use of ethionamide is because of the low therapeutic index and high 
risk of toxicities. Two research groups reported the identification of ethionamide potentiators 
that significantly sensitise M. tuberculosis to the drug through the inactivation of a key 
resistance mechanism (Wolff & Nguyen, 2012). 
The NDoH (2011) mentions that kanamycin and amikacin are parenteral drugs that 
are structurally similar. Strains of TB that are resistant to streptomycin are usually susceptible 
to kanamycin and amikacin. When a patient is resistant to kanamycin, the kanamycin often 
induces almost complete cross-resistance with amikacin, and thus they should be considered 
as the same drug. Amikacin is as active as kanamycin and better tolerated, but is much more 
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expensive, and thus kanamycin is more frequently used (Rossiter et al., 2012). Capreomycin 
can be considered as the injectable in place of kanamycin and amikacin for patients with 
hearing loss, as it is less toxic. It is also more expensive, and not as readily available. Culture 
conversion guides the duration of the injectable phase which occurs when a patient obtains 
two consecutive negative TB cultures (30 days apart). The injectable phase is determined by 
adding four months to the culture conversion date if the total duration is less than six months 
and then adding 18 months to the culture conversion date without the injectables.  
Recently, third line drugs have been introduced for the management of DR-TB, and 
includes bedaquiline, delaminid, andlinezolid, however, these medications are currently only 
available at designated sites and are only available to patients with specific criteria. Third-line 
drugs would replace the injectable, yet have strict eligibility criteria, such as XDR and pre-
XDR, MDR with inhA and katG mutations both present, any RR-TB patient (MDR or 
rifampicin mono resistant) who develops treatment-related toxicity (hearing loss, renal 
failure, psychosis, etc.) and any rifampicin resistant patient who has pre-existing hearing loss 
or renal failure (NDoH, 2015). bedaquiline, delaminid, and dinezolid are not yet widely 
available, and so toxicity is still occurring. However, linezolid in managing XDR-TB has also 
shown limitations due to its high cost as well as other toxicity (myelosuppression and 
neuropathy), which appears to be determined by dose (>600 mg daily) and duration (Pontali 
et al., 2013). Studies have shown delamanid is one of the most promising compounds; it 
demonstrated an increase in the sputum-culture conversion rate at two months in patients 
with MDR-TB, when used in combination with a background regimen developed according 
to the WHO guidelines (Pontali et al., 2013). Capreomycin is considered a third-line drug as 
well in the new South African Department of Health Guidelines (2015). In practice, when 
patients are receiving their treatment as outpatients, they only receive their injectable five 
days a week, instead of the above stated ‘at least six times’ a week. 
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Despite these new drugs, a paediatric study showed that more than 90% of children 
receive successful treatment and a non-severe disease could be treated with reduced treatment 
duration. Reduced treatments duration is however generally for children younger than eight 
years, as they metabolise drugs differently. There is no regimen though specifically for 
children (less than eight years); only according to weight bands (Seddon, Hesseling, Godfrey-
Faussett & Schaaf, 2015). This shows the necessity to possibly ‘fine-tune’ the dosing regimen 
based on various factors, other than weight, and the possibility of incorporating the existing, 
less expensive drugs, with a change in administration and/or dosage, possibly guided by 
pharmacokinetics. 
2.7.4.2. Decentralisation. 
Prior to the implementation of the new guidelines, TB treatment in South Africa was 
centralised (NDoH, 2011). It involved the hospitalisation of patients from diagnosis with DR-
TB (RR-TB and MDR-TB) and XDR-TB until they received two negative TB cultures taken 
30 days apart. Thus, patients were hospitalised for months, and there were long waiting lists 
for patients needing admission to these centralised DR-TB treatment units. This centralised 
treatment resulted in a delay in the initiation of treatment in some provinces of up to three or 
four months. Of approximately 9070 cases of MDR-TB notified in 2009, fewer than 5000 
started treatment in the nine provinces. In 2010, there was a higher percentage of those 
diagnosed with MDR-TB starting treatment; however, there was still a significant gap (71% 
in 2010 in comparison to less than 55% in 2009). Thus, several patients could die before 
starting treatment. The number of patients diagnosed with MDR-TB far exceeded the number 
of hospital beds in the centralised MDR-TB units. The waiting times and waiting lists also 
resulted in many infectious and untreated patients exposing family and community members 
to DR-TB bacilli (NDoH, 2011).  
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 Furthermore, nosocomial transmission of MDR/XDR-TB occurs in health facilities 
when infection control measures are not adequately implemented as there is substantial 
evidence that more than half of all XDR-TB infections are acquired in hospitals (NDoH, 
2011). Patients also refused hospitalisation, and post hospitalisation, the monthly follow-ups 
were lengthy and unpleasant, which contributed to poor outcomes (NDoH, 2011).  
From other studies, full inpatient treatment or centralisation is also costly. A study by 
Sinanovic, Ramma, Vassall et al. (2015) investigated the costs of inpatient treatment in South 
Africa. They found that a fully hospitalised model was 42% more costly than the fully 
decentralised model (US $13 432 versus US $7 753 per patient). The annual total cost of 
treating all diagnosed cases ranged from US $110 million in the fully decentralised model to 
US $190 million in the fully hospitalised model. This cost of inpatient treatment may be 
unaffordable for a developing country such as South Africa. Based on this unfeasible option 
of hospitalisation, the NDoH proposed the decentralisation of treatment of patients with 
MDR-TB (not XDR-TB).  
The rationale for decentralisation was that it would shorten the number of days 
between diagnosis and treatment, increase treatment coverage, reduce the transmission by 
initiating treatment sooner, make it possible for patients to receive treatment in their homes 
and increase the social acceptance of treatment (NDoH, 2011). It would improve cost-
effectiveness by reducing lengthy hospital stays in specialised hospitals. This model mentions 
that each province should still have a specialised MDR/XDR-TB unit, yet additional DR-TB 
decentralised units with the establishment of several satellite units. These guidelines mention 
a study by Nardell and Churchyard (2011) who describe the long-standing evidence 
suggesting that TB patients on effective therapy rapidly become non-infectious and that 
unsuspected, untreated TB cases account for most transmission.  
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Despite the positive aspects of decentralisation, areas of concern have been identified 
with this model. A community-based DR-TB treatment program in Khayelitsha, South Africa 
was investigated (Moyo et al., 2015). Moyo et al. (2015) investigated loss from treatment 
(LFT), and post-treatment outcomes of DR-TB patients in this setting. Loss from treatment 
was defined as an interruption of treatment for ≥2 consecutive months, and it was assessed 
among patients initiating DR-TB treatment for the first time. Patients were traced through 
conventional data sources to identify those who subsequently restarted treatment and those 
who died. Community DR-TB counsellors and provided additional information on patient 
status and survival as well as the use of the national death registry. Among 452 patients 
initiating treatment for the first time within the given period, 30% were LFT, with 67% 
retention at 18 months. Treatment was restarted in 20% of the patients, with additional 
resistance recorded in 8%, excluding two with presumed DR-TB. Overall, 25% of the 
patients died. In summary, LFT was high, occurred throughout the treatment period and was 
unusually high among males and those aged 15-25 years. Overall long-term survival was 
poor. Community-based treatment is not merely an alternative to centralised treatment, and 
the decentralisation model needs to address these issues (Moyo et al., 2015). 
In order to compromise and find a fair ‘medium’, Padayatchi and Friedland (2008) 
proposed an intermediate suggestion, between centralisation and decentralisation. They 
suggested the admission to institutions of patients with MDR-TB or XDR-TB closer to their 
homes with subsequent discharge and home-based care. Intermediate – between 
centralization and decentralisation could perhaps alleviate the transmission of the infection to 
others as they would be hospitalised in the infectious stage. However, infection control within 
DR-TB hospitals within South Africa has been shown to be poor, which is also a concern of 
inpatient treatment, whether long- or short-term (Farley et al., 2012). Although this 
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decentralisation model is based on valid facts, decentralisation is not the simple solution, and 
perhaps this medium or a partially centralised system needs further investigation. 
2.7.5. Factors that influence treatment outcomes 
Treatment outcomes, despite the regimens available, appear to be mediocre, and often 
unavailable. Globally in 2012, a mere 17% of total estimated cases of MDR-TB started 
treatment (Günther, 2014). Of the cohort of patients with MDR-TB who started treatment in 
2010, only 48% had a successful treatment outcome, reflecting high rates of either loss to 
follow up and/or mortality. In 2012, 78,000 MDR-TB cases were estimated in the European 
region, as defined by the WHO, yet only approximately 30,000 patients were detected, and 
even fewer started treatment (Günther, 2014). Falzon et al. (2013) reported a successful 
treatment outcome for 64% of patients with MDR-TB, yet only 40% of patients with XDR-
TB. 
Similarly, in an article by Gajee et al. (2016), in 2014, South Africa initiated 11 538 
patients with RR-TB, including MDR-TB, on second-line TB treatment. Of the 2012 cohort 
of RR-TB cases, only 52% had a reported treatment outcome, with no reports on the 
remainder. Among the patients with outcomes, the RR-TB treatment success rate was 49% 
(Gajee et al., 2016). This unavailability of data or LTF is an important factor with regards to 
the feasibility of research. 
Whether treatment is centralised, decentralised or partially centralised, other factors 
may also affect treatment outcomes and needs to be addressed. HIV has shown to have 
significant influence on the treatment outcomes. Adherence to treatment, particularly with 
decentralisation has also become a factor affecting outcomes.  
2.7.5.1. Influence on HIV on TB treatment and outcomes. 
A particularly prevalent factor within the TB population includes HIV (Narasimhan et 
al., 2013). HIV coinfection exacerbates the severity of TB disease while additionally, TB 
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coinfection accelerates HIV replication in affected organs including lungs and pleura 
(Narasimhan et al., 2013). In 2007 nearly 20% of South Africa’s adult population was 
infected with HIV, making South Africa home to one of the world’s worst HIV epidemics, 
and one of the highest TB burdens (Andrews, Shah, Gandi, Moll & Friedland, 2007). These 
two diseases, HIV and TB, are seemingly related. In an article published in 2010 by Getahun, 
Gunneberg, Granich and Nunn, it described how of the 33.2 million individuals infected with 
HIV, one-third are projected also to be infected with TB. This article mentioned in 2008, that 
there were an estimated 1.4 million new cases of TB among persons with HIV infection, and 
TB accounted for 26% of AIDS-related deaths. The relative risk of TB among HIV-infected 
persons, compared with that among HIV-uninfected persons, ranges from 20- and 37-fold, 
depending on the state of the HIV epidemic (Getahun et al., 2010).  
Also, diagnosis of TB and DR-TB is challenging in the presence of HIV disease, and 
HIV-infected individuals undergoing treatment for MDR-TB have lower rates of treatment 
success and higher mortality rates than do HIV-uninfected patients (Andrews et al., 2007). 
The treatment success rate for HIV-uninfected patients in South Africa was 53%, contrasted 
with 38% for HIV infected patients. Andrews et al. (2007) further mentions that HIV clinics 
are sites are clustering of TB susceptible individuals, and, in the presence of unrecognised 
TB, they provide another favourable setting for the rapid spread of DR-TB (Andrews et al., 
2007).  
In 2012 about 320 000 people died of HIV-associated TB. Also, almost 25% of deaths 
among people with HIV are due to TB. In 2012, there were an estimated 1.1 million new 
cases of HIV-positive new TB cases, 75% of whom were living in Africa (WHO, 2013). Due 
to the devastating effect of HIV on susceptibility to TB, sub-Saharan Africa has been affected 
disproportionately and accounts for four of every five cases of HIV-associated TB (Lawn & 
Zumla, 2011). 
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE 
RELATIONSHIP BETWEEN HEARING LEVELS: A FEASIBILITY STUDY 
43 
Furthermore, Gandhi et al. (2010) conducted a study in Tugela Ferry, South Africa 
regarding DR-TB outcomes with the DR-TB population. They illustrate that from 2005 to 
2007, 272 MDR-TB and 382 XDR-TB cases were diagnosed, while the HIV coinfection rates 
were 90-98% respectively. Also, mortality within a year was 71% for MDR-TB and 83% for 
XDR-TB patients with 40% of MDR-TB and 51% of XDR-TB cases dying within 30 days of 
sputum collection. In contrast, patients with MDR-TB and XDR-TB have achieved treatment 
success rates of 60 to 80% and 44 to 60%, respectively, in low HIV–prevalence settings 
(Gandhi et al., 2010). 
2.7.5.2. Treatment adherence. 
Adherence is described as the extent to which patients follow the instructions they are 
given for prescribed treatments (Munro, Lewin, Smith, Engel, Fretheim & Volmink, 2007).  
Gajee et al. (2016) discuss the concern of missing appointments and adherence to 
treatment with the implementation of outpatient decentralised RR-TB treatment in South 
Africa since late 2011. These missed appointments can also lead to treatment interruptions 
contributing to the constant amplification of resistance, ongoing transmission of RR-TB, and 
an increased risk of morbidity and mortality. They found at an outpatient clinic, at Helen 
Joseph Hospital, more than half the patients missed at least one appointment which occurred 
within the first three months after treatment initiation and 39.5% missed three or more (Gajee 
et al., 2016). 
Other variables can further influence the adherence, within this outpatient treatment 
regimen. These factors are multifactorial and can include social factors such as poverty, 
education, support systems, stigma, emotional influences such as depression, coping skills; as 
well as the perception about TB and treatment. 
To illustrate these factors, a study done in Zambia looked at drug adherence for TB 
(not DR-TB) in a community-based intervention. This study found that 29.8% of the patients 
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stopped taking their medication while age, marital status, and educational levels were not 
significantly associated with compliance. The primary factors leading to noncompliance 
included patients beginning to feel better, inadequate knowledge on the benefits of 
completing a course, running out of drugs at home and the adverse effects (Kaona, Tuba, 
Siziya & Sikaona, 2014). Adherence was further investigated in a hypertension study 
(Morisky, Ang, Krousel-Wood & Ward, 2008); which can be applied to patients with TB or 
DR-TB. This study noted that adherence to the medication was affected negatively by 
depression, lack of knowledge about hypertension, the complexity of the medication regimen, 
health care system perceptions by the patient, sexual dysfunction, side effects of medication, 
and reduced quality of life. This study found that awareness of hypertension, patient 
fulfilment, and coping skills was significantly associated with medication adherence 
(Morisky et al., 2008). Three themes emerged in another study with regards to loss to follow-
up, namely: struggle with prolonged treatment, strive against stigma and toward support and 
divergent perceptions and practices. Daily injections, pill burden, DOT, migratory work, 
social problems, prior TB treatment, and adverse drugs effects were reported as significant 
barriers to treatment adherence and retention-in-care by patients and providers. This study 
also reported the influence of traditional healers (Shringarpure et al., 2016).  
Additionally, level of education, age, and social support can influence this adherence. 
A study by Hutapea (2009) in Indonesia looked at factors affecting compliance to medication 
in TB (not DR-TB). He found that the higher the education, the greater the age and the more 
family support indicated better adherence to medication.  
Poverty is a significant influence on adherence. A study conducted in Uganda looked 
at non-adherence to TB drugs among TB/HIV co-infected patients (Amuha, Kutyabami, 
Kitutu, Odoi-Adome & Kalyamgo, 2009). One of the findings in this study for non-adherence 
was a lack of transport money to collect more drugs when they were finished as well as being 
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busy at work (Amuha et al., 2009). This issue, such as lack of transport money needs 
addressing to improve retention in patient care (Gajee et al., 2016). 
Addressing some of the issues with adherence could improve retention. The 
implementation of a psychosocial support program showed success in reducing default 
among MDR-TB patients (Kaliakbarova et al. 2013). Based on the factors mentioned 
affecting adherence, this could be a measure to assist in retaining patients in the treatment 
programs. 
An issue, looking beyond social and emotional factors of patients, looked at 
discrepancies between what doctors prescribe and what patients take in actual practice, 
regardless of disease or illness (Bedell, et al., 2000). This study showed discrepancies in 
outpatient treatment among 76% of the sample. Although this study did not explicitly address 
HIV and TB medication, it can be extrapolated to this population (Bedell et al., 2000).  
As adherence is an issue, new drugs need development, or the treatment needs 
refining. The extension of the TB regimen often causes side effects. Therefore, for the first 
time in four decades, new TB drugs are developing, and many are currently in clinical trials. 
There are also several TB vaccines in Phase I or Phase II trials (WHO, 2014a). Not only is 
active TB management critical, but latent TB management is a new component of the WHO 
new post-2015 End TB Strategy (WHO, 2015). 
Non-adherence to treatment remains a significant obstacle to effective TB and DR-TB 
control in developing countries. Additionally, the dual infection of TB and HIV presents 
further adherence problems because of high pill burden and adverse effects (Amuha et al., 
2009). These adherence factors affect the feasibility of the implementation of studies in this 
population that are specifically drug related. 
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Chapter 3: Pharmacology of Kanamycin and 
Capreomycin 
This chapter introduces pharmacology to include pharmacokinetics, 
pharmacodynamics, and pharmacotherapeutics. Pharmacokinetics is further introduced and 
includes routes of drug administration, absorption, distribution, metabolism, and elimination 
of drugs. Pharmacodynamics in then briefly introduced. The concept of design and 
optimisation of a dosage regimen is presented followed by aminoglycoside pharmacokinetics 
and optimisation of the regimen. The chapter concludes by describing the pharmacokinetics 
of kanamycin and capreomycin which are utilised to treat patients with DR-TB.  
3.1. Pharmacology 
Pharmacology is the study of all aspects of drugs (Brucker & King, 2011). 
Pharmacotherapeutics, a further branch of pharmacology, is defined as “the study of the 
therapeutic uses and effects of drugs” (Merriam-Webster, 2018) or in other words the study 
of beneficial and adverse effects of drugs, concentrating on the treatments’ effect of drugs 
(Brucker & King, 2011). Various terms are used to explain the scope in this field of study, 
such as pharmacokinetics and pharmacodynamics. Pharmacokinetics describes the 
absorption, distribution, metabolism, and excretion of drugs (Brucker & King, 2011).  
3.2. Pharmacokinetics  
Pharmacokinetics refers to what the body does to the drug. It includes factors namely 
absorption, distribution, metabolism and elimination (Brucker & King, 2011; Clark et al., 
2012). These pharmacokinetic factors determine the amount of the drug at the target sites for 
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action. Pharmacokinetic considerations allow the clinician to develop and optimise treatment 
regimens (Clark et al., 2012). These decisions include amongst other the route of 
administration for the specific drug, the amount and frequency of each dosage and the length 
of treatment (Clark et al., 2012; Cianfrone et al., 2011).  
3.2.1. Routes of drug administration 
The administration of drugs transpires through several routes namely topical, enteral 
and/ or parenteral (Satoskar, Bhandarkar, & Rege, 2009). Enteral administration, the most 
commonly used route for administration of drugs, includes oral and sublingual 
administration. Enteral administration is the safest, often particularly accessible and is a very 
cost-effective method of drug dispensation. Parenteral administration includes intravenous 
(IV), intramuscular (IM) and subcutaneous (SC). The dispensation of a drug’s route is 
determined by the drug properties, as well as the therapeutic objectives (Clark et al., 2012). 
DR-TB drugs are administered both enterally and parentally; the regimen consists of both 
oral drugs and the injectable which is administered intramuscularly. 
Oral drug preparations include enteric-coated and extended release medication. Oral 
drugs have a low risk of systemic infections compared to parenteral administration, but many 
factors affect the route of administration. The pathways in oral absorption are the highly 
complex and the low pH of the stomach can disable some drugs (Clark et al., 2012). The 
standardised DR-TB regimen includes two phases; phase one which is the 
intensive/injectable phase where a combination of injectable and oral drugs is provided. 
Phase two is the continuation phase where only oral drugs are used. The DR-TB regimen 
includes five oral drugs throughout treatment (NDoH, 2013). Yet, disadvantages of this oral 
administration can include the limited absorption of some drugs, patients’ compliance is 
necessary, and food may affect absorption (Clark et al., 2012).  
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Sublingual route of administration, although also enteral, is not included in the DR-
TB regimen. It includes placement of the drug under the tongue to allow the drug to distribute 
into the capillary network and therefore enter the systemic circulation promptly (Clark et al., 
2012).  
While enteral involves oral administration, parenteral administration introduces a drug 
directly across the barrier defences into the systemic circulation (Clark et al., 2012). This 
parenteral route of administration in the DR-TB regimen is also used. These parenteral routes 
are used for drugs that are inadequately absorbed and unstable in the gastro-intestinal (GI) 
tract as they have the highest bioavailability and are not sovereign to first-pass metabolism or 
severe GI environments. It allows a rapid effect and a concentrated measure of control over 
the spreading levels of the drug as absorption is not required.  
The aminoglycoside compound, such as kanamycin for DR-TB, consists of an 
aminocyclitol moiety with two or more amino sugar rings. Aminoglycosides are polycationic 
(positive charge) and are highly polar, this means that enteral absorption is reduced, and 
aminoglycosides are administered generally parenterally or topically (Huth et al., 2011). The 
parenteral method for DR-TB drugs is mostly IM injections, such as for kanamycin, 
capreomycin, amikacin or viomycin (NDoH, 2013). Intramuscular drugs can be administered 
in aqueous solutions which are absorbed rapidly or in specialised depot arrangements which 
are absorbed slowly. As the medium circulates out of the muscle, the drug precipitates at the 
site of the injection. The drug then dissolves gradually, providing a constant dose over a 
protracted period (Clark et al., 2012).  
Intravenous is the most common parenteral route for drugs that cannot be absorbed 
orally, but it is not used typically in the DR-TB regimen. Intravenous drugs can be 
administered via an injection or an IV infusion over a more extended period. Intravenous 
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infusion allows for a reduction in the uttermost plasma concentration and an enhancement of 
the time of the drug in the system (Clark et al., 2012).  
Subcutaneous administration, like IM, requires absorption via simple diffusion and is 
slower than the IV route. SC minimises the risks of haemolysis or thrombosis accompanied 
with IV injection and may provide constant, slow and lasting effects (Clark et al., 2012).  
Other routes of administration can include oral and nasal inhalation, 
intrathecal/intraventricular, transdermal, rectal and topical (Clark et al., 2012; Satoskar et al., 
2009). 
3.2.2. Pharmacokinetic Parameters 
After administration of the TB drugs, via the enteral or parenteral route, further 
movement of the drug through and out of the body is determined by the four pharmacokinetic 
parameters, namely absorption, distribution, metabolism, and elimination. 
3.2.2.1. Absorption of drugs. 
Absorption of a drug refers to the transfer of the drug from the site of administration to 
the bloodstream (Clark et al., 2012; Atkinson et al., 2012). The drug absorption from the site 
of administration allows the entry of the therapeutic agent into the plasma. The rate and 
efficacy of the absorption depend on intrinsic and extrinsic factors medication (Martinez, 
Gordon & Amidon, 2002). 
Intrinsic factors are described as patient attributes that can affect drug absorption, such 
as the integrity of the gastrointestinal tract, physiological status, site of drug absorption, 
membrane transporters and pre-systemic drug metabolism medication (Martinez, Gordon & 
Amidon, 2002). Furthermore, the blood flow to the absorption site also has an effect; as the 
intestines have a much better blood flow than the stomach, incorporation from the intestine is 
preferred to absorption from the stomach (Peck et al., 2014). When a drug moves extremely 
fast through the GI tract, for example in cases of diarrhoea, absorption will be reduced, 
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demonstrating how the contact time at the absorption surface has an effect of the absorption 
(Clark et al., 2012).  
Extrinsic variables, unlike patient attributes, involve aspects such as the effects of 
food or other concomitant medication (Martinez, Gordon & Amidon, 2002). With the DR-TB 
population, there may be other concomitant medication, such as ARV. Furthermore, extrinsic 
factors, such as malnutrition (Williams, Davis & Lowenthal, 1993), may also be present 
affecting the absorption. The pH of the drug can affect the absorption, as the drug will pass 
through membrane more readily if it is uncharged (Peck et al., 2014). Likewise, the 
expression of P-glycoprotein will have an effect. P-glycoprotein is a multidrug 
transmembrane courier protein in charge of transporting various molecules, as well as 
medications, across the cell membrane. Thus, in areas of high presence, P-glycoprotein 
diminishes drug absorption, as it transfers many drugs out of the cells. It is also correlated 
with multidrug resistance (Mahar, Doan et al., 2002; Clark et al., 2012). 
These extrinsic factors influence the drugs’ bioavailability, defined as the fraction of the 
drug that reaches the systemic circulation (Clark et al., 2012). For IV administration, 
absorption is complete, and 100% bioavailability is achieved (Clark et al., 2012). Drug 
distribution by other routes may result in less incorporation, and less bioavailability (Clark et 
al., 2012), such as oral administration of some of the DR-TB drugs.  
With aminoglycosides, after parenteral administration, plasma levels peak between 30 
to 90 minutes (Huth et al., 2011). The absorption of capreomycin, the polypeptide, is 
expected and achieves a peak serum concentration in one to two hours after administration 
(Black, Griffith & Peabody, 1966). 
Dependant on drug properties; the drugs are absorbed from the gastrointestinal tract by 
either passive diffusion, facilitated diffusion, active transport or endocytosis (Clark et al., 
2012). The majority of drugs are absorbed by passive diffusion where drugs move from a 
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region of high concentration to low concentration (Di et al., 2012; Le, 2016). Facilitated 
diffusion occurs when agents enter the cell through dedicated transmembrane carrier proteins 
that facilitate the movement of sizeable molecules, while active transport also includes 
exclusive carrier proteins that traverse the membrane (Peck, Hill & Williams, 2014). Lastly, 
endocytosis and exocytosis involve drug delivery whereby the drugs are exceptionally large 
(Clark et al., 2012).  
When discussing absorption, the consideration of bioavailability is vital. Determining 
the bioavailability is essential when calculating drug dosages. The route of administration and 
the chemical properties of the drug will affect bioavailability (Atkinson et al., 2012).  
3.2.2.2. Distribution of drugs. 
Distribution is the process by which a drug reversibly leaves the bloodstream and 
enters the interstitium and intracellular fluids (Clark et al., 2012). Four main factors are 
considered in the distribution of drugs namely; blood flow, capillary permeability, the amount 
of uniting of the drug to the plasma and tissue proteins and the volume of distribution (Clark 
et al., 2012).  
The rate of blood flow can affect the distribution (Galvin, Drummond & Nirmalan, 
2007). The rate of blood flow to the tissue capillaries varies widely between individuals 
because of the unequal circulation of cardiac production to the various organs. For example, 
blood flow to the brain, liver, lungs, and kidneys is higher than to the skeletal muscles. This 
is relevant as DR-TB occurs in the lungs. Adipose tissue, skin, and viscera have lower rates 
of blood flow, while high blood flow is seen in the central nervous system, as this high blood 
flow and high lipid solubility produces anaesthesia (Clark et al., 2012).  
Capillary permeability, another factor affecting distribution, refers to the capacity of 
the capillary to allow the flow of the drugs in and out of the capillary (Levitt, 2002). This is 
determined by the capillary composition and by the chemical type of the drug. Capillary 
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formation varies widely regarding the fraction of the cellar membrane that is exposed by 
fissure junctions in the endothelial cells (Clark et al., 2012). Aminoglycosides, such as 
kanamycin, may enter the endolymph from fibrocytes and capillaries in the lateral wall, strial 
capillaries or from the perilymphatic scalae (Steyger & Karasawa, 2008). 
The third factor, the connecting of drugs to plasma proteins and tissues, is described 
according to three aspects; binding to plasma proteins, binding to tissue proteins and 
hydrophobicity (Beaumont, Cole, Gibson & Gosset, 2010). Binding to plasma proteins is 
relatively non-selective regarding the biochemical assembly and takes place at the sites of the 
proteins to which endogenous composites usually attach. The reversible binding to plasma 
proteins sequesters drugs on a non-diffusible form and slows their transfer out of the vascular 
compartment (Clark et al., 2012). While binding to tissue proteins describes drugs that can 
accrue as a result of binding to lipids, proteins or nucleic acids. Numerous drugs amass in 
tissues which can lead to elevated concentrations of the drug in tissues than in extracellular 
fluid and blood (Clark et al., 2012). Hydrophobic drugs can dissolve in the lipid membranes 
and therefore saturate the entire cell façade. Hydrophilicity contrasts with hydrophilic drugs, 
such as aminoglycosides, which do not readily penetrate the cell membranes. The chemical 
make-up of a drug compellingly shapes its ability to cross cell membranes (Clark et al., 2012; 
Gulyaeva et al., 2003). 
Lastly, the volume of distribution can be described as the fluid quantity that is 
compelled to hold the whole drug in the body at the same concentration in the measured 
plasma. This is useful to compare the dissemination of the drug to the quantities of the water 
sections in the body (Clark et al., 2012; Atkinson et al., 2012; Beaumont et al., 2010). 
Once a drug enters a body, it has the capability to spread into any one of the three 
definite sections of body water or to become segregated into a cellular site. These 
compartments include the plasma, extracellular fluid and/or total body water. If a drug has a 
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE 
RELATIONSHIP BETWEEN HEARING LEVELS: A FEASIBILITY STUDY 
53 
substantial molecular weight or joins considerably to plasma proteins, it is too sizable to 
move through the endothelial slit seams of the capillaries and is accordingly confined in the 
plasma, which makes up about 6% of the body weight. However, if a drug has a low 
molecular weight but is hydrophilic, it can move through the endothelial slit junctions and 
into the interstitial fluid. However, a drug cannot move across the lipid membrane of the cell 
to enter the water phase inside the cell. These drugs, therefore, dispense into extracellular 
fluid (plasma plus interstitial fluid), which makes up about 20% of the body weight. Then, if 
a drug has a low molecular weight and is hydrophobic, it can move through the plasma and 
extracellular fluid to the intracellular fluid, which makes up about 60% of the body fluid 
(Clark et al., 2012; Beaumont et al., 2010). 
Many drugs, such as aminoglycosides, distribute into several compartments and often 
bind cellular components such as lipids, proteins, and nucleic acids. The column into which 
drugs distribute, to be precise the ‘apparent volume of distribution’ is a valuable 
pharmacokinetic constraint useful for determining a drug loading dose (Clark et al., 2012).  
The drugs’ clearance usually allows the calculation of the volume of distribution, as a 
perpetual segment of the drug is excreted per unit time. Therefore, it can be analysed by 
mapping a graph of plasma blood concentration versus time (Benet & Zia-Amirhosseini, 
1995, Clark et al., 2012). 
A large volume of distribution has an effect of the half-life of a drug because drug 
elimination depends on the amount of drug delivered to the kidney (or other organs where 
metabolism occurs) per unit time. Delivery of a drug to the organ of elimination depends on 
blood flow as well as on the fraction of the drug in the plasma (Clark et al., 2012).  
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3.2.2.3. Metabolism of drugs. 
Metabolism refers to the process where the drug may be bio-transformed by 
metabolism of the liver, gut wall, lungs, kidney, and plasma or other tissues. The liver, 
however, is the most common site of metabolism (Schonborn & Gwinnutt, 2010).  
Metabolism of drugs, by oxidation, reduction, hydrolysis, hydration, conjugation, 
condensation, or isomerisation, allow the drug’s elimination (Le, 2016). When discussing 
metabolism of drugs, consider the kinetics of metabolism as well the reactions of drug 
metabolism (Clark et al., 2012).  
The kinetics of metabolism consists of zero-order kinetics and first-order kinetics. 
Zero-order kinetics refers to a drug where a constant amount per unit time is metabolised and 
the rate does not increase as the drug concentration increases. In contrast, first-order kinetics 
refers to drugs where a constant fraction per unit time is metabolised, and the rate increases 
as the drug concentration increases (Clark et al., 2012; Croom, 2012).  
The reactions of drug metabolism are an essential factor to consider as the kidney 
cannot efficiently eliminate lipophilic drugs that readily cross cell membranes and are 
reabsorbed in the distal convoluted tubules. Therefore, lipid-soluble agents must first be 
metabolised into more polar (hydrophilic) substances in the liver (Clark et al., 2012).  
Drug metabolism for aminoglycosides administered parentally is nominal as 
approximately 99% of the aminoglycosides are eliminated unaltered by glomerular filtration 
in the proximal tubule (Huth et al., 2011). As capreomycin is exceptionally similar in 
organisation to aminoglycosides, it is often compared to and grouped with aminoglycoside 
antibiotics, such as kanamycin (Reisfeld et al., 2012). Thus, the same would apply regarding 
the metabolism of capreomycin or kanamycin. 
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3.2.2.4. Elimination of drugs. 
Elimination of drugs from the body requires the drugs to be sufficiently polar for 
efficient excretion. As the drug enters a system, elimination begins via one or more of the 
three main routes of elimination namely; (i) hepatic metabolism, (ii) elimination in bile and 
(iii) elimination in urine. These exclusion processes decrease the strength of a drug in the 
plasma exponentially. That is, a continuous portion of the drugs’ presence is eliminated in a 
unit of time (Clark et al., 2012; Beaumont et al., 2010). 
Elimination or clearance of a drug through the kidney into the urine involves 
glomerular filtration, proximal tubular excretion and distal tubular reabsorption (Clark et al., 
2012; Atkinson et al, 2012). Dissipation via other means include via the intestines, the bile, 
the lungs, breast milk and others. Aminoglycosides are eliminated unaltered by glomerular 
filtration in the proximal tubule. The plasma half-life of aminoglycosides ranges from one 
and a half to three and a half hours but is prolonged in neonates, infants, and conditions with 
decreased kidney function (Huth et al., 2011). 
3.3. Pharmacodynamics 
Pharmacodynamics refers to the action of drugs in the body and the influence of drug 
concentrations on the magnitude of the response (Brucker & King, 2011; Clark et al., 2012). 
Pharmacodynamics together with pharmacokinetics can help explain the relationship between 
the dose of the drug and response, in other words, the effect of the drug. This 
pharmacodynamic response can be affected by a disorder, ageing or other drugs.  
Most drugs effects, both beneficial and harmful are through interaction with receptors 
of the cell surface or within the cell. The drug-receptor complex commences fluctuations in 
biochemical and/or molecular motion of a cell by signal transduction (Clark et al., 2012).  
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Other disorders can change receptor binding, alter the level of binding proteins, or 
decrease receptor sensitivity Ageing can affect pharmacodynamic responses through changes 
in receptor binding or post-receptor response sensitivity. Furthermore, drug-drug interactions 
can create competition for receptor binding sites, or they can alter post-receptor responses 
(Farinde, 2016). 
Therefore, in order to maximise a drugs response through TDM, both 
pharmacokinetics and pharmacodynamics must be considered.  
3.4. Therapeutic Drug Monitoring 
Therapeutic drug monitoring is the clinical practice of measuring certain drugs at 
specific intervals to maintain a constant concentration in a patient's bloodstream in order to 
optimise their dosage regimen (Kang & Lee, 2009). The goal of a drug therapy is to achieve 
and maintain therapeutic concentration resulting in a therapeutic response while reducing 
toxic or adverse side effects (Clark et al., 2012). A dosage regimen consists of two main 
factors; the size of the drug dose and the frequency of drug administration (Shargel, Wu-Pong 
& Yu, 2012). The dosage and dosage frequency can generally be adjusted if not within this 
therapeutic range (Clark et al., 2012). To design and optimise the drug regimen, three main 
areas are considered, namely; continuous-infusion regimens, fixed-dose/fixed-time regimens 
and optimisation of the dosages (Clark et al., 2012).  
Continuous infusion regimens describe some drug therapies that may involve 
continuous administration of a drug (such as IV) in comparison to a single administration of a 
drug. The continuous regimens result in the accumulation until stable condition occurs, which 
is the point at which the amount of drug eliminated equals the amount of drug administered 
(Clark et al., 2012; Shargel, Wu-Pong & Yu, 2012).  
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In contrast, a fixed-dose or fixed-time regimen refers to drugs given in fixed doses 
rather than by continuous infusion as it is often more convenient. Here, fixed-doses and 
fixed-time periods are dispensed with numerous IV injections or oral administration. Fixed-
dose regimens results in time-dependent variabilities in circulating the level of the drug, 
which contrasts with the soft elevation of drug concentration as with the continuous infusion. 
With multiple IV injections at regular intervals, the plasma concentration can increase 
pending the attainment of a steady state. This is the aim of the DR-TB injectables (Clark et 
al., 2012; Ratain & Plunkett, 2003). The DR-TB regimen involving the injectable 
aminoglycosides/polypeptides requires the administration of an injection daily when 
individuals treated as inpatients and injections five days a week when treated as outpatients. 
(Clark et al., 2012).  
Although it is advised in the NDoH guidelines (2015) to reduce the dosage or increase 
the length of dosing interval when toxicity is observed, the specifics are not explained. From 
personal communication with medical staff at the two study sites in this current research, the 
injection is changed often to three days a week when toxicity is noted; however, this is 
generally after culture conversion. This regimen, however, is at fixed dose/fixed-time 
intervals to assist in reaching steady state. 
Optimisation of the dose is the goal of TDM; to maintain therapeutic efficacy while 
minimising toxicity and adverse effects. The maintenance of this efficacy by reaching an 
ideal plasma concentration where therapeutic efficacy is determined. Often, if this plasma 
concentration is not reached, the prescription and dosage rate can be regulated (Kang & Lee, 
2009).  
This drug concentration is measured in the plasma with a Liquid Chromatography-
Mass Spectrometer (LC-MS). LC-MS/MS is an increasingly vital tool in TDM as it offers 
improved sensitivity and specificity (Adaway & Keevil, 2012; Grebe & Singh, 2011). 
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However, the choice of sample preparation method, column technology, internal standard and 
mass spectrometric conditions is vital to ensure accurate drug measurement and to avoid 
interference from matrix effects and drug metabolites. This Mass Spectrometry technique is 
more involved than automated immunoassays, however technological advances such as 
robots and other automated procedures are being attractive tools and convenient methods to 
assist in the mass spectrometry technique for therapeutic drug monitoring (Adaway & Keevil, 
2012). Mass spectrometry was used in this current study to identify the kanamycin and 
capreomycin pharmacokinetic properties. A method was developed for this study by a 
clinical pharmacist and biochemist at Sefako Makgatho Health Sciences University. This 
method was established to identify the kanamycin within the serum, where the method of 
identification of capreomycin within the serum is already described. 
Once the levels of the drugs have been measured with an LC-MS, pharmacokinetic 
parameters are calculated. From these parameters, dosages can be adjusted. TDM allows the 
individualisation of dosing strategies to allow for a higher percentage of the population to 
achieve ideal concentrations compared to patients who receive a fixed dosing strategy 
(Avent, Rogers, Cheng & Paterson, 2011). Drug dosages are calculated according to patients’ 
differences regarding pharmacokinetic factors and inter-patient variability (Clark et al., 
2012). In some instances, dosage adjustments, or TDM can optimise individual dosages and 
reduce adverse effects (Kang & Lee, 2009). It would be ideal to understand the 
pharmacokinetic properties in patients with DR-TB and subsequently adjust medication 
regimens possibly to improve efficacy and reduce toxicity.  
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3.5. Pharmacokinetic Properties of Kanamycin and 
Capreomycin  
There are very few studies and a dearth of literature identifying the ideal 
pharmacokinetic levels of kanamycin and capreomycin, specifically in patients with DR-TB. 
Aminoglycosides, such as kanamycin, are a well-known and efficacious category of 
antibiotics (Huth, et al., 2011) and thus used to treat DR-TB. Capreomycin, a polypeptide, is 
also a second line injectable drug used to treat DR-TB, yet it is used generally for those 
patients who have had previous exposure or resistance to kanamycin and streptomycin 
(Reisfeld et al., 2012).  
3.5.1. Kanamycin 
There are variations between the reported pharmacokinetics properties of kanamycin 
as well as aminoglycosides in general. However, the various studies were conducted on 
individuals with different health statutes. Kanamycin pharmacokinetic levels were obtained 
in patients with MDR-TB with and without HIV infection (Mugabo et al., 2015). Mugabo et 
al. (2015) identified an ideal peak range from previous studies in healthy participants and one 
study in HIV negative patients with MDR-TB of between 20 μg/ml to 35 μg/ml, and a trough 
of below 10 μg/ml to prevent toxicity. The volume of distribution was 5 ℓ/h to 6 ℓ/h in healthy 
patients and 17 ℓ/h to 23 ℓ/h in HIV negative patients with MDR-TB. Yet, in their study on 
patients with MDR-TB, the mean plasma concentrations after 24 hours of administration 
were 1.27 μg/ml and 1.97 μg/ml for HIV positive and negative patients respectively. After 24 
hours, there was an undetectable amount of kanamycin in the blood (0.05 μg/ml) which could 
demonstrate the insufficient amount of kanamycin in the blood after 24 hours of the previous 
dosing. Looking at HIV-positive and HIV-negative patients, the peak levels were 16.35 
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μg/ml and 18 μg/ml respectively. The low concentration at the time the drug administration is 
completed (Cmax) could have resulted in reduced DR-TB outcomes. The median dose for this 
study was 18.9 mg/kg for both HIV-positive and HIV-negative patients. Also, kanamycin 
was administered with other MDR-TB drugs to all patients. Lamivudine, stavudine, and 
efavirenz were also given to some of the HIV-positive patients. None of these other drugs 
affected the metabolism, distribution and renal elimination of kanamycin (Mugabo et al., 
2015). 
In another study on healthy participants, the half-life was 3.2 (SD ±1) hours for 
kanamycin, and the apparent volume of distribution for kanamycin was 30.4 (SD ±9.8) (Park 
et al., 2015). This volume of distribution is different to that reported by Mugabo et al. (2015), 
however, this study looked at healthy participants (Park et al., 2015). In another study 
(Mugabo et al., 2015) on MDR-TB patients using kanamycin, the volume of distribution was 
38.6 ℓ/h 2 in HIV-negative patients and 50.18 ℓ/h in HIV-positive patients, as the absorption 
has been shown to be different in HIV-positive and HIV-negative patients. These figures on 
both HIV-positive and HIV-negative patients are similar to the figure by Park et al. (2015) of 
30.4 ℓ/h and significantly higher than the volume of distribution in this current study of 2.5 
ℓ/h for kanamycin. While the volume of distribution is significantly smaller in this study, the 
half-lives were significantly larger than expected, as it was compared to 3.2 ℓ/h in healthy 
participants (Park et al., 2015) and 1.67 in MDR-TB HIV negative patients and 1.29 ℓ/h in 
MDR-TB HIV-positive patients (elimination half-life) and 4.45 in MDR-TB HIV-negative 
patients and 4.62 ℓ/h in MDR-TB HIV-positive patients (absorption half-life) (Mugabo et al., 
2015). The long-term outcomes of patients with variable pharmacokinetics are unknown, as 
relapse or reoccurrence of TB, is common, and the reasons are not understood fully (Millet et 
al., 2013).  
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The pharmacokinetics of various aminoglycosides (kanamycin, gentamicin, 
tobramycin, amikacin, sisomicin, netilmicin) are also discussed by Pechere and Dugal (1979). 
They placed emphasis on the multi-compartmental characterisation of aminoglycoside 
kinetics, especially as it relates to specific inexplicable observations such as tissue 
accumulation and deferred elimination. The primary route of elimination for aminoglycosides 
is glomerular filtration, and aminoglycosides undergo some tubular reabsorption (Pechere & 
Dugal, 1979). Aminoglycosides are small, hydrophilic molecules with a volume of 
distribution similar to extracellular fluid volume and clearance proportional to glomerular 
filtration rate (Roberts, Norris, Paterson et al., 2012). The penetration of aminoglycosides 
into the cerebrospinal fluid, bronchial secretions, and biliary tract remains somewhat random, 
dependent on the underlying diseases. Due to the almost exclusive excretion from the body 
by glomerular filtration, impairment of renal function significantly affects the elimination rate 
of aminoglycoside antibiotics. The predictive potential of nomograms can be significantly 
improved by consideration of some physiological parameters such as sex, age, lean body 
mass, haematocrit and characterisation of disposition kinetics by multi-compartmental 
models. However, definite serial monitoring of aminoglycoside concentrations in serum 
appears to be the most reliable method for TDM (Pechere & Dugal, 1979). Also, the volume 
of distribution per kilogram of body weight is somewhat smaller in obese and dehydrated 
subjects than in healthy patients which can lead to overdosing when dosages are calculated 
according to body mass (Pechere & Dugal, 1979; Droege, Van Fleet & Meuller, 2016). 
Alterations in the volume of distribution can be extensive in conditions leading to unstable or 
unknown fluid balances (e.g. sepsis of burn injuries), resulting in a reduced peak 
concentration if the dose is unchanged. With concentration-dependent antimicrobials, an 
increased volume of distribution will reduce the ability of a prescribed dose to achieve a 
target Cmax (Roberts et al., 2012). 
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Yet, as aminoglycosides are hydrophilic, the doses should be based on body weight or 
adjusted body weight in obese patients. The volume of distribution of aminoglycosides in 
critically ill patients is generally low (Droege et al., 2016). Anaemia, fever, hypoxemia and 
significant burns are other pathological states which notably influence the pharmacokinetics 
of aminoglycosides (Pechere & Dugal, 1979).  
There are various studies on aminoglycosides, but not necessarily on kanamycin and 
capreomycin. As kanamycin falls under the class of aminoglycosides, these studies can still 
assist with the understanding of kanamycin (and although not an aminoglycoside, 
capreomycin as well due to the similar structure). The pharmacokinetics of gentamicin were 
described in critically ill patients with acute kidney dysfunction (Roberts et al., 2010). 
Dosages varied between 3 mg/kg to 7 mg/kg. The plasma half-life of gentamicin during 
extended daily diafiltration (EDD-f) (a hybrid therapy that delivers a gentle yet effective 
diffusive and convective treatment for patients with acute renal failure) was 13.8 hours, 
whereas it was 153.4 hours without EDD-f. The Monte Carlo simulations propose that dosing 
with 6 mg/kg every 48 hours either 30 minutes or 1 hour before the commencement of EDD-f 
results in 100% realisation of the target maximum concentration drug in plasma (<10 
mg/litre) and ample attainment of the target area under the concentration-time curve from 0 to 
24 hours. In summary, this showed dosing of gentamicin 30 minutes to 1 hour before the 
commencement of an EDD-f treatment enables attainment of target peak concentrations for 
maximal therapeutic effect while enhancing drug clearance to minimise toxicity (Roberts et 
al., 2010). This study showed that the dosing and pharmacokinetics of a specific 
aminoglycoside could vary greatly depending on the treatment of the illness and other 
medications used in combination. Therefore, it further enhances the necessity to establish the 
pharmacokinetics in patients with DR-TB, and not only on healthy participants, or with other 
disorders. Aminoglycoside dosing for critically ill patients (for example gentamicin at 7 
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mg/kg) with normal renal function is suggested, where possible, to target Cmax: MIC ratio of 
10 and monitor the trough and aim for undetectable plasma concentrations. Further 
suggestions for patients with moderate to severe renal dysfunction in this critically ill 
population is also suggested to use high doses where possible and monitor the trough 
thereafter (36 to 48 extended hourly interval dosing acceptable). In these patients, MIC data 
can guide dosing if available with dose reductions (Roberts & Lipman, 2009).  
3.5.2. Capreomycin 
Capreomycin is further explained as a polypeptide antibiotic composed of four 
molecular analogues, IA, IIA, IB, and IIB, with its mode of action involving ribosomal 
inhibition of protein synthesis (Reisfeld et al., 2012). Its action, however, is not understood 
fully. It is structurally similar to viomycin and is active against DR-TB (Akbergenov et al., 
2011). It differs structurally from kanamycin and amikacin and thus does not always exhibit 
uniform cross-resistance with the aminoglycosides. It appears that capreomycin binds to, and 
inhibits the function of, the 16S rRNA molecule of the Mycobacterium tuberculosis 30S 
ribosomal subunit, as supported by upregulation of a methyltransferase gene and the 16S 
rRNA-processing protein gene. Due to its similar organisation, side effects, and mode of 
action, capreomycin is often compared to and grouped with aminoglycoside antibiotics, such 
as kanamycin. Even though capreomycin has been used for a significant number of years as 
an antibiotic, there is limited pharmacokinetic information on capreomycin (Reisfeld et al., 
2012).  
The pharmacokinetics of capreomycin was investigated by Reisfeld et al. (2012), 
where they conducted an exploratory study on mice with capreomycin, yet not in 
combination with the other DR-TB drugs. Reisfeld et al. (2012) did, however, take individual 
differences into account in their model of calculation. They identified an ideal peak range 
between 20 μg/ml to 40 μg/ml, and a trough life of below10 μg/ml for capreomycin. 
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In summary, there are varying reports of pharmacokinetics with aminoglycosides and 
capreomycin, yet they are variable, and most do not include hearing and overview treatment 
efficacy. More conclusive evidence is required to identify target ranges within the DR-TB 
population. 
3.6. Aminoglycoside Pharmacokinetics and Optimization 
of Drug Regimen  
The injectable drugs, specifically for DR-TB, appear to have variable 
pharmacokinetic properties which can affect efficacy and adverse effects (Clark et al., 2012). 
This would indicate that the aminoglycosides, specifically kanamycin, and polypeptides, 
specifically capreomycin, would vary in their pharmacokinetic properties as well, and thus 
individualisation of dosing regimens may enhance efficacy and reduce toxic events.  
Yet, there is variable research regarding the outcomes of TDM with aminoglycosides 
(Demczar, Nafziger & Bertino, 1997; Namazi, Sagheb, Hashempour & Sadatsharif, 2016; 
van Altena et al., 2017). The investigation of different dosing regimens using 
aminoglycosides revealed controversial outcomes (Demczar et al., 1997; Namazi, et al., 
2016; van Altena et al., 2017). Once-daily dosing of aminoglycosides has become popular 
due to apparent advantages observed with this dosing method (Conly, Gold & Shafran, 1994). 
However, much of the focus of this research is about in vitro pharmacodynamics of the 
antibacterial effect and the concentration-dependent killing and post-antibiotic effect. The 
various studies, as outlined, provide information regarding the potential positive outcomes of 
TDM, but also the lack of outcomes.  
Demczar et al. (1997), demonstrate the pharmacokinetics of gentamicin at large doses 
(7 mg/kg) differ significantly from those at traditional doses (2 mg/kg). This study showed 
significance in distribution half-life and clearance between the two groups. This could have 
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implications for once-daily aminoglycoside literature when the Cmax values reported are 
distributional and therefore show falsely high Cmax/minimum inhibitory concentration (MIC) 
ratio estimates (Demczar et al., 1997). Adverse events, such as toxicity, was not reported in 
these groups. 
The diagnosis of the patient must also be considered when investigating 
pharmacokinetics. This was observed in an amikacin study where pharmacokinetic factors of 
patients in intensive care unit (ICU) on amikacin with different diagnoses were compared. 
These groups included sepsis, trauma, pneumonia and ‘other’. The ICU patients were found 
to have increased values for the amikacin volume of distribution (0.52 ± 0.21 litres/kg), and 
the septic and trauma patients showed higher values for the amikacin volume of distribution. 
This highlights the fact that the clinical diagnosis can also impact the pharmacokinetics (de 
Gatta et al., 1996). Thus, patients with DR-TB may be displaying different kinetics to those 
with other infections mentioned above. These differences of diagnosis – highlights the 
importance for individualisation of treatment. These studies provide evidence for the possible 
positive effects of optimising dosage regimens of aminoglycosides and the need for obtaining 
more evidence regarding the ideal pharmacokinetic properties in these patients. 
Although Heychendorf et al. (2014) does not mention the personalisation of drug 
therapy through pharmacokinetics, they describe the necessity of the individualisation of drug 
therapy and duration for participants. They describe the importance of searching for various 
host markers from a range of procedures, including clinical scores (general characteristics of 
the patient), imaging, immunological markers (cytokines and proteins) and X-Omics 
(analysis of metabolites, proteins, or transcription products from blood products, urine, or 
sputum can provide disease stage-specific molecular patterns).  
Amikacin pharmacokinetics were measured in Iran, yet the treatment outcomes of 
patients with various illnesses were examined and not necessarily toxicity (Namazi et al., 
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2016). The dosage was calculated according to conventional methods, and the prescribed 
dose was correct in 25% of the patients. Treatment failure occurred in 19% of the patients, 
and 76% had renal failure. Dosage adjustments occurred initially in 19% of the patients, yet 
57% of patients needed dose readjustment, and only 6.5% were adjusted. Desired peak and 
trough concentrations were obtained in 38% and 45% of the patients, respectively. In 52.2%, 
peak levels were below the therapeutic level. Nevertheless, 89% responded to treatment 
successfully (Namazi et al., 2016). This shows that sometimes, in cases, treatment success 
may be achieved without ideal peak and trough levels. This study, however, was not for DR-
TB patients, and re-infection was not discussed. Furthermore, the findings with regards to the 
low peak levels could yield important data with regards to the possibility of the low cure rate 
of DR-TB and reinfection at later stages. Preliminary studies show that Resuscitation-
promoting factors (Rpf), which are peptidoglycan-hydrolysing enzymes, are required for the 
resuscitation of non-replicating bacilli and pathogenesis in a murine tuberculosis infection 
model. They are proteins produced by MTB that accelerate mycobacterial growth. Although 
this model is ill-defined in human infection, it is possible that Rpf plays a role in human 
tuberculosis pathogenesis. From the mouse models, Rpf supports bacterial survival and 
reactivation of TB. Also, the bacilli may be dependent upon Rpf for growth for the outcome 
of human tuberculosis. These Rpf are indiscernible to the conventional culture and is 
enhanced progressively in relative terms during chemotherapy, indicating a form of 
phenotypic resistance that may be significant for both chemotherapy and transmission 
(Mukamolova, Turapov, Malkin, Woltmann & Barer, 2010; Rosser, Stover, Pareek & 
Mukamolova, 2017). Therefore, these low peak levels could indicate, that although patients 
may culture covert on the conventional testing methods, these proteins may still be present, 
and responsible for the reinfection at a later stage, and thus the low peak levels could, in fact, 
correlate to poor outcomes. 
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Another study investigated the use amikacin to treat MDR-TB. Peak and trough levels 
were not predictors in the classification of ototoxicity (Modongo et al., 2015). Probit analysis 
of the amikacin study revealed that the probability of ototoxicity occurring increased sharply 
after six months of therapy to near maximum at nine months. This study showed that 
cumulative AUC and duration of drug therapy is more of an indicator of ototoxicity, rather 
than peak concentrations (Modongo et al., 2015). 
A study conducted in the Netherlands looked at TDM of amikacin and kanamycin in 
patients with MDR-TB or XDR-TB. Serum levels as well as well as cumulative dose and 
dose per kg were collected (van Altena et al., 2017). The peak levels were obtained 30 
minutes post the infusion, with the trough being obtained immediately before the infusion. 
The aminoglycoside dose was adjusted based on an amikacin and kanamycin concentration 
and MIC. Audiometry was obtained up to 8 kHz with a 20 dBHL reduction in a hearing 
threshold from bassline, irrespective of the ear. Treatment outcome was evaluated two years’ 
post completion of the treatment. The patients received their dose five times a week or three 
times a week (post the five time a week regimen). Within the first three weeks, dosage 
changed for 18 patients based on serum concentrations. Three participants had an increase in 
dosage and dosage decreased in 15 participants. Audiometry results were available in 87.5% 
of patients, generally at the start of the aminoglycoside treatment and after that every 3 – 4 
weeks. The results of the audiometry showed a hearing loss in 11.3% of patients, 
predominantly at higher frequencies (4 and 8 kHz). The mean hearing loss was 37.5 dB 
(range 25 dB – 50 dB) at 4 kHz and 46.1 dB (range 25 dB – 70d B) at 8 kHz. Cumulative 
dose, dose per kg bodyweight, duration, bodyweight, gender, age, and BMI did not correlate 
with the occurrence of ototoxicity. This may explain the fact that the dosage was guided by 
the Cmax/MIC in individual patients since the Cmax/MIC correlates to the efficacy of 
aminoglycosides (van Altena et al., 2017).  
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In South Africa, the administration of the standardised DR-TB regimen occurs across 
four weight bands to accommodate the formulations available in the country while complying 
with the international requirements for minimum, maximum and average dose per kilogram 
(NDoH, 2011). This current administration is not based on individual pharmacokinetic 
parameters, however, with the knowledge of pharmacokinetics, pharmacodynamics, and 
pharmaceutics, TDM enables the assessment of the efficacy and safety of a particular 
medication, in this case, kanamycin and capreomycin. Patients taking kanamycin and 
capreomycin for DR-TB should not be exposed to any higher risk of toxicity than justified by 
the need for the drug, nor obtain any less of the drug that is needed minimally for its effect 
(Touw et al., 2009). However, the pharmacokinetics need further understanding in the DR-
TB population; with regards to relationships to toxicity and efficacy of treatment in this 
population before TDM would be considered as the standard of care. 
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Chapter 4: Ototoxicity 
This chapter describes ototoxicity; its definition, possible mechanisms of action as 
well as the incidence. It then continues to describe ototoxicity in the DR-TB population as 
well as the impact it is having, specifically in the South African population. Subsequently, 
various methods of monitoring and trends are described, and trends, both internationally and 
nationally are mentioned. Therapeutic drug monitoring with aminoglycosides is discussed 
with the possibility of it used for ototoxicity monitoring and management. The chapter 
concludes with the summary and brief rationale for this study. 
4.1. Overview 
Toxicity due to medication can cause nephrotoxicity and cochleotoxicity/ 
vestibulotoxicity. Ototoxicity is defined as a toxic or poisonous reaction to medication 
causing damage to the inner ear, the auditory system, and/or the vestibular system, which 
often results in hearing and balance difficulties (Frymark et al., 2010).  
4.1.1. Ototoxicity, cochleotoxicity and vestibulotoxicity 
Ototoxicity is caused by medications such as cancer chemotherapeutics, loop-
inhibiting diuretics, salicylate analgesics, aminoglycosides, or a combination of these agents 
(Konrad-Martin et al., 2005). Ototoxicity has also been recorded in some polypeptides (e.g. 
capreomycin), which is similar in structure to aminoglycosides (Akbergenov et al., 2011).  
Cochleotoxicity research supports the notion that the damage is initially occurring to 
the outer hair cells (OHC) at the basal end of the cochlea. Here, the high frequencies are 
transduced, and thus cochleotoxicity initially affects the ability to hear high-frequency 
sounds. With the prolonged exposure to the ototoxic drug, damage progresses to the apical 
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end of the cochlea which is responsible for the processing of low-frequency sounds (Peterson 
& Rogers, 2015). Degeneration of nerve fibres, spiral ganglion neurons and supporting cells 
are secondary to hair cell damage. Strial degeneration is also described however it is unclear 
whether strial degeneration is a secondary or primary effect of the aminoglycosides (Guthrie, 
2008). Cochleotoxicity is generally irreversible as hair cells in humans are not yet capable of 
regeneration (Peterson & Rogers, 2015).  
Vestibulotoxicity is the ability of a substance to destroy or damage the structures and 
function of the labyrinthine hair cells and their connections through the eighth cranial nerve 
to the central nervous system (Selimoglu, Kalkandelen & Erdogan, 2003). The initial and 
most extensive damage occurs at the apex of the cristae and striolar regions of the maculae. 
The damage can extend to the periphery of the vestibular receptor, and additional injury can 
occur to the otoconial membrane and the otolith structures (Selimoglu et al., 2003). The 
effect of vestibulotoxicity is normally permanent and may affect an individual’s quality of 
life negatively (Rogers & Peterson, 2011), as balance disorders can affect social, family and 
professional activities (Patatas, Ganança & Ganança, 2009).  
There are varying reports regarding the onset, degree, and progression of ototoxicity. 
Ototoxic side effects have been shown to occur within days or weeks after systemic 
application and are often bilateral in presentation (Huth et al., 2011).  
The differences in reports regarding the degree, onset and progression can be due to 
intrinsic and extrinsic factors (Peterson & Rogers, 2015) while the different definitions used 
to define and report ototoxicity (Huth et al., 2011) could contribute to the variance. Different 
studies use different protocol and classifications, as some include ultra-high frequencies, 
where others do not (Sharma, Bhagat, Verma, Singh & Singh, 2016; Fausti, Henry, Schaffer 
et al., 1992). Different methods of testing would identify different percentages of hearing 
loss. Also, there are various ways to classify significant hearing loss, such as the different 
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grading scales (see section 4.7.4). Different classifications of hearing loss could result in the 
varying reports on ototoxicity. 
4.1.2. Intrinsic factors 
Intrinsic factors may include previous treatment with ototoxic medications (Wang et 
al., 1999), prolonged exposure to ototoxic medication (Peloquin et al., 2004), renal 
impairment (Harris & Heinze, 2015), other illnesses (Bisht & Bist., 2011), genetic 
susceptibility (Fischel-Ghodsian, 1999), poor nutrition (Hoffman, Whitworth, Jones & 
Rybak, 1987), advanced age (Paterson, Robson & Wagener, 1998), excessive noise exposure 
(Schellack & Naude, 2013), pre-existing hearing loss and vestibular dysfunction (Mudd, 
Glatz, Campbell & Gatz,  2016) and HIV (Khoza, 2010).  
Wang et al. (1999) explain the effects of previous treatment with ototoxic medication, 
as they demonstrated that ototoxicity might persist for up to one year after discontinuing the 
drug. Therefore, the drug may still be having an ototoxic effect after treatment. Furthermore, 
having aminoglycosides in one’s system, in addition to new aminoglycosides, can increase 
the cumulative dosage of the drug which can enhance ototoxicity (Peloquin et al., 2004).  
Prolonged exposure to ototoxic medication is linked to the destruction of the OHC in 
the organ of Corti (Rybak & Ramkumar, 2007). This prolonged exposure can also result from 
a large cumulative dose (Peloquin et al., 2004). Renal impairment can potentiate hearing loss 
from ototoxic medication in a similar way, in that impaired renal function affects the 
excretion of the drug, and so result in higher serum levels and thus prolonged half-life (Rybak 
& Ramkumar, 2007; Harris & Heinze, 2015).  
Various illnesses, such as the presence of infected emboli, hypoxia, fever, and 
dehydration can influence ototoxicity (Bisht & Bist, 2011). Diabetes mellitus has also shown 
to cause hearing impairments (Kakarlapudi, Sawyer & Staecker, 2003) as well as HIV, which 
can influence ototoxicity. Human Immunodeficiency Virus can have a direct and indirect 
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effect on the auditory system. Opportunistic effects are deemed indirect by some; while 
others feel that these auditory manifestations are a direct effect on the compromised immune 
system. The sensorineural hearing loss has been associated in a direct manner causing neural 
disturbances of the vestibulocochlear nerve; however, these neural disturbances can also be 
caused indirectly by opportunistic illnesses such as cytomegalovirus (Friedmann & Arnold, 
1993; Khoza & Ross, 2002). Hearing loss with HIV patients has shown to range in type, from 
conductive to sensorineural as well as retrocochlear or central (Bankaitis, 1996; Khoza, 
2010). However, many people with MDR-TB have HIV, and thus it is difficult to separate the 
effects of the MDR-TB medication from the effects of HIV (Brits et al., 2012). There is some 
evidence that some ARV drugs used for the management of HIV may be ototoxic (Khoza-
Shangase, 2011). Also, pre-existing hearing loss and vestibular dysfunction, although not an 
illness, can also enhance ototoxicity (Mudd et al., 2016). Pre-existing hearing and vestibular 
dysfunction result in a vulnerable auditory system which makes it more susceptible to 
ototoxicity. 
There is also a genetic link to aminoglycoside ototoxicity (Fischel-Ghodsian, 1999). 
A study by Guan, Fischel-Ghodsian and Attardi (2000) showed that the A115G mutation in 
mitochondrial 12S rRNA is associated with non-syndromic and aminoglycoside-induced 
deafness (Guan et al., 2000; Rybak & Ramkumar, 2007). Likewise, there are another known 
mitochondrial mutations which are linked to aminoglycoside-induced hearing loss namely 
A1555G, C1494T, T1095C, T1291C, 961delT+C(n) and A827G; A1555G is, however, the 
most common (Harris & Heinze, 2015). 
Poor nutrition can play a role in hearing loss, as seen in a study by Hoffman et al., 
1987) where chinchillas deprived of food for 48 hours prior to the administration of a 
combined dose of ethacrynic acid (10 mg/kg) and kanamycin (100 mg/kg) suffered a 
profound hearing loss, when compared to animals that were fed, who showed a lesser degree 
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of hearing loss. Poor nutrition places the auditory system under stress, and combined with the 
aminoglycosides could enhance the ototoxicity. Houston et al., (1999) also investigated how 
poor vitamin B-12 and folate levels may be associated with age-related auditory dysfunction. 
This could potentially also affect hearing loss from other causes, such as aminoglycosides. 
According to the trading economics statistics of the last three months in 2016, 26.5% of 
South Africans were unemployed (Trading Economics, 2017). Therefore, poverty and poor 
nutrition is a reality for many South Africans. 
As ageing patients are at risk for presbycusis (Lin, Thorpe, Gordon-Salant & Ferrucci, 
2011), it is possible, that this increased age, which, if combined with an ototoxic 
aminoglycoside, could place an already vulnerable system under more stress. Further, animal 
studies have suggested that the susceptibility to aminoglycoside -related nephrotoxicity in the 
elderly arises from the declining renal excretory function in this age group. It is possible that 
this is due to the impaired capacity for cellular repair and regeneration in the elderly 
(Paterson et al., 1998).  
4.1.3. Extrinsic factors 
Extrinsic factors are not as vast and may include concomitant treatment with other 
ototoxic or nephrotoxic drugs (Peloquin et al., 2004), dosage (Schellack & Naude, 2013), 
health practitioners’ knowledge (Peterson & Rogers, 2015) and the attitude of the staff 
(Peterson & Rogers, 2015). 
Excessive noise exposure can also enhance ototoxicity. Aminoglycosides block the 
ion channels which may be mediated via endocytosis or possibly aminoglycosides. This 
mechanism might be due to the aminoglycosides blocking the depolarising transduction 
current of the mechanoelectrical transducer (MET) channel. The MET channel is located in 
the stereocilia and can function as a one-way valve, promoting intracellular accumulation of 
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the aminoglycosides. Acoustic stimulation may aggravate this as it may enhance the 
aminoglycoside uptake (Schellack & Naude, 2013). 
While other illnesses were included in the intrinsic factors, concomitant treatment 
with other ototoxic or nephrotoxic drugs in considered extrinsic. Other ototoxic drugs result 
in a more extensive cumulative build-up of the drugs, and this larger cumulative dose has 
been associated with ototoxicity (Peloquin et al., 2004). The ototoxic loop diuretics can 
potentiate ototoxicity as well (Rybak & Ramkumar, 2007). 
The total administered dose and dosing frequency links to the toxicity of the 
aminoglycosides. Dosages twice daily or more frequently are associated with more 
ototoxicity in comparison to once daily dosing (Schellack & Naude, 2013). In contrast, 
Peloquin et al. (2004) looked at the incidence of toxicities associated with two recommended 
dosing regimens (daily vs three times per week of intravenous streptomycin, kanamycin, or 
amikacin) in TB patients and found that the magnitude of the dose and frequency of 
administration were not associated with ototoxicity, but ototoxicity was associated with a 
more substantial cumulative dose (Peloquin et al., 2004). 
Health practitioners’ knowledge of and attitudes to cochleotoxicity, as well as the 
availability of diagnostic/monitoring services, are important in reducing ototoxicity (Peterson 
& Rogers, 2015). It is essential that the healthcare practitioner has adequate knowledge about 
ototoxicity in order to manage and refer the patient appropriately (Peterson & Rogers, 2015) 
as well as their attitudes can determine whether the patient seeks help when noticing 
symptoms of hearing loss. A study in South Africa found that nurses caring for TB patients 
were found to be authoritarian, scolding and frustrated. These behaviours can deter patients 
from reporting symptoms (Peterson & Rogers, 2015). 
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These intrinsic and extrinsic factors are numerous, and all need consideration for 
patients at risk to develop ototoxicity, specifically those with DR-TB. By understanding these 
factors, one may potentially be able to facilitate a reduction of ototoxicity.  
4.2. Theories: Aminoglycoside and Polypeptide 
Ototoxicity 
Aminoglycosides are often toxic; to both the kidney (nephrotoxicity) and the inner ear 
(ototoxicity). Nephrotoxicity, however, is often reversible, while ototoxicity is generally 
permanent (Huth et al., 2011), demonstrating the importance of understanding and managing 
this ototoxicity due to its permanence. 
Furthermore, aminoglycosides and some polypeptides are reported to cause damage to 
both the auditory and vestibular system (Dooley et al., 2012; Huth et al., 2011; 
Roongruangpitayakul & Chuchottaworn, 2013). In some instances, the ototoxicity and 
vestibulotoxicity were reversible, particularly with capreomycin (Roongruangpitayakul & 
Chuchottaworn, 2013), Yet in most cases, it seemed to be irreversible and permanent (Dooley 
et al., 2012; Peterson & Rogers, 2015). Typically, either the auditory system or vestibular 
system is affected more than the other (Hutch et al., 2011). For example, gentamicin and 
tobramycin are predominantly vestibulotoxic, whereas neomycin, kanamycin, and amikacin 
are mainly cochleotoxic (Huth et al., 2011). Although the majority of reports show 
capreomycin as cochleotoxic (Dooley et al., 2012; Peterson & Rogers, 2015), there are 
reports of it being vestibulotoxic too (Roongruangpitayakul & Chuchottaworn, 2013). 
Studies indicate that ototoxicity can occur as early as 72 hours after aminoglycoside 
administration (Konrad-Martin et al., 2005). Ototoxicity may also continue after the 
termination of aminoglycoside treatment as aminoglycosides can remain within the cells of 
the inner ear for up to six months; thus, ototoxic injury and associated hearing loss may 
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progress for weeks following cessation of treatment (Harris & Heinze, 2015). Wang et al. 
(1999) demonstrated that ototoxicity might persist for up to one year after discontinuing the 
drug.  
There are various theories regarding aminoglycosides ototoxicity. There are fewer 
however on polypeptide ototoxicity. Yet, polypeptides, specifically capreomycin and 
vancomycin are similar in structure to the aminoglycosides with similar mechanisms of 
action, and so capreomycin is often compared to aminoglycosides, due to its similar 
nomenclature, side effects, and mode of action, despite its structural distinction (Reisfeld et 
al., 2012).  
As there are fewer data available on polypeptides’ specific mechanism of action with 
regards to ototoxicity, they are likened to the aminoglycosides (Petersen & Rogers, 2015). 
Therefore, the aminoglycoside theories, discussed further, in this case, will be regarded as the 
polypeptides, specifically capreomycin.  
These various theories of aminoglycoside ototoxicity, which likely do not work in 
isolation, but a combination of all three, include oxidative stress and free radical formation 
(Poirrier, Pincemail, Ackerveken, Lefebvre & Malgrange, 2010), uptake and penetration of 
the aminoglycosides within the cochlear cells (Xie, Talaska & Schacht, 2011) and well as 
drug concentrations (Touw et al., 2009).  
4.2.1. Oxidative stress and free radical formation 
The first theory provides evidence for oxidative stress in aminoglycoside ototoxicity 
(Campbell, 2004), such as with aminoglycosides used to treat DR-TB. The aminoglycosides 
used to treat DR-TB can cause irreversible hearing loss, as they destroy the OHC in the 
cochlea. The exact pathophysiological mechanism is not entirely understood (Avent et al., 
2011).  
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Furthermore, many aminoglycosides have shown to be ototoxic and nephrotoxic as 
well (Rybak & Ramkumar, 2007). Some aminoglycosides are also more vestibulotoxic, such 
as streptomycin and gentamicin, while and others are more cochleotoxic, such as amikacin, 
neomycin, dihydrosterptomycin, and kanamycin (Selimoglu, 2007). This oxidative stress and 
reactive oxygen species formation are described particularly to those that are cochleotoxic.  
Reactive oxygen species play a pivotal role in aminoglycoside ototoxicity as these 
aminoglycosides have been suggested to have ototoxic effects due to intracellular cytotoxic 
effects. Similarly, recent research suggests that these also play a role in ageing and 
presbycusis (Poirrier et al., 2010).  
The outer hair cells in the cochlea appear to be vulnerable to reactive oxygen species 
injury. However, the exact way in which the reactive oxygen species enter the cochlear fluid 
is not understood entirely (Poirrier et al., 2010). Nevertheless, once the aminoglycosides are 
inside these cochlea cells, they start to generate reactive oxygen species, which is central to 
the destruction of these hair cells (Poirrier et al., 2010). 
Aminoglycosides are considered as redox-inactive compounds, whereby the molecule 
is not toxic by itself but requires the redox-capacity of a transition metal ion to induce 
ototoxicity (Guthrie, 2008). Therefore, the generation of these reactive oxygen species 
involves the formation of an aminoglycoside -iron complex, which catalyses the oxidation of 
unsaturated fatty acids located in the plasma membrane (Poirrier et al., 2010). 
In the absence of iron, arachidonic acid enriched in phosphoinositides can serve as an 
electron donor. In this case, aminoglycosides interfere with phosphoinositides metabolism, 
particularly phosphatidylinositol-biphosphate (PIP2), by binding to their polar head. This 
binding induces sequestration of PIP2 and therefore prevents PIP2-dependent processes, 
including the reduction of phosphatidylinositol-trisphosphate (PIP3) formation and thus 
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aminoglycosides, seem to inhibit cell survival pathways such as PI 3-kinase/Akt signalling 
pathway (Xie et al., 2011; Poirrier et al., 2010). 
Aside from the actual reactive oxygen species formation, aminoglycosides also 
directly control the activity of enzymes involved in reactive oxygen species metabolism. The 
aminoglycosides, therefore, inhibit the antioxidant activity to protect the cochlea from 
reactive oxygen species potentially, or they activate inducible nitric oxide synthases 
producing nitric oxide (Poirrier et al., 2010). 
Nitric Oxide has been suggested to be involved in hair cell death induced by 
gentamicin, and these aminoglycosides have also been shown to indirectly promote the 
activation of nitrogen oxides leading to the production of superoxide which can initiate a 
cascade of reactive oxygen species production (Poirrier et al., 2010). 
Reactive oxygen species subsequently activates apoptotic or necrotic intracellular 
pathways. They promote the opening of the mitochondrial permeability pore and activate the 
Jun N-terminal kinases pathway leading to hair cell apoptosis. It has been shown that the 
inhibition of Jun N-terminal kinases pathway rescues hair cells injured by aminoglycosides 
(Poirrier et al., 2010). 
Following aminoglycoside-induced hair cell injury, there is a progressive loss of 
spiral ganglion neurons because of loss of neurotrophic support from the OHCs. 
Neurotrophin withdrawal increases reactive oxygen species production in neuronal cell lines 
and spiral ganglion neurons in culture. The interaction of reactive oxygen species and free 
radicals with membrane phospholipids creates lipid peroxidation products that act as 
mediators of apoptosis (Poirrier et al., 2010). 
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4.2.2. Uptake and penetration of the aminoglycosides within the 
cochlear cells 
The second theory describes the uptake of aminoglycosides whereby the 
aminoglycosides penetrate almost all cell types of the cochlea including those not damaged 
by the drugs (Xie et al., 2011). Aside from the hair cells, the areas with highest affinity for 
and most extended retention of aminoglycosides are the mesenchymal cells under the basilar 
membrane, the interdental cells of the spiral ligament, and type III fibrocytes. The 
glycoprotein megalin has been suggested as an aminoglycoside transporter in proximal 
tubules of the kidney, but its distribution in the inner ear does not match the pattern of 
aminoglycoside uptake and ototoxicity (Xie et al., 2011).  
Various animal studies suggested an endocytotic uptake at the apex of the hair cell or 
uptake regulated by myosin VII-A (Xie et al., 2011). Other potential transport mechanisms 
include a polyamine-like transport and vesicular receptor-mediated endocytosis at the base of 
hair cells. Entry through ion channels such as the mechano-electrical transducer channels is 
another option (Xie et al., 2011; Poirrier et al., 2010). Studies have shown that gentamicin 
rapidly enter the marginal cells in the stria vascularis and hair cells in mice which suggests 
that these drugs penetrate the endolymphatic scala media of the inner ear (Poirrier et al., 
2010). 
Another study by Steyger and Hongzhe (2011) mentioned that systemic 
aminoglycosides are trafficked across the blood-endolymph barrier and preferentially enter 
hair cells across their apical membranes. This route is predominant over the basilar 
membrane entry by perilymph infusion (Steyger & Hongzhe, 2011).  
From the various theories, it is possible that there is more than one mechanism of 
uptake. Nevertheless, it is postulated that the OHCs in the cochlea appear to be vulnerable to 
Reactive Oxygen Species (ROS) injury, despite the exact way in which the reactive oxygen 
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species enter the cochlear fluid is not understood entirely (Poirrier et al., 2010). Currently 
otoprotection research supports the theory of promoting antioxidant activity, and in turn 
protect the OHC from reactive oxygen species (Poirrier et al., 2010). It could perhaps be 
beneficial to fully understand the uptake of these aminoglycosides, in order to block this 
pathway into the OHCs and prevent the production of reactive oxygen species, rather than by 
destroying them (Poirrier et al., 2010). 
4.2.3. Drug Concentrations 
Lastly, aminoglycosides are inhibitors of prokaryotic protein synthesis at commonly 
accepted therapeutic concentrations (Touw et al., 2009). They exhibit concentration-
dependent bactericidal activity, and intermittent doses overcome adaptive bacterial resistance 
(Peloquin et al., 2004). However, they may also affect the protein synthesis of cells at larger 
concentrations, leading to toxicity, such as ototoxicity and/or nephrotoxicity (Touw et al., 
2009).  
There is a dearth of literature regarding this topic. However, a few studies have been 
performed showing that the adjustment of dosages can reduce ototoxicity (van Altena et al., 
2017; Engler, Schellack, Naude & Gous., 2015), which would indicate that drug 
concentration levels can be pertinent to ototoxicity. This current study investigates this topic 
further. 
4.2.4. Summary 
Therefore, with any of the above theories; the more extensive the concentration - the 
greater the ototoxicity. At this time, it appears that all three aspects, including the ROS, 
uptake of the aminoglycosides and drug concentrations should be considered as vital 
contributing factors to ototoxicity, and thus all should be considered in research to reduce this 
toxicity. 
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4.3. Prevalence of Aminoglycoside and Peptide 
Ototoxicity 
Despite the resulting ototoxicity from aminoglycosides, these agents are utilised 
widely in developing countries because they are cost effective. The various aminoglycosides 
differ with regards to their toxicity profiles (Rybak & Ramkumar, 2007) and the prevalence 
of this cochleotoxicity differs in various populations and with different drugs (Petersen & 
Rogers, 2015, Davidson, Brish, Rein & Rubinstein, 1980; Youw, Tengg, Bangs, Bangs & 
Stephenson, 1962; Waterstrom, Bredberg, Lindquist,Lyttkens & Rask-Andersen, 1986; Al-
Malky, Suri, Dawson, Sirimanna & Kemp D., 2011; Black, Lau, Weinstein, Young & Hewitt, 
1976; Fausti et al., 1993). Some peptide antibiotics, despite having evidence of ototoxicity 
(Petersen & Rogers, 2015; Forouzesh, Moise & Sakoulas, 2009) have been studied in less 
detail, yet are also used to treat bacteria, such as in TB (Sagwa, 2017). 
Aminoglycosides, including kanamycin, amikacin, tobramycin, netilmicin, 
streptomycin and gentamicin have different reports of ototoxicity (Petersen & Rogers, 2015, 
Davidson et al., 1980; Youw et al., 1962; Waterstrom et al., 1986; Al-Malky et al., 2011; 
Black et al., 1976; Fausti et al., 1993). Peptide antibiotics are numerous (Hancock & Chapple, 
1999), and so only three specific peptides will be mentioned, namely capreomycin and 
triethanolamine (polypeptide) and vancomycin (glycopeptide) as they have indicated some 
ototoxicity (Forouzesh et al., 2009; Akorn, Inc. Package Insert, 2015; Daniel, Sahmkow, 
Munguia, Schloss & Akache, 2008). However, according to Peterson & Rogers (2015), 
capreomycin, a polypeptide, can have a similar effect on the auditory system as 
aminoglycosides.  
The prevalence of cochlear damage due to aminoglycosides ranges from seven to 90% 
(Petersen & Rogers, 2015). This variability could be due to a potential of underreporting, as 
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well as the lack of distinct parameters for monitoring ototoxicity (Edson & Terrell, 1991; 
Petersen & Rogers, 2015). Different studies also detail different dosages and methods of 
monitoring, which could account for the difference in incidence (Arslan, Orzan & Santarelli, 
1999). Furthermore, there are very few human and animal studies using kanamycin and 
capreomycin when not treating TB.  
Studies with kanamycin have shown diverse results when used to treat infections (not 
TB). In a paediatric study, kanamycin at a relatively low dose (15 mg/kg daily for less than 
17 days or a total dose of 280 mg) did not result in hearing loss (Davidson et al., 1980). This 
hearing loss was defined as a 20 dB decrease in hearing thresholds above 4 kHz and up to and 
including 8 kHz. Although, kanamycin did cause hearing loss in a much smaller case study of 
two infants who received dosages of more than 500 mg/kg (Youw et al., 1962). This small 
case study did not take other perinatal factors into account which could have contributed to 
the hearing loss. Kanamycin ototoxicity was further illustrated in an animal study with 
Guinea pigs, (Waterstrom et al., 1986) where ototoxicity was noted in the group that received 
200 mg/kg per day for 21 days as well as in the group that received 60 mg/kg per days for 90 
days. This study indicated how kanamycin, on raised dosages or increased periods can result 
in ototoxicity (Waterstrom et al., 1986). 
Ototoxicity, from aminoglycosides, has been observed in various other studies (Fausti 
et al. 1993; Moore, Smith & Lietman, 1984). These studies, in some instances, investigated 
aminoglycosides in general and did not separate the different drugs (Fausti et al. 1993; Moore 
et al., 1984). Amikacin, an aminoglycoside often used to treat DR-TB (Sagwa, 2017), has 
demonstrated ototoxicity through a variety of studies. Black et al. (1976) looked at amikacin 
at dosages of ≥7.5 mg/kg every eight hours in patients who were leukopenic, infected with 
gentamicin-resistant organisms or had cystic fibrosis. They found, using pure tone 
audiometry (PTA), that 24% were associated with the development of high-frequency hearing 
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loss, which was usually bilateral. Also, the onset of cochlear damage occurred in one patient 
after therapy was stopped (Black et al., 1976). Hotz, Harris and Probst (1994) found a higher 
incidence of amikacin induced ototoxicity, at 90%, when used for more than 12 days. 
However, this was a small sample (10 ears), and Transient Evoked Otoacoustic Emissions 
(TEOAEs) were utilised in contrast to Black et al. (1976), where the use of audiometry. 
Lerner and Matz (1979), with a larger group using gentamicin or amikacin, found a hearing 
loss in 7% of those taking gentamicin and 9% on amikacin. However, as per Black et al. 
(1976), PTA was used in contrast to TEOAEs. 
Moore et al. (1984) investigated incidence as well as risk factors for the expansion of 
auditory toxicity in patients receiving aminoglycosides, specifically gentamicin, tobramycin 
and amikacin. Ototoxicity, found in 22.3%, was found to be associated with drug therapy for 
a more extended period, patients who were more likely to be bacteremic, and had a higher 
temperature on average. The factors that did not significantly associate with hearing loss 
included plasma aminoglycoside levels, aminoglycoside type, furosemide use, diabetes, age, 
sex, renal function, initial auditory acuity, hematocrit value and shock (Moore et al., 1984). 
Fee (1980), while investigating tobramycin and gentamicin, found only 16.4% ototoxicity in 
the gentamicin sample, which also showed more toxicity than tobramycin. The hearing loss 
from gentamicin progressed after the discontinued drug. This incidence of gentamicin 
toxicity is less than Moore et al. (1984) of 22.3%, yet Moore et al. (1984) did not separate the 
drugs. As with Moore et al. (1984), associations between ototoxicity with high temperature 
and duration of therapy, and well as no associations with serum levels and age occurred. In 
contrast to Moore et al. (1984), Fee (1980) showed positive associations with ototoxicity with 
renal function and hematocrit value. 
There is significantly more research on aminoglycoside ototoxicity than polypeptides, 
such as capreomycin. Yet, polypeptide ototoxicity, with capreomycin has been shown 
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through a human study (Akorn, Inc. Package Insert, 2015), and with ototopic triethanolamine 
polypeptide oleate-condensate in an animal (chinchilla) study (Daniel et al., 2008). 
Capreomycin (injectable Capastat Sulfate) resulted in a subclinical auditory loss in 
approximately 11% of 722 healthy patients (5 – 10 dB loss in the 4 – 8 kHz range) and a 
clinically apparent hearing loss in 3% of the subjects. Some audiometric changes were 
reversible, and cases with permanent loss were not gradual following withdrawal of Capastat 
Sulfate. Tinnitus and vertigo were also reported (Akorn, Inc. Package Insert, 2015). However, 
these losses from capreomycin were in healthy individuals, where sick patients, such as those 
with TB, may have other risk factors, for example, previous exposure to ototoxic 
medications, which would perhaps make them more at risk and susceptible to ototoxicity 
(Wang et al., 1999). Additionally, ototopic triethanolamine polypeptide oleate-condensate 
10% was investigated in chinchillas (Daniel et al., 2008) as this composition is utilised as 
cerumenex, an earwax softener used in humans. Mean DPOAEs (between 1 kHz and 9 kHz) 
in the chinchillas were reduced from the first day of the study. This study demonstrated the 
possible ototoxic effects of another polypeptide other than capreomycin, however, has so far 
only been investigated in an animal model (Daniel, 2008).  
Furthermore, vancomycin, a glycopeptide, has resulted in ototoxicity (Forouzesh et 
al., 2009), when investigated through a retrospective case-control analysis of audiometry 
results for patients on vancomycin therapy. Results showed a pattern of high-frequency 
hearing loss in 12% of the sample, with a trend in univariate analysis toward a higher rate 
with advanced age (Forouzesh et al., 2009). Although there are few human studies on 
peptides and polypeptides, specifically on capreomycin and vancomycin, results do indicate a 
relationship to ototoxicity.  
There is some controversy regarding the incidence of hearing loss in various human 
and animal studies, yet it is evident that ototoxicity occurs. Further investigation to 
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understand the cause and risk factors to predict an overall definitive incidence of the hearing 
loss with the various aminoglycosides and polypeptides is necessary. Also, the method the 
monitor and define ototoxicity needs to be established in order for consistent statistics and 
studies. 
4.4. Ototoxicity in the DR-TB Population 
The inclusion of kanamycin and capreomycin as part of the international and national 
DR-TB treatment regimen (NDoH, 2013; WHO, 2016b), places patients with DR-TB at risk 
for ototoxicity (Jacobs & Ross, 2012; de Jager & van Altena, 2002; Duggal & Sarkar, 2007; 
Ramma & Ibekwe, 2012; Sturdy et al., 2011; Sagwa et al., 2015; Melchionda et al., 2013; 
Akbergenov et al., 2011). 
Various studies reported varying degrees of ototoxicity in the DR-TB population 
(Harris et al., 2012), yet these studies defined and reported ototoxicity differently. Harris et 
al. (2012) showed 57% of patients with MDR-TB developed high-frequency hearing loss. 
Similarly, Ramma and Ibekwe (2012) found 47% to show a hearing loss in a cross-sectional 
study of adult MDR and XDR-TB patients in Cape-Town. Yet, Jacobs and Ross (2012) found 
28.7% of patients treated with amikacin or kanamycin for DR-TB developed hearing loss and 
vestibular disturbances. This study did not describe the audiological tests and frequencies 
measured (Jacobs & Ross, 2012).  
Furthermore, de Jager and van Altena (2002) showed even less ototoxicity in patients 
treated with amikacin, kanamycin and/or streptomycin, as measured by PTA. This hearing 
loss was found in 18% of the total population treated with aminoglycosides, while 15.6% 
were from kanamycin. This contrasts with Sagwa et al. (2015), who showed that amikacin 
appeared to be more ototoxic than kanamycin, yet also found a much higher percentage of 
hearing loss in MDR-TB patients, at 58%. This incidence is similar to the studies by Harris et 
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al. (2012) and Ramma and Ibekwe (2012). Sagwa et al. (2015) presented a unique report, as 
no other studies could be found showing that amikacin is more toxic than kanamycin. Most of 
the hearing loss in their study was bilateral (83%), with 32% classified as mild, 23% as 
moderate, 16% as moderate-severe, 10% as severe and 15% as profound in severity (Sagwa 
et al., 2015). 
Ototoxicity has been noted in many other DR-TB studies. Duggal and Sarkar (2007) 
looked at patients on amikacin, kanamycin, and capreomycin, and found 18.75% of the 
patients acquired sensorineural hearing loss involving higher frequencies while 6.25% were 
involved of speech frequencies also. No threshold shift (better or worse) was seen after 
discontinuation of therapy, and the hearing losses were permanent. In addition, Sturdy et al. 
(2011) found 28% of patients experienced ototoxicity in their retrospective study on 
injectable antimicrobials for MDR-TB in the UK. The type of injectable antimicrobial varied, 
as with many other studies.  
Interestingly, shorter treatment (approximately three to six months) was observed in 
London (Melchionda et al., 2013). Amikacin was used, and trough levels were consistently 
within the target range. Hearing was tested between 0.25 kHz and 8 kHz. An audiologically 
detectable hearing loss occurred in seven patients. Only four had a gradable hearing loss 
according to the Cancer Institute Common Terminology Criteria for Adverse Events (NCI 
CTCAE) scale. Despite the shorter regimen, there have been no cases of TB reactivation 
since treatment completion in the reported study (Melchionda et al., 2013).  
Bardien et al. (2009) further describe how aminoglycosides persist in the inner ear 
tissues for six months or longer after administration and can cause further hearing loss. This 
does not always occur, as seen in the study by Duggal and Sarkar (2007). Despite these 
adverse effects, in this case, ototoxicity, these aminoglycosides and capreomycin are utilised 
for the treatment of MDR-TB in South Africa (NDoH, 2011). More so, the ARV medication 
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may further augment hearing loss (Khoza, 2010). The South African health professionals are 
therefore potentially facing the risk of a significant proportion of the population acquiring 
permanent drug-induced hearing loss due to these aminoglycosides and capreomycin used to 
treat MDR-TB (Bardien et al., 2009). 
In addition to the aminoglycosides and capreomycin, there is conflicting evidence 
indicating that antiretroviral drugs, used to treat HIV, may be ototoxic. This is of particularly 
relevant, as 50% of TB patients are HIV positive in South Africa, yet this statistic does not 
differentiate between TB and DR-TB (Harris & Heinze, 2015). This potential ototoxicity has 
been described with an in-vitro study which yields evidence of auditory toxicity resulting 
from HIV drugs (Thein, Kalinec, Park & Kalinec, 2014). In contrast, human studies are 
difficult to retrieve conclusive evidence, as it is challenging to separate effects of the HIV 
itself from the effects of the HIV drugs (Khoza, 2010).  
Thein et al. (2014), with an in vitro study, described how the cocktails of HIV drugs 
decreased auditory cells' viability, specifically the HEI-OC1 auditory cells, with high 
significance. Epzicom® was shown to be most affected while Truvada® was the least. In 
contrast, a study conducted on HIV patients in a real-life setting found no statistically 
significant relationship between ARVs and hearing loss (Vieira, Greco, Teófilo & Gonçalves, 
2008). Furthermore, Khoza (2010) conducted a systematic review on hearing loss in adults 
with HIV with a particular focus on the possibility of ototoxicity of ARVs. This review 
highlighted points such as ART ototoxicity reported is mainly from case reports as well as the 
lack of sensitive tools to assess ototoxicity in more significant samples (Khoza, 2010). As 
there is evidence of possible ototoxicity from ARVs, despite it being conflicting and weak, 
HIV and its treatment must be considered as a possible factor contributing to the ototoxicity 
in the DR-TB population. Furthermore, the proportion of known HIV-positive TB patients 
globally on ART was 78% globally according to the WHO TB report in 2016. This HIV 
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treatment and its adverse effects must be considered when describing hearing loss in DR-TB 
patients. 
4.5. Configuration of this Ototoxic Hearing Loss 
Hearing loss resulting from aminoglycosides is usually gradual, bilateral and 
symmetrical (Harris & Heinze, 2015; Schmidt, Knief, Lagosch, Deuster & am Zehnhoff-
Dinnesen, 2008). However, asymmetry has been noted in some instances (Huizing & de 
Groot, 1987), with possible explanations presented below. The degrees of the hearing losses 
tend to differ, and details regarding the degree of hearing loss are not always reported.  
Moreover, with increased exposure to the drugs, this high-frequency hearing loss 
often progresses to involve the lower frequencies. As aminoglycosides can stay within ones 
system for six months to a year after completion of aminoglycoside drug therapy, hearing 
loss can continue to occur after the cessation of treatment (Harris & Heinze, 2015). These 
hearing losses are likely to cause a hearing handicap, defined as the disadvantage imposed by 
a hearing impairment on a person's communicative performance in the activities of daily 
living (American Speech-Language-Hearing Association, 1981). 
4.5.1. Degree 
A typical audiogram from an MDR-TB patient may appear as per Figure 4.1. This 
figure displays the initial high-frequency hearing loss progressing to include the lower 
frequencies. 
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Figure 4.1. Baseline and follow-up audiograms of a patient on treatment for MDR-TB 
(Adapted from Harris & Heinze, 2015, p. 3) 
High-frequency nature aminoglycosides induced hearing loss described in various 
studies (Sharma et al., 2016; Javadi et al., 2011; Fausti et al., 1992). Although they mostly 
report the bilateral hearing loss (Sharma et al., 2016; Javadi et al., 2011) in some instances, 
unilateral hearing loss is described, which depicts asymmetry.  
This high-frequency loss was observed in an MDR-TB study using kanamycin in 
India (Sharma et al., 2016). Of the 100 patients examined, ototoxicity was found in 18% of 
participants, with majority displaying high-frequency hearing loss. The hearing loss was also 
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mainly bilateral, yet the hearing loss was unilateral in 5% of these patients (Sharma et al., 
2016). High-frequency hearing loss was described further in a paediatric TB study (Ghafari, 
Rogers, Peterson & Singh, 2015). Furthermore, high-frequency hearing loss was seen in the 
majority of the patients that experienced ototoxicity with 62% being bilateral and 48% being 
unilateral (Javadi et al., 2011). All these studies only tested up to 8 kHz. However, when 
testing frequencies higher than 8 kHz (9 kHz to 20 kHz), as with Fausti et al. (1992), it was 
possible to identify an early change in hearing in 82% of the ears. 
4.5.2. Laterality and symmetry 
Unilateral and asymmetrical hearing loss is not understood in relation to ototoxicity, 
yet it has been reported in the above studies. Various ideas have however been proposed. 
McFadden (1993) discusses two main differences known in hearing sensitivity, namely 
gender and ear when measured with OAEs. McFadden (1993) describes this as females being 
more sensitive than males, and right ears being more sensitive than left ears. This right ear 
advantage is described mainly in individuals’ exposure to intense sounds, where the right ear 
displayed a lesser hearing loss than the left ears. However, the difference of this was 
minimal; the magnitude of the right-ear advantage in sensitivity was rarely more than 2-4 dB 
at a given frequency, and it differed as a function of several variables. This article noted the 
plausibility of a developmental linkage between efferent-based asymmetries insensitivity and 
asymmetries in adult cortical lateralisation (McFadden, 1993). Furthermore, in a study by 
Chung, Masoon, Gannon and Willson (1983), with a participant group of more than 50 000 
people, differences of about 1.5-2.5 dB were noted for male adults in the range 2-6 kHz 
between the ears. The right ear always appeared to have the superior hearing levels.  
A variety of studies by Khalfa, Morlet, Micheyl, Morgon and Collect (1997) also 
show ear differences. Khalfa et al. (1997) showed higher amplitudes of TEOAEs in right 
ears. Khalfa et al. (1997) showed right ears to have more significant tone decay and for left 
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ears to show a higher temporary threshold shift. The right medial olivocochlear system also 
shows significantly higher activity (Khalfa & Collet, 1996). 
This right ear advantage thus may explain differences in the symmetry of ototoxic 
hearing loss, where the left ear displays more hearing loss than the right ear. Yet the 
differences observed in the aminoglycoside studies were more than 2-4 dB as proposed by 
McFadden (1993). 
Further, possible asymmetry with ototoxicity from cisplatin has been observed in the 
study by Schmidt et al. (2008). They investigated the possibility of the right ear advantage in 
children undergoing chemotherapy (cisplatin). The study included 55 children and found that 
the left ear was slightly more affected in the range of 2-8 kHz to 8 kHz. The difference was 
significant at 4, 6 and 8 kHz. McFadden (1993) concludes that it is possible that the 
asymmetry in the efferent system may be related to the well-known cortical asymmetries that 
are believed to underlie speech perception, speech production, and other human abilities. This 
study shows that contrary to other literature, the cisplatin-induced hearing loss is not 
necessarily symmetrical. Additionally, asymmetrical or unilateral hearing loss in the case of 
cancer is often a result of tumour location or surgical or radiotherapeutic intervention 
(Schmidt et al., 2008). There is only limited evidence of asymmetric hearing loss, such as a 
case with initially bilateral, symmetric hearing loss after aminoglycoside therapy, in which 
the right ear recovered although the left ear remained hearing impaired (Moffat & Ramsden, 
1977).  
Another study by Huizing and de Groot (1987) mentioned that aminoglycoside 
induced hearing loss is not necessarily symmetrical. This study, however, occurred in 1987 
and did not explicitly describe reasoning for this. Most studies appear to describe hearing loss 
resulting from ototoxicity as symmetrical; however, vestibular disturbances are described 
more often as asymmetrical (Waterston & Halmagyi, 1998; Elidan, Lin & Honrubia, 1987). 
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It appears that many studies are reporting high frequency and mostly bilateral hearing 
loss. Also, the degree of the hearing loss varies. In many instances, unilateral components 
have been reported, indicating asymmetry. Although some possible ideas have been 
presented to explain this, there is no conclusive evidence as to why these unilateral hearing 
losses are occurring.  
4.6. Impact of Ototoxic Induced Hearing Loss on Quality of 
Life 
Hearing loss can affect an individual’s quality of life, due to impact on one 
communication.  
In 2001, the WHO endorsed the International Classification of Functioning, 
Disability, and Health (ICF). This model can be displayed according to the figure below, as 
seen in the article by McDougall, Wright, and Rosenbaum (2010). This concept provides a 
framework for understanding functioning and disability whereas functioning encompasses all 
body functions and structures, activities, and participation, while the disability is an 
overarching term for impairments, activity limitations and participation restrictions. A 
person’s functioning and disability are considered to arise from the interaction among health 
conditions, environmental factors, such as accessibility of the environments, peer 
relationships, service availability etc. and personal factors, such as age, gender, values, 
lifestyle, etc. (McDougall et al., 2010). Figure 4.2 depicts all these interactions which affect 
functioning and disability. 
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Figure 4.2. The World Health Organisation’s model of functioning and disability (McDougall 
et al., 2010) 
 
Burden of disease may be quantified with quality-adjusted life years (QALY) or 
DALYs. These both quantify the number of years lost due to a specific disease. The 
foundation for the QALY calculation is based on a multi-attribute theory where the following 
conditions are considered: utility independence between life years and health status, constant 
proportional trade-off and risk neutrality on life years. The QALYs are used in many costs 
analysis situations and can be a productive part of a decision-making process. Zeckhauser and 
Shepard (1976) first used the term ‘quality-adjusted life year’ to indicate a health outcome 
measurement unit that combines duration and quality of life. The QALY primarily calculates 
life expectancy based on the health-related quality of life, although it is not as simple (Sassi, 
2006).  
The QALYs provide a framework for the development of the DALY which is 
primarily a measure of disease burden as it weights the disability to the loss of functioning. 
The DALY considers age, the origin of disability as well as the quality of life weights 
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differently as to with the QALY. Both these measures are calculations to assess the outcomes 
(Sassi, 2006). The WHO assesses Burden of Disease using the DALYs as it is a time-based 
measure that combines years of life lost due to premature mortality and years of life lost due 
to time lived in states of less than full health. The DALY metric assesses the burden of 
disease consistently across diseases, risk factors, and region (WHO, 2016c). Although these 
calculations are not being utilised in this research study, it highlights important aspects to 
consider when assessing the quality of life, and the effect that hearing loss can have on ones 
functioning and disability.  
The potential disability of hearing loss from an already disabling disease such as TB 
highlights the disability aspect of the ICF where activity and overall functioning is affected. 
The effect of hearing loss or deafness can in-turn affect all spheres of a person’s life, 
including socialisation, employment, and occupational aspects, emotional and self-esteem 
and overall and general wellbeing (Peterson & Rogers, 2015). A survey, conducted in the 
USA, found that 36% of individuals with hearing difficulty were unemployed in comparison 
to an unemployment rate of 25% for individuals with no disability (Ruben, 2000). The WHO 
estimated that 360 million people (over 5% of the world’s population) are living with 
disabling hearing loss. Disabling hearing loss is distributed unequally across the world, with 
the highest burden living in low and middle-income countries (WHO, 2017). Even more so, 
TB is viewed as a disability in itself as South Africa will now provide disability grants for 
patients with TB (Green, 2015). The emotional aspects of hearing loss, which can also 
include anxiety, lack of self-confidence, depression and/or social isolation (Peterson & 
Rogers, 2015), combined with the stigma, depression, and anxiety from TB (Aydin & 
Ulusahin, 2001) places a ‘double disability’ on these individuals. Also, the current production 
of hearing aids meets less than 10% of the global need, and less than 3% in developing 
countries (WHO, 2017). Hearing loss can have a major impact on the ability of affected 
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individuals to secure jobs (Kidd, Sloane & Ferko, 2000) and, since most of TB patients are 
from poor socio-economic backgrounds (Lawn, Bekker, Middelkoop, Myer & Wood 2006), 
there will be increased demands on the country's social welfare and health budgets. There are 
currently demands on the budget as TB patients apply for social grants while they are sick. 
Yet, when they are physically well, they often need to apply for further disability grants 
resulting from their hearing loss. 
The identification of the extent and pattern of hearing loss in the DR-TB population is 
essential to evaluate the QALY and DALY, but also to improve functioning and lessen this 
‘double disability’. 
4.7. Ototoxicity Monitoring  
Objective and subjective monitoring of cochlear and vestibular function can help 
identify the toxic effect of the medication (Schellack & Naude, 2013). Monitoring for 
ototoxicity allows for the early detection of audiologic changes in order to permit the 
consideration of changes or alternative treatment regimen, as well as to allow for intervention 
once hearing handicap has occurred (Durrant et al., 2009; ASHA, 1994; Schellack & Naude, 
2013).  
The changes in treatment can comprise of a reduction in the dosage, a change in the 
timing of the dosage schedule, a temporary discontinuation of therapy so that the ear can 
"rest" and/or a switch to a less ototoxic drug (Vasquez & Mattucci, 2003; Durrant et al., 
2009). In some cases, however, the physician will not be able to change the drug regimen 
because of the intensity or severity of the patient's illness (Vasquez & Mattucci, 2003). 
According to the NDoH Guidelines in 2015, suggestions to stop the drug, reduce the dose or 
increase the length of the dosing interval is recommended upon the detection of ototoxicity. 
However, it further mentioned that there is no evidence from randomised controlled trials to 
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support any of these interventions (NDoH, 2015). Nevertheless, changes in medication often 
occur in practice and are reported anecdotally by clinicians/audiologists to reduce the 
ototoxicity.  
Furthermore, intervention allows the patients and/or the family to maintain effective 
communication should the hearing loss worsen, in cases when alternative treatment may not 
be a suitable or viable option (Durrant et al., 2009). When ototoxicity occurs, referral for 
vestibular and/or aural rehabilitation is indicated, particularly for patients who experience 
permanent hearing loss (Vasquez & Mattucci, 2003). Intervention for this hearing loss can 
include counselling (Konrad-Martin et al., 2005), hearing aid fitting (NDoH, 2015), 
implementation of communication strategies (Konrad-Martin et al., 2005), and in some cases, 
cochlear implants (Nichani et al., 2013). 
4.7.1. Ototoxicity Monitoring Guidelines 
There are three primary audiological methods to ototoxicity monitoring that have 
been dominant over the past few decades. These dominant trends include the basic audiologic 
assessment, high-frequency audiometry (HFA), and otoacoustic emission (OAE) 
measurement. These three methods vary in utility, reliability, purpose and applicability to 
different populations (Durrant et al., 2009).  
Other measures mentioned by Durrant et al. (2009) include auditory evoked potentials 
such as high-frequency Auditory Brain Stem Responses (ABRs) or Auditory Steady-State 
Evoked Response (ASSR). While these electrophysiological measures may show overall 
technical efficacy, the results for high-frequency measurements are not as encouraging due to 
a considerably reduced dynamic range, another major challenge (in addition to the issue of 
standing waves) in all areas of high-frequency testing. These measures may, however, be 
useful in a paediatric population who may not be able to respond behaviourally with 
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traditional HFA (Durrant et al., 2009). However, as sedation may be needed, this may not be 
advisable because of sedation relation complications (Tobias & Leder, 2011).  
Currently, there are very few guidelines published internationally recommending a 
monitoring protocol for ototoxicity. Various individual studies have proposed ideas. 
However, the existing guidelines available have been issued from ASHA (1994) and the 
American Academy of Audiology by Durrant et al. (2009). In 2015, the South African NDoH 
issued a recommended monitoring protocol for patients with DR-TB. They were adapted 
from the ASHA guidelines and recommend grading. 
4.7.1.1. South African guidelines. 
Despite the availability of a South African policy for monitoring ototoxicity (NDoH, 
2015), research has shown that various hospital in South Africa follows their own protocols 
(Khoza-Shangase & Stirk, 2016). It was found that some hospitals in South Africa have 
implemented their own programs for monitoring ototoxicity from TB treatment, and there 
was no clear standard for managing the detected ototoxicity. They suggested that a 
monitoring program with an intervention method needs to be established in South Africa 
(Khoza-Shangase & Stirk, 2016). 
4.7.2. Assessment of Ototoxicity 
The Guidelines for the Audiologic Management of Individuals Receiving 
Cochleotoxic Drug Therapy developed by the ASHA Ad Hoc Committee on Audiologic 
Management of Individuals Receiving Ototoxic and/or Vestibulotoxic Drug Therapy and 
adopted by the ASHA Legislative Council (LC 36-93) in November 1993. This document 
discusses the role of the audiologists, various ototoxic drugs, the incidence of 
cochleotoxicity, basic principles of cochleotoxicity monitoring, procedures of cochleotoxicity 
monitoring, responsive/limited responsiveness and unresponsive patients, testing 
environments, children and aural rehabilitation. This document states it is the audiologists’ 
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responsibility to identify at-risk patients and design and implement a suitable ototoxicity 
monitoring protocol, as well as the implementation of rehabilitative procedures (ASHA, 
1994). In South Africa, the doctors and nurses are also responsible for identifying patients, 
and many nurses conduct testing due to the limited availability of audiologists. 
Furthermore, this article (ASHA, 1994) mentions that the relationship between 
cochleotoxicity and drug administration parameters such as dosage, duration of treatment, 
and serum concentration is highly variable, and so dependence of sole reliance on dosage or 
serum concentrations is not reliable. The authors mention that the available evidence 
indicates that high-frequency audiometry is the method of choice for the earliest detection of 
ototoxic hearing loss. A monitoring protocol includes patient identification (those patients at 
risk and taking ototoxic medication), pre-treatment counselling, and baseline testing (for 
kanamycin it is suggested that baseline is indicted within 72 hours of the first dose 
administration (ASHA, 1994) as ototoxicity can occur after only a single dose (Vasquez & 
Mattucci, 2003). Subsequently, the recommendation for monitoring and follow-up tests at 
intervals that would allow the detection of the earliest signs of ototoxicity (ASHA, 1994). 
The South African guidelines recommend baseline measures within the first seven days of 
treatment, and subsequently weekly testing where possible, else monthly. In the continuation 
phase, three monthly testing is recommended for a total of six months (NDoH, 2015). 
An outline of assessment and monitoring procedures, including the identification of 
risk factors and counselling, followed by audiological tests that can include the primary test 
battery, ultra-high frequency PTA and OAEs are detailed below. In addition, the timing of the 
testing should be considered in different populations and with different ototoxic drugs. 
4.7.2.1. Identification of risk factors. 
It is advised that risk factors develop ototoxicity be identified (Vasquez & Mattucci, 
2003). These risk factors include previous use of an ototoxic agent, simultaneous exposure to 
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multiple ototoxic agents, administration of an ototoxic agent for more than 14 days, 
administration of multiple courses of an ototoxic drug, administration of an aminoglycoside 
in combination with a loop diuretic, high serum levels of an ototoxic agent (a consequence of 
a failure to monitor peak and trough levels), pre-existing sensorineural hearing loss with 
evidence of outer-hair-cell loss, impaired renal function and compromised hepatic function, 
age and individual genetic factors (Vasquez & Mattucci, 2003). Konrad-Martin et al. (2005) 
also mention poor general medical condition and reduced renal function as risk factors. A 
high temperature and duration of drug therapy can also be regarded as risk factors (Moore et 
al., 1984). Further aspects should be noted including ototoxicity occurring in patients who 
take an appropriate dose and in those who have average peak and trough levels.  
The identification of all risk factors would be ideal, however, sometimes may not be 
possible. Genetic testing is extremely expensive, and identification of all the risk factors is 
not always possible, especially in South Africa, where the tester may not speak the language 
of the patient. Also, the patient may be unaware of his/her history. Therefore, even though 
risk factor identification would be an added benefit; the absence of risk factors cannot 
exclude a patient from ototoxicity monitoring.  
4.7.2.2. Pre-treatment counselling. 
Prior to the initiation of ototoxic treatment, patients should have counselling regarding 
the potential effects of the drugs on the auditory system. The medical doctor should include 
the risks and benefits of drug therapy, and the audiologist should counsel patients on signs 
and symptoms of cochlear damage and potential effects on communication ability (ASHA, 
1994). The audiologist can further counsel patients and their families concerning ototoxicity-
induced hearing loss, tinnitus, and dizziness, communication strategies, and the synergistic 
effects of noise and ototoxic damage (Konrad-Martin et al., 2005). 
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As patients have a right to information about their condition and the treatment options 
available, it is crucial to meet language and communication needs, and thus, due to the 
multitude of languages in South Africa, interpreters may be necessary (Health Professions 
Council of South Africa [HPCSA], 2008). 
4.7.2.3. Basic audiological assessment. 
The traditional necessary audiological test battery includes otoscopy, tympanometry, 
PTA (PTA), including air and bone conduction, and speech audiometry (Durrant et al., 2009).  
Baseline evaluations are imperative for ototoxicity monitoring. This allows one to 
consider possible pre-existing hearing loss that may not be a result of the current ototoxic 
regimen. It thus allows for a clear basis for interpretation. Ideally, this should take place 
before the administration of the initial dose of the ototoxic regimen (Durrant et al., 2009, 
ASHA, 1994). Ideally, this baseline evaluation should include all tests that may be needed in 
subsequent testing, even if only a few are utilised for the follow-up monitoring. This is 
because, if a change does subsequently occur on the follow-up testing, more extensive testing 
will be needed at that time to determine if the change is secondary to the drug, or other 
factors, such as otitis media. A comprehensive basis will assist in preventing ambiguity with 
analysis of the results. The baseline tests should be as comprehensive as possible which can 
include PTA (up to 8 kHz), tympanometry, ultra-high frequency audiometry (UHFA), OAEs 
and speech audiometry (Durrant et al., 2009). 
Yet, the traditional necessary audiological test battery only includes otoscopy, 
tympanometry, PTA including air and bone conduction, and speech audiometry (Durrant et 
al., 2009). It does not include UHFA and OAEs. However, all these tests take significant time 
to administer and conduct and may not be feasible at every follow-up. The NDoH (2015) 
recommends otoscopy, tympanometry, PTA (UHF where possible) and OAEs. They do not 
include bone conduction or speech audiometry. 
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• Otoscopy: An otoscopic examination is performed to evaluate the state of the outer ear, 
and tympanic membrane for abnormalities and/or infection (Rappaport & Provencal, 
2002). Otoscopy determines the condition of the external auditory meatus and tympanic 
membrane and to ensure that there are no obstructions in the external canal or conditions 
that could influence additional testing procedures. 
• Cerumen Management: Impacted cerumen can affect the reliability of tympanometry, 
distortion product otoacoustic emissions (DPOAE), and PTA. Therefore, the removal of 
cerumen allows for a clear external auditory meatus to assist in ensuring further reliable 
audiometric measures. 
• Tympanometry: Tympanometry evaluates middle ear status through the depiction of 
tympanic membrane motility as a function of variations in air pressure (Clark, Roeser & 
Mendrygal, 2007). This test serves as an invaluable evaluative tool representing middle 
ear functioning (Clark et al., 2007). Also, the presence of middle ear pathologies results in 
severely diminished OAEs, and more severe cases may also influence the results obtained 
with ABR testing (Swanepoel et al., 2007), thus affecting the reliability of the OAE 
measures and air conduction PTA measures. Tympanometry is essential in South Africa, 
precisely due to high rates of HIV co-infection in XR-TB settings. Chronic outer and 
middle ear infections are prevalent in this population which can complicate testing and 
interpretation (Seddon, Godfrey-Faussett, Jacobs et al., 2012). 
• Pure Tone Audiometry: PTA assesses hearing sensitivity as a function of frequency 
(Bess & Humes, 2008). It is a psychophysical assessment of auditory sensitivity and 
provides insight into the integrity of the auditory system as well as information relating to 
the symmetry, laterality, degree, and configuration of a patient’s hearing thresholds 
(Harrell, 2002). In this hearing test, a hearing threshold is obtained at various frequencies 
with a calibrated audiometer (Guthrie, 2008). The purpose of testing hearing this way is 
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to help aid in making decisions regarding both the type and the extent of a patient’s 
hearing loss (Martin & Clark, 2003). For those who can cooperate and participate in 
testing, PTA in the currently preferred method to test hearing (Seddon et al., 2012). Pure 
tones are presented (air and/or bone conduction) via circumaural headphones, ear canal 
insert transducers, sound field arrays or an oscillating bone transducer positioned on the 
mastoid. Patients are aware and instructed to respond in a manner that is consistent and 
conducive to their physical ability (Guthrie, 2008). Bilateral testing takes place for a 
range of frequencies, and the minimum volume or amplitude is recorded when the patient 
responds. Frequencies above 2 kHz are considered high frequency (Seddon et al., 2012). 
The necessary procedure for threshold determination consists of (i) familiarisation with 
the test signal and (ii) threshold measurement. The procedure is the same regardless of 
frequency, an output transducer, or ear under test (ASHA, 2005). The purpose of testing 
hearing this way is to help aid in making decisions regarding both the type and the extent 
of a patient’s hearing loss (Martin & Clark, 2003). There is controversy about the 
audiometric criteria for threshold shift, which frequencies should be tested and what step 
size should be used when evaluating ototoxicity. A study by Konrad-Martin et al. (2010) 
explored the evaluation of a significant threshold shift, and which octave steps should be 
tested (sixth, third or half-octave steps). They evaluated 78 ears of 41 participants on 
cisplatin in comparison to 53 ears of 28 hospitalised participants not receiving ototoxic 
antibiotics. They found that compared with the half octave step size that is utilised 
clinically, use of smaller frequency steps improved test performance for threshold shifts 
at ≥2 or ≥3 adjacent frequencies. Best overall test performance was achieved using a 
criterion cut from ≥10 dB threshold shift at ≥2 adjacent frequencies tested in sixth-octave 
steps. Best test performance for the half octave step size was achieved for shifts ≥15 dB at 
one or more frequencies. As there is currently no set criteria more monitoring ototoxicity 
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE 
RELATIONSHIP BETWEEN HEARING LEVELS: A FEASIBILITY STUDY 
103 
and the grading scales clearly have their limitations as noted above, it is a critical study to 
note when drawing up a protocol.  
• Speech Audiometry: Speech audiometry assesses one’s auditory ability using words, 
which are much more representative, when compared to pure tones, of everyday listening 
experiences than pure tones. Measuring the ability to perceive speech provides the 
audiologist with a clearer picture of ones’ functional hearing ability (van Zyl, n.d). 
For this current study, air conduction PTA was chosen without bone conduction and 
speech audiometry due to the time it takes to test, and the medical status the patients may 
have (Durrant et al., 2009).  
Apart from the conventional means of conducting the basic test battery, other methods 
are being explored to conduct tests where audiologists may not be available. The study by 
Jacobs et al. (2012) introduces the idea of telehealth in ototoxicity monitoring. They describe 
a system, with ototoxicity identification (OtoID), that includes a portable audiometer with 
high-frequency test functionality that meets ANSI/ASA S3.6-2010 standards and is capable 
of reliably detecting ototoxicity relative to a baseline period using an automated test. The 
system includes a wireless cellular modem that is capable of notifying a remote healthcare 
professional in the event that a significant change in hearing has occurred in the patient. The 
system was evaluated within a sound-proof booth, a noisy hospital ward, and within patients’ 
homes and results indicated that the OtoID system could be utilised by patients to efficiently 
monitor ototoxicity remotely, which can ultimately enable early detection of ototoxicity and 
potentially avoiding this hearing loss (Jacobs et al., 2012). There is increasing interest from 
academics and clinicians in harnessing smartphone applications as a means of delivering 
health intervention. Despite the growing availability of a range of health-related mobile 
applications on the market, academic research on the development and evaluation of such 
apps is in the relatively early stages (Dennison, Morrison, Conway & Yardley, 2013). As 
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE 
RELATIONSHIP BETWEEN HEARING LEVELS: A FEASIBILITY STUDY 
104 
many patients living in rural areas do not have access to audiologists, this could be an option 
to explore. However, mobile health and telehealth needs exploration with extreme caution. 
Currently, the NDoH has purchased portable automated audiometers for this population, and 
although an official study has not yet occurred, various issues and unreliable results are noted 
from personal communication with audiologists and nurses in the field. These issues include 
difficulties with insert earphone placement and with the automated instructions and protocol. 
Furthermore, technological difficulties have been reported upon via personal communication 
with nurses required to use this system. Also, the test has not been validated on the DR-TB 
population. Therefore, in conclusion, telehealth has an important place in a resource-limited 
country; however, it needs careful implementation and it needs to be executed in consultation 
with many professionals in the field. Those implementing the procedures also need adequate 
training; not only how to operate the equipment, but how to note patient factors and possible 
defaults in the results. 
4.7.2.4. Ultra-High Frequency Audiometry. 
As ototoxicity manifests, initially in the outer hair cells, ultra-high frequencies are 
affected first. The ASHA guidelines for ototoxicity monitoring emphasise the increased test 
sensitivity achieved using ultra-high-frequency monitoring to detect ototoxicity (Konrad-
Martin et al., 2005). UHFA comprises of air-conduction threshold testing for the frequencies 
above 8 kHz, ranging up to 16 or 20 kHz (Durrant et al., 2009).  
UHFA allows for the detection of changes well before it becomes evident in the 
speech-related frequencies. This allows for a possible change in the drug therapy before a 
hearing handicap is evident (Durrant et al., 2009). However, there are limitations to UHFA as 
it may not always be suitable, especially for patients with the pre-existing hearing loss. Test-
retest differences for ultra-high-frequency thresholds using modern equipment are generally 
reported being within ±10 dB for frequencies between 9 and 14 kHz (Konrad-Martin et al., 
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2005). ASHA (1994) state that for patients with limited responsiveness, testing can be 
shortened, by reducing the frequencies tested but the high frequencies should be a priority. 
The specific frequencies with the most sensitivity for ototoxicity monitoring (with 
aminoglycosides and cisplatin) were investigated. The frequencies that showed the most 
significant sensitivity was 8, 9, 10, 11.2 and 12.5 kHz (generally separated by 1/6 octave) 
(Fausti et al., 1999). 
PTA is not performed routinely at above 8 kHz as frequencies in this range do not 
involve speech sounds (0.25kHz to 6/8kHz). Although in a study by Al-Malky et al., (2014) 
that was conducted in paediatric patients, it displayed that UHFA can detect ototoxic hearing 
loss more than standard PTA (Al-Malky et al., 2014). Yet PTA normative values for 
frequencies above 8 kHz are not yet established clearly (de Sá et al., 2007). Despite this, they 
are still useful for audiological monitoring of ototoxicity. By detecting a change in 
frequencies above 8 kHz, ototoxicity can be identified before it involves speech frequencies 
and affects communication (Singh, Saxena & Varshney, 2008).  
4.7.2.5. Otoacoustic Emissions. 
Otoacoustic emission testing is a recording of sounds generated within the cochlea 
(Prieve & Fitzgerald, 2002). OAEs are generally used as they can detect minor changes in 
cochlear function prior to changes in thresholds on either the conventional audiogram or 
UHFA (Guthrie, 2008). DPOAEs allow for information pertaining to the integrity of the 
cochlea to be obtained, therefore contributing to the differential diagnosis linked to auditory 
functioning at this level of the auditory system (Prieve & Fitzgerald, 2002). OAEs are 
physiological assessments of cochlear function and are extremely sensitive measures 
(Guthrie, 2008). As ototoxicity manifests in the outer hair cells initially (Durrant et al., 2009), 
it is a useful measure in patients receiving ototoxic medication. OAEs are classified 
according to the stimulus that elicits the emission, namely spontaneous and evoked OAEs 
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(Hall, 2000). In this assessment, coherent acoustic reflections and acoustic distortion products 
are measured in the external auditory meatus. These acoustic occurrences are obtained by 
specific stimulus frequencies or bandwidths via a transducer positioned close to the tympanic 
membrane and acoustically coupled to the external auditory meatus. The emissions generated 
are dependent on the homeostasis of outer hair cells electromechanical and mechanoelectrical 
transduction processes (Guthrie, 2008). The mechanoelectrical process involves the OAEs 
arising from a nonlinear electromechanical distortion within the human cochlear. This 
distortion is turn creates a source of energy in the outer ear which is then measured as the 
emission (Gorga et al., 1997).  
Evoked OAEs require a stimulus, while spontaneous OAEs require no such stimulus. 
Spontaneous OAEs have little clinical value (Hall, 2000). Evoked OAEs includes into three 
types, namely TEOAEs, Stimulus Frequency OAEs (SFOAEs) and DPOAEs. These types 
require different stimuli to elicit the emissions, being a click stimulus, a continuous pure tone 
stimulus and two pure tones as the stimulus respectively (Martin, Jassir, Stagner, Whitehead 
& Lonsbury-Martin, 1998). TEOAEs and DPOAEs, however, remain the most useful in 
clinical practice. The presence of OAEs with normal middle ear functioning implies hearing 
within reasonable limits, while the reduction or absence of OAEs indicates reduced outer hair 
cell functioning and thus implies hearing loss. TEOAEs have been shown to measure a 
hearing loss up to 30 dB, yet when the hearing loss is greater, the TEOAEs are shown to be 
absent. DPOAEs, in contrast, the measure can still be measured when a hearing loss is 
between 50-70 dBHL (Gorga et al., 1997). As hearing loss resulting from ototoxicity may 
result in a moderate-severe or severe hearing loss (Sagwa et al., 2015), DPOAEs are likely 
more useful for this population. 
Also, despite the clinical utility of behavioural hearing thresholds being primarily 
explored, it is well established that these measures are influenced by factors such as attention, 
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motivation, and patient compliance. Objective measures, such as DPOAEs, show clinical 
relevance and may be one of the only other practical ways to evaluate children and adults 
unable to respond behaviuorally. DPOAEs are a convenient and non-invasive means to detect 
an ototoxic change in outer hair cell function, which is the area affected explicitly by initial 
ototoxicity. Distortion generated in the cochlea in response to the two simultaneous pure 
tones (ƒ1 and ƒ2, ƒ1<ƒ2) can be recorded in the ear canal at frequencies mathematically 
linked to the stimulus frequencies. The most comprehensively studied and clinically used is 
the DPOAE at the frequency 2ƒ1-ƒ2. Compared to normal-hearing ears, DPOAE levels are 
reduced with mild to moderate hearing losses and are rarely present when hearing thresholds 
exceed 60 dB HL (Poling, Lee, Siegel & Dahr et al., 2012).  
Gender has shown to impact DPOAEs where females tend to have larger emissions 
when elicited with a low-frequency stimulus (Dunckley & Dreisbach, 2004), while males lose 
more DPOAE amplitude with a hearing loss that is proportional in females (Cilento, Norton 
& Gates, 2003). Age also shows the impact on DPOAEs; as age increases, DPOAE 
amplitudes decreases (Dorn, Piskorski, Keefe, Neely & Gorga, 1998). Ethnicity has shown to 
impact of TEOAEs, yet not on DPOAEs (Hall, 2000).  
Interpretation of DPOAEs relies on a few factors, such as low environmental ambient 
noise levels, repeated replicated reading that confirms the results and the assurance of no 
middle ear pathologies that could affect the readings (Hall, 2000). The ambient noise level in 
the DPOAE is regarded at the noise floor, whereas the Declustering Potential is the emission 
level. The signal to noise ratio is the difference between the noise floor and Declustering 
Potential, and acceptance of the response is dependent on this (Hall, 2000). The ratio of 10 
dB sound pressure level (SPL) or greater is accepted widely, as this is a clear indication of a 
cochlear response and that ambient noise levels have not interfered in the reading. However, 
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other studies have shown a 6 dB SPL, or even 3 dB SPL signal to noise ratio is acceptable 
(Chan, Wong & McPherson, 2004).  
Determining effective ototoxicity detection and monitoring strategies using objective 
measures such as DPOAEs is an active area of research. However, there currently are no 
accepted protocols or criteria for ototoxic change using DPOAEs (Durrant et al., 2009). Most 
reports in patients receiving ototoxic drugs which have utilised objective measures such as 
DPOAEs, in which sensitivity was defined as a clinically significant change in the value of 
the objective measure (Konrad-Martin et al., 2005). Stavroulaki et al. (2002) reported that a 
significant change could be 2.4 dB. Cunningham (2011) however discusses that from clinical 
experience changes of 3-6 dB SPL from one test session to the next (while all other test 
parameters are held constant, or an attempt at that occurs) are accepted as significant and 
indicate a change in cochlear function. Opinions vary, and there are no agreed-upon decisions 
of a universal dB SPL amount that indicates a "significant change" from one test session to 
the next (Cunningham, 2011). 
Therefore, for this current study, a clinically significant change attributed to 
ototoxicity is defined 6 dB or more at or above 2 kHz at one or more frequency unilaterally or 
bilaterally. A clinically significant change can be classified as 6 dB sound pressure level 
(SPL) or higher, as adapted from Cunningham (2011). Therefore, variability in detection 
threshold or standard deviation is from 0 to 5 dB SPL (Roede, Harris, Probst & Xu, 1993). 
The grading systems below also only take PTA into account, and no grading system has been 
developed to grade OAEs. 
Screening with DPOAEs may be enhanced by testing only in the 3- to the 5.2-kHz 
range, thus decreasing testing time. Higher time averages to increase the signal-to-noise ratio 
and use of this narrower bandwidth might also allow for accurate bedside testing (Ress et al., 
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1999). There are thus various considerations to consider when monitoring ototoxicity; 
including the population under investigation and resources available. 
Both PTA (including UHFA) and DPOAE measures can complement each other. PTA 
is a psycho-physical measurement of hearing with the aim of getting complete knowledge of 
an individual’s ability to interpret various kinds of acoustic stimuli (Huizing, 1951), whereas 
DPOAE have higher sensitivity than PTA in the monitoring of cochlear function (Sakashita 
et al., 1998), but not interpretation. OAEs can detect minor changes accounting from 
ototoxicity before they are evident on the audiogram (Guthrie, 2008). As DPOAEs do not 
require an individual to respond physically, this can occur when patients are too weak to 
participate in PTA. PTA is measured by placing earphones on an individual while the 
clinician presents different pure tones with various frequencies to each ear via the earphones. 
Whereas, with DPOAEs, the clinician places a probe in an individual’s ear. This probe emits 
the stimulus of two ‘primary tones’ that vary in frequency, and the cochlea responds by 
producing sounds. The microphone then picks these miniature sounds/emissions on the 
probe, and this is a measurement of cochlear functioning, and not hearing, as hearing extends 
beyond the cochlea to the temporal lobe (Martin & Clark, 2003). Therefore, this study 
utilised both DPOAEs, PTA, and UHFA to allow for a comprehensive overview of the 
participants audiological functioning. 
Despite the beneficial clinical utility of these DPOAEs, the correlation between 
DPOAEs and audiometric thresholds has been a topic of investigation. Varying degrees of 
correlation has been observed when comparing DPOAE to PTA as well as UHFA. These 
investigations are important as they allow the determination whether PTA, UHFA as well as 
DPOAEs need to be conducted, or whether the DPOAEs can be conducted instead of PTA of 
UHFA to save time. 
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Correlation was noted between DPOAEs (up to 8 kHz) and UHFA (up to 20 kHz) 
when used to detect ototoxicity in cisplatin patients. Results showed that they both detected 
the same ototoxicity; five of the ten patients (Yu et al., 2014). Correlation was further noted 
between DPOAEs and PTA in individuals with normal hearing (2 to 6 kHz). Moreover, 
extended high frequency (EHF) PTA (PTA) (up to 20 kHz) and DPOAEs (up to 8 kHz) were 
compared in patients receiving cisplatin. Although both EHF-PTA and DPOAE showed the 
same sensitivity in detecting ototoxicity, they did not produce the same results in all patients, 
and so perhaps the two tests can complement each other, not outweigh each other (Yu et al., 
2014). A positive correlation was further noted in ordinary hearing persons between PTA and 
DPOAE at 2, 3, 4, 6 kHz (Campos & Carvalho, 2011). 
However, weak correlation between DPOAEs and PTA was observed in the industrial 
setting. This study stated that there is no relevant predictive relationship between DPOAEs 
and PTA to monitor noise-induced hearing loss (Wooles, Mulheran, Bray, Brewster & 
Banerjee, 2015). Also, DPOAEs were shown to detect more hearing loss than PTA at 8.9,10 
kHz (Daud, Mohamadi, Haron & Rahman, 2014), showing a reduced correlation between 
DPOAEs and UHFA. 
In summary, both DPOAEs and PTA, specifically UHFA have a place in ototoxicity 
monitoring. Although there is a correspondence between the DPOAEs and PTA; the 
relationship is not always consistent. This translates into the need for both DPOAEs and 
PTA, specifically UHFA to complement each other, instead of their use in isolation.  
4.7.2.6. Other tests to consider. 
In addition to the possible inclusion of auditory evoked potentials such as high-
frequency ABRs or ASSR (Durrant et al., 2009), other areas of the auditory system may also 
need further consideration. These could include the assessment of the vestibular system 
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(Walther, Hülse, Lauer & Wenzel, 2015), as well as the evaluation of tinnitus (Konrad-
Martin, Reavis, McMillan & Dille, 2014). 
A comprehensive monitoring program was developed for veterans undergoing 
chemotherapy. This program recommends the screening for tinnitus as well as patient 
education about ototoxic hearing loss and tinnitus. The Tinnitus Monitoring overview 
(TOMI) is mentioned as a clinical tool to detect tinnitus onset or tinnitus changes in the 
tinnitus perception during treatment. An ototoxicity risk assessment is also recommended to 
allow for an individualised treatment profile (Konrad-Martin et al., 2014).  
Also, not only is hearing assessment advised for some ototoxic agents, but vestibular 
damage may also occur. Walther et al. (2015) suggest that for diagnosis of suspected 
vestibulotoxic effects, the video head impulse test and vestibular evoked myogenic potentials 
seem to be suitable procedures for objective assessment. Yet kanamycin and capreomycin 
appear to be more ototoxic whereas some drugs are more vestibulotoxic.  
4.7.2.7. Timing of testing. 
The monitoring of hearing levels should regularly be monitored. The timing of 
monitoring tests is recommended as per Figure 4.3.
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Figure 4.3 Monitoring Protocol for patients who are undergoing treatment with a potentially ototoxic drug (Vasquez & Mattucci, 2003)
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ASHA (1994) discuss that patients receiving antibiotics should have a weekly 
evaluation and the frequency of monitoring should be increased or decreased depending on 
the changes observed. If a decrease in hearing is noted, the patient should be retested within 
24 hours to confirm the damage, and the physician should be informed as soon as possible of 
a validated change. Also, patients who complain of symptoms consistent with cochlear or 
vestibular damage must be seen immediately by the audiologist. This basic monitoring plan 
can evolve to be more sensitive if the time and personnel are available. A more stringent plan 
includes monitoring every two to three days for patients receiving aminoglycosides, which 
could result in earlier identification of ototoxicity (ASHA, 1994).  
In contrast, weekly to fortnightly audiograms are recommended after baseline 
evaluation, though financial and logistical barriers can limit this (Duggal & Sarker, 2007). 
From ASHA (1994), Duggal and Sarkar (2007) and Vasquez and Mattucci (2003), 
monitoring is recommended from every two to three days to fortnightly. This protocol needs 
also to consider the feasibility of patients attending the follow-up monitoring and may need 
adjustment based on the specific population and resources. Counselling is not noted typically 
as a monitoring procedure, yet as ototoxicity monitoring is to allow for opportunities for 
counselling (Konrad-Martin et al., 2005), implementation of the counselling should be in 
conjunction with the serial audiometric tests.  
The NDoH recommends testing as adapted from ASHA (1994), however, with a few 
changes. They recommend baseline testing, ideally prior to administration of the ototoxic 
drug, and if this is not possible, they recommend baseline testing within the first seven days 
of treatment. Subsequently, as per ASHA, they recommend weekly tests (ASHA, 1994), yet 
if this is not possible, monthly testing is recommended, and in the continuation phase of DR-
TB treatment, testing every three months is recommended for six months in total. This 
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE 
RELATIONSHIP BETWEEN HEARING LEVELS: A FEASIBILITY STUDY 
114 
continuation phase is from the time that the use of the injectable (aminoglycoside or 
capreomycin) until termination (NDoH, 2015).  
The specific interval to initiate management and treatment is unclear. Vasquez and 
Mattucci (2003) discuss that referral for vestibular and/or aural rehabilitation is indicated 
when ototoxicity occurs. The NDoH (2015) guidelines discuss that should ototoxicity be 
detected; the drug could be stopped, dosage to be reduced, the length of the dosing interval to 
be increased or to retain current therapy while increasing the frequency of monitoring to 
identify further deterioration early. It then states that with the pre-existing hearing loss, the 
initiation of the patient onto bedaquiline or linezolid should occur, or if a change occurs, then 
the patient can be switched to these drugs (NDoH, 2015). The NDoH (2015) also suggest 
aural rehabilitation following the diagnosis of hearing loss. Therefore, counselling and 
communication strategies can begin to be implemented as part of management while 
monitoring is taking place. Counselling is often difficult due to language barriers, and 
interpreters may be needed (HPCSA, 2008). It is unclear when to consider hearing aid fitting; 
during treatment when hearing loss is detected, post-treatment, or six months post the 
termination of the aminoglycoside treatment. Also, in South Africa, hearing aids are often 
unavailable in the public sector, due to budget constraints, and availability of audiologists. 
From observation and consultation with other audiologists, often, baseline testing is 
not conducted due to concern around the infectious nature of the patient. Also, patients often 
do not return consistently for their follow-up treatment and audiological monitoring due to 
transport and employment constraints. As per Konrad-Martin et al. (2005), monitoring is to 
allow counselling and implementation of aural rehabilitation (Konrad-Martin et al., 2005). 
Perhaps, should this be implemented, return for monitoring may be more successful.  
Furthermore, the benefit of hearing aids is minimal to moderate (NDoH, 2015), and 
cochlear implantation is limited due to facilities available. In Gauteng Province, only two 
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state hospitals conduct cochlear implants (South African Cochlear Implant Group [SACIG], 
2017). 
4.7.2.8. Challenges with ototoxicity monitoring in South Africa. 
The NDoH guidelines (2015) describe some critical factors, yet they are missing a 
few aspects that are important for the population as well as for the correct implementation of 
the guidelines. The guidelines do not discuss the type of OAE (DPOAE versus TEOAE) as 
well as the protocol of repeated measures, noise monitoring and the classification of a 
significant audiological shift with OAEs. It considered the ASHA criteria as a significant 
shift for PTA (NDoH, 2015) however, this is not necessarily ideal for the South African 
population, and do not guide the change in treatment. 
There are also multiple challenges with monitoring ototoxicity in the South African 
population (and many other developing countries). Importantly, primary audiological 
equipment is often lacking, and so alternate ways of assessing hearing need further 
investigation. Ramma and Ibekwe (2012) investigated a self-report of auditory dysfunction 
questionnaire in adults with DR-TB (n = 53). The questionnaire was followed by an 
audiometric examination, including otoscopy, screening tympanometry, and PTA. They 
found self-report of hearing loss was a poor indication of auditory function in patients with a 
mild to moderate degree of hearing loss, yet it was good when the hearing loss was severe. 
Self-report is therefore unreliable, and it is essential for audiometric equipment to be 
available at DR-TB treatment centres (Ramma & Ibekwe, 2012). Yet, the NDoH (2015) 
recommends the use of the Hearing Handicap Inventory when equipment is not available. 
Although the guideline does note that it is only used once hearing loss has already developed, 
it does not discuss the degree of this hearing loss. As per Ramma and Ibekwe (2012), if it is 
used, it will only detect profound loss, and so the applicability is questioned.  
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Furthermore, as budget may be limited in South Africa, an ideal protocol may need 
adaptation to include fewer tests. However, equipment is vital to obtaining accurate and valid 
audiological monitoring, and a relevant and specific protocol needs to be drawn up for DR-
TB patients within South Africa. These protocols, however, need additional development for 
the South African context, as the ASHA guidelines, provide useful information, do not take 
many South African specific contextual aspects into account. Unique monitoring protocols 
are relevant specific populations and vary according to the clinical purpose and practicalities 
available. For example, PTA may not be possible for extremely ill and non- or limited- 
responsive patients, where OAEs may be suitable as no behavioural response is required. On 
the other hand, OAEs do not always indicate hearing loss, but rather the loss of cochlear 
function. Also, HFA and OAEs may not be useful in patients with the pre-existing hearing 
loss, as they may already have absent OAEs and ‘no response’ at the high frequencies, and 
then the basic assessment in this case in more suitable (Durrant et al., 2009). Moreover, with 
any protocol chosen, infection control is essential to prevent the transmission of infection 
(Franklin & Grady, 2001), which is specifically relevant to this DR-TB population in South 
Africa. 
4.7.3. Therapeutic Drug Monitoring 
More recently there have been suggestions of TDM to prevent toxicity when using 
aminoglycosides (Harris & Heinze, 2015). The evidence for this is suggested in various 
studies (van Altena et al., 2017; Engler et al., 2015; Black et al., 1976). However, the exact 
recommendations for adjustments are not clear.  
There is conflicting evidence regarding the effects of dosage adjustments to reduce 
ototoxicity (van Altena et al., 2017; Engler et al., 2015; Black et al.,1976; Ried, Horn & 
McKenna., 1990; Peloqion et al., 2004; Rybak et al., 1999; Avent et al., 2011). A recent 
study, published after this current study took place, indicated the correlation between TDM 
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and ototoxicity in the DR-TB population (van Altena et al., 2017). This study aimed to use 
TDM targeting to maintain efficacy while reducing ototoxicity. This study included 57 
patients with MDR-TB or XDR-TB receiving amikacin or kanamycin as part of their TB 
treatment for at least three days. The results showed that the extent of hearing loss was 
limited and correlated with the cumulative drug dose per kg body weight during daily 
administration. At a median dose of 6.5 mg/kg, a correlation was found between the dose per 
kg bodyweight during daily dosing and the extent of hearing loss in dB at 8 kHz. This study 
suggested that the efficacy at this lower dosage is maintained with limited toxicity, however 
also suggested that further randomised controlled trials need to be conducted to provide more 
proof regarding safety and efficacy of TDM (van Altena et al., 2017). 
Furthermore, the positive effect of TDM to reduce ototoxicity was noted in a neonatal 
study with amikacin (Engler et al., 2015). Correlations with high trough levels and ototoxicity 
were observed (Engler et al., 2015). Black et al. (1976) also showed the causative relationship 
between amikacin trough levels and ototoxicity. This study showed 57% of patients with a 
peak serum level exceeding 32 μg/ml, and 55% of patients with trough levels exceeding 10 
μg/ml developed cochlear damage (Black et al., 1976). According to a study by Peloquin et 
al. (2004), the pharmacokinetics of streptomycin, kanamycin, and amikacin were nearly 
identical, and so this theory could potentially be transferred to kanamycin. Moreover, a meta-
analysis, conducted by Ried, Horn and McKenna (1990), highlighted a study whereby 
patients who underwent TDM showed less ototoxicity compared to patients who were not 
monitored. These patients were taking theophylline or digoxin. 
However, another study, however, showed that the trough levels of aminoglycosides 
(gentamicin, kanamycin, and streptomycin) were not associated with ototoxicity, yet duration 
of treatment and treated total dose received was associated with hearing loss (Peloquin et al., 
2004). This study showed that the size of the dose (milligrams per kilogram), the frequency 
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of administration (daily or thrice-weekly), and the Cmax did not predict ototoxicity. This study 
further detailed that the median Cmax for ototoxic patients was 55 mg/ml (range, 32–113 
mg/ml), and it was 53 mg/ml (range, 26–100 mg/ml) for nontoxic patient. All patients, but 
two patients had troughs of ‹2 mg/ml at 24 hours after dosing, and all had calculated troughs 
at 48 hours after dosing of 0 mg/ml. The streptomycin group had the lowest percentage of 
ototoxic patients (19%, compared with 42% of those receiving kanamycin and 55% of those 
receiving amikacin) (Peloquin et al., 2004). This study conflicts the above studies as the 
pharmacokinetics factors. Specifically, the trough levels were not associated with ototoxicity. 
The study above showed that the size of the dose, the frequency of the dose and Cmax did not 
affect ototoxicity.  
Though, in contrast to Peloqion et al. (2004), a study by Rybak et al. (1999) did show 
that the frequency of the dose can affect ototoxicity. This study included twice daily and once 
daily dosages of aminoglycosides. For the twice-daily dosing group, target peak 
concentrations in serum were 8 to 10 mg/litre for those with respiratory infections and 5 to 6 
mg/litre for those with all other indications for gentamicin and tobramycin treatment, with 
trough concentrations of ‹2.0 mg/litre. For patients who received amikacin, peak 
concentrations in serum were 30 to 40 mg/litre for those with respiratory infections and 20 to 
30 mg/litre for all other patients. Desired trough amikacin concentrations were ‹10.0 mg/litre. 
Target peak concentrations of gentamicin or tobramycin in serum concentrations for the 
once-daily dosing group were 16 to 20 mg/litre for those with respiratory infections and 10 to 
12 mg/litre for patients with other infections. The desired peak serum amikacin 
concentrations were 60 to 80 mg/litre for patients with respiratory infections and 40 to 60 
mg/litre for all others. The desired trough concentrations for once-daily dosing were targeted 
to be below one mg/litre. These target concentrations were based on doubling of the 
conventional target ranges for the Detroit Receiving Hospital and University Health Centre. 
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Initial dosing was based on population parameters in conjunction with the patient’s calculated 
creatinine clearance and estimated ideal body weight. After obtaining serum aminoglycoside 
levels, dosing regimens were adjusted to maintain peak and trough concentrations in the 
targeted ranges. Trough concentrations (at 12 and 24 hours for groups who received 
aminoglycosides twice and once daily, respectively) were extrapolated by using a one-
compartment equation with data for the serum samples obtained at the various times. 
Audiologic testing performed at the baseline (within 72 hours of the start of therapy), weekly 
thereafter or sooner if deemed clinically necessary, and after the cessation of therapy. 
Ototoxicity was defined as a decrease in the auditory threshold of at least 15 dB at two 
adjacent tested frequencies in one or both ears. Twenty-two patients, ten with twice-daily 
dosing and 12 with once-daily dosing, received two or more audiometric evaluations during 
and after treatment. Of these patients, one who received twice-daily aminoglycoside therapy 
met the criteria for ototoxicity. This study may show that twice daily dosing portrays a higher 
possibility for ototoxicity than once daily. However, the sample size was too small to make 
this correlation statistically. It is important to note, that as long as once-daily dosing of an 
aminoglycoside is at least as efficacious as conventional dosing, it may be beneficial to 
reduce toxicity (both ototoxicity and nephrotoxicity) (Rybak et al., 1999).  
As, mycobacteria replicate at a significantly slower rate than other pathogenic 
bacteria, aminoglycoside treatment of these infections has traditionally been on a daily, three 
times per week, or even two times per week basis (Peloquin et al., 2004). Aminoglycosides 
may adversely affect auditory, vestibular, and renal function. It is unclear which parameter, if 
any, is most associated to the development of these toxicities, namely the peak serum 
concentration (Cmax), the trough serum concentration, or the total milligrams per kilogram 
received (Peloquin et al., 2004). 
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Although these parameters are unclear, there has been some research displaying 
possible relationship, whether it be between trough levels and ototoxicity (van Altena et al., 
2017; Engler et al., 2015) or between duration of treatment and total dose with ototoxicity 
(Peloqion et al., 2004), and/or between the frequency of dosing with ototoxicity (Rybak et al., 
1999). Despite these possible relationships, there are currently no guidelines of 
pharmacokinetic modelling to reduce ototoxicity, specifically for kanamycin and 
capreomycin in the DR-TB population. 
However, with a literature search, a few recommendations that have been proposed 
for pharmacokinetic modelling of aminoglycosides (Avent et al., 2011; Droege et al., 2016). 
As capreomycin is similar in structure to aminoglycosides, these recommendations could also 
apply. 
Avent et al. (2011) mention there are two pharmacodynamic predictors of efficacy for 
aminoglycosides which are: the AUC: MIC and the Cmax: MIC ratios. Dosing should thus aim 
to optimise these parameters. Target AUC values of 80 to 100 μg /ml and C max 8 to 10, 
respectively are based on animal and human pharmacodynamic studies. The patients 
influence these parameters; as the Cmax: MIC ratio is related almost exclusively to the volume 
of distribution, whereas the AUC: MIC ratio is influenced by both volume of distribution and 
clearance (Avent et al., 2011). 
When patient individualisation dosing strategies are used based on the subject's 
weight and aimed at a therapeutic range to optimise clinical outcomes, a more significant 
percentage of patients will achieve the targeted concentration as compared with patients who 
receive a fixed dose strategy. Patients who attained targeted therapeutic serum concentrations 
of aminoglycosides early in their treatment course have shown an improved clinical outcome 
(Avent et al., 2011). Also, the frequency of pharmacokinetic monitoring depends on the 
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patients’ clinical status, and there are no formal recommendations to date (Droege et al., 
2016). 
Several nomograms and algorithms have been developed to individualise 
pharmacokinetic monitoring for gentamicin. Three significant methods of dose 
individualisation commonly used to target specific pharmacokinetic parameters are (i) linear 
regression analysis (one compartment model), (ii) population methods and (iii) Bayesian 
estimation procedures. This standard can be extrapolated for kanamycin and capreomycin, as 
they are similar compounds (Avent et al., 2011). The skills of a clinical pharmacologist or 
clinical pharmacist are required for this type of ototoxicity monitoring and thus would form 
part of an ototoxicity monitoring team (Schellack & Naude, 2013). 
Despite the use of aminoglycosides for decades, the ideal method of administration 
and the preferred dosing schemes for most of their therapeutic indications needs further 
enhancement. Individualized pharmacokinetic and pharmacodynamic monitoring has the 
potential of minimising toxicity and clinical failures of these agents. Also, many 
pharmacokinetic parameters of aminoglycosides have been obtained from healthy volunteers 
and not sick patients (Pagkalis, Mantadakis, Mavros, Ammari & Falagas, 2011). 
Thus, the establishment of a pharmacokinetic model within the DR-TB population is 
imperative in order to allow for the monitoring and possible reduction of toxicity. Monitoring 
of blood concentrations of patients taking kanamycin and capreomycin may be greatly 
advantageous in the adjustment of the treatment which may influence ototoxicity. 
Aminoglycosides display concentration-dependent efficacy and toxicity, and thus these 
patients may benefit from pharmacokinetic modelling and subsequent therapeutic drug 
monitoring (Touw et al., 2009). Pharmacokinetic modelling and therapeutic drug monitoring 
are currently not recommended as part of the routine monitoring of ototoxicity for DR-TB. 
With more substantial evidence, it is possible that the monitoring of serum levels may be 
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included in the ototoxicity monitoring protocol. However, more research in this area is 
required and could be useful, specifically with kanamycin and capreomycin for DR-TB. 
4.7.4. Grading Systems 
For research studies or clinical application, a grading system is often used to describe 
the hearing loss as measured by air conduction PTA. Several systems have been developed, 
namely the National Cancer Institute (NCI) Common Terminology Criteria for Adverse 
Events (CTCAE) Ototoxicity Grades (Fisher et al., 2004), TUNE (Theunissen et al., 2014), 
Brock’s Hearing Loss Grades (Brock, Bellman, Yeomans, Pinkerton & Pritchard, 1991), 
Chang and Chinosornvatana (Chang & Chinosornvatana, 2010) as well as the SIOP Boston 
Ototoxicity Scale (Brock et al., 2012) (see Table 4.1). Although mainly designed for children, 
some have adult applications, such as the CTCAE scale, while the others, for example, the 
Brock and SIOP scales, do not. There has been a need identified for ototoxicity grading 
systems to allow clinicians to understand the severity of ototoxicity and standardised 
treatment based on the grades (Peterson & Rogers, 2015). These grading scales, such as the 
CTCAE (for adults and children), TUNE, Brock, Chang and Chinosornvatana and SIOP are 
described in Table 4.1. 
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Table 4.1 
Ototoxicity Grading Scales according to NCI CTCAE and TUNE in adults and children 
ADULT SCALES 
NCI CTCAE 
(Grades up to 8 kHz) 
(Durrant et al., 2009; (Fisher et al., 2004) 
TUNE 
(Grades up to 12.5 kHz) 
(Theunissen et al., 2014) 
Originally developed for children yet has adult applications Developed for Adults 
  Grade 0 No Hearing Loss 
Grade 1 Threshold shift or loss of 15-25 dB relative to baseline, 
averaged at two or more adjacent frequencies in at least one 
ear. 
Grade 1a 
 
Grade 1b 
Threshold shift ≥ 10 dB at [8-10-12.5] OR subjective 
complaints in the absence of a threshold shift 
Threshold shift ≥ 10 dB at [1-2-4] 
Grade 2 Threshold shift or loss of >25-90 dB, averaged at two adjacent 
test frequencies in at least one ear 
Grade 2a 
Grade 2b 
Threshold shift ≥ 20 dB at [8-10-12.5] 
Threshold shift ≥ 20 dB at [1-2-4] 
Grade 3 Hearing loss sufficient to indicate therapeutic intervention, 
including hearing aids. Adults: >25-90 dB, averaged at three 
adjacent test frequencies in at least one ear. 
Grade 3 Hearing level ≥ 35 dB HL at [1-2-4] de novo 
Grade 4 Indication for cochlear implant and requiring additional speech 
language-related services. For adults, a profound hearing loss 
is at >90 dB HL. 
Grade 4 Hearing level ≥ 70 dB HL at [1-2-4] de novo 
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PAEDIATRIC SCALES 
Brock (1991) 
(Grades up to 8 kHz) 
(Brock et al., 2011) 
Chang and Chinosornvatana 
(Grades up to 12 kHz) 
(Chang & Chinosornvatana, 2010) 
Based on absolute hearing level rather than change from baseline and based 
on bilateral loss 
Based on absolute hearing threshold levels and a modification to the Brock 
scale. It detects milder degrees of hearing loss (Bass et al., 2014). 
Grade 0 < 40 dB at all frequencies Grade 0 ≤ 20 dB at 1.2, and 4 kHz 
Grade 1 ≥ 40 dB at 8 kHz only Grade 1a 
Grade 1b 
≥40 dB at any frequency 6 to 12 kHz 
>20 and < 40 dB at 4 kHz 
Grade 2 ≥ 40 dB at 4 kHz and above Grade 2a 
Grade 2b 
≥40 dB at 4 kHz and above 
>20 and < 40 dB at any frequency below 4 kHz 
Grade 3 ≥ 40 dB at 2 kHz and above Grade 3 ≥40 dB at 2 or 3 kHz and above 
Grade 4 ≥ 40 dB at 1 kHz and above Grade 4 ≥40 dB at 1 kHz and above 
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SIOP 
(Grades up to 8 kHz) 
(Brock, et al., 2012) 
NCI CTCAE  
(Grades up to 8 kHz) 
(Durrant et al., 2009) 
Modification of the Children’s Hospital of Boston functional hearing loss 
scale, and based on hearing thresholds, and is sensitive to high-frequency 
hearing loss and mild degrees of impairment (Bass et al., 2014) 
Based on loss from baseline and hearing thresholds 
Grade 0 ≤20 dB HL at all frequencies   
Grade 1 >20 dB HL (i.e. 25 dB HL or greater) SNHL above 4 kHz (i.e. 
6 or 8 kHz) 
Grade 1 Threshold shift or loss of 15-25 dB relative to baseline, 
averaged at two or more adjacent frequencies in at least one ear. 
Grade 2 >20 dB HL SNHL at 4 kHz and above Grade 2 Threshold shift or loss of >25-90 dB, averaged at two adjacent 
test frequencies in at least one ear 
Grade 3 >20 dB HL SNHL at 2 kHz or 3 kHz and above Grade 3 Hearing loss sufficient to indicate therapeutic intervention, 
including hearing aids.  
Grade 4 >40 dB HL (i.e. 45 dB HL or more) SNHL at 2 kHz and above Grade 4 Indication for cochlear implant and requiring additional speech 
language-related services.  
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Although not a grading scale, ASHA (1994) developed specific criteria to document 
change in hearing, which is beneficial for both high-frequency audiometry and the 
conventional audiometry. They, however, do not define the specific frequencies (Theunissen 
et al., 2014). These criteria describe significant ototoxic change when one of the following 
three criteria are met: (a) ≥20 dB decrease at any one test frequency, (b) ≥10 dB decrease at 
any two adjacent frequencies, or (c) loss of response at three consecutive frequencies where 
responses were obtained previously (Konrad-Martin et al., 2005). 
The WHO also uses specific criteria to describe hearing loss which includes the use of 
a speech frequency pure tone average (average of hearing thresholds at 0.5, 1, 2, and 4 kHz). 
According to the WHO, hearing loss is described as a pure tone average of greater than 25 dB 
HL in both ears (Lin, Niparko & Ferriucci, 2011). The definition of hearing loss, however, is 
not necessarily useful for ototoxicity, as hearing loss may be unilateral as observed in various 
studies (Sharma et al., 2016; Javadi et al., 2011), as well as initiates in the high frequencies 
first (Harris & Heinze, 2015). The WHO criteria do not appear to be useful for early 
identification of ototoxicity. 
While these grading scales have gone through various studies, none have been 
developed for patients with DR-TB, and no system is currently utilised in South Africa. It 
would be useful for medical doctors, nurses, pharmacists, and audiologists to understand the 
relevant grades of hearing loss and subsequent relative management to patients DR-TB 
medication regimen. Thus, the proposal of a new grading system in the DR-TB population is 
imperative to assist in management decisions for the treating clinicians.  
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Chapter 5: Methodology 
This chapter describes the method implemented in this study. For the purposes of this 
study, it begins with the aims and objectives of the study. It progresses to explain the research 
design and research sites. Following this, the participants are described in detail, including 
the sample selection procedures and size. Subsequently, the data collection procedure is 
illustrated, which includes an overview, the personnel involved, the enrolment process, 
audiological and pharmacological measures and other measures and equipment involved in 
the data collection. The ethical considerations are discussed followed by the reliability and 
validity of the study. Lastly, the data management plan and statistical analysis and procedures 
are outlined.  
5.1. Research aims  
5.1.1. Main Aim 
The main aim of this study was to determine the feasibility of investigating the 
pharmacokinetics and pharmacodynamics of kanamycin and capreomycin in patients 
with DR-TB and the relationship with hearing levels. 
• The willingness of patients to participate in a pharmacokinetic study in conjunction 
with hearing evaluations. 
• To investigate whether TDM could potentially be utilised in terms of dosage 
adjustments of kanamycin and capreomycin. 
The following sub-aims and objectives are delineated in order to achieve the main aim: 
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5.1.2. Sub Aims 
5.1.2.1. To determine the changes in hearing levels in patients 
undergoing treatment with kanamycin and capreomycin for DR-
TB. 
▪ To determine the prevalence of abnormal findings on baseline hearing 
assessments. 
▪ To determine the change in hearing levels from baseline. 
5.1.2.2. To investigate the kanamycin and capreomycin 
pharmacokinetics in patients undergoing treatment for DR-TB. 
▪ To investigate the peak and trough levels of kanamycin and capreomycin at 
two weekly intervals for the first three months of treatment. 
▪ To investigate the relationship between the kanamycin and capreomycin 
kinetics with creatinine levels. 
▪ To examine the relationship between the pharmacokinetics/ 
pharmacodynamics of kanamycin and capreomycin to culture conversion after 
the three-month period.  
5.1.2.3. Examine the relationship between kanamycin and 
capreomycin pharmacokinetics and hearing levels. 
▪ To examine the relationship between kanamycin and capreomycin dosing and 
hearing levels throughout the three-month study period. 
▪ To explore the relationship between kanamycin and capreomycin dosing and 
the progression of hearing loss. 
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5.2. Research Design 
This study was conducted within a quantitative research paradigm. This feasibility 
study employed a prospective, exploratory, descriptive and case series research design that 
was also cross-sectional in nature.  
Quantitative research refers to the traditional scientific approach to research, driven 
by systematic and methodological procedures which places value on objectivity, prediction, 
and control (Koch & Harrington, 1998; Streubert & Carpenter, 1999). The goal of this type of 
research is further described as to determine the relationship between an independent variable 
and a dependent or outcome variable within a population (Babbie, 2010). In this study, the 
independent variable was the pharmacokinetics of kanamycin and capreomycin with the 
dependent variable or outcome being the hearing levels. This study utilised objective and 
quantifiable methods of data collection, including the audiometric evaluations and 
pharmacokinetic measurements.  
5.2.1. Feasibility 
A feasibility study is, for the purpose of this current study, described according to the 
conceptual framework proposed by Eldridge et al. (2016) that specifically relates to the 
preparation for randomised control studies that evaluate the effect of an intervention. A 
feasibility study asks whether something can be carried out and if the researchers should 
proceed with the aim. If the answer is yes, then it addresses how this should transpire 
(Eldridge et al., 2016). Therefore, this study assessed the feasibility of investigating 
kanamycin and capreomycin pharmacokinetics in relation to the hearing levels (Eldridge et 
al., 2016). 
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5.2.2. Exploratory 
Exploratory research is useful and appropriate for studies that are addressing a subject 
about which there are high levels of uncertainty and a relatively unfamiliar field (Mouton & 
Marais, 1990). These studies typically use a smaller sample size and explore unknown 
phenomena (Huttlinger, 2006).  
This form of research is often conducted to determine the feasibility of or need for 
more extensive research or to establish some sort of baseline that could lay the groundwork 
of a future study (Huttlinger, 2006).  
Exploratory research has a flexible design that enables the researcher to investigate 
and examine all aspects of the phenomenon being studied. It allows the researcher to explore 
all new emerging ideas, and change direction if needed. It often lacks formal structure 
(Huttlinger, 2006). 
A critique of this design includes that these studies may be limited in scope and focus 
and may not be generalizable to a larger population and cannot be utilised as a basis for 
prediction. However, these studies are used to uncover or discover information about little-
known concepts, to explore relationships between and among variables, to uncover more 
information about human behaviours in a naturalistic environment and to lay the groundwork 
for more systematic testing of hypotheses (Huttlinger, 2006). 
This study was exploratory as the pharmacokinetics of kanamycin and capreomycin in 
patients with DR-TB had not been measured previously. Also, the investigation of the 
relationships between capreomycin and kanamycin with hearing levels was not investigated 
previously.  
5.2.3. Descriptive research 
Descriptive research, a level of quantitative research (Walker, 2005), provides an 
account of the characteristics of individuals, groups or situations (Jack & Clarke, 1998) that 
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may form the initial stage of more intricate designs. The overall aim is to discover new 
meanings, describe what currently exists and as well detail the frequency of occurrences and 
the categorisation of information (Walker, 2005). The purpose of these studies is to observe, 
describe and document aspects of a situation which may serve as a starting point for the 
conceptualisation of a further hypothesis. This study aimed to describe the pharmacokinetics 
of kanamycin and capreomycin in relation to the hearing levels. Descriptive designs, as such, 
have a crucial role to play in the development of new knowledge, generating questions and 
hypotheses that could form the basis of further research (Walker, 2005). The analysis of this 
study included the description of group differences, trends within the group, and relationships 
within the different variables (Gravetter & Forzano, 2011).  
5.2.4. Prospective 
This study was prospective in nature as it was carried out into the future, and could be 
tailored to collect specific exposure data (Levin, 2003). The protocol was developed, and 
subsequently, the data collected. Advantages can include the ability to gather data regarding a 
sequence of events, and it can assess causality. Furthermore, it is useful for investigating rare 
exposures and calculating rates of disease in exposed and unexposed individuals over time 
(Song & Chung, 2010). Importantly, Levin (2003) mentions that these studies can be 
expensive to carry out and are prone to high dropout rates (Levin, 2003). This wasa limitation 
in this current study as dropout rates were high, as well as it was expensive to conduct. Levin 
(2003) further mentions that prospective designs are mostly longitudinal but may be cross-
sectional. 
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5.2.5. Cross-Sectional 
One of the most common and well-known study designs is the cross-sectional study 
design. In this type of research study, either the entire population or a subset thereof is 
selected, and from these individuals, data are collected to help answer research questions of 
interest. It is called cross-sectional because the information about X and Y that is gathered 
represents what is going on at only one point in time (Olsen & St. George, n.d). A cross-
sectional study often has predictive limitations and is often more expensive. Furthermore, the 
disease process may alter the exposure, affecting the overall resulting, and there is little or no 
data on the temporal relationship between risk factors and disease development (Ford, 2010).  
This study was cross-sectional as it was carried out over a three-month period (out of 
the entire 18-month to two-year treatment period) for each participant (unless dropout or 
withdrawal from the study). The pharmacokinetic measurements and audiological data were 
collected at specific points in time. 
5.2.6. Case Series 
A case series design was employed, which is a design that follows a group of patients 
who have a similar diagnosis or who are undergoing the same procedure over a specified 
period. As there is no experimental protocol or control for allocation of patients to treatment, 
medical professionals decide on whether treatment is given, making the clinical sample 
representative of a typical clinical population. Results of case series, as with this study, can 
generate hypotheses that are useful in designing further studies, including randomised 
controlled trials. However, no causal inferences should be made from case series regarding 
the efficacy of the investigated treatment (Kooistra, Dijkman, Einhorn & Bhandari, 2009). 
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5.3. Research Sites 
Data collection took place at two of three main hospital-based TB focal points that 
treat DR-TB patients in the Johannesburg area of the Gauteng Province in South Africa, 
namely the Helen Joseph Hospital TB Focal Point and the South Rand Hospital TB Focal 
Point. Post ethical clearance (Appendix A), permission was obtained from the CEOs 
(Appendix B). 
 The first site was the TB focal point at the Themba Lethu Clinic at HJH. Helen 
Joseph Hospital provides services to approximately 1 million people. HJH consists of a total 
of 21 wards with in-patients, the majority of which are medical wards, a Psychiatric unit, a 
10-bed Intensive Care Unit (ICU), a 12 bed-High Care/ Step-down unit, a Theatre complex 
comprising of 12 theatres. HJH also includes speciality clinics including Stoma unit, Renal 
dialysis unit, Pain clinic, Endoscopy unit, Breast clinic, the TB focal point and the Themba 
Lethu HIV clinic (Gauteng Department of Health, n.d.) 
The Themba Lethu Clinic is one of the country’s oldest HIV treatment clinics. The 
clinic was established in 1992, in response to the threat posed by HIV in the days when ART 
was not available in South African public healthcare facilities. The clinic operates as a 
partnership between HJH and Right to Care, a non-governmental organisation whilst 
academic, clinic, and research support is provided by the Clinical HIV Research Unit 
(CHRU), which is affiliated to the University of the Witwatersrand. The Themba Lethu 
Clinic offers integrated services to patients with HIV and TB. In addition to HIV counselling- 
and testing, TB screening, diagnosis, and treatment is provided that includes a decentralised 
DR-TB management program. The clinic annually performs over 10 000 HIV tests, 4000 TB 
screens, and 4000 CD4 counts (Clinical HIV Research Unit, 2012).  
AT HJH, patients enrolled for RR-TB management are provided with a scheduled 
appointment date to return to the clinic two weeks after RR-TB treatment initiation and then 
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every four weeks for 18 - 24 months. The patients can also choose whether they want to 
attend the HJH RR-TB clinic or an alternative primary healthcare clinic closer to their home 
for daily directly observed treatment support and injections during the intensive phase (Gajee 
et al., 2016).  
The second site was the South Rand Hospital, a level one district hospital that opened 
in 1954. This hospital is situated on the outskirts of Johannesburg South. The hospital has 
314 beds and serves a population of ± 450 000. In addition to being one of five rehabilitation 
hospitals in Gauteng, it is also one of two Gauteng-based hospitals that treat DR-TB patients 
on both an out- and in-patient basis. It is in partnership with the University of the 
Witwatersrand to provide a TB centre of excellence, along with other centres of excellence, 
such as a virology and mother and child centres of excellence (Gauteng Department of 
Health, n.d.) The treatment period for DR-TB at this hospital ranges from between two and 
eight weeks. The hospital has two DR-TB wards, one male and one female ward and serves 
as a referral site from many outlying hospitals.  
5.4. Participant selection and description 
5.4.1. Participant selection 
5.4.1.1. Sampling strategy. 
Sampling involves the selection of a portion of a limited population being studied 
(Battaglia, 2008). This study utilised a purposive sampling, a non-probability sampling 
strategy to select participants. 
Non-probability sampling is a type of participant sampling does not involve random 
selection from the population. Thus, certain members of the population have a greater chance 
of selection for a study than others. It is often used to gain insight into a variety of specified 
issues (Skowronek & Duerr, 2009). This method of sampling is, however, susceptible to bias 
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because it does not guarantee that all eligible members of a population have an equal chance 
of selection into the sample (Skowronek & Duerr, 2009).  
This study utilised purposive sampling, a type of non-probability sampling (Teddlie & 
Yu, 2007). The primary objective of purposive sampling is to produce a sample considered as 
‘‘representative’’ of the population (Battaglia, 2008). It is used to address specific purposes 
related to research questions (Teddlie & Yu., 2007). The selection of a purposive sample is 
often accomplished by applying expert knowledge of the population to select in a -non-
random manner a sample of elements that represent a cross-section of the population. 
Purposive sampling took place as the researcher selected the population of interest based on 
various factors, such as a predisposition to hearing loss (such as due to previous 
aminoglycoside use) and other inclusion and exclusion factors such as diabetes, middle ear 
dysfunction and so on that could influence the study outcomes (Battaglia, 2008). 
A clear limitation of purposive sampling is that another expert (audiologist) may 
come up with a different sample when identifying important characteristics and select 
common elements to be in the sample. However, in the instance of this study, various 
audiologists and professionals working within this population were consulted (Battaglia, 
2008). 
Another limitation is that it does not necessarily allow for generalisation (Brink, 
1996). This study was conducted in Johannesburg, Gauteng and the results cannot necessarily 
be generalised to other regions within South Africa. 
5.4.1.2. Inclusion and exclusion criteria. 
Participants had to meet specific selection criteria for inclusion in the study (See 
Table 5.1 for inclusion criteria and Table 5.2 for exclusion criteria). Previously, the study 
coordinator obtained consent to assess whether they fit the criteria (Appendix C). The study 
coordinator determined these inclusion criteria, who was a professional nurse. She 
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determined whether the participants met the inclusion and exclusion criteria. The criteria, 
justifications, and method for choosing and ensuring the inclusion and exclusion criteria can 
be seen below.
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Table 5.1 
Inclusion Criteria of participants in the sample 
Criteria Justification Method 
Both male and female 
participants 
Male and females have shown to display slight differences in 
hearing, specifically in the high frequencies where the male 
population displays poorer hearing (4 kHz to 8 kHz) 
(Osterhammel & Osterhammel, 1978). Gender differences have 
also been shown to affect otoacoustic emission (OAE) results, 
with regards to phase delay (Bowman, Brown & Kimberley, 
2000). 
Both genders were considered for the study. At SRH, 
recruitment took place from both the male and female wards. 
Both HIV-positive 
and HIV-negative 
patients. 
HIV can cause opportunistic infections and neural disturbances 
that may place participants at greater risks for hearing loss 
(Friedmann & Arnold, 1993).  
However, excluding participants based on HIV status would 
have reduced the sample size, due to the high HIV prevalence 
within the DR-TB population.  
The patient’s HIV status was detailed in the consent procedure 
where participants were informed about the criteria, and the 
necessity of the researcher to know their HIV status; whether 
they were positive or negative.  
As per the NDoH (2011) guidelines, all HIV infected patients 
who are not on ARV therapy should be initiated on this 
treatment once drug-resistant TB is diagnosed. This was done 
accordingly. 
Consent to HIV test 
(if one not already 
present) 
If participants did not have a documented HIV test, they were 
requested to consent to an HIV test. This was a requirement of 
the study and thus conducted in the screening procedures. If 
When their HIV status was not available, and consent was 
given, HIV testing, counselling and initiation of treatment was 
done according to NDoH protocols. 
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Criteria Justification Method 
they did not wish to consent, they were not included in the 
study. 
Written informed 
consent 
Consent forms part of ethical practice for clinical research (SA 
GCP, 2006). 
This was done according to the South African Good Clinical 
Practice guidelines (SA GCP, 2006). 
Patients treated at 
HJH and SRH and 
anticipated to return 
for treatment for 
three months.  
As HJH and SRH are two of the main sites of DR-TB treatment 
in Johannesburg, they were chosen.  
The study coordinator was in constant communication with the 
nursing staff involved in new intake of all new intake patients at 
these hospitals to ensure enrolment when possible 
Patients who were 
anticipated to be 
receiving treatment 
for DR-TB with KM 
and/or CM for a 
period of at least 
three3 months. 
As the study was investigating the injectables, those patients on 
kanamycin or capreomycin were included. 
The treatment plan and specific injectable were discussed by the 
study coordinator with the doctor prior to enrolment, to ensure 
that the participant was to be treated with either kanamycin or 
capreomycin. 
Proficient in English, 
isiZulu or SeSotho 
 For informed consent to be carried out appropriately, the 
participants’ comprehension must be addressed. In South 
Africa, this must be conducted by using culturally accepted 
The study coordinator obtained details regarding the 
participant’s language of choice during the screening procedure. 
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Criteria Justification Method 
practices and the participant’s language of choice (SA GCP, 
2006).  
According to the South Africa Statistics in the 2011 Census in 
the provincial profile, English (20.1%), isiZulu (23.4%) and 
SeSotho (9.6%) were the top three spoken languages in 
Johannesburg (Stats SA, 2011).  
Thus, proficiency in the top three languages was required for 
the study coordinator to be fluent.  
She asked which language was the patient comfortable in and 
would prefer the discussion about the research to be in. 
Between the ages of 
18 to 55 years 
Presbycusis usually presents in the fifth decade of life, generally 
above 55 years of age (Arvin, Prepageran & Raman, 2011).  
As all participants were required to give informed consent to 
participate in the study, the minimum age of 18 years was 
selected as all adults are assumed to have the capacity to 
consent unless otherwise proven.  
The participant’s date of birth was obtained during the 
screening procedure. Identification documents were checked to 
confirm to date of birth. 
Normal middle ear 
status at baseline as 
determined by 
otoscopy and 
tympanometry.  
An abnormal Tympanogram can indicate middle ear 
dysfunction which could affect DPOAEs as well as PTA. 
This is because OAEs cannot be conducted reliably as the 
presence of middle ear pathology results in severely diminished 
OAEs (Swanepoel et al., 2007).  
Furthermore, a conductive hearing loss is often indicated by air 
conduction threshold that is worse than the bone conduction 
Hearing screening was conducted once consent was obtained. 
Screening measures included otoscopy, tympanometry, and 
PTA. 
Normal middle ear status for this study was classified as:  
• Type A tympanogram [ECV of 0.2 to 2.0 ml, SC of 0.2 to 
1.8 ml; MEP of +50 to -100daPa (Jerger, 1975)],  
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Criteria Justification Method 
threshold. Conductive losses are associated with outer and 
middle ear systems (Moore & Zouridakis, 2003).  
• Type As with a slightly decreased static compliance, 
however, not yet flat compliance as with a Type B 
tympanogram (Martin & Clark, 2003) or a  
• Type Ad with slightly increased static compliance.  
Patients with Type B tympanograms (flat compliance) or Type 
C tympanograms (negative pressure) were excluded but were 
referred for medical management. 
Participants who developed middle ear infection during the 
course of their treatment (and research) were not excluded.  
Patients with no 
hearing loss of >70 
dB at 3 or more 
frequencies 
bilaterally  
Ototoxic hearing loss can vary in the degree of the loss. The 
audiometer can only record hearing loss up to 110 dBHL. 
Should a severe hearing loss (70 dB) worsen by more than 40 
dB, it cannot be recorded.  
Any hearing loss with a lesser degree of severity at baseline 
would have a broader range to allow accurate measures. 
Screening audiometry was conducted by the study coordinator 
to ensure the hearing was within these limits. 
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Table 5.2 
Exclusion Criteria of participants in the sample 
Criteria Justification Method 
Diagnosis of 
Diabetes Mellitus 
Diabetes Mellitus has shown to cause hearing impairment, and 
this would have impacted on the reliability of the results 
(Kakarlapudi et al., 2003). 
Potential participants were asked if they had diabetes during the 
screening procedure. If they had diabetes, they were then 
excluded. 
Limited language 
Proficiency in 
English, isiZulu 
and/or SeSotho 
In order for informed consent to be carried out appropriately, the 
participants’ comprehension must be addressed. In South Africa, 
this must be conducted by using culturally accepted practices 
and the participant’s language of choice (SA GCP, 2006).  
According to the South Africa Statistics in the 2011 Census in 
the Provincial Profile, English (20,1%), isiZulu (23.4%) and 
SeSotho (9.6%) were the top three spoken languages in 
Johannesburg (Stats SA, 2011).  
Thus, proficiency in the top three languages was required for the 
study coordinator to be fluent.  
The study coordinator obtained details regarding the 
participant’s language of choice during the screening procedure. 
She asked the language of preference and subsequently 
conducted the informed consent procedures in this language. 
Should the language of preference not be either English, isiZulu 
or SeSotho, the potential participant was not included in the 
study. 
History of 
significant 
substance abuse 
(alcohol and/or 
drugs)  
Substance abuse is associated with poor medication adherence 
(Magura, Rosenblum & Fong, 2011). If the participant was not 
adherent to the DR-TB treatment regimen, it could have affected 
the outcomes of the study.  
The study coordinator gauged this during the screening 
procedure. 
She enquired regarding alcohol use, frequency, and type as well 
as substance abuse in the case history. The study coordinator had 
been involved in several drug trials previously and also used her 
experience to gauge this. 
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Criteria Justification Method 
Intravenous 
treatment with 
aminoglycosides 
and/or polypeptide 
within the last seven 
months. These 
drugs included 
capreomycin, 
kanamycin, 
amikacin, 
gentamicin, 
tobramycin, 
neomycin or 
streptomycin  
Aminoglycosides can stay in an individual’s system for six 
months and possibly cause ototoxicity (Mudd et al. 2016). As the 
focus of the study was capreomycin and kanamycin, possible 
effects of previous aminoglycoside toxicity needed to be 
excluded. 
The study coordinator obtained a comprehensive medical history 
from potential participants which included previous treatment 
(See Screening Case Report forms in Appendix D). This was 
confirmed by reviewing the participants’ available medical 
records. Individuals who were treated with intravenous 
aminoglycosides and/or polypeptide within the last seven 
months were excluded from participation in the study. 
Patients with 
hearing loss of >70 
dB at three or more 
frequencies 
bilaterally  
Ototoxic hearing loss can vary in the degree of the loss. The 
audiometer can only record hearing loss up to 110 dBHL. 
Should a severe hearing loss (70 dB) worsen by more than 40 
dB, it cannot be recorded. This would thus have impacted the 
validity of the measures, as should the hearing loss progress 
even more than 40 dB; it could not have been documented with 
these audiometric measures.  
The study coordinator conducted screening audiometry to ensure 
the hearing was not greater than 70 dB at three or more 
frequencies bilaterally. 
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5.4.2. Sample Size 
The initially proposed sample size was 80 participants from HJH. Based on the 
number of patients admitted to HJH, the number of patients that may have been eligible to 
participate, in combination with the various extraneous variables, attrition, and incidence of 
reported hearing loss, the sample size was estimated to be 80 participants when accounting 
for dropout (See Table 5.3). Therefore, 80 participants were intended for enrolment. From the 
time of enrolment, each participant was to be followed for three months or until death or 
withdrawal from the study. Based on expected dropout, about 60 participants were expected 
to complete the three-month period based on the table. Drop out from all causes was 
estimated at 30%. 
This total sample size of 60 was calculated using a power calculation. This calculation 
included the above criteria of a significant change of hearing as described by Konrad-Martin 
et al., (2005) according to the ASHA (2004) guidelines, with a standard deviation of 1-5dB 
SPL and ≤10dB HL for DPOAEs and pure tone audiometric measurements respectively.  
With a sample size of 60 patients a two-sided two-tailed t test at the 5% level of 
significance would have 99% power to detect a mean difference of 10db with the pure tones 
assuming a common standard deviation of 10dB. The same test would have 90% power to 
detect a mean difference of 6dB with the DPOAEs assuming a common standard deviation of 
10dB. 
Table 5.3  
Original expected reasons for withdrawal from the study 
Reason withdrawal from study Frequency (%) 
Loss to follow-up 10 
Transfer out  10 
Other 10 
All causes (total) 30% 
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After six months of recruitment at HJH, a decision was made to also include SRH as a 
second site as the proposed sample size could not be achieved at only one site. Permission 
was obtained to recruit participants at South Rand Hospital.  
South Rand Hospital treats patients on an inpatient regimen for two to eight weeks. 
SRH initially appeared as an ideal recruitment site. However, SRH often treated with 
capreomycin; injectable that is not as ototoxic as kanamycin.  
Although this inpatient regimen was more ideal for participant treatment, it did create 
more variability in the study. However, this variation was unavoidable, especially as 
capreomycin, although more expensive, and thus rarely used at other hospitals, is a less toxic 
drug for patients.  
Permission was obtained from the hospital, however, a few protocols needed to be 
adjusted to fit within this hospital structure. This included the use of capreomycin, as well as 
the need to conduct more study related creatinine blood tests, as they were not done as 
frequently at SRH as at HJH as part of the standard of care. Ethical clearance was also 
reobtained to include this new study site and adjusted protocol.  
Nevertheless, despite the hospital treating patients with an inpatient regimen, 
recruitment and enrolment were not as successful as hoped. After 12 months of recruitment at 
HJH (January to December 2015) and six months at SRH (July to December 2015), 
enrolment was only at 22 participants. Only a few of these participants completed the full 12-
week period of data collection. 
The reasons for not achieving the sample size are outlined in Table 5.4. 
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Table 5.4 
Detailed Potential Participant Enrolment Description 
 HJH1 
n 
SRH2 
n 
No. of DR-TB patients initiated on treatment at research site 137 131 
No. of potential participants approached 36 46 
No. of participants enrolled 9 13 
No. of participants dropped out before 12 weeks 4 12 
No. of participants who completed the study 5 1 
Reasons for exclusion before approaching potential participant 
• Not within study age range 5 8 
• Diabetic 0 1 
• Pregnant 1 1 
• Previous defaulters on regimen two 6 26 
• Live too far to return for follow-up visits 48  
• History of substance abuse 1 13 
• Participating in other studies 35  
• Renal Problems 5 7 
• Transferred out  29 
Total excluded prior to approaching patient 101 85 
Participants approached to participate in the study 36 46 
Reasons for exclusion once potential participant was approached   
• Too ill to undergo consent process and initial baseline 
testing 
7 13 
• Presence of middle ear pathology at the time of enrolment 2 2 
• Keen to participate however did not return the following 
day for baseline measures (reason unknown) 
8  
• Refused to participate 10 18 
Total excluded once approached 27 33 
Total Remaining Participants 9 13 
Note: 1 January to December 2015, 2 July to December 2015 
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Twelve months after the initiation of recruitment, enrolment ceased due to limited 
resources and the view that statistically, saturation was adequate for a feasibility study. 
Funding for the salary of the study coordinator was limited due to an initial 12 months’ 
contract and the audiological equipment made available by Amtronix for a period of 18 
months had to be returned to the company. The study coordinator was funded for a year to 
assist with procedures. After this time, she started assisted with another study. The researcher 
could not fulfil her role as she is not a trained phlebotomist and not fluent in all the languages 
needed to conduct informed consent. Although the researcher would have liked to continue 
enrolment, it was suspected that by enrolling for another six to 12 months would not yield 
considerable more data (due to the other studies). 
The final sample size comprised 22 participants followed for three months or until 
dropout. A total of 80 study visits were completed. Only a few of these participants 
completed the full twelve-week period of data collection. 
Although this study had a small sample size, it is essential to place the sample size in 
the broader context of TB treatment adherence, where adherence is often poor (Gajee et al., 
2016). A systematic review demonstrated poor adherence, from which three central themes 
stemmed; health services factors, social factors (family and community structures) as well as 
the financial strain of the treatment process (Munro, Lewin, Smith & Volmink, 2007). 
Furthermore, Gajee et al. (2016) found that 53.5% of patients missed one or more 
appointments during outpatient treatment at HJH, which is of concern.  
5.4.3. Participant Description  
The mean age of participants at baseline was 33.78 years (Range: 18.6 – 42.8y; ± 7.3). 
The mean age of the participants at HJH was 29.56 years (Range: 18.6 - 40.7; ± 7.59). The 
mean age of the participants at SRH was 36.71 years (Range: 22.4 - 42.8; ±5.73). 
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The general description of participants including gender, treatment status, marital 
status, the language of choice, and employment status (at baseline) are detailed in Table 5.5.  
Table 5.5  
General Description of the Participants (n = 22) 
General Description HJH SRH Total 
Gender Male 3 4 7 
Female 6 9 15 
Treatment status Inpatient 0 13 13 
Outpatient 9 0 9 
Marital status Married 2 1 3 
Single 6 10 16 
Cohabitating 1 2 3 
Language of choice English 3 5 8 
SeSotho 0 1 1 
isiZulu 0 2 2 
English & SeSotho 2 1 3 
English & isiZulu 4 1 5 
English, SeSotho & isiZulu 0 3 3 
Education  Grade 10 6 4 10 
Grade 11 2 4 6 
Grade 12 1 3 4 
Tertiary 0 2 2 
Employment Status Employed 2 4 6 
Unemployed 7 9 16 
 
Furthermore, the participant's audiological history can be seen in Table 5.6. The most 
prominent aspect was that 8 participants reported struggling with localising sound at baseline. 
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Table 5.6  
Audiological History of the patients in this study 
Audiological History 
HJH 
n 
SRH 
n 
Total 
n 
Previous Ototoxic Medication 0 2 2 
Previous Hearing Test 1 0 1 
Struggle to Hear at Baseline 0 1 1 
Family History of Hearing Loss 1 2 3 
History of Noise Exposure 2 1 3 
Tinnitus 0 1 1 
Difficulty Localizing 4 4 8 
 
Majority of participants were HIV positive (81%), as expected. However, the majority 
(50%) were not on ARVs at baseline. Subsequently, their treating doctor initiated ARV 
treatment. This is evident in Table 5.7.  
Table 5.7  
The number of patients’ HIV Infection and Treatment Regimen. 
HIV infection and Treatment Regimen 
at baseline 
HJH 
n 
SRH 
n 
Total 
n 
Positive 7 11 18 
Negative 2 2 4 
On treatment 3 6 9 
No treatment (if positive) 4 5 9 
EFC, TDF, 3TC 0 4 4 
FDC 0 1 1 
FDC, FTC, TDF 0 1 1 
Nevirapine, TDF 1 0 1 
TDF, ATV, RTV 1 0 1 
EFC, d4T, 3TC 1 0 1 
Note: Abbreviations in Table 5.7: EFV: efavirenz, TDF: tenofovir disoproxil fumarate, 3TC: lamivudine, D4T: 
stavudine, FDC: emtricitabine, ATV: atazanavir, RTV: ritonavir 
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Medical history of participants is described in Table 5.8. In conjunction with table 
5.8, no one had a history of cancer, measles, mumps, significant ear infections, encephalitis, 
meningitis, diabetes, endocrine, cardiovascular (CVS), central nervous system (CNS) or 
gastrointestinal (GUT) problems. Furthermore, no participants reported any other medication 
at baseline, apart from ARVs, as described above.  
Table 5.8  
Detailed Medical History of Participants  
History Description 
HJH 
n 
SRH 
n 
Total 
n 
Smoking History of Smoking 6 9 6 
Presently Smoking 0 1 0 
Alcohol Drink at Present 4 7 4 
Previous Surgery Gallstones, Laparotomy, 
Gunshot, C-Section, 
Unknown 
3 8 3 
Previous Head Injury Types Unknown 2 2 2 
Allergies Tinned Fish 0 1 0 
History of GUT Problems None 7 7 7 
Dermatological Problems at 
Baseline 
Circular Hyper-Pigmented 
Lesion, Hyper Pigmented 
Rash: face, hand, trunk 
0 2 0 
Other Observations at 
Baseline 
Bilateral parotid 
lymphnode 
0 1 0 
Weight (kg) Mean 51.66 57,13 54.83 
Range 42-59 34-73 34-73 
SD 5.10 14.07 11.31 
5.5. Data Collection 
Data collection included a variety of procedures and involved a team of personnel. 
Firstly, an overview of the data collection process is described, followed by a description of 
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the research team involved in this process. Then, the data collection procedures are described, 
including the audiological, pharmacological and medical aspects. 
5.5.1. Data Collection Overview 
Data collection consisted of a number of procedures that needed conducting at 
specific time intervals with each participant. Therefore, a schedule of the procedures and time 
intervals was drawn up and followed for each participant. The standard of care procedures 
includes the procedures that take place at the hospital as part of their general standard of care. 
This included the measurement of weight, height, HIV status, creatinine, CD4 count, 
Potassium, Thyroid Stimulating Hormone (TSH), Liver Enzymes and a full blood count. 
Thus, at times, procedures were not conducted as part of the study protocol as the results 
were utilised from the standard of care procedures. Creatinine was not always conducted as 
part of the study because at times, it was conducted as part of the standard of care at the 
hospital. The protocol differed slightly between HJH and SRH due to their slight variation on 
the standard of care procedures (Table 5.9).  
Table 5.9 provides an overview of the protocol data collection procedures. Details in 
the table are included for the 2-week intervals. Although not included in the table, there were 
daily and weekly procedures to be carried out. 
The daily procedures included the administration of kanamycin/capreomycin at either 
SRH, HJH, or at the local clinics, and documented in the drug diary. Furthermore, the study 
coordinator or local clinic nurse at the various outpatient clinics were required to complete a 
drug ‘diary’ daily, specifying the time and dosage of kanamycin/capreomycin, and the 
concomitant medications. 
The weekly or twice weekly procedures involved sending the blood samples to SMU 
in bulk from all the participants, depending on the availability of the driver. 
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Lastly, money was provided to participants as will be in the data collection procedure below. 
It was only provided for the outpatients. 
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Table 5.9  
Data Collection Overview 
Evaluations 
Screening and Baselines Follow Up Visits Final Visit 
Day 1 
(T0) 
Day2 
(T0) 
Day 3 
(T0) 
Day 15 
(T1) 
Day 28 
(T2) 
Day 40 
(T3) 
Day 54 
(T4) 
Day 68 
(T5) 
Day 84 
(T6) 
Screening Baseline Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 
Window  0 days (if 
clinic pt.) 
±3 days (if 
ward pt.) 
(must be 
the day 
after day 2) 
±3 days 
Standard of Care ✓         
Weight ✓   ✓ ✓  ✓   
Height ✓         
HIV status ✓         
Creatinine (Cr, GFR) (Helen Joseph) ✓   ✓   ✓   
Creatinine (Cr, GFR) (South Rand) ✓         
CD4 ✓      ✓   
Potassium (K) ✓      ✓   
TSH ✓         
Liver Enzymes (GGT, ALT, Bili) ✓         
FBC ✓         
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Evaluations 
Screening and Baselines Follow Up Visits Final Visit 
Day 1 
(T0) 
Day2 
(T0) 
Day 3 
(T0) 
Day 15 
(T1) 
Day 28 
(T2) 
Day 40 
(T3) 
Day 54 
(T4) 
Day 68 
(T5) 
Day 84 
(T6) 
Screening Baseline Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 
Case Report Forms          
Screening/Eligibility Consent ✓         
Informed Consent ✓         
Medical History ✓         
Medication History ✓         
Baseline Case Report Forms ✓         
Follow up Case Report Forms    ✓ ✓ ✓ ✓ ✓ ✓ 
Pharmacological          
Peak  ✓  ✓ ✓ ✓ ✓ ✓ ✓ 
Trough   ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Creatinine (HJH)*     ✓ ✓  ✓ ✓ 
Creatinine (SRH)*    ✓ ✓ ✓ ✓ ✓ ✓ 
HIV Confirmation (if necessary)   ✓       
Package & Refrigerate  ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Audiology          
Screening Audiology (Otoscopy, 
tymp, pure tones, Cerumen Mx if 
needed) 
✓         
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Evaluations 
Screening and Baselines Follow Up Visits Final Visit 
Day 1 
(T0) 
Day2 
(T0) 
Day 3 
(T0) 
Day 15 
(T1) 
Day 28 
(T2) 
Day 40 
(T3) 
Day 54 
(T4) 
Day 68 
(T5) 
Day 84 
(T6) 
Screening Baseline Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 
Cerumen Mx (if indicated) ✓ ✓  ✓ ✓ ✓ ✓ ✓ ✓ 
Case Report  ✓  ✓ ✓ ✓ ✓ ✓ ✓ 
Otoscopy  ✓  ✓ ✓ ✓ ✓ ✓ ✓ 
Tympanometry  ✓  ✓ ✓ ✓ ✓ ✓ ✓ 
DPOAEs  ✓  ✓ ✓ ✓ ✓ ✓ ✓ 
PTA  ✓  ✓ ✓ ✓ ✓ ✓ ✓ 
Other          
Administer Kanamycin/Capreomycin  ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Weight  ✓ ✓   ✓  ✓ ✓ 
Money to participant (if outpatient) # ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Appointment Card for Next Visit ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Note: *The protocol differed slightly between HJH and SRH due to their slight variation on the standard of care procedures. South Rand Hospital conducted creatinine measurements as part of 
the standard of care at baseline, where Helen Joseph conducted creatinine measures more frequently as part of the standard of care. Therefore, the study protocol included more creatinine tests at 
South Rand to compensate for the lack of measures as part of the standard of care.  
#Although weight was measured as part of the standard of care; this was not at every study visit. Hence the measurement of weight and height were included in study related procedures.
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5.5.2. Research team 
This study was a multidisciplinary study, including pharmacology, audiology, and 
medicine. Therefore, the research team consisted of experts in these fields, as well as 
significant support and administrative staff. All the roles were defined clearly prior to the 
study to ensure valid and reliable results. The research team consisted of: 
• Principal Investigator: A medical doctor whose extensive experience as an 
investigator in clinical drug trials at Wits Health Consortium CHRU was appointed to 
oversee the study. The principal investigator was responsible for all the participants’ 
DR-TB treatment at HJH. As the principal investigator did not have authority at SRH, 
the treating doctors at SRH were thus responsible for the SRH participants.  
• Medical Doctors/Specialist Physician: Two medical doctors (SRH) and one specialist 
physician (HJH) were responsible for the daily and overall management of the 
participants. 
• Biochemist and Laboratory Personnel: The biochemist and laboratory personnel 
from the Sefako Makgatho Health Sciences University (SMU) assisted in the 
development of the procedure for the measurement of kanamycin pharmacokinetics in 
patients with DR-TB specifically for this study. 
• Clinical Pharmacist/s: The clinical pharmacist and specialist in pharmacokinetics 
from the SMU conducted the pharmacokinetic calculations of the kanamycin and 
capreomycin and interpreted the results.  
• Audiologist and researcher: The audiologist/researcher was responsible for the 
development of the protocol and standard operating procedures, obtaining relevant 
permissions and ethical clearances. This also included the training of relevant 
personnel according to the study protocol and standard operating procedures, quality 
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assurance (QA), continuous monitoring and management of the study and issues, 
coordination and funding for the study.  
• Statisticians and Epidemiologist: An independent bio-biostatistician/epidemiologist 
from Right to Care NGO was involved with the statistical plan in the development of 
the protocol and well as was involved with the final statistical analysis of the study. An 
independent, experienced statistician at the University of The Witwatersrand was also 
involved with the protocol development and final analysis and interpretation of the 
results. 
• Study Coordinator: The study coordinator was a nurse from Right to Care TB Focal 
Point and was employed on a full-time basis (5 days per week) for the duration of the 
study’s training and data collection (15 months). The study coordinator is an 
experienced research nurse in this field, with eight years’ experience in research at the 
start of the study. She received comprehensive training (with complete training manual 
- available on request) on how to perform the audiological measures and how to 
communicate with individuals with a hearing loss. The study coordinator was 
responsible for participant recruitment and enrolment, the informed consent process, 
drawing and packaging of blood, audiological measures, other measures such as 
weight and height, collating the information from the patient files, case history and 
follow-up records, various administrative duties, communication between the 
pharmacist and doctors and follow-up procedures. The study coordinator moved 
between HJH and SRH for five days a week full time to conduct the study-related 
procedures and ensured all procedures were done according to Good Clinical Practice 
(GCP) guidelines (SA GCP, 2006).  
• Local Clinic Nurses: A specific nurse was assigned from the local clinic to inject the 
participants daily with their dose of kanamycin or capreomycin and documented the 
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time and dosage in the drug diary. These clinics were identified as the clinic closest to 
the patient’s residence, where they received their daily, outpatient injections. 
• Hospital-Based Nurses: The nurses in the wards were required to notify the study 
coordinator as soon as a patient with DR-TB was admitted, and prior to the initiation 
of kanamycin or capreomycin, if possible. The nurses at HJH and SRH were required 
to treat the patients as per hospital protocol and communicate relevant information to 
the study coordinator collecting data for this study.  
• Quality Assurance (QA): Personnel: The QA team at CHRU checked that the 
informed consents were complete and done according to GCP guidelines at HJH. The 
study coordinator and researcher performed QA procedures at SRH when the CHRU 
team was not available.  
• Phlebotomists: The phlebotomists at CHRU assisted with the drawing of blood when 
necessary and centrifuged and stored the blood samples daily. 
• Receptionist: The receptionist at HJH provided payment for the outpatient 
participants. 
5.5.3. Data collection procedures 
The data collection procedures comprised participant recruitment, participant 
enrolment, and application of the research protocol which included audiological measures 
and pharmacological procedures. The recruitment and enrolment procedures obtained data 
and thus is considered part of the data collection procedures. 
5.5.3.1. Participant recruitment. 
Participant recruitment involved the study coordinator advertising the participation in 
the study at the various hospitals. Recruitment took place in the waiting room at HJH, and the 
wards at SRH. The study coordinator informed patients that a study about hearing was taking 
place, and participants were invited to participate in the study if they fulfilled specific criteria. 
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A brief and general description and overview regarding the study was provided, to establish 
whether patients were interested in possible screening and further enrolment. 
5.5.3.2. Enrolment: screening for eligibility and consent. 
After recruitment to the study, the screening process was conducted to ensure 
eligibility prior to the full consent forms and baseline measures. However, in order for 
screening measures to be conducted, a consent form for these measures needed to be 
administered. A screening consent form (Appendix C) was signed before the screening 
procedures (Appendix D). Only once the participant was eligible to participate, the full 
consent forms and baseline procedures were conducted (Appendices E and F). The details are 
below in Table 5.10  
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Table 5.10  
Detailed Description of Screening and Baseline Forms of Eligibility 
Screening measures of eligibility 
Category Appendix Content Rationale Procedure 
Information 
Leaflet 
Screening 
Consent Form 
(English, 
isiZulu, and 
SeSotho) 
C Overview of the criteria for inclusion These forms were used to obtain informed 
consent from potential research participants 
for the screening procedures in order to 
confirm eligibility. The consent process 
was conducted according to South African 
GCP standards (SA GCP, 2006) and 
adhered to the Declaration of Helsinki 
guidelines (WMA, 2013) for informed 
consent. 
The study coordinator discussed the 
consent forms in detail with the participants 
and allowed for questions and concerns 
regarding the study in the potential 
participants’ first language.  
If the potential participants’ first language 
was not isiZulu, SeSotho or English, he/she 
was excluded, as a reliable informed 
consent could not be taken. 
Three forms were signed and placed in 
the 1) hospital file, 2) patients study 
file and 3) given to the participant. 
Screening Case 
History/ 
Information 
and report 
forms  
D Name, Date of Birth, Race, Social 
History, Medical History, Surgical 
History, TB History, Pregnancy, 
Willingness to Consent to an HIV test, 
Language of proficiency, Checklist of 
previous possible ototoxic medications, 
Audiology History 
The screening case history was conducted 
to confirm eligibility for inclusion. 
The study coordinator asked potential 
participant all the questions and conducted 
the audiological screening measures. 
The answers and results were documented 
on the report form.  
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Baseline measures of enrolment 
Information 
Leaflet and 
Informed 
Consent Form 
(English, 
isiZulu, 
SeSotho) 
E, F  This contained information regarding 
the purpose of the study, study 
procedures, risk add benefits, and all 
information regarding the process and 
procedures in the study.  
These forms were used to obtain 
informed consent from research 
participants for the screening 
procedures in order to confirm 
eligibility. The consent process was 
conducted according to South African 
GCP standards (SA GCP, 2006) and 
adhered to the Declaration of Helsinki 
guidelines (WMA, 2013) for informed 
consent. 
The study coordinator discussed the 
consent forms in detail with the participants 
and allowed for questions and concerns 
regarding the study in the potential 
participants’ first language.  
If the potential participants’ first language 
was not isiZulu, SeSotho or English, he/she 
was excluded, as a reliable informed 
consent could not be taken. 
Three forms were signed and placed in the 
1) hospital file, 2) patients study file and 3) 
given to the participant. 
Baseline Case 
Report Forms 
G The baseline case report forms detailed 
the procedure for the blood sampling 
(pharmacokinetics, HIV testing, and 
creatinine testing), audiology measures, 
as well as all the case histories and 
physical examinations 
These forms were developed to record 
all baseline results to allow for 
comparison from the follow-up results. 
The study coordinator conducted the 
procedures and completed the forms. The 
completed forms were filed in the 
participants’ study file. 
Patient Contact 
Information 
Form 
 
H Language of participant, contact phone 
number, new contact number (if 
changed during the study) 
The participant's basic contact details 
were documented in every study file. It 
was imperative to have recent contact 
details for all participants in the event 
of follow-up for missed appointments.  
The study coordinator recorded the 
participant contact details. 
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HIV Testing 
Consent Form 
As per 
NDoH 
form 
This form details the counselling 
discussion which includes the 
description of HIV and AIDS, risk 
factors, cure, the test procedures and 
interpretation of the results as well as 
the consent form.  
When HIV data was not readily available, 
HIV testing was conducted for 
documentation as part of the study 
protocol.  
Informed consent was done separately to 
this according to Department of Health 
Guidelines for HIV testing. However, 
Clinical Laboratory Services performed the 
analysis of the sample. 
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5.5.3.3. Detailed history. 
Prior to the audiological and pharmacological data collection procedures, detailed 
case history questionnaires were administered. This occurred at the baseline measure. 
Subsequently, further case report forms were administered at the follow-ups to determine any 
changes. Details can are visible in Table 5.11
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Table 5.11  
Case History and Case Report Forms 
BASELINE 
CASE HISTORY (appendix G) 
Category 
No. of 
Questions 
Content Rationale Procedure 
Medical 
History 
30 Head, Ears, Eyes, Nose, Throat, Neck, 
Cardiovascular System, Respiratory System, 
Gastrointestinal Tract, Urogenital Tract, 
Haematological System, Rheumatological System, 
Endocrine System, Central Nervous System, 
Dermatological System, Reticulo-Endothelial 
System, Allergies, Other problems, CD4 count 
The medical history of patients 
could impact their risk of hearing 
loss. In particular, patients were 
asked about their history of TB, 
measles, mumps, frequent ear 
infections, encephalitis, meningitis, 
cancer, trauma (especially to the 
head), and hospitalisations 
(Wood, 1979; Robinette & Cevette, 
2002).  
The study coordinator conducted a 
detailed interview with the 
participants and also reviewed 
participants’ medical file (with 
participant permission). 
Both the medical history and 
audiological history were recorded 
on the specific history forms and 
placed within the participants’ 
study file. 
Auditory 
History 
14 Previous medication, Family History of Hearing 
Loss, Otalgia, Otorrhea, Tinnitus, Dizziness, Aural 
Fullness, Hearing Loss, Noise Exposure 
Audiological History can assist in 
identifying contributing factors of 
hearing loss (Robinette & Cevette, 
2002).  
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FOLLOW UP WEEKS (T1 to T6) 
CASE REPORT FORMS (Appendices H to M) 
Category Content Rationale Procedure 
Follow up 
Case 
Report 
Forms 
Checklist of procedures, Inpatient/outpatient details, 
Interim medical history, Details of the last 
injectable, audiological, behavioural, psychological 
changes, willingness to continue participation, 
audiological measures record forms 
The follow-up case report forms 
contained checklists to ensure all the 
measures were conducted and 
allowed accurate recording. 
The baseline and follow up case report forms 
detailed the procedure for the audiology measures. 
The study coordinator completed them when doing 
the procedures. 
On day 84, the participant was referred to the 
audiology department within their district for 
further monitoring and hearing aid 
management. If the participant terminated the 
study earlier, they were referred earlier to an 
audiology department. 
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5.5.3.4. Audiological procedures. 
Audiological testing was to be carried out every second week (Baseline and weeks 2, 
4, 6, 8, 10 and 12). The total duration was three months or until dropout.  
The audiological measures consisted of otoscopy, tympanometry, cerumen 
management (if indicated), PTA and DPOAEs. Testing was conducted in the same order for 
all the participants, with the left ear being tested first.  Noise levels were monitored 
throughout, and universal infection control was carried out. The details can be seen in Table 
5.12 
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Table 5.12  
Audiological Measures and Equipment 
Audiological Measures and Equipment 
Measure Equipment Rationale Description 
Otoscopy Welch Allyn 
Pocket Otoscope 
Speculae 
An otoscopic examination is performed to evaluate the 
state of the outer ear, and tympanic membrane for 
abnormalities and/or infection (Rappaport & Provencal, 
2002). 
 
Otoscopy is used to determine the condition of the 
external auditory meatus and tympanic membrane, to 
ensure that there were no obstructions in the external 
canal or conditions that may have influenced additional 
testing procedures (Rappaport & Provencal, 2002. 
The normal otoscopic examination was considered as a 
visible tympanic membrane, no perforations, cone of 
light, with no obstructions in the canal (besides for 
cerumen). 
Cerumen 
management (if 
indicated) 
YX932S Cerumen 
Suction Machine 
(supplied by Trojan 
Medical) 
Impacted cerumen can affect the reliability of 
tympanometry and OAEs (Wilson & Roeser, 1997). 
Therefore, the removal of cerumen allowed for a clear 
external auditory meatus to assist in ensuring further 
reliable audiometric measures. 
Cerumen management for cerumen occlusion of more 
than 70% was performed via the suctioning procedure. 
No participants however required cerumen 
management. 
Tympanometry Tympanometer 
(Maico Easytymp – 
supplied by 
Amtronix) 
Tympanometry evaluates middle ear status through the 
depiction of tympanic membrane motility as a function of 
variations in air pressure (Clark, Roeser & Mendrygal, 
2007). This test serves as an irreplaceable evaluative tool 
The appropriate size nub was chosen, and the test was 
conducted according to the equipment’s’ procedure 
manual to ensure accurate outcomes. 
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Audiological Measures and Equipment 
Measure Equipment Rationale Description 
 representing middle ear functioning (Clark et al., 2007). The 
presence of middle ear pathologies results in severely 
diminished OAEs, and more severe cases may also 
influence the results obtained with ABR testing 
(Swanepoel et al., 2007), thus affecting the reliability 
of the OAE measures and air conduction PTA 
measures. 
Normal middle ear status for this study was classified 
as:  
• Type A tympanogram [ECV of 0.2 to 2.0 ml, SC of 
0.2 to 1.8 ml; MEP of +50 to -100daPa (Jerger, 
1975) 
• Type As with a slightly decreased static 
compliance, however, not yet flat compliance as 
with a Type B tympanogram (Martin & Clark, 
2003) or a  
• Type Ad with slightly increased static compliance.  
Distortion 
Product 
Otoacoustic 
Emissions 
(DPOAE) 
Otoread: High 
frequency, up to 12 
kHz. Supplied by 
Interacoustics 
OAEs were measured to obtain objective measures 
regarding the integrity of the cochlea (Prieve & 
Fitzgerald, 2002). Therefore, contributing to the 
differential diagnosis linked to auditory functioning at 
this level of the auditory system. They provide 
obtainable results for a wider range of hearing 
impairment (Prieve & Fitzgerald, 2002) and offer 
greater frequency specificity (Prieve & Fitzgerald, 
2002).  
DPOAEs were measured by placing a probe tip (of the 
appropriate size) in the patients’ ear canal, presenting 
the tone into the external ear canal and measuring the 
distortion response obtained from the cochlea. 
The frequencies included: 2 kHz, 4 kHz, 6 kHz, 8 kHz, 
10 kHz, 12 kHz 
Repeated measures were conducted, and noise levels 
were monitored throughput to ensure valid responses.  
This is an objective test as the participant was not 
required to respond. 
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Audiological Measures and Equipment 
Measure Equipment Rationale Description 
DPOAE testing, prior to and after the treatment with 
kanamycin/capreomycin allowed the researcher to 
determine changes in amplitude related to the treatment 
with these drugs. 
Responses were from +20 to -20, where -20 was 
considered absent. 
Selected appropriate SNR was +6 dB (see chapters 6 
and 7) 
PTA Path Sentiero 
supplied by 
Amtronix 
Acer Laptop 
 
PTA assesses hearing sensitivity as a function of 
frequency (Bess & Humes, 2008). This provides insight 
into the integrity of the auditory system as well as 
information relating to the symmetry, laterality, degree, 
and configuration of a patients hearing thresholds 
(Harrell, 2002).  
PTA can include air (AC) and bone conduction. Yet, 
only AC testing was done, as pure tone bone 
conduction (BC) thresholds cannot be done over 4 kHz. 
Generally, ototoxicity would begin in the high 
frequencies, and BC audiometry cannot assist in 
monitoring this. Bone conduction audiometry is often 
used to rule out conductive components; however, in 
this case, tympanometry was used to assist with this. 
Although BC would have been ideal, the participants 
Frequencies tests included: 
0.25, 0.5, 1, 2, 3, 4, 6, 8, 9, 10, 11.2, 12.5, 14 and 16 
kHz. 
Response Mode: Press Button  
A mobile diagnostic audiometer was used so that 
testing could take place at the participants’ bedside if 
necessary. This was important, as in the beginning 
stages when participants were hospitalised and were 
too sickly to leave their beds, testing could be done at 
their bedsides.  
A laptop was used to transfer the results to an excel 
spreadsheet for accurate recording, and to be placed in 
the study file. 
Change in hearing loss from baseline was recorded, and 
the overall hearing thresholds and norms were used to 
monitor the ototoxicity. 
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Audiological Measures and Equipment 
Measure Equipment Rationale Description 
were sick and fatigued quickly, and thus reliable BC 
results were unlikely to be achieved. 
Noise 
Monitoring 
ST-109 Type 1 
integrating sound 
level meter, data 
logging with 
software and USB 
cable supplied by 
A.W.R. Smith 
Process 
Instrumentation cc 
Noise levels were monitored throughout the testing with a 
sound level meter.  
The sound level meter was placed next to the 
participant when conducted DPOAEs and PTA. Noise 
levels did not exceed 55 dB SPL.  
Infection 
Control 
Gloves, alcohol 
swabs, disinfectant, 
masks. 
Infection control is essential to prevent the transmission 
of infection (Franklin& Grady, 2001) and allows for 
ethical and safe research. 
Universal precautions were taken to ensure infection 
control. 
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5.5.3.5. Pure Tone Audiometry. 
The ASHA guidelines for ototoxicity monitoring emphasise the increased test 
sensitivity achieved using ultra-high-frequency monitoring to detect ototoxicity (Konrad-
Martin et al., 2005). With regards to the PTA results, frequency ranges were broken down 
into low frequencies (0.25 kHz until and including 2 kHz). Seddon et al. (2012) described 
that frequencies above 2 kHz are considered high frequencies (HFA). Thus, the analysis was 
investigated further from 3 kHz until and including 8 kHz; 8 kHz is where the conventional 
audiogram subsides and where speech frequencies generally care Then, as high frequencies 
are where ototoxicity is reported to start, further ultra-high (UHFA) frequencies were 
analysed in the PTA; from 9 kHz until and including 16 kHz. 
Ototoxic HL as only confirmed should the above criteria occur from (and including) 2 
kHz and above, or should the HL start at the higher frequencies and progress to the lower 
frequencies according to the ASHA criteria unilaterally or bilaterally. Test-retest differences 
for ultra-high-frequency thresholds using modern equipment are generally reported being 
within ±10 dB for frequencies between 9 and 14 kHz (Konrad-Martin et al., 2005). Therefore, 
the standard deviation (SD) for PTA was up to and including 10 dB. 
5.5.3.6. Distortion Product Otoacoustic Emissions. 
This probe emitted the stimulus of two ‘primary tones’ that vary in frequency and the 
cochlea responded by producing sounds. The microphone then picked these miniature 
sounds/emissions on the probe, and thus was a measurement of cochlear functioning, and not 
hearing, as hearing extends beyond the cochlea to the temporal lobe (Martin & Clark, 2003). 
 A clinically significant change can be classified as 6 dB SPL or greater. Therefore, 
variability in detection threshold or standard deviation is from 0 to 5 dB SPL (Roede et al., 
1993). Determining effective ototoxicity detection and monitoring strategies using objective 
measures such as DPOAEs is an active area of research. However, there currently are no 
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accepted protocols or criteria for ototoxic change using DPOAEs. Most reports in patients 
receiving ototoxic drugs which have utilised objective measures such as DPOAEs, in which 
sensitivity was defined as a clinically significant change in the value of the objective measure 
(Konrad-Martin et al., 2005). Therefore, for this study, a clinically significant change that can 
be attributed to ototoxicity has been defined 6 dB or more at or above 2 kHz at one or more 
frequency unilaterally or bilaterally.  
Both PTA and DPOAE measures were utilised to complement each other. PTA is a 
psycho-physical measurement of hearing with the aim of getting complete knowledge of an 
individual’s ability to interpret various kinds of acoustic stimuli (Huizing, 1951), whereas 
DPOAEs have higher sensitivity than PTA in the monitoring of cochlear function (Sakashita 
et al., 1998), but not interpretation. As DPOAEs do not require an individual to respond 
physically, this can occur when the participant is too weak to participate in PTA. PTA was 
measured by placing earphones on an individual while the nurse/audiologist presented 
different pure tones with various frequencies to each ear via the earphones. The nurse/ 
audiologist needed to establish the individuals hearing threshold levels, i.e. the softest sounds 
that the individual can respond. Whereas, with DPOAEs, the nurse/audiologist placed a probe 
in an individual’s ear.  
5.5.4. Pharmacological and Laboratory Measures and 
Equipment 
The pharmacological tests included the HIV (when no results were available) and 
creatinine testing as well as the pharmacokinetics of kanamycin and capreomycin. Moreover, 
in order to analyse the blood, various types of equipment needed to be purchased. The 
pharmacological equipment that needed to be obtained can be seen in Table 5.13. 
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Table 5.13  
Pharmacological Equipment 
Item/s Discussion of Item/s 
Liquid Chromatography-Mass 
Spectrometer (LC-MS) 
Aim: An LC-MS combines the chemical separating power of LC with 
the ability of an MS to detect and confirm molecular identity selectively.  
Rationale: Mass Spectrometry is one of the most sensitive and highly 
selective methods of molecular analysis and provides information on the 
molecular weight as well as the fragmentation pattern of the analyte 
molecule. The information obtained from MS is invaluable for 
confirming the identities of the analyte molecules. 
Use: The mass spectra of various components present in medicines have 
been obtained online from the LC-MS run and matched with known 
standards for structural confirmation. Integrated MS databases have also 
been used for identification of various compounds. In this way, GC-MS, 
LC-MS, and MS-MS fingerprinting profiles of the active ingredients of 
various medicines have been obtained, and information has been stored 
in the form of an electronic database, which can be used for routine 
comparison of chemical profiles of individual compounds for quality 
control purposes. 
Fridge/ Freezer This fridge was needed to store blood samples before they were sent to 
SMU for analysis (between 2 and 8oC). The samples were stored in a 
fridge if they were kept for seven days or less and in a -80 oC freezer if 
they were stored for more than seven days. 
The samples sent to CLS were not stored and sent immediately for 
analysis. 
Other (scale, consumables for 
blood tests and infection 
control) 
This included: alcohol swabs, disinfectant, needles, syringes, red top 
tubes, yellow top tubes, storage containers, scale, stickers for the tubes, 
packets, and plasters. 
Acer Laptop A computer was necessary for the study for a variety of reasons: to 
access the creatinine and lab results for the participants from the National 
Health Laboratory Service, to download the audiological results from the 
path Sentiero, electronic communication between all the parties involved 
in the research and to organize a weekly schedule of events of all the 
participants. 
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In order for these tests to be executed reliably, correct documentation was needed to 
record the blood being drawn and results. Also, for reliable results, it was essential to know 
the dosages administered daily, hence drug diaries were implemented (Table 5.14). 
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Table 5.14  
Description of Pharmacological Forms and Case Report Forms for weeks T1 to T6 
Category Appendix Content Rationale Procedure 
Follow up Case 
Report Forms 
I to N Checklist of procedures  
Inpatient/outpatient details 
Interim medical history 
Physical Examination 
Details of last injectable 
Behavioural, psychological changes  
Willingness to continue participation 
The follow-up case report forms 
contained checklists to ensure all the 
measures were conducted and allowed 
accurate recording. 
The baseline and follow up case report forms 
detailed the procedure for the blood sampling 
(pharmacokinetics, HIV testing, and 
creatinine testing) as well as all the case 
histories and physical examinations. 
The study coordinator completed the 
forms when doing the procedures. 
Daily Drug 
Diaries 
O, P Daily Drug Diary for Hospital and Study File 
Daily Drug Diary for Clinics 
The daily drug diaries for hospitals and 
clinics documented the dosage and times 
the injectables were injected 
• This allowed the researcher to 
track missed dosages. 
The kanamycin and capreomycin dosing 
details (times and dosage) were explicitly 
essential to understand the 
pharmacokinetic results. 
 
Drug diaries were either completed daily 
at the hospital when the study coordinator 
administered the injectable or at the local 
clinic when the injectable was 
administered at the clinic. 
The hospital drug diary was more 
detailed as the study coordinator was 
completing it; however, less information 
was obtained due to the time constraints 
of the clinic nurses.  
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Laboratory 
Requisition 
Form for 
Creatinine and 
HIV Testing 
(CLS) 
Q The requisition forms included participant 
identification details, weight as well as details 
of the test to be done and of the sample taken.  
This form allowed for the documentation 
the specific test requested and specific 
week for the HIV tests and/or creatinine 
to be sent with the blood samples to CLS. 
The study coordinator completed the 
form when the blood was drawn and sent 
it with the sample/s to CLS.  
Laboratory 
Requisition Form 
for Kanamycin 
and Capreomycin 
Pharmacokinetics 
(SMU) 
R The requisition forms included participant 
identification details, weight, details of the 
sample that was drawn (date and time of 
collection) as well as details of the test to be 
done. 
These forms allowed for the 
documentation of the date and time that 
blood had been drawn for the 
pharmacokinetic measures to be sent to 
SMU with the relevant blood samples 
The study coordinator completed the 
form when the blood was drawn and sent 
it with the sample/s to SMU. 
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5.5.4.1. Sample collection. 
Samples were collected at the relevant study sites by the study coordinator. The 
collection of the samples and procedures were as follows: 
• Body Mass Index (BMI) was recorded with each measure  
• For the baseline measurements, the blood samples were collected at the first injectable 
dose. For this first dose, the peak sample was collected four to six hours post the 
administration of the injectable, and the trough sample was collected on the following 
day, 30 minutes prior to the administration of the second dose. 
• The follow-up samples were collected on the relevant weeks: week 2, 4, 6, 8, 10 and 
12. The peak and trough samples were collected on the same day: the sample for the 
trough was drawn 30 minutes prior to the injection, and the sample for the peak was 
drawn four to six hours after the injection. 
• 2 mls of venous blood for the trough level and 2mls of venous blood for the peak level 
was drawn and placed in separate red top tubes. 
• The study coordinator recorded the time the peak and troughs were taken, the dosages 
and other drugs administered to the participant, the day of therapy and the amount of 
drug given. 
• The samples were centrifuged (4000 revs per minute for 10 minutes at 4oC) prior to 
storage and then stored immediately in a (between 2 and 8 oC) fridge if stored for 
seven days or less, or in a -80 oC freezer if stored for more than a week. This was 
dependent on the laboratory’s availability to analyse the samples. 
• Creatinine results were also measured. When the test was not part of the standard of 
care procedures at the relevant hospital, then an extra three mls of blood was drawn 
(and placed in yellow top tubes) to measure this. Clinical Laboratory Services 
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performed these tests. However, the creatinine results conducted by the NHLS were 
not always accessible as stated above. This is a limitation. 
• HIV testing was conducted if there was no laboratory documentation in the 
participants’ hospital file. This occurred in accordance with the standard procedures in 
SA. 
5.5.4.2. Pharmacokinetic calculations. 
The clinical pharmacist from SMU calculated the pharmacokinetic parameters for the 
kanamycin and capreomycin for all participants to determine at what drug concentration 
toxicity was occurring.  
The laboratory at SMU was prepared with all the necessary equipment. This study 
was entirely exploratory for correlating kinetics for kanamycin and capreomycin to hearing 
loss in a South African population. Pharmacokinetics in this population with kanamycin was 
the first of its kind. The sample analyses did not necessarily occur in ‘real time’. Therefore, 
samples were sent weekly or twice weekly to SMU for analysis, and not immediately post 
sample collection. Prior to transportation, they were stored at the CHRU. 
The lack of this type of study is demonstrated through a systematic review by the 
audiologist/researcher through database searches using various keywords. A total of 154 239 
records were identified using ‘Kanamycin’ OR ‘Capreomycin’ OR ‘Aminoglycosides’. 
Furthermore, this was refined to include ‘Ototoxicity’ OR ‘Hearing’ resulting in 3411 
records. By further adding the search terms ‘Pharmacokinetics’ OR ‘Kinetics’ the number 
was reduced appreciably to 292. Thereafter, studies regarding ‘Tuberculosis’ were searched, 
finding nine articles. These nine articles were refined to zero when looking at the date 
published (six were after the development of the protocol) as well as excluding animal studies 
and reviews (see Figure 5.1). 
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Figure 5.1. Systematic review of similar studies 
 
The pharmacokinetic parameters were calculated by a clinical pharmacist and 
pharmacokinetics expert at SMU. The pharmacist recorded the amount and time of doses 
given, the values and times of measured drug concentrations using a pharmacokinetic graph. 
The calculations of the kinetics included: 
• Calculation of the elimination rate (ke) and half-life (t1/2) from peak and trough 
concentrations 
• Determination of the Cmax (concentration at the time the completion of the drug 
administration) 
• Calculation of the Cmin (concentration at the end of dosing interval) 
• Calculation of the volume of distribution (Vd) 
• Calculation of the Creatinine Clearance (CrCl) 
The drug toxicity was subsequently correlated to trough levels. 
154239  
Identified: Kanamycin OR 
Capreomycin OR AG
3411
Added search hearing or 
ototoxicity
292
Added search regarding specific 
discipline of kinetics OR 
pharmacokinetics
9
Screening with regards to 
human studies and TB
0
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5.5.5. Medical Treatment and Financial Arrangements 
The medical management was not a specific study related procedure, however, 
occurred as part of the standard of care at the hospitals. The doctors, however, were involved 
in the study and therefore informed the study coordinator about a treatment change, such as 
from an adverse event, when necessary.  
Furthermore, participants were not paid for the participation in the study, yet they 
received reimbursement for their transport and a possible day off work. This was in 
accordance with GCP guidelines (2006).  
5.5.5.1. Treatment by the medical doctor. 
• HIV treatment: Each participant continued with their DR-TB treatment and HIV 
regimen as per the protocol at research sites. As per the NDoH (2011), all patients that 
were on ARV treatment at the time of the diagnosis of DR-TB continued their ARV 
treatment and started the MDR-TB treatment immediately. If patients were on 
tenofovir, lamivudine and efavirenz or nevirapine for their HIV, it was advised that the 
patients be stopped on tenofovir and switched to zidovudine or stavudine during the 
injectable phase. Then tenofovir could be re-introduced in the continuation phase of 
the DR-TB treatment. All the participants’ HIV and DR-TB treatment thus continued 
as per government guidelines.  
• Adverse events: When a participant displayed any such symptom that was unusual for 
patients with DR-TB, it was recorded. When a participant displayed an atypical 
symptom, that was likely a result of their DR-TB, it was still recorded and reviewed. 
The treating doctor or doctor on duty decided on the management of this patient. The 
adverse events in this study that was reported where nephrotoxicity. As per the 
protocol, when the doctors withdrew a participant from kanamycin or capreomycin 
and switched to another drug for DR-TB treatment, the participant was withdrawn 
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from the study. If the participant were however switched to a three-day kanamycin or 
capreomycin regimen in contrast to a five-day regimen, they would continue in the 
study. This would take place if there were a significant decline in hearing or kidney 
function, although is generally only implemented after the first three months. At SRH 
patients switched to capreomycin when toxicity was noted. If the nephrotoxicity 
continued, participants were withdrawn from kanamycin and capreomycin; if renal 
function deteriorated to a Glomerular Filtration Rate (GFR) < 60 then kanamycin or 
capreomycin. This did occur at SRH and participants were withdrawn from the study. 
This was the only adverse event reported.  
5.5.5.2. Financial arrangements. 
The participants were provided with R 150.00 for study visits where blood was 
drawn for study-related procedures, and hearing tests were done. This took at least 5 
hours (excluding travel), and thus participants were compensated for their time and the 
potential of missing a day of work. 
The participants were provided with R 50.00 to go to their local clinical daily and 
receive their kanamycin or capreomycin injections during the study, or to visit the study 
coordinator daily for his/her injection at either SRH or HJH. When this R 50,00 was not 
sufficient for transport, R 70,00 was given on an individual basis (as stipulated by the 
GCP guidelines and travel distance). 
5.6. Ethical Considerations 
Many ethical considerations were taken into account. The World Medical 
Association's [WMA], Declaration of Helsinki principles, guided the research (WMA, 2013). 
These principles were applied to this study as a means of promoting its’ execution in a 
manner that was honest and truthful to participants and valid in implementation. The ethical 
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aspects considered can be categorised into four categories namely: (i) the respect for 
autonomy, (ii) confidentiality, and anonymity, (iii) beneficence and non-maleficence, and (iv) 
justice (McCormick, 2013). The manner in which these principles were reviewed and applied 
to this study is outlined below. 
5.6.1. Respect for Autonomy 
Autonomy, or respect for people, as explained by Owonikoko (2013) demands that 
the ability of competent participants to make their own decisions and for this to be recognised 
as respected, while also protecting the autonomy of the vulnerable populations by preventing 
the imposition of the unwanted decision. 
This principle of autonomy brings forth the concept of informed consent (Owonikoko, 
2013). Therefore, the GCP principle guided this informed consent procedure. Information 
sheets and consent forms were given to each potential participant. The study coordinator 
explained the consent form, in a language of choice for the patient, to ensure that the patient 
understood the reason of the study, what was required of him/her as well as his/her right to 
not consent to participate or withdraw at any time without any negative consequences. 
Informed consent was obtained to collect blood samples and to participate in the audiological 
testing. The signing of the consent form was done in accordance with GCP guidelines. The 
participant was given the opportunity to ask further questions or express any concerns. The 
study coordinator and specific investigators provided their contact details in the cover letter, 
should patients have felt that they required additional information. The responsibility for the 
protection of participants always rested with the researcher and personnel involved and never 
the research participants, even though they had given consent. Furthermore, participants were 
given the option of not participating or withdrawing from the study at any time without any 
repercussions or penalty. 
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5.6.2. Confidentiality and Anonymity 
“The concept of confidentiality is closely connected with anonymity. Confidentiality is 
regarded as spoken or written with confidence. Anonymity, on the other hand, is one way to 
apply confidentiality. Anonymity in practice means that information on the identity of 
research” (Dube, Mhlongo & Ngulube, 2014, p.202).  
All documents will remain confidential and will be stored for 15 years post-trial. It will 
be kept in a locked cabinet, and the database is password protected. Furthermore, 
participants’ confidentiality was assured in that only the personnel in the hospital involved in 
the study, the researchers and supervisors will have access to the data. Should a participant 
not have completed the study, their existing data was kept safe and confidential. 
In many research studies; it is the right of the participants to remain anonymous. In 
this study, the patients were required to give their name, as the researcher and the medical 
professionals needed to document the participants’ progress. However, the information was 
not provided to anyone external to the study and names have not been mentioned in the final 
write-up of the results.  
5.6.3. Beneficence and Non-Maleficence 
“Beneficence and the twin concept of Non-Maleficence demand that subjects should 
not be harmed through the conduct of the study” (Owonikoko, 2013, pg. 242).  
“Beneficence is defined as an act of charity, mercy, and kindness with a strong 
connotation of doing good to others including moral obligation. All professionals have the 
foundational moral imperative of doing right.” (Kinsinger, 2009). In contrast, non-
maleficence involves an ethical and legal duty to avoid harming others (Beauchamp & 
Childress, 2008). 
The Helsinki principles also mention that medical research involving human 
participants may only be conducted if the importance of the objective outweighs the inherent 
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risks and burdens to the research subjects (WHO, 2001). There were few risks of the 
pharmacokinetic measures, mainly which included the risk of bruising from the needle entry. 
This was monitored, and patients displaying notable reactions that are causing significant 
discomfort would have been excluded from the study. Should this study lead to the future 
individualisation of drug therapy and dosage adjustments to reduce toxicity, it could improve 
the quality of life for future patients. The immediate benefit of the study involved the 
constant hearing testing every two weeks, and thus awareness of hearing status. This would 
not have otherwise been possible. The beneficence was upheld with the guiding idea, that 
without a hearing loss or with a lesser degree of hearing loss, patients are not restricted or not 
as restricted from many job applications and thus not limited to state grants, which would 
place the government under financial burden.  
Furthermore, with regards to non-maleficence, in all research involving the 
investigation of human participants, ethical approval is required in order to ensure the 
psychological and physical safety of each person. The need to conduct research ethically is 
vital to every research project and is essential to obtain credibility of the collected data 
(O’Leary, 2004). Therefore, firstly, permission to conduct this study was obtained from the 
University of the Witwatersrand’s Human Research Ethics Committee (Medical) (Appendix 
A). Subsequently, in addition, permission to conduct the study at the hospitals was obtained 
from the relevant hospitals CEOs. Lastly, permission from the individual patients 
participating was obtained. No change to the protocol took place without consideration and 
approval by the committee (see Appendices A and B). 
The research team did everything in their power to protect the life, health, dignity, 
integrity, right to self-determination, privacy, and confidentiality of personal information of 
the participants participating in the study. The research and data collection were conducted by 
individuals with the appropriate scientific training and qualifications. 
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5.6.4. Justice 
Justice in research demands that all participants or clinical subjects be treated fairly 
(Owonikoko, 2013). At the conclusion of the study, participants entered into the study were 
entitled to be informed about the outcome of the study. 
Daniels (2004) further discusses the principles of veracity as part of ethical research in 
human participants. This principle would refer to truthfulness. Deception can take many 
forms: intentional lying or non-disclosure of information or partial disclosure information. 
Nothing was hidden from the participants. 
After the three months of data collection or dropout from the study, participants were 
referred to the hospitals’ audiology department to continue monitoring of hearing, and for the 
management of possible hearing loss post DR-TB treatment (i.e. with hearing aids). Should 
HJH or SRH not have been in the participants’ catchment area, the department referred the 
participant to the relevant hospital. The participants were also fairly provided with money for 
their transport to the clinic/hospital for study-related procedures when they were not treated 
as inpatients. R 150.00 was provided for study visits where blood was drawn for study-related 
procedures, and hearing tests were done. This could take a day, and thus participants were 
compensated for missing a day of work. R 50.00 was provided for the participant's transport 
to go to their local clinical daily and receive their kanamycin/capreomycin injection during 
the study. Should this not have covered the transport, it was discussed on an individual basis 
and arrangements were made to increase this amount to R 70.00.  
5.7. Reliability, Validity, and Bias of Data 
Reliability and validity are the key indicators of the quality of a measuring instrument 
(Kimberlin & Winterstein, 2008). “In healthcare and social science research, many of the 
variables of interest and outcomes that are important are abstract concepts known as 
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theoretical constructs. Using tests or instruments that are valid and reliable to measure such 
constructs is a crucial component of research quality”. (Kimberlin & Winterstein, 2008, p 
2277). 
5.7.1. Reliability 
Reliability is a measure of precision or accuracy of an instrument (Roberts, Priest & 
Traynor, 2006; Heale & Twycross, 2015) and refers to the consistency of a measure 
(Gravetter & Forzano, 2011). There are different ways of estimating the reliability of any 
measure, which include the evaluation of the stability of the measures (test-retest reliability), 
the equivalence of sets of items from the same test (internal consistency) or different 
observers scoring a behaviour or event using the same instrument (interrater reliability) 
(Kimberlin & Winterstein, 2008). 
5.7.1.1. Stability or test-retest reliability. 
Stability is tested using test-retest and parallel or alternate-form reliability testing 
(LoBiondo & Haber, 2014). Test-retest reliability is assessed when an instrument is given to 
the same participants more than once under similar circumstances. A statistical comparison is 
made between participant’s test scores for each of the times they have completed it. This 
provides an indication of the reliability of the instrument (LoBiondo & Haber, 2014).  
Test-retest reliability was obtained when training the study coordinator. The study 
coordinator and an independent audiologist conducted PTA on the researcher. Testing was 
done within the same month, and responses were required to be within 5 dB of each other to 
ensure reliable testing procedures. This took place primarily to ensure interrater reliability, 
but also to ensure the stability and repeatability of the test. When results with PTA were 
within 5 dB, then the results were considered stable, and the efficiency of the study 
coordinator was adequate. Testing by the study coordinator and audiologist could not 
repeatedly be done on participants as they tired quickly. 
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Furthermore, the test-retest reliability of the audiological measures has undergone 
previous investigation during the development of the actual procedures. Franklin, McCoy, 
Martin & Lonsbury-Martin, (1992) investigated test-retest reliability of DPOAEs and 
concluded that the consistency of the measures was excellent. Furthermore, test-retest 
reliability for PTA was also shown to be excellent up to 12 kHz, yet with slightly more 
variability between 14 kHz and 16 kHz (Schmuziger, Probst & Smurzynski, 2004). However, 
Ahmed et al. (2001) showed test-retest reliability with UHFA was as reliable as the 
conventional audiometry.  
With regards to the pharmacokinetics, test-retest reliability was established with the 
mass spectrometer prior to the collection of participant samples. Serum levels with 
kanamycin and capreomycin were repeatedly tested to confer consistent results. This is 
explained further in 5.6.2.3. 
5.7.1.2. Equivalence or internal consistency. 
Internal consistency provides an estimate of the equivalence of sets of items from the 
same test, for example, a set of questions aimed at assessing the quality of life or disease 
severity) (Kimberlin & Winterstein, 2008). In this study, the audiological tests, in 
combination, aimed to assess ototoxicity; a protocol devised from consideration of various 
sources. 
The coefficient of internal consistency provides an estimate of the reliability of 
measurement and assumes that items measuring the same construct should correlate 
(Kimberlin & Winterstein, 2008). In split-half reliability, the results of a test, or instrument, 
are divided in half. Correlations are calculated comparing both halves. Strong correlations 
indicate high reliability, while weak correlations indicate the instrument may not be reliable 
(LoBiondo & Haber, 2014).  
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The reliability of the hearing tests was assessed with split-half reliability. The 
DPOAEs and PTA did show correlation. This ensued by looking at the frequencies in the 
PTA in relation to the frequencies of the DPOAEs that showed the most change through the 
various weeks. Although the greater change in the hearing was noticed on the DPOAEs, this 
was to be expected as DPOAEs are more sensitive. Yet, the correlation was not always 
noticed, which could indicate shortfalls in the reliability of the measures (Chapter 6 and 7). 
5.7.1.3. Interrater reliability. 
Interrater reliability, or interobserver agreement, establishes the equivalence of ratings 
obtained with an instrument when used by different observers (Kimberlin & Winterstein, 
2008). This test includes a process for qualitatively determining the level of agreement 
between two or more observers. This is used to assess the degree to which different 
raters/observers give consistent estimates of the same phenomenon (Zanarini, Frankenburg, 
Chauncey & Gunderson, 1987).  
As there was only one study coordinator, interrater reliability was not assessed during 
the study. Although at times, the researcher did conduct audiometry, it was not conducted at 
the same time on the same participant. This would have been difficult as the participants were 
ill and tired easily. They could not return the following day for the ‘re-test’, and the changes 
noted between the weeks were an indication of ototoxicity and not poor interrater reliability 
(when the researcher and study coordinator conducted testing on the same participant at 
different weeks). However, the researcher viewed the results, and inconsistencies were noted. 
No notable errors with testing were identified, and so testing was not repeated. 
5.7.2. Validity 
Validity is a measure of accuracy (Roberts et al., 2006) and refers to whether the 
study was able to scientifically answer the questions that it was intended to answer (Gravetter 
& Forzano, 2011). Validity requires a reliable instrument. However, the instrument can be 
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reliable without being valid (Kimberlin & Winterstein, 2008). Validity can be assessed by 
examining the internal and external validity, which encompass various aspects (Yu, 2017). 
Test validity is discussed further due to its specific relevance to this current study, followed 
by the inclusion of the pilot study to ensure the validity further. 
5.7.2.1. Internal validity. 
“Internal validity refers specifically to whether an experimental treatment/condition 
makes a difference in the outcome or not, and whether there is sufficient evidence to 
substantiate the claim” (Yu, 2017, p.1). It is concerned with correctly concluding that an 
independent variable is responsible for the variation of the dependent variable and can be 
affected when research participants try to figure out what is expected of them and perform 
accordingly (Kirk, 2009).  
Thus, in this study, the internal validity would refer to whether the pharmacokinetic 
factors were responsible for the lack of change of hearing the status of patients on kanamycin 
and capreomycin for DR-TB. Internal validity addresses whether an observation co-variation 
or experimental condition should be considered a causal relationship (Yu, 2017).  
Internal validity can be affected when research involves individuals, because of 
demand characteristics, which is when participants are told to perform a task; they try to 
figure out what is expected of them and perform accordingly. There were participant 
predisposition effects (such as genetic influences of susceptibility to aminoglycoside toxicity) 
as well as experimenter bias (Kirk, 2009). Because some of the measures were objective, 
such as with the audiological measures including tympanograms and OAEs as well as 
pharmacological testing, the participants and experimenter had no control over the outcome 
of these measures, which strengthened the internal validity.  
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There are various threats to internal validity which were noted, and subsequently, 
considerations were implemented to minimise these threats: 
• History: the specific events which occur between the first and second measurement 
(Yu, 2017). In this study, it could apply to the participant's activities between the study 
related procedures. It was difficult to track the medications that participants may or 
may not have taken between the study visits. However, in-depth counselling was 
conducted to explain the importance of complying with all study-related procedures. 
Furthermore, for the outpatients, the clinic sisters were required to sign when the 
participant received the injectable, and the participant was further required to complete 
a drug diary to track drugs ingested. However, it must be noted that there may have 
been deviations that were not reported. Furthermore, it is possible that participants 
were exposed to noise in between the study visits which could have affected the 
audiological outcomes. 
• Maturation: the processes within subjects which act as a function of the passage of 
time (Yu, 2017). As this study only took place over a maximum of 12 weeks for each 
participant, maturation was not affected. 
• Testing: the effects of taking a test on the outcomes of taking a second test. In other 
words, the pre-test becomes a form of "treatment" (Yu, 2017). Learning effects 
(practice or carryover effects) or experimental fatigue (physical and mental fatigue of 
participants) were considered (Savage & Waldman, 2008). The blood sampling and 
DPOAEs were objective measures, and thus the validity was not affected. With 
regards to PTA, the effects of the multiple tests could affect the validity, however, as 
tones were presented inconsistently, the participant could not ‘learn’ the response. 
• Instrumentation: the changes in the instrument, observers, or scorers who may 
produce changes in outcomes (Yu, 2017). This could include the personal 
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characteristics of the researcher, which influenced the choices made during a study; 
and non-verbal cues that the researcher gave out that may have influenced the 
behaviour and responses of participants. However, the study coordinator was 
instructed to maintain neutral throughout the audiology testing as well as a collection 
of information during the case report forms. 
• Experimental mortality: the loss of subjects this current study, where the sample size 
was smaller than expected, and so the validity of the outcomes need to be considered 
further in a larger sample. However, this study aimed to assess feasibility, and this 
aspect of validity impacted the feasibility. (Yu, 2017).  
5.7.2.2. External validity. 
External validity describes whether the causal relationship discovered can be 
generalised to other people, times and contexts (Rothwell, 2005). Threats to external validity 
relevant to this current study can include population and ecological validity. 
Population validity refers to the extent to which the findings can be generalised form 
the sample group towards a more substantial target population (Onwuegbuzie, 2000). As 
there are three outpatient treatment sites for DR-TB (involving smear negative DR-TB 
patients), and two of the three were included in this study, the researcher could assume that 
the accessible population is representative of the target population. Data was collected from 
all the participants who consented and fitted the inclusion and exclusion criteria. These 
criteria were determined to exclude variables that could contribute to hearing loss unrelated 
to the study aims. Although the sample was small, it should represent other patients receiving 
treatment for DR-TB in similar treatment regimens. 
Ecological validity refers to the extent to which the findings from a given study can 
be generalised across settings, conditions, variables, and contexts (Onwuegbuzie, 2000). This 
could influence the study, as the data and final results were dependent on the setting and 
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location it which they were obtained. The researcher will not attempt to minimise this effect, 
as the aim of the study is focused on this specific context, and on feasibility. Future research 
should aim to generalise to a different setting where DR-TB is treated. 
5.7.2.3. Test validity. 
Validity is defined as the extent to which a concept is measured accurately in a 
quantitative study. Validity is defined as the extent to which a concept is measured accurately 
in a quantitative study.  
Test validity: This category determines whether the instrument adequately covers all 
the content that it should with respect to the variable content 
Content validity examines whether the instrument adequately covers all content that is 
should with respect to the variable (Heale & Twycross, 2015). This can be considered with 
audiological and pharmacological measures:  
• Audiological Measures: Hearing tests were conducted using PTA and DPOAEs. 
High-frequency measures were conducted explicitly to detect early changes in hearing 
levels and cochlear functioning. Using both these measures allowed for the detection 
of sub-clinical changes to cochlear functioning, such as with DPOAEs as well as early 
changes with hearing levels as testing included up to 16 kHz with pure tones. 
Measures such as otoscopy, tympanometry, and noise monitoring ensured that the PTA 
and DPOAEs revealed valid data, and outer/middle ear status, as well as noise levels, 
were not affecting the results. 
• Pharmacological Measures: The instrument, namely the mass spectrometer, was 
chosen to detect the kanamycin and capreomycin levels in the serum. This occurred 
after the investigation of other methods, such as the use of an HPLC, which was not 
sensitive enough. 
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Construct Validity refers to whether one can draw inferences about test scores related 
to the content being studied; the extent to which a research instrument (or tool) measures the 
intended construct. 
• Audiological Procedures: The audiological tests used in this study have been 
validated. ASHA recommends the use of high-frequency PTA and DPOAEs to detect 
changes in hearing resulting from ototoxicity (ASHA, 1994). Thus, the validity of 
these measures has already been established. Also, the signal to noise ratio (SNR) 
assisted in determining validity. Those with SNRs below 3 dB were automatically 
discarded and viewed as a missing response. SNRs of 3 to 6 dB (inclusive) was 
initially planned to be analysed. However, it only included three readings of various 
participants during several weeks at different frequencies. As there were only three 
readings at a 3-5 dB SNR, with the majority at 6 dB or above, the results of the 6 dB 
SNR were utilised to ensure reliability and validity of the results. Additionally, two 
DPOAE readings obtained for each measure, with the assistance of the validity of the 
measures. The DP responses were averaged out, and then the single average was used.  
• Laboratory Procedures: The validity of the detection of the kanamycin and 
capreomycin levels in the serum was validated by the biochemist before the test. The 
following procedures were followed for the validation for data analysis: 
Sample Preparation: The samples were centrifuged (4000 revs per minute for 
10 minutes at 4o C) prior to storage and then stored immediately in a (between 
2 and 8o C) fridge if stored for seven days or less, or in a -80o C freezer if 
stored for more than a week. This was dependent on the laboratory’s 
availability to analyse the samples. 
Preparation of Standard Curve for Calibration and Sample Extraction: A stock 
solution of kanamycin (100 ppm) was prepared. From this secondary standard 
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was prepared (10 ppm) and used to fortify the following levels in blank serum; 
1.69, 4.99, 9.99, 16.65, 23.30, 33.30 µg/ml. 
- The sample extraction procedure involved deproteinising the samples 
using organic solvents. Three millilitres of acetonitrile (Merck or Sigma, 
grade) was added to 1 ml of serum. The samples were briefly vortexed and 
were then centrifuged using Beckman Coulter (AllegraTM X-22) centrifuge 
at 5000 g for 20 min at 4 0C. The supernatants were collected immediately; 
filtered using nylon syringe filters (0.22 µm, 13 mm) into a 2 ml vial, and 
subjected to LC-MS/MS analysis.  
Chromatography and detection 
- ASCIEX 3200Qtrap (SCIEX) mass spectrometer with turbo spray source 
was operated in both positive using an Agilent 1200 series binary pump 
system. Multiple reaction monitoring (MRM) was used with 5000 V at 
500° C source temperature. The curtain gas was set to 20 psi, with GS1 
and GS2 both at 40 psi. The CAD gas was set to 8 psi with the collision 
energy and declustering potential (DP) set to compound specific 
optimisation conditions (refer to MRM table). Chromatographic separation 
was achieved in a 14-minute gradient run using 350 µℓ/min flow rate on a 
Zorbax Extend C18, 2.1 x 100 mm, 3.5 µm particle size, 100 x 2.00 mm 
(Agilent) column at 40°C. The mobile phases were; A –3.2 mM 
ammonium formate, with 50 mM Heptafluorobutyric acid (Sigma Aldrich) 
in water (H2O); B – 0.1% formic acid in acetonitrile. Column conditions 
were kept at 95% A for the first minute, then gradually increased to 98% B 
over 2 minutes, and kept at 98% B for another 7 minutes, then returned to 
initial gradient conditions. The ion spectra were acquired by injecting 20 
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µL of the sample on the autosampler, and quantification was performed by 
comparing the peak areas with authentic matrix-matched standards of each 
compound as listed in Table 5.15. 
Table 5.15  
Multiple Reaction Monitoring for kanamycin and capreomycin 
Compound 
Precursor 
mass 
 (m/z) 
Production 
mass  
(m/z) 
Declustering 
potential  
(Volts) 
Collision 
energy 
(Volts) 
Kanamycin MRM1 485.300 163.1 41 35 
Kanamycin MRM2 485.300 324.4 41 25 
Capreomycin IA MRM1 669.360 98.3 111 91 
Capreomycin IA MRM2 669.360 507.2 111 37 
Capreomycin IA MRM3 669.360 127.1 111 95 
Capreomycin IB MRM1 653.367 98.1 126 91 
Capreomycin IB MRM2 653.367 491.3 126 35 
Capreomycin IB MRM3 653.367 70.0 126 101 
 
Criterion validity examines the ability of a measure to predict a variable that is 
designated as a criterion (Epstein, Preston, Stewart, & Shaham, 2006). This looks at the 
relationship between a test score and an outcome. Because much of the audiological testing 
was objective, there was no room for individual interpretation and subjective findings, which 
ensured the validity of the tests, in looking at the cochlear functioning. The equipment is 
calibrated annually which ensures that the results were indeed valid, and the equipment was 
working efficiently. 
5.7.2.4. Pilot study. 
Pilot tests can be viewed as ‘dress rehearsals’ of the full operation, in this case, a 
study with a larger population. It is implemented to determine whether existing problems can 
be addressed effectively before putting the entire production to play (Lavrakas, 2008).  
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As this data collection process had never been applied in practice, a pilot test was 
conducted to establish any possible issues that could arise. The purpose of this was to ensure 
that the data collection process and equipment was sufficient and contained every aspect that 
the researcher wanted to address in the study. By performing a pilot test, the researcher was 
able to highlight any shortcomings, mistakes, unnecessary or insufficient aspects and to 
correct and adjust the data collection sheet accordingly. The pilot test was conducted once the 
protocol received ethical clearance. It was part of the data collection process and involved the 
first five participants. After the first five participants, it was decided that the protocol could 
continue unchanged and these participants were included in the main study. 
5.7.3. Bias 
Bias can be defined as any systematic error with a tendency for selectivity or 
influence, meaning that the research findings deviate from the ‘true findings’. Bias can occur 
at any stage of the research (Pannucci & Wilkins, 2010). 
Sampling bias occurs when the sample is collected in such a way that some members 
of the intended population are less likely to be included than others. This effect was 
minimised through the means of using the same protocol in the various contexts. Purposive 
sampling was also done to include all participants that would qualify according to inclusion 
and exclusion criteria. 
Analytical bias results from differences in methods and techniques used to evaluate 
the results. All results were evaluated using the same method and technique to capture and 
analyse data. 
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5.8. Data Management and Analysis 
All data was captured and managed as per procedures at the CHRU at Wits Health 
Consortium. All participants were given a study number generated by a specified database. 
Thus, all data could be synchronised. 
The quality assurance of data was ensured via various aspects. In the design phase of 
the study, the project aims guided the development of the case report forms for the collection 
of data. This took place to ensure quality (rather than quantity) of data as well to ensure all 
the steps of the data collection could be adhered to (Needham et al., 2009). These data 
collection forms were drawn up in collaboration with a skilled data management team at 
CHRU. 
In the data collection phase, standardised data collection forms were utilised for all 
the participants (Needham et al., 2009). These data collection forms adhered to the GCP 
guidelines and layout of the general CHRU data collection forms. This was done to ensure 
that the study coordinator and data capturers were familiar with the forms to ensure the 
correct capturing of data.  
Furthermore, the data management included comprehensive staff training, and a well-
designed database can help maximise the quality of the data (Needham et al., 2009). The 
researcher conducted the staff training (for the study coordinator and data capturers). The 
training included the clear explanation of specified defined data elements. Also, the data 
collection forms were reviewed by data manager at CHRU to ensure a quality according to 
their standards. Additionally, the database was designed by the database design IT employee 
at CHRU. The data capturer captured the data monthly on this specified secure database. 
Quality assurance reviews of both collection and entry and system-based controls 
reduce the likelihood of error (Needham et al., 2009). The data manager assisted with the 
review of captured data onto the database, while the researcher reviewed the paper-based data 
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as well. This was to ensure that missing data should be identified quickly and corrected with 
system-based controls to minimise the missing data. This missing data, however, was not 
always recovered due to the nature of the outpatient study design, which was a shortfall in the 
quality assurance plan in the current study. 
Finally, in the data analysis phase, sensitivity analysis aided in managing and 
understanding the effects of missing data and outliers (Needham et al., 2009). Due to the 
small sample size, the data were analysed descriptively using tables, graphs, means, medians, 
and standard deviations.  
All data used Microsoft Excel as an analysis tool. Audiological results were analysed 
according to change from the baseline at the various frequencies. The mean values were 
considered for each ear separately. 
The pharmacokinetic results analysed the results in relation to the hearing levels, yet 
for both ears combined as well, in comparison to the ears separately. The mean peak and 
trough values were analysed for kanamycin and capreomycin separately, throughout the 
weeks, as well as the half-lives, volumes of distribution and dosages where possible. The 
mean creatinine values were used. 
5.9. Conclusion 
This chapter detailed the method of this study, including the design, sample selected 
and the research team. It then described the data collection process including the forms and 
equipment used as well as procedures. Ethical guidelines were discussed, as well as validity 
and reliability measures. Lastly, data analysis procedures were discussed which were used to 
analyse the data that are presented in Chapter 6. 
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Chapter 6: Results 
This chapter describes the findings of the study in a clinically descriptive manner 
according to the aims of the study. Firstly, the audiological results of the study have been 
described, followed by the pharmacokinetic results, and subsequently the relationship 
between the audiology and pharmacokinetics. The chapter concludes with the main aim, 
namely the feasibility component. 
6.1. Audiological Results 
This section addresses the following sub-aims of this study: 
To determine the changes in hearing levels in patients undergoing treatment with 
kanamycin and capreomycin for DR-TB. 
• To determine the prevalence of abnormal findings on baseline hearing assessments. 
• To determine the change in hearing levels from baseline. 
These sub-aims will be addressed by discussing PTA, and subsequently the DPOAEs. 
Each ear will be described as separate entities initially, and then correlated after. The various 
frequency ranges will be described. 
6.1.1. Pure Tone Audiometry  
The results are presented in three frequency ranges; namely low frequencies, high 
frequencies and ultra-high frequencies. Low frequencies are, for the purpose of this study, 
0.25 kHz until and including 2 kHz, whilst high frequencies are described as frequencies 
between and including 3 kHz and 8 kHz as measured on the conventional audiogram (Seddon 
et al., 2012). Ultra-high frequencies in this current study are specified as 9 kHz until and 
including 16 kHz.  
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The mean thresholds for all participants were calculated at each frequency for the 
seven study visits (T0 - T6) and are presented in the three frequency ranges for the right ear 
(Table 6.1) and the left ear (Table 6.2). 
In addition, the hearing loss for all participants is graded according to the existing 
adult grading scales for hearing loss, namely the TUNE and CTCAE scales. The ASHA 
(1994) criteria are also used to describe the hearing loss, however, is not considered a grading 
scale. 
The CTCAE, although designed for children, has adult applications, yet only grades 
up to 8 kHz. The CTCAE consists of four grades, from a threshold shift of 15-25 dB from 
baseline at two or more adjacent frequencies in at least one ear (grade 1), a threshold shift of 
greater than 25 dB to 90 dB in at least two adjacent frequencies in at least one ear (grade 2), 
the requirement of intervention such as 25-90 dB, averaged at three adjacent test frequencies 
in at least one ear (grade 3) to the final grade 4 of requiring a cochlear implant (Durrant, et al, 
2009). The TUNE scale, in contrast, grades up to 12.5 kHz, but also grades up to grade 4. It, 
however, consists of grade 0 indicating no hearing loss, with grade 4 being a hearing level 
≥70 dB at 1 kHz to 4 kHz. Grades 1 and grade two contain an ‘a’ and ‘b’ which both discuss 
the same in decibel loss in the respective grade, however, include different frequencies. 
Grade 1 indicates a change of greater than 10 dB, with grade 2 indicating a shift of more than 
20 dB. The ‘a’ for both grades refers to frequencies between 8 kHz to 12.5 kHz, with the ‘b’ 
indicating a change from 1 kHz to 4 kHz. Subsequently, grade 3 indicates a hearing level of ≥ 
35 dB at 1 kHz to 4 kHz (Theunissen et al., 2014). The ASHA criteria, on the other hand, 
define a significant change from baseline, yet does not differentiate the frequencies (Konrad-
Martin et al., 2005). 
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6.1.1.1. Low frequencies. 
The low frequencies are from 0.25 kHz to2 kHz, inclusive. In both ears, minimal 
changes in hearing thresholds occurred across the study visits as the mean thresholds were all 
between 16 dB and 25 dB, showing a slight hearing impairment (ASHA, 2015). The right 
ears showed its most significant change at 0.5 kHz of 7 dB where the left ears largest 
threshold change was at 2 kHz of 3 dB. However, both ears showed no clinically significant 
change at the low frequencies and no ototoxicity was observed (Tables 6.1 and 6.2). This loss 
of hearing does not fit the criteria to be graded. 
6.1.1.2. High frequencies. 
The higher frequencies in the conventional audiogram are from 3 kHz to 8 kHz. In 
both ears, it is evident that hearing thresholds deteriorated over time from T0 to T6. See 
Tables 6.1 and 6.2.  
As participants were required to respond behaviourally, results could not always be 
obtained. When participants were tired and sickly, they did not want to and/or could not 
participate reliably. This occurred three times; twice at T2 and once at T4. The PTA results 
were not conducted at 9 kHz for one participant at T1, and so all the other participants mean 
results were used. In the right ear, the significant changes were observed at 6 kHz and 8 kHz 
from T0 to T6 (10 dB or greater mean change) (Table 6.1). At 6 kHz and 8 kHz, the hearing 
can be classified as a mild hearing loss (ASHA, 2015), as well as it can be graded according 
to the TUNE scale and acknowledged as significant according to the ASHA criteria.  
The left ear, in contrast, shows a significant shift at only 8 kHz of 10 dB. This can be 
graded as a grade 1a according to the TUNE grading scale, which is a threshold shift ≥ 10 dB 
at 8 kHz to 12.5 kHz. It does not fit the criteria for a grade on the CTCAE scale nor the 
ASHA system (Table 6.2). 
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6.1.1.3. Ultra-high frequencies. 
Ultra-high frequencies in this study are considered from and including 9 kHz up to 
and including 16 kHz. It is important to note that at 16 kHz specifically, a limitation was 
observed, as the audiometer was only able to record a hearing loss of 55 dB and better 
(PATH manual, 2015). During data collection, for participants with a threshold of ≥ 56 dB, 
the results were recorded as no response. However, for statistical and graphical reasons, these 
participants' thresholds were recorded at 55 dB, despite that assumption that their thresholds 
were ≥ 56 dB. Although we know that their hearing loss is greater, we cannot assume at what 
dB level the threshold is at, and so a 55 dB was recorded for these participants. As will be 
observed below, 16 kHz showed a lesser hearing loss than the other ultra-high frequencies.  
In both ears, the greatest change in hearing levels in noticed in these UHFs above 8 
kHz: the greatest change in hearing was at 11.2 kHz bilaterally.  
In the right ears, the smallest change was noted at 16 kHz of 11 dB; however, this is 
possible a skewed result as those with no responses were still recorded at 55 dB. All the ultra-
high frequencies in the right ear showed significant change, while only 9 kHz, 10 kHz, and 
11.2 kHz showed a significant change in the left ears Tables (6.1. and 6.2).
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Table 6.1  
Mean Pure-Tone Thresholds: Right Ear 
Frequencies (kHz) 
Mean Pure-Tone Thresholds (dB) (right ear) 
T0 
(n = 22) 
T1 
(n = 15) 
T2 
(n = 9) 
T3 
(n = 9) 
T4 
(n = 9) 
T5 
(n = 7) 
T6 
(n = 6) 
Low frequencies 0.25 19.77 21.00 20.56 21.00 26.11 20.71 24.17 
0.5 21.36 21.67 22.78 22.78 25.00 22.14 27.50 
1 18.64 19.33 18.89 18.89 22.22 20.71 21.67 
2 14.55 13.00 17.22 15.56 16.11 16.43 19.17 
High frequencies 
(* Grade 1a, #) 
3 17.73 17.67 21.11 21.11 22.22 20.00 20.83 
4 15.00 17.33 16.11 18.89 20.00 17.14 17.50 
6 15.91 22.00 20.00 27.22 28.33 20.00 25.83 
8 20.45 23.67 26.67 26.11 27.78 30.71 32.50 
Ultrahigh frequencies 
(* Grade 1a, #) 
9 19.09 22.14 23.89 28.33 32.78 32.86 35.83 
10 19.55 21.00 23.33 30.00 33.89 33.57 39.17 
11.2 20.68 28.00 31.67 33.89 38.89 39.29 46.67 
12.5 29.55 35.67 41.11 42.22 46.67 46.43 50.83 
14 36.14 43.33 49.44 50.00 55.56 48.57 56.67 
16 35.91 42.67 45.00 46.11 46.11 42.86 46.67 
Note: *TUNE: Significant change from T0 (baseline) to T6, +CTCAE: Significant change from T0 (baseline) to T6, # ASHA: Significant change from T0 
(baseline) to T6 
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Table 6.2  
Mean Pure-Tone Thresholds: Left Ear 
Frequencies (kHz) 
Mean Pure-Tone Thresholds (dB) (left ear) 
T0 
(n = 22) 
T1 
(n = 15) 
T2 
(n = 9) 
T3 
(n = 9) 
T4 
(n = 9) 
T5 
(n = 7) 
T6 
(n = 6) 
Low frequencies  0.25 19.77 20.67 19.44 20.00 20.56 17.86 21.67 
0.5 23.64 21.33 17.78 22.78 24.44 21.43 24.17 
1 22.27 20.67 19.44 20.00 22.22 19.29 21.67 
2 16.36 15.67 17.78 16.67 17.22 15.00 19.17 
High frequencies  
(* Grade 1a) 
3 18.18 18.00 20.56 20.56 18.89 18.57 19.17 
4 16.14 19.67 18.33 21.11 25.00 20.71 21.67 
6 19.55 21.33 20.00 24.44 30.00 24.29 24.17 
8 21.82 24.67 23.89 30.56 31.11 33.57 31.67 
Ultrahigh frequencies  
(* Grade 1a. #) 
9 17.73 21.43 23.33 29.44 27.78 35.71 30.83 
10 17.05 21.67 23.33 30.00 30.00 37.86 30.83 
11.2 22.27 33.33 27.22 36.11 36.11 35.71 35.83 
12.5 26.14 30.33 32.22 37.78 35.56 37.14 32.50 
14 32.27 37.00 41.67 43.33 43.33 40.71 34.17 
16 30.00 30.67 43.33 40.00 41.11 35.71 39.17 
Note: *TUNE: Significant change from T0 (baseline) to T6, +CTCAE: Significant change from T0 (baseline) to T6, # ASHA: Significant change from T0 
(baseline) to T6 
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6.1.1.4. Summary of Pure Tone Audiometry. 
In conclusion, the basic audiological pattern of hearing loss was similar bilaterally, in 
that the low frequencies were affected minimally, 8 kHz in the high frequencies was most 
affected, and 11.2 kHz in the ultra-high frequencies was most affected. However, the right 
ears displayed a more clinically significant hearing loss than the left ears according to the 
PTA. 
6.1.2. Distortion Product Otoacoustic Emissions 
There are several DPOAE results missing for participants, due to equipment issues 
and SNR variations. This occurred four times in total. Yet, in another two instances, only 
some DPOAE results were missing at some frequencies in the right ears. This occurred at T1 
where the DPOAE results were missing in 6 kHz, 8 kHz and 12 kHz in the right ear, as well 
as at T5, where the right ears DPOAE results were missing at 6 kHz, 8 kHz, and 10 kHz. 
Repeat readings were not obtained at these frequencies and thus discarded. 
Those with SNRs below 3 dB were discarded automatically and viewed as a missing 
response. SNRs of 3 - 5 dB (inclusive) was planned initially to be analysed. However, it only 
included two readings of various participants during various weeks at different frequencies. 
As there were only two readings at a 3-5 dB SNR, with the majority at 6 dB or above, the 
results of the 6 dB SNR were utilised. 
DPOAEs were not split with the frequency ranges when analysed, as were the pure 
tone results. This is due to the fact that fewer frequencies were tested using the DPOAEs; 
from 2 kHz to 12 kHz, with six frequencies in total bilaterally. Two DPOAE readings were 
obtained for each measure. The DP responses were averaged out, and then the single average 
was used.  
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE 
RELATIONSHIP BETWEEN HEARING LEVELS: A FEASIBILITY STUDY 
205 
6.1.2.1. Low to ultra-high frequencies. 
In both ears (Tables 6.3 and 6.4), DPOAE responses were recorded from baseline 
(T0) to week 12 (T6). Significant changes of 6 dB or greater, from baseline to week 12, were 
noted at all frequencies bilaterally, except for 12 kHz in the left ear, where a change of 5 dB 
was noted. 
Table 6.3  
Distortion Product Otoacoustic Emission Mean Thresholds: Right Ear 
Frequencies (kHz) 
DPOAE Thresholds (dB) (right ear) (SNR=6 dB+) 
T0 
(n = 22) 
T1 
(n = 15) 
T2 
(n = 9) 
T3 
(n = 9) 
T4 
(n = 9) 
T5 
(n = 7) 
T6 
(n = 6) 
Low frequency 2* 10.76 5.71 2.80 3.06 2.10 1.29 -1.92 
High frequencies 4* 8.17 2.67 2.40 0.22 -2.70 -0.71 -0.67 
6* 6.00 -2.32 -2.55 -5.61 -6.50 -3.00 -7.50 
8* 2.21 -5.50 -5.25 -6.00 -8.28 -7.83 -10.50 
Ultrahigh 
frequencies 
10* 4.52 -1.17 -3.20 -8.28 -8.75 -7.83 -12.00 
12* -5.45 -9.60 -5.50 -13.44 -12.94 -14.50 -15.75 
Note: *significant change from T0 (baseline) to T6 
Table 6.4  
Distortion Product Otoacoustic Emission Mean Thresholds: Left Ear 
Frequencies (kHz) 
DPOAE Thresholds (dB) (left ear)(SNR=6 dB+) 
T0 
(n = 22) 
T1 
(n = 15) 
T2 
(n = 9) 
T3 
(n = 9) 
T4 
(n = 9) 
T5 
(n = 7) 
T6 
(n = 6) 
Low frequency  2* 5.33 3.04 1.50 1.11 0.56 1.50 -3.00 
High 
frequencies  
4* 2.21 -3.08 -1.55 -2.44 -6.75 -3.21 -7.58 
6* 0.67 -4.08 -1.40 -3.17 -7.25 -4.07 -8.83 
8* -2.07 -7.33 -4.40 -6.78 -7.80 -9.43 -9.17 
Ultrahigh 
frequencies 
10* 1.40 -6.67 -5.60 -7.67 -9.10 -9.00 -8.67 
12 -4.68 -9.18 -6.39 -10.67 -10.11 -5.50 -10.00 
Note: *significant change from T0 (baseline) to T6 
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6.1.2.2. Summary of DPOAEs. 
In summary, the right ear, as for PTA, on average showed a greater shift when 
compared to the left ear. The ears showed the greatest loss in amplitude in different 
frequencies as well. However, both ears showed reduced amplitude over time in all 
frequencies (except at 12 kHz in the left ear). 
6.1.3. Comparison of Pure Tone Audiometry and DPOAEs 
Overall, PTA showed decreased hearing acuity while the DPOAEs showed reduced 
OHC function in the cochlea from baseline to week 12. Both PTA and the DPOAEs showed 
that the right ear displayed greater loss of hearing and cochlear function respectively than the 
left ears. However, PTA did not identify a significant loss of hearing at 2 kHz, where, the 
DPOAEs did. The high-frequency hearing loss identified is in accordance with literature, 
where DPOAEs are more sensitive than PTA (Guthrie, 2008). The PTA showed the most 
significant shift at 11.2 kHz, where the DPOAEs showed the most significant shift at 10 kHz. 
This does PTA does not correlate entirely with the DPOAEs. However, 11.2 kHz was not 
measured with the DPOAES due to limits of the DPOAE machine, and thus this frequency 
could not be compared with a DPOAE response. In the left ear, 4 kHz displayed the greatest 
change with the DPOAEs, which does not correlate to the 11.2 kHz with the PTA. 
6.1.4. Symmetry of Hearing Loss 
For this current study, symmetry was defined as similarity in dB responses within 10 
dB between ears, based on the combination of various opinions (Djalilian, 2015; Mabgham, 
1991; Sabini, 2000; Urben, Benninger & Gibbons, 1999).  
Sabini (2000) considered the asymmetrical hearing loss as 10 dB or greater in 2 
consecutive frequencies or 15 dB in any one frequency between 0.25 and 6 kHz (Sabini, 
2000). Djalilian (2015) defined asymmetric hearing loss as a difference of 15 dB between the 
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right and left ears at three contiguous frequencies while Pittman and  Stelmachowicz (2003) 
describe asymmetric losses as more than 20 dB at one or more test frequencies. Another 
approach by Mangham (1991) of asymmetry analysed it as an average interaural difference of 
greater than 10 dB at 1, 2, 4, and 8 kHz. Urben et al. (1999) defined asymmetrical hearing 
loss as asymmetries of 10 dB or greater at two or more frequencies or 15 dB or greater at one 
frequency. 
 No clear-cut definition has been found for asymmetry, specifically for ototoxicity 
that includes ultra-high frequencies. As 10 dB for PTA (Konrad-Martin et al., 2005) and 6 dB 
for DPOAEs (Roede et al., 1993) was considered a significant change in this current study, it 
was also used to describe significant asymmetries for the specified individual frequencies. 
Hearing loss resulting from aminoglycosides is symmetrical (Harris & Heinze, 2015). 
The symmetry of the ears with PTA and DPOAEs are presented in Tables 6.5 and 6.6 
respectively. The left ears’ decibel response for both PTA and DPOAEs was subtracted from 
the right ears’ response at each frequency for kanamycin and capreomycin. 
The asymmetry differs on PTA and DPOAEs. Asymmetry was noticed on visits T1, 
T4 and T6 with PTA, yet on visits T0, T1, T5 and T6 with DPOAEs. 
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Table 6.5  
Symmetry of PTA: Right Ear dB Response (MEAN) Minus Left Ear dB Response (MEAN) 
kHz  T0 T1 T2 T3 T4 T5 T6 
3 kHz 0 0 1 1 3 1 0 
4 kHz -1 -2 -2 -2 -5 -4 -4 
6 kHz -4 1 0 3 -2 -4 1 
8 kHz -1 -1 3 -4 -3 -3 1 
10 kHz 3 -1 0 0 4 -4 7 
11.2 kHz -2 -5 4 -2 3 -2 9 
12.5 kHz 3 5 9 4 11* 9 16* 
14 kHz 4 6 8 7 12* 8 19* 
16 kHz 6 12* 2 6 5 7 6 
Note: *Asymmetry (Difference of ≥10 dB)  
 
Table 6.6  
Symmetry of Distortion Product Otoacoustic Emissions: Right Ear dB Response (MEAN) Minus 
Left Ear dB Response (MEAN) 
 kHz  T0 T1 T2 T3 T4 T5 T6 
2 kHz 5 3 1 2 1 0 1 
4 kHz 6* 6* 4 2 4 3 6* 
6 kHz 5 1 -1 -2 1 2 1 
8 kHz 4 1 -1 1 0 3 -1 
10 kHz 3 6* 2 -1 0 2 -3 
12 kHz 0 -1 1 -3 -2 -8* -5 
Note: *Asymmetry (Difference of ≥6 dB)  
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Furthermore, audiological history was taken at the baseline, and already, eight 
participants reported difficulty localising (n = 4 from HJH, n = 4 from SRH). This was before 
the DR-TB treatment was started and before asymmetry was noted. 
Yet, half of the participants displayed some sort of mild hearing loss at baseline, 
ranging from 30 dB in a single frequency to 40 dB in four frequencies bilaterally. 
6.1.5. Percentage and Overall Changes in Hearing/Cochlear 
Function 
The overall changes in hearing and cochlear function from baseline at the various 
frequencies are outlined in Table 6.7; DPOAEs are shown from 2 kHz to 12 kHz, while PTA 
is shown from 3 kHz to 16 kHz. Each participant has two results under each of these 
frequencies. The top result is of the right ear, while the bottom is the left ear. These PTA 
results are then related to the various grading scales and their applicability. As there is no 
grading scale for DPOAEs, any loss of 6 dB or greater was considered a loss and marked as 
‘yes’.  
In some instances, with PTA, loss of hearing is observed in the ultra-high frequencies, 
yet not depicted as a gradable loss on a grading scale. For example, participant 2 showed a 
change of 10 dB in three frequencies in the right ear and 10 dB in the left ear, however, they 
are not consecutive frequencies.  
Although the sample size was small, and the percentage is not entirely suitable for 
such a small sample, it depicts how different the results can be, based on the different grading 
scales used. The number of participants that experienced hearing loss thus further described 
as a percentage. Fifteen participants completed more than the baseline measurements, and so 
these were used to calculate the percentage. 
When looking at the DPOAEs, all participants had readings showing a significant 
change of at least 6 dB in at least one frequency in at least one ear. This could be regarded as 
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100% of the participants had loss of cochlear function. Different percentages can be 
described with PTA, depending on which frequencies and grading scales used. 
When using at the TUNE grading scale, 14 of the 15 could be graded with a hearing 
loss; whenever they completed the study, whether at T1 or T6. This shows that 93% 
experienced some sort of loss of hearing. The CTCAE only graded up to 8 kHz, and thus only 
identified one hearing loss (7%). The ASHA method to describe hearing loss identified 14 of 
the 15 participants with significant hearing loss (93%). The ASHA scale did not specify the 
specific frequencies that it includes, and so it was used for all the frequencies up to and 
including 16 kHz.  
Thus, depending on which frequency range is used to describe hearing loss, between 
7% to 93% of participants experienced ototoxicity. However, 7% experienced this at 8 kHz or 
below. Although the sample is small, it still indicates the different results based on the 
different grading scales used. 
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Table 6.7  
Overall Change in Hearing from Baseline with Ototoxicity Grading Scales (right and left ears) 
Grading Scales DPOAE Level (dB) PTA (dB) (Overall change from baseline to week of dropout) 
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1 0,1,2 
R YES 2a - YES -19.5 -3 -7 -20 -9 -9 -5 5 0 -10 0 -5 -30 -50 -45 -5 
L YES 1a - YES -7 -8 -8.5 -1 -13 -6 0 -5 0 -5 0 -5 -5 -10 -15 -60 
2 0,1 
R - 0 - NO * * * * * * 0 0 -15 0 -5 0 -10 -5 -5 -15 
L - 1a - NO * * * * * * 0 0 5 -10 -5 0 0 -5 -5 -10 
4 
0,1,2,3,4
,5,6 
R YES 1a - YES -9.5 -12 -8.5 -13 -10.5 -15 0 -10 -10 -5 -5 -5 0 -10 -10 -10 
L YES 0 - NO -6 -5.5 -8 -10 -5.5 -7.5 -5 -5 -10 -5 0 0 -5 -5 -10 -5 
5 
0,1,2,3,4
,5,6 
R YES 1a - YES -13 -12 -21.5 -10 0 0 5 -5 -15 -5 -10 -5 -10 -5 -10 -5 
L YES 2a - YES -11.5 -13 -16 -13.5 -22 -20 -10 -10 -5 -10 -25 -25 -35 -35 -45 -35 
6 0,1,2 
R YES 0 - YES -7.5 -1 -6 8 -6 -7.5 0 -5 0 -5 0 5 -5 -10 -35 0 
L YES 0 - YES -1 -7.5 1.5 -2.5 -5.5 -1 -5 -5 5 0 0 0 0 -5 0 -30 
7 
0,1,2,3,4
,5,6 
R YES 2a - YES -8 -13 -1.5 -20 -17 -29 0 -5 -5 -10 -10 -15 -50 -50 -60 -50 
L YES 0 - YES -16 -7.5 -6.5 -7.5 -11 0 0 -5 0 -5 -15 -5 -5 
0 
 
-5 -25 
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Grading Scales DPOAE Level (dB) PTA (dB) (Overall change from baseline to week of dropout) 
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8 
0,1,2,3,4
,5,6 
R YES 2a - YES -4 -4 -16.5 -18 -14.5 -15 0 0 -10 0 -10 -10 -50 -40 -30 -10 
L YES 1a - YES -12.5 -6 -13 -5.5 -7 -17.5 -5 0 -10 0 -10 -5 -10 -10 -15 -10 
9 
0,1,2,3,4
,5,6 
R YES 1a - YES -29 -6.5 -16 -16 -16 -4.5 -10 0 -10 -5 0 -5 -15 -10 -30 -15 
L YES 1a - YES -7 -8 -10 -8 -14 -17 0 0 -5 -5 -5 -10 -15 -15 -15 -25 
10 
0,1,2,3,4
,5,6 
R YES 2a - YES -10.5 -18 -6 -18 -20 -15 0 -5 0 -35 -50 -45 -50 -35 0 -5 
L YES 2a - YES -7 -1 -4 -2 -12 0 15 10 5 -15 -35 -50 -20 0 0 0 
12 0,1 
R YES 2a 1 YES -11 -6 -23 -8 -36 -34.5 -5 -5 -15 -15 -45 -55 -70 -65 -60 -50 
L NO 1a - YES -1 0 1.5 2.5 -4 -3.5 15 10 10 0 10 0 -15 -15 -20 0 
14 0,1,2,4 
R YES 1a - YES -11.5 -8.5 -1.5 -1.5 -18 -6 -5 0 0 -5 -5 -10 -5 -15 -10 -10 
L YES 1a - YES -11.5 -10.5 -17.5 -10 -17 -22 0 0 -10 -10 0 -5 -5 -10 -35 -30 
15 0,1, 
R YES 1a - YES -6 0.5 -14 -11 -6 0 0 0 -10 -10 5 5 -10 -10 0 -5 
L YES 1a - YES -0.5 -5 -5.5 -5.5 -20 -1.5 0 -15 -10 -10 0 -15 -10 -10 -15 0 
16 0,1,2,3,4 
R YES 2a - YES -10 -4 -9 -5.5 -5.5 -4 -10 5 0 0 0 0 -10 -20 -5 -5 
L YES 1a - YES -7 -4.5 0 0 -9.5 -0.5 -5 -10 -5 -10 0 0 -5 0 -20 -5 
17 0,1,2,3,4 R YES 2a - YES -11 -20.5 -32 -21.5 -27.5 -6.5 -20 -10 -45 -25 -20 -20 -15 -20 -10 0 
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Grading Scales DPOAE Level (dB) PTA (dB) (Overall change from baseline to week of dropout) 
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L YES 1a - YES -23.5 -23.5 -27 -3.5 -20.5 0.0 5 -25 -45 -5 0 -20 -20 -10 10 -5 
18 0,1,3,4,5 
R YES 1a - YES -15 -24 * * * -16 0 -5 0 0 -10 -10 -15 -10 -20 -20 
L YES 2a - YES -3 -9 -3 -8 0 -1 0 -5 -5 -10 -15 -25 -15 -25 -10 0 
Note: ‘-‘ indicates no grade is applicable, * Missing data due to poor signal to noise ratio, TUNE Grading system only grades up to 12.5 kHz and does not include 9 and 11.2kHz. CTCAE 
only grades up to 8 kHz. ASHA is for all the frequencies, Audiology results not included for those that dropped out before week 2, Audiology results included are at last study visit before 
dropout or last audiology results available. Yellow shading indicates the limits of the audiometer. 
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6.1.6. Weeks of Greatest Change in Hearing/Cochlear Function 
The time period/ study week that displayed the greatest change with PTA and 
DPOAEs was examined in further detail. Although this was not a direct sub-aim, it is 
important to establish to assist in the development of an ototoxicity monitoring protocol. 
Table 6.8 shows the specific weeks where the greatest mean change in PTA (high and 
ultra-high frequencies) and DPOAEs occurred. The means were calculated with the ears 
combined. The most significant changes with DPOAEs from the previous study visit was 
noted at week 2 at 2 kHz, 8 kHz, 10 kHz, and 12 kHz. The greatest changes with PTA from 
the previous study visit was noted at both weeks 2 (11.2 kHz, 12 kHz and 14 kHz) and 6 (6 
kHz, 8 kHz, and 10 kHz). 
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Table 6.8  
Study Weeks of Biggest Mean Change in dB at various frequencies from the previous study visit 
  
OAE (dB) PTA (dB) 
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Week 2 -4.08 -3.65 -4.35 -5.15 -6.31 -3.98 1 -1.67 -3.00 -3.17 -3.39 -3.67 -10.17 -7.83 -8 -5.17 
Week 4 -2.64 0.00 0.02 -0.65 -2.44 -1.20 -2.11 1.94 3.56 3.17 -1.33 -1.33 0.72 -2.44 -3.11 -4.00 
Week 6 -0.64 -1.52 -1.45 -1.81 0.11 -1.35 -1.11 -2.50 -6.11 -3.53 -2.78 -3.89 -1.94 -0.56 0.00 -0.28 
Week 8 -1.35 -4.06 -3.17 -1.06 -2.39 -0.45 0.28 -2.50 -2.78 -1.19 -0.83 -1.94 -2.50 -1.11 -2.78 -1.39 
Week 10 1.07 2.12 3.18 -1.29 2.14 -1.81 0.52 2.58 4.05 -2.78 -5.24 -3.10 -2.18 -4.13 -1.47 0.12 
Week 12 -3.52 -1.77 -4.86 -1.83 -3.57 -2.92 0.60 -0.77 -1.96 -0.83 -1.01 -1.07 -6.01 -1.85 -3.81 -5.54 
Week of biggest 
change from 
previous study visit 
2 8 12 2 2 2 4 10 6 6 10 6 2 2 2 12 
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6.1.7. Differences in hearing for participants on treatment with 
kanamycin and capreomycin 
At SRH, capreomycin was used when those taking kanamycin started to show a 
decline in hearing. They were subsequently switched onto capreomycin to reduce the 
ototoxicity. These differences in change in hearing and cochlear function were therefore 
examined at weeks 10 and 12 using the PTA and DPOAEs. 
Table 6.10 depicts the change in cochlear function (DPOAEs) and change in hearing 
(PTA) from baseline for weeks 10 and 12. Week 10 was included as there was only one 
participant on capreomycin at week 12. The frequencies with an asterisk show where 
kanamycin resulted in more ototoxicity than capreomycin. Hence without an asterisk is where 
capreomycin resulted in more ototoxicity.  
It is difficult to ascertain whether kanamycin or capreomycin is more ototoxic 
according to this study. Often, the participants that were experiencing ototoxicity were 
switched to capreomycin. Therefore, it is possible that these patients were more susceptible to 
ototoxicity and cannot to be attributed to the toxicity of the drug, but possibly to other factors. 
However, the differences at week 10 and 12 were calculated. It is important to note 
that the capreomycin column includes participants that were not necessarily on capreomycin 
throughout the study, as they all started on kanamycin. Hence, weeks 10 and 12 were used to 
allow a better determination of hearing loss from capreomycin. The values in Table 6.9 are 
means values of the participants and ears combined at the relevant frequency and specific 
week 10 or week 12.
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Table 6.9  
Differences in hearing loss between kanamycin and capreomycin at weeks 10 and 12: Change in dB in right and left ears combined from baseline 
Measure 
Frequency 
(kHz) 
Week 12 Week 10 
Capreomycin  
(n = 1) 
Kanamycin  
(n = 5) 
Capreomycin  
(n = 2) 
Kanamycin  
(n = 5) 
Mean SD Mean SD Mean SD Mean SD 
DPOAE (dB) 2* -8.8 2.5 -11.2 7.1 -6.5 6.2 -8.1 4.5 
4 -9.5 12 -8.9 3.4 -11.4 10.1 -5.4 4.2 
6* -5 1.4 -10.6 5.9 -3.5 1.3 -6.5 8.9 
8* -10 11.3 -11.8 4.8 -9.3 8.1 -10.2 5 
10 -16 5.7 -12.5 6.4 -10.7 10.1 -8.4 6.2 
12* -7.5 10.6 -11.7 9.4 -8 8.7 -9.1 10.6 
PTA (dB) 3* 7.5 10.6 -0.8 4.9 0 0 -2 2.6 
4* 2.5 10.6 -2.9 3.9 0 7.1 -3 2.6 
6* 2.5 3.5 -6.3 4.2 -1.3 2.5 -5.5 9.3 
8 -25 14.1 -8.3 3.3 -15 14.7 -4.5 6.4 
9 -42.5 10.6 -14.6 7.4 -27.5 18.5 -8 10.6 
10 -47.5 3.5 -15 7.1 -32.5 18.5 -6.5 12 
11.2 -35 21.2 -22.1 18.6 -25 16.8 -12.5 18.4 
12.5*  -17.5 24.7 -17.9 17.2 -17.5 15.5 -15.5 19.4 
14* 0 0 -19.2 18 -6.3 11.1 -19 19.1 
16* -2.5 3.5 -16.3 14.7 -5 10 -13 17.5 
*frequency where kanamycin ototoxicity in greater
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6.1.8. Summary of Audiological Results 
In summary, this section addressed the audiological aim which was to determine the 
changes in hearing levels in patients receiving treatment with kanamycin and capreomycin 
for DR-TB. This included investigating the prevalence of abnormal findings on baseline 
hearing assessments and determine the change in hearing levels from baseline.  
The changes were noted using PTA and DPOAEs. With the PTA, no clinically 
significant mean change was noted in the low frequencies bilaterally, yet significant change 
occurred from T0 to T6 in specific high frequencies; 6 kHz and 8 kHz in right ears and 8 kHz 
in left ears. Furthermore, the ultra-high frequencies showed significant hearing loss 
bilaterally, as expected, except for 12.5 kHz, 14 kHz and 16 kHz in the left ears.  
Significant changes with DPOAEs were also observed from T0 to T6 bilaterally in all 
frequencies except 12 kHz in the left ear.  
Percentage of ototoxicity was calculated, even though not ideal for a small sample. 
These percentages were difficult to ascertain due to various grading systems available to 
classify hearing loss. Despite the small sample size, the percentage was calculated from the 
15 participants that completed more than the baseline visit. DPOAEs showed a mean loss of 6 
dB or more at more than one frequency, and so 100% could be described as having a loss of 
cochlear function. Different percentages can be described with PTA, depending on which 
frequencies and grading scales used. When using the TUNE scale and ASHA system, 93% 
could be described as having ototoxicity, or ototoxicity in 7% of the sample when using the 
CTCAE scale. This variability is a result of the different scales, and thus a standardised scale 
is necessary for this population, in order to obtain reliable and standardised percentages. 
 The asymmetry differs on PTA and DPOAEs. Differences of 10 dB between ears for 
PTA and 6 dB for DPOAESs were considered as asymmetry. Asymmetry was noticed on 
visits T1, T4 and T6 with PTA, yet on visits T0, T1, T5 and T6 with DPOAEs. 
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In this current study, kanamycin revealed more ototoxicity than the capreomycin as 
determined by PTA and DPOAEs, as would be expected. Also, although not a sub-aim, yet 
useful for recommendations for a monitoring protocol, week 2 was found to show the greatest 
change in the DPOAEs and weeks 2 and 6 showed the greatest change with the PTA. 
6.2. Pharmacokinetic Findings of Kanamycin and 
Capreomycin 
In this section, the findings of the following sub-aims and objectives are addressed: 
To investigate the kanamycin and capreomycin pharmacokinetics in patients 
undergoing treatment for DR-TB. 
• To investigate the peak and trough levels of kanamycin and capreomycin at two 
weekly intervals for the first three months of treatment. 
• To investigate the relationship between the kanamycin and capreomycin kinetics with 
creatinine levels. 
• To examine the relationship between the pharmacokinetics/ pharmacodynamics of 
kanamycin and capreomycin to culture conversion after the three-month period.  
6.2.1. Investigation of the Mean Peak and Trough Levels for 
kanamycin and capreomycin: Pharmacokinetic Results  
Pharmacokinetic factors were calculated for kanamycin and capreomycin. These 
factors included doses (mg/kg), peaks (μg/ml), troughs (μg/ml), half-lives (hours), and 
volumes of distribution (ℓ/kg).  
Tables 6.10 and 6.11 depicts the pharmacokinetic results from baseline (T0) up until 
week 12 (T6) (2 weekly intervals) as well as the mean pharmacokinetic results from T1 to T6 
respectively. The results are described separately for kanamycin and capreomycin, where the 
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mean dose/kg, peak levels, trough levels, half-lives and volume of distribution are described 
in both tables. 
The weight of participants on kanamycin remained relatively stable from T0 to T6 
within the weights 51.2kg to 55.4kg (mean: 54,13kg, SD±1.55). The average weights of 
participants on capreomycin fluctuated between 48.8kg and 56.3kg (mean: 52.82kg, SD ±3.8) 
(Table 6.10). 
The average dosages of kanamycin varied between the weeks from 13.5 mg/kg - 16 
mg/kg (mean: 14.56; SD 1 and 4.8). The average peak levels of kanamycin ranged between 
4.4 μg/ml – 41.2 μg/ml (mean: 20.03; SD ±2.3 and 15.4) throughout the weeks with the 
trough levels of kanamycin ranging between 0.4 μg/ml – 2.4 μg/ml (mean: 1.33; SD ±0.3 and 
4.6).  
The average half-life of kanamycin varied between 5 – 13.7 hours (mean: 9.3; SD 
±0.6 and 6) throughout the weeks and the average volume of distribution of kanamycin 
varied between 0.4 ℓ/kg – 5.8 ℓ/kg (mean: 2.47; SD ±0.2 and 5,1) throughout the weeks 
(Table 6.11). Overall, the pharmacokinetic results appeared erratic. 
The average dosages of capreomycin varied between the weeks from 13.5 mg/kg – 
17.8 mg/kg (mean: 15.45; SD ±3.2 and 0) respectively. The average peak levels of 
capreomycin ranged between 3.3 μg/ml – 16.8 μg/ml (mean: 8,1; SD 1.8 and 16.8) 
throughout the weeks with the trough levels of capreomycin ranging between 0.5 μg/ml – 1.9 
μg/ml (mean: 0.73; SD± 0 and 4).  
The average half-life of capreomycin varied between and 6.2 – 9.6 hours (mean: 7.2; 
SD ±0.8 and 1.5) throughout the weeks and the average volume of distribution of 
capreomycin varied between 1.3 ℓ/kg – 6.9 ℓ/kg (mean: 3.3; SD ±1,1 and 5.4) throughout the 
weeks (Table 6.11). Overall, the pharmacokinetic results appeared erratic. 
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The total drug levels have also been averaged out between from T0 and T6 and can be 
seen in Table 6.12. The overall peak levels differed between kanamycin and capreomycin, 
with peak levels of 20 μg/ml and 8.1 μg/ml respectively.
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Table 6.10 
Pharmacokinetic Results for kanamycin and capreomycin from T0 to T6 
  
T0  
(KM) 
T0  
(CM) 
T1 
(KM) 
T1 
(CM) 
T2 
(KM) 
T2 
(CM) 
T3 
(KM) 
T3 
(CM) 
T4 
(KM) 
T4 
(CM) 
T5 
(KM) 
T5 
(CM) 
T6 
(KM) 
T6 
(CM) 
n 
 
22 0 11 4 8 3 5 4 5 5 5 2 5 1 
dropout /CM* 0 0 7 0 3 1 3 0 0 0 0 3 0 1 
Gender M 7 0 3 0 2 0 1 1 1 1 1 0 1 0 
F 15 0 7 4 6 3 4 3 4 4 4 2 4 1 
Age  
(in years) 
Mean 33.8  31.8 32.1 28.3 32.0 26.5 38.0 27.8 35.0 26.6 36.7 26.6 35.4 
SD 7.3  8.3 7.8 6.8 8.3 6.1 2.2 6.2 7.2 6.1 2.0 6.1  
Min 18.6  18.6 18.6 18.7 22.5 18.7 35.2 18.7 22.6 18.8 35.3 18.8 35.4 
Max 42.8  42.0 42.0 40.5 38.2 -32.6 40.5 32.6 40.6 32.7 38.1 32.7 35.4 
Med 35.1  30.1 32.5 29.4 35.2 29.6 38.2 30.0 38.1 29.7 36.7 29.7 35.4 
Weight  
(in kg) 
Mean 54.1  53.5 53.8 55.4 48.8 51.2 48.9 54.0 50.5 55.4 56.3 53.8 55.6 
SD 10.9  8.7 9.9 2.7 6.8 6.8 8.0 1.4 8.5 3.6 ⁑ 7.7 ⁑ 
Min 34.0  37.0 52.8 54.0 41.9 40.0 43.7 52.0 41.9 50.2 56.3 40.0 55.6 
Max 73.0  69.0 72.4 59.4 58 -57.0 58.1 55.0 59.4 59.0 56.3 59.0 55.6 
Med 54.5  54.0 54.0 54.0 46.4 54.0 44.8 54.5 50.4 57.0 56.3 57.0 55.6 
Dose 
(mg/kg) 
Mean 16.0  14.1 14.3 13.7 15.3 14.9 13.5 14.8 13.9 13.5 17.8 14.9 18.0 
SD 4.8  1.5 1.8 2.1 3.9 2.3 3.2 2.0 3.5 1.0 ⁑ 2.5 ⁑ 
Min 11.6  12.0 14.2 10.6 10.8 13.2 11.2 13.6 11.2 12.7 17.8 12.7 18.0 
Max 34.1  18.0 18.0 17.8 17.9 -18.8 18.8 18.3 17.9 14.9 17.8 18.8 18.0 
Med 14.5  13.9 13.9 13.9 17.2 13.9 12.2 13.9 12.6 13.1 17.8 13.2 18.0 
Peak 
(μg/ml) 
Mean 21.0  18.2 16.8 11.1 6.4 10.2 5.9 34.1 3.3 41.2 ⁑ 4.4 ⁑ 
SD 38.6  17.4 16.8 7.9 2.1 3.1 1.3 31.1 1.8 15.4 ⁑ 2.3 ⁑ 
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T0  
(KM) 
T0  
(CM) 
T1 
(KM) 
T1 
(CM) 
T2 
(KM) 
T2 
(CM) 
T3 
(KM) 
T3 
(CM) 
T4 
(KM) 
T4 
(CM) 
T5 
(KM) 
T5 
(CM) 
T6 
(KM) 
T6 
(CM) 
Min 1.1  4.6 55.2 3.7 4.9 6.9 4.9 12.1 2.1 30.4 ⁑ 2.0 ⁑ 
Max 148.9  55.2 55.2 26.2 7.9 -13.1 13.1 56.1 4.6 52.1 ⁑ 7.5 ⁑ 
Med 5.2  12.4 8.0 7.7 6.4 10.6 5.9 34.1 3.3 41.2 ⁑ 4.1 ⁑ 
Trough 
(μg/ml) 
Mean 0.4  2.4 1.9 1.4 0.5 1.6 0.5 1.7 0.5 0.9 0.5 0.9 0.5 
SD 0.3  4.6 4.0 1.5 0.0 1.9 0.1 1.9 0.1 0.6 0 0.4 0 
Min 0.1  0.5 15.7 0.1 0.5 0.5 0.4 0.5 0.5 0.5 0.5 0.5 0.5 
Max 1.0  15.7 15.7 5.0 0.5 -4.9 4.9 5.0 0.7 1.6 0.5 1.6 0.5 
Med 0.5  0.9 0.5 1.0 0.5 0.9 0.5 0.9 0.5 0.5 0.5 1.0 0.5 
Half-life 
(hours) 
Mean 7.5  7.2 6.7 7.2 6.3 13.3 6.2 11.2 9.6 5.0 ⁑ 13.7 ⁑ 
SD 5.5  2.5 2.5 1.5 0.8 10.3 0.8 9.5 1.5 0.6 ⁑ 6.0 ⁑ 
Min 2.2  4.5 13.0 5.9 5.7 6.0 5.7 4.4 8.5 4.5 ⁑ 10.5 ⁑ 
Max 19.4  13.0 13.0 9.2 6.9 -20.6 20.6 17.9 10.7 5.4 ⁑ 22.7 ⁑ 
Med 5.3  6.6 6.2 6.3 6.3 13.3 6.2 11.2 9.6 5.0 ⁑ 10.8 ⁑ 
VD (ℓ/kg) Mean 4.5  1.3 1.3 2.3 2.2 2.2 2.7 0.8 6.9 0.4 ⁑ 5.8 ⁑ 
SD 5.1  1.1 1.1 1.5 0.1 1.0 1.3 0.9 5.4 0.2 ⁑ 5.1 ⁑ 
Min 0.1  0.3 0.3 0.6 2.2 1.1 1.8 0.2 3.1 0.2 ⁑ 2.1 ⁑ 
Max 19.7  3.3 3.3 4.8 2.3 -3.0 3.6 1.8 10.7 0.5 ⁑ 13.3 ⁑ 
Med 2.8  0.8 0.8 2.7 2.2 2.5 2.7 0.4 6.9 0.4 ⁑ 4.0 ⁑ 
Note: *number of participants who dropped out from the study or who were switched to capreomycin, ⁑missing pharmacokinetic data due to haemolysis, Med=median value  
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Table 6.11  
Total Mean and SD Pharmacokinetic Results of kanamycin and capreomycin from T1- T6 
 
Kanamycin Capreomycin 
Mean SD Mean SD 
Dose (mg/kg) 14.6 2.3 15.5 2.7 
Peak (μg/ml) 20.0 16.5 8.1 5.5 
Trough (μg/ml) 1.3 1.6 0.7 1.0 
Half Life (hours) 9.3 5.1 7.2 1.4 
Volume of Distribution (ℓ/kg) 2.5 2.1 3.3 2.0 
 
The total number of participants on kanamycin and on capreomycin is not mentioned 
in table 6.12. This is due to the fact that all participants started on kanamycin, and then some 
were switched to capreomycin, yet at different weeks. Only five participants that were 
initiated on kanamycin at T0 remained on kanamycin at T6. The overall kanamycin and 
capreomycin pharmacokinetic values were therefore calculated throughout the weeks where 
they used.  
6.2.2. The relationship between the kanamycin and capreomycin 
pharmacokinetics with creatinine levels 
The creatinine levels (adjusted to gender) are described in relation to the kanamycin 
and capreomycin trough levels (Table 6.12).  
Reduced Calculation of the Creatinine Clearance (CrCl) is measured below 80ml/min 
(Messa et al., 1988) and trough levels exceeding 10 μg/ml are considered possibly toxic 
(Black et al., 1976).  
For participants taking kanamycin, the average creatinine clearance was reduced, yet 
the drug was still cleared through the system, as seen with trough levels below 10 μg/ml 
(Table 6.12). 
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For participants taking capreomycin, the majority of the creatinine clearance was 
within the normal range (80 – 130 ml/min). The trough levels were below 10 μg/ml showing 
appropriate clearance, even when the creatinine levels were reduced as in weeks two and four 
(Table 6.12). 
Table 6.12  
CrCl (adjusted according to gender) in relation to mean trough levels 
 Kanamycin Capreomycin 
 CrCl Mean 
(ml/min) 
Trough Mean 
(μg/ml) 
CrCl Mean 
(ml/min) 
Trough Mean 
(μg/ml) 
T0 60.88 0.48 * * 
T1 68.92 2.45 66.1 0.45 
T2 81.56 1.44 77.37 0.48 
T3 59.86 1.57 97.09 0.46 
T4 59.28 1.69 163.97 0.55 
T5 57.11 0.92 88.12 0.5 
T6 58.28 0.99 ⁑ 0.5 
Note: *participants were not taking capreomycin at baseline hence N/A at baseline, ⁑ At week 12, the creatinine 
results could not be found on the NHLS database, hence unavailable. 
6.2.3. The Relationship between the Pharmacokinetics/ 
Pharmacodynamics of kanamycin and capreomycin to 
Culture Conversion  
The objective was to establish whether participants had culture converted by the end 
of the week 12, or the last week before dropout, in order to document differences between 
kanamycin and capreomycin. 6.14 described the culture results for kanamycin and 
capreomycin. However, in some instances, that are explained, culture results could not be 
accessed (Table 6.13). 
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It is evident, that in two instances participants converted slightly later than at HJH. 
Those participants at SRH were on capreomycin. Despite the low peak levels, participants 
appeared to have culture converted (Table 6.13). 
Table 6.13  
Culture conversion results from participants of kanamycin (n = 9) and capreomycin (n = 13) 
 Helen Joseph Hospital 
(kanamycin) 
South Rand Hospital  
(mostly capreomycin) 
n 9 13 
Missing culture 
results 
3 4 
Reasons for 
missing culture 
results 
One participant dropped out due to 
transfer Sizwe Hospital 
One participant withdrew from the 
study prior to transfer to another 
hospital. 
-One participant refused hospital 
treatment, and so no further culture 
results were available 
Three participants were transferred to 
Sizwe Hospital* 
Two participants passed away before 
culture results were available 
Existing culture 
results 
Six participants converted by 
month one 
Seven participants converted by month 
one. 
One participant converted by week six  
One participant converted by month two 
Note: *Culture results from participants who were transferred to Sizwe Hospital could not be accessed. 
6.2.4. Summary of kanamycin and capreomycin 
Pharmacokinetics 
In summary, the pharmacokinetics yielded erratic results. The total dosages of 
kanamycin and capreomycin were similar, although did differ slightly. The average dosages 
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varied between the weeks from 13.5 mg/kg - 16 mg/kg (mean: 14.56; ± 1 - 4.8) and 13.5 
mg/kg – 17.8 mg/kg (mean: 15.5; ±3.2 and 0) respectively for kanamycin and capreomycin.  
The most erratic results were within the peak levels, particularly with kanamycin. The 
average peak levels of kanamycin and capreomycin ranged between 4.4 μg/ml – 41.2 μg/ml 
(mean: 20.03; SD ±2.3 and 15.4) and 3.3 μg/ml – 16.8 μg/ml (mean: 8.1; SD 1.8 and 16.8) 
throughout the weeks, yet the trough levels were always below 10 μg/ml and not within a 
toxic range. 
Average CrCl was reduced for those taking kanamycin, yet majority was within the 
normal range for capreomycin.  
All participants that could be documented culture converted within the first two 
months. However, this included one negative culture, in comparison to the two standard two 
consecutive cultures. This was not possible to document due to the short duration of the 
study. 
6.3. Pharmacokinetics of kanamycin and capreomycin in 
Relation to Hearing Levels 
This section discusses the following sub-aims: 
Examine the relationship between kanamycin and capreomycin pharmacokinetics 
and hearing levels 
• To examine the relationship between kanamycin and capreomycin dosing and hearing 
levels. 
• To explore the relationship between kanamycin and capreomycin dosing and the 
progression of hearing loss. 
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6.3.1. The Relationship between Pharmacokinetics of 
kanamycin and capreomycin, including Dosing, with Hearing 
Levels 
The pharmacokinetic results are presented separately for each week (T0 to T6) in 
relation to the change in hearing at the various frequencies for both kanamycin and 
capreomycin separately. The dose per kilogram, peak and trough levels, as well as half-lives 
and volumes of distribution, are mentioned. The peak readings were measured at 4 to 6 hours 
after the injection was administered while the trough measurements were taken 30 minutes 
prior to the administration of the injection (after the previous days’ injectable). 
The audiology results are tabulated for both DPOAEs and PTA, which are figures 
depicting the change from baseline in decibels. For these DPOAE and PTA results, the 
change was calculated by dB level at baseline minus dB reading at the various weeks; a 
negative result shows the deterioration of hearing at the specific week, whereby a positive 
result shows an improvement from baseline at that specific frequency. 
The dB responses for DPOAEs and PTAs are tabulated for each frequency for each 
ear. The right ear response is noted on the first line in the relevant section, with the left ears 
response being noted under the right ear. A significant change was considered as 6 dB for 
DPOAEs and 10 dB for PTA.  
The high frequencies and UHF are included in this section. However, as 3 kHz was not 
tested with the DPOAEs, 2 kHz and above are included, while 3 kHz and above are included 
for PTA.  
Pharmacokinetically the distribution of the drugs should be equal to both ears. Drugs 
distribute as a percentage of body weight (Burton, Shaw, Schentag & Evans, 2006), which 
does not allow the drugs to enter the endolymph differently in the right and left ears. 
Therefore, the mean levels are described as the combination of the right and left ears at each 
frequency. 
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In a few instances, there is missing pharmacokinetic, DPOAE and PTA data. This 
missing data is highlighted in purple. The missing pharmacokinetic data is generally a result 
of haemolysis of the samples or errors with small samples drawn from the patients. In the 
cases of missing DPOAE data, issues with SNR ratios, repeat reading and equipment errors 
occurred, where the missing PTA data was a result of uncooperative or unresponsive 
participants. In one instant, 9 kHz was not tested due to tester error.  
Lastly, the responses highlighted in yellow show the limit of the machine. The 
hearing loss possibly deteriorated more than noted, yet could not be recorded by the relevant 
equipment. Therefore, for statistical purposes, the maximum limit response was recorded, 
even when the response may have been worse. 
6.3.1.1. Baseline – study visit T0. 
The baseline measurements did not measure the change in hearing, and so hearing 
levels are not mentioned in this table (Table 6.14). Table 6.1 describes the pharmacokinetics 
results of kanamycin; capreomycin was not used at baseline. The details the peak readings 
that were measured at the first dose of the injectable (four to six hours post the first injection), 
while the trough measurements were taken the following day, 30 minutes prior to the second 
injection. 
All participants were given kanamycin at the baseline, even in cases where they 
presented with hearing loss. The average dose per kilogram was 16 mg/kg (±4.8) (Table 
6.14). 
Peak levels were calculated at baseline, with the mean being 21 μg/ml (SD ± 38.6). 
The minimum peak was 1.1 μg/ml, and the maximum was 148.9 μg/ml. The trough levels 
included a mean of 0.4 μg/ml (SD ± 0.3). The minimum trough level was 0.1 μg/ml while the 
maximum was 0.9 μg/ml (Table 6.14). 
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The half-lives were also calculated when possible for each participant and measured 
in hours. The mean half-life was 7.5 hours (SD ± 5.5) with a mean volume of distribution 
being 4.5 ℓ/kg (SD ± 5.1 ℓ/kg) (Table 6.14).
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Table 6.14  
Baseline pharmacokinetic results of kanamycin (n = 22) 
Study ID 
Age  
(years) 
Gender 
Weight 
(kg) 
Dose  
(mg/kg) 
Peak 
(μg/ml) 
Trough 
(μg/ml) 
Half-life 
(hours) 
VD  
(I /kg) 
1 24.4 F  48 15.6 5.2 0.1 3.9 2.8 
2 40.1 M  58.7 12.8 * 0.5 * * 
3 40.7 M 59 12.7 2.5 0.1 4.6 4.9 
4 21.2 F 42 18.0 7.9 0.1 3.4 2.1 
5 32.4 M 52.3 14.4 2.6 0.1 4.7 5.4 
6 29.1 F 55 13.6 6.6 0.9 8.1 2.3 
7 18.6 F 54 13.9 2.3 1.0 19.3 10.0 
8 29.4 F 50 15.0 3.3 1.0 12.9 6.1 
9 30.1 F 53 14.2 35.3 0.9 4.6 0.4 
10 35.1 F 63 15.9 * 0.5 * * 
11 35.11 F 58 12.9 1.1 0.5 19.4 19.7 
12 41.11 F 69 14.5 26.9 0.1 7.1 0.5 
13 42.8 M 35 21.4 9.3 0.5 5.3 2.3 
14 22.4 F 42 34.1 * 0.5 * * 
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Study ID 
Age  
(years) 
Gender 
Weight 
(kg) 
Dose  
(mg/kg) 
Peak 
(μg/ml) 
Trough 
(μg/ml) 
Half-life 
(hours) 
VD  
(I /kg) 
15 41 F 34 14.7 * 0.5 * * 
16 40.4 M 64.5 11.6 * 0.5 * * 
17 38.1 F 41.9 17.9 4.9 0.5 6.8 3.8 
18 37.11 F 71 14.1 * 0.5 * * 
19 33.5 F 48.4 20.7 3.3 0.5 8.2 6.9 
20 40.3 F 73 13.7 * 0.5 * * 
21 29.4 M 64 11.7 148.9 0.1 2.2 0.1 
22 40.9 M 55 18.3 55.2 0.1 2.6 0.3 
Mean 33.8 F 54.13 16.0 21.0 0.4 7.5 4.5 
STD 7.3  10.94 4.8 38.6 0.3 5.5 5.1 
Min 18.6  34 11.6 1.1 0.1 2.2 0.1 
Max 42.8  73 34.1 148.9 1.0 19.4 19.7 
Med 35.1  54.5 14.5 5.2 0.5 5.3 2.8 
* indicating missing data due to haemolysis 
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6.3.1.2. Week 2 – study visit T1. 
The participant’s pharmacokinetic readings and their change in hearing from baseline 
at week two are described in Table 6.15 (kanamycin participants) and 6.16 (capreomycin 
participants). 
Four of these 15 participants had switched to capreomycin by week two due to 
adverse events. Therefore, kanamycin and capreomycin results are presented separately in the 
tables below (see Table 6.15 and 6.16). 
The mean dose of kanamycin and capreomycin was similar, at 14.13 mg/kg (SD ± 
1.5) and 14.3 mg/kg (SD ± 1.8) respectively. Peak levels for kanamycin and capreomycin 
were 18.2 μg/mg (SD ± 17.4) and 16.8 μg/mg (SD ±16.8) respectively with trough levels of 
2.4 μg/mg (SD ±4.6) and 1.9 μg/mg (SD ±4) respectively. The half-life was 7.2 hours (SD 
±2.5) for kanamycin and 6.7 hours (SD ±2.5) for capreomycin. The volume of distribution 
was equal between kanamycin and capreomycin of 1.3ℓ/ kg hours (SD±1.1).  
For participants taking kanamycin, a mean significant change of DPOAEs was noted 
at 8 kHz and 10 kHz of -7.1 dB (SD ±6.8) and -8.2 dB (SD ±9.4) respectively. There were 
significant individual changes at all the other frequencies, yet not a mean significant change. 
There was no mean significant change (10 dB) noted in the PTA. However, there were 
significant individual changes noted at each PTA frequency (see Table 6.15).  
For those participants that had been switched to capreomycin, a mean significant 
change of DPOAEs was noted at 10 kHz of -6.3 dB (SD ±8.8) and of -10.2 dB at 11.2 kHz 
with PTA. Individual significant changes were noted at all frequencies with DPOAEs and 
PTAs, yet this was not mean results (Table 6.16) 
It is possible that a mean significant change was observed in the DPOAEs highlighted 
in yellow. The limits of the machined cannot describe responses effectively as once the 
DPOAEs were absent, they could not be ‘more absent’.
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Table 6.15  
Week 2 Pharmacokinetic Results and Change in Audiology Results from Baseline for kanamycin (Audiology Baseline minus Week 2:  
Right and Left ears, n = 11) 
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1 24.5 F 52.8 14.2 55.2 15.7 13.0 0.3 
R -9.5 -6.0 -6.0 -21.0 -6.0 10.0 0.0 0.0 -5.0 -15.0 -5.0 0.0 0.0 -5.0 -20.0 -5.0 
L 10.0 3.0 1.5 -2.5 -13.0 -6.0 10.0 5.0 15.0 0.0 -15.0 0.0 0.0 0.0 0.0 5.0 
2 40.1 M  58.7 12.8 30.7 4.7 8.9 0.5 
R * * * * * * 0.0 0.0 -15.0 0.0 -5.0 0.0 -10.0 -5.0 -5.0 -15.0 
L * * * * * * 0.0 0.0 5.0 -10.0 -5.0 0.0 0.0 -5.0 -5.0 -10.0 
4 21.3 F  41.7 18.0 * 0.5  * 
R * * * * * * 10.0 0.0 0.0 -5.0 * 5.0 -10.0 -5.0 -5.0 -20.0 
L * * * * * * 5.0 5.0 5.0 5.0 * -5.0 -10.0 -5.0 -5.0 0.0 
5 32.5 M  55.0 13.6 8.0 0.5 5.6 1.7 
R -13.0 -8.0 -4.0 -10.0 0.0 0.0 5.0 -5.0 0.0 -5.0 -5.0 0.0 0.0 -5.0 -5.0 0.0 
L 3.5 -1.0 0.0 -10.5 -2.0 -2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -5.0 
6 29.2 F 51.8 14.5 16.9 1.3 6.2 0.9 
R -11.0 1.0 -13.0 6.0 -4.5 -6.0 -5.0 -5.0 -15.0 0.0 0.0 0.0 0.0 -5.0 -5.0 0.0 
L -6.5 -5.0 2.0 -2.0 -7.0 -4.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -5.0 -5.0 -10.0 
7 18.6 F 54.3 13.8 7.2 0.9 7.3 2.1 
R -4.5 -10.0 -1.5 -15.0 1.0 -4.5 0.0 0.0 -15.0 -10.0 0.0 5.0 -5.0 0.0 -10.0 5.0 
L -6.0 0.0 -8.5 -11.0 -8.5 0.0 -5.0 -5.0 -10.0 -10.0 -10.0 -10.0 -15.0 -5.0 -15.0 
 
0.0 
8 29.5 F 54.0 13.9 17.7 0.9 5.4 0.8 
R * * * * * * 10.0 -5.0 -10.0 0.0 -5.0 5.0 -5.0 5.0 0.0 0.0 
L * * * * * * -5.0 5.0 -10.0 0.0 0.0 -5.0 -5.0 -5.0 -5.0 10.0 
9 30.1 F 53.0 14.2 30.9 0.9 4.5 0.4 
R -4.0 -3.5 -5.0 -7.5 0.0 9.5 -5.0 0.0 0.0 0.0 10.0 10.0 0.0 10.0 0.0 0.0 
L -1.0 -2.5 0.0 -3.0 -7.0 -7.0 -10.0 0.0 -5.0 -5.0 0.0 -10.0 -15.0 -5.0 10.0 10.0 
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12 42 F 69.0 14.5 4.6 0.5 7.0 3.3 
R -11.0 -6.0 -23.0 -8.0 -36.0 -34.5 -5.0 -5.0 -15.0 -15.0 -45.0 -55.0 -70.0 -65.0 -60.0 -50.0 
L -1.0 0.0 1.5 2.5 -4.0 -3.5 15.0 10.0 10.0 0.0 10.0 0.0 -15.0 -15.0 -20.0 0.0 
15 41.1 F 37.0 13.5 * 0.5  * 
R -6.0 0.5 -14.0 -11.0 -6.0 0.0 0.0 0.0 -10.0 -10.0 5.0 5.0 -10.0 -10.0 0.0 -5.0 
L -0.5 -5.0 -5.5 -5.5 -20.0 -1.5 0.0 -15.0 -10.0 -10.0 0.0 -15.0 -10.0 -10.0 -15.0 0.0 
16 40.4 M  61.6 12.0 5.0 0.5 6.6 2.5 
R -7.0 -2.5 -5.0 -8.0 -10.0 -2.0 0.0 0.0 10.0 0.0 0.0 -15.0 0.0 -10.0 0.0 -10.0 
L -10.0 -4.0 0.0 1.0 -14.0 -5.0 10.0 -5.0 0.0 5.0 0.0 0.0 -30.0 0.0 0.0 0.0 
Mea
n 
31.8  53.5 14.1 18.2 2.4 7.2 1.3 
 -4.5 -3.0 -5.4 -7.1 -8.2 -3.4 1.0 -0.7 -3.6 -4.3 -3.7 -4.0 -8.6 -7.1 -8.1 -4.8 
STD 8.3  8.7 1.5 17.4 4.6 2.5 1.1 
 6.0 3.7 7.0 6.8 9.4 9.9 6.2 5.1 9.1 5.8 11.6 13.4 15.2 14.3 13.9 12.8 
Max 18.6  37.0 12.0 4.6 0.5 4.5 0.3  -13.0 -10.0 -23.0 -21.0 -36.0 -34.5 -10.0 -15.0 -15.0 -15.0 -45.0 -55.0 -70.0 -65.0 -60.0 -50.0 
Min 42.0  69.0 18.0 55.2 15.7 13.0 3.3 
 10.0 3.0 2.0 6.0 1.0 10.0 15.0 10.0 15.0 5.0 10.0 10.0 0.0 10.0 10.0 10.0 
Med 30.1  54.0 13.9 12.4 0.9 6.6 0.8  -6.0 -2.5 -5.0 -8.0 -6.0 -2.0 0.0 0.0 -5.0 0.0 0.0 0.0 -5.0 -5.0 -5.0 0.0 
Note: * indicating missing data, either due to haemolysis with regards to the pharmacokinetic data, or equipment issues/SNR discrepancy (DPOAEs) and tester errors (PTA at 9 kHz); Yellow shading indicates 
the limits of the audiometer.  
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Table 6.16  
Week 2 Pharmacokinetic Results and Change in Audiology Results from Baseline for capreomycin (Audiology Baseline minus Week 2:  
Right and Left ears, n = 4) 
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10 35.1 F 60.0 16.7 * 0.5 * * 
R 0.0 -13.0 0.0 2.0 6.0 -15.0 5.0 0.0 0.0 5.0 0.0 5.0 -35.0 -30.0 0.0 0.0 
L 6.0 -1.0 1.5 0.0 -8.0 0.0 0.0 -5.0 5.0 5.0 0.0 0.0 -5.0 0.0 0.0 0.0 
14 22.4 F 43.0 17.4 * 0.5 * * 
R -0.5 -2.5 5.5 4.5 -13.0 -4.0 -5.0 0.0 0.0 -5.0 -5.0 -10.0 -5.0 -15.0 -10.0 -10.0 
L -1.0 -4.0 -6.5 -7.0 0.5 -10.5 0.0 0.0 10.0 -10.0 0.0 -5.0 -5.0 -10.0 -35.0 -30.0 
17 38.2 F 42.8 11.7 42.6 0.5 3.5 0.3 
R -12.0 -5.0 -6.0 1.0 -3.0 -4.5 0.0 -5.0 0.0 0.0 0.0 5.0 5.0 -5.0 -5.0 0.0 
L -3.0 -3.0 -7.0 -8.5 4.5 0.0 0.0 -5.0 0.0 0.0 0.0 0.0 -30.0 0.0 0.0 0.0 
18 37.1 F 72.4 13.8 5.6 0.4 6.1 2.5 
R -2.0 -2.0 * * -1.5 * -5.0 -5.0 0.0 -5.0 -10.0 -10.0 -10.0 -5.0 -10.0 -15.0 
L -8.0 -8.0 -7.0 -5.0 0.0 -1.0 5.0 -10.0 -10.0 0.0 -10.0 -10.0 -10.0 -20.0 -10.0 0.0 
Mea
n 
32.1  53.8 14.3 16.8 1.9 6.7 1.3  -4.1 -3.7 -4.4 -5.2 -6.3 -4.0 1.0 -1.7 -3.0 -3.2 -3.4 -3.7 -10.2 -7.8 -8.0 -5.2 
STD 7.8  9.9 1.8 16.8 4.0 2.5 1.1  5.8 3.7 6.3 6.6 8.8 8.5 5.8 4.8 8.1 5.8 9.8 11.6 14.8 13.1 13.0 12.0 
Min 18.6  52.8 14.2 55.2 15.7 13.0 0.3  10.0 3.0 5.5 6.0 6.0 10.0 15.0 10.0 15.0 5.0 10.0 10.0 5.0 10.0 10.0 10.0 
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Max 42.0  72.4 18.0 55.2 15.7 13.0 3.3  -13.0 -13.0 -23.0 -21.0 -36.0 -34.5 -10.0 -15.0 -15.0 -15.0 -45.0 -55.0 -70.0 -65.0 -60.0 -50.0 
Med 32.5  54.0 13.9 8.0 0.5 6.2 0.8  -4.3 -3.3 -5.0 -5.5 -5.3 -3.5 0.0 0.0 0.0 0.0 0.0 0.0 -5.0 -5.0 -5.0 0.0 
Note: *indicating missing data, either due to haemolysis with regards to the pharmacokinetic data or due to equipment issues/SNR discrepancy (DPOAEs), Yellow shading indicates the limits 
of the audiometer.  
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6.3.1.3. Week 4 – study visit T2. 
The participants’ pharmacokinetic readings and their change in hearing from baseline 
at week four are described in Table 6.17 (kanamycin participants) and 6.18 (capreomycin 
participants). 
Dropout from baseline was 11 participants, and thus 11 participants were present at 
week 4 (n = 11). At week 4, the mean age shifted to 29.3 years, in comparison to 33.78 years 
at baseline. The mean weight also shifted slightly to 55.88 kg at week four compared to 54.13 
kg at baseline. Three of these 11 participants were using capreomycin as the injectable by 
week 4.  
The mean dose of kanamycin was 13.7 mg/kg (SD ± 2.1) and of capreomycin was 
15.3 mg/kg (SD ± 3.9). Peak levels for kanamycin and capreomycin were 11.1 μg/mg (SD ± 
7.9) and 6.4 μg/mg (SD ±2.1) respectively. The peak levels dropped from the previous study 
visit, particularly with capreomycin. Trough levels also dropped from the previous study 
visit, yet not to the same extent to 1.4 μg/mg (SD ±1.5) and 0.5 μg/mg (SD ±0) respectively. 
The half-life was 7.2 hours (SD ±1.5) for kanamycin and 6.3 hours (SD ±0.8) for 
capreomycin. The volume of distribution was 2.3 ℓ/kg (SD ± 1.5) for kanamycin and 2.2 ℓ/kg 
(SD ± 0.1) for capreomycin. 
For participants taking kanamycin, a mean significant change of DPOAEs was noted 
at 2 kHz, 8 kHz, 10 kHz and 12 kHz of -6.8 dB (SD ±5.4), -6.7 dB (SD ±7.6), -8.7 dB (SD± 
6.4) and -6.4 dB (SD ±7.1) respectively. There were significant individual changes at all the 
other frequencies (4 kHz and 6 kHz), yet not a mean significant change. There was a mean 
significant change (10 dB) noted in the PTA at 12.5 kHz, 14 kHz and 16 kHz of -10 dB (SD 
±16.2), -15.4 dB (SD ±16.3) and -13.1 dB (SD ±18.3) respectively (see Table 6.17).  
For those participants taking capreomycin, a mean significant change of DPOAEs was 
noted at 4 kHz and 10 kHz of -6 dB (SD ±5) and -12.7 dB (SD ±3.1) respectively and at 9 
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kHz, 10 kHz. 11.2 kHz and 12.5 kHz of -13.3 dB (SD ± 11.5), -16.7 dB (SD ± 14.4), -16.7 
dB (SD ± 25.7) and -15 dB (SD ± 21.8) respectively (see Table 6.18). 
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Table 6.17  
Week 4 Pharmacokinetic Results of kanamycin and Change in Audiology Results from Baseline (Audiology Baseline minus Week 4: Right and Left ears, n = 8) 
II
D
 
A
g
e 
G
en
d
e
r 
W
e
ig
h
t 
(k
g
) 
D
o
se
 (
m
g
/k
g
) 
P
ea
k
 (
μ
g
/m
l)
 
T
ro
u
g
h
 (
μ
g
/m
l)
 
H
a
lf
-l
if
e
 (
h
o
u
r
s)
 
V
D
 (
ℓ/
k
g
) 
E
A
R
 
DPOAE (dB) PTA (dB) 
2
 k
H
z 
4
 k
H
z 
6
 k
H
z 
8
 k
H
z 
1
0
 k
H
z 
1
2
 k
H
z 
3
 k
H
z 
4
 k
H
z 
6
 k
H
z 
8
 k
H
z 
9
 k
H
z 
1
0
 k
H
z 
1
1
.2
 k
H
z 
1
2
.5
 k
H
z 
1
4
 k
H
z 
1
6
 k
H
z 
1 24.5 F 51.7 10.6 3.7 0.1 4.5 2.7 
R -19.5 -3.0 -7.0 -20.0 -9.0 -9.0 -5.0 5.0 0.0 -10.0 0.0 -5.0 -30.0 -50.0 -45.0 -5.0 
L -7.0 -8.0 -8.5 -1.0 -13.0 -6.0 0.0 -5.0 0.0 -5.0 0.0 -5.0 -5.0 -10.0 -15.0 -60.0 
4 21.3 F 42.1 17.8 5.8 0.9 9.2 3.5 
R -2.0 -4.0 -3.5 -12.0 -4.0 -5.0 0.0 0.0 -5.0 -5.0 0.0 0.0 -5.0 0.0 -5.0 -5.0 
L -3.0 -1.0 4.0 -1.0 -5.5 -2.5 0.0 5.0 10.0 10.0 5.0 0.0 0.0 0.0 -5.0 0.0 
5 32.5 M 56.3 13.3 14.8 1.0 6.1 0.9 
R -13.5 -6.0 -20.0 -8.0 0.0 0.0 0.0 0.0 -15.0 -15.0 -5.0 -5.0 -10.0 -10.0 -5.0 0.0 
L -3.0 5.0 -5.5 -9.0 -20.0 -18.0 0.0 5.0 0.0 0.0 -30.0 -20.0 -25.0 -25.0 -25.0 -35.0 
6 29.2 F 51.8 14.5 26.2 2.1 6.3 0.6 
R -7.5 -1.0 -6.0 8.0 -6.0 -7.5 0.0 -5.0 0.0 -5.0 0.0 5.0 -5.0 -10.0 -35.0 0.0 
L -1.0 -7.5 1.5 -2.5 -5.5 -1.0 -5.0 -5.0 5.0 0.0 0.0 0.0 0.0 -5.0 -20.0 -30.0 
7 18.7 F 54.0 13.9 13.6 0.9 5.9 1.0 
R -7.0 -9.0 -1.5 -18.5 -16.5 -13.5 * * * * * * * * * * 
L -7.0 -1.0 -1.0 -5.5 -20.0 -3.5 * * * * * * * * * * 
8 29.5 F 54.0 13.9 5.7 1.0 8.4 2.8 
R -4.0 -11.0 -8.5 -13.0 0.0 -7.5 5.0 -5.0 5.0 5.0 0.0 10.0 -10.0 15.0 5.0 -5.0 
L -3.0 4.5 -6.0 2.0 -3.0 -11.5 -10.0 15.0 -5.0 5.0 -15.0 -5.0 -5.0 -5.0 0.0 5.0 
9 30.2 F 54.0 13.9 7.7 5.0 35.6 4.8 
R -10.0 -0.5 -3.5 -9.0 -10.0 10.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.0 -5.0 -10.0 
L -1.0 -0.5 -1.0 -2.0 -11.0 -17.0 0.0 0.0 0.0 5.0 5.0 -10.0 -5.0 -10.0 -40.0 -15.0 
16 40.5 M 59.4 12.0 * 0.5 * * 
R -13.5 -3.0 -9.0 -9.0 -6.5 -4.0 -10.0 0.0 10.0 -15.0 0.0 -5.0 -20.0 -25.0 -5.0 -10.0 
L -9.0 -6.0 0.0 1.0 -8.5 -1.0 0.0 -15.0 -15.0 50.0 0.0 0.0 0.0 0.0 -10.0 0.0 
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n 
28.3  55.4 13.7 11.1 1.4 7.2 2.3  -6.8 -3.1 -5.0 -6.7 -8.7 -6.4 -1.9 0.8 0.4 -2.3 -3.1 -3.1 -9.2 -10.0 -15.4 -13.1 
STD 6.8  2.7 2.1 7.9 1.5 1.5 1.5  5.4 4.6 5.6 7.6 6.4 7.1 4.3 5.7 6.6 7.8 9.5 7.2 9.8 16.2 16.3 18.3 
Max 18.7  54.0 10.6 3.7 0.1 5.9 0.6  -19.5 -11.0 -20.0 -20.0 -20.0 -18.0 -10.0 -5.0 -15.0 -15.0 -30.0 -20.0 -30.0 -50.0 -45.0 -60.0 
Min 40.5  59.4 17.8 26.2 5.0 9.2 4.8  -1.0 5.0 4.0 8.0 0.0 10.0 5.0 15.0 10.0 10.0 5.0 10.0 0.0 15.0 5.0 5.0 
Med 29.4  54.0 13.9 7.7 1.0 6.3 2.7  -7.0 -3.0 -5.5 -8.0 -6.5 -6.0 0.0 0.0 0.0 0.0 0.0 -5.0 -5.0 -10.0 -5.0 -5.0 
Note: * indicating missing data, either due to haemolysis with regards to the pharmacokinetic data, or participant variables (PTA), Yellow shading indicates the limits of the audiometer. 
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Table 6.18  
Week 4 Pharmacokinetic Results of capreomycin and Change in Audiology Results from Baseline (Audiology Baseline minus Week 4: Right and  
Left ears, n = 3) 
ID
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10 35.2 F 58.0 17.2 7.9 0.5 5.7 2.2 
R -1.0 -0.5 -1.0 -2.0 -11.0 -17.0 0.0 0.0 0.0 5.0 5.0 -10.0 -5.0 -10.0 -40.0 -15.0 
L 1.0 -11.0 -1.5 -7.5 -16.0 -15.0 5.0 0.0 5.0 -5.0 -20.0 -25.0 -45.0 -40.0 5.0 0.0 
14 22.5 F 41.9 17.9 * 0.5 * * 
R -9.0 -1.0 5.5 -2.0 -12.0 0.0 5.0 5.0 15.0 -5.0 -20.0 -25.0 -10.0 0.0 5.0 5.0 
L * * * * * * * * * * * * * * * * 
17 38.2 F 46.4 10.8 4.9 0.5 6.9 2.3 
R -8.0 -6.0 -10.0 0.5 -10.0 8.5 -5.0 0.0 0.0 0.0 0.0 0.0 5.0 -5.0 0.0 0.0 
L -7.5 -3.0 -5.0 -7.5 1.5 0.0 0.0 5.0 0.0 -10.0 -5.0 0.0 0.0 -10.0 0.0 0.0 
Mea
n 
32.0  58.0 15.3 6.4 0.5 6.3 2.2  
-5.3 -6.0 -2.0 -3.0 -12.7 -2.2 1.7 1.7 6.7 -3.3 -13.3 -16.7 -16.7 -15.0 3.3 1.7 
STD 8.3  58.0 3.9 2.1 0.0 0.8 0.1  5.5 5.0 7.8 4.1 3.1 11.9 5.8 2.9 7.6 2.9 11.5 14.4 25.7 21.8 2.9 2.9 
Max 22.5  58.0 10.8 4.9 0.5 5.7 2.2  -9.0 -11.0 -10.0 -7.5 -16.0 -15.0 -5.0 0.0 0.0 -5.0 -20.0 -25.0 -45.0 -40.0 0.0 0.0 
Min 38.2  58.0 17.9 7.9 0.5 6.9 2.3  1.0 -1.0 5.5 0.5 -10.0 8.5 5.0 5.0 15.0 0.0 0.0 0.0 5.0 0.0 5.0 5.0 
Med 35.2  58.0 17.2 6.4 0.5 6.3 2.2  -8.0 -6.0 -1.5 -2.0 -12.0 0.0 5.0 0.0 5.0 -5.0 -20.0 -25.0 -10.0 -5.0 5.0 0.0 
Note: * indicating missing data, either due to haemolysis with regards to the pharmacokinetic data, or equipment issues/SNR discrepancy (DPOAEs), or participant variables (PTA). Yellow 
shading indicates the limits of the audiometer. 
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6.3.1.4. Week 6 – study visit T3. 
The participant’s pharmacokinetic readings and their change in hearing from baseline 
at week six are described in Table 6.19 (kanamycin participants) and 6.20 (capreomycin 
participants). 
Dropout from baseline was 13 participants, and thus nine participants were present at 
week 6 (n = 9). The mean age shifted slightly to 31.61 years, in comparison to 33.78 years at 
baseline. The total mean weight (kanamycin and capreomycin) also shifted slightly to 50, 35 
kg at week 6 compared to 54.13 kg at baseline. Although the sample size is different, mean 
weight appeared to be dropping. 
Four of these nine participants were now taking capreomycin as their injectable by 
week 6. The mean dose of kanamycin was 14.9 mg/kg (SD ± 2.3) and of capreomycin was 
13.5 mg/kg (SD ± 3.2). Peak levels for kanamycin and capreomycin were 10.2 μg/mg (SD ± 
3.1) and 5.9 μg/mg (SD ±1.3) respectively. The peak levels dropped from the previous study 
visit. Trough levels were 1.6 μg/mg (SD ±1.9) and 0.5μg/mg (SD ±0.1) respectively. The 
half-life was 13.3 hours (SD ±10.3) for kanamycin and 6.2 hours (SD ±0.8) for capreomycin. 
The volume of distribution was 2.2 ℓ/kg (SD ± 1.0) for kanamycin and 2.7 ℓ/kg (SD ± 1.3) for 
capreomycin. 
For participants taking kanamycin, a mean significant change of DPOAEs was noted 
at 8 kHz, 10 kHz and 12 kHz of -9.5 dB (SD ±8.8), -7.1 dB (SD±4.6) and -6.8 dB (SD±7) 
respectively. The frequency of 2 kHz appeared to have improved from the previous study 
visit and was not significant. There was a mean significant change (10 dB) noted in the PTA 
at 11.2 kHz, 14 kHz and 16 kHz of -10 dB (SD ±8.8), -15.5 dB (SD ±10.7) and -13 dB (SD 
±18.3) respectively (see Table 6.19). The frequency 12 kHz improved and was not significant 
this study visit. 
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For those participants taking capreomycin, a mean significant change of DPOAEs was 
noted at 2 kHz, 4 kHz, 6 kHz, 10 kHz and 12 kHz of -9.3 dB (SD ±5.5), -7.8 dB (SD ±5.6), -
8.2 dB (SD ±10.7), -10.6 dB (SD ±7.1) and -6.2 dB (SD ±6.4) respectively and at 10 kHz, 
11.2 kHz and 12.5 kHz of -15.6 dB (SD ±12.1), -13.1 dB (SD ±16.2), and -15 dB (SD ±11) 
respectively (see Table 6.20). 
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Table 6.19  
Week 6 Pharmacokinetic Results of kanamycin and Change in Audiology Results from Baseline (Audiology Baseline minus Week 6: Right and Left ears, n=5) 
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4 21.4 F 40.0 18.8 6.9 0.9 7.8 3.0 
R -3.5 -9.0 0.0 -12.0 -6.0 -12.5 5.0 0.0 0.0 -5.0 0.0 0.0 -5.0 -10.0 -5.0 -5.0 
L -3.5 3.5 3.0 -1.0 -7.5 -7.5 0.0 0.0 0.0 5.0 -5.0 0.0 -10.0 -5.0 -5.0 0.0 
5 32.6 M 55.0 13.6 13.1 1.0 6.0 1.1 
R -12.0 -7.0 -23.0 -30.0 0.0 0.0 5.0 -5.0 -20.0 -10.0 0.0 0.0 -5.0 0.0 0.0 0.0 
L 4.5 1.0 0.0 -4.0 -15.5 -17.5 0.0 0.0 0.0 0.0 -15.0 -15.0 -25.0 -20.0 -30.0 -35.0 
7 18.7 F 50.2 14.9 10.6 4.9 20.6 2.5 
R -8.0 -10.0 0.5 -16.0 -10.5 -5.0 -5.0 -5.0 -10.0 -10.0 -15.0 -10.0 -15.0 -10.0 -25.0 -55.0 
L -5.0 0.0 -7.5 -3.5 -9.0 2.0 -5.0 -5.0 -15.0 -5.0 -5.0 -10.0 -5.0 0.0 -10.0 -10.0 
8 29.6 F 54.0 13.9 * 0.5 * * 
R -3.0 -3.0 -5.5 -12.0 -4.5 -15.0 0.0 0.0 0.0 5.0 -10.0 0.0 -25.0 -20.0 -30.0 0.0 
L -9.5 -2.0 -3.0 -1.5 -3.0 -9.5 0.0 0.0 0.0 0.0 -10.0 5.0 -5.0 -5.0 -15.0 0.0 
9 30.2 F 57.0 13.2 * 0.5 * * 
R -11.0 -2.5 -0.5 -9.0 -11.5 2.5 0.0 0.0 5.0 0.0 0.0 -5.0 -5.0 0.0 -15.0 -10.0 
L -7.0 -1.5 -2.5 -5.5 -3.5 -5.5 0.0 0.0 -5.0 -5.0 0.0 0.0 0.0 -5.0 -20.0 -15.0 
Mea
n 
26.5  51.2 14.9 10.2 1.6 13.3 2.2 NA -5.8 -3.1 -3.9 -9.5 -7.1 -6.8 0.0 -1.5 -4.5 -2.5 -6.0 -3.5 -10.0 -7.5 -15.5 -13.0 
STD 6.1  6.8 2.3 3.1 1.9 10.3 1.0 NA 4.8 4.4 7.4 8.8 4.6 7.0 3.3 2.4 8.0 5.4 6.1 6.3 8.8 7.5 10.7 18.3 
Max 18.7  40.0 13.2 6.9 0.5 6.0 1.1 NA -12.0 -10.0 -23.0 -30.0 -15.5 -17.5 -5.0 -5.0 -20.0 -10.0 -15.0 -15.0 -25.0 -20.0 -30.0 -55.0 
Min -32.6  -57.0 -18.8 -13.1 -4.9 -20.6 -3.0 NA -4.5 -3.5 -3.0 1.0 0.0 -2.5 -5.0 0.0 -5.0 -5.0 0.0 -5.0 0.0 0.0 0.0 0.0 
Med 29.6  54.0 13.9 10.6 0.9 13.3 2.5 NA -6.0 -2.3 -1.5 -7.3 -6.8 -6.5 0.0 0.0 0.0 -2.5 -5.0 0.0 -5.0 -5.0 -15.0 -7.5 
Note: * indicating missing data due to haemolysis with regards to the pharmacokinetic data. Yellow shading indicates the limits of the audiometer.  
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Table 6.20  
Week 6 Pharmacokinetic Results of capreomycin and Change in Audiology Results from Baseline (Audiology Baseline minus Week 6:  
Right and Left ears, n = 4) 
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10 35.2 F 58.1 17.2 4.9 0.5 6.8 3.6 R -5.0 -18.0 -2.0 -6.0 -20.0 -15.0 0.0 -10.0 0.0 0.0 -15.0 -35.0 -50.0 -35.0 0.0 0.0 
L -19.0 -1.0 -2.5 -2.0 -12.0 0.0 -5.0 0.0 5.0 -5.0 -10.0 -30.0 -15.0 0.0 0.0 0.0 
16 40.5 M  43.7 12.2 6.8 0.4 5.7 1.8 R -9.5 -7.0 -9.0 -6.0 -20.0 -4.0 0.0 0.0 0.0 0-5 -10.0 -10.0 0.0 -20.0 -10.0 -15.0 
L -10.5 -0.5 0.0 0.0 -13.0 -7.0 -5.0 -5.0 -10.0 -5.0 0.0 -10.0 -5.0 -10.0 0.0 -5.0 
17 38.3 F 44.8 11.2 * 0.5 * * R -9.0 -9.0 -32.0 -3.0 -8.0 -6.5 -20.0 -5.0 -40.0 -5.0 0.0 0.0 0.0 -10.0 -5.0 0.0 
L -6.5 -9.0 -5.0 -6.5 -5.5 0.0 0.0 0.0 0.0 -5.0 -10.0 -5.0 -5.0 -10.0 -5.0 -5.0 
18 38 F * * * * * * R -14.0 -11.0 -14.0 -14.0 -6.0 -16.0 -5.0 0.0 -5.0 -5.0 -15.0 -15.0 -15.0 -10.0 -15.0 -10.0 
L -1.0 -7.0 -1.0 -5.0 0.0 -1.0 -5.0 -5.0 -5.0 -10.0 -15.0 -20.0 -15.0 -25.0 -10.0 -5.0 
Mea
n 
38.0 
 
48.9 13.5 5.9 0.5 6.2 2.7 NA -9.3 -7.8 -8.2 -5.3 -10.6 -6.2 -5.0 -3.1 -6.9 -5.0 -9.4 -15.6 -13.1 -15.0 -5.6 -5.0 
STD 2.2 
 
8.0 3.2 1.3 0.1 0.8 1.3 NA 5.5 5.6 10.7 4.2 7.1 6.4 6.5 3.7 14.1 2.9 6.2 12.1 16.2 11.0 5.6 5.3 
Min 35.2 
 
43.7 11.2 4.9 0.4 5.7 1.8 NA -19.0 -18.0 -32.0 -14.0 -20.0 -16.0 -20.0 -10.0 -40.0 -10.0 -15.0 -35.0 -50.0 -35.0 -15.0 -15.0 
Max 40.5 
 
58.1 18.8 13.1 4.9 20.6 3.6 NA -19.0 -18.0 -32.0 -30.0 -20.0 -17.5 -20.0 -10.0 -40.0 -10.0 -15.0 -35.0 -50.0 -35.0 -30.0 -55.0 
Med  38.2 
 
44.8 12.2 5.9 0.5 6.2 2.7 NA -9.3 -8.0 -3.8 -5.5 -10.0 -5.3 -5.0 -2.5 -2.5 -5.0 -10.0 -12.5 -10.0 -10.0 -5.0 -5.0 
Note: * indicating missing data due to haemolysis with regards to the pharmacokinetic data, Yellow shading indicates the limits of the audiometer. 
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6.3.1.5. Week 8 – study visit T4. 
The participant’s pharmacokinetic readings and their change in hearing from baseline 
at week eight are described in Table 6.21 (kanamycin participants) and 6.22 (capreomycin 
participants). 
Dropout from baseline was 12 participants, and thus 10 participants were present at 
week 8 (n = 10). This is one participant more than the previous week where there were nine 
participants. At week 8, the mean age shifted to 30, 75 years, in comparison to 33.78 years at 
baseline. The total mean weight also shifted slightly to 52.25kg at week 8. 
Half of the participants present at week 8 were using capreomycin as the injectable. 
The mean dose of kanamycin was 14.8 mg/kg (SD ± 2) and of capreomycin was 13.9 mg/kg 
(SD ± 3.5). Peak levels for kanamycin and capreomycin were 34.1 μg/mg (SD ± 31.1) and 
3.3 μg/mg (SD ±1.8) respectively. Trough levels were 1.7 μg/mg (SD ±1.9) and 0.5μg/mg 
(SD ±0.1) respectively. The half-life was 11.2 hours (SD ±9.5) for kanamycin and 9.6 hours 
(SD ±1.5) for capreomycin. The volume of distribution was 0.8 ℓ/kg (SD ± 0.9) for 
kanamycin and 6.9 ℓ/kg (SD ± 5.4) for capreomycin. 
For participants taking kanamycin, a mean significant change of DPOAEs was noted 
at 2 kHz, 6 kHz, 8 kHz, 10 kHz and 12 kHz of -7.7 dB (SD ±4.1), -6.6d B (SD±7.4), -9.8 dB 
(SD ±6.3), -6.1 (SD ±6.3) and -6.0 (SD ±8.1) respectively. There was a mean significant 
change (10 dB) noted in the PTA at 14 kHz and 16 kHz of -18 dB (SD ±17.2) and -16 dB 
(SD ±17.3) respectively (see Table 6.21). The 11.2 kHz mean response improved from the 
previous study visit.  
For those participants taking capreomycin, a mean significant change of DPOAEs was 
noted at 2 kHz, 4 kHz, 6 kHz, 8 kHz, 10 kHz and 12 kHz of -9.7 dB (SD ±6.5), 12.6 dB (SD 
±8.9), 11.4 dB (SD ±11.3), -7.6 dB (SD ±7.7), -16 dB (SD ±9.6) and -7.1 dB (SD ±7.9) 
respectively. The significant changes were not solely a deterioration of cochlear function, but 
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in some instances, an improvement. With regards to PTA at 6 kHz, 9 kHz, 10 kHz, 11.2 kHz 
and 12.5 kHz changes of -12.5 dB (SD ±20.5), -11.3 dB (SD ±14.3), -20 dB (SD ±19.8), -
19.4 dB (SD ±15.9) and -16.3 dB (SD ±15.3) respectively (see Table 6.22). These pure tone 
results do not correlate entirely with the PTA, and DPOAEs showed improvement at 6 kHz 
where PTA showed deterioration. 
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Table 6.21  
Week 8 Pharmacokinetic Results of kanamycin and Change in Audiology Results from Baseline (Audiology Baseline minus Week 8: Right and Left ears, n = 5) 
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4 21.4 F 41.1 18.3 40.5 0.9 3.4 0.4 
R -4.5 -8.0 -2.5 -13.0 -8.0 -6.0 0.0 0.0 0.0 -5.0 0.0 0.0 -5.0 0.0 0.0 -15.0 
L  -1.0 1.0 -19.5 -5.5 -2.5 0.0 0.0 -5.0 -10.0 0.0 0.0 -5.0 0.0 -10.0 0.0 
5 32.6 M 55.0 13.6 12.1 5.0 17.9 1.8 
R -13.0 -8.0 -21.0 -9.5 0.0 0.0 5.0 0.0 -15.0 -5.0 -5.0 -5.0 -10.0 -10.0 -10.0 -10.0 
L -0.5 -14.5 -18.0 -11.5 -20.0 -20.0 0.0 -10.0 -15.0 -5.0 -25.0 -25.0 -25.0 -25.0 -25.0 -25.0 
7 18.7 F 55.0 13.6 * 0.5 * * 
R -8.0 -13.0 -1.5 -16.5 -7.0 -7.0 -5.0 -5.0 -5.0 -5.0 -5.0 0.0 -5.0 -5.0 -50.0 -50.0 
L -10.0 -5.5 -0.5 -6.5 -6.0 3.0 -5.0 -5.0 -5.0 -10.0 0.0 0.0 0.0 -5.0 0.0 -25.0 
8 29.6 F 52.0 14.4 * 0.5 * * 
R -9.0 -5.0 -8.5 -12.0 -3.0 -15.0 5.0 0.0 -5.0 10.0 -10.0 0.0 -30.0 -30.0 -35.0 5.0 
L -3.0 0.5 -5.0 2.0 -6.0 -6.5 5.0 5.0 0.0 5.0 -15.0 -10.0 -10.0 0.0 -10.0 5.0 
9 30.3 F 54.0 13.9 56.1 1.5 4.4 0.2 
R -11.0 -3.5 -6.5 -8.0 -9.0 2.5 -5.0 0.0 0.0 0.0 0.0 0.0 -5.0 5.0 -5.0 -15.0 
L -10.0 -0.5 -3.0 -3.0 4.0 -17.0 0.0 0.0 0.0 5.0 0.0 5.0 0.0 -15.0 -35.0 -30.0 
Mea
n 
27.8  54.0 14.8 34.1 1.7 11.2 0.8 NA -7.7 -5.9 -6.6 -9.8 -6.1 -6.9 0.0 -1.5 -5.0 -2.0 -6.0 -3.5 -9.5 -8.5 -18.0 -16.0 
STD 6.2  1.4 2.0 31.1 1.9 9.5 0.9 NA 4.1 5.1 7.4 6.3 6.3 8.1 4.1 4.1 5.8 6.7 8.4 8.5 10.1 11.6 17.2 17.3 
Max 18.7  52.0 13.6 12.1 0.5 4.4 0.2 NA -13.0 -14.5 -21.0 -19.5 -20.0 -20.0 -5.0 -10.0 -15.0 -10.0 -25.0 -25.0 -30.0 -30.0 -50.0 -50.0 
Min 32.6  55.0 18.3 56.1 5.0 17.9 1.8 NA -0.5 0.5 1.0 2.0 4.0 3.0 5.0 5.0 0.0 10.0 0.0 5.0 0.0 5.0 0.0 5.0 
Med 30.0  54.5 13.9 34.1 0.9 11.2 0.4 NA -9.0 -5.3 -4.0 -10.5 -6.0 -6.3 0.0 0.0 -5.0 -5.0 -2.5 0.0 -5.0 -5.0 -10.0 -15.0 
Note: * indicating missing data due to haemolysis with regards to the pharmacokinetic dat  
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Table 6.22  
Week 8 Pharmacokinetic Results of capreomycin and Change in Audiology Results from Baseline (Audiology Baseline minus Week 8:  
Right and Left ears, n = 5) 
ID
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10 35.3 F 55.9 17.9 * 0.5 * * R -7.0 -18.0 -6.0 -12.5 -20.0 -15.0 0.0 -10.0 0.0 0.0 -15.0 -30.0 -45.0 -35.0 0.0 0.0 
         L -2.0 -1.0 -2.5 -2.0 -12.0 0.0 -5.0 0.0 0.0 -5.0 -15.0 -35.0 -20.0 0.0 5.0 0.0 
14 22.6 F 41.9 17.8 2.1 0.5 10.7 10.7 R -11.5 -8.5 -1.5 -1.5 -18.0 -6.0 * * * * * * * * * * 
         L -11.5 -10.5 -17.5 -10.0 -17.0 -22.0 * * * * * * * * * * 
16 40.6 M 59.4 12.6 4.6 0.7 8.5 3.1 R -10.0 -4.0 -9.0 -5.5 -5.5 -4.0 -10.0 5.0 0.0 0.0 0.0 0.0 -10.0 -20.0 -5.0 -5.0 
         L -7.0 -4.5 0.0 0.0 -9.5 -0.5 -5.0 -10.0 -5.0 -10.0 0.0 0.0 -5.0 0.0 -20.0 -5.0 
17 38.3 F 44.8 11.2 * 0.5 * * R -11.0 -20.5 -32.0 -21.5 -27.5 -6.5 -20.0 -10.0 -45.0 -25.0 -20.0 -20.0 -15.0 -20.0 -10.0 0.0 
         L -23.5 -23.5 -27.0 -3.5 -20.5 0.0 5.0 -25.0 -45.0 -5.0 0.0 -20.0 -20.0 -10.0 10.0 -5.0 
18 38.1 F  * * * * * R -13.0 -26.5 -16.0 -18.5 -30.5 -16.0 0.0 -15.0 -10.0 -20.0 -40.0 -55.0 -40.0 -40.0 -40.0 -20.0 
         L 0.0 -9.0 -2.0 -1.0 0.5 -1.0 0.0 -5.0 5.0 0.0 0.0 0.0 0.0 -5.0 -10.0 0.0 
Mea
n 
35.0  50.5 13.9 3.3 0.5 9.6 6.9  -9.7 -12.6 -11.4 -7.6 -16.0 -7.1 -4.4 -8.8 -12.5 -8.1 -11.3 -20.0 -19.4 -16.3 -8.8 -4.4 
STD 7.2  8.5 3.5 1.8 0.1 1.5 5.4  6.5 8.9 11.3 7.7 9.6 7.9 7.8 9.2 20.5 9.6 14.3 19.8 15.9 15.3 15.8 6.8 
Max 22.6  41.9 11.2 2.1 0.5 8.5 3.1  -23.5 -26.5 -32.0 -21.5 -30.5 -22.0 -20.0 -25.0 -45.0 -25.0 -40.0 -55.0 -45.0 -40.0 -40.0 -20.0 
Min 40.6  59.4 17.9 4.6 0.7 10.7 10.7  0.0 -1.0 0.0 0.0 0.5 0.0 5.0 5.0 5.0 0.0 0.0 0.0 0.0 0.0 10.0 0.0 
Med 38.1  50.4 12.6 3.3 0.5 9.6 6.9  -10.5 -9.8 -7.5 -4.5 -17.5 -5.0 -2.5 -10.0 -2.5 -5.0 -7.5 -20.0 -17.5 -15.0 -7.5 -2.5 
Note: * indicating missing data, either due to haemolysis with regards to the pharmacokinetic data, or participant variables (PTA)
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6.3.1.6. Week 10 – study visit 5. 
The participant’s pharmacokinetic readings and their change in hearing from baseline 
at week 10 are described in Table 6.23 (kanamycin participants) and 6.24 (capreomycin 
participants). 
Dropout from baseline was 15 participants, and thus 7 participants were present at 
week 10 (n = 7). At week 10, the mean age was 29.49 years. The total mean weight also 
shifted slightly to 55.52 kg at week 10. 
Two of these 7 participants were using capreomycin as the injectable. The others that 
had been using capreomycin had dropped out. The mean dose of kanamycin was 13.5 mg/kg 
(SD ± 1) and of capreomycin was 17.8 mg/kg (SD ± 0). Peak levels for kanamycin were 41.2 
μg/mg (SD ± 15.4), with trough levels at 0.9 μg/mg (SD ±0.6). With kanamycin, the half-life 
was 5 hours (SD ±0.6), and volume of distribution was 0.4 ℓ/kg (SD ±0.2). Due to too little 
blood that reached the laboratory, only the trough was measured at 0.5 μg/mg for 
capreomycin. The peak levels, half-lives and volume of distribution were not obtained.  
For participants taking kanamycin, a mean significant change of DPOAEs was noted 
at 2 kHz, 6 kHz, 8 kHz, 10 kHz and 12 kHz of -8.1 dB (SD ±4.5), -6.5 dB (SD±8.9), -10.2 dB 
(SD ±5), -8.4 (SD ±6.2) and -9.1 (SD ±10.6) respectively. There was a mean significant 
change (10 dB) noted in the PTA at 11.2 kHz, 12.5 kHz, 14 kHz and 16 kHz of -12.5 dB (SD 
±18.4), -15.5 dB (SD ±19.4), -19 dB (SD ±19.1) and -13 dB (SD ±17.5) respectively (see 
Table 6.23).  
For those participants taking capreomycin, a mean significant change of DPOAEs was 
noted at 2 kHz, 4 kHz, 8 kHz, 10 kHz and 12 kHz of -6.5 dB (SD ±6.2), -11.4 dB (SD ±10.1), 
-9.3 dB (SD ±8.1), -10.7 dB (SD ±10.1) and -8 dB (SD ±8.7) respectively. With regards to 
PTA at 8 kHz, 9 kHz, 10 kHz, 11.2 kHz and 12.5 kHz changes of -15 dB (SD ± 14.7), -27.5 
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dB (SD ±18.5), -32.5 dB (SD ±16.8), -25 dB (SD ±16.8) and -17.5 dB (SD ±15.5) 
respectively (see Table 6.24). 
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Table 6.23  
Week 10 Pharmacokinetic Results of kanamycin and Change in Audiology Results from Baseline (Audiology Baseline minus Week 10:  
Right and Left ears, n = 5) 
ID
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4 21.5 F 50.2 14.9 * 0.5 * * R -9.5 -8.0 -0.5 -16.0 -11.0 -12.0 0.0 -5.0 0.0 -5.0 -5.0 -5.0 -10.0 -10.0 0.0 0.0 
         L -6.0 -1.5 3.0 -8.0 -13.5 -2.5 -5.0 -5.0 0.0 0.0 -5.0 -5.0 0.0 0.0 -15.0 0.0 
5 32.7 M 59.0 12.7 * 0.5 * * R -12.0 -11.0 -23.0 -10.0 0.0 0.0 0.0 -5.0 -20.0 -10.0 -5.0 0.0 -10.0 -10.0 -10.0 0.0 
         L -1.5 -4.0 -20.0 -15.0 -22.0 -20.0 -5.0 -5.0 -25.0 -20.0 -35.0 -40.0 -45.0 -50.0 -50.0 -30.0 
7 18.8 F 57.0 13.2 * 0.5 * * R -11.0 -13.0 1.5 -13.0 -8.0 -29.0 0.0 -5.0 0.0 -5.0 -5.0 -5.0 -15.0 -45.0 -55.0 -50.0 
         L -11.0 -6.5 -3.5 -5.5 -6.0 2.0 0.0 -5.0 -5.0 -5.0 -15.0 0.0 0.0 -5.0 -10.0 -30.0 
8 29.7 F 53.3 14.07 30.4 1.6 5.4 0.5 R -1.0 -4.0 -9.5 -17.0 -5.0 -15.0 -5.0 0.0 0.0 0.0 -10.0 -5.0 -45.0 -30.0 -25.0 -5.0 
         L -5.0 -3.5 -6.0 -4.0 -6.0 -14.5 -5.0 0.0 -5.0 0.0 0.0 -5.0 -5.0 -10.0 -15.0 -5.0 
9 30.3 F 57.3 13.1 52.1 1.6 4.5 0.2 R -14.0 -2.5 -6.5 -10.0 -9.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -5.0 0.0 -10.0 -10.0 
         L -10.0 0.0 0.0 -3.0 -3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.0 5.0 0.0 0.0 
Mean 26.6  55.4 13.5 41.2 0.9 5.0 0.4 NA -8.1 -5.4 -6.5 -10.2 -8.4 -9.1 -2.0 -3.0 -5.5 -4.5 -8.0 -6.5 -12.5 -15.5 -19.0 -13.0 
STD 6.1  3.6 1.0 15.4 0.6 0.6 0.2 NA 4.5 4.2 8.9 5.0 6.2 10.6 2.6 2.6 9.3 6.4 10.6 12.0 18.4 19.4 19.1 17.5 
Max 18.8  50.2 12.7 30.4 0.5 4.5 0.2 NA -14.0 -13.0 -23.0 -17.0 -22.0 -29.0 -5.0 -5.0 -25.0 -20.0 -35.0 -40.0 -45.0 -50.0 -55.0 -50.0 
Min 32.7  59.0 14.9 52.1 1.6 5.4 0.5 NA -1.0 0.0 3.0 -3.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 10.0 5.0 0.0 0.0 
Med 29.7  57.0 13.1 41.2 0.5 5.0 0.4 NA -9.8 -4.0 -4.8 -10.0 -7.0 -7.3 0.0 -5.0 0.0 -2.5 -5.0 -5.0 -7.5 -10.0 -12.5 -5.0 
Note: * indicating missing data due to haemolysis with regards to the pharmacokinetic data, Yellow shading indicates the limits of the audiometer. 
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Table 6.24  
Week 10 Pharmacokinetic Results of capreomycin and Change in Audiology Results from Baseline (Audiology Baseline minus Week 10: Right and Left ears, n 
= 2) 
ID
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10 35.3 F 56.3 17.8 * 0.5 * * R -7.0 -13.0 -5.0 -18.0 -20.0 -15.0 0.0 0.0 0.0 -35.0 -50.0 -45.0 -50.0 -35.0 5.0 0.0 
         L -1.0 0.5 -2.5 -2.0 -12.0 0.0 0.0 10.0 0.0 -15.0 -35.0 -50.0 -20.0 0.0 0.0 0.0 
18 38.1 F  * * * * * R -15.0 -24.0 * * * -16.0 0.0 -5.0 0.0 0.0 -10.0 -10.0 -15.0 -10.0 -20.0 -20.0 
         L -3.0 -9.0 -3.0 -8.0 0.0 -1.0 0.0 -5.0 -5.0 -10.0 -15.0 -25.0 -15.0 -25.0 -10.0 0.0 
Mea
n 
36.7  56.3 17.8 * 0.5 
* * NA 
-6.5 -11.4 -3.5 -9.3 -10.7 -8.0 0.0 0.0 -1.3 -15.0 -27.5 -32.5 -25.0 -17.5 -6.3 -5.0 
STD 2.0        NA 6.2 10.1 1.3 8.1 10.1 8.7 0.0 7.1 2.5 14.7 18.5 18.5 16.8 15.5 11.1 10.0 
Max 35.3  56.3 17.8 0.0 0.5 0.0 0.0 NA -15.0 -24.0 -5.0 -18.0 -20.0 -16.0 0.0 -5.0 -5.0 -35.0 -50.0 -50.0 -50.0 -35.0 -20.0 -20.0 
Min 38.1  56.3 17.8 0.0 0.5 0.0 0.0 NA -1.0 0.5 -2.5 -2.0 0.0 0.0 0.0 10.0 0.0 0.0 -10.0 -10.0 -15.0 0.0 5.0 0.0 
Med 36.7  56.3 17.8  0.5   NA -5.0 -11.0 -3.0 -8.0 -12.0 -8.0 0.0 -2.5 0.0 -12.5 -25.0 -35.0 -17.5 -17.5 -5.0 0.0 
Note: * indicating missing data, either due to haemolysis with regards to the pharmacokinetic data, or equipment issues/SNR discrepancy (DPOAEs), Yellow shading indicates the limits of the 
audiometer. 
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6.3.1.7. Week 12 – study visit T6. 
The participant’s pharmacokinetic readings and their change in hearing from baseline 
at week 12 are described in Table 6.25 (kanamycin participants) and 6.26 (capreomycin 
participants). 
Dropout from baseline was 16 participants, and thus 6 participants were present at 
week 12 (n = 6). Due to the reasons described above, only 6 participants completed the entire 
study. At week 12, the mean age was 28.08 years. The total mean weight shifted again 
slightly to 53.78kg at week 12. 
One of these 6 participants were using capreomycin as the injectable. The others that 
had been using capreomycin had dropped out. The mean dose of kanamycin was 14.9 mg/kg 
(SD ± 2.5), and the dose of capreomycin was 18 mg/kg. Peak levels for kanamycin were 4.4 
μg/mg (SD ± 2.3) with trough levels at 0.9 μg/mg (SD ±0.4). For kanamycin, the half-life 
was 13.7 hours (SD ±6.0), and the volume of distribution was 5.8 ℓ/kg (SD ± 5.1). Only the 
trough level was obtained for capreomycin at 0.5 μg/mg. 
For participants taking kanamycin, a mean significant change of DPOAEs was noted 
at 2 kHz, 4 kHz, 6 kHz, 8 kHz, 10 kHz and 12 kHz of -11.2 dB (SD ±7.1), -8.9 dB (SD±3.4), 
-10.6 dB (SD ±5.9), -11.8 (SD ±4.8), -12.5 dB (SD ±6.4) and -11.7 dB (SD ±9.4) 
respectively. There was a mean significant change (10 dB) noted in the PTA at 9 kHz, 10 
kHz, 11.2 kHz, 12.5 kHz, 14 kHz and 16 kHz of -14.6 dB (SD ±7.4), -15 dB (SD ±7.1), -22.1 
dB (SD ±18.6), -17.9 dB (SD ±17.2), -19.2 dB (SD ±18) and -16.3 dB (SD ±14.7) 
respectively (see Table 6.25) 
For the one participant taking capreomycin, a mean significant change of DPOAEs 
was noted at 2 kHz, 4 kHz, 8 kHz, 10 kHz and 12 kHz of -8.8 dB (SD ±2.5), -9.5 dB (SD ± 
12), -10 dB (SD ±11.3), -16 dB (SD ±5.7) and -7.5 dB (SD ±10.6) respectively. With regards 
to PTA at 8 kHz, 9 kHz, 10 kHz, 11.2 kHz and 12.5 kHz changes of -25 dB (SD ±14.1), -42.5 
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE 
RELATIONSHIP BETWEEN HEARING LEVELS: A FEASIBILITY STUDY 
256 
dB (SD ±10.6), -47.5 dB (SD ± 3.5), -35 dB (SD ±21.2) and -17.5 dB (SD ±24.7) 
respectively (see Table 6.26).  
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Table 6.25 
Week 12 Pharmacokinetic Results of kanamycin and Change in Audiology Results from Baseline (Audiology Baseline minus Week 12:  
Right and Left ears, n = 5) 
ID
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4 21.5 F 40 18.8 * 0.5 * * R -9.5 -12.0 -8.5 -13.0 -10.5 -15.0 0.0 -10.0 -10.0 -5.0 -5.0 -5.0 0.0 -10.0 -10.0 -10.0 
         L -6.0 -5.5 -8.0 -10.0 -5.5 -7.5 -5.0 -5.0 -10.0 -5.0 0.0 0.0 -5.0 -5.0 -10.0 -5.0 
5 32.7 M 59 12.7 7.5 1.6 10.8 2.1 R -13.0 -12.0 -21.5 -10.0 0.0 0.0 5.0 -5.0 -15.0 -5.0 -10.0 -5.0 -10.0 -5.0 -10.0 -5.0 
         L -11.5 -13.0 -16.0 -13.5 -22.0 -20.0 -10.0 -10.0 -5.0 -10.0 -25.0 -25.0 -35.0 -35.0 -45.0 -35.0 
7 18.8 F 57 13.2 4.4 1.0 10.5 3.7 R -8.0 -13.0 -1.5 -20.0 -17.0 -29.0 0.0 -5.0 -5.0 -10.0 -10.0 -15.0 -50.0 -50.0 -60.0 -50.0 
         L -16.0 -7.5 -6.5 -7.5 -11.0 0.0 0.0 -5.0 0.0 -5.0 -15.0 -5.0 -5.0 0.0 -5.0 -25.0 
8 29.7 F 54.1 13.9 2.0 1.0 22.7 13.3 R -4.0 -4.0 -16.5 -18.0 -14.5 -15.0 0.0 0.0 -10.0 0.0 -10.0 -10.0 -50.0 -40.0 -30.0 -10.0 
         L -12.5 -6.0 -13.0 -5.5 -7.0 -17.5 -5.0 0.0 -10.0 0.0 -10.0 -5.0 -10.0 -10.0 -15.0 -10.0 
9 30.4 F 57 13.2 3.8 0.9 10.8 4.3 R -29.0 -6.5 -16.0 -16.0 -16.0 -4.5 -10.0 0.0 -10.0 -5.0 0.0 -5.0 -15.0 -10.0 -30.0 -15.0 
         L -7.0 -8.0 -10.0 -8.0 -14.0 -17.0 0.0 0.0 -5.0 -5.0 -5.0 -10.0 -15.0 -15.0 -15.0 -25.0 
Mean 26.6  53.78 14.9 4.4 0.9 13.7 5.8 NA -11.2 -8.9 -10.6 -11.8 -12.5 -11.7 -0.8 -2.9 -6.3 -8.3 -14.6 -15.0 -22.1 -17.9 -19.2 -16.3 
STD 6.1  6.89 2.5 2.3 0.4 6.0 5.1 NA 7.1 3.4 5.9 4.8 6.4 9.4 4.9 3.9 4.2 3.3 7.4 7.1 18.6 17.2 18.0 14.7 
Max 18.8  40 12.7 2.0 0.5 10.5 2.1 NA -29.0 -13.0 -21.5 -20.0 -22.0 -29.0 -10.0 -10.0 -15.0 -10.0 -25.0 -25.0 -50.0 -50.0 -60.0 -50.0 
Min 32.7  59 18.8 7.5 1.6 22.7 13.3 NA -4.0 -4.0 -1.5 -5.5 0.0 0.0 5.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -5.0 -5.0 
Med 29.7  57 13.2 4.1 1.0 10.8 4.0 NA -10.5 -7.8 -11.5 -11.5 -12.5 -15.0 0.0 -5.0 -10.0 -5.0 -10.0 -5.0 -12.5 -10.0 -15.0 -12.5 
* indicating missing data due to haemolysis with regards to the pharmacokinetic data, Yellow shading indicates the limits of the audiometer.  
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE RELATIONSHIP BETWEEN HEARING LEVELS: A FEASIBILITY STUDY 
258 
Table 6.26 
Week 12 Pharmacokinetic Results of capreomycin and Change in Audiology Results from Baseline (Audiology Baseline minus Week 12:  
Right and Left ears, n = 1) 
ID
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10 35.4 F 55.6 18.0 * 0.5 * * R -10.5 -18.0 -6.0 -18.0 -20.0 -15.0 0.0 -5.0 0.0 -35.0 -50.0 -45.0 -50.0 -35.0 0.0 -5.0 
         L -7.0 -1.0 -4.0 -2.0 -12.0 0.0 15.0 10.0 5.0 -15.0 -35.0 -50.0 -20.0 0.0 0.0 0.0 
Mean 35.4  55.6 18.0  0.5   NA -8.8 -9.5 -5.0 -10.0 -16.0 -7.5 7.5 2.5 2.5 -25.0 -42.5 -47.5 -35.0 -17.5 0.0 -2.5 
STD NA  NA      NA 2.5 12.0 1.4 11.3 5.7 10.6 10.6 10.6 3.5 14.1 10.6 3.5 21.2 24.7 0.0 3.5 
Max 35.4  55.6 18.0  0.5   NA -10.5 -18.0 -6.0 -18.0 -20.0 -15.0 0.0 -5.0 0.0 -35.0 -50.0 -50.0 -50.0 -35.0 0.0 -5.0 
Min 35.4  55.6 18.0  0.5   NA -7.0 -1.0 -4.0 -2.0 -12.0 0.0 15.0 10.0 5.0 -15.0 -35.0 -45.0 -20.0 0.0 0.0 0.0 
Med 35.4  55.6 18.0  0.5   NA -8.8 -9.5 -5.0 -10.0 -16.0 -7.5 7.5 2.5 2.5 -25.0 -42.5 -47.5 -35.0 -17.5 0.0 -2.5 
Note: * indicating missing data, due to haemolysis with regards to the pharmacokinetic data, Yellow shading indicates the limits of the audiometer. 
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6.3.1.8. PTA and DPOAE changes in relation to 
pharmacokinetics. 
The significant mean PTA and DPOAE changes in relation to the pharmacokinetics of 
both kanamycin and capreomycin are detailed in Table 6.27 and Table 6.28. Furthermore, 
Table 6.29 highlights the various grading scales, together with the relevant injectables and 
dosages as well as the HIV status. 
• PTA and DPOAEs in relation to pharmacokinetics 
With regards to PTA (Table 6.27), the most significant changes were seen in the later 
weeks, particularly from T4 to T6. As described in Table 6.8 where the significant changes of 
kanamycin and capreomycin were detailed at weeks 10 and 12 (T4 and T6), and kanamycin 
showed changes in more frequencies than the capreomycin participants.  
However, in Table 6.27, when not taking 3 kHz and 4 kHz into account, capreomycin 
appeared to be potentially more ototoxic. Yet, the sample sizes were different at the various 
weeks, and those on capreomycin were initially on kanamycin and were switched to 
capreomycin, as they were demonstrating a hearing loss. Therefore, they may have been more 
susceptible to hearing loss. The toxicity profile, however, was under observation of the 
various frequencies and decibels changes, but could not be calculated statistically due to the 
sample size. 
The doses were similar between kanamycin and capreomycin, yet at T5, the 
kanamycin dose was 13.5 mg/kg with capreomycin being 17.8 mg/kg, and capreomycin 
displayed more toxicity than kanamycin (at these frequencies). Similarly, at T6, when 
looking at frequencies of 6 kHz and above, the capreomycin dosage was higher at 18 mg/kg 
when compared to the kanamycin dosage of 14.9 mg/kg, where capreomycin also appeared to 
display more toxicity. Yet, this result could be skewed as there was only one participant on 
capreomycin at T6. Furthermore, the trough levels for both kanamycin and capreomycin were 
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below 10 μg/ml and not toxic, yet ototoxicity still occurred. It is postulated that the 
ototoxicity is related to dosage per kg and not to trough levels.  
However, this was not observed with DPOAE, as toxicity in the latter weeks were 
similar (weeks 10 and 12) (Table 6.28). 
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Table 6.27  
Significant PTA changes in relation to pharmacokinetics for kanamycin and capreomycin from baseline to week 12 
  
T0 
(KM) 
T0  
(CM) 
T1 
(KM) 
T1  
(CM) 
T2 
|(KM) 
T2  
(CM) 
T3 | 
(KM) 
T3  
(CM) 
T4  
(KM) 
T4  
(CM) 
T5  
(KM) 
T5 
 (CM) 
T6 
 (KM) 
T6  
(CM) 
N 
 
22 0 11 4 8 3 5 4 5 5 5 2 5 1 
Dropout/ CM* Frequency 0 0 7 0 3 1 3 0 0 0 0 3 0 1 
Mean PTA 
significant changes 
(dB) 
6 kHz   - - - - - - - 12.5 - - - - 
SD   - - - - - - - 20 - - - - 
8 kHz    - - - - - - - - - -15 - -25 
SD   - - - - - - - - - 14.7 - 14.1 
9 kHz    - - - -13.3 - - - -11.3 - -27.5 -14.6 -42.5 
SD   - - - 11.5 - - - 14.3 - 18.5 7.4 10.6 
10 kHz   - - - -16.7 - 15.6 - -20 - -32.5 -15 -47.5 
SD   - - - 14.4 - 12.1 - 19.8 - 16.8 7.1 3.5 
11.2 kHz   - -10.2 - -16.7 -10 -13.1 - -19.4 -12.5 -25 -22 -35 
SD   - 14.8 - 25.7 8.8 16.2 - 15.9 18.4 16.8 18.6 21.2 
12.5 kHz   - - -10 -15 - -15 - -16.3 15.5 -17.5 -17.9 -17.5 
SD   - - 16.2 21.8 - 11 - 15.3 19.4 15.5 17.2 24.7 
14 kHz    - - -15.4 - -15.5 - -18 - -19 - -19.2 - 
SD   - - 16.3 - 10.7 - 17.2 - 19.1 - 18 - 
16 kHz    - - -13.1 - -13 - -16 - -13 - -16.3 - 
SD   - - 18.3 - 18.3 - 17.3 - 17.5 - 14.7 - 
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T0 
(KM) 
T0  
(CM) 
T1 
(KM) 
T1  
(CM) 
T2 
|(KM) 
T2  
(CM) 
T3 | 
(KM) 
T3  
(CM) 
T4  
(KM) 
T4  
(CM) 
T5  
(KM) 
T5 
 (CM) 
T6 
 (KM) 
T6  
(CM) 
Age (in years) Mean 33.8  31.8 32.1 28.3 32.0 26.5 38.0 27.8 35.0 26.6 36.7 26.6 35.4 
SD 7.3  8.3 7.8 6.8 8.3 6.1 2.2 6.2 7.2 6.1 2.0 6.1  
Dose (mg/kg) Mean 16.0  14.1 14.3 13.7 15.3 14.9 13.5 14.8 13.9 13.5 17.8 14.9 18.0 
SD 4.8  1.5 1.8 2.1 3.9 2.3 3.2 2.0 3.5 1.0  2.5  
Peak (μg/ml) Mean 21.0  18.2 16.8 11.1 6.4 10.2 5.9 34.1 3.3 41.2 
 
4.4 
 
SD 38.6  17.4 16.8 7.9 2.1 3.1 1.3 31.1 1.8 15.4 
 
2.3 
 
Trough (μg/ml) Mean 0.4  2.4 1.9 1.4 0.5 1.6 0.5 1.7 0.5 0.9 0.5 0.9 0.5 
SD 0.3  4.6 4.0 1.5 0.0 1.9 0.1 1.9 0.1 0.6  0.4  
Half-life (hours) Mean 7.5  7.2 6.7 7.2 6.3 13.3 6.2 11.2 9.6 5.0  13.7  
SD 5.5  2.5 2.5 1.5 0.8 10.3 0.8 9.5 1.5 0.6  6.0  
VD (ℓ/kg) Mean 4.5  1.3 1.3 2.3 2.2 2.2 2.7 0.8 6.9 0.4  5.8  
SD 5.1  1.1 1.1 1.5 0.1 1.0 1.3 0.9 5.4 0.2  5.1  
‘-‘ No significant change detected, *participant, dropped out from the study or switched to capreomycin, 
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Table 6.28 
Significant DPOAE changes in relation to pharmacokinetics for kanamycin and capreomycin from baseline to week 12 
 Frequency 
T0  
(KM) 
T0 
 (CM) 
T1  
(KM) 
T1  
(CM) 
T2  
(KM) 
T2  
(CM) 
T3  
(KM) 
T3  
(CM) 
T4  
(KM) 
T4 
 (CM) 
T5  
(KM) 
T5  
(CM) 
T6 
 (KM) 
T6  
(CM) 
N  22 0 11 4 8 3 5 4 5 5 5 2 5 1 
Dropout/  
switched to 
capreomycin 
 0 0 7 0 3 1 3 0 0 0 0 3 0 1 
Mean DPOAE 
significant change 
(dB) 
2 kHz    - - -6.8 - - -9.3 -7.7 -9.7 -8.1 -6.5 -8.8 -8.8 
SD   - - 5.4 - - 5.5 4.1 6.5 4.5 6.2 2.5 2.5 
4 kHz    - - - -6 - -7.8 - 12.6 - -11.4 - -9.5 
SD   - - - 5 - 5.6 - 8.9 - 10.1 - 12 
6 kHz    - - - - - -8.2 -6.6 11.4 -6.5 - -9.5 - 
SD   - - - - - 10.7 7.4 11.3 8.9 - 12 - 
8 kHz    -7.1 - -6.7 - -9.5 - -9.8 -7.6 -10.2 -9.3 -10 -10 
SD   6.8 - 7.6 - 8.8 - 6.3 7.7 5 8.1 11.3 11.3 
10 kHz   -8.2 -6.3 -8.7 -12.7 -7.1 -10.6 -6.1 -16 -8.4 -10.7 -16 -16 
SD   9.4 8.8 6.4 3.1 4.6 7.1 6.3 9.6 6.2 10.1 5.7 5.7 
12 kHz   - - -6.4 - -6.8 -6.2 -6 -7.1 -9.1 -8 -7.5 - 
SD   - - 7.1 - 7 6.4 8.1 7.9 10.6 8.7 10.6 - 
Age (in years) Mean 33.8  31.8 32.1 28.3 32.0 26.5 38.0 27.8 35.0 26.6 36.7 26.6 35.4 
SD 7.3  8.3 7.8 6.8 8.3 6.1 2.2 6.2 7.2 6.1 2.0 6.1  
Dose (mg/kg) Mean 16.0  14.1 14.3 13.7 15.3 14.9 13.5 14.8 13.9 13.5 17.8 14.9 18.0 
SD 4.8  1.5 1.8 2.1 3.9 2.3 3.2 2.0 3.5 1.0  2.5  
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 Frequency 
T0  
(KM) 
T0 
 (CM) 
T1  
(KM) 
T1  
(CM) 
T2  
(KM) 
T2  
(CM) 
T3  
(KM) 
T3  
(CM) 
T4  
(KM) 
T4 
 (CM) 
T5  
(KM) 
T5  
(CM) 
T6 
 (KM) 
T6  
(CM) 
Peak (μg/ml) Mean 21.0  18.2 16.8 11.1 6.4 10.2 5.9 34.1 3.3 41.2 
 
4.4 
 
SD 38.6  17.4 16.8 7.9 2.1 3.1 1.3 31.1 1.8 15.4 
 
2.3 
 
Trough (μg/ml) Mean 0.4  2.4 1.9 1.4 0.5 1.6 0.5 1.7 0.5 0.9 0.5 0.9 0.5 
SD 0.3  4.6 4.0 1.5 0.0 1.9 0.1 1.9 0.1 0.6  0.4  
Half-life (hours) Mean 7.5  7.2 6.7 7.2 6.3 13.3 6.2 11.2 9.6 5.0  13.7  
SD 5.5  2.5 2.5 1.5 0.8 10.3 0.8 9.5 1.5 0.6  6.0  
VD (ℓ/kg) Mean 4.5  1.3 1.3 2.3 2.2 2.2 2.7 0.8 6.9 0.4  5.8  
SD 5.1  1.1 1.1 1.5 0.1 1.0 1.3 0.9 5.4 0.2  5.1  
‘-‘ No significant change detected.  
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6.3.1.9. Kanamycin and capreomycin mean dose in relation to 
ototoxicity. 
This section describes the kanamycin and capreomycin mean dosages in relation to the 
ototoxicity detected by using the grading systems available (Table 6.29). Each participant has 
two results in the last four columns; the top result is of the right ear, while the bottom is the 
left ear. The gradable hearing loss is detailed according to the existing adult grading scales 
(according to PTA). As there is no grading scale for DPOAEs, any loss of 6 dB or greater 
was considered a loss and marked as ‘yes’ (Table 6.29). 
It must be noted that in some instances, with PTA, loss of hearing is observed in the 
higher frequencies, yet not depicted as a gradable loss on a grading scale. Overall, significant 
changes were noticed more with DPOAEs than the PTA results. Patients on capreomycin did 
not show less of a hearing loss than those on kanamycin. However, they were often switched 
to capreomycin when they were experiencing ototoxicity. Their auditory system could have 
been vulnerable to develop hearing loss by this stage (Table 6.29). 
The lowest dosage of kanamycin was 11.9 mg/kg (participant 16). This participant was 
switched to capreomycin (12.4 mg/kg) however at week 4. The highest dosage was 34 mg/kg 
of kanamycin (participant 14), but she was also switched onto capreomycin. Participant 16 
shows more of a gradable hearing loss than participant 14. Also, the HIV negative 
participants displayed similar loss of hearing as the HIV positive patients, yet the sample was 
too small to make the assumption that there is no relationship between HIV status and 
hearing (Table 6.29). 
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE RELATIONSHIP BETWEEN HEARING LEVELS: A FEASIBILITY STUDY 
266 
Table 6.29 
Injectable Mean Dose from Baseline and Ototoxicity Grading Scales (right and left ears) 
Patient 
Weeks in the 
Study (T) 
HIV Status Age (Baseline) Gender KM mean dose CM mean dose 
DPOAE  
6 dB 
TUNE CTCAE ASHA) 
1 0,1,2 POS 24.4 F 13.5 NA 
YES 2a - YES 
YES 1a - YES 
2 0,1 POS 40.1 M 12.8 NA 
- 0 - NO 
- 1a - NO 
4 0,1,2,3,4,5,6 POS 21.2 F 17.8 NA 
YES 1a - YES 
YES 0 - NO 
5 0,1,2,3,4,5,6 POS 32.4 M 13.4 NA 
YES 1a - YES 
YES 2a - YES 
6 0,1,2 POS 29.1 F 14.2 NA 
YES 0 - YES 
YES 0 - YES 
7 0,1,2,3,4,5,6 NEG 18.6 F 13.8 NA 
YES 2a - YES 
YES 0 - YES 
8 0,1,2,3,4,5,6 POS 29.4 F 14.2 NA 
YES 2a - YES 
YES 1a - YES 
9 0,1,2,3,4,5,6 POS 30.1 F 13.6 NA 
YES 1a - YES 
YES 1a - YES 
10 0,1,2,3,4,5,6 POS 35.1 F 15.9 17.5 
YES 2a - YES 
YES 2a - YES 
12 0,1 POS 41.11 F 14.5 NA 
YES 2a 1 YES 
NO 1a - YES 
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Patient 
Weeks in the 
Study (T) 
HIV Status Age (Baseline) Gender KM mean dose CM mean dose 
DPOAE  
6 dB 
TUNE CTCAE ASHA) 
14 0,1,2,4 POS 22.4 F 34.1 17.7 
YES 1a - YES 
YES 1a - YES 
15 0,1, NEG 41 F 14.1 NA 
YES 1a - YES 
YES 1a - YES 
16 0,1,2,3,4 POS 40.4 M 11.9 12.4 
YES 2a - YES 
YES 1a - YES 
17 0,1,2,3,4 POS 38.1 F 17.9 11.2 
YES 2a - YES 
YES 1a - YES 
18 0,1,3,4,5 POS 37.11 F 14.1 13.8 
YES 1a - YES 
YES 2a - YES 
Note: ‘-‘ indicates no grade is applicable, TUNE Grading system only grades up to 12.5 kHz and does not include 9 and 11.2 kHz. CTCAE only grades up to 8 kHz. ASHA is for all the 
frequencies. Audiology results not included for those that dropped out before week 2. Audiology results included are at last study visit before dropout, or last audiology results available
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6.3.2. Summary of Pharmacokinetics in Relation to Hearing 
In summary, the sample was too small to understand the hearing loss at the various 
weeks in relation to the dosage and trough levels. Overall, the trough levels did not correlate 
to ototoxicity. In some instances, when looking at mean levels (Table 6.27 and 6.28), dosage 
did correlate to ototoxicity, yet when looking at individual patients, such as in Table 6.29, 
dosage did not correlate to ototoxicity. 
Overall, the pharmacokinetic results were erratic and differed significantly between 
individuals. A conclusive positive or negative relationship between dosage and trough levels 
was not observed with the progression of hearing loss. 
6.4. Feasibility Findings 
Lastly, the audiological and pharmacokinetics findings assisted in determining the 
main aim of feasibility: 
Establishing the feasibility of investigating the pharmacokinetics and 
pharmacodynamics of kanamycin and capreomycin in patients with DR-TB and the 
relationship with hearing levels. 
This further included establishing: 
• The willingness of patients to participate in a pharmacokinetic study in conjunction 
with hearing evaluations 
• To investigate whether TDM could potentially be utilised regarding dosage 
adjustments of kanamycin and capreomycin 
 
The primary aim of this study was to determine the feasibility of investigating the 
pharmacokinetics and pharmacodynamics of kanamycin and capreomycin in patients with 
DR-TB and the relationship with hearing levels. This feasibility study was impacted by 
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various aspects, including the willingness of participation, issues with blood samples, quality 
assurance including record keeping and data management, medical management and changes 
in protocols and lack of resources. Furthermore, the results yielded in sections 6.2 and 6.3 
regarding the pharmacokinetics of kanamycin and capreomycin in relation to hearing levels 
impacted the possibility of TDM of kanamycin and capreomycin. 
6.4.1. Willingness to Participate and Respondent Enrolment  
Participation was entirely voluntary. Participants were approached and counselled by 
a skilled and trained study coordinator and in some cases, assisted by a study social worker 
regarding the study. However, despite the potential participants identified, at both study sites, 
willingness to participate was poor. Of the 36 potential participants at HJH and 46 at SRH, 
only nine and 13 consented respectively. 
Thus, despite the significant number of potential participants identified, patients were 
not keen to take part in this involved study, which impacted the overall results and statistical 
outcomes. It is important to note this for the determination of a more involved 
pharmacokinetic study. The reasons for refusal of participation are evident in Table 6.30. 
Furthermore, adherence was also an issue after enrolment.  
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Table 6.30  
Reasons for Refusal of Participation and Dropout 
Reasons for refusing to participate HJH SRH 
• Overwhelmed by the research protocol 5 9 
• Overwhelmed by the DR-TB treatment protocol 2 0 
• Family members refused participation 1 1 
• No reason 2 3 
Reasons for dropout from the study (and likely dropout 
from treatment) 
  
• Return to work   1 
• Patient decided to withdraw (no reason) 1  
• Sputum positive therefore transferred to Sizwe Tropical 
Disease Hospital 
1 3 
• Passed away  1 
• Refused hospital treatment (reason unknown) 1  
• Return to ‘homeland’ (other provinces, neighbouring 
countries) 
 3 
• Injectable discontinued due to high creatinine levels  3 
• Ototoxicity: thus, investigation of bedaquiline trial  1 
• Non-compliance with study procedures 1  
 
Many patients were extremely ill and too weak to visit the clinic for their injections. 
Medication adherence and infection control could not be examined conclusively as the 
participants were not followed when they were at home.  
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The study coordinator enrolled 22 participants; nine form HJH and 13 from SRH. 
However, only six completed the entire study. The participant genders, ages, weights and 
HIV statuses are described in Tables 6.31 and 6.32 below. Majority of the participants were 
female, on kanamycin, with mean ages between 26.5 and 38 years. Also, many of the 
participants were HIV positive. 
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Table 6.31  
Description of Participants on kanamycin 
    T0 T1 T2 T3 T4 T5 T6 
n   22 11 8 5 5 5 5 
dropout (or switched to 
capreomycin)  
0 7 3 3 0 0 0 
Gender 
M 7 3 2 1 1 1 1 
F 15 8 6 4 4 4 4 
Age (years) 
Mean 33.8 31.8 28.3 26.5 27.8 26.6 26.6 
SD 7.3 8.3 6.8 6.1 6.2 6.1 6.1 
Min 18.6 18.6 18.7 18.7 18.7 18.8 18.8 
Max 42.8 42.0 40.5 -32.6 32.6 32.7 32.7 
Median 35.1 30.1 29.4 29.6 30.0 29.7 29.7 
Weight (kg) 
Mean 54.1 53.5 55.4 51.2 54.0 55.4 53.8 
SD 10.9 8.7 2.7 6.8 1.4 3.6 7.7 
Min 34.0 37.0 54.0 40.0 52.0 50.2 40.0 
Max 73.0 69.0 59.4 -57.0 55.0 59.0 59.0 
Median 54.5 54.0 54.0 54.0 54.5 57.0 57.0 
HIV Status 
POS 18 9 7 4 4 4 4 
NEG 4 2 1 1 1 1 1 
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Table 6.32 
Description of Participants on capreomycin. 
  T0 T1 T2 T3 T4 T5 T6 
n  0 4 3 4 5 2 1 
dropout   0 1 0 0 3 1 
Gender M 0 0 0 1 1 0 0 
F 0 4 3 3 4 2 1 
Age (years) Mean  32.1 32.0 38.0 35.0 36.7 35.4 
SD  7.8 8.3 2.2 7.2 2.0  
Min  18.6 22.5 35.2 22.6 35.3 35.4 
Max  42.0 38.2 40.5 40.6 38.1 35.4 
Median  32.5 35.2 38.2 38.1 36.7 35.4 
Weight (kg) Mean  53.8 48.8 48.9 50.5 56.3 55.6 
SD  9.9 6.8 8.0 8.5   
Min  52.8 58.0 43.7 41.9 56.3 55.6 
Max  72.4 58.0 58.1 59.4 56.3 55.6 
Median  54.0 58.0 44.8 50.4 56.3 55.6 
HIV Status POS  4 3 4 5 2 1 
NEG  0 0 0 0 0 0 
 
Many participants were first time TB infections; they had not been previously treated 
for TB or DR-TB (Table 6.33). 
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Table 6.33  
History of TB treatment  
 
HJH SRH Total 
n % n % n % 
First Time Infection 5 56 8 62 13 59 
Previously been Treated for 
TB 
4 44 5 38 9 41 
Switched to capreomycin 
rather than kanamycin 
0 0 5 39 5 23 
 
When looking at the participants that were most adherent to the study protocols (the 
six participants that completed the study), no distinct pattern was observed with age, 
education or marital status (Table 6.34).  
 
Table 6.34  
Age Education and Marital Status of Most Adherent Participants 
Participant Age (years at 
enrolment) 
Education Level 
Completed 
Marital Status 
K004 21.2 Grade 10 Single 
K005 32.4 Grade 12 Cohabiting 
K007 18.6 Grade 11 Single 
K008 29.4 Grade 10 Single 
K009 30.1 Grade 10 Single 
K010 35.1 Grade 10 Cohabiting 
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Majority of the participants had only completed a Grade 10 level of education. 
Furthermore, the majority were unemployed. Although the language of choice varied, the 
majority of the participants reported being most comfortable in English with regards to 
conduct study-related procedures (Figure 6.1). 
 
Figure 6.1. Education, employment, and language of participants enrolled 
6.4.2. Blood Samples 
The collection of blood samples for the pharmacokinetic measurements as well as 
creatinine measurement proved difficult for various reasons. 
With regards to the pharmacokinetic measurements; this study started by analysing 
kanamycin only, and then moved onto capreomycin to increase the sample size. 
Initially, the kanamycin pharmacokinetics in this study was the first to be measured in 
DR-TB patients in South Africa. Moreover, thus, a protocol needed to be developed. The 
established laboratories such as CLS, National Health Laboratory Service (NHLS) or other 
private laboratories could not perform these measurements, and so the pharmacokinetics and 
biochemists at SMU were responsible for this. Although they had the expertise and 
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equipment, the laboratory was over an hour drive away, and this resulted in some 
complications, such as haemolysis of the blood samples and spillage on the way to SMU 
despite the correct storage of these samples. These complications resulted in a significant 
amount of missing pharmacokinetic data.  
Also, although creatinine was measured as per standard hospital care, the results were 
difficult to track on the NHLS website. When the study team searched the NHLS database 
(multiple times under numerous searches) results could not be accessed/found when 
searching for participants ID numbers, hospital numbers, names and so on. From observation, 
it appeared possible that the results may have been captured incorrectly, perhaps with 
incorrect digits with ID and hospital numbers, as well as incorrect spelling of participant 
names. 
The complications of performing these pharmacokinetic measurements, including the 
transportation of samples have been established and need to be taken into consideration for a 
more extensive study.  
6.4.3. Quality Assurance, including Record Keeping and Data 
Management 
QA was an issue in this study and needs to be considered for more extensive studies. 
These issues with QA were portrayed mainly with the record keeping and data management. 
Each participant had two files: a study file and a hospital file. At times, information 
was obtained from the hospital file for the study file. Also, various results were planned to be 
obtained from the hospital file for the study. However, much of this information was not in 
the hospital files, which made the obtaining of information for the study file extremely 
difficult. This included height and medical changes noted in the participants (physical and 
psychological). 
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Also, much of the results, specifically the sputum results as well the creatinine results 
were required from the NHLS. However, these results were often not placed in the hospital 
file. Subsequently, when searching the NHLS website, the results could not be found. This is 
possibly due to the incorrect capturing of the data. However, this impacted the study 
significantly as much of the information became missing, although the tests were carried out 
as per the protocol.  
6.4.4. Medical Management, including Change in Protocols and 
Medications 
Medical management of participants in this study took place as per the NDoH 
guidelines for patients with DR-TB. However, on observation, between sites, the 
management differed, which affected the uniformity of the study, but also made statistics and 
record keeping for National Guidelines difficult. 
HJH is an outpatient facility while SRH is an inpatient facility (for the first few weeks 
of treatment). Availability of drugs also differs, as HJH only had kanamycin (and bedaquiline 
is some cases), while SRH had kanamycin and capreomycin. Therefore, patients at HJH were 
provided mostly with kanamycin, and only in some cases, the motivation for bedaquiline was 
possible; whereas, at SRH, capreomycin was readily available for those participants 
displaying adverse effects from kanamycin. As these participants were switched to 
capreomycin, it created a variance between the sites. 
Furthermore, HJH had multiple counsellors as part of their team, whereas SRH did 
not. This could impact the compliance of patients. The audiology services available at SRH 
and HJH were also different, due to the inpatient and outpatient setup. 
These differences in treatment complicate the feasibility of studies, mainly where 
sample sizes may be small, and so variations of treatment are difficult to analyse.  
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6.4.5. Resources 
In general hospital settings, the limited resources with regards to personnel, 
equipment, and training were identified. This would impact the feasibility of future studies. 
This current study compensated and planned for the lack of recourses, however, 
despite this, the impact was still felt. 
As UHF PTA equipment and DPOAE equipment was not available in the hospital 
settings, the PTA audiometer was borrowed specifically for the purpose of the study for a 
limited period. Therefore, when the company required the borrowed equipment, further 
testing could not take place. Although testing was possible for this study, the equipment it is 
not freely available, which impacts further studies, as well as the general standard of care 
where UHF monitoring would be ideal. 
Furthermore, the study coordinator was funded for a 12-month period to assist with 
this study, and thus after this period, there was no personnel available to assist with the day to 
day running of study procedures. As per the dropout rate initially calculated, one year was 
sufficient to collect the data. However, due to unforeseen dropout rates, the sample obtained 
was extremely small. The researcher was not able to draw blood samples as it is outside her 
scope of practice, and so this impacted the feasibility of this study, but would also impact the 
feasibility of future studies. Furthermore, in daily practice, there are not enough skilled 
personnel to assist with ototoxicity monitoring and possible pharmacokinetic measurements. 
In summary, a pharmacokinetic study as such, requires audiological equipment, 
skilled personnel, various equipment, as well as support personnel for QA and transportation 
of blood samples. These aspects are expensive, and thus a larger budget is needed for a more 
extensive scale study.  
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6.4.6. The potential of whether TDM could potentially be utilised 
regarding dosage adjustments of kanamycin and 
capreomycin 
This study aimed to measure these pharmacokinetic factors and to evaluate it 
according to the efficacy of treatment as well as ototoxicity. However, upon testing these 
pharmacokinetic factors, the mean peak level for kanamycin was 20 μg/ml (±16.5) and 8.1 
μg/ml for capreomycin (±5.5).  
The range of desired peak levels for capreomycin appears to be between 20 μg/ml and 
40 μg/ml (Reisfeld et al., 2012) and between 20 μg/ml and 35 μg/ml (Mugabo et al., 2015). 
Although the mean peak from kanamycin was within the desired range, the SD was 
substantial, indicating many peak levels below this range.  
Adjustment of these drugs would require, at times, to quintuple the dosages. This is a 
significant adjustment, with not enough evidence to support the need for this, as cultures 
often did covert, despite these low peak levels. Research supports that increased trough levels 
result in toxicities, specifically ototoxicity. The larger the dose, the likelihood of more 
significant trough levels, and thus toxicities (Mugabo et al., 2015; Pechere & Dugal, 1979). 
As many participants were outpatients, there was not enough medical monitoring of the 
participants to deal with problems or emergencies that may arise with dosage adjustments. 
Therefore, from this study, the feasibility of conducting TDM in the treatment of DR-
TB patients was not established. However, more extensive studies are recommended to 
explore this possibility further. 
6.4.7. Summary of Feasibility Findings 
In summary, of a potential 268 participants at both hospitals, only 22 were enrolled 
after 12 months of recruitment. This poor enrolment and retention were for a variety of 
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reasons; from a willingness to participate in exclusion based on the study inclusion and 
exclusion criteria. 
The peak levels of many kanamycin patients were sub-therapeutic, even though the 
mean peak was 20 μg/ml (±16.5), while the peak levels of capreomycin were all sub-
therapeutic with a mean of 8.1 μg/ml (±5.5). Trough levels for both kanamycin and 
capreomycin were below 10 μg/ml, which would indicate non-toxic levels. 
However, despite these pharmacokinetic results, changes in hearing was noted (more 
so for kanamycin than capreomycin), as well as reduced CrCl levels with the kanamycin 
patients. Therefore, toxicity was noted. Lastly, despite the sub-therapeutic peak levels, 
patients culture converted within the first two months of treatment.  
Therefore, with the small sample size achieved, as well as erratic levels with regards 
to the pharmacokinetics, substantial issues with regards to the feasibility of larger studies 
were identified. These issues, such as willingness to participate, blood sampling issues, large 
variations with results, QA, as well protocol variations between institutions need 
consideration in order to conduct a larger and necessary study.
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Chapter 7: Discussion  
In this chapter, the results as presented in chapter 6, will be discussed in relation to the 
literature and probable explanations where possible. As above, the audiological and 
pharmacological results will be discussed in the relevant sections, concluding with feasibility 
aspects of this study.  
7.1. Audiological Results 
The audiological results address the aim of determining the changes in hearing levels 
in patients treated with kanamycin and capreomycin for DR-TB, by looking at the prevalence 
of abnormal findings on baseline assessments and determining the change in hearing levels 
from baseline. 
7.1.1. Pure Tone Audiometry and Distortion Product 
Otoacoustic Emissions  
When examining the audiological results (PTA and DPOAEs), a definite pattern was 
observed, indicating the ultra-high frequencies (9kHz to 16 kHz) being affected first, 
followed by some high frequencies (specifically 6 kHz and 8 kHz).  
An aim of this current study included the identification of changes in hearing from 
baseline measures. The mean results at the relevant weeks were explicitly presented in 
chapter 6 where the loss in the high frequencies (8 kHz and below) was seen from week 6, 
with UHFs being affected from week 4. The right ear showed a significant change from week 
six to 6 kHz, and week ten at 8 kHz, yet from week four at 11.2 kHz and above. The left ear 
showed mean significant change from week eight at 6 kHz and 8 kHz, yet from week four at 
16 kHz. With the DPOAEs, a mean loss of 6 dB or higher was seen by week two in the right 
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ears at 6 kHz and 8 kHz, yet only from week 8 in the left ear. From week 2, a significant 
change of 10 dB or greater (with PTA) identified 23 ears (77%). This was at one or more of 
the ultra-high frequencies. Slightly less change was noted with the DPOAE ultra-high 
frequencies whereby week two, half the participants showed a deterioration of 6 dB or 
greater. However, the ultra-high frequencies with DPOAEs only tested up to 10 kHz, where 
the PTA tested up to 16 kHz. Furthermore, at baseline, half the participants displayed some 
sort of hearing loss, as measured with PTA. This ranged from a 30 dBHL threshold at one 
frequency to a 40 dBHL threshold at four frequencies bilaterally.  
As cochleotoxicity research supports the damage initially occurring to the other hair 
cells at the basal end of the cochlea, the higher frequencies are initially affected (Peterson & 
Rogers, 2015). From this research, as well as from the limitation of the audiometer, we can 
assume the hearing loss is greater than recorded as depicted below at 16 kHz. 
The findings of the current study support the literature regarding the general nature 
and configuration of an aminoglycoside /polypeptide induced hearing loss (Harris & Heinze, 
2015) in the DR-TB population (Harris et al., 2012). In both ears, the greatest change in 
hearing levels is noticed in the ultra-high frequencies (9 kHz to 16 kHz). The greatest change 
in hearing was at 11.2 kHz bilaterally. As with ototoxicity, the outer hair cells are affected 
first, indicating the higher frequencies being affected by the lower frequencies (Peterson & 
Rogers, 2015). This was evident in the current study, where, the UHF and HF were affected.  
Many studies investigating ototoxicity in the TB population only studied ototoxicity 
up to 8 kHz, and the loss in the UHFs was not necessarily monitored (Sharma et al., 2016; 
Ghafari et al., 2015; Javadi et al., 2011). Sharma et al. (2016) identified high-frequency 
hearing loss, of 12% after week 6. Likewise, this current study showed mean high 
frequencies being affected from week 6. The high-frequency hearing loss has further been 
identified in other populations being treated with aminoglycosides (Black et al., 1976; Fausti 
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et al., 1993), yet UHF testing showed the increased sensitivity of identifying ototoxicity. This 
was observed where UHF identified 95% of ears in comparison to 67% with general high 
frequencies (Fausti et al., 1993), as well as another study identifying 82% of ears with change 
when monitoring up to 20 kHz (Fausti et al., 1992). This current study identified a significant 
change in 77% of ears with UHF PTA at week 2, where general high frequencies did not 
detect any change at this week.  
However, in contrast, Duggal and Sarkar (2007) discuss that in their sample of MDR-
TB patients, 18.75% of the patients developed sensorineural hearing loss involving higher 
frequencies (4 kHz to 8 kHz) while only 6.25% also had involvement of speech frequencies 
(0.5 kHz to 3 kHz). This could imply the limited relevance of testing the high frequencies, 
and specifically the UHF. However, according to the review by Moore, Stone, Fullgrabe, 
Glasberg & Puria, (2008), a benefit for speech intelligibility is observed in the higher 
frequencies, specifically in a noisy environment. Therefore, identifying loss in the UHF, 
before it moves into the high frequencies is beneficial to reduce difficulty with speech 
discrimination possibly. 
Presence of the hearing loss at baseline could be a result of various factors. However, 
no specific cause was reported by any of the participants. The hearing loss could potentially 
have been caused by previous use of aminoglycosides, other illnesses that were not reported, 
noise exposure, HIV and/or poor nutrition (Wang et al., 1999; Bisht & Bist., 2011; Schellack 
& Naude, 2013; Khoza, 2010; Hoffman, et al., 1987).  
In summary, this current study identified significant UHF loss of hearing and cochlear 
function as measured with PTA and DPOAEs. The UHF loss was noted before the high-
frequency loss, which in this current study was at 6 kHz and 8 kHz with PTA and from 2 kHz 
with DPOAEs. However, PTA is not routinely performed at above 8 kHz when monitoring 
ototoxicity. PTA normative values for frequencies above 8 kHz are not yet established clearly 
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE 
RELATIONSHIP BETWEEN HEARING LEVELS: A FEASIBILITY STUDY 
284 
(de Sá et al., 2007). However, these UHF are still useful for audiological monitoring of 
ototoxicity. By detecting a change in frequencies above 8 kHz, ototoxicity can be identified 
before it involves speech frequencies and affects communication (Singh, Saxena & Varshney, 
2008). The need for standardised measures to monitor and grade this loss is essential to fully 
understand the extent and pattern of this ototoxicity, specifically in the DR-TB population.  
7.1.2. Comparison of Pure Tone Audiometry and DPOAEs 
The current study utilised both PTA and DPOAEs as a method of identifying and 
monitoring ototoxicity resulting from kanamycin and capreomycin. DPOAEs were chosen to 
compliment the PTA as they can detect minor changes in cochlear function prior to changes 
in hearing thresholds on either the conventional audiogram or UHF audiometry (Guthrie, 
2008).  
Some association of these PTA and DPOAE measures was observed in this current 
study. They both identified the right ears showing greater loss of hearing and cochlear 
function than the left ears. However, PTA did not identify a significant loss of hearing at 2 
kHz, where, the DPOAEs did. This is in accordance with the literature, where DPOAEs are 
more sensitive than PTA (Guthrie, 2008). 
This association, however, was not evident through the study; the PTA showed the 
greatest shift at 11.2 kHz, where the DPOAEs showed the greatest shift at 10 kHz. This does 
not correlate entirely, however, 11.2 kHz was not measured with DPOAEs, making a definite 
conclusion difficult. In the left ear, 4 kHz was the frequency most affected in the DPOAEs, 
which does not correlate to the 11.2 kHz in the PTA.  
Despite these discrepancies in association in this current study, a positive relationship 
has been shown in various other studies. A positive correlation was shown between UHF 
PTA and conventional DPOAEs (up to 8 kHz) (Yu et al., 2014) with general PTA and 
DPOAEs (between 2 kHz and 6 kHz) (Campos & Carvallo, 2011) when monitoring 
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ototoxicity. Yet, there was no evidence of a robust relationship between DPOAEs and PTA in 
the industrial setting (Wooles et al., 2015). These discrepancies in the current study could be 
a result of a small sample size, as well as some missing data due to poor signal to noise ratios. 
DPOAEs have however been useful in detecting early ototoxicity, where DPOAEs 
detected more ototoxicity earlier than with PTA. DPOAEs detected 70% of the ototoxicity by 
day 28, with PTA only detecting 22% at this time (Daud et al., 2014). In the current study, 
conflicting results are observed; the UHF PTA detected more ototoxicity by week 2 
compared to the DPOAEs, yet DPOAEs detected ototoxicity at lower frequencies than the 
general PTA. The sensitivity of OAEs was seen by Hotz et al. (1994); when using TEOAEs, 
90% of participants on amikacin were identified as showing ototoxicity (Hotz et al., 1994), 
where PTA found 7% of ototoxicity on a larger sample of patients on gentamicin and 
amikacin (Lerner & Matz, 1979). This was TEOAEs and not DPOAEs as with this current 
study. 
In conclusion, this current study showed advantages when making use of DPOAEs to 
monitor ototoxicity in patients with DR-TB, as it allowed for early identification at 2 kHz. 
However, it is unclear if this would translate into behavioural changes and correlate to PTA at 
a later stage of treatment.  
The investigation of the potential to use DPOAES to monitor ototoxicity in isolation, 
is relevant, specifically in South Africa where the prevalence of DR-TB is high, and the 
availability of audiologists and equipment, especially in rural areas may be low.  
7.1.3. Symmetry of Hearing Loss 
For this current study, asymmetry was considered as a 10 dBHL difference for PTA 
(Konrad-Martin et al., 2005) and 6 dB for DPOAEs (Roede et al., 1993) between ears.  
The findings of the current study indicate that this difference between the right and 
left ears were noted with PTA in the UHF; 12.5 kHz and 14 kHz (noted on weeks 8 and 12) 
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and 16 kHz (noted on week 2). Asymmetry was further noted in different frequencies with 
DPOAES; at 4 kHz (on baseline, weeks 2 and 12), 10 kHz (on week 2) and 12 kHz (on week 
10). Additionally, 36% of the participants reported difficulty localising at baseline. 
Yet, hearing loss resulting from aminoglycosides is usually bilateral and symmetrical 
(Harris & Heinze, 2015). Furthermore, Black et al. (1976) showed a high-frequency loss with 
amikacin that was usually bilateral, and a study in Namibia on MDR-TB with kanamycin and 
amikacin showed that most of the hearing loss was also bilateral (83%) (Sagwa et al., 2015). 
Although the hearing loss was bilateral, symmetry was not discussed in this study. Yet, an 
audiogram provided in the article depicted symmetry (Sagwa et al. 2015). 
Though a right ear advantage has been found in various studies, where the right ear 
generally displays less damage of cochlear functioning when measured with OAEs (Chung et 
al., 1983; Khalfa et al., 1997; McFadden, 1993). This could potentially describe some 
asymmetry; however, these differences are usually small of 2-4 dB (McFadden, 1993). This 
right ear advantage was further seen in male adults between 2-6 kHz, with differences of 1.5 
to 2.5 dB between ears (Chung et al., 1983). However, these ‘asymmetries’ are minimal and 
not as much as 6 dB as found in the DPOAEs in the current study, and also the mean of the 
right ears showed a greater loss than the left ears. 
This phenomenon of a difference between ears was noticed further at 4 kHz to 8 kHz 
where the left ear was more affected from cisplatin than the right ear (Schmidt et al., 2008), 
which shows that contrary to other literature, the cisplatin-induced hearing loss is not 
necessarily symmetrical. Huzing and de Groot (1987) also mention that aminoglycoside-
induced hearing loss is not necessarily symmetrical, however, does not describe clear 
reasoning. Unilateral hearing loss, indicating asymmetry, was reported in patients taking 
amikacin where the bilateral hearing loss was noted in 18 patients, and unilateral loss in 11 
patients (Javadi et al., 2011). Also, Sharma et al. (2016) described bilateral hearing loss in 13 
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patients and unilateral in five patients at week 6 of treatment of 100 patients (Sharma et al., 
2016). In this current study, asymmetry was not explicitly noted at week 6.  
As eight participants in the current study reportedly struggled with localisation at 
baseline, the overall baseline PTA results were examined. This was initially thought to assist 
in explaining the asymmetry that developed later. Yet, at baseline, half the participants 
displayed some sort of hearing loss, as measured with PTA. This ranged from a 30 dB HL 
threshold at one frequency to a 40 dB threshold at four frequencies bilaterally.  
This reduced PTA at baseline could potentially explain the localisation difficulties 
reported, even in instances with no asymmetry. Localisation difficulties are present in people 
with hearing impairment (Brungart, Cohen, Zion & Romigh, 2017). More participants in this 
current study had some hearing loss at baseline than localisation difficulties reported. In some 
instances, localisation difficulties can also be present in individuals with normal hearing, 
explained by potential issues with auditory processing (Shamma, 2011). Hence, alternatively, 
these localisation issues could result from potential issues with auditory processing. As this is 
a very complicated auditory function (Shamma, 2011), these issues are not understood 
entirely. 
The localisation difficulties could not directly be linked to asymmetry. It could bring a 
potential explanation in some cases, however, is not definitive and cannot be generalised to 
the entire group. There is thus no clear explanation for the asymmetry noticed, in that the 
right ear displayed a more significant hearing loss than the left ear. The explanations above 
do not account for the substantial differences noted at some frequencies. Pharmacologically, 
the drug does not enter one ear more than the other. Therefore, we may hypothesise that the 
asymmetry in hearing loss is likely a result of previous trauma to the ears or other such 
hearing loss. Conversely, the localisation complications, however, could potentially be 
identified by a loss of hearing at baseline or auditory processing issues. Furthermore, the 
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previously understood configuration for a symmetrical hearing loss resulting from 
aminoglycosides may need to be redefined and understood.  
7.1.4. Percentage and Overall Change in Hearing/Cochlear 
Function 
This study aimed to look at the prevalence of abnormal findings at baseline 
assessments and determine the change in hearing levels from baseline. At baseline, half the 
participants (50%) displayed some hearing loss as measured with PTA (ranging from a 30 dB 
threshold at one frequency to a 40 dB threshold at four frequencies bilaterally). From the 
results of the 15 that were present for more than the baseline; all showed ototoxicity in 
DPOAEs, 93% showed ototoxicity with TUNE and ASHA, and 7% with CTCAE. These 
scales (CTCAE and TUNE), as well as the ASHA system, only, looked at PTA. Although the 
sample was small, it does portray the variation of percentage of hearing loss based on the 
different grading scales used; depicting the need for a standardised description of ototoxicity 
in this population. 
This percentage calculation did not separate those on kanamycin and capreomycin, as 
many started on kanamycin and switched to capreomycin, which made it difficult to describe. 
Thus, depending on which frequency range that was used to describe the hearing loss, 
between 7% and 93% of participants experienced a significant loss of hearing. However, only 
7% experienced this at 8 kHz or below. 
This range identified in the current study is seen across various other studies, 
depending on the classification method. In other research, the incidence of cochlear damage 
due to aminoglycosides ranges from 7–90% (Petersen & Rogers, 2015). An MDR-TB study 
with amikacin, using the ASHA criteria (up to 8 kHz), found 70% experienced ototoxicity 
(Javadi et al., 2011). Another MDR-TB study using the WHO guidelines (Lin et al., 2011) 
identified approximately 23% with hearing and vestibular issues post-treatment (Jacob & 
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Ross, 2012). Ramma and Ibekwe (2012) identified 47% of patients with MDR-TB and XDR-
TB with ototoxicity.  
Other studies using aminoglycosides and capreomycin, not specifically with DR-TB 
show variable results. Ototoxicity from kanamycin in premature children was not statistically 
significant (Savidson et al., 1980), and kanamycin used in guinea pigs showed ototoxicity 
(Waterstrom, 1986). Subclinical loss from capreomycin was found 11% of healthy 
individuals (Akorn, Inc. Package Insert, 2015), which has been defined as a pure-tone 
average hearing loss of >25 dB at high (4  kHz) and low (1  kHz) frequencies (Nakajima, 
Kanda, Hosobuchi & Suwa, 2014). The definition of subclinical however is not found in the 
package insert. Furthermore, other aminoglycosides, not specifically kanamycin, showed 
21% in cystic fibrosis patients with short-term treatment (Al-Malky et al., 2011). 
This variability could be due to a potential of under-reporting, as well as the lack of 
clear guidelines for monitoring ototoxicity (Edson & Terrell, 1991; Petersen & Rogers, 
2015). These grading scales, although detected some hearing loss, have broad criteria, and do 
not provide any recommendations based on the grades. These grades were also not developed 
in the DR-TB population, but mainly on the cancer population.  
As per the previous sections, the definite presence of hearing loss was identified in 
this study, yet the criteria to grade the loss, and classify the percentage was complicated and 
varied. Therefore, although there is a correlation to other studies, the direct comparison is 
difficult to the variability in testing hearing and describing hearing loss. 
7.1.5. Week of Greatest Change in Hearing Levels 
In the current study, the greatest changes with DPOAEs from the previous study visit 
presented at week 2 for 2, 8, 10 and 12 kHz. The greatest changes with PTA from the 
previous study visit was week 2 (11.2 kHz, 12 kHz, and 14 kHz) and week 6 (6 kHz, 8 kHz 
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and 10 kHz). The least DPOAE changes were noted at weeks 6 and 10, and the least PTA 
changes were noted at weeks 4 and 8. 
When describing the correlation between the DPOAEs and PTA in this study, it was 
concluded that although there were positive correlations between the two measures, there 
were various instances where the correlation was not noted. This discrepancy here, 
identifying the weeks of greatest change, is another instance of no correlation. The exact 
correlation of the DPOAE changes, in translating to the PTA as functional changes at a later 
stage are not known, however, should also not be disregarded. As per the conclusion in 7.1.2, 
the potential for the use of DPOAEs alone to monitor ototoxicity, without the use of PTA, 
needs to be further investigated in different situations and larger samples before 
recommending it to be used in isolation.  
The most significant audiology results observed was in week 2 and week 6. 
Moreover, for outpatient treatment, specifically at HJH, the patients visit the doctor at 
baseline, week 2, and subsequently every four weeks, so at weeks 6, 10, 14 and so on (Gajee 
et al., 2016). This can translate into practical ways to monitor ototoxicity when devising a 
protocol to monitor DR-TB patients. As PTA is generally used to grade hearing loss and as 
well as to direct the change of dosage and treatment adjustments, PTA greatest changes will 
mainly be utilised. Therefore, in the first three months of monitoring, it is recommended that 
baseline testing, as well as week 2 and week 6 be conducted. As week 4 and 8 showed the 
least change, then the following test could be conducted at week 10 or 12.  
Also, as patient dropout is exceptionally high, as seen in the current study, as well as 
from Gajee et al. (2016), combining audiological and medical visits are more beneficial, to 
ensure the patient only needs to visit the clinic once for both medical and audiological visits 
combined. This combination of audiological and medical visits would allow for immediate 
changes in treatment regimen by the doctor when ototoxicity is identified. This monthly 
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testing is recommended for a low resource setting, despite that two-weekly testing would be 
ideal in a setting with more resources and patient participation.  
7.1.6. Differences in hearing for participants being treated with 
kanamycin and capreomycin 
In this study, it was difficult to ascertain whether kanamycin or capreomycin was 
more ototoxic, as often, the participants that were experiencing ototoxicity were switched to 
capreomycin. Also, the sample size was small. Therefore, it is possible that these patients that 
were switched to capreomycin were more susceptible to ototoxicity, and the hearing loss 
cannot be attributed to the toxicity of the drug, but possibly to other factors such as genetic 
susceptibility, previous use of aminoglycosides, and other risk factors. Yet, when looking at 
weeks 10 and 12, those on kanamycin showed greater ototoxicity to those on capreomycin. 
These results are potentially skewed due to the switch to capreomycin and possible 
susceptibility of these patients to develop hearing loss. 
When compared to other studies, the incidence of cochlear damage due to 
aminoglycosides, such as kanamycin, varies from 7–90% (Petersen & Rogers, 2015) as seen 
from the above studies. However, very little information is available on capreomycin alone; 
despite the 11% subclinical loss in healthy individuals (Akorn, Inc. Package Insert, 2015). 
The exact difference in ototoxicity, within the DR-TB, is therefore not exactly understood. 
As capreomycin is more expensive, it is rarely used. Thus, the investigation of 
ototoxicity caused by capreomycin is difficult. Further investigation is imperative, as should 
the toxicity profile differ greatly, the expense of the medication could outweigh the expenses 
of post-kanamycin management.  
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7.1.7. Summary  
In conclusion, hearing loss was noted in the UHFs first, prior to the high frequencies, 
as well and the correlation was not always noted between PTA and DPOAEs. Furthermore, 
the greatest weeks of change with PTA were at weeks 2 and 6. These factors have 
implications for ototoxicity monitoring.  
In addition, symmetry, as previously understood for ototoxicity, was present in this 
study, as well as some other studies. This brings forth the need to revise the description of 
ototoxicity being bilateral and symmetrical, despite the pharmacological understandings of 
the mechanism.  
It also highlighted the lack of ototoxicity grading scales, specifically relevant for DR-
TB in the ultra-high frequencies. The already existing adult grading scales, namely the 
CTCAE and TUNE scales only grade up to 8 kHz and 12.5 kHz respectively. The ASHA 
system, although not a grading scale, identifies significant ototoxicity. However, the criteria 
are broad and do not provide different levels/grades of ototoxicity. 
The potential for the use of DPOAEs to monitor ototoxicity alone, without the use of 
PTA, needs to be investigated further in different situations and larger samples before 
recommending them to be used in isolation without PTA. Lastly, the monitoring and 
description of ototoxicity specifically need to be standardised to obtain accurate and 
generalizable statistics.  
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7.2. Pharmacokinetic Findings of Kanamycin and 
Capreomycin 
This section will discuss the results as presented in section 6.1., where the mean peak 
and trough levels are discussed for kanamycin and capreomycin, the results in relation to 
creatinine levels, and lastly the results in relation to culture conversion. 
7.2.1. Investigation of the Mean Peak and Trough Levels for 
kanamycin and capreomycin: Pharmacokinetic Results  
The results, which are described in further detail in section 6.2.1, depicted different 
dosages of kanamycin and capreomycin. Overall, the pharmacokinetic results obtained 
appeared erratic. 
There are very few studies identifying the ideal pharmacokinetic levels of kanamycin 
and capreomycin, specifically in patients with DR-TB.  
Reisfeld et al. (2012) identified an ideal peak range between 20 μg/ml to 40 μg/ml, 
and a trough of below 10 μg/ml with regards to capreomycin, yet this study was conducted on 
mice (Reisfeld et al., 2012). In this current study, the mean peak throughout the weeks was 
8.1 μg/ml (SD ±5.5). This is significantly lower than the desired range, even with the SD 
considered; emphasising the possible non- therapeutic effects of capreomycin. The mean 
trough level was within the desired range with a mean of 0.7 μg/ml and thus did not reach 
toxic levels. Yet, in many instances, it was undetectable at 0.05 μg/ml. 
In the kanamycin study by Mugabo et al. (2015), kanamycin was undetectable after 
24 hours, showing possible insufficient dosing of kanamycin in the previous dosing. It is 
likely that this was the same in this current study. In this current study, this could perhaps be 
explained because, at times, the trough levels were taken after 24 hours after the previous 
dosing. As in-patients, it should have been approximately 24 hours, as the nurses did their 
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rounds at 10:00, yet as out-patients, it would depend as to when they reached the front of the 
line at the local clinic (if they went at all). It was the same as for the kanamycin trough levels 
when compared to capreomycin, as the mean was slightly higher at 1.3 μg/ml, yet it was also 
undetectable in many instances. Again, in some cases it may have been at more than 24 
hours, but not in all cases.  
Desired peak levels for kanamycin appear to be between 20 μg/ml and 35 μg/ml 
(Mugabo et al., 2015). In the current study, the mean kanamycin peak levels were higher than 
the capreomycin peak levels, at a mean of 20 μg/ml, yet with a large SD of ±16.5. Although 
at times kanamycin dosing reached the therapeutic range, the results were erratic and 
fluctuated considerably. 
The lower peak levels would indicate that the drug is not reaching therapeutic levels 
and likely not ‘curing’ the DR-TB. Yet, in the study in Iran, 52.2% had peak levels below the 
therapeutic level, yet 89% responded to treatment successfully (Namazi et al., 2016). In this 
current DR-TB study, perhaps other drugs are assisting in the treatment in combination with 
the low peak levels. Although patients may culture convert, they are not followed generally 
for years after treatment, and thus they could relapse.  
Generally, the elimination of aminoglycosides is significantly affected by impaired 
renal function (Pechere & Dugal, 1979). The treating doctors, particularly at SRH, withdrew 
the participants from the study drug when they were showing renal problems (n = 3). This 
was only seen in the patients taking capreomycin. Therefore, the elimination would not have 
been affected in this study at SRH due to renal issues, as participants withdrew. Pechere and 
Dugal (1979) further discuss how other pathological states, such as anaemia, fever, 
hypoxemia, major burns and so on, can affect the desired pharmacokinetic levels of 
aminoglycosides. All these patients in this study had DR-TB, which perhaps could have 
affected these low peak levels. 
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The kanamycin study had slightly different levels of HIV positive and HIV negative 
patients (Mugabo et al., 2015). In this current study, due to the small sample size, the HIV 
positive and negative patients were not analysed separately as initially planned.  
The mean dose per kilogram for kanamycin was 14.6 mg/kg and for capreomycin was 
15.2 mg/kg. According to the WHO (2014), a dose of 15 mg/kg is suggested for kanamycin 
and capreomycin once daily (5 – 7 days per week). Both the doses for kanamycin and 
capreomycin were thus on the target, yet the peak levels were still below the therapeutic 
range.  
The mean half-lives for kanamycin and capreomycin were 9.3 hours (SD ±5.1) and 
7.2 hours (SD ±1.4) respectively. Moreover, the volume of distribution (ℓ/kg) was for 
kanamycin and capreomycin was 2.5 (SD± 2.1) and 3.3 (SD ±2) respectively. In a study on 
healthy participants, the half-life was 3.2 (SD ±1) hours for kanamycin, and the apparent 
volume of distribution (ℓ) for kanamycin was 30.4 (SD ±9.8) (Park et al., 2015). In another 
study on MDR-TB patients (Mugabo et al., 2015) using kanamycin, the volume of 
distribution was 38.62 in HIV negative patients and 50.18 in HIV positive patients, as the 
absorption has been shown to be different in HIV positive and HIV negative patients. These 
figures on both HIV positive and HIV negative patients are a lot closer to the figure by Park 
et al. (2015) of 30.4 and significantly higher than the volume of distribution in this current 
study of 2.5 for kanamycin. While the volume of distribution of significantly smaller in this 
study, the half-lives were significantly larger than expected, as it was compared to 3.2 in 
healthy participants (Park et al., 2015) and 1.67 in MDR-TB HIV negative patients and 1.29 
in MDR-TB HIV positive patients (elimination half-life) and 4.45 in MDR-TB HIV negative 
patients and 4.62 in MDR-TB HIV positive patients (absorption half-life) (Mugabo et al., 
2015). 
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Furthermore, despite the ideal peak and trough levels, diagnosis can impact on 
pharmacokinetics, as seen with the pharmacokinetics of amikacin, where the patients in ICU 
with different diagnoses displayed different values with the volume of distributions. This 
highlights the fact that the clinical diagnosis can also impact the pharmacokinetics (de Gatta 
et al., 1996). Thus, patients with DR-TB may be displaying different kinetics to those with 
other infections. This highlights the importance for individualisation of treatment. These 
studies provide evidence for the possible positive effects of optimising dosage regimens of 
aminoglycosides. However, this study displayed erratic levels with considerable differences 
among individuals, indicating the need for a further study with a larger sample size to fully 
understand the pharmacokinetics in this population.  
7.2.2. The relationship between the kanamycin and capreomycin 
kinetics with creatinine levels 
The CrCl results, indicated that for participants taking kanamycin, the average 
creatinine clearance was reduced, yet the drug was still cleared through the system, as seen 
with trough levels below 10 μg/ml, while for participants taking capreomycin, much of the 
creatinine clearance was within the normal range (80 – 130 ml/min).  
Due to the almost exclusive excretion from the body by glomerular filtration, the 
elimination rate of aminoglycoside antibiotics is affected significantly by an impairment of 
renal function (Pechere & Dugal, 1979). The predictive potential of nomograms can be 
significantly improved by consideration of some physiological parameters such as sex, age, 
lean body mass, haematocrit and characterisation of disposition kinetics by multi-
compartmental models. Anaemia, fever, hypoxemia and significant burns are other 
pathological states which notably influence the pharmacokinetics of aminoglycosides 
(Pechere & Dugal, 1979).  
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Those participants taking kanamycin showed greater renal impairment than those 
taking capreomycin. This is consistent with the study by de Jager and van Altena (2002) 
where a high percentage of patients taking kanamycin showed renal impairment. In contrast, 
minimal renal impairment was noted in patients taking capreomycin (Aquinas & Citron, 
1972). 
However, in this current study, in those patients showing renal impairments, trough 
levels were still within a non-toxic range (below 10 μg/ml), even though mean peak levels 
were within the therapeutic range. Those with average creatinine clearance level 
(capreomycin), showed normal trough levels, yet reduced peak levels. 
7.2.3. The Relationship between the Pharmacokinetics and 
Pharmacodynamics of kanamycin and capreomycin to 
Culture Conversion  
Culture conversion for DR-TB is defined as two consecutive negative TB cultures (30 
days apart) (Prasad, 2012). Culture conversion is this study was defined as one negative 
culture post-baseline- measurements. Although culture conversion is often referred to as two 
consecutive negative cultures, many cultures were missing from the various databases, and so 
for consistency between the participants, one negative culture was utilised. Furthermore, the 
study was conducted in the first three months of treatment, and so often another culture was 
not conducted. 
According to the WHO and NDoH guidelines, although capreomycin and kanamycin 
are both used for DR-TB treatment; efficacy is not differentiated, only the toxicity profiles. 
Efficacy in this current study does not appear to be different in the beginning stages of 
treatment; despite the low peak levels. However, the long-term results were not obtained, and 
possibly participants reverted to positive cultures. However, the sub-therapeutic peak levels 
of kanamycin in some instances and capreomycin does not correlate to the negative cultures. 
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Yet, as per Namazi et al. (2016), despite the low peak levels being below the therapeutic 
range, 89% responded to treatment successfully. This could explain the low peak levels in 
this current study with the positive culture conversions. 
Although, there is also the possibility reinfection at later stages, due to the 
Resuscitation-promoting factors (Rpf). Although this model is ill-defined in human infection, 
from the mouse models, Rpf support bacterial survival and reactivation of TB despite a 
culture conversion as these Rpf are invisible to the conventional culture (Mukamolova et al., 
2017). Therefore, these low peak levels could indicate, that although patients may culture 
covert on the conventional testing methods, these proteins may still be present, and 
responsible for the reinfection at a later stage, and thus the low peak levels could, in fact, 
correlate to poor outcomes 
7.2.4. Summary of Pharmacokinetic Findings 
Overall, the pharmacokinetics of both kanamycin and capreomycin were not as 
expected. The peak levels of kanamycin (in some instances), and capreomycin were 
subtherapeutic, which does not correlate to literature. In accordance with the literature, 
capreomycin is not as toxic as kanamycin, and thus less nephrotoxicity in these patients was 
noted. In both the kanamycin and capreomycin, participants did culture convert, despite the 
low peak levels. 
7.3. Pharmacokinetics of kanamycin and capreomycin in 
Relation to Hearing Levels 
The findings of the current study indicate that the trough levels did not correlate to 
ototoxicity. In some instances, when looking at mean levels, dosage did correlate to 
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ototoxicity, yet when looking at individual patients, dosage often did not correlate to 
ototoxicity. This section will discuss these results in relation to the current literature.  
7.3.1. The Relationship between Pharmacokinetics of 
kanamycin and capreomycin, including Dosing, with Hearing 
Levels 
Ototoxicity of aminoglycosides is correlated with elevated trough concentrations 
and/or prolonged duration of exposure rather than with peak concentration (Droege et al., 
2016). Yet, this was not observed in the current study, as trough levels for kanamycin were 
below 3 μg/ml at all times indicating no toxic levels, yet ototoxicity was observed at all 
weeks in different frequencies. With regards to PTA, at all weeks, ototoxicity was observed 
only above 8 kHz, showing that it did not yet affect speech frequencies: only the ultra-high 
frequency range. Yet, with DPOAEs for kanamycin, 2 kHz was affected (at four of the six-
time points). However most changes were observed at 8 kHz and above. The capreomycin 
sample size was smaller, and often the trough levels were undetectable. These are participants 
that had initially started with kanamycin. The trough levels always remained below 2 μg/ml. 
Yet, with PTA, significant changes, at times extended to some speech frequencies, such as at 
6 kHz at week 8 (T5). Majority of the changes were above 8 kHz, as with the changes 
observed with kanamycin. With DPOAEs in the capreomycin participants, the change was 
detected at all the frequencies in different weeks. These results do not correlate to this 
literature that elevated trough levels are associated with toxicity. However, the snall sample 
size could have influenced this.  
In contrast, another study was done on amikacin used to treat MDR-TB. Peak and 
trough levels were not predictors in the classification of ototoxicity (Modongo et al., 2015). 
This is similar to the current study where trough levels were not related to ototoxicity. This 
study showed that cumulative AUC and duration of drug therapy is more of an indicator of 
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE 
RELATIONSHIP BETWEEN HEARING LEVELS: A FEASIBILITY STUDY 
300 
ototoxicity, rather than peak concentrations, as the ototoxicity increased sharply after six 
months of therapy (Modongo et al., 2015). However, as the current study on capreomycin and 
kanamycin only looked at ototoxicity up to three months, it is likely that the ototoxicity may 
still have appeared, despite the low trough levels. Recently, with the STREAM study, a 
protocol of nine months of treatment is introduced. The study is in phase 3, and final 
outcomes will likely be available in 2018 (RESIST TB, 2017). Yet, based on Modongo et al. 
(2015), it may not reduce ototoxicity. 
A study conducted in the Netherlands looked at TDM of amikacin and kanamycin in 
patients with MDR-TB or XDR-TB (van Altena et al., 2017). Therapeutic drug monitoring 
from the beginning of treatment took place when necessary, and hearing tested from baseline 
(up to 8 kHz). The results of the audiometry showed a hearing loss in nine patients (11.3%), 
predominantly at higher frequencies (4 and 8 kHz). Cumulative dose, dose per kg 
bodyweight, duration, bodyweight, gender, age, and BMI did not correlate with the 
occurrence of ototoxicity. This may be explained by the fact that the dosage was guided by 
the Cmax /MIC in individual patients since the Cmax /MIC correlates to the efficacy of 
aminoglycosides (van Altena et al., 2017). Yet, this study only looked at frequencies up to 8 
kHz, and cannot be compared to this current study, as audiometry tested up to 16 kHz. 
However, when looking at frequencies 8 kHz and below, only 7% of hearing loss was 
detected, without TDM. These two studies yield conflicting results.  
7.3.2. Summary of Pharmacokinetics in Relation to Hearing 
Levels 
The findings of the current study indicate that no correlation was observed with 
trough levels and ototoxicity. The dose per kg throughout the weeks for kanamycin remained 
stable and can thus not be correlated to the change in hearing. Further studies with larger 
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sample size and UHFA are needed to ascertain the exact relationship between 
pharmacokinetics and hearing levels.  
7.4. Feasibility of the Study 
Various factors impacted the feasibility of this study, but notably, participant factors, 
including a willingness to participate, enrolment and attrition, as well as data acquisition 
factors, such as issues with blood samples and quality assurance of the data. 
7.4.1. Participant Factors: Respondent Enrolment, Willingness 
to Participate and Attrition. 
Attrition and adherence were prominent themes in this current study, which impacted 
the feasibility. Attrition is often affected by adherence (Munro et al., 2007). In this current 
study, adherence to visiting the clinics for injectables, taking oral medication and returning 
for study visits was poor, with high dropout. 
The sample was small; however, 62.5% of participants completed the study at Helen 
Joseph Hospital, when those that withdrew for medical reasons were not accounted for (five 
of eight participants). 20% completed the study at South Rand Hospital, when those that 
withdrew for medical reasons were not accounted for (one of five participants).  
Adherence was an important concern with the decentralisation of treatment, which 
was also observed by Evans et al. (2017) showing that fewer than half the patients diagnosed 
in Johannesburg initiated appropriate treatment. 
Gajee et al. (2016) also mentioned that missing at least one scheduled appointment at 
the RR-TB clinic (HJH) was strongly associated with poor treatment outcomes. Thus, it is 
likely that the poor adherence in this current study, which took place at the same site, affected 
the participants’ overall treatment outcome. However, this data was unavailable.  
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It is postulated that the factors that contribute to poor adherence and willingness to 
participate are multifaceted.  
Thus, each factor influences multiple others. Some of these aspects, however, include 
emotional factors, lapses in communication and educational level.  
Emotional factors can affect the willingness to participate, as well as the adherence to 
participation. Furthermore, emotional facets can be influenced by counselling, 
communication and patient education (Awofeso, 2008; Das et al., 2014). 
While this study has identified poor adherence factors and high attrition rate, there 
were several eligible patients who chose not to be a participant. It appeared that the diagnosis 
initially overwhelmed participants, especially with having to receive daily injections for 
months. The emotional aspect and idea of more needles and blood tests appeared to be too 
overwhelming. As the participants had nothing to gain directly from the study, willingness to 
participate was poor. Additional, inpatient influential factors affected willingness. 
Particularly at SRH, patients appeared to discuss the protocol among one another and 
‘convinced’ each other of the negative impact of the studies. It was the view that they were 
utilised for tests to help other people and not themselves. One patient compared themselves in 
the study to ‘lab rats’. This view was not observed at HJH, as participants did not necessarily 
interact with each other. 
Adverse effects, including depression, likely affected the adherence. Morisky et al. 
(2008) further found adherence to medication can be affected by depression, lack of 
knowledge about hypertension, the complexity of the medication regimen, health care system 
perceptions by the patient, sexual dysfunction, side effects of medication, and reduced quality 
of life (Morisky et al., 2008). Although this study by Morisky et al. (2008) was not about TB, 
the majority of these factors are prevalent in patients with DR-TB. Many patients suffer from 
depression (Das et al., 2014) as well as the regimen is complicated. DR-TB medication side 
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effects can include gastrointestinal disturbances, psychiatric disorders, arthralgia, hepatitis, 
peripheral neuropathy, hypothyroidism, epileptic seizures, dermatological effects, ototoxicity 
and nephrotoxicity (Yang et al., 2017). Therefore, based on the hypertension study where 
adverse effects affected adherence, and the adverse events resulted from DR-TB, it is likely 
that these effects can influence adherence in the DR-TB population (Awofeso, 2008). 
Due to the adverse effects of the DR-TB and medication regimen, coping skills are 
necessary. Morisky et al. (2008) found that knowledge of hypertension, patient satisfaction, 
and coping skills was significantly associated with medication adherence. With regards to 
patients with DR-TB; many receive counselling upon diagnosis. This immediate counselling 
may not be adequate and practical, due to the devastating aspects of the diagnosis and 
treatment regimen. Thus, the patients’ capacity to understand the implications for treatment at 
the time of the education may be inadequate due to feeling completely overwhelmed. This 
could imply that education and counselling need to take place multiple times. Das et al. 
(2017) recommend regular monitoring of mental health status by trained counsellors.  
Counselling is a critical aspect of DR-TB therapy (Das et al., 2014) as it can assist 
with coping skills, but also improves patient education, deals with stigma as well as social 
factors. The language of preference and skills of the counsellors also affect counselling and 
its ability to be effective. Counselling is vital for patient education (Awofeso, 2008). In 
Zambia, the significant factors leading to noncompliance for TB treatment included patients 
beginning to feel better, inadequate knowledge on the benefits of completing a course, 
running out of drugs at home and the TB drugs were too strong (Kaona et al., 2014). 
Furthermore, daily injections, pill burden, DOT, seasonal work, social problems, prior TB 
treatment, and adverse drugs effects were reported as major barriers to treatment adherence 
and retention-in-care by patients and providers (Shringarpure et al., 2016). With DR-TB 
drugs, many participants complained of vomiting from the drugs, as well as the painful 
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injections, likely reducing adherence. Counselling, regarding the explanation of the 
symptoms as well as outcomes of correct protocol compliance, could potentially improve 
adherence. 
Furthermore, counselling will help address stigma and social practices. Shringarpure 
et al. (2016) identified three themes affecting adherence, namely: struggle with prolonged 
treatment, strive against stigma and toward support and divergent perceptions and practices. 
This study also reported the influence of traditional healers (Shringarpure et al., 2016). Many 
of these patients have poor socioeconomic backgrounds, are ill, are suffering from the stigma 
of TB and have a reduced quality of life (Kibrisli, Bez, Yuilmaz et al., 2015). Although this 
was not a study aim and was not recorded, various patients were noted to have received other 
medications from traditional healers. The study coordinator was not able to obtain much 
information regarding this topic, as patients did not want to share, but two patients mentioned 
visiting a healer. No other information was obtained; however, it is possible that this could 
also have affected retention and adherence, and perhaps the low pharmacokinetic levels. A 
psychosocial support program implemented for at risk of defaulting patients showed success 
in reducing default among MDR-TB patients (Kaliakbarova et al., 2013). Perhaps the 
implementation of this would be useful.  
Social influences also affect patients’ adherence. In two cases, the patients were keen 
to participate in the study, yet their husbands would not allow them to. Although it was up to 
the patient to consent, both these female patients appeared to have domineering husbands to 
whom they listened to. No reason was obtained as to why their husbands did not want them to 
take part. Again, the theme of counselling recurs, but in this case, counselling for the 
significant others also appears to be necessary. 
Despite the positive effects of counselling, there are issues, including language 
barriers and proficiency of counselling. Specifically, in South Africa, language barriers must 
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be respected, due to there being 11 official languages. This study identified a variety of 
languages of preference. Two participants could only speak isiZulu, one could only speak 
SeSotho, and eight reported only being proficient in English. The remaining 11 participants 
spoke either: English and SeSotho, English and isiZulu or English, isiZulu and SeSotho. 
Thus, if the treating doctor was only proficient in English, the language barrier could have 
disrupted this communication with three participants; a significant number of the 22 
participants. Communication can become hindered, and thus would affect education.  
Also, the counsellors may not be as proficient in the TB regimen as the doctor, which 
may affect the education of the patient. Perhaps, the implementation of a more structured 
protocol of counselling would be beneficial. This structure protocol could be adapted from 
Morisky et al. (2008) where treatment-related attitude and behaviour problems that the 
patient may face for health care providers to provide reinforcement and advice. A scale as 
such may be a useful tool to assist in identifying those patients at risk of defaulting with their 
DR-TB medication and to assist in improving adherence.  
Outpatients received counselling from counsellors at the clinic regarding the necessity 
of taking their medication. The inpatients received counselling from doctors administering 
the drugs, and sometimes from the nurses. However, no follow-up was done regarding the 
counsellors’ efficacy. Sanchez-Padilla et al. (2014) found that poor treatment tolerance, a 
perception that treatment was inefficient, lack of information, incorrect perception of being 
cured, working factors and behavioural problems were factors related to treatment default. 
Many of these factors can be changed by correct and efficient counselling.  
In addition to counselling by trained counsellors, family support has also shown to 
assist with compliance (Hutapea, 2009). Patients with TB showed increased levels of 
performance-avoidance and social avoidance than healthy control subjects (Kibrisli et al., 
2015). Lastly, Hutapeas study (2009) showed that the more significant family support 
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indicated improved compliance. However, four of the most compliant participants were 
single, and two were cohabiting with partners. The married participants did not show the 
greater compliance. However, this study did not look at other family support such as parents 
and other significant family members.  
Poverty is also a reality for many South African patients, possibly affecting 
adherence, and thus the feasibility of treatment and this current study. In a Uganda TB study, 
one of the findings for non-adherence was a lack of transport money to collect more drugs 
when they were finished as well as being busy at work (Amuha et al., 2009). From the current 
study, those few patients that were employed were hesitant to miss work for treatment. In a 
developing country where the unemployment rate is tremendous, losing a job due to illness is 
a scare for many. However, out of the six participants employed at enrolment, only one 
participant dropped out for work-related reasons, while another one of these did complete the 
study. Perhaps the combination of this family support structure assisted with his participation. 
The remaining four either were transferred elsewhere for treatment such as Sizwe Hospital, 
returned to their homeland or withdrew for other medical reasons.  
Moreover, increased education level and age have been shown to improve adherence 
(Hutapea, 2009). Though, both education level and age did not appear to be associated with 
adherence in this current study. Hutapea (2009) found that the higher the education, the 
greater the age and the more family support indicated better adherence to medication. In this 
current study, six of the 22 participants completed the full three-month study period. They 
were considered compliant with the study procedures, which indicated that they were 
compliant with their DR-TB medication regimen, as it was a condition of participation. When 
looking at education, the majority of the participants had completed grade 10 (n = 10), with 
the minority having some sort of tertiary education (n = 2). The most compliance participants 
(n = 6) had mostly completed grade 10 (n = 4) with only one participant having completed 
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grade 11 and one having completed grade 12. These results by Hutapea (2009) are thus in 
contrast to this current study, where education level did not seem to influence adherence. 
Also, the average age however in this study was 33.78 years, where the six most compliance 
participants were mostly below this age, with only one of these participants being 35.1 years. 
This current study does not support the notion that increased age, education and family 
support improves adherence. However, the sample was small to make a definite conclusion. 
Although many of these factors, such as poverty, stigma and emotional difficulties 
were observed in the participants by the study coordinator at the study visits, and are 
necessary to consider, no single pattern could be observed. However, the sample was too 
small to find trends. The most significant trend that could be a smaller dropout from HJH 
compared to SRH. HJH had more trained counsellors, who spoke a variety of languages. This 
support and DR-TB education appear to have positively affected adherence and reduced 
attrition. As individual counselling may not always be feasible, possible support groups by a 
trained counsellor would assist in adherence. 
7.4.1.1. HIV Status, ARVs, and DR-TB. 
There is an increasing number of MDR-TB and XDR-TB cases in South Africa, 
which is likely representing an unrecognised and evolving epidemic rather than sporadic, 
localised outbreaks. The combination of a mostly affected HIV population provides an ideal 
condition for a DR-TB epidemic. HIV infection has shown to adversely affect the outcome of 
DR-TB treatment (Andrew et al., 2007). Someone who is infected with HIV and TB is more 
likely to become sick with active TB (WHO, 2013). Andrews et al. (2007) further mention 
that HIV clinics are sites are clustering of TB susceptible individuals, and, in the presence of 
unrecognised TB, they provide another favourable setting for the rapid spread of DR-TB.  
The majority of participants in the current study had HIV co-infection and relative 
risk of TB among HIV-infected persons, compared with that among HIV-uninfected persons, 
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ranges from 20- and 37-fold, depending on the state of the HIV epidemic (Getahun et al., 
2010). However, in South Africa, where HIV is rife, the risk of TB is as well. In 2015, there 
were an estimated 480 000 new cases MDR-TB cases worldwide and 100 000 RR-TB cases 
who were eligible for treatment, yet only 12 000 enrolled (20%), with the top six countries 
accounting for 60% of the new cases, one of which being South Africa (WHO, 2015). Also, 
with 33.2 million persons infected with HIV, one-third are also estimated to be infected with 
TB (Getahun et al., 2010). 
Interestingly, another study showed the stepwise evolution of drug resistance, despite 
stringent treatment adherence, which is impacted by HIV. This study took place at a South 
African gold mine with a well-functioning TB control program (Calver et al., 2010). The 
findings suggested that existing TB control measures were inadequate to control the spread of 
drug-resistant TB in this HIV co-infected population. The data from this study call for 
improved infection control measures, implementation of rapid diagnostics, enhanced active 
screening strategies, as well as pharmacokinetic studies to determine optimal dosages and 
treatment regimens (Calver et al., 2010).  
Although South Africa has one of the most extensive ARV programs internationally, 
only half of the HIV infected participants were on ARV therapy at enrolment, while the other 
half began treatment within the first month of TB treatment. Of the six participants that 
completed the full three months of the study protocol, five were HIV infected. Of the four 
total participants transferred to Sizwe Tropical Disease Hospital as they were sputum 
positive, one was HIV negative. Therefore 25% of the sputum positive participants were HIV 
negative. The outcomes of the HIV negative participants are unknown, as one wished to 
withdraw from the study, one was transferred to Sizwe Hospital, one completed the study and 
the last of the four returned to his hometown. 
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HIV infected patients are considered high risk for missing appointments in the 
treatment of DR-TB (Gajee et al., 2016). The feasibility was affected possibly by this 
sizeable HIV-DR-TB coinfection rate, as HIV patients are at higher risk of adherence to 
medication. This must be noted in further studies with a specific focus on retention of HIV 
patients.  
7.4.1.2. Decentralisation of treatment. 
The decentralisation of treatment identified many complications. Specifically, for this 
study, the decentralisation identified issues with participants returning for treatment, which 
impacted the feasibility of the study. 
This was observed through the two sites at SRH and HJH; a variety of inpatient and 
outpatient treatment. HJH, SRH, and Charlotte Maxeke Johannesburg Academic Hospital are 
the three decentralised DR-TB hospitals in Gauteng (Evans et al., 2017). However, SRH it is 
also one of two Gauteng-based hospitals that treat DR-TB patients on both an out- and 
inpatient basis. (Gauteng Department of Health, n.d.) South Rand Hospitals’ inpatient 
treatment period for DR-TB ranges from between two and eight weeks and they treated as 
outpatients. Helen Joseph Hospital, in contrast, treats patients as outpatients, whereby they 
visit their clinics daily and return to Helen Joseph hospital for follow-up visits at scheduled 
intervals (Gajee et al., 2016). Thus, for this study, nine participants received treatment at 
Helen Joseph Hospital and 13 at South Rand Hospital. 
Decentralization of treatment, as discussed by the NDoH (2011) was necessary as the 
number of patients diagnosed with MDR-TB far exceeded the number of hospital beds in the 
centralised MDR-TB units. The waiting times and waiting lists also resulted in many 
infectious and untreated patients exposing family and community members to DR-TB bacilli 
(NDoH, 2011). They further described DR-TB as a human-made problem, primarily due to 
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human error in either management of drug supply, patient management, prescription of 
chemotherapy or patient adherence. 
However, as per the data from this current study, 59% of this participant sample had 
never been treated with TB before, and the DR-TB was their first infection. Only 41% had 
been treated with TB before. Thus, due to these first time TB infections, it cannot be a direct 
result of errors in the prescription of chemotherapy, patient adherence, management of drug 
supply and patient management. It is probable that these newly infected TB patients were 
infected from others with DR-TB in the community who were still currently infectious. 
This study also further identified various themes with the decentralisation model, as 
noted from informal interviews with the participants. The issues encompassed problems with 
visiting the clinics daily for injections, as participants complained of the painful nature of the 
injections with no recovery noted yet resulting in unpleasant side effects. Furthermore, the 
participants reported anxiety regarding the waiting times at the clinic, which impacted 
employment and job sustainability. The need to provide food for their families in conjunction 
with the stigma of visiting the clinic daily outweighed the desire to receive the injections. 
Many feared isolation and judgement based on their diagnosis.  
Control of the spread of the disease, upon observation, was also identified as an issue 
with decentralisation. Participants received the in-depth counselling of DR-TB transmission 
and requirement to wear masks. However, this further enhanced the stigma and isolation. 
Participant reports also comprised of transportation issues when wearing a mask; they may 
not have been allowed in the taxi wearing a mask, for fear of infection of the others, and as a 
result, they did not wear the mask in the taxi. Many participants were only seen putting the 
mask on when they entered the hospital for follow-ups. Furthermore, Evans et al. (2017) 
showed that the median time from sputum collection to treatment initiation was 33 days. This 
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demonstrated how many patients remained infectious in various communities prior to 
treatment. 
Many patients were extremely ill and too weak to visit the clinic for their injections. 
Due to poverty, access food was a prominent issue. Patients reported taking the oral 
medications on empty stomachs and subsequently vomiting. As many of the participants in 
this current study lived in informal settlements, consideration was given to the lack of 
adequate heating and ventilation. Medication adherence and infection control could not be 
examined conclusively as the participants were not followed when they were at home. Also, 
Bedell et al. (2000) showed 76% with discrepancies between what doctors prescribe and what 
patients take in actual practice. Although this study was not explicitly done on HIV/TB 
medication, it can be extrapolated to this population (Bedell et al., 2000). 
A study in California reported high success cure rates of MDR-TB when treated as 
outpatients; however, those with underlying HIV had poor outcomes. They also reported no 
secondary cases (Burgos et al., 2004). Moyo et al. (2015) considered a community-based DR-
TB program that was implemented in Khayelitsha. Loss to follow-up was high, and overall 
long-term survival was poor. This study, by Moyo et al. (2015) concluded by stating that 
further research is needed to support retention of DR-TB patients on treatment, even within 
the community-based treatment programs (Moyo et al., 2015). In South Africa, where HIV is 
rife, and living situations are complicated, secondary infection is a high possibility. 
Therefore, the success of inpatient versus outpatient treatment is not merely based on the 
hospitalisation factors, but many other variables that must be considered 
The decentralisation model has some positive factors, although many shortfalls were 
noted. In this current study, as 59% were new TB infections, it is a clear indicator that 
infectious patients are spreading DR-TB to others, and the model of reducing the infection is 
not ideal.  
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Community-based treatment is not merely an alternative to centralised treatment, even 
though inpatient treatment is extremely costly (Sinavonic et al., 2015). When comparing this 
study to the current study conducted, only six participants continued throughout the three-
month period which is a mere 27% of the sample. It is unsure whether they completed the 
remainder of their DR-TB therapy, however, based on their reasons for dropout from the 
study, it is likely that many did not complete their therapy. As some participants transferred 
to a centralised treatment program (Sizwe Tropical Disease Hospital), it is likely they 
continued treatment due to the inpatient regimen.  
Padayatchi and Friedland (2008) suggest that patients with MDR-TB or XDR-TB 
could be admitted to institutions closer to their homes with subsequent discharge and home-
based care. This could perhaps alleviate the transmission of the infection to others as they 
would be hospitalised in the infectious stage. However, infection control within DR-TB 
hospitals within South Africa has been shown to be poor, which is also a concern of inpatient 
treatment, whether long or short term (Farley et al., 2012). Thus, we can see, from this 
sample, that loss to follow up was high. Moreover, based on this, it is hypothesised that the 
outcomes were poor. 
In summary, the treatment factors affecting the outcomes for DR-TB treatment are 
complex. On the one hand, long-term inpatient care is ideal, as it prevents transmission to 
uninfected counterparts. However, this results in further social and emotional issues. 
Therefore, centralisation or decentralisation is not the only factor to be considered; 
instead counselling education, support and individualised treatment programs depending on 
each patients’ needs. This, however, is difficult in a low resource setting. Yet, this 
decentralisation did significantly affect the feasibility outcome of this study and must be 
considered for further research. 
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7.4.2. Blood Sampling, Quality Assurance and Medical 
Management  
Various other aspects affected the feasibility of the study. This included difficulties 
with the blood sampling, as well as various quality assurance hurdles, that must be considered 
for a future study. However, this depicts a real-life situation in South Africa, where DR-TB 
patients receive treatment as outpatients, and so they had to wait for hours to between the 
peak and trough levels.  
Due to the limited resources in South Africa and capability of the laboratories, the 
pharmacokinetic measurements needed to transpire at SMU; over an hour’s drive. Due to 
this, haemolysis of the samples occurred as well as spillage. Occasionally, blood was also not 
drawn due to participants’ wishes. Thus, in many cases, part of the pharmacokinetic results 
was missing a total of 30 times, where only 51 samples were analysed fully. At times, the 
trough levels were obtained for some of the 30 samples. However, the peak levels were often 
missing. All efforts were taken to transport the samples correctly, according to GCP 
guidelines, yet as expected various difficulties still occurred. This highlights the need for 
more laboratories to perform these complicated measures. With the provision of services, 
correct transportation must also be ensured. Furthermore, many creatinine levels were not 
obtained. The creatinine results were planned to be obtained from the NHLS. However, much 
was accessed after the study. Upon searching for the creatinine levels on the NHLS database, 
many results were missing. The samples were drawn from the patient as noted by the study 
coordinator. The reason for missing results are unknown, but it could be a result of incorrect 
data capturing. Overall, the laboratory system within South Africa needs to be strengthened 
to provide efficient, cost-effective and reliable services to the large population that requires 
these tests. With a stronger national health laboratory system, the feasibility of research 
within this population will also be increased. 
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Also, as the medical management differs slightly between sites, national health 
statistics become compromised. As the protocol was slightly different between HJH and 
SRH, as discussed in Chapter 5, there was variability in results, and subsequently, the 
feasibility of the original study was affected. 
7.4.3. Summary of Feasibility of Performing TDM on DR-TB 
Patients on kanamycin and capreomycin  
Many aspects were identified that affected the feasibility this study, which affected 
the validity of generalisation of the results to a larger scale. Participant enrolment, 
willingness and attrition were a prominent factor, and various reasons were hypothesised.  
The central theme that may be able to assist this is more in-depth counselling and 
emotional support for participants. Also, it is imperative to ensure that another study does not 
rely on the data capturing of the NHLS as data can become lost, impacting the overall 
outcomes of the study. Furthermore, as the pharmacokinetics method is clearly established, 
better quality control can be put in to place for a more extensive study with regards to blood 
sampling. 
In summary, based on the audiological and pharmacokinetic results, TDM would not 
be feasible at present based on the limited data. More conclusive data and more prominent 
studies need to be conducted to further establish the pharmacokinetics of kanamycin and 
capreomycin in relation to toxicity and efficacy in patients with DR-TB. 
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Chapter 8: Ototoxicity Mobile Application 
Hearing loss and pharmacokinetics factors have been described, with the existing 
monitoring protocols. From Chapters 4, 6 and 7, it was evident that there is no clear-cut 
definition and protocol for monitoring ototoxicity as well as a description of a significant 
hearing loss suitable to be used in this specific DR-TB population. Therefore, this chapter 
recommends a standard ototoxicity monitoring protocol with a defined grading system 
relevant in the South African DR-TB context. It further discusses the development of a 
mobile application that was created through this research study. 
8.1. Rationale for the development of an ototoxicity 
monitoring protocol and grading system for the DR-
TB population and considerations for the South 
African context 
In South Africa, there is currently no set protocol for monitoring ototoxicity in the TB 
population. A study by Khoza-Shangase and Stirk (2016), showed that some hospitals that 
included have since implemented their own programs, yet there was no clear standard for 
managing the detected ototoxicity. The establishment of a monitoring program with an 
intervention method is needed.  
However, various cultural, social and context-specific considerations need to be 
considered. These considerations include the acknowledgement of patients defaulting on their 
treatment, the influence of African Traditional Healers on many patients, the 11 official 
languages that can contribute to communication difficulties, as well as the limited number of 
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audiologists available in South Africa to implement and manage an ototoxicity monitoring 
protocol.  
There are other factors for consideration which are specific to this DR-TB population. 
Defaulting from treatment and dropout rate was a dominant theme in this current study. 
Various issues have been identified in other studies as well. These reasons ranged from 
economic issues and poor tolerance and response to treatment. Economic issues included a 
return to work and complex social situations. Other reasons for default included behavioural 
problems (mainly substance abuse) (Sanchez-Padilla et al., 2014; Dooley et al., 2011), lack of 
belief in treatment, side effects and feeling healthy (Sanchez-Padilla et al., 2014). Dooley et 
al. (2011) further found that hospitalisation and positive sputum after three months of 
treatment was a risk of default.  
These issues are important to identify and incorporate into a monitoring program. As 
identified in this study, among employed patients, their jobs were a priority over treatment 
and audiological monitoring. Also, many patients were living in poverty, and so essential 
human needs were not always met, such as food, shelter and hygiene. Thus, expecting these 
patients to return for DR-TB treatment and monitoring may not be feasible until their basic 
needs are met. This is an aspect to consider when counselling the patient, and in-patient 
treatment may need motivation for in some cases. Also, referral to a social worker to assist 
with grant applications may be necessary. Interdisciplinary communication would be 
necessary as well to communicate with employers to explain the necessity of attending 
hospital visits, as well as the legal implications of not allowing patients to attend. A new, 
time-efficient protocol within South Africa needs to be developed to assist in accommodating 
issues such as time off work.  
Another factor to consider is African Traditional Healers, as they have a significant 
influence on people’s behaviour when they seek help. de Andrade (2011) proposed that when 
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a clinician and client share the same values, this may evoke confidence of the patient towards 
health practitioners. This article further explains that in order to maximise health care 
programs, health practitioners need to be aware of as well as recognise and work within the 
patients’ worldview. This view can be carried through to an ototoxicity monitoring program. 
The audiologist or counsellor needs to recognise the belief system of patients, specifically in 
relation to TB and hearing loss. Another study by de Andrade (2015) noted that patients 
might believe the hearing loss is a curse, and in this case, not because of the medication. This 
is important to assist with retention of patients with TB treatment, and with the ototoxicity 
monitoring program. By understanding their belief system, one can counsel the patient 
around this, without ‘chasing’ the patient away.  
Furthermore, South Africa has 11 official languages which can impact the treatment 
and monitoring protocol. In conjunction with this, many patients receive DR-TB treatment in 
South Africa from other countries. Even within the small sample size of this current study, 
two participants were from neighbouring countries, which contributes to further language 
barriers. This is extremely difficult for counselling, as the above factors mentioned seem to 
be imperative for patient retention, and thus for a successful ototoxicity monitoring program. 
It also needs consideration for necessary testing, when instructing and counselling the patient. 
Thus, although not ideal, interpreters are essential, even if they interpret electronically, such 
as via Skype, to make it more feasible. 
The number of audiologists available in South Africa needs to be taken into 
consideration. There are not enough audiologists to service this population, and many areas 
have no audiologists at all. This research used an extremely trained nurse to conduct the 
testing. At present, the current policy in South Africa is for nurses to conduct the automated 
audiometric testing (Koekemoer, n.d). However, the training of these nurses is insufficient, 
which only includes the basics of PTA, such as placement of the headphones, operating the 
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software, and patient requirements to complete the test. The success of this program is 
questionable (upon personal observation and personal communication with nurses conducting 
the tests as well as audiologists within the field). Therefore, for the initiation of a successful 
ototoxicity program countrywide, in-depth training of nurses to conduct at least otoscopy, 
immittance audiometry, PTA and DPOAE testing is essential. These nurses need adequate 
training in counselling of patients as well. 
Lastly, during the study period, it was noted that medical doctors were required to 
understand audiological results. Also, the audiologists were required to recommend dosage 
adjustments based on hearing loss. Moreover, in some instances, audiologists were not 
present, and so nurses were required to assist. Yet there was no set protocol for evaluating 
hearing for ototoxicity and what was considered a considerable hearing loss to motivate for 
dosage or drug changes (Khoza-Shangase & Stirk, 2016). At different hospitals, various 
frequencies are tested, making uniformity between hospitals difficult; in that, some hospitals 
have ultra-high frequency audiometers, and some have standard audiometers. Based on the 
varying equipment found at different hospitals, and elements found in the study, the 
researcher, therefore, proposes a method for healthcare professionals to identify significant 
hearing loss and recommend whether dosage changes should be considered.  
This method aims to be user-friendly with the use of a mobile application called 
Otocalc; an ototoxicity calculator which calculates significant hearing loss and provides 
recommendations. 
8.2. Proposed ototoxicity monitoring protocol and 
procedures 
An ototoxicity monitoring system has been designed specifically for the DR-TB 
population in South Africa. It is specific for this population as it includes aspects specifically 
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relevant to the patients and in line with the NDoH DR-TB treatment guidelines. The system 
includes counselling, interdisciplinary implementation, a proposed grading system and 
mobile application as well as an ototoxicity monitoring protocol. 
8.2.1. Settings 
This monitoring protocol acknowledges the limited resource settings. The mobile 
application was designed to be low cost, and available to those in the field. However, the 
correct equipment still needs to be available to test. 
In an ideal setting, the audiometric equipment would be available, including UHF 
PTA and DPOAEs. Further, there would be an audiologist available to assist the nurses, 
mostly with the management of the identified hearing loss, and to assist with issues that may 
arise. 
However, in a limited resource setting, this protocol would still require essential 
audiometric equipment, such as an otoscope, tympanometer, and PTA audiometer. In reality, 
there are few audiologists available, and so a nurse would be present, without an audiologist, 
to implement this protocol. Referral to an audiologist would be necessary for management of 
the hearing loss identified. 
8.2.2. Interdisciplinary Implementation 
Management of patients with DR-TB requires interdisciplinary team management. 
This involves the communication between the ototoxicity team regarding the monitoring and 
management of the patient, and not the multidisciplinary team, where each practitioner works 
in isolation. The core team should include at least a doctor, audiologist, and nurse whereas a 
support team should include a pharmacist, occupational therapist, physiotherapist, social 
worker, dietician, interpreter and psychologist (NDoH, 2011). The management team should 
further include the patients themselves, family members and other support structures (Mohr 
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE 
RELATIONSHIP BETWEEN HEARING LEVELS: A FEASIBILITY STUDY 
320 
et al., 2015). Interpreters are also shown to increase participation in treatment (Jacobs, 
Shepard, Suaya & Stone, 2004). 
However, specifically for the TB ototoxicity monitoring program and retention, the 
doctors, audiologists, social workers, and pharmacists are imperative. Furthermore, the 
support structure such as family and friends (Mohr et al., 2015) is advisable where possible to 
supplement the interdisciplinary team. Also, interdisciplinary communication in contrast to 
multidisciplinary is essential, and ototoxicity monitoring and management of a joined effort 
between these parties together. 
8.2.3. Counselling 
Research has shown that counselling can improve adherence to treatment programs 
(Liefooghe, Suetens, Meulemans, Moran & De Muynck, 1999; Peltzer, Friend-du Preez, 
Ramlagan & Anderson, 2010). This was seen in a TB treatment adherence study by Liefooghe 
et al. (1999) where adherence was improved with counselling at every study visit. Adherence 
was not improved significantly; however, the improvement was still noticed. Another study 
looked at adherence and counselling, in particular with regards to HIV treatment and found 
that the more social support, the greater the adherence, where the use of herbal medicine was 
associated with lower adherence (Peltzer et al., 2010). As many of the patients with DR-TB 
are HIV infected, as with the participants in this current study, the importance of counselling 
is highlighted. 
Therefore, as counselling can improve adherence, it needs to be a vital component of 
the ototoxicity monitoring program. If a patient is not adherent to the TB treatment, it is 
unlikely he/she will be adherent to the monitoring program. Also, counselling needs to be 
conducted at every visit; as sometimes, especially initially upon diagnosis, the patient may 
feel overwhelmed and need repetition. The family members should also be included in this 
counselling. Counselling should cover: 
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• What is TB and why adherence and completion of treatment adherence are important? 
• What is hearing loss? 
• TB drugs may cause hearing loss. 
• Signs and Symptoms of hearing loss. 
• Communication with Hearing loss 
• Rehabilitation procedures and success. 
• Alternate belief systems of the patient regarding hearing loss and TB. This is 
important as some cultures may believe hearing loss is a curse. 
• Alternate medications that the patient is taking or would like to take. 
• Importance of support systems at home and feasibility of adherence. If a patient does 
not have food at home, the likelihood of them completing the treatment is reduced. In 
cases like these, the treatment team needs to be notified, and social grants need to be 
applied for. 
• Questions and comments of the patient. 
 
Because there may be language barriers, this counselling session should be recorded 
in the eleven official languages. Although this is not ideal, it will allow the patient to 
understand somewhat. Brochures should also be available in the 11 official languages for the 
literate patients. 
When interpreters are available, the interpreter can ensure that the patient can 
communicate with the service provider, be it the audiologist, doctor or nurse. Jacobs et al. 
(2004) found that the use of interpreters, in the USA, resulted in significant increases in the 
uptake of preventive services, physician visits, and prescription drugs, suggesting that 
interpreter services improved patients’ access to primary and preventive care for a moderate 
increase in cost. They further discussed interpreters as a financially viable method for 
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE 
RELATIONSHIP BETWEEN HEARING LEVELS: A FEASIBILITY STUDY 
322 
enhancing service delivery. However, the cost estimate was done in the USA, at $279 per 
person per year (Jacobs et al., 2004). Interpreters are recommended within the South African 
population, however, if the specific site does not have the budget, recorded counselling and 
brochures should be used.  
Furthermore, support groups may also assist the patients. The psychosocial factors are 
imperative and are the core of treatment adherence and compliance. Bateganya, Amanyeiwe, 
Roxo & Dong (2015) discussed the benefits of HIV support groups on morbidity, retention in 
care, mortality and quality of life for a person living with HIV. They mention, however, that 
it is unclear whether this would be cost-effective given the paucity of studies (Batenganya et 
al., 2015)  
8.2.4. Audiological monitoring 
The audiological protocol includes patient identification (those patients at risk and 
taking ototoxic medication), and baseline testing (for kanamycin it is suggested that baseline 
is indicted within 72 hours of the first dose) administration, monitoring and follow-up tests. 
These follow-ups are recommended at intervals that would allow the detection of the earliest 
signs of ototoxicity 
8.2.4.1. Risk factor identification. 
Early identification of patient’s risk factors may assist in guiding the frequency of 
testing and possible outcomes. Counselling can address these risk factors and the 
likelihood of patients losing their hearing based on the risk factors. This depicts the 
necessity for interdisciplinary work. A risk factor checklist (Table 8.1), as below, was 
incorporated in the mobile application. 
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Table 8.1  
Potential Risk Factors Identification Checklist 
Potential Risk Factors Yes No Not 
sure 
Details 
Existing Hearing Loss     
Previous Ototoxic Agent, such as: 
• Antibiotics (aminoglycosides when given IV): 
gentamicin, amikacin, tobramycin, netilmicin, 
kanamycin, streptomycin, neomycin 
• Antibiotics (macrolides): clarithromycin, ketolides, 
erythromycin (2-4g per 24h, IV only), azithromycin, 
glycopeptide, vancomycin (IV) 
• Antibiotics (peptide): capreomycin 
• Salicylates (more than 6-8 tablets a day): aspirin 
• NSAIDs (more than 6-8 tablets per day): ibuprofen, 
indomethacin, naproxen, diclofenac, mephenamic 
acid 
• Quinine 
• Loop diuretics (only when IV): furosemide, 
bumetanide, torasemide, piretanide  
• Chemotherapeutic agents: cisplatin, carboplatin, 
oxaliplatin, deferoxamine, vinca alkaloids, 
vincristine, vinblastine, vinorelbine, 
cyclophosphamide, chlorambucil, melphalan, 
fosfamide 
• Antiretrovirals (potentially ototoxic)  
    
Renal problems or impaired hepatic function     
Subjective report of difficulty hearing (difficulty with TV, 
radio, restaurant, co-workers, clients, customers, friends, 
relatives, neighbours) 
    
Above 55 years of age     
Diabetes mellitus     
Family history of Hearing Loss     
Excessive noise exposure (works in music industry, in noisy 
factories) 
    
Previous illnesses such as cancer, meningitis, encephalitis, 
mumps, measles, chronic ear infections. 
    
Previous head injury     
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8.2.4.2. Baseline Testing.  
Baseline testing should be as comprehensive as possible. However, in limited 
resource settings, the minimum testing should include otoscopy, tympanometry (screening is 
sufficient), air conduction PTA (HF) from 0.25 kHz to 8 kHz (0.25, 0.5, 1, 2, 3, 4, 6, 8). 
Ideally, baseline testing should include otoscopy, tympanometry (screening is sufficient), air 
conduction from 0.25 kHz to 20 kHz (0.25, 0.5, 1, 2, 3, 4, 6, 8, 9, 10, 11.2, 12.5, 14, 16, 18 
and 20 kHz), and bone conduction up to 6 kHz. If equipment is available, DPOAE testing 
should also be performed for follow-up ease of monitoring. Speech audiometry should be 
performed if possible. However, language differences must be noted. The recorded English 
and isiZulu wordlists should be used if available.  
8.2.4.3. Follow-up monitoring (intervals and frequency range).  
Intervals: monitoring twice a month (bi-weekly) is recommended in an ideal setting, 
however, if this is not possible, alternatively, the initial follow up should be two weeks post 
baseline, and monthly thereafter. This is recommended for the entire period that the patient 
receives treatment for DR-TB.  
As PTA is generally used to grade hearing loss and as well as to direct the change of 
dosage and treatment adjustments, PTA’s most considerable changes will mainly be used. 
Therefore, in the first three months of monitoring, it is recommended that baseline testing, as 
well as week 2 and week 6 undoubtedly be conducted. As week 4 and 8 showed the least 
change, the following test could be conducted at week 10 or 12. This would be for a limited 
resource setting, and ideally, testing should be conducted every two weeks. This schedule of 
an initial visit two weeks post baseline, and monthly thereafter often coincides with the 
general required doctor visits to the hospital. Subsequently, monitoring should take place 
every 3 months for a total of 6 months post-treatment. If there is a hearing loss, annual 
monitoring and management are recommended. 
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE 
RELATIONSHIP BETWEEN HEARING LEVELS: A FEASIBILITY STUDY 
325 
Frequency Range for follow-up testing: Follow-up should include limited frequency 
range, as patients tire easily. When UHF testing is available, testing can include 6 to 16 kHz 
(6 to 8 kHz and inclusive being HF, with 9 to 16 kHz being UHF). According to Fausti et al. 
(1999), the frequencies that showed the most significant sensitivity were 8, 9, 10, 11.2 and 
12.5 kHz (generally separated by 1/6 octave. When high-frequency testing is not available, 3 
kHz to 8 kHz should be safe. At the high frequencies, there is an abrupt decrease in hearing 
sensitivity already from youth. Hitherto, no international standard for 0 dB hearing level 
exists for frequencies above 8 kHz.  
It is questioned whether a general standard is meaningful at all and that normative 
data for various age groups should instead be used as a reference level (Osterhammel & 
Osterhammel, 1978). 
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Table 8.2 
Suggested time periods and frequencies for new ototoxicity monitoring protocol 
Ideal Setting 
Limited Recourse 
Setting 
Frequency Range (PTA) 
Baseline Baseline 0.25 kHz to 20 kHz, where available 
Week 2 Week 2 6 kHz to at least 16 kHz when UHF equipment 
available. 
3 kHz to 8 kHz when HF equipment available  
Week 4  6 kHz to at least 16 kHz when UHF equipment 
available. 
3 kHz to 8 kHz when HF equipment available 
Week 6 Week 6 6 kHz to at least 16 kHz when UHF equipment 
available. 
3 kHz to 8 kHz when HF equipment available 
Week 8  6 kHz to at least 16 kHz when UHF equipment 
available. 
3 kHz to 8 kHz when HF equipment available 
Week 10 Week 10 6 kHz to at least 16 kHz when UHF equipment 
available. 
3 kHz to 8 kHz when HF equipment available 
Week 12  6 kHz to at least 16 kHz when UHF equipment 
available. 
3 kHz to 8 kHz when HF equipment available 
Week 14 Week 14 0.2 5 kHz to 20 kHz when UHF equipment 
available 
0.25 kHz to 8 kHz when HF equipment available 
Biweekly  
(if ototoxicity 
identified) 
Monthly  
(if ototoxicity 
identified in limited 
recourse setting) 
-6 kHz to at least 16 kHz when UHF equipment 
available. 
-3 kHz to 8 kHz when HF equipment available 
-0.25 kHz to 20 Hz every three months 
Monthly  
(if no ototoxicity 
detected) 
Monthly  
(if no ototoxicity 
detected) 
-6 kHz to at least 16 kHz when UHF equipment 
available. 
- 3 kHz and above when HF equipment available 
-0.25 kHz to 20 kHz at the conclusion of the 
injectable period 
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Ideal Setting 
Limited Recourse 
Setting 
Frequency Range (PTA) 
3 monthly for a total of 
6 months (post 
treatment) 
3 monthly for a total 
of 6 months (post-
treatment 
-6 kHz to at least 16 kHz when UHF equipment 
available. 
-3 kHz w to 8 kHz hen HF equipment available 
-0.25 kHz to 20 kHz where UHF equipment 
available at the conclusion of this 6-month 
period 
--0.25 kHz to 8 kHz when HF equipment 
available at the conclusion of this 6-month 
period 
Note: should the hearing loss progress to 6 kHz with UHF, or 3 kHz with HF monitoring, the 
lower frequencies must be tested as well 
 
DPOAEs: When the patient is not responsive, DPOAE monitoring alone can be done. 
High-frequency diagnostic DPOAEs should be done, with ambient noise less than 55 dBA 
SPL. Repeat readings must be done at every measure, and a significant change can be 
considered 6 dB. 
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE RELATIONSHIP BETWEEN HEARING LEVELS: A FEASIBILITY STUDY 
328 
 
Figure 8.1. Basic flowchart for ototoxicity monitoring of DR-TB patients
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8.3. Proposed Grading System with Mobile Application 
8.3.1. Proposed Grading System with Mobile Application 
A grading system provides a systematic framework to classify loss of hearing from 
baseline. It allows a clear understanding of the degree of this loss and assists with methodical 
and uniform management. 
From observation and individual consultation with medical doctors in the field, many 
are unable to interpret audiograms when provided. Hearing loss guides the motivation for 
changes in the treatment regimen. These changes in the treatment regimen may involve the 
doctor changing the drug and perhaps reducing the days of therapy, and thus, it is essential 
that the doctors and nurses understand the correct interpretation of audiograms in order to 
implement these changes, as well as for the counselling of the patients. 
It is generally the audiologists’ role to interpret audiograms; however, audiologists are 
often not available TB management clinics. If a trained nurse, as recommended above will be 
conducting audiological testing, a grading system will assist in the interpretation. This will 
guide the management protocol. 
Also, many audiologists are unsure how to classify a significant ototoxic hearing loss, 
and when to advise the medical doctor to adjust the medication regimen. 
Therefore, through this research, the development of a mobile application was 
developed to assist in the classification of hearing loss and guide the management. This 
application acts as an ‘ototoxicity calculator’. This application will be discussed further is 
8.3.2 
The purpose of this mobile grading system is two-fold. Firstly, it can assist the health 
professional in assessing the patient for ototoxicity as well as establishing the clinical 
significance of this ototoxicity. Secondly, it can be used for ongoing care by the healthcare 
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professional, who will update the variable component of the application at each visit to 
monitor the progression of hearing loss. This system provides a systematic basis for referral 
and management of patients according to their needs.  
This ‘otocalc’ application acts as an ‘ototoxicity calculator’.  
There are two avenues in which this application can be used: 
1. Ototoxicity Calculator: the doctor/nurse/audiologist can access the application, 
enter the baseline and follow up pure tone audiograms, and subsequently the 
application will provide the correct grade of hearing loss as well as possible 
recommendations. This can be used as a ‘once off’ calculation, and patient 
details are not stored on the system. The user does not need to register for this 
option. 
2. Ototoxicity Monitoring Application: this would be available to those working 
within the field of TB, specifically DR-TB management. Those conducting the 
audiograms or receiving the completed audiograms (for example the doctor) 
would enter the patient’s results. These results can be uploaded to a database. 
The reasoning for this is should a patient be transferred to another hospital or 
area, the doctor in that area will be able to access the patients’ audiology results. 
However, only healthcare professionals working in this field and registered on 
the application would be granted access to the database. Moreover, access to 
individual patients can only be obtained with the patients’ identity number 
and/or hospital number, as it would be unethical for a professional not working 
with the patient to access his/her results. This limited access page will also act 
as an ototoxicity calculator. 
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8.3.2. Development of ‘Otocalc’ 
The development of this mobile application took approximately one year, where the 
developer and the audiologist worked in the application to make it user-friendly and relevant 
to diverse healthcare professionals. 
Various professionals were involved in the development of the application. These 
professionals included a software engineer who built the application, an audiologist and the 
researcher who designed the application. Various healthcare professionals, including a 
pharmacist, medical doctor and two audiologists (one involved in the field, as well as an 
audiologist on private practice) were involved in piloting the application and advising on 
suggested changes.  
These changes included multiple user accessibility modifications and changes with 
the ‘recommendations’ framework as well as additions and deletions of aspects such as the 
risk identification checklist, storage of the data on the database, and grading descriptions. 
From initial development, the app underwent 14 modifications, until it was ready for upload 
on the Android and iOS stores for download. It will be uploaded to these stores once approval 
is obtained by the university.  
8.3.3. Newly Developed Grading System 
The calculator contains the grades as per table 8.3, with interpretation and 
recommendations. Counselling should be conducted as per 8.2.3; however, a summary is 
included in the recommendation column. As UHF is often not conducted, the majority of 
individuals would present with either a grade three and above, or hearing that is not gradable 
(no ototoxicity). When the hearing presents as grade three, the loss in hearing is likely 
interfering with daily functioning.
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Table 8.3 
Mobile application grading system: grade, description, explanation & recommendations as used in the ‘otocalc’ mobile application 
Grade Description Interpretation Management recommendations Recommendations for counselling 
1 10 dB or 
greater 
change in 
thresholds at 
two or more 
ultra-high 
frequencies (9 
kHz to 20 
kHz) from 
baseline in at 
least one ear 
• The patient will likely 
not notice a 
deterioration of hearing 
abilities. 
• It is the early stages of 
hearing loss, but it is 
not yet affecting the 
frequency range of 
speech sounds (250Hz 
– 8 kHz). 
• It is possible that 
should the patient 
continue with the 
current drug regimen; 
the hearing loss may 
progress to speech 
frequencies. 
Goal: Possible prevention or reduction of 
clinical hearing loss through early identification. 
Team: 
Medical doctor: 
• Consider dosage adjustment. 
• Consider the use of an alternate non-ototoxic 
drug. 
Audiologist or nurse: 
• Inform the medical doctor of the change in 
thresholds. 
• Motivate for dosage adjustment. 
• Motivate for the use of an alternate non-
ototoxic drug. 
• A follow-up appointment in 2 weeks for 
repeat audiogram. 
Goal: Possible prevention or reduction of 
clinical hearing loss through early identification. 
Team: 
Medical doctor: 
• Consider dosage adjustment. 
• Consider the use of an alternate non-ototoxic 
drug. 
Audiologist or nurse: 
• Inform the medical doctor of the change in 
thresholds. 
• Motivate for dosage adjustment. 
• Motivate for the use of an alternate non-
ototoxic drug. 
• A follow-up appointment in 2 weeks for 
repeat audiogram. 
2 20 dB or 
greater 
change in 
• The patient will likely 
not notice a 
deterioration of hearing 
Goal: Possible prevention or reduction of 
clinical hearing loss through early identification. 
Team: 
Goal: For patients to understand the nature and 
implications of hearing loss, but also the 
implications should they refuse treatment. It is 
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Grade Description Interpretation Management recommendations Recommendations for counselling 
thresholds at 
more than two 
frequencies in 
ultra-high 
range (9 kHz 
to 20 kHz) 
from baseline 
in at least one 
ear 
abilities unless he/she 
is a musician. 
• This is a significant 
loss of cochlear hair 
cell function in the 
ultra-high frequencies 
that are not yet 
affecting the frequency 
range of speech sounds 
(0.25 kHz – 8 kHz). 
It is possible that should 
the patient continue with 
the current drug regimen; 
the hearing loss may 
progress to speech 
frequencies. 
Medical doctor: 
• Consider dosage adjustment. 
• Consider the use of an alternate non-ototoxic 
drug. 
Audiologist or nurse: 
• Inform the medical doctor of the change in 
thresholds. 
• Motivate for dosage adjustment. 
• Motivate for the use of an alternate non-
ototoxic drug. 
• A follow-up appointment in 2 weeks for 
repeat audiogram. 
important that patients feel supported and not 
alone. 
Team: 
All health professionals should discuss the 
following with the patient and his/her family: 
• The possibility that some drugs used in the 
treatment of TB may cause a hearing loss. 
• Importance of adherence to treatment 
despite the potential hearing loss. 
• Hearing loss is not always preventable but 
that a motivation for the alternate non-
ototoxic drug will be done. 
• Hearing loss will in most cases be 
permanent. 
• Hearing loss may impact on their 
communication abilities are home, work and 
with family or friends. 
• Amplification devices (e.g. hearing aids) are 
available if hearing loss is identified. 
• Discuss and address the fears and concerns 
of the patient and family members. 
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Grade Description Interpretation Management recommendations Recommendations for counselling 
•  Provide the patient and his/her family with 
all the medical and audiological options 
relevant to the management of hearing loss. 
The patient should report any change in medical 
and hearing status to health professionals. 
3 10 dB or 
greater 
change in 
thresholds 
into two 
frequencies 
from 8 kHz 
and below 
from baseline 
in at least one 
ear 
• The hearing loss is now 
in the speech frequency 
range. 
• Depending on the 
patients' listening 
demands and 
processing abilities, the 
hearing loss may affect 
his/her day to day 
functioning.  
• The patient may hear 
people talking, 
however, may not 
always be able to 
discriminate the words 
spoken, for example 
‘eight versus fate’. 
Goal: The identification of early clinical 
hearing loss, and exploration or alternative 
treatment to prevent/ reduce further hearing loss 
and functional impairment.  
Team: 
Medical doctor: 
• Consider dosage adjustment 
• Consider the use of an alternate non-ototoxic 
drug. 
• Refer to audiologist for diagnostic 
audiological assessment. 
Nurse: 
• Inform the medical doctor of the change in 
thresholds. 
• Motivate for dosage adjustment. 
• Motivate for the use of an alternate non-
ototoxic drug. 
Goal: For the patients to understand hearing 
loss, as well as its possible management in the 
future. It is important for patients to understand 
that DR-TB treatment is imperative, despite the 
hearing loss; but also, that they are not alone, 
and management is possible.  
Team: 
All health professionals should discuss the 
following with the patient and his/her family: 
• The possibility that some drugs used in the 
treatment of TB may cause a hearing loss. 
• Importance of adherence to treatment 
despite the potential hearing loss. 
• Hearing loss is not always preventable but 
that a motivation for the alternate non-
ototoxic drug will be done. 
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Grade Description Interpretation Management recommendations Recommendations for counselling 
• The patient will likely 
also struggle to 
discriminate speech in 
the presence of 
background noise. 
• Refer to audiologist for diagnostic 
audiological assessment. 
Audiologist: 
• Conduct diagnostic audiological assessment. 
• Consider hearing amplification for future. 
• Inform the medical doctor of the change in 
thresholds. 
• Motivate for dosage adjustment. 
• Motivate for the use of an alternate non-
ototoxic drug. 
A follow-up appointment in 2 weeks for repeat 
audiogram. 
• Hearing loss will in most cases be 
permanent. 
• Hearing loss may impact on their 
communication abilities are home, work and 
with family or friends. 
• The patient is not alone, and there are others 
who are also suffering from this hearing loss 
(try and put patients in touch with each other 
for support). 
• Amplification devices (e.g. hearing aids) are 
available if hearing loss is identified. 
• Discuss and address the fears and concerns 
of the patient and family members. 
•  Provide the patient and his/her family with 
all the medical and audiological options 
relevant to the management of hearing 
loss.The patient should report any change in 
medical and hearing status to health 
professionals. 
4 10 dB or 
greater 
change in 
• The hearing loss is now 
in the speech frequency 
range. 
Goal: The identification of early clinical 
hearing loss, and exploration or alternative 
treatment to prevent/ reduce further hearing loss 
Goal: For the patients to understand hearing 
loss, as well as its possible management in the 
future. It is essential for patients to understand 
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Grade Description Interpretation Management recommendations Recommendations for counselling 
thresholds in 
any 3 or more 
frequencies 
from 8 kHz 
and below 
from baseline 
in at least one 
ear 
• Depending on the 
patients' listening 
demands and 
processing abilities, the 
hearing loss may affect 
his/her day to day 
functioning.  
• The patient may hear 
people talking, 
however, may not 
always be able to 
discriminate the words 
spoken, for example 
‘eight versus fate’. 
• The patient will likely 
also struggle to 
discriminate speech in 
the presence of 
background noise. 
. 
and functional impairment. Audiological 
management can be considered. 
Team: 
Medical doctor: 
• Consider dosage adjustment. 
• Consider the use of an alternate non-ototoxic 
drug. 
• Refer to audiologist for diagnostic 
audiological assessment. 
Nurse: 
• Inform the medical doctor of the change in 
thresholds. 
• Motivate for dosage adjustment. 
• Motivate for the use of an alternate non-
ototoxic drug. 
• Refer to audiologist for diagnostic 
audiological assessment. 
Audiologist: 
• Conduct diagnostic audiological assessment. 
• Consider hearing amplification. 
• Discuss communication strategies with the 
patient and his/her family. 
that DR-TB treatment is imperative, despite the 
hearing loss; but also, that they are not alone, 
and management is possible. Patients need to 
start understanding the process of amplification. 
Team: 
All health professionals should discuss the 
following with the patient and his/her family: 
• The possibility that some drugs used in the 
treatment of TB may cause a hearing loss. 
• Importance of adherence to treatment 
despite the potential hearing loss. 
• Hearing loss is not always preventable but 
that a motivation for the alternate non-
ototoxic drug will be done. 
• Hearing loss will in most cases be 
permanent. 
• Hearing loss may impact on their 
communication abilities are home, work and 
with family or friends. 
• The patient is not alone, and there are others 
who are also suffering from this hearing loss 
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Grade Description Interpretation Management recommendations Recommendations for counselling 
• Inform the medical doctor of the change in 
thresholds. 
• Motivate for dosage adjustment. 
• Motivate for the use of an alternate non-
ototoxic drug. 
A follow-up appointment in 2 weeks for repeat 
audiogram. 
(try and put patients in touch with each other 
for support). 
• Amplification devices (e.g. hearing aids) are 
available. 
• Discuss and address the fears and concerns 
of the patient and family members. 
•  Provide the patient and his/her family with 
all the medical and audiological options 
relevant to the management of hearing loss. 
• The patient should report any change in 
medical and hearing status to health 
professionals. 
5 20 dB and 
above change 
in thresholds 
at 3 
frequencies or 
more at 8 kHz 
or below from 
baseline in at 
least one ear 
• This hearing loss is 
affecting the patients' 
ability to hear, 
discriminate and 
understand speech.  
• The hearing loss is 
likely to affect the 
patient considerably in 
communicating at 
Goal: The prevention or reduction of further 
hearing loss by treatment adjustments/changes. 
The audiological team can consider 
amplification. 
Team: 
Medical doctor: 
• Consider dosage adjustment. 
• Consider the use of an alternate non-ototoxic 
drug. 
Goal: For the patients to understand hearing 
loss, as well as its possible management in the 
future. It is important for patients to understand 
that DR-TB treatment is imperative, despite the 
hearing loss; but also, that they are not alone, 
and management is possible. Patients need to 
start understanding the process of amplification. 
Team: 
All health professionals should discuss the 
following with the patient and his/her family: 
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Grade Description Interpretation Management recommendations Recommendations for counselling 
home, work and with 
family or friends.  
• The patient will 
struggle significantly to 
hear speech in noisy 
situations. 
• The hearing difficulties 
may affect the patient 
socially and 
emotionally. 
 
• Refer to audiologist for diagnostic 
audiological assessment. 
Nurse: 
• Inform the medical doctor of the change in 
thresholds. 
• Motivate for dosage adjustment. 
• Motivate for the use of an alternate non-
ototoxic drug. 
• Refer to audiologist for diagnostic 
audiological assessment. 
Audiologist: 
• Conduct diagnostic audiological assessment. 
• Consider hearing amplification. 
• Discuss communication strategies with the 
patient and his/her family. 
• Inform the medical doctor of the change in 
thresholds. 
• Motivate for dosage adjustment. 
• Motivate for the use of an alternate non-
ototoxic drug. 
A follow-up appointment in 2 weeks for repeat 
audiogram. 
• The possibility that some drugs used in the 
treatment of TB may cause a hearing loss. 
• Importance of adherence to treatment 
despite the potential hearing loss. 
• Hearing loss is not always preventable but 
that a motivation for the alternate non-
ototoxic drug will be done. 
• Hearing loss will in most cases be 
permanent. 
• Hearing loss may impact on their 
communication abilities are home, work and 
with family or friends. 
• The patient is not alone, and there are others 
who are also suffering from this hearing loss 
(try and put patients in touch with each other 
for support). 
• Amplification devices (e.g. hearing aids) are 
available. 
• Discuss and address the fears and concerns 
of the patient and family members. 
•  Provide the patient and his/her family with 
all the medical and audiological options 
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Grade Description Interpretation Management recommendations Recommendations for counselling 
relevant to the management of hearing 
loss.The patient should report any change in 
medical and hearing status to health 
professionals. 
6 More than 40 
dB change in 
threshold in 
up to 2 
frequencies 
from 8 kHz 
and below 
from baseline 
in both ears 
• This hearing loss is 
affecting the patients' 
ability to hear, 
discriminate and 
understand speech.  
• The hearing loss is 
likely to affect the 
patient considerably in 
communicating at 
home, work and with 
family or friends.  
• The patient will 
struggle significantly to 
hear speech in noisy 
situations. 
• The hearing difficulties 
may affect the patient 
Goal: Treatment changes are imperative. And 
audiological management is essential at this 
stage, if possible. 
Team: 
Medical doctor: 
• Consider dosage adjustment. 
• Consider the use of an alternate non-ototoxic 
drug. 
• Refer to audiologist for diagnostic 
audiological assessment. 
Nurse: 
• Inform the medical doctor of the change in 
thresholds. 
• Motivate for dosage adjustment. 
• Motivate for the use of an alternate non-
ototoxic drug. 
• Refer to audiologist for diagnostic 
audiological assessment. 
Goal: The patient must understand that if he/she 
stops treatment, the hearing will not recover, 
and it will have life-threatening implications. 
The patient must start coming to terms with the 
possibility of losing their hearing entirely, and 
its life-changing implications ahead. 
Team: 
All health professionals should discuss the 
following with the patient and his/her family: 
• The possibility that some drugs used in the 
treatment of TB may cause a hearing loss. 
• Importance of adherence to treatment 
despite the potential hearing loss. 
• Hearing loss is not always preventable but 
that a motivation for the alternate non-
ototoxic drug will be done. 
• Hearing loss will in most cases be 
permanent. 
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Grade Description Interpretation Management recommendations Recommendations for counselling 
socially and 
emotionally. 
 
Audiologist: 
• Conduct diagnostic audiological assessment. 
• Consider hearing amplification. 
• Discuss communication strategies with the 
patient and his/her family. 
• Inform the medical doctor of the change in 
thresholds. 
• Motivate for dosage adjustment. 
• Motivate for the use of an alternate non-
ototoxic drug. 
A follow-up appointment in 2 weeks for repeat 
audiogram. 
• Hearing loss may impact on their 
communication abilities are home, work and 
with family or friends. 
• The patient is not alone, and there are others 
who are also suffering from this hearing loss 
(try and put patients in touch with each other 
for support). 
• Amplification devices (e.g. hearing aids) are 
available. 
• Discuss and address the fears and concerns 
of the patient and family members. 
•  Provide the patient and his/her family with 
all the medical and audiological options 
relevant to the management of hearing loss. 
The patient should report any change in medical 
and hearing status to health professionals. 
7 More than 40 
dB change in 
thresholds at 
3 or more 
frequencies 
from 8 kHz 
• This hearing loss is 
affecting the patients' 
ability to hear, 
discriminate and 
understand speech.  
Goal: Treatment changes are imperative. And 
audiological management is essential at this 
stage, if possible. 
Team: 
Medical doctor: 
• Consider dosage adjustment. 
Goal: The patient must understand that if he/she 
stops treatment, the hearing will not recover, 
and it will have life-threatening implications. 
The patient must start coming to terms with the 
possibility of losing their hearing altogether, and 
its life-changing implications ahead. 
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Grade Description Interpretation Management recommendations Recommendations for counselling 
and below 
from baseline 
both ears 
• The hearing loss is 
likely to affect the 
patient considerably in 
communicating at 
home, work and with 
family or friends.  
• The patient will 
struggle significantly to 
hear speech in noisy 
situations. 
• The patient will 
struggle significantly to 
hear in small group 
situations. 
• The patient will 
struggle significantly 
with one-to-one 
conversation. 
• The hearing difficulties 
may affect the patient 
socially and 
emotionally. 
• Consider the use of an alternate non-ototoxic 
drug. 
• Refer to audiologist for diagnostic 
audiological assessment. 
Nurse: 
• Inform the medical doctor of the change in 
thresholds. 
• Motivate for dosage adjustment. 
• Motivate for the use of an alternate non-
ototoxic drug. 
• Refer to audiologist for diagnostic 
audiological assessment. 
Audiologist: 
• Conduct diagnostic audiological assessment. 
• Consider hearing amplification. 
• Discuss communication strategies with the 
patient and his/her family. 
• Inform the medical doctor of the change in 
thresholds. 
• Motivate for dosage adjustment. 
• Motivate for the use of an alternate non-
ototoxic drug. 
Team: 
All health professionals should discuss the 
following with the patient and his/her family: 
• The possibility that some drugs used in the 
treatment of TB may cause a hearing loss. 
• Importance of adherence to treatment 
despite the potential hearing loss. 
• Hearing loss is not always preventable but 
that a motivation for the alternate non-
ototoxic drug will be done. 
• Hearing loss will in most cases be 
permanent. 
• Hearing loss may impact on their 
communication abilities are home, work and 
with family or friends. 
• The patient is not alone, and there are others 
who are also suffering from this hearing loss 
(try and put patients in touch with each other 
for support). 
• Amplification devices (e.g. hearing aids) are 
available. 
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Grade Description Interpretation Management recommendations Recommendations for counselling 
• A follow-up appointment in 2 weeks for 
repeat audiogram. 
 
• Discuss and address the fears and concerns 
of the patient and family members. 
•  Provide the patient and his/her family with 
all the medical and audiological options 
relevant to the management of hearing 
loss.The patient should report any change in 
medical and hearing status to health 
professionals. 
8 Hearing 
thresholds at 
80 dB or 
greater in 4 or 
more speech 
frequencies 
(250 Hz to 8 
kHz) in both 
ears 
• The patient has now 
lost most of his/her 
hearing. 
• The patient will most 
likely be unable to 
communicate with 
family, friends and 
colleagues effectively. 
• The patient will, as a 
result, be isolated in 
various ways, 
specifically in social 
and occupational 
situations. 
Goal: Cochlear implant consideration and 
referral audiological considerations for long-
term management.  
Team: 
Medical doctor and nurse: 
• Refer to an audiologist for aural 
rehabilitation. 
Goal: This is an extremely vulnerable place for 
patients, as they are often entirely isolated. It is 
important they understand that they are not 
alone and that there are still options for jobs and 
life in the Deaf world. Facilitation into this 
‘Deaf’ world needs to be guided, addressing all 
the fears and concerns. 
Team: 
All health professionals should discuss the 
following with the patient and his/her family: 
• The possibility that some drugs used in the 
treatment of TB may cause a hearing loss. 
• Importance of adherence to treatment 
despite the potential hearing loss. 
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Grade Description Interpretation Management recommendations Recommendations for counselling 
• Depending on the 
patient’s job, it is 
possible that he/she 
will be unable to 
continue work due to 
the hearing disability. 
• Hearing loss is not always preventable but 
that a motivation for the alternate non-
ototoxic drug will be done. 
• Hearing loss will in most cases be 
permanent. 
• Hearing loss may impact on their 
communication abilities are home, work and 
with family or friends. 
• The patient is not alone, and there are others 
who are also suffering from this hearing loss 
(try and put patients in touch with each other 
for support). 
• Amplification devices (e.g. hearing aids) are 
available. 
• Discuss and address the fears and concerns 
of the patient and family members. 
•  Provide the patient and his/her family with 
all the medical and audiological options 
relevant to the management of hearing loss. 
The patient should report any change in medical 
and hearing status to health professionals. 
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8.3.4. Steps to use the mobile application: ‘otocalc’ 
The mobile application will be downloadable on all android devices and iPhones. The 
application name, ‘otocalc’ will be explained in various steps. 
8.3.4.1. Step 1. 
Step 1 is the introduction and registration of the application.  
The four images below include the steps from downloading the application, to the 
home page where the user can register on the application. 
Once the user is on the homepage (Figure 8.2d), they can further re-read the purpose 
of the application, by clicking onto the ‘about’ section, it will explain the purpose and use of 
the application. Then a registered user can sign in. Alternatively, a healthcare professional 
can register as a user. Or, the application can be utilised as a once off calculator to calculate 
the significance of possible ototoxicity. 
 
Figure 8.2a. First page after download. 
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Figure 8.2b. Description of the application. 
 
 
Figure 8.2c. Explanation of ‘otocalc’ feature. 
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Figure 8.2d. Otocalc home page. 
 
8.3.4.2. Step 2. 
Should the healthcare professionals wish to register as a user, they will be directed to 
the page as per Figure 8.3. This page is to ensure that only health care professionals within 
the field will have access to patient data, to ensure ethical practice of this application and 
patient confidentiality. The potential user will be requested to enter their information as per 
Figure 8.3. This information will be sent to the mobile application administrator, who will 
assess the request, and either grant or decline access (Figure 8.4). Access will be based on a 
valid HPCSA number (where relevant), occupation must be relevant to the use of the app 
(audiologist, pharmacist, doctor, counsellor, occupational therapist, physiotherapist, social 
worker, nurse and psychologist) and lastly, the healthcare professional must be working in an 
institution that treats DR-TB patients in the public or private sector. Once access is granted, 
the user will be able to set their password, and subsequently sign in as a registered user. 
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Figure 8.3. Health professional registration page. 
 
 
Figure 8.4. Administrators access request page. 
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8.3.4.3. Step 3.  
Once the user signs in, they can either enter details regarding a new patient, enter new 
data about existing patients as a new visit, or search for results of another patient. The user 
would need to enter the ID or hospital number of a patient in order to access their details. 
This would be in the case that a patient is referred to another clinic or treatment site that 
would like to access the patients’ previous audiological data. 
 
Figure 8.5a. New patient identification entry page. 
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Figure 8.5b. Continuation of new patient identification entry page. 
 
8.3.4.4. Step 4. 
Once the user selects the participant, they will be directed to a page as per Figure 8.6. 
All the patients and names used are aliases, and are not actual patients, yet used for the 
purpose of this explanation.  
The user must choose the ‘new consultation’ tab and enter the information as in Figure 
8.7. 
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Figure 8.6. Patient home page once identification data has been entered. 
 
 
Figure 8.7. New consultation home page for patient data entry. 
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The user can subsequently enter details on the risk factor checklist (Figure 8.8a), by 
choosing ‘tap to edit’ tab by the risk factor checklist (Figure 8.8a) 
 
Figure 8.8a. Tab for risk factor checklist. 
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Figure 8.8b. Risk Factor Checklist 
 
The page as per Figure 8.9a appears when the user chooses the on ‘tap to edit’ by the 
hearing thresholds as per Figure 8.8. Figure 8.9b, however, contains the already entered 
results from the baseline. 
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Figure 8.9a. PTA threshold entry page 
 
 
Figure 8.9b. Continuation of PTA threshold entry page 
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Once the thresholds are entered, the application plots the audiogram (see Figure 8.10) 
 
Figure 8.10. Audiogram plotted based on thresholds entered 
 
8.3.4.5. Step 5. 
Once the user has entered all the baseline data and saved it, he will be directed to the 
page as per Figure 8.11. For the follow-up visits, the user needs to choose the relevant 
patient, in this case, ‘Test Three’ (Figure 8.11) and then go to ‘new consultation’ (Figure 
8.12) 
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Figure 8.11. Homepage after baseline consultation has been saved 
 
 
Figure 8.12. Homepage of patient ‘test three’ for new consultation to be initiated 
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8.3.4.6. Step 6.  
In this case, the baseline data has already been entered, and the follow-up data can 
now be entered. The user would be required to update the patient details, as well as weight, 
height, and drug information where possible. The entering of the data is the same as per the 
baseline data (Figures 8.13, 8.14a and 8.14b). 
The user would subsequently enter the follow-up results in a similar fashion to the entry 
of baseline results. It would then be plotted automatically on an audiogram. If the user rotates 
their phone screen, the audiogram is clearer.  
Should the user only be using this application as an ototoxicity calculator, he/she will be 
directed to a page like this to enable the entering of baseline and follow-up data. It would 
grade the hearing loss and provide with recommendations. Other information is not required, 
and data is not saved to a database.  
 
Figure 8.13. Follow up patient data entry page 
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Figure 8.14a. Follow -up PTA threshold entry page  
 
 
Figure 8.14b. Continuation of follow -up PTA threshold entry page  
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8.3.4.7. Step 7. 
Once baseline and follow-up audiological data have been entered, the results will be 
calculated, as per the yellow block in Figure 8.15. When the user taps the yellow block, the 
description and recommendations as per Table 8.2 will be displayed. 
 
Figure 8.15. Page, when follow up consultation, has been entered and results calculated 
 
8.3.4.8. Step 8. 
The user can scroll down the recommendations, after choosing the yellow block, as 
per Figures 8.16, 8.17a, 8.17b, 8.17c. 
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Figure 8.16. Interpretation and recommendation based the yellow block 
 
 
Figure 8.17a. Recommendation for patient 
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Figure 8.17b. Continuation of recommendations 
 
 
Figure 8.17c. Continuation of recommendations- final page 
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8.3.4.9. Step 9.  
For every new consultation, patient data can be updated or changed Figure 8.18. 
 
Figure 8.18. Homepage once follow-up data has been entered, interpreted and saved 
 
8.3.4.10. Conclusion. 
All this data is saved onto a database which can be used for reliable statistics and 
research. This can only be done if permission is obtained from the patient, gatekeeper and 
ethical clearance from the relevant organisation. 
8.3.5. Sensitivity of ‘Otocalc’ 
The data from this current study was used to establish the sensitivity of ‘Otocalc’. The 
sensitivity of Otocalc was compared to the existing grading systems. When using Otocalc, 
ototoxicity was identified in all, but two ears (participants 2 and 4). This is more than the 
other scales (Table 8.4). However, the grades also give an indication of the frequencies 
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affected, in order for understanding; for example, a grade 3 indicates a loss in the high 
frequencies and not UHF, whereas grades 1 and 2 indicates UHF hearing loss.  
 
Table 8.4 
Sensitivity of ‘Otocalc’ 
Patient 
Weeks in the 
Study (T) 
EAR ‘Otocalc’ TUNE CTCAE ASHA 
1 0,1,2 
R 2 2a - YES 
L 2 1a - YES 
2 0,1 
R 2 0 - NO 
L 0 1a - NO 
4 0,1,2,3,4,5,6 
R 3 1a - YES 
L 0 0 - NO 
5 0,1,2,3,4,5,6 
R 1 1a - YES 
L 3 2a - YES 
6 0,1,2 
R 1 0 - YES 
L 2 0 - YES 
7 0,1,2,3,4,5,6 
R 2 2a - YES 
L 1 0 - YES 
8 0,1,2,3,4,5,6 
R 2 2a - YES 
L 1 1a - YES 
9 0,1,2,3,4,5,6 
R 3 1a - YES 
L 1 1a - YES 
10 0,1,2,3,4,5,6 
R 3 2a - YES 
L 1 2a - YES 
12 0,1 
R 3 2a 1 YES 
L 1 1a - YES 
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Patient 
Weeks in the 
Study (T) 
EAR ‘Otocalc’ TUNE CTCAE ASHA 
14 0,1,2,4 
R 1 1a - YES 
L 3 1a - YES 
15 0,1, 
R 3 1a - YES 
L 4 1a - YES 
16 0,1,2,3,4 
R 1 2a - YES 
L 3 1a - YES 
17 
T0, T1, T2, 
T3, T4 
R 5 2a - YES 
L 3 1a - YES 
18 0,1,3,4,5, 
R 1 1a - YES 
L 2 2a - YES 
8.4. Need for further research 
This newly developed application needs to be trialled by various health care 
professionals, such as doctors, nurses, pharmacists and audiologists within the DR-TB 
population. It has the potential to standardize monitoring and dosage adjustments based on 
hearing, while also allowing for reliable statistics and follow-up of the patients on a single 
database throughout the country.  
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Chapter 9: Conclusion 
This chapter will conclude the thesis, with the provision of a summary of the study 
results and outcome as well as the strengths and the limitations of the findings. The study’s 
implications will be discussed with further recommendations for research, and lastly, the 
thesis will be concluded. 
 
9.1. Summary of the Findings 
9.1.1. Audiological Results 
The audiological results and discussion address the aim of determining the changes in 
hearing levels in patients undergoing treated with kanamycin and capreomycin for DR-TB; 
by looking at the prevalence of abnormal findings on baseline assessments and determining 
the change in hearing levels from baseline.  
Upon discussing the PTA and DPOAEs, a definite pattern was observed which 
indicated the ultra-high frequencies being affected first, and more so within the first three 
months than the conventional audiogram. The findings also highlighted the lack of grading 
scales developed for high-frequency testing, specifically in the DR-TB population. The 
identification of the UHF and high-frequency hearing loss highlights the possibility of 
ototoxicity monitoring only from 3 kHz and above, in order to save time, with baseline 
testing from 0.25 kHz in order to assist with management as well as to rule out other possible 
influencing factors.  
Furthermore, the evidence of replacing the PTA with DPOAEs is not substantial, as 
correlation is not definitive. Although the use of DPOAEs for monitoring ototoxicity would 
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be ideal, as they detect extremely small changes prior to PTA as well as they are quicker and 
require less patient participation, more research needs to be conducted in this area.  
Also, asymmetry was noted in this current study, in contrast to the bilateral and 
symmetrical configuration that has been previously understood. Moreover, although 
kanamycin appeared to be more ototoxic in this study, as well as in other studies, more details 
should be obtained on the toxicity profile of capreomycin in patients with DR-TB, in order to 
rationalise the possible implementation of this more expensive drug in the general treatment 
regimen. 
Additionally, as per the other studies, it was difficult to ascertain the percentage and 
prevalence of the hearing loss identified. From the results of the 15 that were present for 
more than the baseline; 100% showed ototoxicity in DPOAEs, 93% showed ototoxicity with 
TUNE and ASHA, and 7% with CTCAE. This is in accordance with other studies which 
shows about 7-90% (Peterson and Rogers, 2015). Nevertheless, it is unclear as to which 
description should be used.  
Also, the results seem to fluctuate between the weeks, and so hearing aid fitting may 
be questionable during treatment, and perhaps should be considered post-treatment. This does 
not take the psycho-social factors into account. As the most significant changes in the hearing 
were noted in weeks 2 and 6 with PTA, these weeks are suggested to be incorporated in a 
DR-TB monitoring protocol, where testing every one to two weeks may not be possible in a 
low resource setting. 
9.1.2. Pharmacokinetics of kanamycin and capreomycin 
In summary, the pharmacokinetics yielded erratic results, mostly within the peak 
levels, particularly with kanamycin. The capreomycin target range is between 20 μg/ml and 
40 μg/ml, yet the mean peak was 8.1 μg/ml. The kanamycin target peak is between 20μg/ml 
and 35 μg/ml, and the mean peak levels found were at 20 μg/ml, yet with a large SD of ±16.5. 
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The average peak levels of kanamycin ranged, but on average were within the therapeutic 
range, where the capreomycin peak levels appeared sub-therapeutic. For both kanamycin and 
capreomycin, the trough levels were always below 10 μg/ml and not within a toxic range. 
The pharmacokinetics of were not as expected. The peak levels of kanamycin in some 
instances and capreomycin were subtherapeutic, which does not correlate to literature. 
Furthermore, average CrCl was reduced for those taking kanamycin, yet majority was 
within the normal range for capreomycin. This is in accordance with literature; capreomycin 
is not as toxic as kanamycin, and thus less nephrotoxicity in these patients was noted. 
Additionally, despite the low peak levels, all participants that could be documented 
culture converted within the first two months. However, this included one negative culture, in 
comparison to the standard two consecutive cultures. This was not as expected, however low 
peak levels with positive treatment outcomes has been observed in another study (Namazi et 
al., 2016). Furthermore, the Resuscitation-promoting factors may also provide an explanation 
for these seemingly positive outcomes. However, this theory is only based on preliminary and 
animal results. 
9.1.3. Pharmacokinetics and Hearing Levels 
It can be concluded that no correlation was observed with trough levels and 
ototoxicity. The pharmacokinetic results were erratic and differed considerably between 
individuals. A conclusive positive or negative relationship between dosage and trough levels 
was not observed with the progression of hearing loss. 
Furthermore, in some instances, when looking at mean levels, dosage did correlate to 
ototoxicity, yet when looking at individual patients, dosage did not correlate to ototoxicity. 
The dose per kg throughout the weeks for kanamycin remained stable, and cannot be 
correlated to the change in hearing yet the dose per kg of capreomycin at week 10 and 12 was 
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the highest, and the most significant change in hearing was noted. This is likely due to the 
fact of accumulation over time and not necessarily the dose per kilogram. 
Further studies with larger sample size and UHFA are needed to ascertain the exact 
relationship between pharmacokinetics and hearing levels.  
9.1.4. Feasibility Findings 
The overall aim of this study was to establish the feasibility of investigating the 
pharmacokinetics and pharmacodynamics of kanamycin and capreomycin in patients with 
DR-TB and the relationship of these medications with hearing levels.  
Various hurdles were identified that affected the feasibility; particularly participant 
factors such as willingness to participate, enrolment and attrition as well as data related 
issues, specifically with the blood sampling, both for pharmacokinetics and creatinine levels. 
Participation in the study was a significant factor. In summary, of a potential 268 
participants at both hospitals, only 22 were enrolled after 12 months of recruitment. This poor 
enrolment and retention were f a variety of reasons; from a willingness to participate, social 
and emotional difficulties, as well as the exclusion based on inclusion and exclusion criteria. 
Furthermore, resources were limited to continue the study for a more extended period and to 
improve the sample size potentially. 
Blood sampling issues arose from destroyed samples for kanamycin and capreomycin 
analysis, mainly from haemolysis. Furthermore, many of the creatinine levels could not be 
found on the NHLS website, despite the samples being drawn. The reason for this is 
unknown. 
Despite the low peak and trough levels with kanamycin and capreomycin, changes in 
hearing were noted (more so for kanamycin than capreomycin), as well as reduced CrCl 
levels with the kanamycin patients. Therefore, toxicity was noted. Lastly, despite the sub-
therapeutic peak levels, patients culture converted within the first two months of treatment.  
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Therefore, with the small sample size achieved, as well as erratic levels with regards 
to the pharmacokinetics, substantial issues with regards to the feasibility of more extensive 
studies were identified. These issues, such as willingness to participate, blood sampling 
issues, large variations with results, quality assurance, resources available in this low 
resource setting, variations between treatment sites as well protocol variations between 
institutions need to be considered to conduct a more substantial, yet necessary study. Based 
on the results achieved, it would not be feasible to perform TDM for kanamycin and 
capreomycin to reduce ototoxicity, and further investigations need to be conducted.  
 
9.2. Strengths of the Study 
The study portrayed various strengths which will be described. This study was unique 
as it was the first study as such. It also led to the development of an ototoxicity monitoring 
protocol specific for the population, together with the mobile application. Further, it 
displayed the feasibility of conducting more extensive studies, by depicting the ‘real life’ 
situation.  
9.2.1. First of its kind 
This study incorporating the pharmacokinetics and correlating them to hearing loss, 
for both kanamycin and capreomycin was the first of its kind. At present, when ototoxicity is 
noted, the injectables are often reduced to three days a week, with no pharmacokinetic 
measurements. This study created awareness to the possible adverse outcomes of this method 
(such as low peak levels which may impact treatment outcomes). 
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9.2.2. Ototoxicity Monitoring Protocol  
This study identified the need for a standardised comprehensive monitoring program, 
specifically for the DR-TB population. Therefore, a recommended monitoring protocol was 
devised, together with a mobile application, taking ultra-high frequencies into account.  
It also brought to light the need for interdisciplinary monitoring and management 
within this population in ensure optimal outcomes. It is vital for doctors, nurses, pharmacists 
and audiologists to understand the basics of each scope in order to work together 
collaboratively and respectfully. 
 This study also highlighted the possibility of nursing staff to implement the 
ototoxicity monitoring protocol when trained appropriately. At present, nurses are 
implementing some type monitoring with no training and understanding. This study shows 
that with the correct training outcomes can be reliable. 
9.2.3. Development of an ototoxicity calculator mobile 
application 
Throughout the study, the need for a standardised and user-friendly method to 
interpret hearing results was identified. It was evident that doctors, audiologists and nurses 
experienced difficulty in identifying a significant hearing loss and the need for dosage 
adjustments based on these audiologic results. Therefore, as an outcome of the study, an 
ototoxicity monitoring protocol for DR-TB and mobile ototoxicity calculator application, 
‘otocalc’, was developed. ‘OtoCalc” assists healthcare workers with the calculation of a 
significant hearing loss, its equivalent grade and recommendations for management.  
However, this newly developed application needs to be trialled by various health care 
professionals, such as doctors, nurses, pharmacists and audiologists within the DR-TB 
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population. Hopefully, it will standardise treatment and allow for reliable statistics and 
follow-up of the patients on a single database throughout the country.  
9.2.4. Data collection portrayed the feasibility of a more 
extensive study by depicting a ‘real life’ clinical situation 
This study, although had many weaknesses, particularly the poor enrolment and high 
dropout, however, it also highlights the extent of the problem with patient follow up and 
continuation of follow through of treatment.  
9.3. Limitations of the Study 
9.3.1. Sample Size Limitation 
The small sample size limited the ability to generalise the findings and the inclusion 
of the covariables in the analysis. Nevertheless, it did depict the challenges we are faced with 
when treating this population and conducting research. 
Also, many of these patients started on kanamycin, were switched to capreomycin, 
and thus it is difficult to ascertain which drug was more ototoxic. Also, those that were 
showing ototoxicity were switched to capreomycin. It is likely that these specific patients had 
the gene for ototoxicity, and thus their loss of hearing at the end was an indication of the gene 
and not general toxicity of the capreomycin or pharmacokinetic factors. 
Although the data that was hoped for was not all obtained, other evidence came to 
light such as the difficulties treating this population, and the problems we are facing with the 
decentralisation of treatment. 
Furthermore, due to the small sample size, covariables could not be included in the 
analysis. Initially, at the development of the protocol, when the sample size was calculated at 
80 participants, the researcher aimed to include various subgroups and covariates (e.g. age, 
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gender, HIV, ARV, BMI, concomitant medications, frequency of kanamycin/capreomycin 
dosing, and difference in the protocol at the research sites) in the analysis. However, based on 
the sample size achieved in the current study, this analysis was not possible. The subgroups 
and covariable included:  
9.3.2. Data Limitations 
There were various shortfalls in the data collection, resulting in limitations with the 
outcomes. Shortfalls included the loss of various pharmacokinetic blood samples, as well as 
the inability to access some of the creatinine measurements from the NHLS database. 
Furthermore, the multisite aspect of this study, although unavoidable at the time, did 
create variability which was not ideal. The two sites had different treating doctors, slightly 
different protocols, as well as different drugs available, which created hurdles when 
interpreting the data. 
Additionally, at times, various data were not collected as planned. This included the 
DPOAE measurements with poor SNR ratios, the study coordinator not measuring the height 
of participants at all times, and so BMI could not be analysed, as well as difficulties with the 
transportation of the blood. The study coordinator reportedly planned to use the 
measurements from the hospital files, so as not to inconvenience the participant by measuring 
it twice. However, when completing this part of the case report forms, it could not be found 
in the hospital files.  
Also, although the cultures converted for those participants where results were 
available, the long-term results were not traced. As thus it was not possible to identify if those 
participants were cured for the long term, which could correlate to the low peak levels. 
Ideally, future studies should investigate the long-term results in correlation to the 
pharmacokinetics.  
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9.3.2.1. Change in Policy 
As the time of the data collection, the NDoH published guidelines introducing then 
new drugs, such as linezolid and bedaquiline. HJH, being a research site, was one of the sites 
that implemented the use of these drugs, specifically bedaqualine. Despite these new 
guidelines, the new drugs are costly, and the aminoglycosides and capreomycin are still being 
used, and consequently, the outcomes of this current study are still relevant.  
9.3.3. Implications of the Study  
9.3.3.1. Clinical implications – audiology. 
Hearing loss can affect ones’ quality of life by affecting the ability to communicate. 
This hindered, or lack of communication can affect socialisation, professional opportunities,  
Additionally, hearing aids are expensive items, well over R2500.00 each for a basic 
hearing device. As so many individuals are infected with DR-TB in South Africa, it is likely 
that these individuals will require hearing aids post-treatment, which correspondingly places 
enormous financial pressure on the government's health department; a department already 
suffering the burdens of a developing country. Hearing aids are not a ‘once off’ cost, as they 
require maintenance including hearing aid repairs, new ear moulds, replacements batteries, 
and new hearing aids every few years as they do not last a lifetime. Audiologists are also 
needed to conduct the hearing evaluations, hearing aid fittings, aural rehabilitation and 
ongoing assistance. Thus, the expense and burden of the government to provide these 
services is tremendous. 
Hearing loss can also further result in emotional and social difficulties, including 
loneliness, decreased self-esteem and various other difficulties (Wallhagen, Strawbridge, 
Cohen & Kaplan, 1997). This can impact on an individual’s ability to function and obtain 
work. Severe depression can become a comorbid disability, resulting in the need for further 
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disability grants; again, placing financial burdens on the country. This individual’s mental 
state also impacts on his/her family, and their entire units’ wellbeing.  
Clinically, a comprehensive audiology monitoring program (as outlined in Chapter 8) 
must be included in practice, with standardised criteria for grading hearing loss and its 
implications for management. The counselling is imperative as well in order to ameliorate the 
impact on quality of life. The ‘ototcalc’ application can also assist with this management.  
In summary, the government needs to ensure adequate resources (financial and 
personnel) for the implementation and maintenance of an ototoxicity monitoring programme 
and aural rehabilitation.  
9.3.3.2. Clinical implications – pharmacokinetics. 
Pharmacotherapy-induced ototoxicity is growing, especially in developing countries 
such as South Africa, where often, more expensive and less toxic drugs are unavailable to the 
majority of the population. This highlights the importance of ototoxicity monitoring and 
management of hearing loss. Due to the nature of the hearing loss, resulting from 
pharmacotherapy, the necessity for interdisciplinary teamwork between the audiologist, 
pharmacist, medical doctor and nursing staff in the wards results in best practice and 
management of patients with ototoxic damage, with the inclusion of pharmacokinetic 
measurements (Schellack, Wium, Ehlert, van Aswegan & Gous, 2015). At present, the 
interdisciplinary aspect is not being carried out in many institutions and outpatient clinics. 
However, due to the multi-faceted nature of ototoxicity, it is clearly a necessity for 
interdisciplinary care. Further training of these professionals through universities and 
continuing professional development (CPD) courses is essential. However, the protocol and 
‘Otocalc’ would assist with this aspect. 
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9.3.3.3. Research implications – audiology and 
pharmacokinetics. 
The identification of this hearing loss, as well as deeper understanding of the hearing 
loss in relation to the injectable pharmacokinetics, is an important step to alleviate or manage 
the hearing loss. Although this study did not yield a causative relationship of trough levels 
and hearing loss, it brings forth the possibility of other factors and drugs that may be 
contributing to hearing loss, which can perhaps be explored further. 
Also, in recent years, the possibility of new drugs has come to life, such as 
bedaquiline and linezolid, as well as a shorter duration of the injectable regimen. These drugs 
and new regimen can add immense improvements to the DR-TB treatment program. 
However, as with most drugs, side effects are inevitable, and bedaquiline and linezolid have 
their own side effects. Therefore, even with the positive additions of new drugs and shorter 
regimens, there will still be the need for aminoglycosides in some instances; although 
hopefully in a much smaller population.  
 Moreover, the full understanding of their pharmacokinetics, side effects and 
outcomes in aminoglycosides is of utmost importance as, despite new drugs, aminoglycosides 
will likely be used in this population. This current study assisted with the understanding of 
this ototoxic hearing loss from aminoglycosides, which will be investigated further in an 
upcoming study. The study will be done with a larger sample, and the newly developed 
protocol and mobile application. 
9.3.3.4. Policy implications. 
Public health aspects need to be considered when treating DR-TB; not purely the 
scientific aspects such as pharmacokinetics, and side effects such as toxicity (nephrotoxicity 
and ototoxicity). van Rie and Enarson (2006) discuss that treating DR-TB is feasible and can 
be effective, even in low-income countries. However, this plan must be based on sound 
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public-health practice including good laboratory infrastructure, appropriate treatment 
regimens, proper management of side-effects, and sufficient resources to maintain adherence 
and prevent further resistance. In summary, the management is a public health problem, 
where all parameters must be treated together to stop the spread of the disease and further 
resistance. This was a prominent finding in this study, showing the poor infrastructure and 
retention of patients in the treatment program. Therefore, in addition to investigating and 
understanding the pharmacokinetics of the injectable as well as the adverse events of the 
treatment, this study suggested the need for a better overall public health system. 
The implications further extend into ototoxicity monitoring methods of patients with 
DR-TB. As there is currently no standard protocol to monitor ototoxicity in patients with DR-
TB, this research proposed a protocol as well as a mobile application in terms of a calculator 
to assist in this process. This calculator and method will further identify the specifics of 
hearing loss, in order to understand its type, configuration, progression and symmetry to 
allow for further relationships with drug properties as well as other individual factors to be 
drawn. This study also introduced the possibility of utilising nurses to implement ototoxicity 
monitoring programs, yet only when appropriately and adequately trained. As our country 
does not have enough audiologists to implement ototoxicity monitoring programs, thus nurses 
can possibly assist with reducing this burden from audiologists. The possibility of nurses 
conducting the testing can be further be explored, as this study presented the feasibility.  
9.4. Recommendations for future research 
9.4.1. Larger Sample Size and Inclusion of Covariables 
A study further investigating the pharmacokinetics of kanamycin and capreomycin as 
well as the relationship to hearing in a more substantial sample size is recommended. This 
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will allow for more conclusive evidence to be drawn including the generalisation of the 
results, as well as the analysis of possible covariables and subgroups to be examined.  
9.4.2. Audiological Recommendations: 
9.4.2.1. Ototoxicity monitoring program and use of ‘otocalc’ in 
South Africa. 
This study proposed the use of a standardised ototoxicity monitoring protocol, as well 
as developed a mobile application to standardise the identification and classification of 
hearing loss. In order for this to be incorporated into guidelines, further research must be 
conducted. The proposed ototoxicity monitoring protocol and the Otocalc application will be 
piloted at one of the research sites in 2018.  
9.4.2.2. DPOAEs. 
Screening with DPOAEs may be enhanced by testing only in the 3- to the 5.2-kHz 
range, thus decreasing testing time. Higher time averages to increase the signal-to-noise ratio 
and use of this narrower bandwidth might also allow for accurate bedside testing (Ress et al., 
1999). However, more research needs to be done with regards to specific frequencies for 
testing. This study showed ototoxicity was detected from 2 kHz. However, higher frequency 
testing is more sensitive. Moreover, DPOAEs are quick to run, 2 to 12 kHz is recommended 
until more supporting evidence can be found with a shorter protocol. 
The grading system recommended does not take DPOAEs into account. However, 
further research is needed to correlate the DPOAEs to the PTA, and make recommendations 
on significant results to motivate for dosage changes.  
9.4.2.3. Ultra-High Frequency normative values. 
It is questioned whether a general standard for hearing levels is meaningful at all and 
that normative data for various age groups should instead be used as a reference level 
(Osterhammel & Osterhammel, 1978). However, based on this study, grades in the higher 
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frequencies were prescribed to assist in guiding treatment. Nevertheless, it would be useful to 
obtain normative data for the ultra-high frequencies, and thus the grading system may need to 
be adjusted over time. 
9.4.2.4. Otoprotection. 
Various otoprotective methods have been studied for quite some time now (Campbell, 
2004). Otoprotective agents may be a useful method of preventing hearing loss in patients 
treated with lifesaving aminoglycosides (Campbell, 2004). Further investigations of the 
safety and efficacy of otoprotective agents such as D-methionine and N-Acetylcysteine 
should be investigated in this population (Campbell, 2004; Atkuri, Mantovani, Herzenberg & 
Herzenberg, 2007). 
9.4.3. Pharmacological Recommendations 
Further studies with larger samples are recommended to establish the 
pharmacokinetics of kanamycin and capreomycin in this population. Also, it is recommended 
that the long-term outcomes, specifically culture conversion and possible relapse be 
investigated in relation to the pharmacokinetics and pharmacodynamics.  
9.5. Conclusion 
Poor TB diagnostic and treatment coverage globally, social and economic instability 
in many high-burden countries and the presumed increasing transmission of drug-resistant 
strains are making the battle against drug-resistant TB one of the most important and relevant 
health challenges of the 21st century (Günther, 2014). This is only increasing the prevalence 
of hearing loss globally, particularly in South Africa. Hearing loss cannot and must not 
continue to be a silent epidemic (Editorial, the Lancet, 2016). Helen Keller once said, 
“Deafness separates people from people” (Sherman, 1997). Hearing loss can have profound 
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effects not only on interpersonal communication, but also on health, independence, well-
being, quality of life, and daily function. Although this hearing loss receives limited research 
funding and public awareness. Global multidisciplinary and collaborative efforts are urgently 
needed to address the health needs of the child and adult with hearing loss (Editorial, the 
Lancet, 2016). 
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Clinical HIV Research Unit, Department of Medicine 
___________________________________________________________________________________________ 
Helen Joseph Hospital, Themba Lethu Clinic, Perth Road, Westdene, Johannesburg 2092, South Africa 
Postnet Suite  
Screening Consent Form (1.5) 
Good day, my name is Cara Hollander and I am an audiologist from the University of the 
Witwatersrand. I would like to invite you to think about joining a research study, called “A feasibility 
study investigating the pharmacokinetics and pharmacodynamics of kanamycin and capreomycin in 
patients with DR-TB and the relationship between hearing levels” 
Before we discuss the study in full (the purpose of the study, benefits, risks and so on), I need to 
establish whether you fit the specific requirement for this study.  
The requirements are as follows: 
1. You will need to provide informed consent if you agree to participate (you would only do this 
if you are suitable for the study, and want to take part) 
2. You will need to provide informed consent for an HIV test (we don’t mind if you are HIV 
positive or negative, but we just need the information when we analyze all the results. We 
will provide you with counseling before and after the test, and you will have time to discuss 
this in details and ask questions. If you would like further counseling, we will refer you 
appropriately) 
3. Your first language or language of choice must be English, Zulu or Sotho. This is so that we 
can be sure that you understand the entire study before you chose to take part. 
4. You must be anticipated to receive treatment for drug resistant tuberculosis with kanamycin 
or capreomycin for a period of at least 3 months. We will need to look in your file for this. 
5. You must be between the ages of 18 and 55 years 
6. You will need to have a normal middle ear status. This means that you can’t have any ear 
infections in your middle ear. We can assess this by doing a quick test. Firstly, I need to look 
in your ear with a light to see if your ear has too much wax, and if your eardrum looks 
healthy. If your ear is not blocked up with wax,  
Prof. Ian Sanne (Clinical Director); Dr Sharla Badal-Faesen (Investigator); Dr FM Conradie (Investigator); Dr 
Cindy Firnhaber (Investigator);  Dr PD Ive (Investigator); Dr E Jongh (Investigator) Prof P MacPhail 
(Investigator); Dr K Mellet (Investigator), Dr T Mwelasi (Investigator) Dr MS Rassool (Investigator)          
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7. I will place a machine in your ear. It is a soft nub and it will pump some air in your ear. It will 
not be sore, but will help us know if you have any infections deep inside your ear, and if there 
is any fluid. If there is fluid, it will affect your hearing, and the results of the hearing test.  
8. This will take about 2 minutes. In order for us to get an accurate reading of this, your ears 
must not be blocked with wax. If they are blocked with wax, I will need to take this wax out 
so it doesn’t affect the other tests. I will put some sweet oil in your ear to make the wax a bit 
softer. Then I will use a special machine to pull the wax out. This whole process will not take 
longer than 5 minutes. It may be a little bit painful, but isn’t always. It is very possible you 
won’t have wax in your ears, and so we won’t need to do this. 
9. Your hearing levels need to be in certain limits to take part. If you already have a hearing 
loss, it can’t be ‘severe’ at 3 or more different pitches in both ears. I need to test if your 
hearing levels will fit with the requirements of the study. We will do this by putting earphone 
on you. You will need to listen to ‘beeps’ and press a button if you hear them. If you don’t 
hear 3 of the beeps in both ears, then you will not be able to take part. If you can hear them, 
then your hearing is OK for the study. 
10. If you are diabetic, you won’t be able to take part, and it may affect our results. 
11. In you have previous treatment with aminoglycosides within the last 7 months (when given 
with injections) or with capreomycin, you will not be able to participate in this study. 
Aminoglycosides will include: amikacin, tobramycin, neomycin or streptomycin. 
 
If you consent to eligibility screening, all the results from these tests as described above, and all the 
information I obtain from your file will be confidential. Only certain study personnel will have access.  
 
Once we know if you are suitable for the study and fit the criteria, we will discuss the study further. 
By consenting to the eligibility tests does not mean you have to agree to take part in the study. You 
only need to decide after everything has been explained with the information booklet. 
 
Do you have any questions? 
 
NO? 
 
YES?  If yes, please explain:  
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INFORMED CONSENT TO PARTICIPATE IN ELIGIBILITY SCREENING TESTS 
I hereby confirm that I have been informed by the study nurse/counsellor/sub-investigator 
.......................................................... (FULL NAME) about the nature of the eligibility screening tests for 
the study  titled “A feasibility study investigating the pharmacokinetics and pharmacodynamics of 
kanamycin and capreomycin in patients with DR-TB and the relationship between hearing levels” 
(PROTOCOL NUMBER 1.5) 
• I have also received, read and understood the above written information about the 
eligibility requirements and tests. 
• I am aware that that if I am eligible, I do not have to agree to take part in the study. I can 
decide this after the full study has been explained with the informed consent form.  
• I understand that all the results for these screening tests will be confidential: only study 
personnel will have access. 
• I consent to participating in the eligibility questions and screening hearing tests 
• I consent to allowing the nurse to look in my file for the information that she needs for the 
study eligibility criteria. 
PARTICIPANT 
 
Printed Name      Signature / Mark or Thumbprint      Date and Time 
STUDY SUB-INVESTIGATOR/ COORDINATOR 
I, .............................................., herewith confirm that the above participant has been fully informed 
about the nature, conduct and risks of the above study. 
Printed Name                      Signature                                     Date and Time 
TRANSLATOR / OTHER PERSON EXPLAINING INFORMED CONSENT (SUB-
INVESTIGATOR) 
 
Printed Name           Signature           Date and Time 
WITNESS (If applicable) 
 
Printed Name   Signature Date and Time  
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Clinical HIV Research Unit, Department of Medicine 
___________________________________________________________________________________________ 
Helen Joseph Hospital, Themba Lethu Clinic, Perth Road, Westdene, Johannesburg 2092, South Africa 
Postnet Suite  
Ifomu Lemvume Yokuhlunga (1.5) 
Sawubona, igama lami ngingu-Cara Hollander, ngingumnakekeli wempilo ephathelene nendlebe 
(audiologist) e-University of the Witwatersrand.Ngingathanda ukukumema ukuba ucabange 
ngokujoyina ucwaningo lokuhlola olubizwa ngokuthi “Ucwaningo lokuhlola ukuthi imithi i-
kanamycin ne-capreomycin ihamba kanjani emzimbeni nemithelela yokusetshenziswa kwayo 
ezigulini ezine-DR-TB kanye nokuhlobana phakathi kwamazinga okuzwa”. 
Ngaphambi kokuba sixoxe ngalolu cwaningo ngokuphelele (inqubo yocwaningo, izinzuzo, izingozi 
nokunye), kudingeka ngithole ukuthi unazo yini izimfuneko ezithile ezidingaw yilolu cwaningo. 
Izimfuneko yilezi ezilandelayo: 
1. Kuyodingeka unikeze imvume oyinikeza unolwazi uma uvuma ukubamba iqhaza (uyokwenza 
kanjalo kuphela uma ufaneleka ukuba kulolu cwaningo, futhi ufuna ukubamba iqhaza). 
2. Kuyodingeka unikeze imvume esekelwe olwazini yokuhlolelwa i-HIV (asinandaba ukuthi 
unayo yini i-HIV noma cha, kodwa sidinga nje lolu lwazi lapho sihlaziya yonke 
imiphumela.Siyokweluleka ngokwengqondo ngaphambi nangemuva kokuhlola, futhi uyoba 
nesikhathi sokuxoxa kabanzi ngalokhu futhi ubuze imibuzo.Uma ungathanda ukuba uphinde 
welulekwe ngokwengqondo, siyokuthumela endaweni efanele). 
3. Ulimi lwakho lokuqala noma ulimi olukhethayo kumelwe kube isiNgisi, isiZulu noma 
isiSuthu.Lokhu kwenzelwa ukuba siqiniseke ukuthi uyaluqonda lonke ucwaningo ngaphambi 
kokuba ukhethe ukubamba iqhaza. 
4. Kumelwe ulindele ukuthola ukwelashwa kwesifo sofuba esingezweli emithini nge-
kanamycin/nge-capreomycinisikhathi esingengaphansi kwezinyanga ezingu-3.Kuyodingeka 
sibheke ifayela lakho mayelana nalokhu. 
5. Kumelwe ube phakathi kweminyaka engu-18 nengu-55 ubudala. 
6. Kuyodingeka ube nesimo sendlebe ephakathi nendawo esivamile.Lokhu kusho ukuthi 
akufanele kube ukuthi utheleleke ngegciwane maphakathi nendlebe.Singakuhlola lokhu 
ngokwenza ukuhlola okusheshayo.Okokuqala, kudingeke ngibheke indlebe yakho ngesibani 
ukuze ngibone ukuthi ayinaso yini isigonogono (wax) esiningi, nokuthi i-eardrum yakho 
ibukeka iphile kahle yini.Uma indlebe yakho ingagcwele isigonogono, ngizofaka umshini 
endlebeni yakho.Uyigenqezana elincane elithambile futhi uzofaka umoya endlebeni 
yakho.Ngeke kube buhlungu, kodwa kuyosisiza sazi ukuthi akhona yini amagciwane 
otheleleke ngawo ekujuleni kwendlebe yakho, nokuthi lukhona yini uketshezi 
oluphakathi.Uma kunoketshezi, lokho kuzoba nomthelela endleleni ozwa ngayo, kanye 
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE 
RELATIONSHIP BETWEEN HEARING LEVELS: A FEASIBILITY STUDY 
455 
nemiphumela yokuhlola kokuzwa.Lokhu kuyothatha imizuzu engaba ngu-2.Ukuze sithole 
imiphumela eshaya emhloleni yalokhu, kumelwe kube ukuthi indlebe yakho ayivaliwe 
isigonogono.Uma ivalwe isigonogono, kuzodingeka ngisikhiphe ukuze singaphazamisi 
okunye ukuhlola.Ngizofaka amafutha anoshukela kancane endlebeni yakho ukuze 
ngithambise isigonogono.Ngiyobe sengisebenzisa umshini okhethekile ukuze ngidonse 
isigonogono ngisikhiphe.Yonke le nqubo iyothatha isikhathi esingengaphezu kwemizuzu 
engu-5.Kungase kube buhlungu kancane, kodwa akubi buhlungu njalo.Kungenzeka kakhulu 
ukuthi ungabi naso isigonogono ezindlebeni zakho, futhi uma kunjalo ngeke kudingeke senze 
lokhu. 
7. Izinga lakho lokuzwa kudingeka libe semazingeni athile ukuze ubambe iqhaza.Uma kakade 
ungezwa ezindlebeni, kumelwe kube ukuthi lokho akukho ‘kubi’ ekuphakameni komsindo 
okungu-3 noma ngaphezulu okuhlukene ezindlebeni zombili.Kudingeka ngihlole ukuthi 
amazinga akho okuzwa azohambisana yini nezimfuneko zocwaningo.Sizokwenza lokhu 
ngokukufaka ama-earphone.Kuzodingeka ulalele ‘ama-beep’ bese ucindezela inkinobho uma 
uwezwa.Uma ungawezwa angu-3 ala ma-beep kuzo zombili izindlebe, ngeke ukwazi 
ukubamba iqhaza.Uma uwezwa, kusho ukuthi uzwa ngendlela EFANELE lolu cwaningo. 
8. Uma unesifo sikashuke, ngeke ukwazi ukubamba iqhaza, futhi lokho kungase kuphazamise 
imiphumela yethu. 
9. Uma wake welashelwa i-aminoglycosides ezinyangeni ezingu-7 ezedlule (lapho inikezwa 
ngemijovo) noma nge-capreomycin.Le mithi iyohlanganisa i-amikacin, i-tobramycin, i-
neomycin noma i-streptomycin. 
 
Uma uvuma ukuhlungelwa ukufaneleka, yonke imiphumela evela kuloku kuhlola njengoba kuchazwe 
ngenhla, kanye nalo lonke ulwazi engiluthola kwifayela lakho, kuyoba yimfihlo.Ngabasebenzi 
bocwaningo abathile kuphela abayokwazi ukufinyelela kulo. 
 
Uma sesazi ukuthi uyafaneleka kulolu cwaningo futhi uyahlangabezana nezimfuneko, siyoxoxa 
kabanzi ngocwaningo.Ukuvuma ukuhlolelwa ukufaneleka akusho ukuthi kudingeka uvume ukubamba 
iqhaza ocwaningweni.Kudingeka unqume kuphela ngemva kokuba usuchazelwe  yonke into 
ngencwajana yolwazi. 
 
Ikhona yini imibuzo onayo? 
 
CHA 
YEBO 
 
Uma uthi Yebo, sicela uchaze:  
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IMVUME ESEKELWE OLWAZINI YOKUBAMBA IQHAZA EKUHLOLWENI 
KOKUFANELEKELA UKUHLUNGA 
Lapha ngiqinisekisa ukuthi unesi wocwaningo, 
.............................................................................(IGAMA NGOKUGCWELE), ungazisile ngesimo 
sokuhlolwa kokufanelekela ukuhlunga kocwaningo olunesihloko esithi “Ucwaningo lokuhlola ukuthi 
imithi i-kanamycin ne-capreomycin ihamba kanjani emzimbeni nemithelela yokusetshenziswa kwayo 
ezigulini ezine-DR-TB kanye nokuhlobana phakathi kwamazinga okuzwa””  (INOMBOLO 
YEPHROTHOKHOLI 1.5). 
• Ngiphinde ngathola, ngafunda futhi ngaluqonda lolu lwazi olubhalwe ngenhla mayelana 
nezimfuneko zokufaneleka nokuhlola. 
• Ngiyazi ukuthi uma ngifaneleka, angiphoqekile ukuba ngibambe iqhaza 
ocwaningweni.Nginganquma lokho ngemva kokuba sengichazelwe ngokuphelele ucwaningo 
ngefomu lemvume esekelwe olwazini. 
• Ngiyaqonda ukuthi yonke imiphumela yoloku kuhlola kokuhlungwa iyoba 
yimfihlo:ngabasebenzi bocwaningo kuphela abayokwazi ukufinyelela kuyo. 
• Ngiyavuma ukubamba iqhaza emibuzweni yokuhlola ukufaneleka nokuhlolwa kokuzwa 
kokuhlunga. 
• Ngiyavuma ukuba unesi abheke ifayela lami ukuze athole ulwazi aludingayo mayelana 
nezimfuneko zokufanelekela ucwaningo. 
UMBAMBIQHAZA 
Igama Eliphrinti Isiginesha/Uphawu noma Ukugingqa Isithupha Usuku Nesikhathi 
UMCWANINGI ONGAPHANSI WOCWANINGO 
Mina,  .................................................................................................., lapha ngiqinisekisa ukuthi lo 
mbambiqhaza ongenhla utshelwe ngokuphelele ngesimo, ukuqhutshwa nezingozi zocwaningo 
olungenhla. 
Igama Eliphrintiwe Isiginesha Usuku Nesikhathi 
UMHUMUSHI / OMUNYE UMUNTU OCHAZA IMVUME ESEKELWE OLWAZINI 
(UMCWANINGI ONGAPHANSI) 
 
Igama Eliphrintiwe Isiginesha Usuku Nesikhathi 
UFAKAZI (Uma ekhona) 
Igama Eliphrintiwe Isiginesha Usuku Nesikhathi 
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Foromo ya Tumello ya Tlhahlobo (1.5) 
 
Dumela, lebitso la ka ke Cara Hollander mme ke audiologist (setsebi sa medumo e utlwahalang) ho 
tswa ho University of the Witwatersrand.  Ke rata ho o mema ho nahana ka ho kenela patlisiso ya 
phuputso e bitswang “Phuputso e fuputsang kgonahalo ya pharmacokinetics le pharmacodynamics ya 
kanamycin le capreomycin bakuding ba nang le DR-TB le kamano pakeng tsa ditekanyo tsa ho utlwa 
ditsebeng”. 
 
Pele re qoqa ka phuputso ka botlalo (sepheo sa phuputso, melemo, dikotsi jwalo jwalo), ke hloka ho 
thea hore o kgotsofatsa dintho tse hlokwang tse kgethehileng bakeng sa phuputso ena. 
 
Dintho tse hlokwang ke tse latelang: 
1. O tla hloka ho nehela ka tumello e utlwisiswang ha o dumela ho nka karolo (o ka etsa hona 
feela ha o tshwanelehile bakeng sa phuputso, mme o batla ho nka karolo). 
2. O tla hloka ho nehela ka tumello e utlwisiswang bakeng sa tekolo ya HIV (ha re tsotelle hore 
o na le HIV kapa ha o na yona, empa re hloka feela tlhahisoleseding ha re hlopholla diphetho.  
Re tla nehela ka boeletsi ho wena pele le ka mora tekolo, hape re tla ba le nako ya ho qoqa ka 
botebo le ho botsa dipotso.  Ha o batla boeletsi bo eketsehileng, re tla o romela ka ho 
tshwanelehileng). 
3. Puo ya hao ya pele kapa puo ya kgetho e tlameha ho ba Senyesemane, Sezulu kapa Sesotho.  
Hona ke hobane re batla ho etsa bonnete hore o utlwisisa phuputso yohle pele o kgetha ho nka 
karolo. 
4. O tlameha ho lebella ho fumana kalafo bakeng sa lefuba le hanyetsang moriana ka kanamycin 
kapa capreomycin bakeng sa nako ya dikgwedi tse 3 bonyane.  Re hloka ho sheba faeleng ya 
hao bakeng sa hona. 
5. O tlameha ho ba pakeng tsa dilemo tse 18 le tse 55. 
6. O tla hloka ho ba le boemo ba bohare ba tsebe bo tlwaelehileng.  Hona ho bolela o ka se be le 
tshwaetso efe kapa efe ya tsebe ho bohare ba hao ba tsebe.  Re ka lekanya ka ho etsa tekolo e 
phakisang.  Pele, ke hloka ho sheba ka hara tsebe ya hao ka lebone ho bona ha tsebe ya hao e 
na le boka bo bongata haholo, le ha moropa wa tsebe (eardrum) ya hao o bonahala o phetse.  
Ha tsebe ya hao e sa thibana ke boka, ke tla beha motjhini tsebeng ya hao.  Ke kotola e 
bonolo mme e tla pompa moya o itseng tsebeng ya hao.  E ka se be bohloko, empa e tla re 
thusa ho tseba ha o na le tshwaetso ka hare botebong ba tsebe ya hao, le hore ho na le 
mokedikedi ofe kapa ofe.  Ha ho na le mokedikedi, ho tla ama ho utlwa ha hao, le diphetho 
tsa tekolo ya ho utlwa.  Hona ho tla nka mabapi le metsotso e 2.  Hore re kgone ho fumana 
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tekanyetso e nepahetseng ya hona, ditsebe tsa hao di tlameha di se ke tsa thibana ke boka.  Ha 
di thibane ke boka, ke tla hloka ho ntsha boka bona hore bo se ke ba ama diteko tse ding.  Ke 
tla tshela sutu-oli e itseng tsebeng ya hao ho etsa boka bo be bonojwana.  Ka mora moo ke tla 
sebedisa motjhini o kgethehileng ho ntsha boka.  Tshebetso ena yohle e ka se nke ho feta 
metsotso e 5.  E ka ba bohloko hanyane, empa ha ho atise ho ba jwalo.  Ho na le kgonahalo e 
kgolo ya hore o ka se be le boka ditsebeng tsa hao, mme re ke ke ra hloka ho etsa hona. 
7. Mephahamo ya hao ya ho utlwa  e hloka ho ba meeding e itseng hore o nke karolo.  Ha o se o 
na le tahlehelo ya ho utlwa, e ke ke ya ba ‘bohale’ ka dihalo tse 3 kapa ho feta tse fapaneng 
ditsebeng ka bobedi.  Ke hloka ho lekola ha mephahamo ya hao ya ho utlwa e tla lokela 
ditlhoko tsa phuputso.  Re tla etsa hona ka ho beha semamela-tsebeng (earphone) ho wena.  O 
tla hloka ho mamela ‘medumo e mekgutshwane e phetaphetang’ mme o tobetse konopo ha o e 
utlwa.  Ha o sa utlwe medumo e mekgutshwane e phetaphetang e 3 ditsebeng ka bobedi, 
kahoo o ke ke wa kgona ho nka karolo.  Ha o ka e utlwa, kahoo ho utlwa ha hao ho LOKILE 
bakeng sa phuputso. 
8. Ha o na le lefu la tswekere (diabetic), o ke ke wa kgona ho nka karolo, ho ka ama diphetho tsa 
hao. 
9. Ha o na e kalafo ya ka pele ya aminoglycosides nakong ya dikgwedi tse 7 tse fetileng (ha e 
nehwa le diente) kapa le capreomycin.  Meriana ena e tla kenyeletsa amikacin, tobramycin, 
neomycin kapa streptomycin. 
 
Haeba o dumela ho etsa tlhahlobo ya ho tshwaneleha, diphetho tsohle tse tswang ditekong tsena jwalo 
ka ha di hlalositswe ka hodimo, le tlhahisoleseding yohle eo ke e fumaneng faeleng ya hao e tla ba 
sephiri.  Ke basebetsi ba phuputso ba itseng feela ba tla ba le phihlello. 
 
Hang ha re tseba hore o tshwanelehile bakeng sa phuputso mme o kgotsofatsa ditlhokeho, re tla qoqa 
ka phuputso ho tswela pele.  Ka ho dumela ho diteko tsa ho tshwaneleha ha ho bolele hore o dumela 
ho nka karolo phuputsong.  O hloka feela ho nka qeto ka mora hore dintho tsohle di hlalositswe le 
bukana ya tlhahisoleseding. 
 
Na o na le dipotso dife kapa dife? 
 
TJHE 
E 
 
Ha o re E, ka kopo hlalosa:  
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TUMELLO E UTLWISISWANG YA HO NKA KAROLO DITEKONG TSA 
TLHAHLOBO YA HO TSHWANELEHA 
 
Ka hona ke tiisa hore ke tsebisitswe ke mooki wa phuputso,.....................................................  
(LEBITSO KA BOTLALO), mabapi le mokgwa wa ditekolo tsa tlhahlobo ya ho tshwaneleha bakeng sa 
phuputso  ya sehloho se reng “Phuputso ya patlisiso ya kgonahalo ya pharmacokinetics le 
pharmacodynamics ya kanamycin le capreomycin  bakuding ba nang le DR-TB le kamano pakeng 
ditekanyo tsa ho utlwa ditsebenga” (NOMORO YA PROTHOKHOLE 1.5). 
• Hape ke fumane, ka bala mme ka utlwisisa tlhahisoleseding e ka hodimo e ngotsweng mabapi 
le ditlhoko le ditekolo tsa ho tshwaneleha. 
• Ke a lemoha hore ha ke tshwaneleha, ha ho hlokehe hore ke dumele ho nka karolo phuputsong.  
Nka etsa qeto ka mora hore phuputso e feletseng e hlalositswe le foromo ya tumello e 
utlwisiswang. 
• Ke a utlwisisa hore diphetho tsohle tsa ditekolo tsena tsa tlhahlobo di tla ba sephiri: Ke 
basebetsi ba phuputso feela ba tla ba le phihlello. 
• Ke dumela ho nka karolo ho dipotso tsa ho tshwaneleha le diteko tsa ho utlwa tsa tlhahlobo 
• Ke dumela ho dumella mooki ho sheba faele ya ka bakeng sa tlhahisoleseding eo a e hlokang 
bakeng sa ditlhoko tsa ho tshwaneleha tsa phuputso. 
MONKAKAROLO 
 
Lebitso le 
hatisitsweng 
Tshaeno / Letshwao kapa 
Kgatiso ya Monwana o Motona 
Mohla le Nako 
 
MOTHUSI WA MOFUPUTSI WA PHUPUTSO 
Nna, ...................................................................., ka hona ke tiisa hore monkakarolo ya ka hodimo o 
tsebisitswe ka botlalo mabapi le mokgwa, tsamaiso le dikotsi tsa phuputso e ka hodimo. 
 
Lebitso le hatisitsweng Tshaeno Mohla le Nako 
 
MOFETOLEDI / MOTHO E MONG YA HLALOSANG TUMELLO E UTLWISISWANG 
(MOTHUSI WA MOFUPUTSI) 
 
Lebitso le hatisitsweng Tshaeno Mohla le Nako 
PAKI (Ha e hlokeha) 
Lebitso le hatisitsweng Tshaeno Mohla le Nako 
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Appendix D 
Screening Case Report Form 
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Visit: Screening (Day 1) 
 
Procedures Yes No 
Screening Consent 1 done   
Standard of Care bloods Done:   
Creatinine (Cr,GRF) (send results to SMU)   
Potassium (K)   
TSH   
Liver Enzymes (GGT,Alt, Bili)   
FBC   
CD4   
Audiology   
Screening Audiology (otoscopy, cerumen management 
if needed, immitance audiometry, screening pure 
tones) 
  
Inclusion/Exclusion Criteria Form   
   
   
 
Visit: Screening (Day 1) 
 
  Time: (HH:MM) I___I___I:I___I___I 
 
   
 
   
  
Weight 
I__I__I__I. I__I  kg 
Height 
I__I__I__I. I__I  cm 
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Subject Details 
Subject Name (First name middle name surname) 
 
___________________________________________________________ 
 
Date of Birth(DD.MMM.YYYY) 
 
I___I___I.I___I___I___I.I___I___I___I___I 
Subject initials  
 
I___I___I___I 
 
Race    Gender  
 M I__I F 
I__I 
 
I__I Black   I__I White            I__I Mixed              I__I Asian  
 
I__I Other _____________________________ Ethnicity specify 
_______________________________ 
Subject’s History  
➔ Social History 
Marital status  
I__I Married I__I Single 
 
I__I Living in relationship  I__I
 Divorced 
 
I__I Other   ______________________________  
 
 
A FEASIBILITY STUDY INVESTIGATING THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND 
CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE RELATIONSHIP BETWEEN HEARING LEVELS 
463 
Highest level of Education  
 
I__I less than standard 8 I__I
 standard 8 
I__I standard 9 I__I
 standard 10 
I__I tertiary education   
  
Occupation  
 
I__I employed as ___________________ 
 
I__I unemployed 
 
 
➔ Medical History 
Smoking history 
Does the subject have a history of smoking?  
I__I Yes  Pack/week  _______________ 
I__I No 
Does the subject currently smoke? ✓ 
I__I Yes  Amount/day ______________ 
I__I No 
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Alcohol history 
 
Does the subject drink 
alcohol?  
 
I__I Yes  
 
 
I__I No 
Drink/day 
Type Amount 
(ml) 
Units 
   
   
Drink/week 
   
   
   
Drink/Occasionally 
   
   
   
Does the subject abuse substances?  
I__I Yes  Type __________________________________________________________  
I__I No 
 
 
Surgical history? 
I__I No 
I__I Yes  
Type Date DateUnknown 
  I__I 
  I__I 
  I__I 
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Have you ever been hospitalized? No I__I Yes I__I 
 
Did you previously have TB? 
 
No I__I Yes I__I 
 
How many times?  
 
Where were you treated?                   
 
For how long? 
 
 
What medication did you 
take? 
 
 
Time and date of last dose of 
kanamycin 
 
 
Have you had or do you have:  If so, when 
Start Date 
 
Stop Date 
 
Measles?  
 
No I__I Yes I__I 
 
  
 
Mumps? 
 
No I__I Yes I__I 
 
  
Chronic ear infections? 
 
No I__I Yes I__I 
 
  
Encephalitis? 
 
No I__I Yes I__I 
 
  
Meningitis? 
 
No I__I Yes I__I 
 
  
Cancer? 
No I__I Yes I__I 
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Diabetes? 
 
No I__I Yes I__I 
 
  
Have you ever been in an 
accident which resulted in a head 
injury or trauma to the head? 
   
Are you pregnant or plan to 
become pregnant during this 
study? 
   
    
Would you consent to an HIV 
test 
   
    
Are you fluent in Zulu, Sotho or 
English 
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Ototoxic Medication Checklist 
Have you ever been treated with any of the following medications (ask for permission to look 
in participant file and get the information)? Please tick the medications you have been treated with, 
and cross the medications you have not been treated with. 
Salicylates Antibiotics 
Aspirin (>6-8 tablets per day)  
          Aminoglycosides 
Non-Steroidal Anti-inflammatory Drugs Gentamicin 
(Garamicin , Septopal ) 
 
Ibuprofen  
(Brufen ) 
 Amikacin 
 
 
Indomethacin  
(Arthrexin , Betacin ) 
 Tobramycin 
(Nebcin ) 
 
Naproxen                                                   (>6-8 
tab’s 
(Aleve )                                                      per day) 
 Netilmicin                                    (when 
given 
(Netromycin )                              IV) 
 
Diclofenac  
(Voltaren , Cataflam D , Veltex ) 
 Kanamycin 
 
 
Mephenamic acid  
(Ponstan , Ponac ) 
 Streptomycin 
 
 
Quinine   Neomycin  
Loop Diuretics 
Macrolides 
 
Furosemide  
(Lasix , Puresis , Beurises ,  
Uretic ) 
 Clarithromycin 
(Klacid , Clacee , Klarithan ) 
 
Bumetanide  
(Burinex )                                               (When 
given IV) 
 Ketolides (Telithromycin) 
(Ketek ) 
 
Torasemide 
(Unat ,Torahexal )              
 Erythromycin          (2-4g per 24h, IV 
only) 
(Erymycin ,Ilosone ,Betamycin ) 
 
Piretanide (Arelix )  Azithromycin 
(Zithromax , Azimax , Binozyt ) 
 
Chemotherapeutic agents 
Glycopeptide 
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Platinum compounds 
Vancomycin                  (when given IV) 
(Vancocin CP ) 
 
Cisplatin (Abiplatin , Platosin )  
Peptide  
 
Carboplatin (Carbosin , Paraplatin RTU )  Capreomycin (Capastat )  
Oxaliplatin (Eloxatin , Oxaliwin )  Add ARV regimens 
Iron – Chelating NNRTIs 
Deferoxamine (Desferal )  Delavirdine  Nevirapine  
Efavirenz  Rilpirivine  
Etravirine    
NRTIs 
ABC  D4T  
 d  TDF  
FTC  ZVD  
3TC    
Protease Inhibitors 
ATV  NFV  
DRV  RTV  
FPV  SQV  
IDV  TPV  
LPV    
Entry & Integrase Inhibitors 
EVG & Cobi  RAL  
MVC    
 
Vinca Alkaloids 
Vincristine  
Vinblastine  
Vinorelbine (Navelbine )  
Nitrogen Mustard analogues 
Cyclophosphamide (Endoxan )  
Chlorambucil (Leukeran )  
Melphalan (Alkeran )  
Ifosfamide (Holoxan , Ifolem )  
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Audiological History 
Do you struggle to hear? If so, please elaborate? 
(when, how often, in what situations, when did it 
start, does it fluctuate, what sounds, examples 
etc) 
 
Has anyone else told you that you struggle to 
hear? If so, please elaborate. 
 
Do you have a family history of hearing loss? If 
so, please elaborate. 
 
Have you ever had your hearing tested? If so, 
please elaborate. 
 
Do you have, or have you ever had a hearing 
aid? 
 
Have you been exposed to very loud noises for a 
long time? (work in factories, army/police force, 
band or loud music daily)  
 
Do you ever have tinnitus? (Ringing or sounds in 
your ears). If so, what kind of sounds, in both 
ears, how often, for how long?) 
 
Do you have ear pain?  
Do you ever have smelly discharge coming out 
of your ears? 
 
Are you able to know where the sound is coming 
from? (Localize) 
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Audiological Measures 
Otoscopy No 
abnormalities 
detected 
Cerumen 
but not 
occluding 
Occluding 
Cerumen 
Other (please 
describe) 
Cerumen 
Removed Via 
Suction 
Right Ear      
Left Ear      
 
Tympanometry Type 
 
Ear Canal 
Volume (ml) 
Pressure 
(daPa) 
Compliance 
(ml) 
Gradient 
(daPa) 
Right Ear      
Left Ear      
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Pure Tone Audiometry (AC) (Screening Audiometry):  Right Ear (dB)/Left Ear (dB) 
 
 
Consistent Co-operative Other 
   
 
  
Signature/Initials  Date  
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Inclusion/Exclusion Criteria 
Inclusion Criteria YES NO 
Consent provided by participant   
Consented to HIV test (if not already done and results in their hospital file)   
First language is/language of choice is English, Zulu or Sotho.   
Receiving treatment for DR-TB with kanamycin/capreomycin for a period of at least 3 
months 
  
Participant between the ages of 18 and 55 years 
 
  
Normal middle ear status as determined by screening otoscopy and tympanometry (not 
a type B or C) 
  
Exclusion Criteria   
Diabetes Mellitus   
Previous treatment of aminoglycosides within the last 7 months when given 
intravenously. These drugs will include: amikacin, tobramycin, neomycin or 
streptomycin. 
  
Previous treatment with kanamycin/capreomycin within the last 7 months. However, 
should they have taken up to 3 dosages of kanamycin prior to enrolment (within a week 
prior to enrolment), then the participant will still be included. 
  
Middle ear pathology   
Severe or profound hearing loss in at 3 or more frequencies above 2000Hz in both ears.   
Significant history of substance abuse that may affect adherence to protocol   
 
 
 
 YES NO 
Does the patient qualify to be enrolled on the study?( If no, state reason)   
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Appendix E 
 
Information Leaflets and Informed Consent Form for Helen Joseph Hospital: English 
 
Information Leaflets and Informed Consent Form for Helen Joseph Hospital: Zulu 
 
Information Leaflets and Informed Consent Form for Helen Joseph Hospital: SeSotho 
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Clinical HIV Research Unit, Department of Medicine 
____________________________________________________________________________________ 
Helen Joseph Hospital, Themba Lethu Clinic, Perth Road, Westdene, Johannesburg 2092, South Africa 
Postnet Suite  
 
 
INFORMED CONSENT VERSION NUMBER: 1.5 
(Helen Joseph Hospital) 
STUDY TITLE: A feasibility study investigating the pharmacokinetics and pharmacodynamics of 
kanamycin and capreomycin in patients with DR-TB and the relationship between hearing levels 
INSTITUTION: University of the Witwatersrand in collaboration with Sefako Makgatho Health 
Sciences University 
DAYTIME AND AFTER HOURS TELEPHONE NUMBER(S): 082 815 8878 (Cara Hollander) 
and/or 011 276 8968 (Dr. Rebecca Berhanu - Doctor) and /or +27 11 276-8813 (Dr. Mohammed Rassool 
– Principal Investigator – Doctor at Helen Joseph – Wits Health Consortium) 
STUDY COORDINATOR: Matshediso Mkhwanazi: speed dial: 50017/ 076 711 2874/ 
Matshidiso.Mkhwanazi@righttocare.org 
 
 
 
To the potential Participant: This consent form may contain words that you do not 
understand. Please ask the study doctor/nurse or the study staff to explain any words or information 
that you do not clearly understand. You may keep an unsigned copy of this consent form to think 
about or discuss with family or friends before making your decision. 
 
INTRODUCTION 
Good day, my name is Cara Hollander and I am an audiologist from the University of the 
Witwatersrand. I would like to invite you to think about joining a research study, called “A feasibility 
study investigating the pharmacokinetics and pharmacodynamics of kanamycin and capreomycin in 
patients with DR-TB and the relationship between hearing levels”. We have just done some tests to 
confirm that you fit the criteria to take part in this study.  
Prof. Ian Sanne (Clinical Director); Dr Sharla Badal-Faesen (Investigator); Dr FM Conradie (Investigator); Dr Cindy 
Firnhaber (Investigator);  Dr PD Ive (Investigator); Dr E Jongh (Investigator) Prof P MacPhail (Investigator); Dr K Mellet 
(Investigator), Dr T Mwelasi (Investigator) Dr MS Rassool (Investigator)          
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1. Before agreeing to take part in this study, it is important that you read and understand the following 
explanations about the reason for the study, the study procedures, benefits, risks, uncomfortable aspects, 
and precautions as well your right to pull out from the study at any time.  
2. This information booklet is to help you to decide if you would like to take part. You need to 
understand everything about the study before you agree to take part in this study.  
3. If you have any questions, please ask me.  
4. You should not agree to take part unless you are happy about all the parts involved.  
5. You may not take part in another research study while you are taking part in this study (unless it is 
approved by me beforehand).  
6. Please be open with me about your health history, since you may otherwise harm yourself by taking 
part in this study.  
7. If you decide to take part in this study, you will be asked to sign this form to confirm that you 
understand the study. You will be given a copy to keep.  
8. If you have a personal doctor outside of this hospital, please discuss with or tell him/her of your 
possible participation in this study. If you would like, I can also tell your personal doctor about this.  
 
PURPOSE OF THE STUDY 
You are in this hospital/clinic because you have Drug Resistant Tuberculosis (DR-TB). I would like 
you to think about taking part in the research to measure your hearing levels throughout your DR-TB 
treatment. You will be receiving medicine (injections) to treat your drug resistant tuberculosis called 
kanamycin together with a few other medications, so that you can get better from your TB, which is 
very important. The medicine you will be receiving is very strong, and has a few risks and one of them 
is hearing loss. However, you need to take this medicine so that you can get healthy again. Many people 
who take the medication will lose some of their hearing; but, although this happens often, it does not 
happen always. It can be very hard to talk to family and friends with a hearing loss and working can 
also be difficult. Therefore, during this research, we want to measure your hearing 7 times in the first 
three months, so that we can understand exactly what happens to your hearing. Then, we would also 
like to do blood tests 8 times in the first 3 months, so that we can look how your medicine for your DR-
TB is working in your body. We will not changing or adjusting your DR-TB medicine based on the 
blood tests, but it will allow us to understand how the medicine works differently in different people, 
so that we can hopefully try and prevent hearing loss in the future. Your assistance will help us treat 
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other patients in the future with this illness and it will also allow us to monitor your hearing throughout, 
and look at a relationship between how the drug is used in your body with your hearing. 
 
LENGTH OF THE STUDY AND NUMBER OF PARTICIPANTS 
The study will take place at this hospital as well as at South Rand Hospital. About 80 people will take 
part in this study. The participants will be between the ages of 18 and 55 years. You will need to take 
your kanamycin for more months than you will be part of this study. We will be doing tests for three 
months for this study, which will be explained below. These tests are blood tests and hearing tests. In 
the first 3 months, you will be asked to visit me 9 times for tests during the study. We will need you to 
come back to the clinic for all these tests. Today will be counted as day 1. Sometimes they will be on 
the same day as your general clinic visits. You will ALSO need to come to either this clinic or the 
clinic closest to your home every day to get your kanamycin injection from a nurse so she can record 
the time and dosage you are receiving.  You will therefore need to come to this clinic at Helen Joseph 
Hospital once every second week for the hearing and blood tests, and then the local clinic daily 
(unless you choose to come to Helen Joseph daily). We will give you R150 for your travelling 
expenses every time you need to come to the hospital for the hearing and blood tests. This will be for 
9 times, every second week. If you are an inpatient in the hospital, you will not be paid for your 
transport, until you get discharged, as you will not need money for your transport. Then, we will give 
you enough money for your transport to go to the local clinic every day (from Monday to Friday) to 
get your kanamycin injections. We will give you R50 for your transport to the clinic every day. When 
you come to the Helen Joseph clinic for your ‘official’ study visits, when you have the hearing and 
blood tests we will give you R150. You will not get extra transport money that you get daily for 
coming for your injections on the days that you get R150.  
 
PROCEDURES 
If you agree to take part in this study, you will be asked questions and then will need to undergo a few 
tests – which will be hearing tests and blood tests. These tests will need to be done in addition to your 
other tests/procedures that are not study related.  
If you agree to take part in this study and consent, I will need to ask you some questions today and 
examine you. Then, you will need to come back tomorrow as well for your blood tests and the first 
hearing tests. 
You will need to come here, or to your local clinic every day (from Monday to Friday – not on the 
weekends) to get your kanamycin injection. Then, every second week, you will need to have blood tests 
and hearing tests. These days will take longer than your daily visits.  
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Purpose of hearing tests  
Our ears are wonderful organs because they can hear so many difference pitches. We can hear low 
pitches which are for example a lawn mower, or a bus, or even a tap dripping. These are different 
sounds, and have different loudness levels, but they all have low pitches. Then we can also hear high 
pitches, for example birds tweeting or alarm clocks ringing.  
 
Speech sounds, words and sentences are all different pitches. Like for example, the /m/, /d/ and /b/ are 
lower pitches where-as the /f/, /s/ and /th/ are higher pitches. In order for us to understand each other, 
we need to be able to hear many different frequencies or pitches, as speech sounds have many different 
pitches.  
 
As soon as we start to only hear low pitches, and not the high pitches, then we struggle to understand 
speech. So, for example, when someone is saying ‘head’, you may mishear, and hear ‘bed’. If someone 
says ‘fate’, you may hear ‘ate’. Therefore a hearing loss at even a few frequencies will make it difficult 
to understand friends, family and doctors.  
 
Many different things can cause hearing loss. Sometime people can be born with a hearing loss, or it 
could be from loud noise, trauma and some medicines. DR-TB is a serious illness, and you need very 
strong medicine to recover and live. However, sometimes, these medicines can cause a hearing loss, 
which could make it difficult for you to hear and communicate.  
 
As the strong medicine (kanamycin) is needed to live, you have to take it. BUT, this research is to try 
to understand the exact kind of hearing loss that is caused by the medicine which will better allow for 
treatment or prevention in the future. We need to measure how you hear all the different sounds and 
pitches when you come into hospital, and then every few weeks, to see if its staying the same, or getting 
worse.  
 
Hearing test procedures  
A hearing test is not painful, and there are a few parts, as follows:  
• Otoscopy – Firstly, I will need to look in your ears with a light to see if there is any wax, or 
other things in your ears, as this can affect your results. This will take about 20 seconds. 
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• Cerumen management – if your ears are clogged with wax, I will take the wax out so it doesn’t 
affect the other tests. I will put some oil in your ear to make the wax soft. Then I will use a 
machine to pull out the wax (suction). The suction will only take a few seconds. It may be 
slightly painful, but it is not always painful.  
• Tympanometry – Then, I will place a machine in your ear. It is a soft nub and it will pump some 
air in your ear. It will not be sore, but will help us know if you have any infections deep inside 
your ear, and if there is any fluid. If there is fluid, it will affect your hearing, and the results of 
the hearing test. This will take about 2 minutes.  
• Distortion Product Otoacoustic Emissions – We have tiny hair cells deep in our ears. The 
different hair cells are important to hear the different pitches. Therefore, and DPOAE machine 
measures how these hair cells are moving and working. We need to put a soft nub in your ear, 
and it will make different sounds. You need to keep still and quiet, and the machine will take 
the measurements of these hair cells. This will take about 5 to 10 minutes.  
• Pure Tone Audiometry – we will put headphones on you. They will give off very soft sounds. 
The sounds will have different pitches. Some will be low, and some will be high. Whenever 
you hear a sound, you will need to press a button. This will take about 15 to 20 minutes.  
 
Once this is done, we are able to put all the results together and understand exactly what you are hearing. 
If we do the test when you come into hospital, and then we do it again at certain intervals, we can see 
if your hearing is changing.  
 
If you agree to this, you will need to do this 7 times in the first 3 months. It would be tomorrow, then 
every second week for the next 3 months.  
 
After 3 months of the study, you will continue to have your hearing monitored by the audiologists at 
this hospital or the hospital or clinic in your region. Should you get a hearing loss, they will continue to 
help you with hearing aids and further management. I will refer you to them after the study.  
 
Blood Sampling  
We will need to take blood as well. We will need to take blood so that we can measure how the DR-TB 
treatment (kanamycin) is being used in your body. We hope this will help us understand why people 
get a hearing loss. Myself, or another nurse, doctor or phlebotomist will take blood from you so that we 
can do the necessary tests. We need to take 2mls of blood for each test. You will need to have at least 
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2 blood tests each time (except for the first 2 visits). Two mls is about 2 drops of blood or half a 
teaspoon. Therefore, we will need to take 4mls of blood each day we see you to measure the kanamycin 
(just under a teaspoon of blood). The first time will be a few hours after you get your injection for your 
DR-TB. Then, the second time will be the following day before you get your injection. And the other 
times, you will need to get your blood taken before your injection, and a few hours after your injection. 
Therefore, for each visit (besides for the second visit when you have blood tests), you will need to be 
at the clinic for at least 4.5 hours. We will need to do this 8 times all together over 3 months (tomorrow 
will be the first time). So altogether, over the 3 months, we will take a total of 28mls of blood, which is 
about 5 and a half teaspoons. We will therefore just be taking the blood and doing the hearing tests.  
 
Then, in order to understand how the medicine may be affecting your kidneys, we would like to measure 
kidney function as well. On 3 out of the 9 visits, we will also need to take another 3 mls of blood, so 
we can measure your kidney function and make the correct dosage changes. Therefore on the visits that 
we will need to test this, we need an extra 3mls of blood, with is just over half a teaspoon. Altogether, 
over the 3 times, we will draw 9 mls or blood, which is just under two teaspoons addition to the other 
blood tests described above. We will draw this at the same time at the blood test for the kanamycin – 
so that there will not be an extra needle prick.  
 
Taking blood is part of your normal medical care at this hospital. We will need to take blood separately 
to the regular hospital procedures. This may present a slight risk of discomfort. We will draw the blood 
in the same way as it is taken for your general blood tests. Drawing blood may result in faintness, 
inflammation of the vein, pain, bruising or bleeding at the puncture site. There is also a slight possibility 
of infection. Experienced nurses, doctors or phlebotomists will take the blood in clean conditions to 
help make sure that is will be safe.  
 
Your blood will be kept safely at Helen Joseph Hospital until it is sent to the laboratory to be tested. It 
will be sent as soon as possible. It will not be kept for more than a week. Your blood will be sent to a 
laboratory at Sefako Makgatho Health Sciences University. Then, the blood we take to measure your 
kidney function will be sent to another laboratory, called CLS. All the personal information about 
these tests and about your general health will be kept private in a file and then in a cupboard during 
after the research study. Personal information will not be discussed with any person not involved in 
the research study. If this is needed, we will ask for your permission before this is done.  
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The hearing tests and blood tests will be done on day 2 (tomorrow), days 15, 28, 40, 54, 68 and 84. The 
blood tests will take place tomorrow (day 2), the next day (day 3), and then on the same day as the 
hearing tests - on days 15, 28, 40, 54, 68 and 84.  
At every visit that you come for the hearing and blood tests (not the days in between when you just 
come for your injections), each visit will take about 5 to 6 hours. This is because we need to wait about 
4 to 6 hours between the 2 blood tests. So, it would be best if you came early in the morning, so you 
can leave by the afternoon.  
 
WILL ANY OF THESE STUDY PROCEDURES RESULT IN DISCOMFORT OR 
INCONVENIENCE? 
Taking blood may cause a small discomfort. We will take the blood in the same way as it is taken for 
your other blood tests. Drawing blood may result in faintness, inflammation of the vein, pain, bruising 
or bleeding in the area that we take the blood from. There is also a slight chance of infection. Only 
experienced nurses (or phlebotomists or doctors) will take your blood to help protect you and everything 
will always be clean. A total of 4 mls of blood (i.e. just under a teaspoon) will be taken on each study 
visit (besides for day 2 and day 3 – only 2mls will be taken). This is a total of 28 mls, which is about 5 
and a half teaspoons of blood. Then, an extra 3 mls will be drawn on days 40, 68 an 84 – an extra total 
of 9mls which just under 2 teaspoons. Therefore, all together, 37 mls will be drawn over the three 
months – which is equivalent to about 7 and a half teaspoons.  
 
The hearing tests as described above will not cause discomfort; however, taking out the wax may be 
slightly painful. We do not need to take out wax for every person though, and it is not always sore. 
Taking out the wax will only last a few seconds though. The rest of the test will take approximately 30 
to 40 minutes of your time for each visit. You will always be able to discuss your results with the nurse 
and ask questions before or after these tests. If you have more questions, you can get in touch with 
myself, who is an audiologist.  
BENEFITS 
• The possible benefit from your participation in this study is you will be able to understand your 
hearing status in more detail, and its relationship with how the kanamycin is being used in your 
body.  
• You may not benefit from this study.  
• Your participation in this study will help develop medical knowledge that may help other 
patients that, like you, have DR-TB and are at risk to develop a hearing loss.   
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ALTERNATIVE TREATMENT 
• At the moment, there is no treatment to reduce or prevent the hearing loss caused by DR-TB 
medicine. Should you get a hearing loss; you will be referred to the local clinic nearest to you 
to assist you to receive a hearing aid.  
• Monitoring the kanamycin in your blood is not a standard procedure, and there is no other 
way besides blood tests to do this at the moment. 
• The Audiology Department at this hospital will be able to assist you if you are in this 
catchment area. This is part of general government procedures with hearing loss management.  
• If you decide not to take part in this study you will still receive the best current care at this 
clinic for your DR-TB. 
 
BENEFITS AND RISKS OF STANDARD ALTERNATIVE TREATMENT 
• As there is currently no medicine that can help to prevent or lessen hearing loss, there is no 
other treatment. If your DR-TB medication causes a hearing loss, it is permanent, and cannot 
be fixed. But it will be possible to get a hearing aid to make all the sounds louder to help you. 
Hearing aids however cannot always help with hearing loss, as sometime the hearing loss is 
so bad, that the hearing aids cannot help. We will not be giving you the hearing aids – the 
hospitals audiology department will be able to assist you with that if you are in this catchment 
area, or we will refer you to the correct clinic or hospital that is in your catchment area.  
• The benefits of the hearing aids can be limited, however may help you if you develop a 
hearing loss from your DR-TB medication. Hearing aids do not have any risks.  
 
ARE THERE ANY WARNINGS OR RESTRICTIONS CONCERNING MY 
PARTICIPATION IN THIS STUDY 
• If you have Diabetes Mellitus you may not take part in this study. Diabetes Mellitus can 
sometimes affect the hearing, and we want to be able to measure your hearing without this 
possibly interfering.  
• If you are any younger than 18 years of age, or older than 55 years of age, you may not take 
part in the study. In this study, we are only measuring people between the ages of 18 and 55 
years.  
• If your doctor changes your medication, you may not be able to continue participating in this 
study.  
• If you have been addicted to any drug and have a history of drug or alcohol abuse, you cannot 
take part in the study if this could impact in your compliance with the test procedures. This 
will be decided at the discretion of the investigators involved.  
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RIGHTS AS A PARTICIPANT IN THIS STUDY 
Voluntary  
Your participation in this study is entirely voluntary and you can choose if you would like to take part 
or not. You can also stop taking part at any time and you do not need to give a reason. If you chose to 
not take part, or decide to stop taking part during the study, you will still get the medical care at this 
hospital, and it will not be affected.  
New findings  
I will provide you with any new information that I have during the study, which may change your 
willingness to continue on the study  
Withdrawal  
Your withdrawal or stopping participation in the study will not affect your other medical care. I have 
the right to withdraw you from the study if it is what is best for you. If your doctor changes your 
medicine for the DR-TB and you will not be taking kanamycin, then you will not be able to continue 
with this study. If you did not give correct and truthful information about your medical history, or did 
not follow the rules of the study, I may take you off the study at any time.  
 
EMERGENCY CARE AND HOSPITALISATION 
If you need emergency care at any time during the study, please call Dr. Mohammed Rassool on 011 
276-8813 or 027 83 415 8967 or Dr. Rebecca Berhanu on 011276 8968 or 072 717 9159.  
 
FINANCIAL ARRANGEMENTS 
• The funders of this study will provide payment for all study tests.  
• Neither you nor your medical aid (if you have one) will need to pay for any study medication 
or study procedures, and they have been all funded by research organizations.  
• When you visit the hospital for the study every second week (for hearing and blood tests) you 
will be provided with R150 for your transport. You will not be paid to take part, but only for 
your transport and refreshments. When you go to your local clinic daily, you will be 
compensated for your transport. You will be provided with R50 to go to your local clinic daily. 
This will only be for the first 3 months. After these 3 months, no money will be provided for 
your transport.  
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ETHICAL APPROVAL 
• This clinical study protocol has been given to the University of the Witwatersrand, Human 
Research Ethics Committee (HREC) and written approval has been given by that committee. 
• The study follows the guidelines of the Declaration of Helsinki (last updated: October 2013), 
which deals with the recommendations for doctors in doing medical research with human 
participants. If you would like a copy of these principles, please let me know, and I will get 
them to you.  
• This study is paid for by a research organisation (South African Medical Research Council). I 
do not have any financial or personal interests with this organization and I am not influenced 
or biased by them.  
 
INSURANCE 
All the medical doctors in this study have insurance. The principal investigator and doctors are insured 
by MPS to conduct the procedures as long as:  
• They obey the procedures of the study protocol.  
• Their compliance with the rules of the Medicines Control Council and the University of the 
Witwatersrand, Human Research Ethics Committee (HREC).  
• The handling and administration of the study medication according to the protocol and 
amendments and other related documents.  
• The indemnification is not intended to be and is not a substitute for any personal malpractice 
insurance.  
 
Please note that if you have a life insurance policy you should find out if your insurance company needs 
to be notified about you taking part in the study. From other information, this should not affect any life 
insurance policy taken out. But it is still important to double check this as sometimes companies are 
different.  
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SOURCE OF ADDITIONAL INFORMATION 
During the study, you will be cared for by the staff at Helen Joseph Hospital. If at any time you feel that 
you have further study related questions, please contact me or the study nurse/coordinator on duty at 
the hospital.  
Members of the study who you can contact:  
• Cara Hollander – 082 815 8878 (Audiologist)  
• Dr. Karin Joubert – 011 717 4561 (Audiologist)  
• Professor. Natalie Schellack – 012 521 3286 (Pharmacist)  
• Dr. Rebbeca Berhanu – 011 276 8968 (Doctor)  
• Dr. Mohammed Rassool –011 276-8813 (Doctor and Principal Investigator)  
 
If you want any information regarding your rights as a research participant, or complaints regarding 
this research study, you may contact Prof. Cleaton-Jones, Chairperson of the University of the 
Witwatersrand, Human Research Ethics Committee (HREC), which is an independent committee to 
help protect the rights of research participants at (011) 717 2301.  
 
For research information you can contact the Study Planner– Cara Hollander from the University of 
the Witwatersrand on 082 815 8878.  
 
CONFIDENTIALITY 
• All information that we collect during this study, which includes hospital records, personal and 
research information will be kept strictly confidential. Only members of the research team, and 
your doctors and nurses will have access to your information. Any information that will be 
written in scientific journals or anything that is published will not have your name on.  
•  We will put different codes on your study information. Therefore, when reviewing your results, 
there will only be a code. Your name, identity number or any other identifying notes will not 
be on the documents, to ensure everything is confidential.  
• This information will be reviewed by authorised representatives of the University of the 
Witwatersrand and Sefako Makgatho Health Sciences University as well and members from 
the funders (Medical Research Council). Auditors of the Wits Health Consortium may look at 
some of the results when they do their inspection to make sure everything is done with good 
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standards. However, not everyone will have access to your name – all your results will have a 
number, so they will not know if it is you.  
• The information might also be inspected by the National Health Research Ethics Committee 
(NHREC), University of the Witwatersrand, Human Research Ethics Committee (HREC), the 
South African Medicines Control Council (MCC) and/or the United States Food and Medicine 
Administration (FDA) as well as your personal doctor. Therefore, you hereby authorize me to 
release your medical records to the Medical Research Council, its employees or agents, 
domestic and foreign regulatory health authorities, the South African Medicines Control 
Council (MCC), the National Health Research Ethics Committee (NHREC) and the University 
of the Witwatersrand, Human Research Ethics Committee (HREC).  
• These records will be used by them only to carry out their duties relating to this clinical study.  
• Any information uncovered regarding your test results or state of health as a result of your 
participation in this study will be strictly confidential. You will be told about any findings of 
importance to your health or continued participation in this study but this information will not 
be given to any third party in addition to the ones mentioned above without your written 
permission. The only exception to this rule will be cases of communicable diseases where a 
legal duty of notification of the Department of Health exists. In this case, I will tell you about 
this and that I will be giving the information to be the authorised state agency.  
 
PERSONAL DOCTOR / SPECIALIST NOTIFICATION OPTION 
Please tell me below, if you want me to notify your personal doctor or your specialist that you will be 
taking part in this study:  
• YES, I want you to tell my personal doctor / specialist of my participation in this study.  
• NO, I do not want you to tell my personal doctor / specialist of my participation in this study.  
• I do not have a personal doctor / specialist  
 
PARTICIPANT QUESTIONS 
Do you, as the participant have any questions?  
YES / NO  
If YES – Please describe. 
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INFORMED CONSENT FOR PARTICIPATION IN THE STUDY 
I hereby confirm that I have been informed by the study nurse/sub-investigator..................................... 
(FULL NAME) about the nature, conduct, benefits and risks of clinical study titled “A feasibility study 
investigating the pharmacokinetics and pharmacodynamics of kanamycin and capreomycin in patients 
with DR-TB and the relationship between hearing levels” 
 (PROTOCOL NUMBER 1.5)  
• I have also received, read and understood the above written information (Participant 
Information Leaflet and Informed Consent) about this clinical study.  
•  I am aware that the results of the study, including personal details about my sex, age, date of 
birth, initials and diagnosis will be anonymously (my name will not be provided) processed 
into a study report.  
•  I am aware that I will need to come to the Helen Joseph clinic every second week for hearing 
and blood tests for 3 months.  
•  I am aware that I can choose to either go to my local clinic or the Helen Joseph clinic daily for 
my injections and I agree to do this daily.  
• In view of the requirements of research, I agree that the data collected during this study can be 
put through a computerised system planned by the researchers involved in this study, the 
funders or on their behalf. 
•  I consent to participating in 7 sets of hearing tests in the first 3 months.  
• I consent to participating in 8 sets of blood tests in these 3 months.  
• I consent to give 2mls of blood 2 times in the first 3 months.  
•  I consent to giving 4mls of blood 6 times during the study. And another 9 mls to measure my 
kidney functions in the first 3 months.  
•  I do know that I can withdraw at any time.  
•  I may, at any stage, without unfairness, pull out my consent and participation in the study.  
•  I have had enough time to ask questions and (of my own free will) declare myself ready to 
participate in the study.  
•  I am aware that should my doctor change my medication to something other than kanamycin, 
I will be withdrawn from the study.  
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PARTICIPANT 
 
___________________________________________________________________________ 
Printed Name                                  Signature / Mark or Thumbprint   Date and Time  
 
 
STUDY SUB-INVESTIGATOR/ COORDINATOR 
 
I, ................................................................................, herewith confirm that the above participant has 
been fully informed about the nature, conduct and risks of the above study.  
 
__________________________________________________________________________ 
Printed Name                                                       Signature                            Date and Time  
 
 
TRANSLATOR / OTHER PERSON EXPLAINING INFORMED CONSENT (SUB-
INVESTIGATOR) 
 
__________________________________________________________________________ 
Printed Name                            Signature                                                          Date and Time  
 
 
WITNESS (If applicable) 
__________________________________________________________________________ 
Printed Name                               Signature                                                    Date and Time 
 
 
  
FEASIBILITY STUDY INVESTIGATING THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND 
CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE RELATIONSHIP BETWEEN HEARING LEVELS 
488 
 
INOMBOLO YOSHICILELO LWEMVUME ENIKEZWA EMVA KOKUTHOLA ULWAZI: 
1.5 
(Isibhedlela sase Helen Joseph) 
 
ISIHLOKO SOCWANINGO: Ucwaningo lokuhlola ukuthi imithi i-kanamycin ne-capreomycin 
isebenza kanjani emzimbeni nemithelela yokusetshenziswa kwayo ezigulini ezine-DR-TB kanye 
nokuhlobana phakathi kwamazinga okuzwa 
 
ISIKHUNGO: Inyuvesi yase-Witwatersrand ibambisene ne-Sefako Makgatho Health Sciences 
University 
 
IZINOMBOLO ZOCINGO (ZEZINGCINGO) NGESIKHATHI SAMAHORA OKUSEBENZA 
NANGEMUVA KWAMAHORA OKUSEBENZA: 082 815 8878 (Cara Hollander) kanye/noma 
011 276 8968 (Dkt.  Rebecca Berhanu - Ongudokotela) kanye /noma +27 11 276-8813 (Dkt.  
Mohammed Rassool – Umcwaningi Omkhulu – Udokotela wase Helen Joseph – Wits Health 
Consortium) 
 
UMXHUMANISI WOCWANINGO: Matshediso Mkhwanazi: Inombolo yocingo esheshayo: 
50017/ 076 711 2874 Matshidiso.  Mkhwanazi@righttocare.org 
Kulowo okunokwenzeka ukuba abambe iqhaza: Leli fomu lemvume kungenzeka ukuthi liqukethe 
amagama ongawaqondisisi.  Uyacelwa ukuba ubuze udokotela wocwaningo noma unesi wocwaningo 
noma umsebenzi wocwaningo ukuze akuchazele noma yimaphi amagama noma ulwazi 
ongaluqondisisi kahle.  Ungakwazi ukuzigcinela ikhophi elingasayiniwe lale mvume ukuze ucabange 
ngalo noma uxoxe mayelana nalo nabomndeni wakho noma 
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ISINGENISO 
Sawubona, igama lami nginguCara Hollander ngingudokotela wezinzwa zokuzwa wase-University of 
the Witwatersrand.  Ngingathanda ukuba ucabange mayelana nokuhlanganyela kulolu cwaningo 
lophenyo, olwaziwa ngokuthiwa “Ucwaningo lokuhlola ukuthi imithi i-kanamycin ne-capreomycin 
isebenza kanjani emzimbeni nemithelela yokusetshenziswa kwayo ezigulini ezone-DR-TB kanye 
nokuhlobana phakathi kwamazinga okuzwa”.  Sisandukwenza okunye ukuhlola okuqinisekisa ukuthi 
uyafaneleka ukubamba iqhaza kulolu cwaningo. 
• Ngaphambi kokuvuma ukubamba iqhaza kulolu cwaningo, kubalulekile ukuthi ufunde lezi 
zincazelo ezilandelayo futhi uziqondisise ezimayelana nenhloso yalolu cwaningo, izinqubo 
zocwaningo, izinsizakalo, ubungozi, izinto ezikwenza ungakhululeki, nezindlela zokuphepha 
kanye nelungelo lakho lokuhoxa kulolu cwaningo noma nini. 
• Leli bhukwana lolwazi lenzelwe ukukusiza ekuthatheni isinqumo sokuthi ungathanda yini 
ukubamba iqhaza.  Kudingeka ukuba wazi yonke into mayelana nalolu cwaningo ngaphambi 
kokuvuma ukubamba iqhaza kulolu cwaningo. 
• Uma unemibuzo, ngizicela ungibuze. 
• Akuphoqelekile ukuba ubambe iqhaza ngaphandle uma wenelisekile mayelana nazo zonke 
izingxenye ezibandakanyekayo. 
• Awuvunyelwe ukubamba iqhaza kolunye ucwaningo lophenyo ngesikhathi usabambe iqhaza 
kulolu cwaningo (ngaphandle uma ngikunikile imvume ngaphambi kwalokho). 
• Ngicela ungangifihleli lutho mayelana nomlando wakho wezempilo, njengoba lokho kungenza 
ukuba uzilimaze ngokubamba iqhaza kulolu cwaningo. 
• Uma unquma ukubamba iqhaza kulolu cwaningo, uzocelwa ukuba usayine leli fomu 
ngenhloso yokuqinisekisa ukuthi uyaluqondisisa lolu cwaningo.  Uzonikezwa ikhophi ukuba 
uzigcinele lona. 
• Uma unodokotela wakho ongasebenzi eHelen Joseph Hospital, ngicela uxoxe naye noma 
umtshele mayelana nokuthi kungenzeka ubambe iqhaza kulolu cwaningo.  Uma uthanda, 
ngingamtshela mina udokotela wakho mayelana nalokhu. 
 
INHLOSO YALOLU CWANINGO 
Ukulesi sibhedlela noma ukulo mtholampilo ngoba unesifo sofuba esibizwa ngokuthi i-Drug Resistant 
Tuberculosis (i-DR-TB).  Ngizothanda ukuba ucabange mayelana nokubamba iqhaza kulolu 
cwaningo lokukala amazinga akho okuzwa ngaso sonke isikhathi usalashelwa i-DR-TB yakho.  
Uzonikezwa umuthi (imijovo) wokwelapha isifo sakho sofuba esimelana nemithi obizwa nge-
kanamycin kanye neminye imithi, ukuze i-TB yakho ibe ngcono, okuyikho okubaluleke kakhulu.  Lo 
muthi ozonikezwa wona unamandla amakhulu futhi unobungozi obumbalwa, obunye balobu bungozi 
wukulahlekelwa wukuzwa.  Noma kunjalo, kudingeka ukuba uwusebenzise lo muthi ukuze uphinde 
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uphile kahle.  Iningi labantu abasebenzisa lo muthi bazolahlekelwa wukuzwa; nakuba lokhu kuvame 
ukwenzeka, akwenzeki njalo.  Kungaba nzima kakhulu ukukhuluma nomndeni kanye nabangane uma 
usungezwa ezindlebeni kanti nokusebenza kungaba nzima.  Ngakho-ke, ngesikhathi kusaqhubeka lolu 
cwaningo, sifuna ukukala amazinga akho okuzwa izikhathi eziyisikhombisa ezinyangeni ezintathu 
zokuqala, ukuze siqonde kahle mayelana nokuthi yini eyenzeka ekuzweni kwakho.  Emva kwalokho 
sizobe sesikuhlola igazi izikhathi eziyisishiyagalombili ezinyangeni ezintathu zokuqala ukuze sibheke 
indlela umuthi wakho wokwelapha i-DR-TB osebenza ngayo emzimbeni wakho.  Ngeke siguqule 
imithi yakho ye-DR-TB ngokokuhlolwa kwegazi, kodwa lokhu kungasenza siqonde ukuthi kuhluke 
kanjani ukusebenza komuthi ebantwini abehlukene ukuze sikwazi ukuzama ukuvimbela ukulahleka 
kokuzwa ngomuso, usizo lwakho luzosisiza ukwelapha ezinye iziguli ezinalesi sifo esikhathini 
esizayo futhi lusenze sikwazi ukuqapha ukuzwa kwakho ngaso sonke isikhathi, kanyenokubheka 
ubudlelwane phakathi kwendlela lo muthi osebenza ngayo emzimbeni wakho kanye nokuzwa 
kwakho. 
 
Ubude besikhathi socwaningo kanye nenani lababambiqhaza 
Lolu cwaningo luzokwenziwa kulesi sibhedlela nasesibhedlela sase South Rand.  Ngabantu 
abalinganiselwa kuma-80 abazobamba iqhaza kulolu cwaningo.  Ababambiqhaza bazobe 
beneminyaka ephakathi kweyi-18 nengama-55 ubudala.  Kuzodingeka ukuba usebenzise i-kanamycin 
yakho izinyanga ezingaphezu kwesikhathi sokubamba kwakho iqhaza kulolu cwaningo.  Sizokwenza 
ukuhlola izinyanga ezintathu zalolu cwaningo, okuzochazwa lapha ngezansi.  Lokhu kuhlola 
wukuhlolwa kwegazi kanye nokuhlolwa kokuzwa.  Ezinyangeni ezintathu zokuqala, uzocelwa ukuba 
ungivakashele izikhathi eziyi-9 ngenhloso yokuzohlolwa ngesikhathi kuqhubeka lolu cwaningo.  
Kuzodingeka ukuba ubuyele kulo mtholampilo mayelana nalokhu kuhlola.  Usuku lwanamhlanje 
luzobalwa njengosuku loku-1.  Kwezinye izikhathi lokhu kuhlola kuzokwenziwa ngalo lolo suku 
lokuvakashela kwakho emtholampilo okuvamile.  Kuzodingeka FUTHI ukuba uze emtholampilo 
nsuku zonke ukuze uzothola umjovo wakho we-kanamycin kunesi ukuze akwazi ukurekhoda isikhathi 
kanye nomthamo owutholayo.  Uma sifuna ukushintsha umthamo wethu, singakwenza lokho 
ngesikhathi salokhu kuvakasha.  Sizokukhokhela ama-R150 mayelana nezindleko zokugibela njalo 
nje uma kudingeka ukuba uze esibhedlela mayelana nokuzohlolelwa ukuzwa negazi.  Lokhu 
kuzokwenziwa izikhathi eziyi-9, njalo esontweni lesibili.  Sizobe sesikunika imali eyanele yokugibela 
ukuza emtholampilo nsuku zonke (kusukela ngoMsombuluko kuya ngoLwesihlanu) ngenhloso 
yokuzothola imijovo yakho ye-kanamycin.  Ngesikhathi uza emtholampilo mayelana nokuvakasha 
kwakho kocwaningo “okusemthethweni” uma uzohlolelwa igazi nokuzwa sizokunika ama-R150.  
Uma uyisiguli esilaliswe esibhedlela, ngeke ukhokhelelwe izindleko zokugibela kuze kube 
uyakhishwa esibhedlela njengoba ungeke ube nesidingo sokugibela. 
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IZINQUBO 
Uma uvuma ukubamba iqhaza kulolu cwaningo, uzobuzwa imibuzo bese wenziwa ukuhlolwa 
okumbalwa – okuzobe kuwukuhlolelwa ukuzwa kanye nokuhlolwa kwegazi lakho.  Lokhu kuhlolwa 
kuzokwenziwa phezu kokunye ukuhlolwa kwakho noma naphezu kwezinye izinqubo ezingahlobene 
nalolu cwaningo. 
Uma uvuma ukubamba iqhaza kulolu cwaningo kuzodingeka ukuba ngikubuze imibuzo embalwa 
namhlanje bese ngikuhlola.  Bese ubuya kusasa ukuze wenze okunye ukuhlolwa kwegazi nokuhlolwa 
kokuzwa kokuqala 
Kuzodingeka ukuba uze lapha nsuku zonke (kusukela ngoMsombuluko kuya kuLwesihlanu – hhayi 
ngezimpelasonto) ngenhloso yokuzothola umjovo wakho we-kanamycin.  Bese kuthi njalo esontweni 
lesibili, kudingeke ukuba uhlolwe igazi uhlolelwe nokuzwa futhi.  Lezo nsuku zizothatha isikhathi eside 
uma kuqhathaniswa nokuvakasha kwakho kwansuku zonke. 
 
Inhloso yokuhlolelwa ukuzwa 
Izindlebe zethu ziyizitho zomzimba ezimangalisayo ngoba ziyakwazi ukuzwa imisindo eminingi 
ehlukahlukene.  Siyakwazi ukuzwa imisindo emincane njengomsindo owenziwa ngumshini 
wokugunda utshani, noma yibhasi, noma ngisho nokuconsa kwamanzi empompini.  Le yimisindo 
ihlukahlukene, futhi inamazinga omsindo ahlukahlukene kodwa yonke le misindo iphansi.  Futhi 
siyakwazi ukuzwa imisindo ephakeme, isibonelo izinyoni ezisho ngengila ephezulu noma ukukhala 
kwe-alamu yewashi. 
Imisindo yenkulumo, amagama nemisho konke lokhu kuyimisindo ehlukahlukene.  Isibonelo, u- /m/, 
u-/d/ no-/b/ kuyimisindo ephansi kodwa u-/f/, u-/s/ no-/th/ kuyimisindo ephezulu.  Ukuze sizwane, 
kudingeka sikwazi ukuzwa imisindo eminingi ehlukahlukene, njengemisindo yenkulumo njengoba 
inemisindo eminingi ehlukahlukene. 
Uma sesiqala sizwa imisindo ephansi yodwa, singasayizwa imisindo ephezulu, kusho ukuthi 
siyehluleka ukuzwa inkulumo.  Ngakho, isibonelo, uma umuntu ethi ‘head’, awube usamuzwa kahle 
ucabange ukuthi uthi ‘bed’.  Uma umuntu ethi ‘fate’, ungezwa kuphela sengathi uthi ‘ate’.  Ngakho-
ke ukulahlekelwa ukuzwa ngisho nasemisindweni embalwa kungenza ukuba ungakuqondi lokho 
okushiwo ngabangane bakho, umndeni kanye nabodokotela bakho. 
Ukulahlekelwa wukuzwa kungadalwa yizinto eziningi ezihlukahlukene.  Kwesinye isikhathi abantu 
kungenzeka bazalwe bengezwa kahle, noma kungenzeka ukungezwa kahle kudalwe ngumsindo 
ophezulu, wukwethuka ngokwedlulele kanye nemithi ethile.  I-DR-TB yisifo esibi kakhulu futhi 
udinga umuthi onamandla amakhulu ukuze uphole uphinde uphile.  Noma kunjalo, kwezinye izikhathi 
le mithi ingadala ukulahlekelwa wukuzwa, okungenza ukuba kube nzima kuwe ukuzwa nokuxhumana 
nabanye abantu. 
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Njengoba kudingeka umuthi onamandla kakhulu (i-kanamycin) ukuze uphile, kumele ukuba 
uwusebenzise.  KODWA, lolu cwaningo luzama ukuqonda ngqo i uhlobo lokulahlekelwa wukuzwa 
oludalwa yilo muthi okuzokwenza ukukwelapha kangcono lokhu kulahlekelwa wukuzwa noma 
ukukuvikela esikhathini esiizayo. 
Sidinga ukukala indlela ozwa ngayo imisindo ehlukahlukene ngesikhathi uza esibhedlela, bese kuthi 
emva kwalokho kube masonto onke ambalwa, ukuze sibone ukuthi kuhlala kunjalo noma kuya 
ngokuya kuba kubi. 
 
Izinqubo zokuhlola ukulahlekelwa wukuzwa 
Ukuhlolela ukuzwa akubuhlungu, futhi kunezingxenye ezimbalwa, ezimi kanje: 
• I-otoscopy – Okokuqala, kuzodingeka ukuba ngibheke phakathi ezindlebeni zakho ukuze 
ngibone ukuthi akukho sigonogono yini, noma ezinye izinto ezindlebeni zakho, njengoba 
lokhu kungenzeka kube nomthelela emiphumelweni yakho.  Lokhu kuzothatha cishe 
imizuzwana engama-20. 
• Ukulawulwa kwesigonogono – Uma izindlebe zakho zivalekile ngenxa yesigonogono, 
ngizosikhipha ukuze singabi nomthelela kokunye ukuhlola.  Ngizofaka amafutha endlebeni 
yakho ukuze isigonogono sakho sithambe.  Ngizobe sengisebenzisa umshini ukukhipha 
isigonogono (ukusimunca).  Ukumunca kuzothatha imizuzwana embalwa nje kuphela.  
Kungenzeka uzwe ubuhlungwana, kodwa akuvamile ukuba buhlungu. 
• I-tympanometry (uhlobo lokuhlola okukala ukusebenza kwengxenye yendlebe ephakathi 
naphakathi) – ngizobe sengibeka umshini phakathi endlebeni yakho.  Lo mshini othambile 
uzofuthela umoya endlebeni yakho.  Ngeke kube buhlungu, kodwa kuzokwenza ukuba sazi 
ukuthi ingabe zikhona yini izifo ngaphakathi ekujuleni kwendlebe yakho, uma kukhona noma 
yiluphi uketshezi.  Uma lukhona uketshezi, lizoba nomthelela ekuzweni kwakho kanye 
nasemiphumelweni yokuhlola.  Lokhu kuzothatha cishe imizuzu emi-2. 
• I-Distortion Product Otoacoustic Emissions – Sinamaseli ezinwedlana ekujuleni kwezindlebe 
zethu.  Amaseli ezinwele ahlukahlukene abalulekile ekuzweni imisindo ehlukahlukene.  
Ngakho-ke umshini i-DPOAE ukala indlela lawa maseli ezinwele ahamba nasebenza ngayo.  
Sidinga ukufaka lo mshininyana othambile endlebeni yakho ukuze wenze imisindo 
ehlukahlukene.  Kumele unganyakazi futhi uthule, lo mshni uzobe usuthatha izilinganiso 
zalawa maseli ezinwele.  Lokhu kuzothatha cishe imizuzu emi-5 kuya kweyi-10. 
• I-Pure Tone Audiometry – Sizokufaka ama-headphone.  Azokhipha imisinjwana.  Le misindo 
izoba namaphimbo ahlukahlukene.  Amanye azoba phansi kanti amanye azoba phezulu.  
Lapho uzwa umsindo, kuzomele ucindezele inkinobho.  Lokhu kuzothatha cishe imizuzu eyi-
15 kuya kwengama-20. 
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• Uma lokhu sekwenziwe, sizobe sesikwazi ukuhlanganisa imiphumela bese siqonda kahle 
ukuthi yikuphi okwazi ukukuzwa.  Uma sikuhlola ngesikhathi uza esibhedlela, bese sikuhlola 
futhi ngezikhathi ezithile, sizokwazi ukubona ukuthi ukuzwa kwakho kuyashintsha yini. 
 
Uma ukuvuma lokhu, kuzodingeka ukuba ukwenze izikhathi eziyisi-7 ezinyangeni ezintathu 
zokuqala.  Kungaba kusasa, bese kuba njalo esontweni lesibili ezinyangeni ezintathu ezilandelayo. 
Emva kwezinyanga ezintathu zalolu cwaningo, odokotela abaphathelene nemizwa yokuzwa 
(audiologists) balesi sibhedlela noma esibhedlela noma emtholampilo wesifunda sakho bazoqhubeka 
nokuqapha ukuzwa kwakho.  Uma kwenzeka ulahlekelwa wukuzwa, bazoqhubeka nokukusiza 
ngezinsizakuzwa kanye nokunye ukulawula ukuzwa kwakho.  Ngizokudlulisela kubo emva kwalolu 
cwaningo. 
 
Amasampula egazi 
Sizodinga ukukuthatha negazi.  Sizodinga ukukuthatha igazi ukuze sikwazi ukulinganisa indlela umuthi 
(i-kanamycin) osetshenziselwa ukwelapha i-DR-TB yakho ukuthi usetshenziswa kanjani emzimbeni 
wakho.  Sethemba ukuthi lokhu kuzosisisza ukuba sikwazi ukuqonda ukuthi yingani abantu 
belahlekelwa wukuzwa.  Mina noma omunye unesi noma i-phlebotomist sizokuthatha igazi ukuze senze 
ukuhlola okudingekayo.  Sizodinga ukukuthatha ama-2 ml egazi mayelana nalokho nalokho kuhlola.  
Kuzodingeka ukuba okungenani sikuhlole igazi kabili ngaleso naleso sikhathi (ngaphandle 
kokuvakasha okubili kokuqala).  Amamililitha amabili cishe alingane namaconsi amabili egazi noma 
uhhafu wethisipuni.  Ngakho-ke, kuzodingeka ukuba sikuthathe ama-4 ml egazi ngalolo nangalolo suku 
esikubona ngalo ukuze sikale i-kanamycin (okuzoba yigazi elingaphansana kwethisipuni).  Uma uqala 
ukuthathwa igazi kuzobe kungemva kwamahora ambalwa uthole umjovo wakho we-DR-TB.  Bese 
sikuthatha igazi okwesibili osukwini olulandelayo ngaphambi kokuthola umjovo wakho.  Kanti 
kwezinye izikhathi, kuzodingeka ukuba uthathwe igazi lakho ngaphambi kokuthola umjovo, futhi 
kumele kudlule amahora ambalwa emva kokuthola umjovo.  Ngakho-ke mayelana nokuvakasha 
ngakunye (ngaphandle kokuvakasha kwesibili lapho uhlolelwa igazi), kuzodingeka ukuba ube 
semtholampilo cishe amahora amane nesigamu.  Kuzodingeka ukuba senze lokhu izikhathi eziyi-8 
sezihlangene zonke ezinyangeni ezintathu (kusasa kuzobe kungokokuqala).  Ngakho-ke sekukonke, 
ezinyangeni ezintathu, sizothatha inani elingama-28 ml legazi selilonke, elicishe libe ngamathisipuni 
amahlanu nesigamu.Ngakho-ke sizobe sithatha igazi senze nokuhlolwa kokuzwa.  Futhi-ke, ukuze 
siqonde ukuthi umuthi unamthelela muni ezinsweni zakho, sizothanda nokuhlola ukusebenza kwezinso. 
 
Ekuvakasheni okuthathu kokuyisishiyagalolunye, sizodinga ukukuthatha elinye igazi elingama-3 ml, 
ukuze sikale ukusebenza kwezinso zakho ukuze senze ushintsho olulungile lomthamo.  Ngakho-ke 
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ngaleso sikhathi sokuvakasha lapho kuzodingeka ukuba sihlole lokhu, sizodinga amanye ama-3ml 
angeziwe egazi, okungaba ngaphezudlwana nje kwethisipuni.  Kumahlandla amathathu sizokuthatha 
igazi elingama-9 ml selilonke, elingaba ngaphansana nje kwamathisipuni amabili ukwengezela 
ekuhlolweni kwegazi osekuchaziwe lapha ngenhla.  Sizokuthatha leli gazi ngesikhathi esisodwa 
nesokuhlolelwa igazi mayelana ne-kanamycin – ukuze ungahlatshwa kaningi ngenalidi. 
Ukuthathwa kwegazi kuyingxenye yokunakekelwa kwakho okuvamile ngokwezempilo kulesi 
sibhedlela.  Kuzodingeka ukuba sikuthathe igazi kodwa lokhu singakuhlanganisi nezinqubo ezivamile 
zasesibhedlela.  Lokhu kungakuzizwa ubuhlungwana.  Sizokuthatha igazi ngendlela efanayo naleyo 
esetshenziswa uma uthathwa igazi ngenhloso yokuhlolelwa kwakho igazi okuvamile.  Ukuthathwa 
kwegazi kungakwenza uquleke, uvuvuke umthambo wegazi, uzwe ubuhlungu, uhuzuke noma wophe 
lapho kungene khona inalidi.  Kukhona namathuba amancane okusuleleka ngesifo.  Ongoti 
babahlengikazi odokotela noma ama-phlebotomist bazokuthatha igazi endaweni ehlanzekile ukuze 
baqinisekise ukuthi kuphephile. 
 
Igazi lakho lizogcinwa ngokuphephile esibhedlela sase-Helen Joseph kuze kufike leso sikhathi 
selithunyelwa elabhorethri ukuze liyohlolwa.  Lizothunyelwa ngaphandle kokuchitha isikhathi.  
Ngeke ligcinwe isikhathi esingaphezu kwesonto.  Igazi lakho liyothunyelwa elabhorethri yase Sefako 
Makgatho Health Sciences University.  Bese kuthi lelo gazi esilithathela ukukala ukusebenza 
kwezinso zakho lona lizothunyelwa kwenye ilabhorethri, ebizwa i-CLS.  Lonke ulwazi oluqondene 
nawe ngqo mayelana nalokhu kuhlola namayelana nezempilo yakho jikelele kuzogcinwa kuyimfihlo 
efayilini ezohlala ekhabetheni ngesikhathi kuqhubeka lolu cwaningo nangesikhathi seluphothuliwe.  
Ulwazi oluqondene nawe ngqo ngeke kuxoxwe ngalo nomunye umuntu ongabandakanyekile kulolu 
cwaningo lophenyo.  Uma lokhu kudingeka, sizocela imvume yakho ngaphambi kokuba kwenziwe.  
Lokhu sikudingela ukuqinisekisa ukuthi lonke ulwazi lurekhodwe ngendlela elungile, ngenhloso 
yokuqinisekisa ukuthi sihlaziya. 
 
imiphumela ukuze sibone ukuthi lokhu kuqashwa komuthi wokwelapha (okungukushintsha imithamo 
yakho ye-kanamycin) kusebenzile yini. 
 
Ukuhlolelwa ukuzwa kanye nokuhlolwa kwegazi kuzokwenziwa ngosuku lwesibili (kusasa), 
nangosuku lwe-15, 28, 40, 54, 68 kanye nolwama-84.  Ukuhlolwa kwegazi kuzokwenziwa kusasa 
(ngosuku lwesi-2), ngosuku olulandelayo (usuku lwe-3), bese kwenziwa ngosuku olulodwa 
lokuhlolelwa kwakho ukuzwa – osukwini lwe-15, 28, 40, 54, 68 kanye nangosuku lwama-84. 
 
Lokho nalokho kuvakasha ngenhloso yokuzohlolelwa ukuzwa kanye nokuzohlolwa igazi (hhayi lezo 
zinsuku eziphakathi oza ngazo uma uzojovwa), kuzothatha cishe amahora ama-5 kuya kwayi-6.  Lokhu 
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kudalwa wukuthi sidinga ukuba silinde amahora amane nesigamu phakathi kokuhlolwa igazi 
okwenziwa kabili.  Ngakho kungabangcono ukuba usheshe ufike ekuseni ukuze ukwazi ukubuyela 
emuva ntambama. 
 
KUNGENZEKA YINI UKUTHI LEZI ZINQUBO ZINGIZWISE UBUHLUNGWANA NOMA 
ZINGIPHAZAMISE? 
 
Ukuthathwa kwegazi kungakuzwisa ubuhlungwana.  Igazi sizolithatha ngendlela efanayo naleyo 
esetshenziswayo ngesikhathi uhlolwa igazi.  Ukuthathwa kwegazi kungakwenza uquleke, uvuvuke 
umthambo wegazi, uzwe ubuhlungu, uhuzuke noma wophe kuleyo ndawo elikhishwe kuyo.  Kukhona 
namathuba amancane okungenwa yisifo.  Igazii lakho lizothathwa ngamanesi (noma ama-
phlebotomists) angongcweti ukuze uvikeleke futhi konke kuzobe kuhlanzekile ngaso sonke isikhathi.  
Uzothathwa isamba segazi elingama-4 ml (elingaphansana kwethisipuni) ngalokho nalokho 
kuvakasha kocwaningo (ngaphandle kosuku lwesi-2 nolwesi-3).  Lesi yisamba esingama-28 ml egazi, 
okuyigazi elingacishe libe ngamathisipuni amahlanu nesigamu egazi.  Uzobe usuthathwa elinye igazi 
elengeziwe elingama-3 ml ngosuku lwama-40, 68 nolwama-84 – isamba esengeziwe esingama-9 ml 
okuyigazi elingaphansana kwamathisipuni amabili.  Ngakho-ke, selilonke igazi ozothathwa lona 
ezinyangeni ezintathu lingama-37 ml – okuyigazi elilingana cishe namathisipuni ayisi-7 nesigamu. 
Lokhu kuhlolelwa ukuzwa okuchaziwe lapha ngenhla ngeke kukuzwise ubuhlungu; noma kunjalo, 
ukukhishwa kwesigonogono kungaba buhlungu.  Angeke kube nesidingo sokukhipha wonke umuntu 
isigonogono, futhi akuvamile ukuba buhlungu.  Ukukhishwa isigonogono kuzothatha imizuzwana 
embalwa nje kuphela.  Kanti ukuhlola sekukonke kuzothatha isikhathi sakho esicishe sibe yimizuzu 
engama-30 kuya kwengama-40 ngalokho nalokho kuhlolwa.  Uzokwazi ngaso sonke isikhathi 
ukuxoxisana nonesi mayelana nemiphumela yakho nokuthi ubuze imibuzo ngaphambi nangemuva 
kwalokhu kuhlola.  Uma uneminye imibuzo, ungathintana nami, i-audiologist. 
 
IZINZUZO 
• Inzuzo ongayithola ngokubamba kwakho iqhaza kulolu cwaningo ukuthi uzokwazi ukuqonda 
isimo sokuzwa kwakho ngokugcwele nokuhlobana kwakho nokusebenza kwe-
kanamycin/kwe-capreomycin emzimbeni wakho 
• Kungenzeka ungazuzi lutho kulolu cwaningo. 
• Ukubamba kwakho iqhaza kulolu cwaningo kuzosiza ekuthuthukiseni ulwazi kwezokwelapha 
olungasiza ezinye iziguli ezine-DR-TB njengawe futhi ezisengcupheni yokulahlekelwa 
wukuzwa. 
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ENYE INDLELA YOKWELASHWA 
• Okwamanje, ayikho enye indlela yokwelapha ngenhloso yokwehlisa amathuba okulahlekelwa 
wukuzwa noma yokugwema ukulahlekelwa wukuzwa okudalwa ngumuthi we-DR-TB.  uma 
kwenzeka ulahlekelwa wukuzwa; uzodluliselwa emtholampilo wangakini ukuze ukusize 
uthole izinsizakuzwa. 
• Ukuqapha i-kanamycin egazini lakho akuyona inqubo ejwayelekile, ayikho enye indlela 
yokwenza lokhu ngaphandle kokuhlola igazi okwamanje. 
•  I-Audiology Department kulesi sibhedlela izokwazi ukukusiza uma ukule ndawo ephakela lesi 
sibhedlela.  Lokhu kuyingxenye yezinqubo zikahulumeni ezivamile mayelana nokuphathwa 
kokulahlekelwa wukuzwa.  Kwesinye isikhathi izinsizakuzwa ziyaye zingasebenzi. 
• Uma unquma ukungalibambi iqhaza kulolu cwaningo, uzoqhubeka nokuthola ukunakekelwa 
okuhle okutholakayo njengamanje okuqondene ne-DR-TB yakho kulo mtholampilo. 
 
IZINZUZO NOBUNGOZI BENYE INDLELA YOKWELASHWA ESEZINGENI 
• Njengoba njengamanje ungekho umuthi ongasiza ekuvimbeleni noma ekwehliseni amathuba 
okulahlekelwa wukuzwa, awukho omunye umuthi.  Uma umuthi we-DR-TB udala 
ukulahlekelwa wukuzwa, kuyaye kungalapheki futhi akukwazi ukulungiseka.  Kodwa 
ungayithola insizakuzwa ezokwenyusa yonke imisindo ukuze usizakale.  Noma kunjalo, 
kwesinye isikhathi izinsizakuzwa ziyaye zingasizi ngalutho, ngoba kuyenzeka ukuthi 
kwesinye isikhathi ukulahlekelwa wukuzwa kuyaye kube kubi kakhulu, okwenza ukuba 
izinsizakuzwa zingakwazi ukukusiza.  Kwezinye izikhathi izinsizakuzwa angeke zikwazi 
ukukusiza mayelana nokulahlekelwa wukuzwa, njengoba kwesinye isikhathi ukulahlekelwa 
wukuzwa kuyaye kube kubi kakhulu ngendlela yokuthi izinsizakuzwa zingabe zisakwazi 
ukukusiza.  Ngeke sikunikeze izinsizakuzwa – iminyango yezibhedlela ye-audiology 
ingakwazi ukukusiza ngalokho uma ukule ndawo ephakela lezi zibhedlela, noma 
singakudlulisela emtholampilo noma esibhedlela esilungile esikuleyo ndawo ephakela leso 
sibhedlela. 
• Izinzuzo zezinsizakuzwa kungenzeka zibe nemikhawulo, kodwa-ke kungenzeka zikusize uma 
kwenzeka ulahlekelwa wukuzwa kwakho ngenxa yokusebenzisa umuthi we-DR-TB.  
Izinsizakuzwa azinabo ubungozi. 
 
NGABE ZIKHONA YINI IZEXWAYISO NOMA IMIBANDELA MAYELANA 
NOKUBAMBA KWAMI IQHAZA KULOLU CWANINGO 
• Uma unesifo sikashukela i-Diabetes Mellitus awuvunyelwe ukubamba iqhaza kulolu 
cwaningo.  I-Diabetes Mellitus kuyenzeka kwesinye isikhathi sibe nomthelela ekuzweni, kanti 
sifuna ukukala ukuzwa kwakho ngaphandle kokuthikamezeka. 
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• Uma uneminyaka yobudala engaphansi kweyi-18, noma uneminyaka yobudala engaphezulu 
kwengama-55, ngeke ukwazi ukubamba iqhaza kulolu cwaningo.  Kulolu cwaningo sikala 
kuphela abantu abaphakathi kweminyaka yobudala eyi-18 nengama-55. 
• Uma udokotela wakho eshintsha imithi yakho, ngeke usakwazi ukuqhubeka nokubamba 
iqhaza kulolu cwaningo. 
• Uma kade ungakwazi ukuphila ngaphandle kwanoma yisiphi isidakamizwa futhi unomlando 
wokusebenzisa budedengu izidakamizwa notshwala, ngeke ukwazi ukubamba iqhaza kulolu 
cwaningo uma lokhu kungaba nomthelela ekulandeleni kwakho imiyalelo yezinqubo 
zokuhlola.  Isinqumo mayelana nalokhu sizothathwa abacwaningi ababandakanyekayo. 
 
AMALUNGELO NJENGOMBAMBIQHAZA KULOLU CWANINGO 
Ukuzithandela 
Ukubamba kwakho iqhaza kulolu cwaningo kungukuzithandela kwakho futhi unokuzikhethela ukuthi 
uyafuna noma awufuni ukubamba iqhaza kulolu cwaningo.  Futhi uyakwazi ukuyeka ukubamba 
iqhaza kulolu cwaningo noma nini ngaphandle kokunikeza isizathu.  Uma unquma ukungalibambi 
iqhaza kulolu cwaningo, noma unquma ukuyeka ukubamba iqhaza ngesikhathi kusaqhubeka lolu 
cwaningo, uzoqhubeka nokuthola unakekelo lwezempilo kulesi sibhedlela, futhi ngeke lokhu 
kuthinteke. 
Okusha okutholwayo 
Ngizokunikeza noma yiluphi ulwazi olusha enginalo ngesikhathi kusaqhubeka lolu cwaningo, 
okungenzeka lukwenze ushintshe umqondo wakho wokufisa ukuqhubeka ukulolu cwaningo. 
Ukuhoxa 
Ukuhoxa kwakho noma ukuyeka ukubamba iqhaza kulolu cwaningo ngeke kuthinte ukunakekelwa 
kwakho ngokwezempilo.  Nginelungelo lokukuhoxisa kulolu cwaningo uma lokho kuzosiza wena.  
Uma udokotela wakho eshintsha imithi yakho ye-DR-TB futhi ungasasebenzisi i-kanamycin, ngeke 
usakwazi ukuqhubeka nokubamba iqhaza kulolu cwaningo.  Uma unganikezanga ulwazi olulungile 
nolwethembekile mayelana nomlando wakho wezempilo, noma ungalandelanga imithetho yalolu 
cwaningo, ngizokukhipha kulolu cwaningo noma nini. 
 
UKUNAKEKELWA NGAPHANSI KWEZIMO EZIPHUTHUMAYO KANYE 
NOKUNGENISWA ESIBHEDLELA 
Uma udinga usizo oluphuthumayo noma nini ngesikhathi kuqhubeka lolu cwaningo, uyacelwa ukuba 
ushayele uDkt Mohammed Rassool ucingo kule nombolo: 011 276-8813 noma kule nombolo: 027 
83 415 8967 noma ushayele uDkt Rebecca Berhanu kule nombolo: 011276 8968 noma kule nombolo: 
072 717 9159. 
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AMALUNGISELELO EZEZIMALI 
• Abaxhasi balolu cwaningo bazokhokhela konke ukuhlola okuzokwenziwa kulolu cwaningo. 
• Wena nabe-medical aid yakho (uma unayo) angeke kudingeke ukuba nikhokhele noma 
yimiphi imithi yalolu cwaningo noma izinqubo zalolu cwaningo, konke lokhu kuxhaswe 
yizinhlangano zalolu cwaningo. 
• Ngesikhathi uvakashela esibhedlela ngokwalolu cwaningo njalo esontweni lesibili (ukuze 
uhlolelwe ukuzwa kanye nokuhlolwa igazi) uzonikezwa ama-R150 okugibela.  Ngeke 
ukhokhelwe ngokubamba iqhaza, kodwa uzokhokhelwa kuphela imali yokugibela neyokudla 
okulula.  Uma uza nsuku zonke ukuzothola umjovo wakho kanye noshintsho lomthamo 
okungenzeka lwenziwe, uzonikezwa imali eyanele yokugibela (kube kubhekwe indawo ohlala 
kuyo).  Lokhu kuzokwenziwa kuphela ezinyangeni ezintathu zokuqala.  Emva kwalezi 
zinyanga ezintathu, uzothola umjovo wakho emtholampilo oseduze nawe, kanti ayikho imali 
yokugibela ozonikezwa yona. 
 
IMVUME YENKAMBISO ELUNGILE 
• Iphrothokholi yalolu cwaningo lwezokwelapha isinikeziwe ku-University of the 
Witwatersrand, Human Research Ethics Committee (HREC) kantileli komidi isinikezele 
ngemvume ebhalwe phansi. 
• Lolu cwaningo lulandela imihlahlandlela ye-Declaration of Helsinki (egcine ukubuyekezwa: 
ngo-Okthoba 2013), ebhekele izincomo mayelana nodokotela abenza ucwaningo 
lwezokwelapha olubandakanya ababambiqhaza okungabantu.  Uma ufisa ukuthola ikhopho 
yale migomo, ngicela ungazise ukuze ngikutholele lona. 
• Lolu cwaningo lukhokhelwe yinhlangano yocwaningo (i-South African Medical Research 
Council).  Akukho nzuzo engiyibhekile yemali noma mina angeke ngizuze ngalutho kule 
nhlangano futhi ayikho ingcindezi engiyithola kule nhlangano noma angichemile nayo. 
 
UMSHWALENSE 
Bonke odokotela abangabacwaningi kulolu cwaningo banomshuwalense. 
Umcwaningi omkhulu nodokotela banomshuwalense we-MPS ukuba benze izinqubo uma nje: 
• Behlonipha izinqubo zephrothokholi yocwaningo. 
• Behambisana nemithetho yesigungu esilawula imithi neye-University of the Witwatersrand 
Research Ethic Committee. 
• Bephatha imithi yocwaningo ngokwephrothokholi nokugguqulwa kwayo kanye nemibhalo 
ehlobene. 
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Lokhu kuvikela akuhlosile futhi akuthathi indawo yomshuwalense yokungasebenzi komuntu 
ngendlela efanele.  Sicela uqaphele ukuthi uma une-policy yomshuwalense wempilo kufanele 
utthole noma inkampani yomshuwalense idinga ukwaziswa mayelana nokubamba kwakho iqhaza 
ocwaningweni.  Ngokolunye ulwazi, lokhu akufanele kuphazamise noma iyiphi enye i-policy 
yomshuwalense wempilo onayo.  Kodwa kubalulekile ukuthi ubhekisise ngoba kuyenzeka 
izinkampani zingafani. 
 
UMTHOMBO WOKUTHOLA OLUNYE ULWAZI 
Ngesikhathi kusaqhubeka lolu cwaningo, uzonakekelwa ngabasebenzi baseHelen Joseph Hospital.  
Noma nini uma ufisa ukubuza eminye imibuzo ehlobene nalolu cwaningo, ngicela ungithinte noma 
uthinte unesi wocwaningo/umdidiyeli wocwaningo osemsebenzini ngalesi sikhathi esibhedlela. 
Amalungu ocwaningo ongaxhumana nawo: 
✓ UCara Hollander – 082 815 8878 (oyi-Audiologist) 
✓ UDkt.  Karin Joubert – 011 717 4561 (oyi-Audiologist) 
✓ UDkt.  Natalie Schellack – 012 521 3286 (onguSokhemisi) 
✓ UDkt.  Rebbeca Berhanu – 011 276 8968 (ongudokotela) 
✓ UDkt.  Mohammed Rassool –011 276-8813 (ongudokotela Nomphenyi 
Omkhulu) 
 
• Uma ufuna noma yiluphi ulwazi oluthe xaxa mayelana namalungelo akho 
njengombambiqahaza ocwaningweni, noma uma ufuna ukudlulisa ukukhalaza mayelana 
nalolu cwaningo lophenyo, ungaxhumana noSlz Cleaton-Jones, uSihlalo we-University of the 
Witwatersrand, Human Research Ethics Committee (HREC), okuyikomidi elizimele elisiza 
ekuvikelweni kwamalungelo ababambiqhaza ocwaningweni kule nombolo: (011) 717 2301. 
• Mayelana nolwazi olumayelana nocwaningo, ungashayela umdidiyeli Wocwaningo – uCara 
Hollander wase-University of the Witwatersrand kule nombolo: 082 815 8878. 
 
UBUMFIHLO 
• Lonke ulwazi esiluqoqa ngesikhathi kuqhubeka lolu cwaningo, olubandakanya amarekhodi 
asesibhedlela, ulwazi oluqondene nomuntu ngqo kanye nolwazi olumayelana nocwaningo 
luzogcinwa luyimfihlo.  Ulwazi lwakho luzobonwa ngamalungu eqembu locwaningo kuphela, 
kanye nosokotela bakho kanye namanesi.  Noma yiluphi ulwazi oluzobe lubhalwe kumajenali 
esayensi noma nanoma yikuphi okushicilelwayo ngeke kube negama lakho kukho. 
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• Sizofaka amakhodi ahlukahlukene olwazini lwakho locwaningo.  Ngakho-ke uma imiphumela 
yakho ibuyekezwa, izobe inekhodi kuphela.  Igama lakho, inombolo yakho kamazisi noma 
nanoma yimaphi amanye amanothi okungenzeka akuhlonze ngeke kufakwe kulawo 
mabhukwana, ukuze kuqinisekiswe ukuthi konke kuyimfihlo. 
• Lolu lwazi luzobuyekezwa ngabaphathiswa abagunyaziwe be-University of the Witwatersrand 
kanye nabase- Sefako Makgatho Health Sciences University kanye namalungu avela 
kubaxhasi (i-Medical Research Council).  Abacwaningimabhuku be-Wits Health Consortium 
bavunyelwe ukubheka eminye imiphumela ngesikhathi behlola ngenhloso yokuqinisekisa 
ukuthi konke kwenziwe ngokulandela amazinga amahle.  Nakuba kunjalo, akusiyena wonke 
umuntu ozofinyelela egameni lakho – yonke imiphumela yakho izoba nenombolo, 
okuzokwenza ukuba bangazi ukuthi nguwe. 
• Kungenzeka futhi ukuthi ulwazi luhlolwe ngabe-National Health Research Ethics Committee 
(NHREC), yi-University of the Witwatersrand, Human Research Ethics Committee (HREC), 
yi-South African Medicines Control Council (MCC) kanye/noma yi-United States Food and 
Medicine Administration (FDA) kanye nodokotela wakho.  Ngakho-ke lapha uyangigunyaza 
ukuthi ngikhulule amarekhodi akho ezokwelapha ngiwanike i-Medical Research Council, 
abasebenzi bayo noma ama-ejenti ayo, abasemagunyeni kwezokulawulwa kwezempilo 
bakuleli lizwe nabakwamanye amazwe, i-South African Medicines Control Council ) i-MCC), 
i-National Health Research Ethics Committee (NHREC) kanye ne-University of the 
Witwatersrand, Human Research Ethics Committee (HREC). 
• Lawa marekhodi azosetshenziswa yibo kuphela ekwenzeni imisebenzi yabo ehlobene nalolu 
cwaningo lwezokwelapha. 
• Noma yiluphi ulwazi oludaluliwe mayelana nemiphumela yokuhlolwa kwakho noma isimo 
sakho sempilo ngenxa yokubamba kwakho iqhaza kulolu cwaningo luzohlala luyimfihlo.  
Uzotshelwa mayelana nanoma yikuphi okutholakele okubalulekile mayelana nezempilo yakho 
noma okubalulekile mayelana nokuqhubeka kwakho ukubamba iqhaza kulolu cwaningo, 
kodwa lolu lwazi ngeke lunikezwe noma yimuphi omunye umuntu phezu kwalabo abashiwo 
lapha ngenhla ngaphandle kwemvume yakho ebhalwe phansi.  Esimweni lapho lo mthetho 
ungeke usebenze khona yikulezo zimo ezimayelana nezifo ezithathelanayo lapho umthetho 
okhona udinga ukuba kwaziswe aboMnyango Wezempilo.  Uma kuba nesimo esinjalo, 
ngiyokwazisa ngaso ngiphinde ngikwazise futhi ukuthi lolo lwazi ngizoludlulisela kwi-ejenti 
kahulumeni egunyaziwe. 
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UKUKHETHA UKUBA KWAZISWE UDOKOTELA WAKHO/UNGOTIWAKHO 
Ngicela ungitshele lapha ngezansi uma ufuna ukuba ngazise udokotela wakho noma isipeshalisti 
sakho mayelana nokuthi uzobamba iqhaza kulolu cwaningo: 
• YEBO, ngifuna wena utshele udokotela wami noma isipeshalisti sami ngokubamba iqhaza 
kulolu cwaningo. 
• CHA, angifuni ukuthi wena utshele udokotela wami noma isipeshalisti sami ngokubamba 
iqhaza kulolu cwaningo. 
• Anginaye udokotela/isipeshalisti okungesami 
 
IMIBUZO YOMBAMBIQHAZA 
Ingabe unayo imibuzo njengombambiqhaza? 
YEBO / CHA 
Uma impendulo yakho kunguYEBO – Sicela uchaze. 
 
IMVUME ETHATHWA EMVA KOKUNIKEZWA ULWAZI MAYELANA 
NOKUBAMBA IQHAZA KULOLU CWANINGO 
Ngiyaqinisekisa lapha ukuthi unesi wocwaningo, ........................................................................  
(IGAMA NGOKUGCWELE) unginikezile ulwazi mayelana nesimo, ukuziphatha, izinsizakalo 
nobungozi obumayelana nalolu cwaningo lwezokwelapha olusihloko esithi “Ucwaningo lokuhlola 
ukuthi imithi i-kanamycin ne-capreomycin isebenza kanjani emzimbeni nemithelela 
yokusetshenziswa kwayo ezigulini ezine-DR-TB kanye nokuhlobana phakathi kwamazinga okuzwa” 
(INOMBOLO YEPHROTHOKHOLI 1.5). 
• Futhi ngilutholile lolu lwazi olubhalwe lapha ngenhla, ngalufunda ngaluqonda (Ibhukwana 
Lolwazi Lombambiqhaza kanye Nemvume Enikezwa Emva Kokunikezelwa Kolwazi) 
mayelana nalolu cwaningo lwezokwelapha. 
• Ngiyazi ukuthi imiphumela yalolu cwaningo, okubandakanya imininingwane eqondene 
nomuntu ngqo emayelana nobulili bami, iminyaka yobudala, usuku lwami lokuzalwa, 
iziqalomagama kanye nokuhlonzwa kwesifo esithile  kuzofakwa embikweni walolu cwaningo 
ngaphandle kokwaziswa ukuthi ngekabani (igama lami ngeke lidalulwe). 
• Ngiyazi ukuthi kumele ngize emtholampilo wase Helen Joseph njalo esontweni lesibili 
enyangeni ukuze ngenze ukuhlolwa kokuzwa nokwegazi  izinyanga ezintathu. 
• Ngiyazi ukuthi ngingakhetha ukuya emtholampilo wendawo engihlala kuyo noma 
emtholampilo waseHelen Joseph nsukuzonke ukuze ngijove, futhi ngiyavuma ukwenza lokhu 
nsukuzonke. 
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• Ngokubhekelela izidingo zalolu cwaningo, ngiyavuma ukuthi imininingwane eqoqwe 
ngesikhathi kuqhubeka lolu cwaningo ifakwe ohlelweni lwekhompyutha oluhlelwe 
ngabacwaningi ababandakanyeka kulolu cwaningo, abaxhasi noma egameni labo. 
• Ngiyavuma ukubamba iqhaza emasethini ayisi-7 okuhlolelwa ukuzwa ezinyangeni ezintathu 
zokuqala. 
• Ngiyavuma ukubamba iqhaza emasethini  ayisishiyagalombili okuhlolwa igazi kulezi zinyanga 
ezintathu. 
• Ngiyavuma ukunikezela ngegazi elingama-2ml amahlandla amabili ezinyangeni ezintathu 
zokuqala.  
• Ngiyavuma ukunikezela ngegazi elingama-4 ml amahlandla ayisithupha ngesikhathi kuqhubeka 
lolu cwaningo.  Kanye nelinye elingama-9 ml ukuze kukalwe ukusebenza kwezinso zami  
ezinyangeni ezintathu zokuqala. 
• Ngiyazi ukuthi ngiyakwazi ukuhoxa noma nini. 
• Ngingakwazi, kunoma yisiphi isigaba, ngaphandle kokuphathwa ngendlela engafanele, 
ukuhoxisa imvume yami kanye nokubamba kwami iqhaza ocwaningweni.  
• Ngibe nesikhathi esanele sokubuza imibuzo futhi ngiyazisholo mina (ngokuzithandela) ukuthi 
ngikulungele ukubamba iqhaza kulolu cwaningo. 
• Ngiyazi ukuthi uma kwenzeka udokotela wami eshintsha imithi yami enginika eminye 
ngaphandle kwe-kanamycin/kwe-capreomycin, ngizohoxiswa kulolu cwaningo. 
 
UMBAMBIQHAZA 
 
Igama elibhaliwe Isiginisha/Uphawu noma Umaka wesithupha Usuku Nesikhathi 
 
 
 UMCWANINGI OMNCANE/UMXHUMANISI 
 
Mina, ............................................................................................., ngiyaqinisekisa lapha ukuthi lo 
mbambiqhaza ongenhla unikeziwe ulwazi olugcwele mayelana nesimo, ukuziphatha nobungozi 
mayelana nalolu cwaningo olungenhla. 
 
 
Igama elibhaliwe Isignisha Usuku Nesikhathi 
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UMHUMUSHI / OMUNYE UMUNTU OCHAZA IMVUME EMVA 
KOKUNIKEZELWA KOLWAZI (UMCWANINGI OMNCANE) 
 
 
Igama elibhaliwe Isignisha Usuku Nesikhathi 
 
UFAKAZI (uma ekhona) 
 
 
Igama elibhaliwe Isignisha Usuku Nesikhathi 
 
FEASIBILITY STUDY INVESTIGATING THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND 
CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE RELATIONSHIP BETWEEN HEARING LEVELS 
504 
NOMORO YA VERSION YA TUMELLO E BONTSHANG KUTLWISISO:1.5 
(Sepetlele sa Helen Joseph) 
SEHLOOHO SA PHUPUTSO: Phuputso e fuputsang kgonahalo ya pharmacokinetics le 
pharmacodynamics ya kanamycin le capreomycin  bakuding ba nang le DR-TB le kamano pakeng 
ditekanyo tsa ho utlwa ditsebeng 
 
INSTITJHUSHENE: Yunivesithi ya Witwatersrand tshebedisanong le Sefako Makgatho Health 
Sciences University 
 
(LI)NOMORO TSA MOHALA TSA LIHORA TSA MOTSHEHARE LE KA MORA 
TSHEBETSO: 082 815 8878 (Cara Hollander) le/kapa 011 276 8968 (Ngaka Rebecca Berhanu - 
Ngaka) le/kapa +27 11 276-8813 (Ngaka Mohammed Rassool – Mofuputsi ya ka Sehloohong – 
Ngaka mane Helen Joseph – Wits Health Consortium) 
 
MOHOKAHANYI EA PHUPUTSO: Matshediso Mkhwanazi: speed dial: 076 711 2874/ 
Matshidiso.Mkhwanazi@righttocare.org 
 
Motho eo e ka bang Monkakarolo: Foromo ena ya tumello e ka ba le mantswe ao o sa a 
utlwisiseng.  Ka kopo kopa ngaka ya phuputso/mooki kapa moifo wa phuputso ho o  hlalosetsa 
mantswe afe kapa afe ao o sa a utlwisiseng ka ho hlakileng.  O ka boloka kopi e sa saenwang 
yatumello ena ya foromo ena ho nahana ka yona kapa ho buisana ka yona le lelapa kapa metswalle 
pele o etsa qeto ya hao. 
SELELEKELA 
Dumela, lebitso la ka ke Cara Hollander mme ke ngaka ya tlhahlobo ya kutlo ditsebeng ho tswa 
Yunivesithing ya Witwatersrand.  Ke lakatsa ho o mema hore o nahane ka ho kena phuputsong, e 
bitswang “Phuputso e fuputsang kgonahalo ya pharmacokinetics le pharmacodynamics ya kanamycin 
le capreomycin bakuding ba nang le DR-TB le kamano pakeng tsa ditekanyo tsa ho utlwa ditsebeng”.  
Re entse diteko tse itseng ho netefatsa hore o a tshwaneleha bakeng sa ho nka karolo phuputsong ena. 
1. Pele o dumela ho nka karolo phuputsong ena, ho bohlokwa hore o bale le ho utlwisisa 
ditlhaloso tse latelang mabapi le phuputso, mekgwatshebetso ya phuputso, melemo, dikotsi, 
dikarolo tse bakang makukuno, le ditemoso hammoho le tokelo ya hao ya ho ikgula phuputsong 
ka nako efe kapa efe. 
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2. Bukana ena ya tlhahisoleseding e o thusa ho etsa qeto haeba o lakatsa ho nka karolo.  Ho 
hlokeha hore o utlwisise ntho e nngwe le e nngwe mabapi le phuputso pele o dumela ho nka 
karolo phuputsong ena. 
3. Haeba o na le dipotso dife kapa dife, ka kopo mpotse. 
4. Ha o a tshwanela ho dumela ho nka karolo ntle le haeba o o thabela ho dikarolo tsohle tse 
amehang. 
5. O ke ke wa nka karolo phuputsong e nngwe nakong eo o nkang karolo phuputsong ena (ntle le 
haeba ke dumella sena pele). 
6. Ka kopo bua le nna o sa pate letho mabapi le nalane ya hao ya bophelo bo botle, hobane ho 
seng jwalo o ka ipeha kotsing haeba o nka karolo phuputsong ena. 
7. Haeba o etsa qeto ya ho nka karolo phuputsong ena, o tla kotjwa hore o saene foromo ena ho 
netefatsa hore o utlwisisa phuputso.  O tla fuwa kopi ya yona ho e boloka. 
8. Haeba o na le ngaka ya hao kantle ho sepetlele sena, ka kopo buisana le yena kapa o mmolelle 
hore ho na le kgonahalo ya hore o nke karolo phuputsong ena.  Haeba o lakatsa, nka bolella 
ngaka ya hao mabapi le sena. 
 
SEPHEO SA PHUPUTSO 
O sepetleng/tliliniking ena hobane o na le Lefuba le Lwantshang Moriana (DR-TB).  Ke lakatsa hore 
o nahane ka ho nka karolo phuputso ho lekanya ditekanyo tsa kutlo ya hao nakong yohle ya karolo ya 
hao ya DR-TB.  O tla amohela moriana (diente) ho alafa lefuba la hao le lwantshang moriana o 
bitswang kanamycin hammoho le meriana e meng, e le hore o ka ba betere lefung la hao la TB, e leng 
taba ya bohlokwa haholo.  Moriana oo o tlang ho o fumana o matla haholo, mme o na le dikotsi tse 
mmalwa mme e nngwe ya tsona ke ho lahlehelwa ke ho utlwa ditsebeng.  Le ha ho le jwalo, o 
tshwanetse ho sebedisa moriana ona e le hore o ikutlwe o le betere hape.  Batho ba bangata ba 
sebedisang moriana ona ba tla lahlehelwa ke ho utlwa ditsebeng; empa, le hoja sena se etsahala 
kgafetsa, ha se etsahele kamehla.  Ho ka ba thata haholo ho bua le lelapa le metswalle ha o 
lahlehetswe ke ho utlwa ditsebeng mme hape ho ka ba thata ho sebetsa.  Ka lebaka lena, nakong ya 
phuputso ena, re lakatsa ho lekanya ho utlwa ditsebeng ka makgetlo a 7 dikgweding tsa pele tse tharo, 
e le hore re ka utlwisisa hantle hore na ho etsahalang ka ho utlwa ha hao ditsebeng.  Mme re tla 
lakatsa ho etsa diteko tsa madi ka makgetlo a 8 dikgweding tsa pele tse 3, e le hore re ka sheba kamoo 
moriana wa hao bakeng sa DR-TB ya hao o sebetsang kateng mmeleng wa hao.  Re ke ke ra fetola 
moriana wa hao wa DR-TB ho ya ka diteko tsa madi, empa sena re tla re dumella ho utlwisisa kamoo 
moriana o sebetsang ka ho fapaneng kateng bathong ba fapaneng, ka lebaka lena re ka leka ka tshepo 
le ho thibela tahlehelo ya kutlo ditsebeng nakong e tlang. Thuso ya hao e tla re thusa ho alafa bakuli 
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ba bang nakong e tlang ba nang le lefu lena mme hape ho tla re dumella ho beha leihlo ho utlwa ha 
hao ditsebeng nako ng yohle ya phuputso, le ho sheba kamano pakeng tsa kamoo moriana o 
sebediswang kateng ke mmele wa hao le kamoo o utlwang kateng ditsebeng. 
 
NAKO YA PHUPUTSO LE PALO YA BANKAKAROLO 
Phuputso e tla etsetswa sepetleng sena hammoho le Sepetleleng sa South Rand.  Batho ba ka bang 80 
ba tla nka karolo phuputsong ena.  Bankakarolo ba tla ba pakeng tsa dilemo tse 18 le 55 ka boholo.  
Ho tla hlokeha hore o sebedise kanamycin ya hao ka dikgwedi tse fetang tseo o tla nka karolo ka tsona 
phuputsong ena.  Re tla etsa diteko ka dikgwedi tse tharo bakeng sa phuputso ena, sena se tla hlaloswa 
mona ka tlase.  Diteko tsena ke diteko tsa madi le diteko tsa ho utlwa ditsebeng.  Dikgweding tsa pele 
tse 3, o tla kotjwa hore o nketele ka makgetlo a 9 bakeng sa diteko nakong ya phuputso.  Re tla hloka 
hore o kgutlele tliliniking bakeng sa diteko tsena tsohle.  Kajeno e tla balwa e le letsatsi 1. Ka dinako 
tse ding e tla ba ka letsatsi le tshwanang le la diketelo tsa hao tse tlwaelehileng tliliniking.  HAPE ho 
tla hlokeha hore o tle tliliniking letsatsi le leng le le leng ho fumana ente ya hao ya kanamycin ho tswa 
ho mooki e le hore a ka ngola nako le tekanyo ya moriana eo o e fuwang.  Haeba o batla ho fetola 
tekanyo ya hao ya moriana, re ka etsa sena nakong ya diketelo tsena.  Re tla o neha R150 bakeng sa 
ditjeo tsa ho palama lekgetlo le leng le le leng ha ho hlokeha hore o tle sepetlele bakeng sa diteko tsa 
ho utlwa le diteko tsa madi.  E tla ba ka makgetlo a 9, bekeng e nngwe le e nngwe ya bobedi.  Haeba o 
le mokudi ya robaditsweng sepetlele, o ke ke wa leshwa bakeng sa ho palama, ho fihlela o ntshwa 
sepetlele, ka hobane o ke ke wa hloka tjhelete ya ho palama.Jwale, re tla o neha tjhelete e lekaneng 
bakeng sa ho palama ho tloha tliliniking letsatsi le leng le le leng (ho tloha ka Mantaha ho fihla ka 
Labohlano) ho fumana diente tsa hao tsa kanamycin.  Ha o tla tliliniking bakeng sa diketelo tsa 
'semolao' tsa phuputso, le ha o etswa diteko tsa ho utlwa ditsebeng le diteko tsa madi re tla o neha 
R150.  O ke ke wa fumana tjhelete e eketsehileng ya ho palama eo o e fumanang letsatsi le le letsatsi 
bakeng sa diente tsa hao matsatsing ao o fumanang R150. 
 
 
 
MEKGWATSHEBETSO 
Haeba o dumela ho nka karolo phuputsong ena, o tla botswa dipotso mme ho tla hlokeha hore o etse 
diteko tse mmalwa – e tla ba diteko tsa ho utlwa le diteko tsa madi.  Ho tla hlokeha hore diteko tsena 
di etswe ho phaella ditekong tse ding tsa hao/mekgwatshebetso e sa amaneng le phuputso. 
Haeba o dumela ho nka karolo phuputsong ena le ho fana ka tumello, ho tla hlokeha hore ke o botse 
dipotso tse itseng kajeno le ho o hlahloba.  Mme, ho hlokeha hore o kgutle hosasane hape bakeng sa 
diteko tsa madi a hao le diteko tsa pele tsa ho utlwa. 
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Ho tla hlokeha  hore o tle letsatsi le leng le le leng (ho tloha ka Mantaha ho fihlela ka Labohlano - e 
seng mafelong a beke) ho fumana ente ya hao ya kanamycin.  Hape re tla etsa diphetoho tekanyong ya 
hao ya moriana haeba ho hlokeha.  Mme, bekeng e nngwe le e nngwe ya bobedi, ho tla hlokeha hore o 
etse diteko tsa madi le diteko tsa ho utlwa.  Matsatsi ana a tla nka nako e telele ho feta diketelo tsa hao 
tsa kamehla. 
 
Sepheo sa diteko tsa ho utlwa 
Ditsebe tsa rona ke ditho tse hlollang ka hobane di ka kgona ho utlwa diphitjhi (pitch) tse mengata tse 
fapaneng.  Re kgona ho utlwa phitjhi e tlase e jwaloka ya motjhini o kutang jwang, kapa bese, kapa 
esita le wa pompo e dutlang.  Ena ke medumo e fapaneng, mme e na le ditekanyo tse fapaneng tsa 
modumo, empa kaofela e na le diphitjhi tse tlase.  Hape re kgona ho utlwa phitjhi e phahameng, ka 
mohlala, ho lla ha dinonyana kapa ho lla ha alamo ya tshupanako. 
Modumo wa puo, mantswe le dipolelo kaofela e na le diphitjhi tse fapaneng.  Ka mohlala /m/, /d/ le 
/b/ ke medumo e tlase athe /f/, /s/ le /th/ ke diphitjhi tse phahameng.  E le hore re utlwisisane, ho 
hlokeha hore re kgone ho utlwa di-frequency tse ngata tse fapaneng kapa diphitjhi, ka hobane 
medumo e jwalo ya puo e na le diphitjhi tse ngata tse fapaneng. 
Ha re qala ho utlwa feela diphitjhi tse tlase, mme e seng diphitjhi tse phahameng, re qala ho ba le 
bothata ba ho utlwisisa puo.  Ka mohlala, ha motho a re ‘head’, o ka utlwa hampe, mme o utlwe ‘bed’.  
Haeba motho a re ‘fate’, o ka utlwa ‘ate’.  Ka lebaka lena tahlehelo ya ho utlwa esita le di-frequency 
tse mmalwa e tla etsa hore ho be thata ho utlwisisa metswalle, lelapa le dingaka. 
Dintho tse ngata tse fapaneng di ka baka tahlehelo ya ho utlwa.  Ka dinako tse ding batho ba belehwa 
ba na le tahlehelo ya ho utlwa, kapa e ka bakwa ke lerata le phahameng, trauma le meriana e meng.  
DR-TB ke lefu le totileng, mme o hloka moriana o matla haholo hore o hlaphohelwe le ho phela.  Le 
ha ho le jwalo, ka dinako tse ding, meriana ena e ka baka tahlehelo ya kutlo, mme e ka etsa hore o be 
thata ho utlwa le ho buisana le ba bang. 
Ka hobane moriana o matla (kanamycin) o hlokeha hore o phele, o tshwanetse ho o sebedisa.  EMPA 
phuputso ena e leka ho utlwisisa hantle-ntle mofuta wa tahlehelo ya kutlo o bakwang ke moriana 
bakeng sa ho dumella kalafo e molemo haholwanyane kapa thibelo ya yona nakong e tlang.  Ho 
hlokahala hore re lekanye kamoo o utlwang medumo kaofela e fapaneng le diphitjhi tsa modumo ha o 
tla sepetlele, mme ka dibeke tse ding le tse ding tse mmalwa, ho bona haeba boemo bo dula bo 
tshwana, kapa bo mpefala. 
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Mekgwatshebetso ya teko ya kutlo ditsebeng 
Teko ya kutlo ditsebeng ha e bohloko, ho na le dikarolo tse mmalwa, jwaloka tse latelang: 
• Otoscopy – Pele, ho hlokeha hore ke shebe hara ditsebe tsa hao ka kganya ho bona haeba ho 
na le dikonokono dife kapa dife ditsebeng, kapa dintho tse ding ditsebeng tsa hao, hobane sena 
se ka ama diphetho tsa hao.  Sena se tla nka hoo e ka bang metsotswana e 20. 
• Cerumen management – Haeba ditsebe tsa hao di thibane ka lebaka la dikonokono, ke tla di 
ntsha e le hore di se ame diteko tse ding tsa hao.  Ke tla tshela oli e itseng tsebeng ya hao ho 
etsa hore dikonokono di be bonolo.  E be ke sebedisa motjhini ho hula dikonokono.  Kgulo ena 
e tla nka feela metsotswana e mmallwa.  Ho ka utlwisisa bohloko hanyenyane, empa ha se ka 
dinako tsohle ho utlwisang bohloko. 
• Tympanometry – E be ke kenya motjhini tsebeng ya hao.  Ke nub e bonolo mme e tla pompela 
moya o itseng ka tsebeng ya hao.  Ho ke ke ha o utlwisa bohloko, empa ho tla re thusa ho tseba 
haeba ho na le ditshwaetso dife kapa dife hara tsebe ya hao, le haeba ho na le mokedikedi ofe 
kapa ofe.  Haeba ho na le mokedikedi, sena se tla ama ho utlwa ha hao, le ho ama diphetho tsa 
teko ya kutlo.  Sena se tla nka hoo e ka bang metsotso e 2. 
• Distortion Product Otoacoustic Emissions (DPOAE) – Re na le disele tse nyenyane tsa moriri 
hare-hare ditsebeng tsa rona.  Disele tse fapaneng tsa moriri di bohlokwa bakeng sa ho utlwa 
diphitjhi tse fapaneng.  Ka lebaka lena, motjhini wa DPOAE o lekanya kamora disele tsena tsa 
moriri di sisinyehang kateng le ho sebetsa.  Ho hlokahala hore re kenye nub e bonolo tsebeng 
ya hao, mme e tla etsa medumo e fapaneng.  O tshwanetse ho dula o sa sisinyehe mme o 
kgutsitse, mme motjhini o tla nka ditekanyo tsa disele tsena tsa moriri.   Sena se tla nka hoo e 
ka bang metsotso e 5 ho isa ho e 10. 
• Pure Tone Audiometry – Re tla o rwesa di-headphone.  Di tla ntsha medumo e bonolo haholo.  
Medumo e tla ba le diphitjhi tse fapaneng.  Tse ding di tla ba tlase, mme tse ding di tla ba 
hodimo.  Nako le nako ha o utlwa modumo, o tshwanetse ho tobetsa konopo.  Sena se tla nka 
hoo e ka bang metsotso e 15 ho isa ho e 20. 
 
Hang ha sena se entswe, re tla kgona ho bokella diphetho tsa hao hammoho le ho utlwisisa hantle seo 
o se utlwang ditsebeng.  Haeba re etsa teko ena nakong eo o tlang sepetlele, mme re e etsa hape ka 
dinako tse itseng dipakeng, re tla kgona ho bona haeba kutlo ya hae e fetoha. 
Haeba o dumela sena, ho tla hlokeha hore o etse sena ka makgetlo a 7 dikgweding tsa pele tse 3.  E tla 
ba hosasane, le bekeng e nngwe le e nngwe ya bobedi bakeng sa dikgwedi tse 3 tse latelang. 
Ka mora dikgwedi tse 3 tsa phuputso, kutlo ya hao e tla tswela pele e behilwe leihlo ke dingaka tse 
hlahlobang kutlo ditseng sepetleleng sena kapa tliliniking e leng sebakeng sa lona.  Haeba o 
lahlehelwa ke kutlo, dingaka tsena di tla tswela pele ho o thusa ka disebediswa tse thusang ho utlwa le 
tlhokomelo e tswelang pele.  Ke tla o romela ho tsona ka mora phuputso. 
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Sampole ya Madi 
Ho hlokeha hore re nke madi.  Ho hlokeha hore re nke madi e le hore re ka lekanya kamoo kalafo ya 
(kanamycin) e sebediswang kateng mmeleng wa hao.  Re tshepa hore sena se tla re thusa ho utlwisisa 
hore na ke hobaneng ha batho ba lahlehelwa ke kutlo ditsebeng.  Nna, kapa mooki e mong kapa setsebi 
se hulang madi bakeng sa phuputso re tla nka madi ho wena e le hore re ka etsa diteko tse hlokehang.  
Ho hlokeha hore re nke 2 ml tsa madi bakeng sa teko ka nngwe.  Ho tla hlokeha hore bonyane o be le 
diteko tse 2 tsa madi lekgetlo ka leng (ntle le diketelong tse 2 tsa pele).  2 ml e ka ba marothodi a 2 a 
madi kapa halofo ya thispuni.  Ka lebaka lena, re hloka 4ml tsa madi letsatsi ka leng ha re o bona e le 
hore re lekanye kanamycin (ka tlase ho thispuni e le nngwe ya madi).  Lekgetlo la pele e tla ba dihora 
tse mmalwa ka mora ho fumana ente ya hao ya DR-TB.  Ka mora moo, lekgetlong la bobedi le tla 
latelwa ke letsatsi pele o fumana ente ya hao.  Mme makgetlong a mang, ho tla hlokeha hore ho nkuwe 
madi a hao pele o hlajwa ente, le dihora tse mmalwa ka mora ho hlajwa ka ente ya hao.  Ka lebaka lena, 
bakeng sa ketelo ka nngwe (ntle le ketelong ya bobedi ha ho etswa diteko tsa madi), ho hlokeha hore o 
be tliliniking ka dihora tse 4.5 bonyane.  Ho tla hlokeha hore re etse sena ka makgetlo a 8 kaofela 
dikgweding tse 3 (hosasane e tla ba lekgetlo la pele).  Ka hoo, dikgweding tse 3, re tla nka kakaretso ya 
28 ml ya madi, hoo e ka bang dithispuni tse 5 le halofo.  Haeba o le sehlopheng se fuputswang, re tla 
etsa diphetoho tekanyong ya moriana kanamycin enteng ya hao eo o e hlajwang letsatsi le letsatsi.  
Haeba o le sehlopha se sa fuweng moriana o fuputswang, re tla nka feela madi le ho etsa diteko tsa kutlo 
ditsebeng. 
 
E le hore re utlwisise kamoo moriana o ka amang diphio tsa hao, re lakatsa ho hlahloba hape le 
tshebetso ya diphio.  Diketelong tse 3 ho tse 9, ho tla hlokeha hape hore re nke 3 ml e nngwe ya madi, 
e le hore re ka lekanya tshebetso ya diphio tsa hao le ho etsa diphetoho tse nepahetseng tsa tekanyo ya 
moriana.  Ka lebaka leo diketelong tseo re hlokang ho etsa teko ena, re tla hloka 3 ml e eketsehileng 
ya madi, e leng kahodimo feela ho halofo ya thispuni.  Ka kakaretso, makgetlong a 3, re tla nka 9 ml 
ya madi, e leng ka tlase feela ho dithispuni tse pedi tse eketsehileng ho phaella ditekong tse ding tsa 
madi tse hlalositsweng ka hodimo mona.  Re tla nka madi ana ka nako e tshwanang le ya teko ya madi 
bakeng sa kanamycin – e le hore ho se hlokehe hore o hlajwe ka ho eketsehileng ka nalete. 
 
Ho nka madi ke karolo ya tlhokomelo ya hao e tlwaelehileng ya bongaka.  Re hloka ho nka madi ka 
ho arohileng ho mekgwatshebetso e tlwaelehileng ya sepetlele.  Sena se ka hlahisa kotsi e nyenyane 
ya makukuno.  Re tla nka madi ka tsela e tshwanang le ha a nkuwa bakeng sa diteko tsa hao tse 
tlwaelehileng tsa madi.  Ho nka madi ho ka etsa hore o akgehe, o ruruhe mothatswaneng wa madi, 
bohloko, ho tswa matetetso kapa ho tswa madi sebakeng se hlabilweng.  Hape ho na le kgonahalo e 
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nyenyane ya ho ba le tshwaetso.  Baoki ba nang le boiphihlelo kapa ditsebi tse hulang madi bakeng sa 
phuputso ba tla nka madi tlasa maemo a hlwekileng ho thusa ho etsa bonnete ba hore sena se 
bolokehile. 
 
Madi a hao a tla bolokwa ka ho sireletsehileng Sepetleleng sa Helen Joseph ho fihlela a romelwa 
laboratoring bakeng sa diteko.  A tla romelwa kapele kamoo ho ka kgonehang.  A ke ke a bolokwa ho 
feta beke e le nngwe.  Madi a hao a tla romelwa laboratoring e Sefako Makgatho Health Sciences 
University.  Hamorao, madi ao re a nkileng bakeng sa ho lekanya tshebetso ya diphio tsa hao a tla 
romelwa laboratoring e nngwe, e bitswang CLS.  Tlhahisoleseding kaofela ya hao mabapi le diteko 
tsena le mabapi le bophelo ba hao bo botle ka kakaretso e tla bolokwa lekunutung faeleng le ho 
kengwa khabotong nakong ya phuputso le kamora phuputso.  Tlhahisoleseding ya hao e ke ke ya 
buisanwa le motho ofe kapa ofe e mong ya sa ameheng phuputsong.  Haeba sena se hlokeha, re tla 
kopa tumello ya hao pele sena se etswa. 
 
Diteko tsa ho utlwa le diteko tsa madi di tla etswa letsatsing la 2 (hosasane), matsatsing 15, 28, 40, 54, 
68 le 84.  Diteko tsa madi di tla etswa hosasane (letsatsi 2), letsatsing le latelang (letsatsi 3), mme e tla 
ba letsatsing le tshwanang jwaloka diteko tsa ho utlwa - matsatsing 15, 28, 40, 54, 68 le 84. 
 
Ketelong e nngwe le e nngwe eo o tlang bakeng sa diteko tsa ho utlwa le tsa madi (e seng matsatsing a 
dipakeng ha o tla feela bakeng sa diente tsa hao), ketelo ka nngwe e tla nka hoo e ka bang dihora tse 5 
ho ya ho tse 6.  Ke hobane ho hlokeha hore re lete hoo e ka bang dihora tse 4 ho ya ho tse 6 pakeng tsa 
diteko tse 2 tsa madi.  Kahoo, ho tla ba molemo haeba o ka tla esale hoseng, e le hore o ka tloha 
motshehare wa mantsiboya. 
 
NA MEKGWATSHEBETSO EFE KAPA EFE ENA YA PHUPUTSO E TLA HLAHISA 
MAKUKUNO KAPA DITSHITISO? 
Ho nka madi ho ka baka makukuno hanyenyane.  Re tla nka madi ka tsela e tshwanang le eo re nkang 
madi bakeng sa diteko tse ding tsa hao tsa madi.  Ho nka madi ho ka etsa hore o akgehe, o ruruhe 
mothatswaneng wa madi, bohloko, ho tswa matetetso kapa ho tswa madi sebakeng seo re nkileng 
madi ho sona.  Hape ho na le kgonahalo e nyenyane ya ho ba le tshwaetso.  Ke feela baoki ba nang le 
boiphihlelo (kapa ditsebi tse hulang madi bakeng sa phuputso) ba tla nka madi a hao ho thusa ho o 
sireletsa mme ntho e nngwe le e nngwe e tla ba e hlwekileng ka dinako tsohle.  Kakaretso ya 4 ml ya 
madi (ke hore, a ka tlase feela ho thispuni) a tla nkuwa ketelong ka nngwe ya phuputso (ntle le 
letsatsing la 2 le la 3 – feela 2ml tse tla nkuwa).  Kakaretso ya 28 ml, hoo e ka bang dithispuni tse 5 le 
halofo tsa madi.  Ka mora moo, madi a eketsehileng a 3 ml a tla nkuwa matsatsing 40, 68 le 84 – 
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kakaretso e eketsehileng ya 9 ml e leng madi a ka tlase ho dithispuni tse 2.  Ka lebaka lena, kakaretso 
ya 37 ml e tla nkuwa dikgweding  tse tharo – a lekana le hoo e ka bang dithispuni tse 7 le halofo. 
 
Diteko tsa kutlo tse hlalositsweng mona ka hodimo di ke ke tsa etsa hore o ikutlwe o sa phutholoha; le 
ha ho le jwalo, ho ntsha dikonokono ho ka ba bohloko hanyenyane.  Le ha ho le jwalo, ha ho hlokehe 
hore re ntshe dikonokono mothong e mong le e mong, mme ha se ka dinako tsohle ho leng bohloko.  
Le ha ho le jwalo, ho ntsha dikonokono ho nka feela metsotswana e mmalwa.  Teko kaofela e tla nka 
hoo e ka bang metsotso e 30 ho isa ho e 40 ya hao bakeng sa teko ka nngwe.  Ka dinako tsohle o tla 
kgona ho buisana le mooki diphetho tsa hao le ho botsa dipotso pele le ka mora diteko tsena.  Haeba o 
na le dipotso tse eketsehileng, o ka iteanya le nna, ngaka e hlahlobang kutlo ditseng. 
 
MELEMO 
Molemo o ka bang teng ka ho nka karolo ha hao phuputsong ena  o tla kgona ho utlwisisa  boemo ba 
hao ba ho utlwa ka ho fumana dintlha tse eketsehileng, le kamano ya  kamoo kanamycin e 
sebediswang ke mmele wa hao. 
 
• Ho ka etsahala hore o se une molemo phuputsong ena. 
• Ho nka karolo ha hao phuputsong ena ho tla thusa mabapi le ho hodisa tsebo ya bongaka e ka 
thusang bakudi ba bang bao, jwaloka wena, ba nang le DR-TB le ba leng kotsing ya ho 
lahlehelwa ke kutlo ditsebeng. 
 
KALAFO E NNGWE 
• Nakong ya hajwale, ha ho na kalafo e nngwe e fokotsang kapa ho thibela tahlehelo ya kutlo 
ditsebeng e bakwang ke moriana wa DR-TB.  Le ha ho le jwalo, haeba o ka lahlehelwa ke 
kutlo ditsebeng, o tla romelwa tliliniking ya sebakeng sa lona e haufi le wena ho fumana thuso 
ya ho fumana disebediswa tse thusang ho utlwa. 
• Ho beha leihlo moriana kanamycin mading a hao ha se mokgwatshebetso o tlwaelehileng, 
mme hona jwale ha ho na mokgwa o mong ntle le diteko tsa madi ho etsa sena nakong ya 
jwale. 
• Lefapha la Tlhahlobo ya Bongaka ya Kutlo Ditsebeng sepetleleng sena le tla kgona ho o thusa 
haeba o le sebakeng sena.  Ena ke karolo ya mekgwatshebetso e tlwaelehileng ya mmuso 
mabapi le tlhokomelo ya tahlehelo ya kutlo ditsebeng.  Ha se ka dinako tsohle disebediswa tse 
thusang ho utlwa di sebetsang. 
• Haeba o etsa qeto ya hore o se nke karolo phuputsong ena o ntse o tla fumana tlhokomelo e 
molemohadi e fumanehang hajwale tliliniking ena bakeng sa DR-TB ya hao. 
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MELEMO LE DIKOTSI TSA KALAFO E NNGWE E TLWAELEHILENG 
• Ka hobane hona jwale ha ho na moriana o ka thusang ho thibela tahlehelo ya kutlo kapa ho e 
fokotsa, ha ho na kalafo e nngwe.  Haeba moriana wa hao wa DR-TB o baka tahlehelo ya 
kutlo, mme e le ka ho feletseng, e ke ke ya lokiswa.  Empa o tla kgona ho fumana sesebediswa 
se thusang kutlo ho phahamisa medumo kaofela ho o thusa.  Disebediswa tse thusang kutlo le 
ha ho le jwalo ha se ka mehla di thusang tahlehelong ya kutlo, ka hobane ka dinako tse ding 
tahlehelo ya kutlo e mpe haholo hoo disebediswa tse thusang kutlo di hlolehang ho o thusa.  
Ha re fane ka disebediswa tse thusang ho utlwa – lefapha la bongaka la tlhahlobo ya kutlo 
ditsebeng la sepetlele le tla kgona ho o thusa ka tsona haeba o sebakeng seo, kapa re tla o 
romela tliliniking kapa sepetleleng se nepahetseng sebakeng sa lona. 
• Melemo ya disebediswa tse thusang ho utlwa e ka fokola, le ha ho le jwalo di ka o thusa haeba 
o qala ho ba le tahlehelo ya kutlo ho tswa moriana wa hao wa DR-TB.  Disebediswa tse 
thusang ho utlwa ha di na dikotsi dife kapa dife. 
 
NA HO NA LE DITEMOSO DIFE KAPA DIFE KAPA DITHIBELO MABAPI LE HO NKA 
KAROLO HA KA PHUPUTSONG ENA? 
• Haeba o na le lefu la tswekere o ke ke wa nka karolo phuputsong ena.  Ka dinako tse ding lefu 
la tswekere le ka ama kutlo, mme re lakatsa ho kgona ho lekanya kutlo ya hao ditsebeng ntle le 
tshitiso ena e ka etsahalang. 
• Haeba o le ka tlase ho dilemo tse 18, kapa o le ka hodimo ho dilemo tse 55, o ke ke wa nka 
karolo phuputsong.  Phuputsong ena, re nka ditekanyo tsa batho ba pakeng tsa dilemo tse 18 le 
55. 
• Haeba o bile lekgoba la sethethefatsi sefe kapa sefe mme o na le nalane ya tshebediso e mpe ya 
dithethefatsi kapa jwala, o ke ke wa kgona ho nka karolo phuputsong ena haeba sena se ka 
sitisa ho boloka ha hao mekgwatshebetso ya teko.  Bafuputsi ba amehang ba tla etsa qeto 
mabapi le sena. 
 
DITOKELO TSA HAO JWALOKA MONKAKAROLO PHUPUTSONG ENA 
Boithaopo 
Ho nka karolo ha hao phuputsong ena ho etswa ka boithaopo ka ho feletseng mme o ka kgetha haeba 
o lakatsa ho nka karolo kapa tjhe.  Hape o ka kgaotsa ho nka karolo ka nako efe kapa efe mme ha ho 
hlokehe hore o fane ka lebaka.  Haeba o kgetha hore o se nke karolo, kapa o etsa qeto ya ho kgaotsa 
ho nka karolo nakong ya phuputso, o tla tswela pele o fumana tlhokomelo ya bongaka sepetleleng 
sena, mme e ke ke ya sitiswa. 
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Diphumano tse ntjha 
Ke tla o neha tlhahisoleseding efe kapa efe e ntjha eo ke e fumanang nakong ya phuputso, e ka 
fetolang boithaopo ba hao ba ho tswela pele phuputsong. 
 
Ho ikgula/ho tloswa 
Ho ikgula ha hao kapa ho kgaotsa ho nka karolo phuputsong ho ke ke ha sitisa tlhokomelo efe kapa 
efe e nngwe ya hao ya bongaka.  Ke na le tokelo ya ho o tlosa phuputsong haeba e le ntho e 
molemong wa hao.  Haeba ngaka ya hao e fetola moriana wa hao bakeng sa DR-TB mme o ke ke wa 
sebedisa kanamycin, o ke ke wa kgona ho tswela pele phuputsong ena.  Haeba o sa fane ka 
tlhahisoleseding e nepahetseng le ya nnete mabapi le nalane ya hao ya bongaka, kapa o sa latele 
melao ya phuputso, nka o tlosa phuputsong ena ka nako efe kapa efe. 
 
TLHOKOMELO MAEMONG A TSHOHANYETSO LE HO ROBATSWA SEPETLELE 
Haeba o hloka tlhokomelo ya tshohanyetso ka nako efe kapa efe nakong ya phuputso, ka kopo letsetsa 
Ngaka Mohammed Rassool mona 011 276-8813 kapa 027 83 415 8967 kapa Ngaka Rebecca Berhanu 
mona 011276 8968 kapa 072 717 9159. 
 
DITOKISETSO TSA DITJHELETE 
• Batshehetsi ba ditjhelete ba phuputso ena ba tla lefella diteko tsohle tsa phuputso. 
• Wena kapa medical aid ya hao (haeba o na le yona) le ke ke la lefella moriana ofe kapa ofe wa 
phuputso kapa mekgwatshebetso ya phuputso, mme kaofela di tshehetswa ka ditjhelete ke 
mekgatlo ya diphuputso. 
• Ha o etela sepetlele bakeng sa phuputso bekeng e nngwe le e nngwe ya bobedi (bakeng sa 
diteko tse kutlo le diteko tsa madi) o tla fuwa R150 bakeng sa ho palama.  O ke ke wa leshwa 
bakeng sa ho nka karolo, empa feela bakeng sa ho palama le dijo tse bobebe.  Haeba o ya 
tliliniking ya heno letsatsi le letsatsi, o tla fuwa tjhelete ya ho palama. O tla fuwa R50 bakeng sa 
ho ya tliliniking ya heno letsatsi le letsatsi. Sena se tla etswa feela ka dikgwedi tsa pele tse 3.  Ka 
mora dikgwedi tsena tse 3,  ha ho tjhelete ya ho palama eo o tla e fuwa. 
 
KAMOHELO YA BOITSHWARO 
• Prothokhole ya phuputso ena ya moriana e dumeletswe ke Yunivesithi ya Witwatersrand, 
Human Research Ethics Committee (HREC) mme tumello e ngotsweng e fanwe ke komiti ena. 
• Phuputso e latela ditataiso tsa Phatlalatso ya Helsinki (e ileng ya ntjhafatswa ka lekgetlo la ho 
qetela ka: Mphalane 2013), e sebetsanang le dikgothaletso bakeng sa dingaka tse etsang phuputso 
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ya bongaka ho bankakarolo ba batho.  Haeba o lakatsa ho fumana kopi ya ditataiso tsena, ka kopo 
mpolelle, mme ke tla o fumanela tsona. 
• Phuputso ena e lefellwa ke mokgatlo wa phuputso (South African Medical Research Council).  
Ha ke na dithahasello dife kapa dife tsa ditjhelete kapa tsa ka mokgatlong ona mme ha ke 
susumetswe kapa ho etswa leeme ke tsona. 
 
INSHORENSE 
Dingaka kaofela tsa bongaka phuputsong ena di na le inshorense.  Mofuputsi ya ka sehloohong le 
dingaka di sireleditswe ka inshorense ke MPS ho tsamaisa mekgwatshebetso ha feela: 
• Ba boloka mekgwatshebetso ya prothokhole ya phuputso. 
• Ba boloka melao ya Medicines Control Council le ya Yunivesithi ya Witwatersrand, Human 
Research Ethics Committee (HREC). 
• Ba tshwara le ho fana ka moriana wa phuputso ho latela prothokhole le dihlomathiso le 
ditokomane tse ding tse amanang le yona. 
• Ho tloswa qosong ya molato ha ho a rerelwa mme ha ho nka sebaka sa inshorense ya motho 
bakeng sa ketso efe kapa efe e mpe. 
Ka kopo lemoha hore haeba o na le pholisi ya inshorense ya bophelo o tshwanetse ho botsa haeba 
khamphani ya hao ya inshorense e hloka hore e tsebiswe mabapi le ho nka karolo ha hao phuputsong.  
Ho tswa tlhahisoleseding e nngwe, sena ha se a lokela ho ama pholisi efe kapa efe ya bophelo eo o e 
nkileng.  Empa ho ntse ho le bohlokwa ho hlahloba hape sena hobane ka dinako tse ding dikhamphani 
di a fapana. 
 
MOHLODI WA TLHAHISOLESEDING E EKETSEHILENG 
Nakong ya phuputso, o tla hlokomelwa ke moifo wa Sepetlele sa Helen Joseph.  Haeba ka nako efe 
kapa efe o nahana hore o na le dipotso tse eketsehileng tse amanang le phuputso, ka kopo iteanye le 
nna kapa mooki wa phuputso/mohokahanyi ya leng mosebetsing sepetlele. 
Litho tsa phuputso tseo o ka iteanyang le tsona: 
✓ Cara Hollander – 082 815 8878 (Ngaka e hlahlobang kutlo ditsebeng) 
✓ Ngaka Karin Joubert – 011 717 4561 (Ngaka e hlahlobang kutlo ditsebeng) 
✓ Moprofesara Natalie Schellack – 012 521 3286 (Rakhemisi) 
✓ Ngaka Rebbeca Berhanu – 011 276 8968 (Ngaka) 
✓ Ngaka Mohammed Rassool –011 276-8813 (Ngaka le Mofuputsi ya ka 
Sehloohong) 
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• Haeba o batla tlhahisoleseding efe kapa efe mabapi le ditokelo tsa hao jwaloka 
monkakarolo phuputsong, kapa o na le ditletlebo mabapi le phuputso ena, o ka iteanya le 
Moprofesara Cleaton-Jones, Modula-setulo wa Yunivesithi ya Witwatersrand, Human Research 
Ethics Committee (HREC), e leng komiti e ikemetseng e thusang ho sireletsa ditokelo tsa 
bankakarolo phuputsong mona (011) 717 2301. 
• Bakeng sa tlhahisoleseding ya phuputso o ka iteanya le mohokahanyi wa Phuputso  – Cara 
Hollander ho tswa Yunivesithing ya Witwatersrand mona 082 815 8878. 
 
LEKUNUTU 
• Tlhahisoleseding kaofela eo re e bokellang nakong ya phuputso ena, e kenyeletsang direkoto 
tsa sepetlele, tlhahisoleseding mabapi le wena le tlhahisoleseding ya phuputso e tla bolokwa e 
le lekunutu le thata.  Ke feela ditho tsa moifo wa phuputso, le dingaka tsa hao le baoki ba tla 
fihlella tlhahisoleseding ya hao.  Tlhahisoleseding efe kapa efe e tla ngolwa dikgatisong tsa 
saense kapa ntho efe kapa efe e tla hatiswa e ke ke ya ngolwa lebitso la hao. 
• Re tla kenya dikhoutu tse fapaneng tlhahisoleseding ya hao ya phuputso.  Ka lebaka lena, ha 
ho hlahlojwa diphetho tsa hao, ho tla ba le khoutu feela.  Lebitso la hao, nomoro ya hao ya 
boitsebahatso kapa dinoutu dife kapa dife tse ding tse ka o tsebahatsang di ke ke tsa kengwa 
ditokomaneng tsena, ho etsa bonnete ba hore ntho e nngwe le e nngwe e bolokwa e le 
lekunutu. 
• Tlhahisoleseding ena e tla hlahlojwa ke baemedi ba dumeletsweng ba Yunivesithi ya 
Witwatersrand le Yunivesithi ya Sefako Makgatho Health Science hammoho le ditho tse 
tswang ho batshehetsi ba ditjhelete (Medical Research Council).  Diodithara tsa Wits Health 
Consortium di ka sheba diphetho tse itseng ha di etsa tlhahlobo ya tsona ho etsa bonnete ba 
hore ntho e nngwe le e nngwe e entswe ho latela ditekanyetso tse loketseng.  Le ha ho le jwalo, 
ha se motho e mong le e mong ya tla fihlella lebitso la hao – diphetho tsohle tsa hao di tla 
kengwa nomoro, kahoo ba ke ke ba tseba hore ke wena. 
• Tlhahisoleseding hape e ka hlahlojwa ke National Health Research Ethics Committee 
(NHREC), Yunivesithi ya Witwatersrand, Human Research Ethics Committee (HREC), 
Medicines Control Council (MCC) ya Afrika Borwa le/kapa Food and Medicine 
Administration (FDA) ya United States hammoho le ngaka ya hao.  Ka lebaka lena, o nneha 
tumello ya ho lokolla direkoto tsa hao tsa bongaka ho di neha Medical Research Council, 
basebetsi ba bona kapa dienjente, ba boholong ba bophelo bo botle hara naha le dinaheng 
disele, Medicines Control Council (MCC) ya Afrika Borwa, National Health Research Ethics 
Committee (NHREC) le Yunivesithi ya Witwatersrand, Human Research Ethics Committee 
(HREC). 
• Direkoto tsena di tla sebediswa ke bona feela ho etsa mesebetsi ya bona e amanang le 
phuputso ena ya moriana. 
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• Tlhahisoleseding efe kapa efe e fumanwang e amanang le diphetho tsa diteko tsa hao kapa 
boemo ba bophelo ba hao bo botle ka lebaka la ho nka karolo ha hao phuputsong ena e tla 
bolokwa e le lekunutu le thata.  O tla bolellwa mabapi le diphumano dife kapa dife tsa 
bohlokwa bophelong ba hao bo botle kapa ho tswela pele ha hao phuputsong ena empa 
tlhahisoleseding ena e ke ke ya fuwa motho ofe kapa ofe wa boraro hammoho le batho ba seng 
ba boletswe mona ka hodimo ntle le tumello ya hao e ngotsweng.  Mokgelo feela tabeng ena e 
tla ba diketsahalong tsa mafu a tshwaetsang moo e leng boikarabelo ba molao ho tsebisa 
Lefapha la Bophelo bo Botle ka ona.  Ketsahalong e jwalo, ke tla o bolella mabapi le sena le 
hore ke tla neha lekgotla la mmuso le dumeletsweng tlhahisoleseding ena. 
 
KGETHO YA HO TSEBISA NGAKA YA HAO / NGAKA E KGETHEHILENG 
Ka kopo mpolelle mona ka tlase, haeba o lakatsa hore ke tsebise ngaka ya  hao kapa ngaka ya hao e 
kgethehileng hore o nka karolo phuputsong ena: 
• E, ke lakatsa hore o bolelle ngaka ya ka / ngaka e kgethehileng mabapi le  ho nka karolo 
ha ka phuputsong ena. 
• TJHE, ha ke lakatse hore o bolelle ngaka ya ka / ngaka e kgethehileng mabapi le  ho 
nka karolo ha ka phuputsong ena. 
• Ha ke na ngaka ya ka / ngaka e kgethehileng 
 
DIPOTSO TSA BANKAKAROLO 
Na wena, jwaloka monkakarolo, o na le dipotso dife kapa dife? 
E / TJHE 
Haeba E – Ka kopo hlalosa. 
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TUMELLO E BONTSHANG KUTLWISISO BAKENG SA BONKAKAROLO 
PHUPUTSONG 
 
Ke netefatsa hore ke ile ka hlahiswa leseding ke mooki wa phuputso, 
....................................................................................  (LEBITSO LE FELETSENG) mabapi le sebopeho, 
tsamaiso, melemo le dikotsi tsa phuputso e nang le sehlooho “Phuputso e fuputsang kgonahalo ya 
pharmacokinetics le pharmacodynamics ya kanamycin le capreomycin bakuding ba nang le DR-TB le 
kamano pakeng tsa ditekanyo tsa ho utlwa ditsebeng” (NOMORO YA PROTHOKHOLE 1.5). 
 
• Hape ke amohetse, ke badile le ho utlwisisa tlhahisoleseding e ngotsweng mona ka hodimo 
(Maqephe a Tlhahisoleseding ya Monkakarolo le Tumello e Bontshang Kutlwisiso mabapi le 
phuputso ena ya moriana. 
• Ke a lemoha hore diphetho tsa phuputso, ho kenyeletswa le tlhahisoleseding ya ka mabapi le 
bong, dilemo, letsatsi la tswalo, ditlhaku tse qalang tsa mabitso a ka le tlhahlobo ya bongaka 
ntle le lebitso la ka e tla etswa tlaleho ya phuputso. 
• Ke a lemoha hore ho hlokeha hore ke tle tliliniking ya Helen Joseph bakeng sa dikgwedi tsena 
tse 3, beke e nngwe le e nngwe. 
• Ke a lemoha hore nka ka kgetha ho ya tliliniking ya sebaka sa rona kapa ya Helen 
JosephHelen Joseph letsatsi le letsatsi bakeng sa diente tsa ka mme ke dumela ho etsa jwalo 
letsatsi le letsatsi. 
• Ka lebaka la ditlhokeho tsa phuputso, ke dumela hore tlhahisoleseding e bokellwang nakong 
ya phuputso ena e ka kengwa sistiming ya khomphutha ke bafuputsi ba amehang phuputsong 
ena, batshehetsi ba ditjhelete kapa lebitsong la bona. 
• Ke dumela ho nka karolo diseteng tse 7 tsa diteko tsa kutlo dikgweding tse 3 tsa pele. 
• Ke dumela ho nka karolo diseteng tse 8 tsa diteko tsa madi dikgweding tsena tse 3. 
• Ke dumela ho fana ka 2 ml tsa madi ka makgetlo a 2 dikgweding tse 3 tsa pele. 
• Ke dumela ho fana ka 4 ml tsa madi ka makgetlo a 6 nakong ya phuputso.  Le 9 ml tse ding 
bakeng sa ho etsa ditekanyo tsa ditshebetso tsa diphio dikgweding tse 3 tsa pele. 
• Ke a tseba hore nka ikgula phuputsong ka nako efe kapa efe. 
• Mohatong ofe kapa ofe, ntle le tshwaro e se nang leeme, nka hula tumello ya ka le 
bonkakarolo phuputsong. 
• Ke bile le nako e lekaneng ya ho botsa dipotso mme (ka bolokolohi) ke bolela hore ke malala-
a-laotswe ho nka karolo phuputsong. 
• Ke a lemoha hore haeba ngaka ya e fetola moriana wa ka hore e be ntho e nngwe ntle le 
kanamycin, ke tla tloswa phuputsong. 
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MONKAKAROLO 
 
 
 
 
Lebitso ka Ditlhaku tse 
Arohantsweng 
Tshaeno / Letshwao kapa Kgatiso ya 
Monwana o Motona 
Letsatsi le Nako 
 
MOFUPUTSI YA TLASANA PHUPUTSONG 
 
Nna, ..........................................................................................................., ke netefatsa hore 
monkakarolo ya ngotsweng mona ka hodimo o ile a hlahiswa leseding ka ho feletseng mabapi le 
sebopeho, tsamaiso le dikotsi tsa phuputso e boletsweng ka hodimo mona. 
 
 
 
Lebitso ka Ditlhaku tse Arohantsweng Tshaeno Letsatsi le Nako 
 
 
MOFETOLEDI / MOTHO E MONG YA HLALOSANG TUMELLO E BONTSHANG 
KUTLWISISO (MOFUPUTSI YA TLASANA PHUPUTSONG) 
 
 
 
Lebitso ka Ditlhaku tse Arohantsweng Tshaeno Letsatsi le Nako 
 
 
PAKI (Haeba e hlokeha) 
 
 
 
Lebitso ka Ditlhaku tse Arohantsweng Tshaeno Letsatsi le Nako 
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Appendix F 
 
Information Leaflets and Informed Consent Form for South Rand Hospital: English 
 
Information Leaflets and Informed Consent Form for South Rand Hospital:  Zulu 
 
Information Leaflets and Informed Consent Form for South Rand Hospital: SeSotho 
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Clinical HIV Research Unit, Department of Medicine 
____________________________________________________________________________________ 
Helen Joseph Hospital, Themba Lethu Clinic, Perth Road, Westdene, Johannesburg 2092, South Africa 
Postnet Suite  
 
INFORMED CONSENT VERSION NUMBER: 1.5 
(South Rand Hospital) 
STUDY TITLE: A feasibility study investigating the pharmacokinetics and pharmacodynamics of 
kanamycin and capreomycin in patients with DR-TB and the relationship between hearing levels 
 
INSTITUTION: University of the Witwatersrand in collaboration with Sefako Makgatho Health 
Sciences University 
 
DAYTIME AND AFTER HOURS TELEPHONE NUMBER(S): 082 815 8878 (Cara Hollander) 
and/or011 681 2184 (Dr. Shilubane and Dr. Damoyi at South Rand Hospital) and /or +27 11 276-8813 
(Dr. Mohammed Rassool – Principal Investigator – Doctor at Helen Joseph – Wits Health Consortium) 
 
STUDY COORDINATOR: Matshediso Mkhwanazi: speed dial: 50017/ 076 711 2874/ 
Matshidiso.Mkhwanazi@righttocare.org 
 
 
INTRODUCTION 
Good day, my name is Cara Hollander and I am an audiologist from the University of the 
Witwatersrand. I would like to invite you to think about joining a research study, called “A feasibility 
study investigating the pharmacokinetics and pharmacodynamics of kanamycin and capreomycin in 
patients with DR-TB and the relationship between hearing levels”. We have just done some tests to 
confirm that you fit the criteria to take part in this study.  
1. Before agreeing to take part in this study, it is important that you read and understand the following 
explanations about the reason for the study, the study procedures, benefits, risks, uncomfortable aspects, 
and precautions as well your right to pull out from the study at any time.  
2. This information booklet is to help you to decide if you would like to take part. You need to 
understand everything about the study before you agree to take part in this study.  
3. If you have any questions, please ask me.  
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4. You should not agree to take part unless you are happy about all the parts involved.  
5. You may not take part in another research study while you are taking part in this study (unless it is 
approved by me beforehand).  
6. Please be open with me about your health history, since you may otherwise harm yourself by taking 
part in this study.  
7. If you decide to take part in this study, you will be asked to sign this form to confirm that you 
understand the study. You will be given a copy to keep.  
8. If you have a personal doctor outside of this hospital, please discuss with or tell him/her of your 
possible participation in this study. If you would like, I can also tell your personal doctor about this.  
 
PURPOSE OF THE STUDY 
You are in this hospital/clinic because you have Drug Resistant Tuberculosis (DR-TB). I would like 
you to think about taking part in the research to measure your hearing levels throughout your DR-TB 
treatment. You will be receiving medicine (injections) to treat your drug resistant tuberculosis called 
kanamycin and/or capreomycin together with a few other medications, so that you can get better from 
your TB, which is very important. You will not be receiving kanamycin and capreomycin together, but 
may get them at different stages. They are both injections.  The medicine you will be receiving is very 
strong, and has a few risks and one of them is hearing loss. However, you need to take this medicine so 
that you can get healthy again. Many people who take the medication will lose some of their hearing; 
but, although this happens often, it does not happen always. It can be very hard to talk to family and 
friends with a hearing loss and working can also be difficult. Therefore, during this research, we want 
to measure your hearing 7 times in the first three months, so that we can understand exactly what 
happens to your hearing. Then, we would also like to do blood tests 8 times in the first 3 months, so 
that we can look how your medicine for your DR-TB is working in your body. We will not changing or 
adjusting your DR-TB medicine based on the blood tests, but it will allow us to understand how the 
medicine works differently in different people, so that we can hopefully try and prevent hearing loss in 
the future. Your assistance will help us treat other patients in the future with this illness and it will also 
allow us to monitor your hearing throughout, and look at a relationship between how the drug is used 
in your body with your hearing. 
 
LENGTH OF THE STUDY AND NUMBER OF PARTICIPANTS 
The study will take place at this hospital as well as at Helen Joseph Hospital. About 80 people will 
take part in this study. The participants will be between the ages of 18 and 55 years. You will need to 
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take your kanamycin or capreomycin (depending on what your doctor decides) for more months than 
you will be part of this study. We will be doing tests for three months for this study, which will be 
explained below. These tests are blood tests and hearing tests. In the first 3 months, you will be asked 
to visit me 9 times for tests during the study. For some of these visits, you will be in hospital, and so 
they can be done in your ward or a separate room in the hospital. However, when you are discharged, 
you will need to come back to this hospital to see me, or to the TB focal point at Helen Joseph 
Hospital. If you are in hospital for 2 months, then you will only need to come see me as an outpatient 
for one month. But it will depend how long you are in hospital for. Today will be counted as day 1. 
You will ALSO need to go to your local clinic closest to your home every day (Monday to Friday) to 
get your injection from a nurse so she can record the time and dosage you are receiving (you will need 
to do this even if you are not part of the study as this is the standard of care). You will therefore need 
to go to South Rand Hospital or Helen Joseph Hospital (whichever one you prefer) once every second 
week for the hearing and blood tests, and then the local clinic daily. We will give you R150 for your 
travelling expenses every time you need to come to the hospital for the hearing and blood tests. When 
you are an inpatient in the hospital, you will not be paid for your transport, until you get discharged, 
as you will not need money for your transport. Then, we will give you enough money for your 
transport to go to the clinic every day (from Monday to Friday) to get your injections. We will give 
you R50 for your transport Monday to Friday to get your injections at your local clinic for the study 
period. When you come to the clinic for your ‘official’ study visits, when you have the hearing and 
blood tests we will give you R150. You will not get extra transport money that you get daily for 
coming for your injections on the days that you get R150.  
 
PROCEDURES 
If you agree to take part in this study, you will be asked questions and then will need to undergo a few 
tests – which will be hearing tests and blood tests. These tests will need to be done in addition to your 
other tests/procedures that are not study related.  
 
If you agree to take part in this study and consent, I will need to ask you some questions today and 
examine you. Then, tomorrow, you will need more blood tests and the first hearing tests. 
 
You will need to go to your local clinic every day (from Monday to Friday – not on the weekends) to 
get your kanamycin/capreomycin injection when you are discharged. Then, every second week, you 
will need to have blood tests and hearing tests. These days will take longer than your daily visits.  
 
A FEASIBILITY STUDY INVESTIGATING THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND 
CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE RELATIONSHIP BETWEEN HEARING LEVELS 
523 
 
Purpose of hearing tests  
Our ears are wonderful organs because they can hear so many difference pitches. We can hear low 
pitches which are for example a lawn mower, or a bus, or even a tap dripping. These are different 
sounds, and have different loudness levels, but they all have low pitches. Then we can also hear high 
pitches, for example birds tweeting or alarm clocks ringing.  
 
Speech sounds, words and sentences are all different pitches. Like for example, the /m/, /d/ and /b/ are 
lower pitches where-as the /f/, /s/ and /th/ are higher pitches. In order for us to understand each other, 
we need to be able to hear many different frequencies or pitches, as speech sounds have many different 
pitches.  
 
As soon as we start to only hear low pitches, and not the high pitches, then we struggle to understand 
speech. So, for example, when someone is saying ‘head’, you may mishear, and hear ‘bed’. If someone 
says ‘fate’, you may hear ‘ate’. Therefore a hearing loss at even a few frequencies will make it difficult 
to understand friends, family and doctors.  
 
Many different things can cause hearing loss. Sometime people can be born with a hearing loss, or it 
could be from loud noise, trauma and some medicines. DR-TB is a serious illness, and you need very 
strong medicine to recover and live. However, sometimes, these medicines can cause a hearing loss, 
which could make it difficult for you to hear and communicate.  
 
As the strong medicine (kanamycin/capreomycin) is needed to live, you have to take it. BUT, this 
research is to try to understand the exact kind of hearing loss that is caused by the medicine which will 
better allow for treatment or prevention in the future. We need to measure how you hear all the different 
sounds and pitches when you come into hospital, and then every few weeks, to see if its staying the 
same, or getting worse.  
 
 
Hearing test procedures  
A hearing test is not painful, and there are a few parts, as follows:  
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• Otoscopy – Firstly, I will need to look in your ears with a light to see if there is any wax, or 
other things in your ears, as this can affect your results. This will take about 20 seconds. 
• Cerumen management – if your ears are clogged with wax, I will take the wax out so it doesn’t 
affect the other tests. I will put some oil in your ear to make the wax soft. Then I will use a 
machine to pull out the wax (suction). The suction will only take a few seconds. It may be 
slightly painful, but it is not always painful.  
• Tympanometry – Then, I will place a machine in your ear. It is a soft nub and it will pump 
some air in your ear. It will not be sore, but will help us know if you have any infections deep 
inside your ear, and if there is any fluid. If there is fluid, it will affect your hearing, and the 
results of the hearing test. This will take about 2 minutes.  
• Distortion Product Otoacoustic Emissions – We have tiny hair cells deep in our ears. The 
different hair cells are important to hear the different pitches. Therefore, and DPOAE machine 
measures how these hair cells are moving and working. We need to put a soft nub in your ear, 
and it will make different sounds. You need to keep still and quiet, and the machine will take 
the measurements of these hair cells. This will take about 5 to 10 minutes.  
• Pure Tone Audiometry – we will put headphones on you. They will give off very soft sounds. 
The sounds will have different pitches. Some will be low, and some will be high. Whenever 
you hear a sound, you will need to press a button. This will take about 15 to 20 minutes.  
Once this is done, we are able to put all the results together and understand exactly what you are hearing. 
If we do the test when you come into hospital, and then we do it again at certain intervals, we can see 
if your hearing is changing.  
 
If you agree to this, you will need to do this 7 times in the first 3 months. It would be tomorrow, then 
every second week for the next 3 months.  
 
After 3 months of the study, you will continue to have your hearing monitored by the audiologists at 
this hospital or the hospital or clinic in your region. Should you get a hearing loss, they will continue to 
help you with hearing aids and further management. I will refer you to them after the study.  
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Blood Sampling  
We will need to take blood as well. We will need to take blood so that we can measure how the DR-TB 
treatment (kanamycin/capreomycin) is being used in your body. We hope this will help us understand 
why people get a hearing loss. Myself, or another nurse, doctor or phlebotomist will take blood from 
you so that we can do the necessary tests. We need to take 2mls of blood for each test. You will need 
to have at least 2 blood tests each time (except for the first 2 visits). Two mls is about 2 drops of blood 
or half a teaspoon. Therefore, we will need to take 4mls of blood each day we see you to measure the 
kanamycin (just under a teaspoon of blood). The first time will be a few hours after you get your 
injection for your DR-TB. Then, the second time will be the following day before you get your injection. 
And the other times, you will need to get your blood taken before your injection, and a few hours after 
your injection. Therefore, for each visit (besides for the second visit when you have blood tests), you 
will need to be at the clinic for at least 4.5 hours (unless you are an inpatient, and are in the hospital 
anyway). We will need to do this 8 times all together over 3 months (tomorrow will be the first time). 
So altogether, over the 3 months, we will take a total of 28mls of blood, which is about 5 and a half 
teaspoons. We will therefore just be taking the blood and doing the hearing tests.  
 
Then, in order to understand how the medicine may be affecting your kidneys, we would like to measure 
kidney function as well. On6 out of the 9 visits, we will also need to take another 3 mls of blood, so we 
can measure your kidney function and make the correct dosage changes. Therefore on the visits that we 
will need to test this, we need an extra 3mls of blood, with is just over half a teaspoon. Altogether, over 
the 3 times, we will draw 18 mls or blood, which is just over 3 teaspoons addition to the other blood 
tests described above. We will draw this at the same time at the blood test for the 
kanamycin/capreomycin– so that there will not be an extra needle prick.  
 
Taking blood is part of your normal medical care at this hospital. We will need to take blood separately 
to the regular hospital procedures. This may present a slight risk of discomfort. We will draw the blood 
in the same way as it is taken for your general blood tests. Drawing blood may result in faintness, 
inflammation of the vein, pain, bruising or bleeding at the puncture site. There is also a slight possibility 
of infection. Experienced nurses, doctors or phlebotomists will take the blood in clean conditions to 
help make sure that is will be safe.  
 
Your blood will be kept safely for no more than a day at South Rand Hospital, and then Helen Joseph 
Hospital until it is sent to the laboratory to be tested. It will be sent as soon as possible. It will not be 
kept for more than a week. Your blood will be sent to a laboratory at Sefako Makgatho Health 
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Sciences University. Then, the blood we take to measure your kidney function will be sent to another 
laboratory, called CLS. All the personal information about these tests and about your general health 
will be kept private in a file and then in a cupboard during after the research study. Personal 
information will not be discussed with any person not involved in the research study. If this is needed, 
we will ask for your permission before this is done.  
 
The hearing tests and blood tests will be done on day 2 (tomorrow), days 15, 28, 40, 54, 68 and 84. The 
blood tests will take place tomorrow (day 2), the next day (day 3), and then on the same day as the 
hearing tests - on days 15, 28, 40, 54, 68 and 84.  
At every visit that you come for the hearing and blood tests (not the days in between when you just 
come for your injections), each visit will take about 5 to 6 hours. This is because we need to wait about 
4 to 6 hours between the 2 blood tests. So, it would be best if you came early in the morning, so you 
can leave by the afternoon.  
 
WILL ANY OF THESE STUDY PROCEDURES RESULT IN DISCOMFORT OR 
INCONVENIENCE? 
Taking blood may cause a small discomfort. We will take the blood in the same way as it is taken for 
your other blood tests. Drawing blood may result in faintness, inflammation of the vein, pain, bruising 
or bleeding in the area that we take the blood from. There is also a slight chance of infection. Only 
experienced nurses (or phlebotomists or doctors) will take your blood to help protect you and everything 
will always be clean. A total of 4 mls of blood (i.e. just under a teaspoon) will be taken on each study 
visit (besides for day 2 and day 3 – only 2mls will be taken). This is a total of 28 mls, which is about 5 
and a half teaspoons of blood. Then, an extra 3 mls will be drawn (except for the first two times) – and 
an extra total of 18 mls which just under over 3 teaspoons. Therefore, all together, 46 mls will be drawn 
over the three months – which is equivalent to just over 9 teaspoons. 
 
The hearing tests as described above will not cause discomfort; however, taking out the wax may be 
slightly painful. We do not need to take out wax for every person though, and it is not always sore. 
Taking out the wax will only last a few seconds though. The rest of the test will take approximately 30 
to 40 minutes of your time for each visit. You will always be able to discuss your results with the nurse 
and ask questions before or after these tests. If you have more questions, you can get in touch with 
myself, who is an audiologist.  
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BENEFITS 
• The possible benefit from your participation in this study is, you will be able to understand 
your hearing status in more detail, and its relationship with how the kanamycin/capreomycinis 
being used in your body.  
• You may not benefit from this study.  
• Your participation in this study will help develop medical knowledge that may help other 
patients that, like you, have DR-TB and are at risk to develop a hearing loss.  
 
ALTERNATIVE TREATMENT 
• At the moment, there is no treatment to reduce or prevent the hearing loss caused by DR-TB 
medicine. Should you get a hearing loss; you will be referred to the local clinic nearest to you 
to assist you to receive a hearing aid.  
• Monitoring the kanamycin/capreomycin in your blood is not a standard procedure, and there is 
no other way besides blood tests to do this at the moment. 
• The Audiology Department at this hospital will be able to assist you if you are in this 
catchment area. This is part of general government procedures with hearing loss management.  
• If you decide not to take part in this study you will still receive the best current care at this 
clinic for your DR-TB. 
 
BENEFITS AND RISKS OF STANDARD ALTERNATIVE TREATMENT 
• As there is currently no medicine that can help to prevent or lessen hearing loss, there is no 
other treatment. If your DR-TB medication causes a hearing loss, it is permanent, and cannot 
be fixed. But it will be possible to get a hearing aid to make all the sounds louder to help you. 
Hearing aids however cannot always help with hearing loss, as sometime the hearing loss is so 
bad, that the hearing aids cannot help. We will not be giving you the hearing aids – the 
hospitals audiology department will be able to assist you with that if you are in this catchment 
area, or we will refer you to the correct clinic or hospital that is in your catchment area.  
• The benefits of the hearing aids can be limited, however may help you if you develop a 
hearing loss from your DR-TB medication. Hearing aids do not have any risks.  
 
ARE THERE ANY WARNINGS OR RESTRICTIONS CONCERNING MY 
PARTICIPATION IN THIS STUDY 
• If you have Diabetes Mellitus you may not take part in this study. Diabetes Mellitus can 
sometimes affect the hearing, and we want to be able to measure your hearing without this 
possibly interfering.  
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• If you are any younger than 18 years of age, or older than 55 years of age, you may not take 
part in the study. In this study, we are only measuring people between the ages of 18 and 55 
years.  
• If your doctor changes your medication (to anything other than kanamycin or capreomycin), 
you may not be able to continue participating in this study.  
• If you have been addicted to any drug and have a history of drug or alcohol abuse, you cannot 
take part in the study if this could impact in your compliance with the test procedures. This 
will be decided at the discretion of the investigators involved.  
 
RIGHTS AS A PARTICIPANT IN THIS STUDY 
Voluntary  
Your participation in this study is entirely voluntary and you can choose if you would like to take part 
or not. You can also stop taking part at any time and you do not need to give a reason. If you chose to 
not take part, or decide to stop taking part during the study, you will still get the medical care at this 
hospital, and it will not be affected.  
 
New findings  
I will provide you with any new information that I have during the study, which may change your 
willingness to continue on the study  
 
Withdrawal  
Your withdrawal or stopping participation in the study will not affect your other medical care. I have 
the right to withdraw you from the study if it is what is best for you. If your doctor changes your 
medicine for the DR-TB and you will not be taking kanamycin/capreomycin, then you will not be able 
to continue with this study. If you did not give correct and truthful information about your medical 
history, or did not follow the rules of the study, I may take you off the study at any time.  
 
EMERGENCY CARE AND HOSPITALISATION 
If you need emergency care at any time during the study, please call Dr. Damoyi or Dr. Shilubane on 
011 681 2184 or Dr. Mohammed Rassool on 011 276-8813 (Helen Joseph Hospital – Principal 
Investigator) or 027 83 415 8967  
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FINANCIAL ARRANGEMENTS 
• The funders of this study will provide payment for all study tests.  
• Neither you nor your medical aid (if you have one) will need to pay for any study medication 
or study procedures, and they have been all funded by research organizations.  
• When you visit the hospital for the study every second week (for hearing and blood tests) you 
will be provided with R150 for your transport (only once you are being treated as an 
outpatient). You will not be paid to take part, but only for your transport and refreshments. 
When you go to your local clinic daily or to this clinic daily, you will be compensated for your 
transport. You will be provided with R50 daily for your transport. This will only be for the 
first 3 months. After these 3 months, no money will be provided for your transport.  
 
ETHICAL APPROVAL 
• This clinical study protocol has been given to the University of the Witwatersrand, Human 
Research Ethics Committee (HREC) and written approval has been given by that committee. 
• The study follows the guidelines of the Declaration of Helsinki (last updated: October 2013), 
which deals with the recommendations for doctors in doing medical research with human 
participants. If you would like a copy of these principles, please let me know, and I will get 
them to you.  
• This study is paid for by a research organisation (South African Medical Research Council). I 
do not have any financial or personal interests with this organization and I am not influenced 
or biased by them.  
 
INSURANCE 
All the medical doctors that are investigators in this study have insurance. The principal investigator 
and doctors are insured by MPS to conduct the procedures as long as:  
• They obey the procedures of the study protocol.  
• Their compliance with the rules of the Medicines Control Council and the University of the 
Witwatersrand, Human Research Ethics Committee (HREC).  
• The handling and administration of the study medication according to the protocol and 
amendments and other related documents.  
• The indemnification is not intended to be and is not a substitute for any personal malpractice 
insurance.  
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Please note that if you have a life insurance policy you should find out if your insurance company needs 
to be notified about you taking part in the study. From other information, this should not affect any life 
insurance policy taken out. But it is still important to double check this as sometimes companies are 
different.  
 
SOURCE OF ADDITIONAL INFORMATION 
During the study, you will be cared for by the staff at South Rand Hospital. If at any time you feel that 
you have further study related questions, please contact me or the study nurse/coordinator on duty at 
the hospital.  
Members (Investigators and Sub-Investigators) of the study who you can contact:  
• Cara Hollander – 082 815 8878 (Audiologist)  
• Dr. Karin Joubert – 011 717 4561 (Audiologist)  
• Professor. Natalie Schellack – 012 521 3286 (Pharmacist)  
• Dr. Shilubane – 011 681 2184 
• Dr. Mohammed Rassool –011 276-8813 (Doctor and Principal Investigator)  
 
If you want any information regarding your rights as a research participant, or complaints regarding 
this research study, you may contact Prof. Cleaton-Jones, Chairperson of the University of the 
Witwatersrand, Human Research Ethics Committee (HREC), which is an independent committee to 
help protect the rights of research participants at (011) 717 2301.  
 
For research information you can contact the Study Planner– Cara Hollander from the University of 
the Witwatersrand on 082 815 8878.  
 
 
 
  
A FEASIBILITY STUDY INVESTIGATING THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND 
CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE RELATIONSHIP BETWEEN HEARING LEVELS 
531 
CONFIDENTIALITY 
• All information that we collect during this study, which includes hospital records, personal and 
research information will be kept strictly confidential. Only members of the research team, and 
your doctors and nurses will have access to your information. Any information that will be 
written in scientific journals or anything that is published will not have your name on.  
•  We will put different codes on your study information. Therefore, when reviewing your 
results, there will only be a code. Your name, identity number or any other identifying notes 
will not be on the documents, to ensure everything is confidential.  
• This information will be reviewed by authorised representatives of the University of the 
Witwatersrand and Sefako Makgatho Health Sciences University as well and members from 
the funders (Medical Research Council). Auditors of the Wits Health Consortium may look at 
some of the results when they do their inspection to make sure everything is done with good 
standards. However, not everyone will have access to your name – all your results will have a 
number, so they will not know if it is you.  
• The information might also be inspected by the National Health Research Ethics Committee 
(NHREC), University of the Witwatersrand, Human Research Ethics Committee (HREC), the 
South African Medicines Control Council (MCC) and/or the United States Food and Medicine 
Administration (FDA) as well as your personal doctor. Therefore, you hereby authorize me to 
release your medical records to the Medical Research Council, its employees or agents, 
domestic and foreign regulatory health authorities, the South African Medicines Control 
Council (MCC), the National Health Research Ethics Committee (NHREC) and the University 
of the Witwatersrand, Human Research Ethics Committee (HREC).  
• These records will be used by them only to carry out their duties relating to this clinical study.  
• Any information uncovered regarding your test results or state of health as a result of your 
participation in this study will be strictly confidential. You will be told about any findings of 
importance to your health or continued participation in this study but this information will not 
be given to any third party in addition to the ones mentioned above without your written 
permission. The only exception to this rule will be cases of communicable diseases where a 
legal duty of notification of the Department of Health exists. In this case, I will tell you about 
this and that I will be giving the information to be the authorised state agency.  
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PERSONAL DOCTOR / SPECIALIST NOTIFICATION OPTION 
Please tell me below, if you want me to notify your personal doctor or your specialist that you will be 
taking part in this study:  
• YES, I want you to tell my personal doctor / specialist of my participation in this study.  
• NO, I do not want you to tell my personal doctor / specialist of my participation in this 
study.  
• I do not have a personal doctor / specialist  
 
PARTICIPANT QUESTIONS 
Do you, as the participant have any questions?  
YES / NO  
If YES – Please describe. 
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INFORMED CONSENT FOR PARTICIPATION IN THE STUDY 
I hereby confirm that I have been informed by the study nurse/sub-investigator..................................... 
(FULL NAME) about the nature, conduct, benefits and risks of clinical study titled “A feasibility study 
investigating the pharmacokinetics and pharmacodynamics  of kanamycin and capreomycin in 
patients with DR-TB and the relationship between hearing levels” 
 (PROTOCOL NUMBER 1.5)  
• I have also received, read and understood the above written information (Participant 
Information Leaflet and Informed Consent) about this clinical study.  
•  I am aware that the results of the study, including personal details about my sex, age, date of 
birth, initials and diagnosis will be anonymously (my name will not be provided) processed 
into a study report.  
•  I am aware that I will need to come to the Helen Joseph clinic every second week for hearing 
and blood tests for 3 months.  
•  I am aware that I can choose to either go to my local clinic or the Helen Joseph clinic daily for 
my injections and I agree to do this daily.  
• In view of the requirements of research, I agree that the data collected during this study can be 
put through a computerised system planned by the researchers involved in this study, the 
funders or on their behalf. 
•  I consent to participating in 7 sets of hearing tests in the first 3 months.  
• I consent to participating in 8 sets of blood tests in these 3 months.  
• I consent to give 2mls of blood 2 times in the first 3 months.  
•  I consent to giving 4mls of blood 6 times during the study. And another 18 mls to measure my 
kidney functions in the first 3 months.  
•  I do know that I can withdraw at any time.  
•  I may, at any stage, without unfairness, pull out my consent and participation in the study.  
•  I have had enough time to ask questions and (of my own free will) declare myself ready to 
participate in the study.  
•  I am aware that should my doctor change my medication to something other than 
kanamycin/capreomycin, I will be withdrawn from the study.  
 
 
 
 
 
  
A FEASIBILITY STUDY INVESTIGATING THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND 
CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE RELATIONSHIP BETWEEN HEARING LEVELS 
534 
PARTICIPANT 
 
__________________________________________________________________________________ 
Printed Name                                  Signature / Mark or Thumbprint                                   Date and 
Time  
 
 
STUDY SUB-INVESTIGATOR/ COORDINATOR 
 
I, ................................................................................, herewith confirm that the above participant has 
been fully informed about the nature, conduct and risks of the above study.  
 
__________________________________________________________________________________ 
Printed Name                                                       Signature                            Date and Time  
 
 
TRANSLATOR / OTHER PERSON EXPLAINING INFORMED CONSENT (SUB-
INVESTIGATOR) 
 
 
__________________________________________________________________________________ 
Printed Name                                                            Signature                       Date and Time  
 
WITNESS (If applicable) 
 
__________________________________________________________________________________ 
Printed Name                                                               Signature                     Date and Time 
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INOMBOLO YOSHICILELO LWEMVUME ENIKEZWA EMVA KOKUTHOLA ULWAZI: 
1.5 
(Isibhedlela sase-South Rand) 
 
ISIHLOKO SOCWANINGO:  Ucwaningo lokuhlola ukuthi imithi i-kanamycin ne-capreomycin 
isebenza kanjani emzimbeni nemithelela yokusetshenziswa kwayo ezigulini ezine-DR-TB kanye 
nokuhlobana phakathi kwamazinga okuzwa  
 
ISIKHUNGO: I-University of the Witwatersrand ibambisene ne-Sefako Makgatho Health Sciences 
University 
 
IZINOMBOLO ZOCINGO (ZEZINGCINGO) NGESIKHATHI SAMAHORA OKUSEBENZA 
NANGEMUVA KWAMAHORA OKUSEBENZA: 082 815 8878 (Cara Hollander) kanye/noma 
011 681 2184  (Dkt. Shilubane no Dkt Damoyi esibhedlela sase-South Rand  kanye /noma +27 11 
276-8813 (Dkt. Mohammed Rassool – Umcwaningi  Omkhulu – Udokotela wasesibhedlela sase 
Helen Joseph- Wits Health Consortium) 
 
UMXHUMANISI WOCWANINGO: Matshediso Mkhwanazi: Inombolo yocingo esheshayo: 
50017/ 076 711 2874 Matshidiso. Mkhwanazi@righttocare.org  
 
Kulowo okunokwenzeka ukuba abambe iqhaza: Leli fomu lemvume kungenzeka ukuthi 
liqukethe amagama ongawaqondisisi. Uyacelwa ukuba ubuze udokotela wocwaningo noma unesi 
wocwaningo noma umsebenzi wocwaningo ukuze akuchazele noma yimaphi amagama noma ulwazi 
ongaluqondisisi kahle.  Ungakwazi ukuzigcinela ikhophi elingasayiniwe lale mvume ukuze ucabange 
ngalo noma uxoxe mayelana nalo nabomndeni wakho noma abangane bakho ngaphambi kokuthatha 
isinqumo. 
ISINGENISO 
Sawubona, igama lami nginguCara Hollander  ngingudokotela wezinzwa zokuzwa wase-
University of the Witwatersrand.  Ngingathanda ukuba ucabange mayelana nokuhlanganyela kulolu 
cwaningo lophenyo, olwaziwa ngokuthi Ucwaningo lokuhlola ukuthi imithi i-kanamycin ne-
capreomycin isebenza kanjani emzimbeni nemithelela yokusetshenziswa kwayo ezigulini ezine-DR-
TB kanye nokuhlobana phakathi kwamazinga okuzwa.  Sisandukwenza okunye ukuhlola 
okuqinisekisa ukuthi uyafaneleka ukubamba iqhaza kulolu cwaningo. 
1. Ngaphambi kokuba uvume ukubamba iqhaza kulolu cwaningo, kubalulekile ukuthi ufunde 
lezi zincazelo ezilandelayo futhi uziqondisise ezimayelana nenhloso yalolu cwaningo, 
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izinqubo zocwaningo, izinsizakalo, ubungozi, izinto ezikwenza ungakhululeki,  nezindlela 
zokuphepha kanye nelungelo lakho lokuhoxa kulolu cwaningo noma nini. 
2. Leli bhukwana lolwazi lenzelwe ukukusiza ekuthatheni isinqumo sokuthi ungathanda yini 
ukubamba iqhaza.  Kudingeka ukuba wazi yonke into mayelana nalolu cwaningo ngaphambi 
kokuvuma ukubamba iqhaza kulolu cwaningo. 
3. Uma unemibuzo, ngicela ungibuze. 
4. Akuphoqelekile ukuba ubambe iqhaza ngaphandle uma wenelisekile mayelana nazo zonke 
izingxenye ezibandakanyekayo. 
5. Awuvunyelwe ukubamba iqhaza kolunye ucwaningo   ngesikhathi usabambe iqhaza kulolu 
cwaningo (ngaphandle uma ngikunikile imvume ngaphambi kwalokho). 
6. Ngicela ungangifihleli lutho mayelana nomlando wakho wezempilo, njengoba lokho 
kungenza ukuba uzilimaze ngokubamba iqhaza kulolu cwaningo. 
7. Uma unquma ukubamba iqhaza kulolu cwaningo, uzocelwa ukuba usayine leli fomu 
ngenhloso yokuqinisekisa ukuthi uyaluqondisisa lolu cwaningo.  Uzonikezwa ikhophi ukuba 
uzigcinele lona. 
8. Uma unodokotela wakho ongasebenzi eHelen Joseph Hospital, ngicela uxoxe naye noma 
umtshele mayelana nokuthi kungenzeka ubambe iqhaza kulolu cwaningo.  Uma uthanda, 
ngingamtshela mina udokotela wakho mayelana nalokhu. 
 
INHLOSO YALOLU CWANINGO 
Ukulesi sibhedlela noma ukulo mtholampilo ngoba unesifo sofuba esibizwa i-Drug Resistant 
Tuberculosis (i-DR-TB).  Ngizothanda ukuba ucabange mayelana nokubamba kwakho iqhaza kulolu 
cwaningo lokukala amazinga akho okuzwa ngaso sonke isikhathi usalashelwa i-DR-TB yakho.  
Uzonikezwa umuthi (imijovo) wokwelapha isifo sakho sofuba esimelana nemithi obizwa nge-
kanamycin kanye/noma ne-capreomycin  neminye imithi embalwa, ukuze i-TB yakho ibe ngcono, 
okuyikho okubaluleke kakhulu.  Ngeke uthole i-kanamycin ne-capreomycin kanye kanye, kodwa 
kungenzeka uyithole ezigabeni ezehlukene.  Yomibili iyimijovo.  Lo muthi ozonikezwa wona 
unamandla amakhulu futhi unobungozi obumbalwa, obunye balobu bungozi wukulahlekelwa 
wukuzwa.  Noma kunjalo, kudingeka ukuba uwusebenzise lo muthi ukuze uphinde uphile kahle.  
Iningi labantu abasebenzisa lo muthi bazolahlekelwa wukuzwa; nakuba lokhu kuvame ukwenzeka, 
akwenzeki njalo.  Kungaba nzima kakhulu ukukhuluma nomndeni kanye nabangane uma usungezwa 
ezindlebeni kanti nokusebenza kungaba nzima.  Ngakho-ke, ngesikhathi kusaqhubeka lolu cwaningo, 
sifuna ukukala amazinga akho okuzwa izikhathi eziyisikhombisa ezinyangeni ezintathu zokuqala, 
ukuze siqonde kahle mayelana nokuthi yini eyenzeka ekuzweni kwakho.  Emva kwalokho sizobe 
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sesikuhlola igazi izikhathi eziyisishiyagalombili ezinyangeni ezintathu zokuqala ukuze sibheke indlela 
umuthi wakho wokwelapha i-DR-TB osebenza ngayo emzimbeni wakho.  Nizohlukaniswa 
ngamaqembu amabili.  Mayelana neqembu elilodwa, kungenzeka sishintshe umithi wakho we-DR-TB 
yakho ukuze siqinisekise ukuthi umunceka kahle (awumunceki kakhulu ngokwedlulele noma kancane 
kakhulu).  Nakuba lokhu kusahlolwa, sethemba ukuthi uma sishintsha umuthi wakho we-DR-TB, 
kungehlisa amathuba okulahlekelwa wukuzwa.  Noma kunjalo, nakuba womabili amaqembu 
ezothathwa igazi, uzokwenziwa ushintsho eqenjini elilodwa kuphela, njengoba lokhu kuzovumela 
ukuba kuqhathaniswe amaqembu ashintshelwe umthamo nalelo qembu elingashintshelwanga 
umthamo ukuze kubonakale ukuthi yiliphi elilahlekelwe wukuzwa kancane.  Nakuba kunjalo akubona 
bona bonke abantu abasebenzisa i-kanamycin abalahlekelwa wukuzwa.  Uma ukulelo qembu 
lokulawula, ngeke siwushintshe umthamo wakho womuthi we-DR-TB yakho usizo lwakho luzosisiza 
ukwelapha ezinye iziguli ezinalesi sifo esikhathini esizayo futhi sizokwazi ukuqapha ukuzwa kwakho 
ngaso sonke isikhathi, kanye nokubheka ubudlelwano phakathi kwendlela lo muthi osebenzangayo 
emzimbeni wakho kanye nokuzwa kwakho. 
 
Ubude besikhathi socwaningo kanye nenani lababambiqhaza 
Lolu cwaningo luzokwenziwa kulesi sibhedlela kanye nasesibhedlela sase Helen Joseph..  Ngabantu 
abalinganiselwa kuma-80 abazobamba iqhaza kulolu cwaningo.  Ababambiqhaza bazobe 
beneminyaka ephakathi kweyi-18 nengama-55 ubudala. Kuzodingeka ukuba usebenzise i-kanamycin 
noma icapreomycin (kuye ngokwesinqumo sikadokotela wakho) yakho ezinye izinyanga emva 
kokubamba iqhaza kulolu cwaningo.  Sizokwenza ukuhlola izinyanga ezintathu zalolu cwaningo, 
okuzochazwa lapha ngezansi. Lokhu kuhlola wukuhlolwa kwegazi kanye nokuhlolwa kokuzwa. 
Ezinyangeni ezintathu zokuqala, uzocelwa ukuba ungivakashele izikhathi eziyi-9 ngenhloso 
yokuzohlolwa ngesikhathi kuqhubeka lolu cwaningo. Kokunye kwalokhu kuvakasha, uzobe 
usesibhedlela, ngakho-ke kungenzeka kwenziwe ewodini noma egumbini elehlukile esibhedlela.  
Kodwa-ke uma usudedeliwe, kuyodingeka ukuba ubuyele kulesi sibhedlela ukuze ubonane nami, 
noma uye esikhungweni esibhekana ne-TB esibhedlela sase Helen Joseph. Uma usesibhedlela 
izinyanga ezimbili, kuyodingeka ukuba uze ubonane nami njengesiguli esilashelwa ngaphandle, 
inyanga eyodwa. Kodwa kuyokuya ngokuthi uhlale esibhedlela isikhathi esingakanani.  Usuku 
lwanamhlanje luzobalwa njengosuku loku-1. Kuzodingeka FUTHI ukuba uye emtholampilo 
oseduzane nekhaya lakho zonke izinsuku (uMsumbuluko kuya ngoLwesihlanu) ukuze uthole umjovo 
wakho kumhlengikazi ukuze arekhode isikhathi nesilinganiso ositholayo (kuzodingeka ukuba wenze 
lokhu ngisho ungeyona ingxenye yocwaningo njengoba lokhu kungukunakekelwa 
okwejwayelekile).Ngakho-ke kuzodingeka ukuba uye esibhedlela sase South Rand noma sase Helen 
Joseph (leso osincamelayo) kanye njalo emasontweni amabili ukuze wenze ukuhlolwa kokuzwa 
nokwegazi, bese uya emtholampilo wendawo zonke izinsuku..  Sizokukhokhela ama-R150 mayelana 
nezindleko zokugibela njalo nje uma kudingeka ukuba uze esibhedlela mayelana nokuzohlolelwa 
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ukuzwa negazi. Uma uyisiguli esilaliswe esibhedlela, ngeke ukhokhelelwe izindleko zokugibela kuze 
kube uyakhishwa esibhedlela njengoba ungeke ube nesidingo sokugibela.  Bese sikunika imali 
eyanele yokugibela ukuze uye emtholampilo zonke izinsuku (ngoMsombuluko kuya ngoLwesihlanu) 
ukuze uthole imijovo yakho.  Lokhu kuzokwenziwa izikhathi eziyi-9, njalo esontweni lesibili.  Sizobe 
sesikunika imali eyanele yokugibela ukuza emtholampilo nsuku zonke (kusukela ngoMsombuluko 
kuya ngoLwesihlanu) ngenhloso yokuzothola imijovo yakho ye-kanamycin.  Ngesikhathi uza 
emtholampilo mayelana nokuvakasha kwakho kocwaningo “okusemthethweni” uma uzohlolelwa 
igazi nokuzwa sizokunika ama-R150.  Ngeke sikunike imali yokugibela ethe xaxa kunaleyo yansuku 
zonke uma uzele imijovo yakho ngalezo zinsuku onikezwa ngazo ama-R150. 
 
IZINQUBO 
Uma uvuma ukubamba iqhaza kulolu cwaningo, uzobuzwa imibuzo bese wenziwa ukuhlolwa 
okumbalwa – okuzobe kuwukuhlolelwa ukuzwa kanye nokuhlolwa kwegazi lakho.  Lokhu kuhlolwa 
kuzokwenziwa ngaphezu kokunye ukuhlolwa/nezinqubo ezingahlobene nalolu cwaningo. 
Uma uvuma ukubamba iqhaza kulolu cwaningo futhi unikeza imvume, kuzodingeka ukuba ngikubuze 
imibuzo embalwa namuhla bese ngikuhlola.  Bese ubuya kusasa ukuze wenze okunye ukuhlolwa 
kwegazi nokuhlolwa kokuzwa kokuqala.  
Kuzodingeka ukuba uye emtholampilo oseduze nawe nsuku zonke (kusukela ngoMsombuluko kuya 
kuLwesihlanu – hhayi ngezimpelasonto) ukuze uthole umjovo wakho we-kanamycin/we-capreomycin 
uma usukhishiwe esibhedlela. Bese kuthi njalo esontweni lesibili, kudingeke ukuba uhlolwe igazi 
uhlolelwe nokuzwa futhi. Lezo nsuku zizothatha isikhathi eside uma kuqhathaniswa nokuvakasha 
kwakho kwansuku zonke. 
 
Inhloso yokuhlolelwa ukuzwa 
Izindlebe zethu ziyizitho zomzimba ezimangalisayo ngoba ziyakwazi ukuzwa imisindo 
eminingi ehlukahlukene.  Siyakwazi ukuzwa imisindo emincane njengomsindo owenziwa ngumshini 
wokugunda utshani, noma yibhasi, noma ngisho nokuconsa kwamanzi empompini.  Le yimisindo 
ihlukahlukene, futhi inamazinga omsindo ahlukahlukene kodwa yonke le misindo iphansi.  Futhi 
siyakwazi ukuzwa imisindo ephakeme, isibonelo izinyoni ezisho ngengila ephezulu noma ukukhala 
kwe-alamu yewashi. 
 
Imisindo yenkulumo, amagama nemisho konke lokhu kuyimisindo ehlukahlukene.  Isibonelo, 
u- /m/, u-/d/ no-/b/ kuyimisindo ephansi kodwa u-/f/, u-/s/ no-/th/ kuyimisindo ephezulu.  Ukuze 
sizwane, kudingeka sikwazi ukuzwa imisindo eminingi ehlukahlukene, njengemisindo yenkulumo 
njengoba inemisindo eminingi ehlukahlukene. 
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Uma sesiqala sizwa imisindo ephansi yodwa, singasayizwa imisindo ephezulu, kusho ukuthi 
siyehluleka ukuzwa inkulumo.  Ngakho, isibonelo, uma umuntu ethi ‘head’, awube usamuzwa kahle 
ucabange ukuthi uthi ‘bed’.  Uma umuntu ethi ‘fate’, ungezwa kuphela sengathi uthi ‘ate’.  Ngakho-
ke ukulahlekelwa ukuzwa ngisho nasemisindweni embalwa kungenza ukuba ungakuqondi lokho 
okushiwo ngabangane bakho, umndeni kanye nabodokotela bakho. 
 
Ukulahlekelwa wukuzwa kungadalwa yizinto eziningi ezihlukahlukene.  Kwesinye isikhathi 
abantu kungenzeka bazalwe bengezwa kahle, noma kungenzeka ukungezwa kahle kudalwe 
ngumsindo ophezulu, wukwethuka ngokwedlulele kanye nemithi ethile.  I-DR-TB yisifo esibi 
kakhulu futhi udinga umuthi onamandla amakhulu ukuze uphole uphinde uphile.  Noma kunjalo, 
kwezinye izikhathi le mithi ingadala ukulahlekelwa wukuzwa, okungenza ukuba kube nzima kuwe 
ukuzwa nokuxhumana nabanye abantu. 
 
Njengoba kudingeka umuthi onamandla kakhulu (i-kanamycin/i-capreomycin) ukuze uphile, 
kumele ukuba uwusebenzise.  KODWA, lolu cwaningo luzama ukuqonda ngqo i uhlobo 
lokulahlekelwa wukuzwa oludalwa yilo muthi okuzokwenza ukukwelapha kangcono lokhu 
kulahlekelwa wukuzwa noma ukukuvikela esikhathini esiizayo.  
Sidinga ukukala indlela ozwa ngayo imisindo ehlukahlukene ngesikhathi uza esibhedlela, 
bese kuthi emva kwalokho kube masonto onke ambalwa, ukuze sibone ukuthi kuhlala kunjalo noma 
kuya ngokuya kuba kubi. 
Izinqubo zokuhlola ukulahlekelwa wukuzwa 
Ukuhlolela ukuzwa akubuhlungu, futhi kunezingxenye ezimbalwa, ezimi kanje: 
• I-otoscopy – Okokuqala, kuzodingeka ukuba ngibheke phakathi ezindlebeni zakho ukuze 
ngibone ukuthi akukho sigonogono yini, noma ezinye izinto ezindlebeni zakho, njengoba 
lokhu kungenzeka kube nomthelela emiphumelweni yakho. Lokhu kuzothatha cishe 
imizuzwana engama-20. 
• Ukulawulwa kwesigonogono – Uma izindlebe zakho zivalekile ngenxa yesigonogono, 
ngizosikhipha ukuze singabi nomthelela kokunye ukuhlola.  Ngizofaka amafutha endlebeni 
yakho ukuze isigonogono sakho sithambe.  Ngizobe sengisebenzisa umshini ukukhipha 
isigonogono (ukusimunca).  Ukumunca kuzothatha imizuzwana embalwa nje kuphela.  
Kungenzeka uzwe ubuhlungwana, kodwa akuvamile ukuba buhlungu. 
• I-tympanometry (uhlobo lokuhlola okukala ukusebenza kwengxenye yendlebe ephakathi 
naphakathi) – ngizobe sengibeka umshini phakathi endlebeni yakho.  Lo mshini othambile 
uzofuthela umoya endlebeni yakho.  Ngeke kube buhlungu, kodwa kuzokwenza ukuba sazi 
ukuthi ingabe zikhona yini izifo ngaphakathi ekujuleni kwendlebe yakho, uma kukhona noma 
yiluphi uketshezi.  Uma lukhona uketshezi, lizoba nomthelela ekuzweni kwakho kanye  
nasemiphumelweni yokuhlola.  Lokhu kuzothatha cishe imizuzu emi-2. 
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• I-Distortion Product Otoacoustic Emissions – Sinamaseli ezinwedlana ekujuleni kwezindlebe 
zethu. Amaseli ezinwele ahlukahlukene abalulekile ekuzweni imisindo ehlukahlukene.  
Ngakho-ke umshini i-DPOAE ukala indlela lawa maseli ezinwele ahamba nasebenza ngayo.  
Sidinga ukufaka lo mshininyana othambile endlebeni yakho ukuze wenze imisindo 
ehlukahlukene.  Kumele unganyakazi futhi uthule, lo mshni uzobe usuthatha izilinganiso 
zalawa maseli ezinwele.  Lokhu kuzothatha cishe imizuzu emi-5 kuya kweyi-10. 
• I-Pure Tone Audiometry – Sizokufaka ama-headphone.  Azokhipha imisinjwana.  Le misindo 
izoba namaphimbo ahlukahlukene.  Amanye azoba phansi kanti amanye azoba phezulu.  
Lapho uzwa umsindo, kuzomele ucindezele inkinobho.  Lokhu kuzothatha cishe imizuzu eyi-
15 kuya kwengama-20. 
• Uma lokhu sekwenziwe, sizobe sesikwazi ukuhlanganisa imiphumela bese siqonda kahle 
ukuthi yikuphi okwazi ukukuzwa.  Uma sikuhlola ngesikhathi uza esibhedlela, bese sikuhlola 
futhi ngezikhathi ezithile, sizokwazi ukubona ukuthi ukuzwa kwakho kuyashintsha yini. 
Uma ukuvuma lokhu, kuzodingeka ukuba ukwenze izikhathi eziyisi-7 ezinyangeni ezintathu 
zokuqala.  Kungaba kusasa, bese kuba njalo esontweni lesibili ezinyangeni ezintathu ezilandelayo. 
Emva kwezinyanga ezintathu zalolu cwaningo, odokotela abaphathelene nemizwa yokuzwa 
(audiologists) balesi sibhedlela noma esibhedlela noma emtholampilo wesifunda sakho bazoqhubeka 
nokuqapha ukuzwa kwakho.  Uma kwenzeka ulahlekelwa wukuzwa, bazoqhubeka nokukusiza 
ngezinsizakuzwa kanye nokunye ukulawula ukuzwa kwakho.  Ngizokudlulisela kubo emva kwalolu 
cwaningo. 
 
Amasampula egazi 
Sizodinga ukukuthatha negazi.  Sizodinga ukukuthatha igazi ukuze sikwazi ukulinganisa 
indlela umuthi (i-kanamycin/i-capreomycin) osetshenziselwa ukwelapha i-DR-TB yakho ukuthi 
usetshenziswa kanjani emzimbeni wakho.  Sethemba ukuthi lokhu kuzosisisza ukuba sikwazi ukuqonda 
ukuthi yingani abantu belahlekelwa wukuzwa.  Mina noma omunye unesi noma i-phlebotomist 
sizokuthatha igazi ukuze senze ukuhlola okudingekayo.  Sizodinga ukukuthatha ama-2 ml egazi 
mayelana nalokho nalokho kuhlola.  Kuzodingeka ukuba okungenani sikuhlole igazi kabili ngaleso 
naleso sikhathi (ngaphandle kokuvakasha okubili kokuqala).  Amamililitha amabili cishe alingane 
namaconsi amabili egazi noma uhhafu wethisipuni.  Ngakho-ke, kuzodingeka ukuba sikuthathe ama-4 
ml egazi ngalolo nangalolo suku esikubona ngalo ukuze sikale i-kanamycin (okuzoba yigazi 
elingaphansana kwethisipuni).  Uma uqala ukuthathwa igazi kuzobe kungemva kwamahora ambalwa 
uthole umjovo wakho we-DR-TB.  Bese sikuthatha igazi okwesibili osukwini olulandelayo ngaphambi 
kokuthola umjovo wakho.  Kanti kwezinye izikhathi, kuzodingeka ukuba uthathwe igazi lakho 
ngaphambi kokuthola umjovo, futhi kumele kudlule amahora ambalwa emva kokuthola umjovo.  
Ngakho-ke mayelana nokuvakasha ngakunye (ngaphandle kokuvakasha kwesibili lapho uhlolelwa 
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igazi), kuzodingeka ukuba ube semtholampilo cishe amahora amane nesigamu (ngaphandle uma 
ulalisiwe uvele usesibhedlela).  Kuzodingeka ukuba senze lokhu izikhathi eziyi-8 sezihlangene zonke 
ezinyangeni ezintathu (kusasa kuzobe kungokokuqala).  Ngakho-ke sekukonke, ezinyangeni ezintathu, 
sizothatha inani elingama-28 ml legazi selilonke, elicishe libe ngamathisipuni amahlanu nesigamu.   
 
Ukuze siqonde ukuthi umuthi unamthelela muni ezinsweni zakho, sidinga nokukala 
ukusebenza kwezinso zakho.  Ekuvakasheni okuyisithupha  kwalokhu  okuyisishiyagalolunye, 
sizodinga ukukuthatha elinye igazi elingama-3 ml, ukuze sikale ukusebenza kwezinso zakho ukuze 
senze ushintsho olulungile lomthamo. Ngakho-ke ngaleso sikhathi sokuvakasha lapho kuzodingeka 
ukuba sihlole lokhu, sizodinga amanye ama-3ml angeziwe egazi, okungaba ngaphezudlwana nje 
kwethisipuni.  Kumahlandla amathathu sizokuthatha igazi elingama-18 ml selilonke, elingaba 
ngaphezudlwana  kwamathisipuni amathathu ngaphezu kokunye ukuhlolwa kwegazi osekuchaziwe  
ngenhla.  Sizokuthatha leli gazi ngesikhathi esisodwa nesokuhlolelwa igazi mayelana ne-
kanamycin/ne-capreomycin – ukuze ungahlatshwa kaningi ngenalidi. 
 
Ukuthathwa kwegazi kuyingxenye yokunakekelwa kwakho okuvamile ngokwezempilo kulesi 
sibhedlela.  Kuzodingeka ukuba sikuthathe igazi kodwa lokhu singakuhlanganisi nezinqubo ezivamile 
zasesibhedlela.  Lokhu kungakuzizwa ubuhlungwana. Sizokuthatha igazi ngendlela efanayo naleyo 
esetshenziswa uma uthathwa igazi ngenhloso yokuhlolelwa kwakho igazi okuvamile.  Ukuthathwa 
kwegazi kungakwenza uquleke, uvuvuke umthambo wegazi, uzwe ubuhlungu, uhuzuke noma wophe 
lapho kungene khona inalidi.  Kukhona namathuba amancane okusuleleka ngesifo.  Ongcweti 
bamanesi noma bama-phlebotomist bazokuthatha igazi endaweni ehlanzekile ukuze baqinisekise 
ukuthi kuphephile. 
 
Igazi lakho lizogcinwa liphephile isikhathi esingevile osukwini esibhedlela sase South Rand 
bese ligcinwa esibhedlela sase Helen Joseph  kuze kufike leso sikhathi selithunyelwa elabhorethri 
ukuze liyohlolwa.  Lizothunyelwa ngaphandle kokuchitha isikhathi.  Ngeke ligcinwe isikhathi 
esingaphezu kwesonto.  Igazi lakho liyothunyelwa elabhorethri yase-Sefako Makgatho Health 
Sciences University.  Bese kuthi lelo gazi esilithathela ukukala ukusebenza kwezinso zakho lona 
lizothunyelwa kwenye ilabhorethri, ebozwa i-CLS.  Lonke ulwazi oluqondene nawe ngqo mayelana 
nalokhu kuhlola namayelana nezempilo yakho jikelele kuzogcinwa kuyimfihlo efayilini ezohlala 
ekhabetheni ngesikhathi kuqhubeka lolu cwaningo nangesikhathi seluphothuliwe.  Ulwazi oluqondene 
nawe ngqo ngeke kuxoxwe ngalo nomunye umuntu ongabandakanyekile kulolu cwaningo lophenyo.  
Uma lokhu kudingeka, sizocela imvume yakho ngaphambi kokuba kwenziwe.  Lokhu sikudingela 
ukuqinisekisa ukuthi lonke ulwazi lurekhodwe ngendlela elungile, ngenhloso yokuqinisekisa ukuthi 
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sihlaziya imiphumela ukuze sibone ukuthi lokhu kuqashwa komuthi wokwelapha (okungukushintsha 
imithamo yakho ye-kanamycin) kusebenzile yini. 
 
Ukuhlolelwa ukuzwa kanye nokuhlolwa kwegazi kuzokwenziwa ngosuku lwesibili (kusasa), 
nangosuku lwe-15, 28, 40, 54, 68 kanye nolwama-84.  Ukuhlolwa kwegazi kuzokwenziwa kusasa 
(ngosuku lwesi-2), ngosuku olulandelayo (usuku lwe-3), bese kwenziwa ngosuku olulodwa 
lokuhlolelwa kwakho ukuzwa – osukwini lwe-15, 28, 40, 54, 68 kanye nangosuku lwama-84. 
 
Lokho nalokho kuvakasha ngenhloso yokuzohlolelwa ukuzwa kanye nokuzohlolwa igazi 
(hhayi lezo zinsuku eziphakathi oza ngazo uma uzojovwa), kuzothatha cishe amahora ama-5.  Lokhu 
kudalwa wukuthi sidinga ukuba silinde amahora amane nesigamu phakathi kokuhlolwa igazi 
okwenziwa kabili.  Ngakho kungabangcono ukuba usheshe ufike ekuseni ukuze ukwazi ukubuyela 
emuva ntambama. 
 
KUNGENZEKA YINI UKUTHI LEZI ZINQUBO  ZINGIZWISE UBUHLUNGWANA NOMA 
ZINGIPHAZAMISE? 
Ukuthathwa kwegazi kungakuzwisa ubuhlungwana.  Igazi sizolithatha ngendlela efanayo naleyo 
esetshenziswayo ngesikhathi uhlolwa igazi.  Ukuthathwa kwegazi kungakwenza uquleke, uvuvuke 
umthambo wegazi, uzwe ubuhlungu, uhuzuke noma wophe kuleyo ndawo elikhishwe kuyo.  Kukhona 
namathuba amancane okungenwa yisifo.  Igazii lakho lizothathwa ngamanesi (noma ama-
phlebotomists) angongcweti ukuze uvikeleke futhi konke kuzobe kuhlanzekile ngaso sonke isikhathi.  
Uzothathwa isamba segazi elingama-4 ml (elingaphansana kwethisipuni) ngalokho nalokho 
kuvakasha kocwaningo (ngaphandle kosuku lwesi-2 nolwesi-3).  Lesi yisamba esingama-28 ml egazi, 
okuyigazi elingacishe libe ngamathisipuni amahlanu nesigamu egazi.  Uzobe usuthathwa elinye igazi 
elengeziwe elingama-3 ml ngosuku lwama-40, 68 nolwama-84 – isamba esengeziwe esingama-18 ml 
okuyigazi elingaphansana kwamathisipuni amabili.  Ngakho-ke, selilonke igazi ozothathwa lona 
ezinyangeni ezintathu lingama-46 ml – okuyigazi elilingana cishe namathisipuni ayisi-7 nesigamu. 
Lokhu kuhlolelwa ukuzwa okuchaziwe lapha ngenhla ngeke kukuzwise ubuhlungu; noma 
kunjalo, ukukhishwa kwesigonogono kungaba buhlungu.  Angeke kube nesidingo sokukhipha wonke 
umuntu isigonogono, futhi akuvamile ukuba buhlungu.  Ukukhishwa isigonogono kuzothatha 
imizuzwana embalwa nje kuphela.  Kanti ukuhlola sekukonke kuzothatha isikhathi sakho esicishe sibe 
yimizuzu engama-30 kuya kwengama-40 ngalokho nalokho kuhlolwa.  Uzokwazi ngaso sonke 
isikhathi ukuxoxisana nonesi mayelana nemiphumela yakho nokuthi ubuze imibuzo ngaphambi 
nangemuva kwalokhu kuhlola.  Uma uneminye imibuzo, ungathintana nami, i-audiologist. 
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IZINZUZO 
• Inzuzo ongayithola ngokubamba kwakho iqhaza kulolu cwaningo ukuthi uzokwazi ukuqonda 
isimo sokuzwa kwakho ngokugcwele nokuhlobana kwakho nokusebenza kwe-
kanamycin/kwe-capreomycin emzimbeni wakho  
• Kungenzeka ungazuzi lutho kulolu cwaningo. 
• Ukubamba kwakho iqhaza kulolu cwaningo kuzosiza ekuthuthukiseni ulwazi kwezokwelapha 
olungasiza ezinye iziguli ezine-DR-TB njengawe futhi ezisengcupheni yokulahlekelwa 
wukuzwa. 
 
ENYE INDLELA YOKWELASHWA 
• Okwamanje, ayikho enye indlela yokwelapha ngenhloso yokwehlisa amathuba okulahlekelwa 
wukuzwa noma yokugwema ukulahlekelwa wukuzwa okudalwa ngumuthi we-DR-TB.  Uma 
kwenzeka ulahlekelwa wukuzwa; uzodluliselwa emtholampilo wangakini ukuze ukusize 
uthole izinsizakuzwa.  
• Ukuqapha i-kanamycin egazini lakho akuyona inqubo ejwayelekile, ayikho enye indlela 
yokwenza lokhu ngaphandle kokuhlola igazi okwamanje.   
•  I-Audiology Department kulesi sibhedlela izokwazi ukukusiza uma ukule ndawo ephakela lesi 
sibhedlela.  Lokhu kuyingxenye yezinqubo zikahulumeni ezivamile mayelana nokuphathwa 
kokulahlekelwa wukuzwa.  Uma unquma ukungalibambi iqhaza kulolu cwaningo, uzoqhubeka 
nokuthola ukunakekelwa okuhle okutholakayo njengamanje okuqondene ne-DR-TB yakho 
kulo mtholampilo. 
 
IZINZUZO NOBUNGOZI BENYE INDLELA YOKWELASHWA ESEZINGENI  
• Njengoba njengamanje ungekho umuthi ongasiza ekuvimbeleni noma ekwehliseni amathuba 
okulahlekelwa wukuzwa, awukho omunye umuthi.  Uma umuthi we-DR-TB udala 
ukulahlekelwa wukuzwa, kuyaye kungalapheki futhi akukwazi ukulungiseka.  Kodwa 
ungayithola insizakuzwa ezokwenyusa yonke imisindo ukuze usizakale. Noma kunjalo, 
kwesinye isikhathi izinsizakuzwa ziyaye zingasizi ngalutho, ngoba kuyenzeka ukuthi 
kwesinye isikhathi ukulahlekelwa wukuzwa kuyaye kube kubi kakhulu, okwenza ukuba 
izinsizakuzwa zingakwazi ukukusiza.  Kwezinye izikhathi izinsizakuzwa angeke zikwazi 
ukukusiza mayelana nokulahlekelwa wukuzwa, njengoba kwesinye isikhathi ukulahlekelwa 
wukuzwa kuyaye kube kubi kakhulu ngendlela yokuthi izinsizakuzwa zingabe zisakwazi 
ukukusiza.  Ngeke sikunikeze izinsizakuzwa – iminyango yezibhedlela ye-audiology 
ingakwazi ukukusiza ngalokho uma ukule ndawo ephakela lezi zibhedlela, noma 
singakudlulisela emtholampilo noma esibhedlela esilungile esikuleyo ndawo ephakela leso 
sibhedlela. 
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• Izinzuzo zezinsizakuzwa kungenzeka zibe nemikhawulo, kodwa-ke kungenzeka zikusize uma 
kwenzeka ulahlekelwa  wukuzwa kwakho  kusaqala ngenxa yokusebenzisa umuthi we-DR-
TB.  Izinsizakuzwa azinabo ubungozi. 
 
INGABE ZIKHONA YINI IZEXWAYISO NOMA IMIBANDELA MAYELANA 
NOKUBAMBA KWAMI IQHAZA KULOLU CWANINGO 
• Uma unesifo sikashukela i-Diabetes Mellitus awuvunyelwe ukubamba iqhaza kulolu 
cwaningo.  I-Diabetes Mellitus kuyenzeka kwesinye isikhathi sibe nomthelela ekuzweni, kanti 
sifuna ukukala ukuzwa kwakho ngaphandle kokuthikamezeka. 
• Uma uneminyaka yobudala engaphansi kweyi-18, noma uneminyaka yobudala engaphezulu 
kwengama-55,  ngeke ukwazi  ukubamba iqhaza kulolu cwaningo.  Kulolu cwaningo sikala 
kuphela abantu abaphakathi kweminyaka yobudala eyi-18 nengama-55. 
• Uma udokotela wakho ekushintshela kweminye imithi (okungeyona i-kanamycin noma i-
capreomycin) ngeke ukwazi ukuqhubeka nokubamba iqhaza kulolu cwaningo.   
•  Uma udokotela wakho eshintsha imithi yakho, ngeke usakwazi ukuqhubeka nokubamba 
iqhaza kulolu cwaningo. 
• Uma kade ungakwazi ukuphila ngaphandle kwanoma yisiphi isidakamizwa futhi unomlando 
wokusebenzisa budedengu izidakamizwa notshwala, ngeke ukwazi ukubamba iqhaza kulolu 
cwaningo uma lokhu kungaba nomthelela ekulandeleni kwakho imiyalelo yezinqubo 
zokuhlola.  Isinqumo mayelana nalokhu sizothathwa abacwaningi  ababandakanyekayo. 
 
AMALUNGELO NJENGOMBAMBIQHAZA KULOLU CWANINGO 
Ukuzithandela 
Ukubamba kwakho iqhaza kulolu cwaningo kungukuzithandela kwakho futhi 
unokuzikhethela ukuthi uyafuna noma awufuni ukubamba iqhaza kulolu cwaningo.  Futhi uyakwazi 
ukuyeka ukubamba iqhaza kulolu cwaningo noma nini ngaphandle kokunikeza isizathu.  Uma 
unquma ukungalibambi iqhaza kulolu cwaningo, noma unquma ukuyeka ukubamba iqhaza 
ngesikhathi kusaqhubeka lolu cwaningo, uzoqhubeka nokuthola unakekelo lwezempilo kulesi 
sibhedlela, futhi ngeke lokhu kuthinteke. 
Okusha okutholwayo 
Ngizokunikeza noma yiluphi ulwazi olusha enginalo ngesikhathi kusaqhubeka lolu cwaningo, 
okungenzeka lukwenze ushintshe umqondo wakho wokufisa ukuqhubeka ukulolu cwaningo. 
Ukuhoxa 
Ukuhoxa kwakho noma ukuyeka ukubamba iqhaza kulolu cwaningo ngeke kuthinte 
ukunakekelwa kwakho ngokwezempilo. Nginelungelo lokukuhoxisa kulolu cwaningo uma lokho 
kuzosiza wena.  Uma udokotela wakho eshintsha imithi yakho ye-DR-TB futhi ungasasebenzisi i-
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kanamycin/i-capreomycin, ngeke usakwazi ukuqhubeka nokubamba iqhaza kulolu cwaningo.  Uma 
unganikezanga ulwazi olulungile nolwethembekile mayelana nomlando wakho wezempilo, noma 
ungalandelanga imithetho yalolu cwaningo, ngizokukhipha kulolu cwaningo noma nini. 
 
UKUNAKEKELWA NGAPHANSI KWEZIMO EZIPHUTHUMAYO KANYE 
NOKUNGENISWA ESIBHEDLELA 
Uma udinga usizo oluphuthumayo noma nini ngesikhathi kuqhubeka lolu cwaningo, 
uyacelwa ukuba ushayele uDkt Damoyi noma uDkt Shilubane kule nombolo: 011 681 2184 noma 
uDkt Mohammed Rassool ucingo kule nombolo: 011 276-8813 noma kule nombolo: 027 83 415 8967 
noma ushayele uDkt Rebecca Berhanu kule nombolo: 011276 8968 noma kule nombolo: 072 717 
9159. 
 
AMALUNGISELELO EZEZIMALI 
• Abaxhasi balolu cwaningo bazokhokhela konke ukuhlola okuzokwenziwa kulolu cwaningo. 
• Wena nabe-medical aid yakho (uma unayo) angeke kudingeke ukuba nikhokhele noma 
yimiphi imithi yalolu cwaningo noma izinqubo zalolu cwaningo, konke lokhu kuxhaswe 
yizinhlangano zalolu cwaningo. 
• Ngesikhathi uvakashela esibhedlela ngokwalolu cwaningo njalo esontweni lesibili (ukuze 
uhlolelwe ukuzwa kanye nokuhlolwa igazi) uzonikezwa ama-R150 okugibela (kuphela uma 
usuyisiguli eselashelwa ngaphandle).  Ngeke ukhokhelwe ngokubamba iqhaza, kodwa 
uzokhokhelwa kuphela imali yokugibela neyokudla okulula.  Uma uza nsuku zonke 
ukuzothola umjovo wakho kanye noshintsho lomthamo okungenzeka lwenziwe, uzonikezwa 
imali eyanele yokugibela Uzonikezwa ama-R50 wokugibela nsukuzonke. Lokhu 
kuzokwenziwa kuphela ezinyangeni ezintathu zokuqala.  Emva kwalezi zinyanga ezintathu, 
uzothola umjovo wakho emtholampilo oseduze nawe, kanti ayikho imali yokugibela 
ozonikezwa yona. 
 
IMVUME YENKAMBISO ELUNGILE  
• Iphrothokholi yalolu cwaningo lwezokwelapha isinikeziwe ku-University of the 
Witwatersrand, Human Research Ethics Committee (HREC) kantileli komidi isinikezele 
ngemvume ebhalwe phansi. 
• Lolu cwaningo lulandela imihlahlandlela ye-Declaration of Helsinki (egcine ukubuyekezwa: 
ngo-Okthoba 2013), ebhekele izincomo mayelana nodokotela abenza ucwaningo 
lwezokwelapha olubandakanya ababambiqhaza okungabantu.  Uma ufisa ukuthola ikhopho 
yale migomo, ngicela ungazise ukuze ngikutholele lona. 
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• Lolu cwaningo lukhokhelwe yinhlangano yocwaningo (i-South African Medical Research 
Council).  Akukho nzuzo engiyibhekile yemali noma mina angeke ngizuze ngalutho kule 
nhlangano futhi ayikho ingcindezi engiyithola kule nhlangano noma angichemile nayo. 
 
UMSHWALENSE 
Bonke odokotela abangabacwaningi kulolu cwaningo banomshuwalense. Umcwaningi 
omkhulu nodokotela banomshuwalense we-MPS ukuba benze izinqubo uma nje:  
• Behlonipha izinqubo zephrothokholi yocwaningo. 
• Behambisana nemithetho yesigungu esilawula imithi neye-University of the Witwatersrand 
Research Ethic Committee. 
• Bephatha imithi yocwaningo ngokwephrothokholi nokugguqulwa kwayo kanye nemibhalo 
ehlobene.  
• Lokhu kuvikela akuhlosile futhi akuthathi indawo yomshuwalense yokungasebenzi komuntu 
ngendlela efanele 
• Sicela uqaphele ukuthi uma une-policy yomshuwalense wempilo kufanele utthole noma 
inkampani yomshuwalense idinga ukwaziswa mayelana nokubamba kwakho iqhaza 
ocwaningweni. Ngokolunye ulwazi, lokhu akufanele kuphazamise noma iyiphi enye i-policy 
yomshuwalense wempilo onayo. Kodwa kubalulekile ukuthi ubhekisise ngoba kuyenzeka  
izinkampani zingafani.  
 
UMTHOMBO WOKUTHOLA OLUNYE ULWAZI 
Ngesikhathi kusaqhubeka lolu cwaningo, uzonakekelwa ngabasebenzi basesibhedlela sase 
South Rand..  Noma nini uma ufisa ukubuza eminye imibuzo ehlobene nalolu cwaningo, ngicela 
ungithinte noma uthinte unesi wocwaningo/umdidiyeli wocwaningo osemsebenzini ngalesi sikhathi 
esibhedlela. 
Amalungu (abacwaningi nabacwaningi abancane) ocwaningo ongaxhumana nawo: 
✓ UCara Hollander – 082 815 8878 (oyi-Audiologist) 
✓ UDkt. Karin Joubert – 011 717 4561 (oyi-Audiologist) 
✓ USolwazi. Natalie Schellack – 012 521 3286 (onguSokhemisi) 
✓ Dr. Shilubane – 011 681 2184  
✓ UDkt. Rebbeca Berhanu – 011 276 8968 (ongudokotela) 
✓ UDkt. Mohammed Rassool –011 276-8813 (ongudokotela Nomphenyi 
Omkhulu) 
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• Uma ufuna noma yiluphi ulwazi oluthe xaxa mayelana namalungelo akho 
njengombambiqahaza ocwaningweni, noma uma ufuna ukudlulisa ukukhalaza mayelana 
nalolu cwaningo lophenyo, ungaxhumana noSlz Cleaton-Jones, uSihlalo we-University of the 
Witwatersrand, Human Research Ethics Committee (HREC), okuyikomidi elizimele elisiza 
ekuvikelweni kwamalungelo ababambiqhaza ocwaningweni kule nombolo: (011) 717 2301. 
• Mayelana nolwazi olumayelana nocwaningo, ungashayela umdidiyeli Wocwaningo  – uCara 
Hollander wase-University of the Witwatersrand kule nombolo: 082 815 8878. 
 
UBUMFIHLO 
• Lonke ulwazi esiluqoqa ngesikhathi kuqhubeka lolu cwaningo, olubandakanya amarekhodi 
asesibhedlela, ulwazi oluqondene nomuntu ngqo kanye nolwazi olumayelana nocwaningo 
luzogcinwa luyimfihlo.  Ulwazi lwakho luzobonwa ngamalungu eqembu locwaningo kuphela, 
kanye nosokotela bakho kanye namanesi.  Noma yiluphi ulwazi oluzobe lubhalwe kumajenali 
esayensi noma nanoma yikuphi okushicilelwayo ngeke kube negama lakho kukho. 
• Sizofaka amakhodi ahlukahlukene olwazini lwakho locwaningo.  Ngakho-ke uma imiphumela 
yakho ibuyekezwa, izobe inekhodi kuphela.  Igama lakho, inombolo yakho kamazisi noma 
nanoma yimaphi amanye amanothi okungenzeka akuhlonze ngeke kufakwe kulawo 
mabhukwana, ukuze kuqinisekiswe ukuthi konke kuyimfihlo. 
• Lolu lwazi luzobuyekezwa ngabaphathiswa abagunyaziwe be-University of the Witwatersrand 
kanye nabase-Sefako Makgatho Health Sciences University kanye namalungu avela kubaxhasi 
(i-Medical Research Council).  Abacwaningimabhuku be-Wits Health Consortium bavunyelwe 
ukubheka eminye imiphumela ngesikhathi behlola ngenhloso yokuqinisekisa ukuthi konke 
kwenziwe ngokulandela amazinga amahle.  Nakuba kunjalo, akusiyena wonke umuntu 
ozofinyelela egameni lakho – yonke imiphumela yakho izoba nenombolo, okuzokwenza ukuba 
bangazi ukuthi nguwe. 
• Kungenzeka futhi ukuthi ulwazi luhlolwe ngabe-National Health Research Ethics Committee 
(NHREC), yi-University of the Witwatersrand, Human Research Ethics Committee (HREC), 
yi-South African Medicines Control Council (MCC) kanye/noma yi-United States Food and 
Medicine Administration (FDA) kanye nodokotela wakho. Ngakho-ke lapha uyangigunyaza 
ukuthi ngikhulule amarekhodi akho ezokwelapha ngiwanike i-Medical Research Council, 
abasebenzi bayo noma ama-ejenti ayo, abasemagunyeni kwezokulawulwa kwezempilo 
bakuleli lizwe nabakwamanye amazwe, i-South African Medicines Control Council ) i-MCC), 
i-National Health Research Ethics Committee (NHREC) kanye ne-University of the 
Witwatersrand, Human Research Ethics Committee (HREC). 
• Lawa marekhodi azosetshenziswa yibo kuphela ekwenzeni imisebenzi yabo ehlobene nalolu 
cwaningo lwezokwelapha. 
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• Noma yiluphi ulwazi oludaluliwe mayelana nemiphumela yokuhlolwa kwakho noma isimo 
sakho sempilo ngenxa yokubamba kwakho iqhaza kulolu cwaningo luzohlala luyimfihlo.  
Uzotshelwa mayelana nanoma yikuphi okutholakele okubalulekile mayelana nezempilo yakho 
noma okubalulekile mayelana nokuqhubeka kwakho ukubamba iqhaza kulolu cwaningo, 
kodwa lolu lwazi ngeke lunikezwe noma yimuphi omunye umuntu phezu kwalabo abashiwo 
lapha ngenhla ngaphandle kwemvume yakho ebhalwe phansi.  Esimweni lapho lo mthetho 
ungeke usebenze khona yikulezo zimo ezimayelana nezifo ezithathelanayo lapho umthetho 
okhona udinga ukuba kwaziswe aboMnyango Wezempilo.  Uma kuba nesimo esinjalo, 
ngiyokwazisa ngaso ngiphinde ngikwazise futhi ukuthi lolo lwazi ngizoludlulisela kwi-ejenti 
kahulumeni egunyaziwe. 
 
UKUKHETHA UKUBA KWAZISWE UDOKOTELA WAKHO/UNGOTI WAKHO  
Ngicela ungitshele lapha ngezansi uma ufuna ukuba ngazise udokotela wakho noma 
isipeshalisti sakho mayelana nokuthi uzobamba iqhaza kulolu cwaningo: 
• YEBO, ngifuna wena utshele udokotela wami noma isipeshalisti sami 
ngokubamba iqhaza kulolu cwaningo. 
• CHA, angifuni ukuthi wena utshele udokotela wami noma isipeshalisti sami 
ngokubamba iqhaza kulolu cwaningo. 
• Anginaye udokotela/isipeshalisti okungesami 
 
IMIBUZO YOMBAMBIQHAZA 
Ingabe unayo imibuzo njengombambiqhaza? 
YEBO / CHA 
Uma impendulo yakho kunguYEBO – Sicela uchaze. 
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IMVUME ETHATHWA EMVA KOKUNIKEZWA ULWAZI MAYELANA 
NOKUBAMBA IQHAZA KULOLU CWANINGO 
 
Ngiyaqinisekisa lapha ukuthi unesi wocwaningo, ......................................................... (IGAMA 
NGOKUGCWELE) unginikezile ulwazi mayelana nesimo, ukuziphatha, izinsizakalo nobungozi 
obumayelana nalolu cwaningo lwezokwelapha olusihloko esithi “Ucwaningo oluhlola into 
ethembekayo ukuthi ingenzeka oluphenya mayelana nendlela i-kanamycin emunceka ngayo ezigulini 
ezine-DR-TB kanye nobudlelwane phakathi kwemithi yokwelapha eqashelwe namazinga okuzwa” 
(INOMBOLO YEPHROTHOKHOLI 1.5). 
• Futhi ngilutholile lolu lwazi olubhalwe lapha ngenhla, ngalufunda ngaluqonda (Ibhukwana 
Lolwazi Lombambiqhaza kanye Nemvume Enikezwa Emva Kokunikezelwa Kolwazi) 
mayelana nalolu cwaningo lwezokwelapha. 
• Ngiyazi ukuthi imiphumela yalolu cwaningo, okubandakanya imininingwane eqondene 
nomuntu ngqo emayelana nobulili bami, iminyaka yobudala, usuku lwami lokuzalwa, 
iziqalomagama kanye nokuhlonzwa kwesifo esithile  kuzofakwa embikweni walolu cwaningo 
ngaphandle kokwaziswa ukuthi ngekabani (igama lami ngeke lidalulwe). 
• Ngiyazi ukuthi kumele ngize emtholampilo wase Helen Joseph njalo esontweni lesibili 
enyangeni ukuze ngenze ukuhlolwa kokuzwa nokwegazi izinyanga ezintathu.  
• Ngiyazi ukuthi ngingakhetha ukuya emtholampilo wendawo engihlala kuyo noma 
emtholampilo waseHelen Joseph nsukuzonke ukuze ngijove, futhi ngiyavuma ukwenza lokhu 
nsukuzonke.Ngokubhekelela izidingo zalolu cwaningo, ngiyavuma ukuthi imininingwane 
eqoqwe ngesikhathi kuqhubeka lolu cwaningo  ifakwe ohlelweni lwekhompyutha oluhlelwe 
ngabacwaningi ababandakanyeka kulolu cwaningo, abaxhasi noma egameni labo. 
• Ngiyavuma ukubamba iqhaza emasethini ayisi-7 okuhlolelwa ukuzwa ezinyangeni ezintathu 
zokuqala. 
• Ngiyavuma ukubamba iqhaza emasethini ayisishiyagalombili okuhlolwa igazi kulezi zinyanga 
ezintathu. 
• Ngiyavuma ukunikezela ngegazi elingama-2ml amahlandla amabili ezinyangeni ezintathu 
zokuqala.  
• Ngiyavuma ukunikezela ngegazi elingama-4 ml amahlandla ayisithupha ngesikhathi kuqhubeka 
lolu cwaningo.  Kanye nelinye elingama-18 ml ukuze kukalwe ukusebenza kwezinso zami i 
ezinyangeni ezintathu zokuqala. 
• Ngiyazi ukuthi ngiyakwazi ukuhoxa noma nini. 
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• Ngingakwazi, kunoma yisiphi isigaba, ngaphandle kokuphathwa ngendlela engafanele, 
ukuhoxisa imvume yami kanye nokubamba kwami iqhaza ocwaningweni. 
• Ngibe nesikhathi esanele sokubuza imibuzo futhi ngiyazisholo mina (ngokuzithandela) ukuthi 
ngikulungele ukubamba iqhaza kulolu cwaningo. 
• Ngiyazi ukuthi uma kwenzeka udokotela wami eshintsha imithi yami enginika eminye 
ngaphandle kwe-kanamycin/capreomycin, ngizohoxiswa kulolu cwaningo. 
 
UMBAMBIQHAZA 
 
Igama elibhaliwe Isignisha/Uphawu noma umaka wesithupha Usuku Nesikhathi 
 
UMCWANINGI OMNCANE/UMXHUMANISI  
 
Mina, ............................................................................................., ngiyaqinisekisa lapha ukuthi lo 
mbambiqhaza ongenhla unikeziwe ulwazi olugcwele mayelana nesimo, ukuziphatha nobungozi 
mayelana nalolu cwaningo olungenhla. 
 
 
 
Igama elibhaliwe Isignisha Usuku Nesikhathi 
 
 
UMHUMUSHI / OMUNYE UMUNTU OCHAZA IMVUME EMVA 
KOKUNIKEZELWA KOLWAZI (UMCWANINGI OMNCANE) 
 
 
 
Igama elibhaliwe Isignisha Usuku Nesikhathi 
 
UFAKAZI (uma ekhona) 
 
 
 
Igama elibhaliwe Isignisha Usuku Nesikhathi 
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NOMORO YA VERSION YA TUMELLO E BONTSHANG KUTLWISISO:1.5 
(Sepetlele sa South Rand) 
 
SEHLOOHO SA PHUPUTSO: Phuputso e fuputsang kgonahalo ya pharmacokinetics le 
pharmacodynamics ya kanamycin le capreomycin bakuding ba nang le DR-TB le kamano pakeng tsa 
ditekanyo tsa ho utlwa ditsebeng 
 
INSTITJHUSHENE: Yunivesithi ya Witwatersrand tshebedisanong le Yunivesithi ya Sefako 
Makgatho Health Sciences 
 
(LI)NOMORO TSA MOHALA TSA LIHORA TSA MOTSHEHARE LE KA MORA 
TSHEBETSO: 082 815 8878 (Cara Hollander) le/kapa  011 681 2184 (Ngaka Shilubane le Ngaka 
Damoyi mona South Rand Hospita le/kapa +27 11 276-8813 (Ngaka Mohammed Rassool – Mofuputsi 
ya ka Sehloohong – Ngaka mona Helen Joseph – Wits Health Consortium) 
 
MOHOKAHANYI EA PHUPUTSO: Matshediso Mkhwanazi: speed dial: 076 711 2874/ 
Matshidiso.Mkhwanazi@righttocare.org 
 
Motho eo e ka bang Monkakarolo: Foromo ena ya tumello e ka ba le mantswe ao o sa a 
utlwisiseng.  Ka kopo kopa ngaka ya phuputso/mooki kapa moifo wa phuputso ho o  hlalosetsa 
mantswe afe kapa afe ao o sa a utlwisiseng ka ho hlakileng.  O ka boloka kopi e sa saenwang 
yatumello ena ya foromo ena ho nahana ka yona kapa ho buisana ka yona le lelapa kapa metswalle 
pele o etsa qeto ya hao. 
SELELEKELA 
Dumela, lebitso la ka ke Cara Hollander mme ke ngaka ya tlhahlobo ya kutlo ditsebeng ho 
tswa Yunivesithing ya Witwatersrand.  Ke lakatsa ho o mema hore o nahane ka ho kena phuputsong, 
e bitswang “Phuputso e fuputsang kgonahalo ya pharmacokinetics le pharmacodynamics ya 
kanamycin le capreomycin bakuding ba nang le DR-TB le kamano pakeng ditekanyo tsa ho utlwa 
ditsebeng”.  Re entse diteko tse itseng ho netefatsa hore o a tshwaneleha bakeng sa ho nka karolo 
phuputsong ena. 
1. Pele o dumela ho nka karolo phuputsong ena, ho bohlokwa hore o bale le ho utlwisisa 
ditlhaloso tse latelang mabapi le phuputso, mekgwatshebetso ya phuputso, melemo, dikotsi, 
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dikarolo tse bakang makukuno, le ditemoso hammoho le tokelo ya hao ya ho ikgula 
phuputsong ka nako efe kapa efe. 
2. Bukana ena ya tlhahisoleseding e o thusa ho etsa qeto haeba o lakatsa ho nka karolo.  Ho 
hlokeha hore o utlwisise ntho e nngwe le e nngwe mabapi le phuputso pele o dumela ho nka 
karolo phuputsong ena. 
3. Haeba o na le dipotso dife kapa dife, ka kopo mpotse. 
4. Ha o a tshwanela ho dumela ho nka karolo ntle le haeba o o thabela ho dikarolo tsohle tse 
amehang. 
5. O ke ke wa nka karolo phuputsong e nngwe nakong eo o nkang karolo phuputsong ena (ntle 
le haeba ke dumella sena pele). 
6. Ka kopo bua le nna o sa pate letho mabapi le nalane ya hao ya bophelo bo botle, hobane ho 
seng jwalo o ka ipeha kotsing haeba o nka karolo phuputsong ena. 
7. Haeba o etsa qeto ya ho nka karolo phuputsong ena, o tla kotjwa hore o saene foromo ena ho 
netefatsa hore o utlwisisa phuputso.  O tla fuwa kopi ya yona ho e boloka. 
8. Haeba o na le ngaka ya hao kantle ho sepetlele sena, ka kopo buisana le yena kapa o mmolelle 
hore ho na le kgonahalo ya hore o nke karolo phuputsong ena.  Haeba o lakatsa, nka bolella 
ngaka ya hao mabapi le sena. 
 
SEPHEO SA PHUPUTSO 
O sepetleng/tliliniking ena hobane o na le Lefuba le Lwantshang Moriana (DR-TB).  Ke 
lakatsa hore o nahane ka ho nka karolo phuputso ho lekanya ditekanyo tsa kutlo ya hao nakong yohle 
ya karolo ya hao yaDR-TB.  O tla amohela moriana (diente) ho alafa lefuba la hao le lwantshang 
moriana o bitswang kanamycin le/kapa capreomycinhammoho le meriana e meng, e le hore o ka ba 
betere lefung la hao la TB, e leng taba ya bohlokwa haholo.  O ke ke wa fumantshwa kanamycin le 
capreomycin hammoho, empa o tla di fumana mekgahlelong e fapaneng. Ka bobedi ke 
diente.Moriana oo o tlang ho o fumana o matla haholo, mme o na le dikotsi tse mmalwa mme e 
nngwe ya tsona ke ho lahlehelwa ke ho utlwa ditsebeng.  Le ha ho le jwalo, o tshwanetse ho sebedisa 
moriana ona e le hore o ikutlwe o le betere hape.  Batho ba bangata ba sebedisang moriana ona ba tla 
lahlehelwa ke ho utlwa ditsebeng; empa, le hoja sena se etsahala kgafetsa, ha se etsahele kamehla.  Ho 
ka ba thata haholo ho bua le lelapa le metswalle ha o lahlehetswe ke ho utlwa ditsebeng mme hape ho 
ka ba thata ho sebetsa.  Ka lebaka lena, nakong ya phuputso ena, re lakatsa ho lekanya ho utlwa 
ditsebeng ka makgetlo a 7 dikgweding tsa pele tse tharo, e le hore re ka utlwisisa hantle hore na ho 
etsahalang ka ho utlwa ha hao ditsebeng.  Mme re tla lakatsa ho etsa diteko tsa madi ka makgetlo a 8 
dikgweding tsa pele tse 3, e le hore re ka sheba kamoo moriana wa hao bakeng sa DR-TB ya hao o 
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sebetsang kateng mmeleng wa hao.  Le tla arolwa ka dihlopha tse 2.  Sehlopha se seng, re ka fetola 
moriana wa hao wa DR-TB le hore o mongwa ka tekanyo e lekaneng (e seng o mongata haholo mme 
e seng o nyenyane haholo).  Le hona ena e le phuputso, re tshepa hore ha re fetola moriana wa hao wa 
DR-TB, sena se ka fokotsa tahlehelo ya hao ya ho utlwa ditsebeng.  Le ha ho le jwalo, dihlopha ka 
bobedi ke tla etswa diteko tsa madi, ke feela sehlopha se le seng se tla ba le diphetoho, sena se tla re 
lumella ho bapisa dihlopha ka diphetoho tsa tekanyo ya moriana sehlopheng se seng  le sehlopha se se 
nang diphetoho tsa ditekanyo tsa moriana, mme tla ka kgona ho bona hore na ke sehlopha sefe se 
nang le tahlehelo e nyenyane ya ho utlwa ditsebeng.  Le ha ho le jwalo, ha se batho kaofela ba 
sebedisang kanamycin ba lahlehelwang ke ho utlwa ditsebeng.  Haeba o le sehlopheng sa fuputseng 
phetoho ya moriana, o ke ke wa fetola ditekanyo tsa hao tsa moriana wa DR-TB.  Le ha ho le jwalo, 
thuso ya hao e tla re thusa ho alafa bakuli ba bang nakong e tlang ba nang le lefu lena mme hape ho 
tla re dumella ho beha leihlo ho utlwa ha hao ditsebeng nako ng yohle ya phuputso, le ho sheba 
kamano pakeng tsa kamoo moriana o sebediswang kateng ke mmele wa hao le kamoo o utlwang 
kateng ditsebeng. 
 
NAKO YA PHUPUTSO LE PALO YA BANKAKAROLO 
Phuputso e tla etsetswa sepetleng sena hammoho le Sepetleleng sa Helen Joseph.  Batho ba ka 
bang 80 ba tla nka karolo phuputsong ena.  Bankakarolo ba tla ba pakeng tsa dilemo tse 18 le 55 ka 
boholo.  Ho tla hlokeha hore o sebedise kanamycin kapa capreomycin (ho itshetlehilwe ka qeto ya 
ngaka ya hao) ka dikgwedi tse fetang tseo o tla nka karolo ka tsona phuputsong ena.  Re tla etsa diteko 
ka dikgwedi tse tharo bakeng sa phuputso ena, sena se tla hlaloswa mona ka tlase.  Diteko tsena ke 
diteko tsa madi le diteko tsa ho utlwa ditsebeng.  Dikgweding tsa pele tse 3, o tla kotjwa hore o 
nketele ka makgetlo a 9 bakeng sa diteko nakong ya phuputso.  Bakeng sa diketelo tse ding, o tla ba 
sepetlele, mme ka hoo di ka etsetswa kamoreng ya bakudi sepetlele kapa kamoreng e ka thoko ya 
sepetlele. Le ha ho le jwalo, ha o ntshwa sepetlele, ho tla hlokeha hore o kgutlele sepetleleng sena ho 
tla mpona, kapa sebakeng sa TB mona Sepetleleng sa Helen Joseph. Haeba o le sepetlele ka dikgwedi 
tse 2, kahoo ho tla hlokeha hore o mpone feela jwaloka mokudi ya kantle ya sa robatsweng sepetlele 
bakeng sa kgwedi e le nngwe. Empa ho tla itshetleha ka hore na o robatswa sepetlele ka nako e telele 
hakae.Kajeno e tla balwa e le letsatsi 1.  HAPE ho tla hlokeha hore o ye tliliniking e leng sebakeng sa 
lona e leng haufi haholo le ntlo ya hao letsatsi le leng le le leng (Mantaha ho isa ho Labohlano) ho 
fumana ente ho tswa ho mooki e le hore a ka ngola fatshe nako le tekanyo ya moriana eo o e 
fumantshwang (o tshwanetse ho etsa sena esita le haeba o se karolo ya phuputso ka hobane sena ke 
tlhokomelo e tlwaelehileng).  Ka lebaka lena o tshwanetse ho ya Sepetleleng sa South Rand kapa 
Sepetleleng sa Helen Joseph (le ha e le efe eo o e kgethang) hammoho bekeng e nngwe le e nngwe ya 
bobedi bakeng sa diteko tsa kutlo ditsebeng le tsa madi, le ho ya tliliniking e leng sebakeng sa lona 
letsatsi le letsatsi.  Re tla o neha R150 bakeng sa ditjeo tsa ho palama lekgetlo le leng le le leng haeba 
ho hlokeha hore o tle sepetlele bakeng sa diteko tsa ho utlwa le diteko tsa madi.  Haeba o le mokudi 
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ya robaditsweng sepetlele, o ke ke wa leshwa bakeng sa ho palama, ho fihlela o ntshwa sepetlele, ka 
hobane o ke ke wa hloka tjhelete ya ho palama. Re tla o neha tjhelete e lekaneng bakeng sa ho palama 
ho tloha tliliniking letsatsi le leng le le leng (ho tloha ka Mantaha ho fihla ka Labohlano) ho fumana 
diente tsa hao.  Re tla o neha R50 bakeng sa ho palama ka Mantaha ho fiha ka Labohlano ho fumana 
diente tsa hao tliliniking ya heno bakeng sa nako ya phuputso.Ha o tla tliliniking bakeng sa diketelo 
tsa 'semolao' tsa phuputso, le ha o etswa diteko tsa ho utlwa ditsebeng le diteko tsa madi re tla o neha 
R150.  O ke ke wa fumana tjhelete e eketsehileng ya ho palama eo o e fumanang letsatsi le le letsatsi 
bakeng sa diente tsa hao matsatsing ao o fumanang R150. 
 
MEKGWATSHEBETSO 
Haeba o dumela ho nka karolo phuputsong ena, o tla botswa dipotso mme ho tla hlokeha hore 
o etse diteko tse mmalwa – e tla ba diteko tsa ho utlwa le diteko tsa madi.  Ho tla hlokeha hore diteko 
tsena di etswe ho phaella ditekong tse ding tsa hao/mekgwatshebetso e sa amaneng le phuputso. 
Haeba o dumela ho nka karolo phuputsong ena le ho fana ka tumello, ho tla hlokeha hore ke o botse 
dipotso tse itseng kajeno le ho o hlahloba.  Jwale, hosasane ho tla hlokahala diteko tse eketsehileng tsa 
madi le diteko tsa pele tsa kutlo ditsebeng. 
Ho tla hlokeha  hore o tle letsatsi le leng le le leng (ho tloha ka Mantaha ho fihlela ka Labohlano - e 
seng mafelong a beke) ho fumana ente ya hao ya kanamycin/capreomycin.  Hape re tla etsa diphetoho 
tekanyong ya hao ya moriana haeba ho hlokeha.  Mme, bekeng e nngwe le e nngwe ya bobedi, ho tla 
hlokeha hore o etse diteko tsa madi le diteko tsa ho utlwa.  Matsatsi ana a tla nka nako e telele ho feta 
diketelo tsa hao tsa kamehla. 
 
Sepheo sa diteko tsa ho utlwa 
Ditsebe tsa rona ke ditho tse hlollang ka hobane di ka kgona ho utlwa diphitjhi (pitch) tse 
mengata tse fapaneng.  Re kgona ho utlwa phitjhi e tlase e jwaloka ya motjhini o kutang jwang, kapa 
bese, kapa esita le wa pompo e dutlang.  Ena ke medumo e fapaneng, mme e na le ditekanyo tse 
fapaneng tsa modumo, empa kaofela e na le diphitjhi tse tlase.  Hape re kgona ho utlwa phitjhi e 
phahameng, ka mohlala, ho lla ha dinonyana kapa ho lla ha alamo ya tshupanako. 
 
Modumo wa puo, mantswe le dipolelo kaofela e na le diphitjhi tse fapaneng.  Ka mohlala /m/, 
/d/ le /b/ ke medumo e tlase athe /f/, /s/ le /th/ ke diphitjhi tse phahameng.  E le hore re utlwisisane, ho 
hlokeha hore re kgone ho utlwa di-frequency tse ngata tse fapaneng kapa diphitjhi, ka hobane 
medumo e jwalo ya puo e na le diphitjhi tse ngata tse fapaneng. 
 
A FEASIBILITY STUDY INVESTIGATING THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND 
CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE RELATIONSHIP BETWEEN HEARING LEVELS 
555 
Ha re qala ho utlwa feela diphitjhi tse tlase, mme e seng diphitjhi tse phahameng, re qala ho 
ba le bothata ba ho utlwisisa puo.  Ka mohlala, ha motho a re ‘head’, o ka utlwa hampe, mme o utlwe 
‘bed’.  Haeba motho a re ‘fate’, o ka utlwa ‘ate’.  Ka lebaka lena tahlehelo ya ho utlwa esita le di-
frequency tse mmalwa e tla etsa hore ho be thata ho utlwisisa metswalle, lelapa le dingaka. 
Dintho tse ngata tse fapaneng di ka baka tahlehelo ya ho utlwa.  Ka dinako tse ding batho ba 
belehwa ba na le tahlehelo ya ho utlwa, kapa e ka bakwa ke lerata le phahameng, trauma le meriana e 
meng.  DR-TB ke lefu le totileng, mme o hloka moriana o matla haholo hore o hlaphohelwe le ho 
phela.  Le ha ho le jwalo, ka dinako tse ding, meriana ena e ka baka tahlehelo ya kutlo, mme e ka etsa 
hore o be thata ho utlwa le ho buisana le ba bang. 
 
Ka hobane moriana o matla (kanamycin/capreomycin) o hlokeha hore o phele, o tshwanetse 
ho o sebedisa.  EMPA phuputso ena e leka ho utlwisisa hantle-ntle mofuta wa tahlehelo ya kutlo o 
bakwang ke moriana bakeng sa ho dumella kalafo e molemo haholwanyane kapa thibelo ya yona 
nakong e tlang.  Ho hlokahala hore re lekanye kamoo o utlwang medumo kaofela e fapaneng le 
diphitjhi tsa modumo ha o tla sepetlele, mme ka dibeke tse ding le tse ding tse mmalwa, ho bona 
haeba boemo bo dula bo tshwana, kapa bo mpefala. 
 
Mekgwatshebetso ya teko ya kutlo ditsebeng 
Teko ya kutlo ditsebeng ha e bohloko, ho na le dikarolo tse mmalwa, jwaloka tse latelang: 
• Otoscopy – Pele, ho hlokeha hore ke shebe hara ditsebe tsa hao ka kganya ho bona haeba 
ho na le dikonokono dife kapa dife ditsebeng, kapa dintho tse ding ditsebeng tsa hao, 
hobane sena se ka ama diphetho tsa hao.  Sena se tla nka hoo e ka bang metsotswana e 20. 
• Cerumen management – Haeba ditsebe tsa hao di thibane ka lebaka la dikonokono, ke tla 
di ntsha e le hore di se ame diteko tse ding tsa hao.  Ke tla tshela oli e itseng tsebeng ya 
hao ho etsa hore dikonokono di be bonolo.  E be ke sebedisa motjhini ho hula 
dikonokono.  Kgulo ena e tla nka feela metsotswana e mmallwa.  Ho ka utlwisisa bohloko 
hanyenyane, empa ha se ka dinako tsohle ho utlwisang bohloko. 
• Tympanometry – E be ke kenya motjhini tsebeng ya hao.  Ke nub e bonolo mme e tla 
pompela moya o itseng ka tsebeng ya hao.  Ho ke ke ha o utlwisa bohloko, empa ho tla re 
thusa ho tseba haeba ho na le ditshwaetso dife kapa dife hara tsebe ya hao, le haeba ho na 
le mokedikedi ofe kapa ofe.  Haeba ho na le mokedikedi, sena se tla ama ho utlwa ha hao, 
le ho ama diphetho tsa teko ya kutlo.  Sena se tla nka hoo e ka bang metsotso e 2. 
• Distortion Product Otoacoustic Emissions (DPOAE) – Re na le disele tse nyenyane tsa 
moriri hare-hare ditsebeng tsa rona.  Disele tse fapaneng tsa moriri di bohlokwa bakeng 
sa ho utlwa diphitjhi tse fapaneng.  Ka lebaka lena, motjhini wa DPOAE o lekanya 
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kamora disele tsena tsa moriri di sisinyehang kateng le ho sebetsa.  Ho hlokahala hore re 
kenye nub e bonolo tsebeng ya hao, mme e tla etsa medumo e fapaneng.  O tshwanetse ho 
dula o sa sisinyehe mme o kgutsitse, mme motjhini o tla nka ditekanyo tsa disele tsena tsa 
moriri.   Sena se tla nka hoo e ka bang metsotso e 5 ho isa ho e 10. 
• Pure Tone Audiometry – Re tla o rwesa di-headphone.  Di tla ntsha medumo e bonolo 
haholo.  Medumo e tla ba le diphitjhi tse fapaneng.  Tse ding di tla ba tlase, mme tse ding 
di tla ba hodimo.  Nako le nako ha o utlwa modumo, o tshwanetse ho tobetsa konopo.  
Sena se tla nka hoo e ka bang metsotso e 15 ho isa ho e 20. 
Hang ha sena se entswe, re tla kgona ho bokella diphetho tsa hao hammoho le ho utlwisisa 
hantle seo o se utlwang ditsebeng.  Haeba re etsa teko ena nakong eo o tlang sepetlele, mme re e etsa 
hape ka dinako tse itseng dipakeng, re tla kgona ho bona haeba kutlo ya hae e fetoha. 
 
Haeba o dumela sena, ho tla hlokeha hore o etse sena ka makgetlo a 7 dikgweding tsa pele tse 
3.  E tla ba hosasane, le bekeng e nngwe le e nngwe ya bobedi bakeng sa dikgwedi tse 3 tse latelang. 
 
Ka mora dikgwedi tse 3 tsa phuputso, kutlo ya hao e tla tswela pele e behilwe leihlo ke 
dingaka tse hlahlobang kutlo ditseng sepetleleng sena kapa tliliniking e leng sebakeng sa lona.  Haeba 
o lahlehelwa ke kutlo, dingaka tsena di tla tswela pele ho o thusa ka disebediswa tse thusang ho utlwa 
le tlhokomelo e tswelang pele.  Ke tla o romela ho tsona ka mora phuputso. 
 
Sampole ya Madi 
Ho hlokeha hore re nke madi.  Ho hlokeha hore re nke madi e le hore re ka lekanya kamoo kalafo ya 
(kanamycin/capreomycin) e sebediswang kateng mmeleng wa hao.  Re tshepa hore sena se tla re thusa 
ho utlwisisa hore na ke hobaneng ha batho ba lahlehelwa ke kutlo ditsebeng.  Nna, kapa mooki e mong 
kapa setsebi se hulang madi bakeng sa phuputso re tla nka madi ho wena e le hore re ka etsa diteko tse 
hlokehang.  Ho hlokeha hore re nke 2 ml tsa madi bakeng sa teko ka nngwe.  Ho tla hlokeha hore 
bonyane o be le diteko tse 2 tsa madi lekgetlo ka leng (ntle le diketelong tse 2 tsa pele).  2 ml e ka ba 
marothodi a 2 a madi kapa halofo ya thispuni.  Ka lebaka lena, re hloka 4ml tsa madi letsatsi ka leng ha 
re o bona e le hore re lekanye kanamycin (ka tlase ho thispuni e le nngwe ya madi).  Lekgetlo la pele e 
tla ba dihora tse mmalwa ka mora ho fumana ente ya hao ya DR-TB.  Ka mora moo, lekgetlong la 
bobedi le tla latelwa ke letsatsi pele o fumana ente ya hao.  Mme makgetlong a mang, ho tla hlokeha 
hore ho nkuwe madi a hao pele o hlajwa ente, le dihora tse mmalwa ka mora ho hlajwa ka ente ya hao.  
Ka lebaka lena, bakeng sa ketelo ka nngwe (ntle le ketelong ya bobedi ha ho etswa diteko tsa madi), ho 
hlokeha hore o be tliliniking ka dihora tse 4.5 bonyane (ntle le haeba o le mokudi ya robaditsweng 
sepetlele, mme se o ntse o le sepetlele).  Ho tla hlokeha hore re etse sena ka makgetlo a 8 kaofela 
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dikgweding tse 3 (hosasane e tla ba lekgetlo la pele).  Ka hoo, dikgweding tse 3, re tla nka kakaretso ya 
28 ml ya madi, hoo e ka bang dithispuni tse 5 le halofo.  Haeba o le sehlopheng se fuputswang, re tla 
etsa diphetoho tekanyong ya moriana kanamycin enteng ya hao eo o e hlajwang letsatsi le letsatsi.  
Haeba o le sehlopha se sa fuweng moriana o fuputswang, re tla nka feela madi le ho etsa diteko tsa 
kutlo. 
 
Jwale, e le hore re etse phetoho tekanyong ya moriana wa hao, ho hlokeha hore re utlwisise 
kamoo diphio tsa hao di sebetsang kateng, e le hore re ka etsa phetoho ntle le hore re ntshe kotsi 
diphio tsa hao.  Haeba o le sehlopheng se sa fetoleng tekanyo ya moriana, re batla ho bona kamoo 
kanamycin e amang diphio tsa hao.  Diketelong tse 6 ho tse 9, ho tla hlokeha hape hore re nke 3 ml e 
nngwe ya madi, e le hore re ka lekanya tshebetso ya diphio tsa hao le ho etsa diphetoho tse 
nepahetseng tsa tekanyo ya moriana.  Ka lebaka leo diketelong tseo re hlokang ho etsa teko ena, re tla 
hloka 3ml e eketsehileng ya madi, e leng kahodimo feela ho halofo ya thispuni.  Ka kakaretso, 
makgetlong a 3, re tla nka 18 ml ya madi, e leng ka hanyenyane kahodimo ho dithispuni tse 3 tse 
eketsehileng ho phaella ditekong tse ding tsa madi tse hlalositsweng ka hodimo mona.  Re tla nka 
madi ana ka nako e tshwanang le ya teko ya madi bakeng sa kanamycin/capreomycin – e le hore ho se 
hlokehe hore o hlajwe ka ho eketsehileng ka nalete. 
 
Ho nka madi ke karolo ya tlhokomelo ya hao e tlwaelehileng ya bongaka.  Re hloka ho nka 
madi ka ho arohileng ho mekgwatshebetso e tlwaelehileng ya sepetlele.  Sena se ka hlahisa kotsi e 
nyenyane ya makukuno.  Re tla nka madi ka tsela e tshwanang le ha a nkuwa bakeng sa diteko tsa hao 
tse tlwaelehileng tsa madi.  Ho nka madi ho ka etsa hore o akgehe, o ruruhe mothatswaneng wa madi, 
bohloko, ho tswa matetetso kapa ho tswa madi sebakeng se hlabilweng.  Hape ho na le kgonahalo e 
nyenyane ya ho ba le tshwaetso.  Baoki ba nang le boiphihlelo kapa ditsebi tse hulang madi bakeng sa 
phuputso ba tla nka madi tlasa maemo a hlwekileng ho thusa ho etsa bonnete ba hore sena se 
bolokehile. 
 
Madi a hao a tla bolokwa ka ho sireletsehileng bakeng sa nako e sa fetseng letsatsi le le leng 
Sepetleleng sa South Rand, le ka mora moo Sepetleleng sa Helen Joseph ho fihlela a romelwa 
laboratoring bakeng sa diteko.  A tla romelwa kapele kamoo ho ka kgonehang.  A ke ke a bolokwa ho 
feta beke e le nngwe.  Madi a hao a tla romelwa laboratoring e Yunivesithing ya Sefako Makgatho 
Health.  Hamorao, madi ao re a nkileng bakeng sa ho lekanya tshebetso ya diphio tsa hao a tla 
romelwa laboratoring e nngwe, e bitswang CLS.  Tlhahisoleseding kaofela ya hao mabapi le diteko 
tsena le mabapi le bophelo ba hao bo botle ka kakaretso e tla bolokwa lekunutung faeleng le ho 
kengwa khabotong nakong ya phuputso le kamora phuputso.  Tlhahisoleseding ya hao e ke ke ya 
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buisanwa le motho ofe kapa ofe e mong ya sa ameheng phuputsong.  Haeba sena se hlokeha, re tla 
kopa tumello ya hao pele sena se etswa. 
 
Diteko tsa ho utlwa le diteko tsa madi di tla etswa letsatsing la 2 (hosasane), matsatsing 15, 28, 40, 54, 
68 le 84.  Diteko tsa madi di tla etswa hosasane (letsatsi 2), letsatsing le latelang (letsatsi 3), mme e tla 
ba letsatsing le tshwanang jwaloka diteko tsa ho utlwa - matsatsing 15, 28, 40, 54, 68 le 84. 
 
Ketelong e nngwe le e nngwe eo o tlang bakeng sa diteko tsa ho utlwa le tsa madi (e seng matsatsing a 
dipakeng ha o tla feela bakeng sa diente tsa hao), ketelo ka nngwe e tla nka hoo e ka bang dihora tse 5.  
Ke hobane ho hlokeha hore re lete hoo e ka bang dihora tse 4.5 pakeng tsa diteko tse 2 tsa madi.  Kahoo, 
ho tla ba molemo haeba o ka tla esale hoseng, e le hore o ka tloha motshehare wa mantsiboya. 
 
NA MEKGWATSHEBETSO EFE KAPA EFE ENA YA PHUPUTSO E TLA HLAHISA 
MAKUKUNO KAPA DITSHITISO? 
Ho nka madi ho ka baka makukuno hanyenyane.  Re tla nka madi ka tsela e tshwanang le eo 
re nkang madi bakeng sa diteko tse ding tsa hao tsa madi.  Ho nka madi ho ka etsa hore o akgehe, o 
ruruhe mothatswaneng wa madi, bohloko, ho tswa matetetso kapa ho tswa madi sebakeng seo re 
nkileng madi ho sona.  Hape ho na le kgonahalo e nyenyane ya ho ba le tshwaetso.  Ke feela baoki ba 
nang le boiphihlelo (kapa ditsebi tse hulang madi bakeng sa phuputso) ba tla nka madi a hao ho thusa 
ho o sireletsa mme ntho e nngwe le e nngwe e tla ba e hlwekileng ka dinako tsohle.  Kakaretso ya 4 
ml ya madi (ke hore, a ka tlase feela ho thispuni) a tla nkuwa ketelong ka nngwe ya phuputso (ntle le 
letsatsing la 2 le la 3 – feela 2ml tse tla nkuwa).  Kakaretso ya 28 ml, hoo e ka bang dithispuni tse 5 le 
halofo tsa madi.  Ka mora moo, madi a eketsehileng a 3 ml a tla nkuwa matsatsing 40, 68 le 84 – 
kakaretso e eketsehileng ya 18 ml e leng madi a ka kahodimo hanyenyane ho ho dithispuni tse 3.  Ka 
lebaka lena, kakaretso ya 46 ml e tla nkuwa dikgweding tse tharo – a lekana le hoo e ka bang 
dithispuni tse kahodimo hanyenyane ho tse 9. 
Diteko tsa kutlo tse hlalositsweng mona ka hodimo di ke ke tsa etsa hore o ikutlwe o sa 
phutholoha; le ha ho le jwalo, ho ntsha dikonokono ho ka ba bohloko hanyenyane.  Le ha ho le jwalo, 
ha ho hlokehe hore re ntshe dikonokono mothong e mong le e mong, mme ha se ka dinako tsohle ho 
leng bohloko.  Le ha ho le jwalo, ho ntsha dikonokono ho nka feela metsotswana e mmalwa.  Teko 
kaofela e tla nka hoo e ka bang metsotso e 30 ho isa ho e 40 ya hao bakeng sa teko ka nngwe.  Ka 
dinako tsohle o tla kgona ho buisana le mooki diphetho tsa hao le ho botsa dipotso pele le ka mora 
diteko tsena.  Haeba o na le dipotso tse eketsehileng, o ka iteanya le nna, ngaka e hlahlobang kutlo 
ditseng. 
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MELEMO 
▪ Molemo o ka bang teng ka ho nka karolo ha hao phuputsong ena o tla kgona ho utlwisisa feela 
boemo ba hao ba ho utlwa ka ho fumana dintlha tse eketsehileng, le kamano ya  kamoo 
kanamycin/capreomycin e sebediswang ke mmele wa hao. 
▪ Ho ka etsahala hore o se une molemo phuputsong ena. 
▪ Ho nka karolo ha hao phuputsong ena ho tla thusa mabapi le ho hodisa tsebo ya bongaka e ka 
thusang bakudi ba bang bao, jwaloka wena, ba nang le DR-TB le ba leng kotsing ya ho 
lahlehelwa ke kutlo ditsebeng. 
 
KALAFO E NNGWE 
▪ Nakong ya hajwale, ha ho na kalafo e nngwe e fokotsang kapa ho thibela tahlehelo ya kutlo 
ditsebeng e bakwang ke moriana wa DR-TB.  Le ha ho le jwalo, haeba o ka lahlehelwa ke kutlo 
ditsebeng, o tla romelwa tliliniking ya sebakeng sa lona e haufi le wena ho fumana thuso ya ho 
fumana disebediswa tse thusang ho utlwa. 
▪ Ho beha leihlo moriana kanamycin/capreomycin mading a hao ha se mokgwatshebetso o 
tlwaelehileng, mme hona jwale ha ho na mokgwa o mong ntle le diteko tsa madi ho etsa sena 
nakong ya jwale. 
▪ Lefapha la Tlhahlobo ya Bongaka ya Kutlo Ditsebeng sepetleleng sena le tla kgona ho o thusa 
haeba o le sebakeng sena.  Ena ke karolo ya mekgwatshebetso e tlwaelehileng ya mmuso mabapi 
le tlhokomelo ya tahlehelo ya kutlo ditsebeng.  Ha se ka dinako tsohle disebediswa tse thusang ho 
utlwa di sebetsang. 
▪ Haeba o etsa qeto ya hore o se nke karolo phuputsong ena o ntse o tla fumana tlhokomelo e 
molemohadi e fumanehang hajwale tliliniking ena bakeng sa DR-TB ya hao. 
 
MELEMO LE DIKOTSI TSA KALAFO E NNGWE E TLWAELEHILENG 
▪ Ka hobane hona jwale ha ho na moriana o ka thusang ho thibela tahlehelo ya kutlo kapa ho e 
fokotsa, ha ho na kalafo e nngwe.  Haeba moriana wa hao wa DR-TB o baka tahlehelo ya kutlo, 
mme e le ka ho feletseng, e ke ke ya lokiswa.  Empa o tla kgona ho fumana sesebediswa se 
thusang kutlo ho phahamisa medumo kaofela ho o thusa.  Disebediswa tse thusang kutlo le ha ho 
le jwalo ha se ka mehla di thusang tahlehelong ya kutlo, ka hobane ka dinako tse ding tahlehelo 
ya kutlo e mpe haholo hoo disebediswa tse thusang kutlo di hlolehang ho o thusa.  Ha re fane ka 
disebediswa tse thusang ho utlwa – lefapha la bongaka la tlhahlobo ya kutlo ditsebeng la sepetlele 
le tla kgona ho o thusa ka tsona haeba o sebakeng seo, kapa re tla o romela tliliniking kapa 
sepetleleng se nepahetseng sebakeng sa lona. 
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▪ Melemo ya disebediswa tse thusang ho utlwa e ka fokola, le ha ho le jwalo di ka o thusa haeba o 
qala ho ba le tahlehelo ya kutlo ho tswa moriana wa hao wa DR-TB.  Disebediswa tse thusang ho 
utlwa ha di na dikotsi dife kapa dife. 
 
NA HO NA LE DITEMOSO DIFE KAPA DIFE KAPA DITHIBELO MABAPI LE HO 
NKA KAROLO HA KA PHUPUTSONG ENA? 
• Haeba o na le lefu la tswekere o ke ke wa nka karolo phuputsong ena.  Ka dinako tse ding lefu la 
tswekere le ka ama kutlo, mme re lakatsa ho kgona ho lekanya kutlo ya hao ditsebeng ntle le 
tshitiso ena e ka etsahalang. 
• Haeba o le ka tlase ho dilemo tse 18, kapa o le ka hodimo ho dilemo tse 55, o ke ke wa nka karolo 
phuputsong.  Phuputsong ena, re nka ditekanyo tsa batho ba pakeng tsa dilemo tse 18 le 55. 
• Haeba ngaka ya hao e fetola moriana wa hao (bakeng sa moriana ofe kapa ofe o mong ntle le 
kanamycin kapa capreomycin), o ka nna wa se kgone ho tswela pele o nka karolo phuputsong ena.  
• Haeba o bile lekgoba la sethethefatsi sefe kapa sefe mme o na le nalane ya tshebediso e mpe ya 
dithethefatsi kapa jwala, o ke ke wa kgona ho nka karolo phuputsong ena haeba sena se ka sitisa 
ho boloka ha hao mekgwatshebetso ya teko.  Bafuputsi ba amehang ba tla etsa qeto mabapi le 
sena. 
 
DITOKELO TSA HAO JWALOKA MONKAKAROLO PHUPUTSONG ENA 
Boithaopo 
Ho nka karolo ha hao phuputsong ena ho etswa ka boithaopo ka ho feletseng mme o ka 
kgetha haeba o lakatsa ho nka karolo kapa tjhe.  Hape o ka kgaotsa ho nka karolo ka nako efe kapa efe 
mme ha ho hlokehe hore o fane ka lebaka.  Haeba o kgetha hore o se nke karolo, kapa o etsa qeto ya 
ho kgaotsa ho nka karolo nakong ya phuputso, o tla tswela pele o fumana tlhokomelo ya bongaka 
sepetleleng sena, mme e ke ke ya sitiswa. 
Diphumano tse ntjha 
Ke tla o neha tlhahisoleseding efe kapa efe e ntjha eo ke e fumanang nakong ya phuputso, e 
ka fetolang boithaopo ba hao ba ho tswela pele phuputsong. 
Ho ikgula/ho tloswa 
Ho ikgula ha hao kapa ho kgaotsa ho nka karolo phuputsong ho ke ke ha sitisa tlhokomelo efe 
kapa efe e nngwe ya hao ya bongaka.  Ke na le tokelo ya ho o tlosa phuputsong haeba e le ntho e 
molemong wa hao.  Haeba ngaka ya hao e fetola moriana wa hao bakeng sa DR-TB mme o ke ke wa 
sebedisa kanamycin/capreomycin, o ke ke wa kgona ho tswela pele phuputsong ena.  Haeba o sa fane 
ka tlhahisoleseding e nepahetseng le ya nnete mabapi le nalane ya hao ya bongaka, kapa o sa latele 
melao ya phuputso, nka o tlosa phuputsong ena ka nako efe kapa efe. 
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TLHOKOMELO MAEMONG A TSHOHANYETSO LE HO ROBATSWA SEPETLELE 
Haeba o hloka tlhokomelo ya tshohanyetso ka nako efe kapa efe nakong ya phuputso, ka kopo letsetsa 
Ngaka Damoyi kapa Ngaka Shilubane mona 011 681 2184kapa Ngaka Mohammed Rassool mona 011 
276-8813 (Sepetleleng sa Helen Joseph – Mofuputsi ya ka Sehloohong) kapa 027 83 415 8967. 
DITOKISETSO TSA DITJHELETE 
• Batshehetsi ba ditjhelete ba phuputso ena ba tla lefella diteko tsohle tsa phuputso. 
• Wena kapa medical aid ya hao (haeba o na le yona) le ke ke la lefella moriana ofe kapa ofe wa 
phuputso kapa mekgwatshebetso ya phuputso, mme kaofela di tshehetswa ka ditjhelete ke 
mekgatlo ya diphuputso. 
Ha o etela sepetlele bakeng sa phuputso bekeng e nngwe le e nngwe ya bobedi (bakeng sa 
diteko tse kutlo le diteko tsa madi) o tla fuwa R150 bakeng sa ho palama (feela haeba o alashwa 
jwaloka mokudi ya kantle ho sepetlele).  O ke ke wa leshwa bakeng sa ho nka karolo, empa feela 
bakeng sa ho palama le dijo tse bobebe.  Ha o tla letsatsi le letsatsi bakeng sa feela ho hlajwa ente 
le diphetoho tse ka bang teng tsa tekanyo ya moriana, o tla fuwa tjhelete e lekaneng bakeng sa ho 
palama.  O tla fuwa R50 letsatsi le letsatsi bakeng sa ho palama.  Sena se tla etswa feela ka 
dikgwedi tsa pele tse 3.  Ka mora dikgwedi tsena tse 3, mme ha ho tjhelete ya ho palama eo o tla e 
fuwa. 
 
KAMOHELO YA BOITSHWARO 
• Prothokhole ya phuputso ena ya moriana e dumeletswe ke Yunivesithi ya Witwatersrand, Human 
Research Ethics Committee (HREC) mme tumello e ngotsweng e fanwe ke komiti ena. 
• Phuputso e latela ditataiso tsa Phatlalatso ya Helsinki (e ileng ya ntjhafatswa ka lekgetlo la ho 
qetela ka: Mphalane 2013), e sebetsanang le dikgothaletso bakeng sa dingaka tse etsang phuputso 
ya bongaka ho bankakarolo ba batho.  Haeba o lakatsa ho fumana kopi ya ditataiso tsena, ka kopo 
mpolelle, mme ke tla o fumanela tsona. 
• Phuputso ena e lefellwa ke mokgatlo wa phuputso (South African Medical Research Council).  
Ha ke na dithahasello dife kapa dife tsa ditjhelete kapa tsa ka mokgatlong ona mme ha ke 
susumetswe kapa ho etswa leeme ke tsona. 
 
INSHORENSE 
Dingaka kaofela tsa bongaka phuputsong ena di na le inshorense.  Mofuputsi ya ka 
sehloohong le dingaka di sireleditswe ka inshorense ke MPS ho tsamaisa mekgwatshebetso ha feela: 
• Ba boloka mekgwatshebetso ya prothokhole ya phuputso. 
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• Ba boloka melao ya Medicines Control Council le ya Yunivesithi ya Witwatersrand, Human 
Research Ethics Committee (HREC). 
• Ba tshwara le ho fana ka moriana wa phuputso ho latela prothokhole le dihlomathiso le 
ditokomane tse ding tse amanang le yona. 
• Ho tloswa qosong ya molato ha ho a rerelwa mme ha ho nka sebaka sa inshorense ya motho 
bakeng sa ketso efe kapa efe e mpe. 
Ka kopo lemoha hore haeba o na le pholisi ya inshorense ya bophelo o tshwanetse ho botsa 
haeba khamphani ya hao ya inshorense e hloka hore e tsebiswe mabapi le ho nka karolo ha hao 
phuputsong.  Ho tswa tlhahisoleseding e nngwe, sena ha se a lokela ho ama pholisi efe kapa efe ya 
bophelo eo o e nkileng.  Empa ho ntse ho le bohlokwa ho hlahloba hape sena hobane ka dinako tse 
ding dikhamphani di a fapana. 
 
MOHLODI WA TLHAHISOLESEDING E EKETSEHILENG 
Nakong ya phuputso, o tla hlokomelwa ke moifo wa Sepetlele sa South Rand.  Haeba ka nako efe 
kapa efe o nahana hore o na le dipotso tse eketsehileng tse amanang le phuputso, ka kopo iteanye le 
nna kapa mooki wa phuputso/mohokahanyi ya leng mosebetsing sepetlele. 
Litho (Bafuputsi le Bafuputsi ba Tlasana) tsa phuputso tseo o ka iteanyang le tsona: 
✓ Cara Hollander – 082 815 8878 (Ngaka e hlahlobang kutlo ditsebeng) 
✓ Ngaka Karin Joubert – 011 717 4561 (Ngaka e hlahlobang kutlo ditsebeng) 
✓ Moprofesara Natalie Schellack – 012 521 3286 (Rakhemisi) 
✓ Ngaka Shilubane – 011 681 2184 
✓ Ngaka Mohammed Rassool –011 276-8813 (Ngaka le Mofuputsi ya ka Sehloohong) 
• Haeba o batla tlhahisoleseding efe kapa efe mabapi le ditokelo tsa hao jwaloka monkakarolo 
phuputsong, kapa o na le ditletlebo mabapi le phuputso ena, o ka iteanya le Moprofesara 
Cleaton-Jones, Modula-setulo wa Yunivesithi ya Witwatersrand, Human Research Ethics 
Committee (HREC), e leng komiti e ikemetseng e thusang ho sireletsa ditokelo tsa bankakarolo 
phuputsong mona (011) 717 2301. 
• Bakeng sa tlhahisoleseding ya phuputso o ka iteanya le mohokahanyi wa Phuputso  – Cara 
Hollander ho tswa Yunivesithing ya Witwatersrand mona 082 815 8878. 
 
LEKUNUTU 
• Tlhahisoleseding kaofela eo re e bokellang nakong ya phuputso ena, e kenyeletsang direkoto tsa 
sepetlele, tlhahisoleseding mabapi le wena le tlhahisoleseding ya phuputso e tla bolokwa e le 
lekunutu le thata.  Ke feela ditho tsa moifo wa phuputso, le dingaka tsa hao le baoki ba tla fihlella 
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tlhahisoleseding ya hao.  Tlhahisoleseding efe kapa efe e tla ngolwa dikgatisong tsa saense kapa 
ntho efe kapa efe e tla hatiswa e ke ke ya ngolwa lebitso la hao. 
• Re tla kenya dikhoutu tse fapaneng tlhahisoleseding ya hao ya phuputso.  Ka lebaka lena, ha ho 
hlahlojwa diphetho tsa hao, ho tla ba le khoutu feela.  Lebitso la hao, nomoro ya hao ya 
boitsebahatso kapa dinoutu dife kapa dife tse ding tse ka o tsebahatsang di ke ke tsa kengwa 
ditokomaneng tsena, ho etsa bonnete ba hore ntho e nngwe le e nngwe e bolokwa e le lekunutu. 
• Tlhahisoleseding ena e tla hlahlojwa ke baemedi ba dumeletsweng ba Yunivesithi ya 
Witwatersrand le Yunivesithi ya Sefako Makgatho Health hammoho le ditho tse tswang ho 
batshehetsi ba ditjhelete (Medical Research Council).  Diodithara tsa Wits Health Consortium di 
ka sheba diphetho tse itseng ha di etsa tlhahlobo ya tsona ho etsa bonnete ba hore ntho e nngwe le 
e nngwe e entswe ho latela ditekanyetso tse loketseng.  Le ha ho le jwalo, ha se motho e mong le 
e mong ya tla fihlella lebitso la hao – diphetho tsohle tsa hao di tla kengwa nomoro, kahoo ba ke 
ke ba tseba hore ke wena. 
• Tlhahisoleseding hape e ka hlahlojwa ke National Health Research Ethics Committee (NHREC), 
Yunivesithi ya Witwatersrand, Human Research Ethics Committee (HREC), Medicines Control 
Council (MCC) ya Afrika Borwa le/kapa Food and Medicine Administration (FDA) ya United 
States hammoho le ngaka ya hao. Ka lebaka lena, o nneha tumello ya ho lokolla direkoto tsa hao 
tsa bongaka ho di neha Medical Research Council, basebetsi ba bona kapa dienjente, ba boholong 
ba bophelo bo botle hara naha le dinaheng disele, Medicines Control Council (MCC) ya Afrika 
Borwa, National Health Research Ethics Committee (NHREC) le Yunivesithi ya Witwatersrand, 
Human Research Ethics Committee (HREC). 
• Direkoto tsena di tla sebediswa ke bona feela ho etsa mesebetsi ya bona e amanang le phuputso 
ena ya moriana. 
• Tlhahisoleseding efe kapa efe e fumanwang e amanang le diphetho tsa diteko tsa hao kapa boemo 
ba bophelo ba hao bo botle ka lebaka la ho nka karolo ha hao phuputsong ena e tla bolokwa e le 
lekunutu le thata.  O tla bolellwa mabapi le diphumano dife kapa dife tsa bohlokwa bophelong ba 
hao bo botle kapa ho tswela pele ha hao phuputsong ena empa tlhahisoleseding ena e ke ke ya 
fuwa motho ofe kapa ofe wa boraro hammoho le batho ba seng ba boletswe mona ka hodimo ntle 
le tumello ya hao e ngotsweng.  Mokgelo feela tabeng ena e tla ba diketsahalong tsa mafu a 
tshwaetsang moo e leng boikarabelo ba molao ho tsebisa Lefapha la Bophelo bo Botle ka ona.  
Ketsahalong e jwalo, ke tla o bolella mabapi le sena le hore ke tla neha lekgotla la mmuso le 
dumeletsweng tlhahisoleseding ena. 
 
KGETHO YA HO TSEBISA NGAKA YA HAO / NGAKA E KGETHEHILENG 
Ka kopo mpolelle mona ka tlase, haeba o lakatsa hore ke tsebise ngaka ya  hao kapa ngaka ya hao e 
kgethehileng hore o nka karolo phuputsong ena: 
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• E, ke lakatsa hore o bolelle ngaka ya ka / ngaka e kgethehileng mabapi le ho nka karolo ha ka 
phuputsong ena. 
• TJHE, ha ke lakatse hore o bolelle ngaka ya ka / ngaka e kgethehileng mabapi le ho nka 
karolo ha ka phuputsong ena. 
• Ha ke na ngaka ya ka / ngaka e kgethehileng 
 
 
DIPOTSO TSA BANKAKAROLO 
Na wena, jwaloka monkakarolo, o na le dipotso dife kapa dife? 
E / TJHE 
Haeba E – Ka kopo hlalosa. 
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TUMELLO E BONTSHANG KUTLWISISO BAKENG SA BONKAKAROLO 
PHUPUTSONG 
Ke netefatsa hore ke ile ka hlahiswa leseding ke mooki wa phuputso, 
....................................................................................  (LEBITSO LE FELETSENG) mabapi le sebopeho, 
tsamaiso, melemo le dikotsi tsa phuputso e nang le sehlooho “Phuputso e fuputsang kgonahalo ya 
pharmacokinetics le pharmacodynamics ya kanamycin le capreomycin bakuding ba nang le DR-TB le 
kamano pakeng tsa ditekanyo tsa ho utlwa ditsebeng” (NOMORO YA PROTHOKHOLE 1.5). 
• Hape ke amohetse, ke badile le ho utlwisisa tlhahisoleseding e ngotsweng mona ka hodimo 
(Maqephe a Tlhahisoleseding ya Monkakarolo le Tumello e Bontshang Kutlwisiso mabapi le 
phuputso ena ya moriana. 
• Ke a lemoha hore diphetho tsa phuputso, ho kenyeletswa le tlhahisoleseding ya ka mabapi le 
bong, dilemo, letsatsi la tswalo, ditlhaku tse qalang tsa mabitso a ka le tlhahlobo ya bongaka 
ntle le lebitso la ka e tla etswa tlaleho ya phuputso. 
• Ke a lemoha hore ho hlokeha hore ke tle tliliniking ya Helen Joseph bakeng sa dikgwedi tsena 
tse 3, beke e nngwe le e nngwe. 
• Ke a lemoha hore nka ka kgetha ho ya tliliniking ya sebaka sa rona kapa tliliniking ya Helen 
Joseph letsatsi le letsatsi bakeng sa diente tsa ka mme ke dumela ho etsa jwalo letsatsi le 
letsatsi. 
• Ka lebaka la ditlhokeho tsa phuputso, ke dumela hore tlhahisoleseding e bokellwang nakong 
ya phuputso ena e ka kengwa sistiming ya khomphutha ke bafuputsi ba amehang phuputsong 
ena, batshehetsi ba ditjhelete kapa lebitsong la bona. 
• Ke dumela ho nka karolo diseteng tse 7 tsa diteko tsa kutlo dikgweding tse 3 tsa pele. 
• Ke dumela ho nka karolo diseteng tse 8 tsa diteko tsa madi dikgweding tsena tse 3. 
• Ke dumela ho fana ka 2 ml tsa madi ka makgetlo a 2 dikgweding tse 3 tsa pele. 
• Ke dumela ho fana ka 4ml tsa madi ka makgetlo a 6 nakong ya phuputso.  Le 18 ml tse ding 
bakeng sa ho etsa ditekanyo tsa ditshebetso tsa diphio dikgweding tse 3 tsa pele. 
• Ke a tseba hore nka ikgula phuputsong ka nako efe kapa efe. 
• Mohatong ofe kapa ofe, ntle le tshwaro e se nang leeme, nka hula tumello ya ka le 
bonkakarolo phuputsong. 
• Ke bile le nako e lekaneng ya ho botsa dipotso mme (ka bolokolohi) ke bolela hore ke malala-
a-laotswe ho nka karolo phuputsong. 
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• Ke a lemoha hore haeba ngaka ya e fetola moriana wa ka hore e be ntho e nngwe ntle le 
kanamycin/capreomycin, ke tla tloswa phuputsong. 
 
MONKAKAROLO 
 
Lebitso ka Ditlhaku tse 
Arohantsweng 
Tshaeno / Letshwao kapa Kgatiso ya 
Monwana o Motona 
Letsatsi le Nako 
 
MOFUPUTSI YA TLASANA PHUPUTSONG 
 
Nna, ..........................................................................................................., ke netefatsa hore 
monkakarolo ya ngotsweng mona ka hodimo o ile a hlahiswa leseding ka ho feletseng mabapi le 
sebopeho, tsamaiso le dikotsi tsa phuputso e boletsweng ka hodimo mona. 
 
 
 
Lebitso ka Ditlhaku tse Arohantsweng Tshaeno Letsatsi le Nako 
 
MOFETOLEDI / MOTHO E MONG YA HLALOSANG TUMELLO E BONTSHANG 
KUTLWISISO (MOFUPUTSI YA TLASANA PHUPUTSONG) 
 
 
 
Lebitso ka Ditlhaku tse Arohantsweng Tshaeno Letsatsi le Nako 
 
PAKI (Haeba e hlokeha) 
 
Lebitso ka Ditlhaku tse Arohantsweng Tshaeno Letsatsi le Nako
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND CAPREOMYCIN IN PATIENTS WITH DR-TB AND 
THE RELATIONSHIP BETWEEN HEARING LEVELS: A FEASIBILITY STUDY 
567 
Appendix G 
Baseline Case Report Forms 
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Procedures Yes No 
Main Informed Consent   
Case History   
 
 
 
Subjects Medical History:  
System History 
Start 
Date 
Stop Date 
HEENT  
NECK 
   
   
   
CVS 
Hypertension                            No I__I Yes 
I__I → 
 
  
   
   
Visit: Baseline (Day 1)  
 YES NO 
Does the patient qualify to be enrolled on the study?( If no, state reason)   
 CM  
Injectable Prescribed for Participant (please circle):       KANAMYCIN    /    CAPREOMYCIN              
 
Kanamycin Study                          Clinical HIV Research Unit                           Visit: Baseline (Day 1) 
Visit Date: __________________ (DD.MMM.YYYY) Initials: _____________        Study Number: 
_________________________ 
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Respiratory System 
TB                                             No I__I Yes 
I__I → 
 
  
   
    
Subjects Medical History:  
 
System 
History Start 
Date 
Stop Date 
GUT 
   
   
   
UGT / Contraception 
/ Safe Sex Method 
LMP                                          No I__I Yes 
I__I → 
 
Reason:  
 
  
Contraception                           No I__I Yes 
I__I  
(if yes, specify): 
  
1. 
 
  
2. 
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Hematological 
Conditions  
   
   
   
   
   
Rheumatological 
(MSS) 
   
   
   
Endocrine 
DiabetesNo I__I Yes I__I   
   
   
CNS 
   
   
   
Dermatology 
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System 
History Start 
Date 
Stop Date 
Reticulo-endothelial 
System  
   
   
   
Allergies 
Allergy to any medication         No I__I Yes 
I__I→ 
  
   
Any allergy to yeast                  No I__I Yes 
I__I→ 
  
Other  
Are you currently  taking any  Medication?                                     
No I__I Yes I__I→ 
   
   
   
Hospitalization in the last          No I__I Yes 
I__I→ 
30 days   
  
CD4 Count 
  
Date 
 
 
 
Signature/Initials  Date  
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Visit: Baseline (Day 2) 
 
Procedures Yes No 
HIV test (if hospital records is not available)   
Pharmacological 
Peak (4-6 hours after KM/CM)   
Package, Centrifuge and Refrigerate Blood   
Audiology   
Cerumen Mx (if indicated)   
Case Report   
Otoscopy   
Tympanometry   
DPOAE   
Pure Tone Audiometry   
Other   
Administer KM/CM (and complete drug diary)  
(please circle whether KM or CM) 
  
 
Visit: Baseline (Day2) 
 
 An Inpatient An Outpatient 
 
Is the participant?  
 
 
 
Any Interim Medical History ➔ 
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Weight 
I__I__I__I. I__I  kg 
Temperature 
 
I__I__I.I__I 
°Celsius 
 
Pulse 
 
PR _________/min 
 
 
Respiratory Rate 
 
RR ________/ min  
 
 
 
Blood Pressure 1 
Bp  _____  / _____   
 mm/Hg 
 
Blood Pressure 2 
Bp  _____  / _____   
 mm/Hg 
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➔Assessment 
 
Are there any previously identified SIGNS & SYMPTOMS that are new/resolved/upgraded?✓
 I__I no 
           I__I yes 
If Yes, complete the Signs/Symptoms page. 
 
 
Are there any previously identified DIAGNOSISthat are new/resolved/upgraded? ✓  I__I no
  
I__I yes 
If Yes, complete the Diagnosis page 
 
 
Are there any CONCONMITANT MEDICATION/TRADITIONAL MEDS updates?✓ I__I no
  
I__I yes 
If Yes, complete the Con Meds page 
 
➔Plan 
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Baseline Audiological Measures 
Date admitted to hospital for DR-TB (if at all)  
Time and date of last dose of 
kanamycin/capreomycin 
 
 
Audiology Checklist 
 YES NO 
Medication   ○Kanamycin             ○ Capreomycin       
○  ARV 
○  High Cholesterol   ○ Diabetes               
○  Other 
 Family History of 
Hearing Loss 
  
Otalgia (ear pain)   
Ottorhea (Discharge)   
Tinnitus (Ringing or 
noises in the ear) 
  
Dizziness   
Aural Fullness   
Hearing Loss   
Noise Exposure   
 
Audiological Measures 
 
Otoscopy No 
abnormalities 
detected 
Cerumen but not 
occluding 
No Cerumen = 1 
↓ 70% occluding = 2 
↑70% occluding = 3 
Occluding 
Cerumen 
Other 
(please 
describe) 
Cerumen 
Removed 
Via 
Suction 
Right Ear      
Left Ear      
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Tympanometry Type 
 
Ear Canal 
Volume 
(ml) 
Pressure 
(daPa) 
Compliance 
(ml) 
Gradient 
(daPa) 
Right Ear      
Left Ear      
 
Signature/Initials  Date  
 
DPOAE 
Please print the DPOAE results and staple them below: 
NB – Do Repeated Measures 
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Pure Tone  Audiometry 
Please print and place pure tone audiometry results here. Please email the results as well. 
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Signature/Initials  Date  
 
 
 
Consistent Co-operative Other 
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Visit: Baseline(Day 3) 
 
 
 
 
Procedures Yes No 
Pharmacological 
Trough (30-60 mins before KM)   
Package, Centrifuge and Refrigerate for SMU 
(with requisition form AND drug diary) 
  
Administer KM/ CM (30 to 60 minutes AFTER trough and 
complete drug diary) 
(please circle whether KM or CM) 
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Visit: Baseline (Day3) 
 
 An Inpatient An Outpatient 
 
Is the participant?  
 
 
 
 
 
Any Interim Medical History ➔ 
 
 
 
 
 
 
  
Name  Signature/Initials  Date  
THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND CAPREOMYCIN IN PATIENTS WITH DR-TB AND 
THE RELATIONSHIP BETWEEN HEARING LEVELS: A FEASIBILITY STUDY 
581 
➔Assessment 
 
Are there any previously identified SIGNS & SYMPTOMS that are new/resolved/upgraded?✓
 I__I no 
           I__I yes 
If Yes, complete the Signs/Symptoms page. 
 
 
Are there any previously identified DIAGNOSISthat are new/resolved/upgraded? ✓  I__I no
  
I__I yes 
If Yes, complete the Diagnosis page 
 
 
Are there any CONCONMITANT MEDICATION/TRADITIONAL MEDS updates?✓ I__I no
  
I__I yes 
If Yes, complete the Con Meds page 
 
➔Plan 
 
 
 
 
Signature/Initials  Date  
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Appendix H 
Patient Contact Information Form 
A FEASIBILITY STUDY INVESTIGATING THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND 
CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE RELATIONSHIP BETWEEN HEARING LEVELS 
583 
Patient Contact Information 
Please update the patient information sheet as follows:  
List of signed consent documents/participant letters: 
 
REASON FOR STUDY/ TREATMENT 
DISCONTINUATION:  
 
 
 
 
 
 
 
Language Version 
Version 
Dated 
Consent type 
(Main, Storage, Participant letter 
etc.) 
Date signed by 
participant 
 
 
    
 
 
    
 
 
    
 
 
    
 
  
 
√ 
 
√ 
 
HOSPITAL 
SR/HJ 
Enrolled to main 
study? 
YES 
 
NO  
 
 
 
 
 
 
 
 
 
Premature 
treatment 
discontinuation?   
YES  NO  
Premature study 
discontinuation? 
YES  NO 
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Telephone contact Update (participants address to be updated on Patient Information sheet): 
 
Initial contact number  : 
____________________________________________________________ 
 
Contact telephone number 
Name of designated 
contact 
Date of 
modification 
Update done by -
Signature 
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Appendix I 
Week 2: Follow Up Case Report Form
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Visit: Week 2 Checklist  
 
 
Procedures Yes No 
Case Report Form   
Follow-up Case Report   
Pharmacological (Study Coordinator)  
Peak (4 to 6 hours after KM/CM)   
Trough (30 to 60 minutes before KM/CM)   
Creatinine (and send to CLS) (both SR and HJ)   
Package, Centrifuge and Refrigerate (with requisition form 
AND drug diary) 
  
Audiology (Study Coordinator)  
Cerumen Mx (if indicated)   
Case Report   
Otoscopy   
Tympanometry   
DPOAE   
Pure Tone Audiometry   
Medical (Doctor/PI) (and study coordinator to copy notes for 
study file) 
  
Physical Exam   
Other   
Administer KM/CM (complete drug diary) 
 
Please circle whether participant on KM or CM 
  
 
  
Kanamycin Study                          Clinical HIV Research Unit                                        Visit: Week 2 
 
Visit Date: __________________ (DD.MMM.YYYY) Initials: _____________ Study Number:_________________ 
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 An Inpatient An Outpatient 
 
Is the participant?  
 
 
 
 
 
 
Not Applicable Date of Discharge 
If the participant was an 
inpatient, and has been 
discharged: 
 
  
 
 
 
 
 
Any Interim Medical History ➔ 
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Weight 
I__I__I__I. I__I  kg 
Temperature 
 
I__I__I.I__I °Celsius 
 
Pulse 
 
PR _________/min 
 
 
Respiratory Rate 
 
RR ________/ min  
 
 
 
Blood Pressure 1 
Bp  ______ / _____   
 mm/Hg 
 
Blood Pressure 2 
Bp  ______ / _____   
 mm/Hg 
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Targeted Physical Exam: 
 
 
System Observations/Findings Body Site/Specify 
Grade 
 
HEENT 
 
 
  
 
  
 
Respiratory  
 
                                      Normal   Abnormal   
 
  
   
CVS  
 
                                      Normal   Abnormal   
 
 
 
  
 
Abdomen 
                                       Normal   
Abnormal   
 
 
 
  
 
GUT 
Pelvic exam done             No        Yes 
 
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Lower 
Extremities  
For Oedema 
                                      Normal   Abnormal   
 
 
 
  
 
MSS 
                                      Normal   Abnormal   
 
 
 
 
  
 
Derm  
                                      Normal   Abnormal   
 
 
 
  
 
CNS 
                                      Normal   Abnormal   
 
 
 
  
 
  
 
Other 
                                       No        Yes 
 
 
 
  
 
 
Signature/Initials  Date  
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➔Assessment 
 
 
 
 
 
 
 
 
Are there any previously identified SIGNS & SYMPTOMS that are new/resolved/upgraded?✓
 I__I no 
           I__I yes 
If Yes, complete the Signs/Symptoms page. 
 
 
Are there any previously identified DIAGNOSISthat are new/resolved/upgraded? ✓ 
 I__I no  
I__I yes 
If Yes, complete the Diagnosis page 
 
 
Are there any CONCONMITANT MEDICATION/TRADITIONAL MEDS 
updates?✓ I__I no  
I__I yes 
If Yes, complete the Con Meds page 
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➔Plan 
 
 
 
 
 
 
 
 
Participant/Case report form 
*for all follow up measures after baseline 
Participant Number  
Current Weight  
Date drug therapy was initiated  
Current drug therapy (drug name, dosage and duration of drug therapy)  
See drug diary 
 
 
 
 
Other illnesses since the previous set of 
measurements (Date, duration, description) 
 
 
 
 
 
Time and date of last dose of 
kanamycin/capreomycin 
 
Any behavioural/ emotional/ psychiatric changes 
reported in the file since the last set of measurements 
 
Signature/Initials  Date  
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Has the participant received kanamycin/capreomycin 
daily since the last visit? If not, which days did the 
participant not go to the clinic and why. 
 
Any hearing changes since the last set of 
measurement recorded in the file 
 
Any hearing changes since the last set of 
measurements as reported subjectively by the 
participant 
 
Other significant co-variables reported in the file 
since the last set of measures 
 
Tinnitus?   
Discharge from the ears?  
Willingness to continue with current set of 
measurements (blood and audiological testing) 
 
Verbal consent to participate in the measures again  
Overall participant compliance with procedures and 
medication. Describe attitude. 
 
 
 
Audiology Checklist 
 
 YES NO 
Medication   ○  Kanamycin             ○ Capreomycin       
○  ARV  ○  High Cholesterol   ○ Diabetes               
○ Other 
Otalgia (ear pain)   
Ottorhea (Discharge)   
Tinnitus (Ringing or 
noises in the ear) 
  
Dizziness   
Aural Fullness   
Hearing Loss   
Noise Exposure   
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Audiological Measures 
 
Otoscopy No 
abnormalities 
detected 
Cerumen but not 
occluding 
No Cerumen = 1 
↓ 70% occluding = 2 
↑70% occluding = 3 
Occluding 
Cerumen 
Other 
(please 
describe) 
Cerumen 
Removed 
Via 
Suction 
Right Ear      
Left Ear      
 
 
Tymanometry Type 
 
Ear Canal 
Volume (ml) 
Pressure 
(daPa) 
Compliance 
(ml) 
Gradient 
(daPa) 
Right Ear      
Left Ear      
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DPOAE 
Please print the DPOAE results and staple them below: 
NB – do repeated measures! 
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Pure Tone Audiometry 
Please print and place pure tone audiometry results here. Please email the results as well. 
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Consistent Co-operative Other 
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Appendix J 
Week 4: Follow Up Case Report Forms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A FEASIBILITY STUDY INVESTIGATING THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND 
CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE RELATIONSHIP BETWEEN HEARING LEVELS 
599 
 
 
 
 
Visit: Week 4 Checklist  
 
Procedures Yes No 
Case Report Form  
Follow-up Case Report   
   
Pharmacological  
Peak (4 to 6 hours after KM)   
Trough (30 to 60 minutes before KM)   
Refrigerate, Centrifuge and Package (with requisition 
form and drug diary) 
  
Creatinine (and send to CLS) (only at SRH)   
Audiology  
Cerumen Mx (if indicated)   
Case Report   
Otoscopy   
Tympanometry   
DPOAE   
Pure Tone Audiometry   
Medical (Doctor/PI)(study coordinator to copy 
physical exam notes for study file) 
  
Physical Exam   
Other   
Administer KM/CM (and complete drug diary) 
 
Please circle if participant on KM/CM 
  
 
 
 
 
Kanamycin Study                          Clinical HIV Research Unit                                        WEEK 4 
 
Visit Date: __________________ (DD.MMM.YYYY) Initials: _____________ Study Number: __________________ 
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 An Inpatient An Outpatient 
 
Is the participant?  
 
 
 
 
 
 
Not Applicable Date of Discharge 
If the participant was an 
inpatient, and has been 
discharged: 
 
  
 
 
 
 
Visit:Week 4 
Any Interim Medical History ➔ 
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Weight 
I__I__I__I. I__I  kg 
Temperature 
 
I__I__I.I__I 
°Celsius 
 
Pulse 
 
PR _________/min 
 
 
Respiratory Rate 
 
RR ________/ min  
 
 
 
Blood Pressure 1 
Bp  _____  / _____   
 mm/Hg 
 
Blood Pressure 2 
Bp  _____  / _____   
 mm/Hg 
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Targeted Physical Exam: 
 
System Observations/Findings Body Site/Specify 
Grade 
 
HEENT 
 
 
  
 
  
 
Respiratory  
 
                                      Normal   Abnormal   
 
  
   
CVS  
 
                                      Normal   Abnormal   
 
 
 
  
 
Abdomen 
                                       Normal   
Abnormal   
 
 
 
  
 
   
 
GUT 
Pelvic exam done             No        Yes 
 
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Lower 
Extremities  
For Oedema 
                                      Normal   Abnormal   
 
 
 
  
 
MSS 
                                      Normal   Abnormal   
 
 
 
 
  
 
Derm  
                                      Normal   Abnormal   
 
 
 
  
 
CNS 
                                      Normal   Abnormal   
 
 
 
  
 
  
 
Other 
                                       No        Yes 
 
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➔Assessment 
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Are there any previously identified SIGNS & SYMPTOMS that are new/resolved/upgraded?✓
 I__I no 
         I__I yes 
If Yes, complete the Signs/Symptoms page. 
 
Are there any previously identified DIAGNOSISthat are new/resolved/upgraded? 
✓I__I   no  
I__I yes 
If Yes, complete the Diagnosis page 
 
 
Are there any CONCONMITANT MEDICATION/TRADITIONAL MEDS 
updates?✓I__I no  
I__I yes 
If Yes, complete the Con Meds page 
 
 
 
 
 
  
A FEASIBILITY STUDY INVESTIGATING THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND 
CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE RELATIONSHIP BETWEEN HEARING LEVELS 
606 
➔Plan 
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Participant/Case report form 
*for all follow up measures after baseline 
Participant Number  
Current Weight  
Date drug therapy was initiated  
Current drug therapy (drug name, dosage and duration of drug therapy)  
 
See drug diary 
 
 
 
Other illnesses since the previous set of 
measurements (Date, duration, description) 
 
 
 
 
 
Time and date of last dose of kanamycin  
Any behavioural/ emotional/ psychiatric changes 
reported in the file since the last set of measurements 
 
Has the participant received kanamycin/capreomycin 
daily since the last visit? If not, which days did the 
participant not go to the clinic and why. 
 
Any hearing changes since the last set of 
measurement recorded in the file 
 
Any hearing changes since the last set of 
measurements as reported subjectively by the 
participant 
 
Other significant co-variables reported in the file 
since the last set of measures 
 
Tinnitus?   
Discharge from the ears?  
A FEASIBILITY STUDY INVESTIGATING THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND 
CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE RELATIONSHIP BETWEEN HEARING LEVELS 
608 
Willingness to continue with current set of 
measurements (blood and audiological testing) 
 
Verbal consent to participate in the measures again  
Overall participant compliance with procedures and 
medication. Describe attitude. 
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Audiology Checklist 
 
 YES NO 
Medication   ○  Kanamycin             ○ Capreomycin       
○  ARV  ○  High Cholesterol   ○ Diabetes               
○ Other 
Otalgia (ear pain)   
Ottorhea (Discharge)   
Tinnitus (Ringing or 
noises in the ear) 
  
Dizziness   
Aural Fullness   
Hearing Loss   
Noise Exposure   
 
Audiological Measures 
 
Otoscopy No 
abnormalities 
detected 
Cerumen but not 
occluding 
No Cerumen = 1 
↓ 70% occluding = 2 
↑70% occluding = 3 
Occluding 
Cerumen 
Other 
(please 
describe) 
Cerumen 
Removed 
Via 
Suction 
Right Ear      
Left Ear      
 
Tymanometry Type 
 
Ear Canal 
Volume (ml) 
Pressure 
(daPa) 
Compliance 
(ml) 
Gradient 
(daPa) 
Right Ear      
Left Ear      
 
Signature/Initials  Date  
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DPOAE 
Please print the DPOAE results and staple them below: 
NB – Do Repeated Measures 
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Pure Tone Audiometry 
Please print and place pure tone audiometry results here. Please email the results as well. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A FEASIBILITY STUDY INVESTIGATING THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND 
CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE RELATIONSHIP BETWEEN HEARING LEVELS 
612 
Consistent Co-operative Other 
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Appendix K 
Week 6: Follow Up Case Report Forms
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Visit: Week 6 Checklist  
 
 
 
Procedures Yes No 
Case Report Form  
Follow-up Case Report   
   
Pharmacological  
Peak (4 to 6 hours after KM)   
Trough (30 to 60 minutes before KM)   
Creatinine (and send to CLS) (HJH AND SRH)   
Refrigerate, Centrifuge and Package for Medunsa (with 
requisition form and drug diary) 
  
Audiology  
Cerumen Mx (if indicated)   
Case Report   
Otoscopy   
Tympanometry   
DPOAE   
Pure Tone Audiometry   
Other   
Administer KM/CM (and complete drug diary) 
 
Please circle whether participant on KM or CM 
  
 
 
  
Kanamycin Study                          Clinical HIV Research Unit                                        WEEK 
6 
 
Visit Date: __________________ (DD.MMM.YYYY) Initials: _____________ Study Number: -
__________________ 
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 An Inpatient An Outpatient 
 
Is the participant?  
 
 
 
 
 
 
Not Applicable Date of Discharge 
If the participant was an 
inpatient, and has been 
discharged: 
 
  
 
 
 
 
 
Visit: Week 6 
Any Interim Medical History ➔ 
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Weight 
I__I__I__I. I__I  kg 
Temperature 
 
I__I__I.I__I 
°Celsius 
 
Pulse 
 
PR _________/min 
 
 
Respiratory Rate 
 
RR ________/ min  
 
 
 
Blood Pressure 1 
Bp  _____  / _____   
 mm/Hg 
 
Blood Pressure 2 
Bp  _____  / _____   
 mm/Hg 
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Targeted Physical Exam: 
 
System Observations/Findings Body Site/Specify 
Grade 
 
HEENT 
 
 
  
 
  
 
Respiratory  
 
                                      Normal   Abnormal   
 
  
   
CVS  
 
                                      Normal   Abnormal   
 
 
 
  
 
Abdomen 
                                       Normal   
Abnormal   
 
 
 
  
 
GUT 
Pelvic exam done             No        Yes 
 
 
 
  
 
  
 
  
 
  
 
Lower 
Extremities  
                                      Normal   Abnormal   
 
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For Oedema 
  
 
MSS 
                                      Normal   Abnormal   
 
 
 
 
  
 
Derm  
                                      Normal   Abnormal   
 
 
 
  
 
CNS 
                                      Normal   Abnormal   
 
 
 
  
 
  
 
Other 
                                       No        Yes 
 
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➔Assessment 
 
 
 
 
 
 
 
 
 
 
 
Are there any previously identified SIGNS & SYMPTOMS that are new/resolved/upgraded?✓
 I__I no 
           I__I yes 
If Yes, complete the Signs/Symptoms page. 
 
 
Are there any previously identified DIAGNOSISthat are new/resolved/upgraded? ✓ 
 I__I no  
I__I yes 
If Yes, complete the Diagnosis page 
 
 
Are there any CONCONMITANT MEDICATION/TRADITIONAL MEDS 
updates?✓ I__I no  
I__I yes 
If Yes, complete the Con Meds page 
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➔Plan 
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Participant/Case report form 
*for all follow up measures after baseline 
Participant Number  
Current Weight  
Date drug therapy was initiated  
Current drug therapy (drug name, dosage and duration of drug therapy)  
 
See drug diary 
 
 
 
Other illnesses since the previous set of 
measurements (Date, duration, description) 
 
 
 
 
 
Time and date of last dose of 
kanamycin/capreomycin 
 
Any behavioural/ emotional/ psychiatric changes 
reported in the file since the last set of measurements 
 
Has the participant received kanamycin/capreomycin 
daily since the last visit? If not, which days did the 
participant not go to the clinic and why. 
 
Any hearing changes since the last set of 
measurement recorded in the file 
 
Any hearing changes since the last set of 
measurements as reported subjectively by the 
participant 
 
Other significant co-variables reported in the file 
since the last set of measures 
 
Tinnitus?   
Discharge from the ears?  
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Willingness to continue with current set of 
measurements (blood and audiological testing) 
 
Verbal consent to participate in the measures again  
Overall participant compliance with procedures and 
medication. Describe attitude. 
 
 
Audiology Checklist 
 
 YES NO 
Medication   ○  Kanamycin             ○ Capreomycin       
○  ARV  ○  High Cholesterol   ○ Diabetes               
○ Other 
Otalgia (ear pain)   
Ottorhea (Discharge)   
Tinnitus (Ringing or 
noises in the ear) 
  
Dizziness   
Aural Fullness   
Hearing Loss   
Noise Exposure   
 
Audiological Measures 
 
Otoscopy No 
abnormalities 
detected 
Cerumen but not 
occluding 
No Cerumen = 1 
↓ 70% occluding = 2 
↑70% occluding = 3 
Occluding 
Cerumen 
Other 
(please 
describe) 
Cerumen 
Removed 
Via 
Suction 
Right Ear      
Left Ear      
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Tymanometry Type 
 
Ear Canal 
Volume (ml) 
Pressure 
(daPa) 
Compliance 
(ml) 
Gradient 
(daPa) 
Right Ear      
Left Ear      
 
 
 
 
 
 
Signature/Initials  Date  
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DPOAE 
Please print the DPOAE results and staple them below: 
NB – do repeated measures! 
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Pure Tone Audiometry 
Please print and place pure tone audiometry results here. Please email the results as well. 
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Consistent Co-operative Other 
   
 
 
 
 
 
 
 
 
 
 
 
Signature/Initials  Date  
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Appendix L 
Week 8: Follow Up Case Report Forms
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Visit: Week 8 Checklist  
 
Procedures Yes No 
Standard of Care at HJH   
Creatinine (Cr,GRF) (study coordinator to send results to 
SMU) 
  
CD4   
Potassium  (K)   
Case Report Forms   
Follow-up case Report forms   
Pharmacological   
Peak (4 to 6 hours after KM/CM)   
Trough (30 to 60 minutes before KM/CM)   
Refrigerate, Centrifuge and Package for SMU (with requisition 
form and drug diary) 
  
Creatinine (SRH ONLY)   
Audiology   
Cerumen Mx (if indicated)   
Case Report   
Otoscopy   
Tympanometry   
DPOAEs   
Pure Tone Audiometry   
Medical (Doctor/PI)  
(study coordinator to copy physical exam results for study file) 
  
Physical Exam   
Other   
Administer Kanamycin and complete drug diary 
 
Please circle whether participant on KM/CM 
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 An Inpatient An Outpatient 
 
Is the participant?  
 
 
 
 
 
 
Not Applicable Date of Discharge 
If the participant was an 
inpatient, and has been 
discharged: 
 
  
 
 
 
 
 
Visit: Week 8 
Any Interim Medical History ➔ 
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Weight 
I__I__I__I. I__I  kg 
Temperature 
 
I__I__I.I__I 
°Celsius 
 
Pulse 
 
PR _________/min 
 
 
Respiratory Rate 
 
RR ________/ min  
 
 
 
Blood Pressure 1 
Bp  _____  / _____   
 mm/Hg 
 
Blood Pressure 2 
Bp  _____  / _____   
 mm/Hg 
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Targeted Physical Exam: 
 
System Observations/Findings Body Site/Specify 
Grade 
 
HEENT 
 
 
  
 
  
 
Respiratory  
 
                                      Normal   Abnormal   
 
  
   
CVS  
 
                                      Normal   Abnormal   
 
 
 
  
 
Abdomen 
                                       Normal   
Abnormal   
 
 
 
  
 
GUT 
Pelvic exam done             No        Yes 
 
 
 
  
 
  
 
  
 
  
 
Lower 
Extremities  
                                      Normal   Abnormal   
 
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For Oedema 
  
 
MSS 
                                      Normal   Abnormal   
 
 
 
 
  
 
Derm  
                                      Normal   Abnormal   
 
 
 
  
 
CNS 
                                      Normal   Abnormal   
 
 
 
  
 
  
 
Other 
                                       No        Yes 
 
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➔Assessment 
 
 
 
 
 
 
 
 
 
 
 
Are there any previously identified SIGNS & SYMPTOMS that are new/resolved/upgraded?✓
 I__I no 
           I__I yes 
If Yes, complete the Signs/Symptoms page. 
 
 
Are there any previously identified DIAGNOSISthat are new/resolved/upgraded? ✓ 
 I__I no  
I__I yes 
If Yes, complete the Diagnosis page 
 
 
Are there any CONCONMITANT MEDICATION/TRADITIONAL MEDS 
updates?✓ I__I no  
I__I yes 
If Yes, complete the Con Meds page 
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➔Plan 
 
 
 
 
 
 
 
 
 
Participant/Case report form 
*for all follow up measures after baseline 
Participant Number  
Current Weight  
Date drug therapy was initiated  
Current drug therapy (drug name, dosage and duration of drug therapy)  
 
See drug diary 
 
 
 
Other illnesses since the previous set of 
measurements (Date, duration, description) 
 
 
 
 
 
Time and date of last dose of 
kanamycin/capreomycin 
 
Any behavioural/ emotional/ psychiatric changes 
reported in the file since the last set of measurements 
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Has the participant received kanamycin/capreomycin 
daily since the last visit? If not, which days did the 
participant not go to the clinic and why. 
 
Any hearing changes since the last set of 
measurement recorded in the file 
 
Any hearing changes since the last set of 
measurements as reported subjectively by the 
participant 
 
Other significant co-variables reported in the file 
since the last set of measures 
 
Tinnitus?   
Discharge from the ears?  
Willingness to continue with current set of 
measurements (blood and audiological testing) 
 
Verbal consent to participate in the measures again  
Overall participant compliance with procedures and 
medication. Describe attitude. 
 
 
 
Audiology Checklist 
 
 YES NO 
Medication   ○  Kanamycin             ○ Capreomycin       
○  ARV  ○  High Cholesterol   ○ Diabetes               
○ Other 
Otalgia (ear pain)   
Ottorhea (Discharge)   
Tinnitus (Ringing or 
noises in the ear) 
  
Dizziness   
Aural Fullness   
Hearing Loss   
Noise Exposure   
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Audiological Measures 
 
Otoscopy No 
abnormalities 
detected 
Cerumen but not 
occluding 
No Cerumen = 1 
↓ 70% occluding = 2 
↑70% occluding = 3 
Occluding 
Cerumen 
Other 
(please 
describe) 
Cerumen 
Removed 
Via 
Suction 
Right Ear      
Left Ear      
 
 
 
Tymanometry Type 
 
Ear Canal 
Volume (ml) 
Pressure 
(daPa) 
Compliance 
(ml) 
Gradient 
(daPa) 
Right Ear      
Left Ear      
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DPOAE 
Please print the DPOAE results and staple them below: 
NB – Do Repeated Measures 
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Pure Tone Audiometry 
Please print and place pure tone audiometry results here. Please email the results as well. 
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Consistent Co-operative Other 
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Appendix M 
Week 10: Follow Up Case Report Forms
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Visit: Week 10 Checklist  
 
 
 
 
 
 
 
Procedures Yes No 
Case Report Form  
Follow-up Case Report   
   
Pharmacological  
Peak (4 to 6 hours after KM/CM)   
Trough (30 to 60 minutes before KM/CM)   
Creatinine (send to CLS) (HJH AND SRH)   
Refrigerate, Centrifuge and Package for SMU (with requisition 
form and drug diary) 
  
Audiology  
Cerumen Mx (if indicated)   
Case Report   
Otoscopy   
Tympanometry   
DPOAE   
Pure Tone Audiometry   
Other   
Administer Kanamycin/Capreomycin and Complete Drug 
Diary 
 
Please circle whether participant on KM/CM 
  
 
  
Kanamycin Study                          Clinical HIV Research Unit                                        
WEEK 10 
 
Visit Date: __________________ (DD.MMM.YYYY) Initials: _____________ Study Number: -
__________________ 
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 An Inpatient An Outpatient 
 
Is the participant?  
 
 
 
 
 
 
Not Applicable Date of Discharge 
If the participant was an 
inpatient, and has been 
discharged: 
 
  
 
 
 
 
Visit: Week 10 
Any Interim Medical History ➔ 
 
 
 
 
 
Weight 
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I__I__I__I. I__I  kg 
Temperature 
 
I__I__I.I__I 
°Celsius 
 
Pulse 
 
PR _________/min 
 
 
Respiratory Rate 
 
RR ________/ min  
 
 
 
Blood Pressure 1 
Bp  _____  / _____   
 mm/Hg 
 
Blood Pressure 2 
Bp  _____  / _____   
 mm/Hg 
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Targeted Physical Exam: 
 
System Observations/Findings Body Site/Specify 
Grade 
 
HEENT 
 
 
  
 
  
 
Respiratory  
 
                                      Normal   Abnormal   
 
  
   
CVS  
 
                                      Normal   Abnormal   
 
 
 
  
 
Abdomen 
                                       Normal   
Abnormal   
 
 
 
  
 
GUT 
Pelvic exam done             No        Yes 
 
 
 
  
 
  
 
  
 
  
 
Lower 
Extremities  
                                      Normal   Abnormal   
 
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For Oedema 
  
 
MSS 
                                      Normal   Abnormal   
 
 
 
 
  
 
Derm  
                                      Normal   Abnormal   
 
 
 
  
 
CNS 
                                      Normal   Abnormal   
 
 
 
  
 
  
 
Other 
                                       No        Yes 
 
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➔Assessment 
 
 
 
 
 
 
 
 
 
 
 
Are there any previously identified SIGNS & SYMPTOMS that are new/resolved/upgraded?✓
 I__I no 
          I__I yes 
If Yes, complete the Signs/Symptoms page. 
 
 
Are there any previously identified DIAGNOSISthat are new/resolved/upgraded? 
✓I__I no  
I__I yes 
If Yes, complete the Diagnosis page 
 
 
Are there any CONCONMITANT MEDICATION/TRADITIONAL MEDS 
updates?✓I__I no  
I__I yes 
If Yes, complete the Con Meds page 
 
 
  
A FEASIBILITY STUDY INVESTIGATING THE PHARMACOKINETICS AND PHARMACODYNAMICS OF KANAMYCIN AND 
CAPREOMYCIN IN PATIENTS WITH DR-TB AND THE RELATIONSHIP BETWEEN HEARING LEVELS 
647 
➔Plan 
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Participant/Case report form 
*for all follow up measures after baseline 
Participant Number  
Current Weight  
Date drug therapy was initiated  
Current drug therapy (drug name, dosage and duration of drug therapy)  
See drug diary 
 
 
 
 
Other illnesses since the previous set of 
measurements (Date, duration, description) 
 
 
 
 
 
Time and date of last dose of 
kanamycin/capreomycin 
 
Any behavioural/ emotional/ psychiatric changes 
reported in the file since the last set of measurements 
 
Has the participant received kanamycin/capreomycin 
daily since the last visit? If not, which days did the 
participant not go to the clinic and why. 
 
Any hearing changes since the last set of 
measurement recorded in the file 
 
Any hearing changes since the last set of 
measurements as reported subjectively by the 
participant 
 
Other significant co-variables reported in the file 
since the last set of measures 
 
Tinnitus?   
Discharge from the ears?  
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Willingness to continue with current set of 
measurements (blood and audiological testing) 
 
Verbal consent to participate in the measures again  
Overall participant compliance with procedures and 
medication. Describe attitude. 
 
 
 
 
Audiology Checklist 
 
 YES NO 
Medication   ○  Kanamycin             ○ Capreomycin       
○  ARV  ○  High Cholesterol   ○ Diabetes               
○ Other 
Otalgia (ear pain)   
Ottorhea (Discharge)   
Tinnitus (Ringing or 
noises in the ear) 
  
Dizziness   
Aural Fullness   
Hearing Loss   
Noise Exposure   
 
 
Audiological Measures 
 
Otoscopy No 
abnormalities 
detected 
Cerumen but not 
occluding 
No Cerumen = 1 
↓ 70% occluding = 2 
↑70% occluding = 3 
Occluding 
Cerumen 
Other 
(please 
describe) 
Cerumen 
Removed 
Via 
Suction 
Right Ear      
Left Ear      
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Tymanometry Type 
 
Ear Canal 
Volume (ml) 
Pressure 
(daPa) 
Compliance 
(ml) 
Gradient 
(daPa) 
Right Ear      
Left Ear      
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DPOAE 
Please print the DPOAE results and staple them below: 
NB – Do Repeated Measures 
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Pure Tone Audiometry 
Please print and place pure tone audiometry results here. Please email the results as well. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consistent Co-operative Other 
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Appendix N 
Week 12: Follow Up Case Report Forms
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Visit: Week 12 Checklist  
 
 
Procedures Yes No 
Case Report Form  
Follow-up Case Report   
   
Pharmacological  
Peak (4 to 6 hours after KM)   
Trough (30 to 60 minutes before KM)   
Creatinine (send to CLS) (HJH AND SRH)   
Refrigerate, Centriguge and Package for Medunsa 
(with requisition form and drug diary) 
  
Audiology  
Cerumen Mx (if indicated)   
Case Report   
Otoscopy   
Tympanometry   
DPOAE   
Pure Tone Audiometry   
Medical (Doctor/PI)  
(study coordinator to copy physical examination and 
place in study file) 
  
Physical Exam   
Other   
Administer Kanamycin/Capreomycin and Complete 
Drug Diary 
 
Please circle whether participant on KM/CM 
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DISCHARGE AND COUNSEL ABOUT CLINIC PROCEDURES FOR INJECTIONS ETC. 
AND REFER TO AUDIOLOGY CLINIC IN THEIR DISTRICT 
 
 
 
 
 
 
 
 
 
 An Inpatient An Outpatient 
 
Is the participant?  
 
 
 
 
 
 
Not Applicable Date of Discharge 
If the participant was an 
inpatient, and has been 
discharged: 
 
  
 
 
Visit: Week 12 
Kanamycin Study                          Clinical HIV Research Unit                                        WEEK 12 
 
Visit Date: __________________ (DD.MMM.YYYY) Initials: _____________ Study Number: __________________ 
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Any Interim Medical History ➔ 
 
 
 
 
 
Weight 
I__I__I__I. I__I  kg 
Temperature 
 
I__I__I.I__I 
°Celsius 
 
Pulse 
 
PR _________/min 
 
 
Respiratory Rate 
 
RR ________/ min  
 
 
 
Blood Pressure 1 
Bp  _____  / _____   
 mm/Hg 
 
Blood Pressure 2 
Bp  _____  / _____   
 mm/Hg 
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Targeted Physical Exam: 
 
System Observations/Findings Body Site/Specify 
Grade 
 
HEENT 
 
 
  
 
  
 
Respiratory  
 
                                      Normal   Abnormal   
 
  
   
CVS  
 
                                      Normal   Abnormal   
 
 
 
  
 
Abdomen 
                                       Normal   
Abnormal   
 
 
 
  
 
GUT 
Pelvic exam done             No        Yes 
 
 
 
  
 
  
 
  
 
  
 
Lower 
Extremities  
                                      Normal   Abnormal   
 
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For Oedema 
  
 
MSS 
                                      Normal   Abnormal   
 
 
 
 
  
 
Derm  
                                      Normal   Abnormal   
 
 
 
  
 
CNS 
                                      Normal   Abnormal   
 
 
 
  
 
  
 
Other 
                                       No        Yes 
 
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➔Assessment 
 
 
 
 
 
 
 
 
 
 
 
Are there any previously identified SIGNS & SYMPTOMS that are new/resolved/upgraded?✓
 I__I no 
           I__I yes 
If Yes, complete the Signs/Symptoms page. 
 
 
Are there any previously identified DIAGNOSISthat are new/resolved/upgraded? ✓ 
 I__I no  
I__I yes 
If Yes, complete the Diagnosis page 
 
 
Are there any CONCONMITANT MEDICATION/TRADITIONAL MEDS 
updates?✓ I__I no  
I__I yes 
If Yes, complete the Con Meds page 
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➔Plan 
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Participant/Case report form 
*for all follow up measures after baseline 
Participant Number  
Current Weight  
Date drug therapy was initiated  
Current drug therapy (drug name, dosage and duration of drug 
therapy) 
 
See drug diary 
 
 
 
 
Other illnesses since the previous set of 
measurements (Date, duration, description) 
 
 
 
 
 
Time and date of last dose of 
kanamycin/capreomycin 
 
Any behavioural/ emotional/ psychiatric 
changes reported in the file since the last set of 
measurements 
 
Has the participant received 
kanamycin/capreomycin daily since the last 
visit? If not, which days did the participant not 
go to the clinic and why. 
 
Any hearing changes since the last set of 
measurement recorded in the file 
 
Any hearing changes since the last set of 
measurements as reported subjectively by the 
participant 
 
Other significant co-variables reported in the 
file since the last set of measures 
 
Tinnitus?   
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Discharge from the ears?  
Willingness to continue with current set of 
measurements (blood and audiological testing) 
 
Verbal consent to participate in the measures 
again 
 
 
Overall participant compliance with procedures 
and medication. Describe attitude. 
 
 
 
Audiology Checklist 
 
 YES NO 
Medication   ○  Kanamycin             ○ Capreomycin       
○  ARV  ○  High Cholesterol   ○ Diabetes               
○ Other 
Otalgia (ear pain)   
Ottorhea (Discharge)   
Tinnitus (Ringing or 
noises in the ear) 
  
Dizziness   
Aural Fullness   
Hearing Loss   
Noise Exposure   
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Audiological Measures 
 
Otoscopy No 
abnormalities 
detected 
Cerumen but not 
occluding 
No Cerumen = 1 
↓ 70% occluding = 2 
↑70% occluding = 3 
Occluding 
Cerumen 
Other 
(please 
describe) 
Cerumen 
Removed 
Via 
Suction 
Right Ear      
Left Ear      
 
 
 
Tymanometry Type 
 
Ear Canal 
Volume (ml) 
Pressure 
(daPa) 
Compliance 
(ml) 
Gradient 
(daPa) 
Right Ear      
Left Ear      
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DPOAE 
Please print the DPOAE results and staple them below: 
NB – Do Repeated Measures 
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Pure Tone Audiometry 
Please print and place pure tone audiometry results here. Please email the results as well. 
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Consistent Co-operative Other 
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Appendix O 
Drug Diary for Hospital Patients
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DAILY DRUG DIARY 
 
 
Drug Dosage  Start Stop Sign 
Moxifloxin 400 mg    
Ethionamide 250 mg 
500 mg 
   
Terizidone 250 mg 
500 mg 
750 mg 
1000 mg 
   
Pyrazinamide 500 mg 
1000 mg 
1500 mg 
   
INH 300 mg    
Pyridoxine 25 mg/ 50 mg 
75 mg/ 125 mg 
150 mg 
Other: 
   
 
 
 
 
 
   
 
 
 
 
 
   
 
 
 
 
 
   
 
 
 
Kanamycin Study                          Clinical HIV Research Unit                  
                       Visit:  
 
Visit Date: ________________ (DD.MMM.YYYY) Initials: _____________Study Number: 
__________ 
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Appendix P 
Daily Drug Diary for Local Clinics 
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DAILY DRUG DIARY – KANAMYCIN STUDY 
Study Coordinator: Matshediso Mkhwanazi: speed dial: 50017/ 076 711 2874 (Helen Joseph TB 
Focal Point) 
 
DATE 
 
 
 
KANAMYCIN 
(KM) or 
CAPREOMYCIN 
(CM) 
ADMINISTERED  
DOSE TIME OF 
INJECTION 
COMMENTS NURSE 
SIGNATURE 
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Appendix Q 
Laboratory Requisition Form to CLS 
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Appendix R 
Laboratory Requisition Form for Sefako Makgatho Health Sciences University 
 
 
